USPatent applicationPatented

Modifications of plant traits using cyclin A

Granted 6 Oct 2009 · 3 office actions

Life of the application

20 dated events
⤢ drag to zoom20042006200820102012201420162018202020222024ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

Novel plant polysaccharide synthesis genes and polypeptides encoded by such genes are provided. These genes and polynucleotide sequences are useful regulating polysaccharide synthesis and plant phenotype. Moreover, these genes are useful for expression profiling of plant polysaccharide synthesis genes. The invention specifically provides cell cycle polynucleotide and polypeptide sequences isolated from Eucalyptus and Pinus . The invention also provides for the expression of cyclin A genes to modify the physical traits of a transgenic plant.

Description

58 parts
›CROSS REFERENCE TO RELATED APPLICATION

This application claims priority to U.S. provisional application Ser. No. 60/533,036, filed on Dec. 30, 2003, which is specifically incorporated in its entirety herein by reference.

›SEQUENCE LISTING

The instant application contains a “lengthy” Sequence Listing which has been submitted via CD-R in lieu of a printed paper copy, and is hereby incorporated by reference in its entirety. Said CD-R, recorded on May 12, 2005, are labeled “CRF”, “Copy 1” and “Copy 2”, respectively, and each contains only one identical 1.63 MB file (44463360.APP).

›FIELD OF THE INVENTION

The present invention relates generally to the field of plant cell cycle genes and polypeptides encoded by such genes, and the use of such polynucleotide and polypeptide sequences for regulating a plant cell cycle. The invention specifically provides cell cycle polynucleotide and polypeptide sequences isolated from Eucalyptus and Pinus and sequences related thereto.

›BACKGROUND OF THE INVENTION · 1 of 3

Cell growth and division are controlled by the temporal expression of different sets of genes, allowing the dividing cell to progress through the different phases of the cell cycle. Continued growth and organogesis in plants requires precise function of the cell cycle machinery. Plant development, which is directly affected by cell division rates and patterns, also is influenced by environmental factors, such as temperature, nutrient availability, light, etc. See Gastal and Nelon, Plant Physiol. 105:191-7 (1994), Ben-Haj-Sahal and Tardieu, Plant Physiol. 109:861-7 (1995), and Sacks et al., Plant Physiol. 114:519-27 (1997). Plant development and phenotype are connected with the cell cycle, and altering expression of the genes involved in the cell cycle can be a useful method of modifying plant development and altering plant phenotype.

The ability to alter expression of cell cycle genes is extremely powerful because the cell cycle drives plant development, including growth rates, responses to environmental cues, and resulting plant phenotype. Control of the plant cell cycle and phenotypes associated with alteration of cell cycle gene expression, in the vascular cambium, in particular, has applications for, inter alia, alteration of wood properties and, in particular, lumber and wood pulp properties. For example, improvements to wood pulp that can be effected by altering cell cycle gene expression include increased or decreased lignin and cellulose content, and altered length, diameter, and lumen diameter of cells. Manipulating the plant cell cycle, and in particular the cambium cell cycle (i.e. the rate and angle of cell division), can also engineer better lumber having increased dimensional stability, increased tensile strength, increased shear strength, increased compression strength, increased shock resistance, increased stiffness, increased or decreased hardness, decreased spirality, decreased shrinkage, and desirable characteristics with respect to weight, density, and specific gravity.

A. Cell Cycle Genes and Proteins

1. Cyclin Dependent Protein Kinase

Progression through the cell cycle is regulated primarily by cyclin-dependent kinases (CDKs). CDKs are a conserved family of eukaryotic serine/threonine protein kinases, which require heterodimer formation with a cyclin subunit for activity. For review see, e.g. Joubes et al., Plant Mol. Biol. 43: 607-20 (2000), Stals and Inze, Trends Plant Sci. 6:359-64 (2001), and John et al., Protoplasma 216: 119-42 (2001).

The are five subclasses of CDK's, each having a different cyclin binding consensus sequence. In CDK type A the cyclin binding consensus sequence is PSTAIRE (SEQ ID NO: 778). Id. The cyclin binding consensus sequence in CDK types B-1, B-2, and C are PPTTLRE (SEQ ID NO: 779), PPTALRE (SEQ ID NO: 780), and PITAIRE (SEQ ID NO: 781), respectively. Joubes et al, Plant Physiol, 126: 1403-15 (2001).

Cell cycle progression is directed, in part, by changes in CDK activity. CDK activity is modulated by a number of different cell cycle protein components, such as changes in the abundance of individual cyclins due to changing rates of biosynthesis and proteolysis. Fluctuations in cyclin concentrations result in commensurate fluctuations in CDK activity. Cyclin accumulation is especially important in terminating the G1 phase of the cell cycle because DNA replication is initiated by an increase in CDK activity.

Activation of CDK also requires phosphorylation of a threonine residue within the T-loop of CDK by a CDK-activating kinase (CAK). Umeda et al., Proc. Nat'l Acad. Sci. U.S.A. 97: 13396-400 (2000). It was suggested by Yamaguchi et al., Plant J. 24: 11-20 (2000), that cyclin H is a regulatory subunit of CAK. CDK activity is further regulated by interaction with a CDK regulatory subunit, a small (70-100 AA) protein involved in cell cycle regulation.

A cell must exit the cell cycle in order to commit to differentiation, senescence or apoptosis. This process involves the down-regulation of CDK activities. CDK inhibitors (CKI) are low molecular weight proteins, which are important for cell cycle regulation and development. CKIs bind stoichiometrically to CDK and down-regulate the activity of CDKs.

Many biochemical properties of ICK1, the first plant CKI to be identified from Arabidopsis thaliana , are known. Wang et al., Nature 386:451-2 (1997) Wang et al., Plant J. 24: 613-23 (2000). ICK1 is expressed at low levels in many tissue types, and there can be a threshold level of ICK1 that must be overcome before a cell can enter the cell cycle. Wang et al., Plant J. 24: 613-23 (2000). ICK1 is induced by the plant growth regulator abscisic acid (ABA), which inhibits cell division by blocking DNA replication. When the expression of ICK 1 increases, there is a corresponding decrease in Cdc2-like H1 histone activity. ICK1 has been shown to bind in vitro with the cyclins C2c2a and CycD3, and deletion experiments have identified different domain regions for these two interactions.

Altering the expression of CDK regulatory protein or a subunit thereof is known to cause changes in plant phenotype. Overexpression of the Arabidopsis CDK regulatory subunit, CKS1At, resulted in a reduction of leaf size, root growth rates and meristem size. Additionally, overexpression of CKS1At resulted in inhibition of cell-cycle progression, with an extension in the duration of the G1 and G2 phases of the cell cycle.

2. Cyclins

Cyclins are positive regulatory subunits of cyclin-dependent kinase (CDK) enzymes and are required for CDK activity. Fowler et al., Mol. Biotech. 10, 123, 126. Cyclins and CDK complexes provide temporal regulation of transition through the cell cycle. Evidence also suggests that cyclins provide spatial regulation of specific CDK activity, differentially targeting the cytoskeleton, spindle, phragmoplast, nuclear envelope, and chromosomes.

Plant cyclins are classified into five major groups: A, B, C, D, and H. Renaudin et al., Plant Mol. Biol. 32: 1003-18 (1996) and Yamaguchi et al., (supra 2000). Cyclins can be divided into mitotic cyclins (A and B) and G 1 cyclins.

›BACKGROUND OF THE INVENTION · 2 of 3

The mitotic cyclins possess a consensus sequence (R-x-x-L-x-x-I-x-N. SEQ ID NO: 782) located at the N-terminal region, termed a destruction box, adjacent to a lysine-rich region. The destruction box and lysine-rich region target the mitotic cyclins for ubiquitin-dependent proteolysis during mitosis. Stals, supra at 361, and Fowler, supra at 126. The destruction box in A versus B cyclins differs slightly and this difference is thought to result in slightly different timing of degradation of A versus B cyclins. Fowler, supra at 126. A-type cyclins accumulate during the S, G2, and early M phase of the cell cycle, whereas B-type cyclins accumulate during the late G2 and early M phase. Mironov et al., Plant Cell 11: 509-22 (1999). Three subgroups of A-type cyclins are known in plants, but only one is known in animals. Cyclin A1 (cycA1;zm;1 from Zea cans ) is most concentrated during cytokinesis at the microtubule-containing phragmoplast. Expression of cyclin A2 is upregulated by auxins in roots, and by cytokinins in the shoot apex. Abrahams et al., Biochim. Biophys. Acta 28: 1-2 (2001).

D-type cyclins, of which five subgroups are known, are thought to control the progression through the G1 phase in response to growth factors and nutrients. Riou-Khamlichi et al., Mol. Cell Biol. 20: 4513-21 (2000). For example, the expression of D-type cyclins is upregulated by sucrose as shown by an increase in cycD2 mRNA 30 minutes after sucrose exposure, and an increase in cycD3 four hours after sucrose exposure. This timing corresponds to early G1-phase and late G1-phase, respectively. Cockcroft et al., Nature 405: 575-9 (2000). Furthermore, in Arabidopsis , a D3 cyclin was shown to be upregulated by the brassinosteroid, epi-brassinolide.

Cyclin D2 proteins bind with CDKA to produce an active complex, which binds to and phosphorylates retinoblastoma-related protein (Rb). This process is found in actively proliferating tissue, suggesting it plays an important function during late G1- and early S-phase. Three different D3-type cyclins are active during tomato fruit development. These proteins all contain a retinoblastoma binding motif and a PEST-destruction motif. There are differences in the spatial and temporal expression of these D3 cyclins, inferring different roles during fruit development.

Overexpression of cyclin D was shown to increase overall growth rate. Over-expression of cyclin D2 in tobacco increases causes shortening the G1-phase which producing a faster rate of cell cycling.

C- and H-type cyclins were characterized in poplar ( Populus tremula ×tremuloides ) and rice ( Oryza sativa ) but their exact function is still unclear. Putative cyclins with a lesser degree of peptide sequence conservation have also been identified. For example, Arabidopsis CycJ18 has only 20% identity with homologues over the cyclin box domain. CycJ18 is expressed predominantly in young seedlings. Arabidopsis F3O9.13 protein also has similarity to the cyclin family.

3. Histone Acetyltransferase/Deacetyltransferase

Histone acetyltransferase (HA) and histone deacetyltransferase (HAD) control the net level of acetylation of histones. Histone acetylation and deacetylation are thought to exert their regulatory effects on gene expression by altering the accessibility of nucleosomal DNA to DNA-binding transcriptional activators, other chromatin-modifying enzymes or multi-subunit chromatin remodeling complexes capable of displacing nucleosomes. Lusser et al., Nucleic Acids Res. 27: 4427-35 (1999). Therefore, in general, the HDAs are involved in the repression of gene expression, while HAs are correlated with gene activation.

HA effects acetylation at the ε-amino group of conserved lysine residues clustered near the amino terminus of core histones which up-regulates gene expression.

HDAs remove acetyl groups from the core histones of the nucleosome. There are numerous family members in the HDA group, many of which are conserved throughout evolution. Lechner et al., Biochim Biophys Acta 5:181-8 (1996). HDAs fimction as part of multi-protein complexes facilitating chromatin condensation.

HDAs and HAs recognize highly distinct acetylation patterns on the nucleosome. It is thought that different types of HDAs interact with specific regions of the genome, to influence gene silencing.

Schultz et al., Genes Dev. 15: 428-43 (2001), demonstrated that the superfamily of Kruppel-associated-box zinc finger proteins (KRAB-ZFPs) are linked to the nucleosome remodelling and histone deacetylation complex via the PHD (plant homeodomain) and bromodomains of co-repressor KAP-1, to form a cooperative unit that is required for transcriptional repression. A maize HDAC (HD2) has been identified that has no sequence homology to other eukaryotic HDACs, but instead contains sequence similarity to peptidyl-prolyl cis-trans isomerases (PPIases).

The effects of interfering with histone deacetylation are discussed in e.g. Tian and Chen, Proc. Nat'l Acad. Sci. USA 98: 200-5 (2001).

4. Peptidyl Prolyl Cis-Trans Isomerase

Peptidylprolyl isomerases (e.g., peptidylprolyl cis-trans isomerase, peptidyl-prolyl cis-trans isomerase, PPIase, rotamase, cyclophilin) catalyze the interconversion of peptide bonds between the cis and trans conformations at proline residues. Sheldon and Venis, Biochem J. 315: 965-70 (1996). This interconversion is thought to be the rate limiting step of protein folding. PPIases belong to a conserved family of proteins that are present in animals, fungi, bacteria and plants. PPIases are implicated in a number of responses including the response to environmental stress, calcium signals, transcriptional repression, cell cycle control, etc. Viaud, et al., Plant Cell 14: 917-30 (2002).

5. Retinoblastoma-Related Protein

Retinoblastoma (Rb)-related protein putatively regulates progression of the cell cycle through the G1 phase and into S phase. Xie et al., EMBO J. 15: 4900-8 (1996) and Ach et al., Mol. Cell Biol. 17: 5077-86 (1997).

Although Rb is well-characterized in mammalian systems, the role of Rb-related proteins in regulation of G1 phase progression and S phase entry is not well characterized in plants. It is known, however, that RB-related protein functions through its association with various other cellular proteins involved in cell cycle regulation, such as the cyclins, WD40 proteins, Soni et al., Plant. Cell. 7:85-103 (1995); Grafi et al., Proc. Natl. Acad. Sci. U.S.A. 93:8962 (1996); Ach et al., Plant Cell 9:1595-606 (1997); Umen and Goodenough, Genes Dev. 15:1652-61 (2001); Mariconti et al., J. Biol. Chem. 277:9911-9 (2002).

›BACKGROUND OF THE INVENTION · 3 of 3

6. WD40 Repeat Protein

WD40 is a common repeating motif involved in many different protein-protein interactions. The WD40 domain is found in proteins having a wide variety of functions including adaptor/regulatory modules in signal transduction, pre-mRNA processing and cytoskeleton assembly. Goh et al., Eur. J. Biochem. 267: 434-49 (2000).

The WD40 domain, which is 40 residues long, typically contains a GH dipeptide 11-24 residues from the N-terminus and the WD dipeptide at the C-terminus. Id. Between the GH dipeptide and the WD dipeptide lies a conserved core which serves as a stable platform where proteins can bind either stably or reversibly. The core forms a propeller-like structure with several blades. Each blade is composed of a four-stranded anti-parallel β-sheet. Each WD40 sequence repeat forms the first three strands of one blade and the last strand in the next blade. The last C-terminal WD40 repeat completes the blade structure of the first WD40 repeat to create the closed ring propeller-structure. The residues on the top and bottom surface of the propeller are proposed to coordinate interactions with other proteins and/or small ligands.

Studies in yeast demonstrated that Cdc20, which contains the WD40 motif, is required for the proteolysis of mitotic cyclins. This process is mediated by an ubiquitin-protein ligase called anaphase-promoting complex (APC) or cyclosome. Following ubiquitination and proteolysis by the 26S proteasome, the cell can segregate chromosomes, and exit from mitosis. Cdc20 also contains a destruction-box domain.

7. WEE1-Like Protein

WEE1 controls the activity of cyclin-dependent kinases. WEE1 itself is a serine/threonine kinase. Sorrell et al., Planta 215: 518-22 (2002). The enzymatic activity of these protein kinases is controlled by phosphorylation of specific residues in the activation segment of the catalytic domain, sometimes combined with reversible conformational changes in the C-terminal autoregulatory tail. This process is conserved among eukaryotes, from fungi to animals and plants. Similarly, there is a high degree of homology between WEE1 proteins from various organisms. For example, there is 50% identity between the protein kinase domains of the human and maize WEE1 proteins.

Expression of WEE1 is shown to occur only in actively dividing tissues and is believed to inhibit cell division by acting as a negative regulator of mitosis. WEE1 is believed to prevent entry from G2 to M by protecting the nucleus from cytoplasmically-activated cyclin B1-complexed CDC2 before the onset of mitosis. For example, over-expression of AtWEE1 (from Arabidopsis ) and ZmWEE1 (from Zea cans ) in fission yeast inhibits cell division which results in elongated cells. Sun et al., Proc. Nat'l Acad. Sci . USA 96: 4180-5 (1999).

B. Expression Profiling and Microarray Analysis in Plant Development

The multigenic control of plant phenotype presents difficulties in determining the genes responsible for phenotypic determination. One major obstacle to identifying genes and gene expression differences that contribute to phenotype in plants is the difficulty with which the expression of more than a handful of genes can be studied concurrently. Another difficulty in identifying and understanding gene expression and the interrelationship of the genes that contribute to plant phenotype is the high degree of sensitivity to environmental factors that plants demonstrate.

There have been recent advances using genome-wide expression profiling. In particular, the use of DNA microarrays has been useful to examine the expression of a large number of genes in a single experiment. Several studies of plant gene responses to developmental and environmental stimuli have been conducted using expression profiling. For example, microarray analysis was employed to study gene expression during fruit ripening in strawberry, Aharoni et al., Plant Physiol. 129:1019-1031 (2002), wound response in Arabodopsis , Cheong et al., Plant Physiol. 129:661-7 (2002), pathogen response in Arabodopsis , Schenk et al., Proc. Nat'l Acad. Sci. 97:11655-60 (2000), and auxin response in soybean, Thibaud-Nissen et al., Plant Physiol. 132:118. Whetten et al., Plant Mol. Biol. 47:275-91 (2001) discloses expression profiling of cell wall biosynthetic genes in Pinus taeda L . using cDNA probes. Whetten et al. examined genes which were differentially expressed between differentiating juvenile and mature secondary xylem. Additionally, to determine the effect of certain environmental stimuli on gene expression, gene expression in compression wood was compared to normal wood. 156 of the 2300 elements examined showed differential expression. Whetten, supra at 285. Comparison of juvenile wood to mature wood showed 188 elements as differentially expressed. Id. at 286.

Although expression profiling and, in particular, DNA microarrays provide a convenient tool for genome-wide expression analysis, their use has been limited to organisms for which the complete genome sequence or a large cDNA collection is available. See Hertzberg et al., Proc. Nat'l Acad. Sci. 98:14732-7 (2001a), Hertzberg et al., Plant J, 25:585 (2001b). For example, Whetten, supra, states, “A more complete analysis of this interesting question awaits the completion of a larger set of both pine and poplar ESTs.” Whetten et al. at 286. Furthermore, microarrays comprising cDNA or EST probes may not be able to distinguish genes of the same family because of sequence similarities among the genes. That is, cDNAs or ESTs, when used as microarray probes, may bind to more than one gene of the same family.

Methods of manipulating gene expression to yield a plant with a more desirable phenotype would be facilitated by a better understanding of cell cycle gene expression in various types of plant tissue, at different stages of plant development, and upon stimulation by different environmental cues. The ability to control plant architecture and agronomically important traits would be improved by a better understanding of how cell cycle gene expression effects formation of plant tissues, how cell cycle gene expression causes plant cells to enter or exit cell division, and how plant growth and the cell cycle are connected. Among the large number of genes, the expression of which can change during development of a plant, only a fraction are likely to effect phenotypic changes during any given stage of the plant development.

›SUMMARY · 1 of 2

Accordingly, there is a need for tools and methods useful in determining the changes in the expression of cell cycle genes that occur during the plant cell cycle. There is also a need for polynucleotides useful in such methods. There is a further need for methods which can correlate changes in cell cycle gene expression to phenotype or stage of plant development. There is a further need for methods of identifying cell cycle genes and gene products that impact plant phenotype, and that can be manipulated to obtain a desired phenotype.

In one aspect, the present invention provides an isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260 and conservative variants thereof.

In another aspect, the present invention provides a DNA construct comprising at least one polynucleotide having the sequence of any one of SEQ ID NOs: 1-260 and conservative variants thereof.

Another aspect of the invention is a plant cell transformed with a DNA construct of comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260 and conservative variants thereof.

A further aspect of the invention is a transgenic plant comprising a plant cell transformed with a DNA construct comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260 and conservative variants thereof.

Another aspect of the invention is an isolated polynucleotide comprising a sequence encoding the catalytic or substrate-binding domain of a polypeptide selected from of any one of SEQ ID NOs: 261-520, wherein the polynucleotide encodes a polypeptide having the activity of said polypeptide selected from any one of SEQ ID NOs: 261-520.

A further aspect of the invention is a method of making a transformed plant comprising transforming a plant cell with a DNA construct comprising at least one polynucleotide having the sequence of any of SEQ ID NOs: 1-260; and culturing the transformed plant cell under conditions that promote growth of a plant.

In another aspect, the invention provides a wood obtained from a transgenic tree.

In a further aspect, the invention provides a wood pulp obtained from a transgenic tree which has been transformed with the DNA construct of the invention.

Another aspect of the invention is a method of making wood, comprising transforming a plant with a DNA construct comprising a polynucleotide having a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260 and conservative variants thereof; culturing the transformed plant under conditions that promote growth of a plant; and obtaining wood from the plant.

The invention further provides a method of making wood pulp, comprising transforming a plant with a DNA construct comprising a polynucleotide having a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260 and conservative variants thereof; culturing the transformed plant under conditions that promote growth of a plant; and obtaining wood pulp from the plant.

In another aspect, the invention provides an isolated polypeptide comprising an amino acid sequence encoded by the isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260 and conservative variants thereof.

The invention also provides, an isolated polypeptide comprising an amino acid sequence selected from the group consisting of 261-520.

The invention further provides a method of altering a plant phenotype of a plant, comprising altering expression in the plant of a polypeptide encoded by any one of SEQ ID NOs: 1-260.

In another aspect, the invention provides a polynucleotide comprising a nucleic acid selected from the group comprising of SEQ ID NOs: 521-772.

An aspect of the invention is a method of correlating gene expression in two different samples, comprising detecting a level of expression of one or more genes encoding a product encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260 and conservative variants thereof in a first sample; detecting a level of expression of the one or more genes in a second sample; comparing the level of expression of the one or more genes in the first sample to the level of expression of the one or more genes in the second sample; and correlating a difference in expression level of the one or more genes between the first and second samples.

A further aspect of the invention is a method of correlating the possession of a plant phenotype to the level of gene expression in the plant of one or more genes comprising detecting a level of expression of one or more genes encoding a product encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260 and conservative variants thereof in a first plant possessing a phenotype; detecting a level of expression of the one or more genes in a second plant lacking the phenotype; comparing the level of expression of the one or more genes in the first plant to the level of expression of the one or more genes in the second plant; and correlating a difference in expression level of the one or more genes between the first and second plants to possession of the phenotype.

In a further aspect, the invention provides a method of correlating gene expression to a stage of the cell cycle, comprising detecting a level of expression of one or more genes encoding a product encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260 and conservative variants thereof in a first plant cell in a first stage of the cell cycle; detecting a level of expression of the one or more genes in a second plant cell in a second, different stage of the cell cycle; comparing the level of the expression of the one or more genes in the first plant cells to the level of expression of the one or more genes in the second plants cells; and correlating a difference in expression level of the one or more genes between the first and second samples to the first or second stage of the cell cycle.

›SUMMARY · 2 of 2

An aspect of the invention is a combination for detecting expression of one or more genes, comprising two or more oligonucleotides, wherein each oligonucleotide is capable of hybridizing to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260.

Another aspect of the invention is a combination for detecting expression of one or more genes, comprising two or more oligonucleotides, wherein each oligonucleotide is capable of hybridizing to a nucleic acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260.

The invention further provides a microarray comprising a combination for detecting expression of one or more genes, comprising two or more oligonucleotides, wherein each oligonucleotide is capable of hybridizing to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260 or wherein each oligonucleotide is capable of hybridizing to a nucleic acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260, wherein each of said two or more oligonucleotides occupies a unique location on said solid support.

In another aspect, the invention provides a method for detecting one or more genes in a sample, comprising contacting the sample with two or more oligonucleotides, wherein each oligonucleotide is capable of hybridizing to a gene comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260 under standard hybridization conditions; and detecting the one or more genes of interest which are hybridized to the one or more oligonucleotides.

The invention also provides a method for detecting one or more nucleic acid sequences encoded by one or more genes in a sample, comprising contacting the sample with two or more oligonucleotides, wherein each oligonucleotide is capable of hybridizing to a nucleic acid sequence encoded by a gene comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-260 under standard hybridization conditions; and detecting the one or more nucleic acid sequences which are hybridized to the one or more oligonucleotides.

The invention further provides a kit for detecting gene expression comprising the microarray of the invention together with one or more buffers or reagents for a nucleotide hybridization reaction.

Other features, objects, and advantages of the present invention are apparent from the detailed description that follows. It should be understood, however, that the detailed description, while indicating preferred embodiments of the invention, are given by way of illustration only, not limitation. Various changes and modifications within the spirit and scope of the invention will be apparent to those skilled in the art from the detailed description.

›BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 : Exemplary microarray sampling parameters.

FIG. 2 : Plasmid map for pWVK202.

FIG. 3 : Plasmid map for pGrowth14.

FIG. 4 : Plasmid map for pGrowth15.

FIG. 5 : Plasmid map for pGrowth16.

FIG. 6 : Plasmid map for pGrowth18.

FIG. 7 : Plasmid map for pGrowth19.

FIG. 8 : Plasmid map for pGrowth20.

›LIST OF TABLES

Table 1: shows genes having greater than doubled signal with any one sample as compared to the mean signal of the other three samples.

Table 2: identifies plasmid(s), genes, and Genesis ID numbers for constructs described in Example 17.

Table 3: Rooting medium for Populus deltoids.

Table 4: pGrowth information.

Table 5: shows genes having greater than doubled signal with any one sample as compared to the mean signal of the other three samples.

Table 6: Differentially expressed cDNAs.

Table 7: Consensus ID information.

Table 8: pGrowth information.

Table 9 : Eucalyptus grandis cell cycle genes and proteins.

Table 10 : Pinus radiata cell cycle genes and proteins.

Table 11: Annotated peptide sequences of the present invention.

Table 12 : Eucalyptus in silico data.

Table 13: Pine in silico data.

Table 14: Oligo table.

Table 15: Peptide table.

Table 16: BLAST sequence alignment table.

›DETAILED DESCRIPTION · 1 of 14

The inventors have discovered novel isolated cell cycle genes and polynucleotides useful for identifying the multigenic factors that contribute to a phenotype and for manipulating gene expression to affect a plant phenotype. These genes, which are derived from plants of commercially important forestry genera, pine and eucalyptus, are involved in the plant cell cycle and are, at least in part, responsible for expression of phenotypic characteristics important in commercial wood, such as stiffness, strength, density, fiber dimensions, coarseness, cellulose and lignin content, and extractives content. Generally speaking, the genes and polynucleotides encode a protein which can be a cyclin, cyclin dependent kinase, cyclin dependent kinase inhibitor, histone acetyltransferase, histone deacetylase, peptidyl-prolyl cis-trans isomerase, retinoblastoma-related protein, WEE1-like protein, or WD40 repeat protein, or a catalytic domain thereof, or a polypeptide having the same function, and the invention further includes such proteins and polypeptides.

The methods of the present invention for selecting cell cycle gene sequences to target for manipulation will permit better design and control of transgenic plants with more highly engineered phenotypes. The ability to control plant architecture and agronomically important traits in commercially important forestry species will be improved by the information obtained from the methods, such as which genes affect which phenotypes, which genes affect entry into which stage of the cell cycle, which genes are active in which stage of plant development, and which genes are expressed in which tissue at a given point in the cell cycle or plant development.

Unless indicated otherwise, all technical and scientific terms are used herein in a manner that conforms to common technical usage. Generally, the nomenclature of this description and the described laboratory procedures, including cell culture, molecular genetics, and nucleic acid chemistry and hybridization, respectively, are well known and commonly employed in the art. Standard techniques are used for recombinant nucleic acid methods, oligonucleotide synthesis, cell culture, tissue culture, transformation, transfection, transduction, analytical chemistry, organic synthetic chemistry, chemical syntheses, chemical analysis, and pharmaceutical formulation and delivery. Generally, enzymatic reactions and purification and/or isolation steps are performed according to the manufacturers' specifications. Absent an indication to the contrary, the techniques and procedures in question are performed according to conventional methodology disclosed, for example, in Sambrook et al., M OLECULAR C LONING A L ABORATORY M ANUAL, 2d ed. (Cold Spring Harbor Laboratory Press, 1989), and C URRENT P ROTOCOLS IN M OLECULAR B IOLOGY , John Wiley & Sons, 1989). Specific scientific methods relevant to the present invention are discussed in more detail below. However, this discussion is provided as an example only, and does not limit the manner in which the methods of the invention can be carried out.

A. Plant Cell Cycle Genes and Proteins

1. Cell Cycle Genes, Polynucleotide and Polypeptide Sequences

One aspect of the present invention relates to novel plant cell cycle genes and polypeptides encoded by such genes. As used herein, the term “plant cell cycle genes” refers to genes encoding proteins that function during the plant cell cycle, and the term “plant cell cycle proteins” refers to proteins that function during the plant cell cycle. There are several known families of plant cell cycle proteins, including cyclin, cyclin dependent kinase, cyclin dependent kinase inhibitor, histone acetyltransferase, histone deacetylase, peptidyl-prolyl cis-trans isomerase, retinoblastoma-related protein, WEE1-like protein, and WD40 repeat protein. Although there is significant sequence homology within each gene and protein family, each member of each family can display different biochemical properties and altering the expression of at least one of these genes can result in a different plant phenotype.

The present invention provides novel plant cell cycle genes and polynucleotides and novel cell cycle proteins and polypeptides. In accordance with one embodiment of the invention, the novel plant cell cycle genes are the same as those expressed in a wild-type plant of a species of Pinus or Eucalyptus . Exemplary novel plant cell cycle gene sequences of the invention are set forth in Tables 9 and 10, which depict Eucalyptus grandis sequences and Pinus radiata sequences, respectively. Corresponding gene products, i.e., oligonucleotides and polypeptides, are also listed in Tables 14, 15, and 16. The Sequence Listing in APPENDIX 1 provides the sequences of these aspects of the invention.

The sequences of the invention have cell cycle activity and encode proteins that are active in the cell cycle, such as proteins of the cell cycle families discussed above. As discussed in more detail below, manipulation of the expression of the cell cycle genes and polynucleotides, or manipulation of the activity of the encoded proteins and polypeptides, can result in a transgenic plant with a desired phenotype that differs from the phenotype of a wild-type plant of the same species.

Throughout this description, reference is made to cell cycle gene products. As used herein, a “cell cycle gene product” is a product encoded by a cell cycle gene, and includes both nucleotide products, such as RNA, and amino acid products, such as proteins and polypeptides. Examples of specific cell cycle genes of the invention include SEQ ID NOs: 1-260. Examples of specific cell cycle gene products of the invention include products encoded by any one of SEQ ID NOs: 1-260. Reference also is made herein to cell cycle proteins and cell cycle polypeptides. Examples of specific cell cycle proteins and polypeptides of the invention include polypeptides encoded by any of SEQ ID NOs: 1-260 or polypeptides comprising the amino acid sequence of any of SEQ ID NOs: 261-520. One aspect of the invention is directed to a subset of these cell cycle genes and cell cycle gene products, namely SEQ ID NOs: 1-12, 14-58, 60-62, 64-70, 72-75, 77-83, 85-86, 88-91, 93-119, 121-130, 132-148, 150-156, 158-191, 193-207, 209-218, 220-221, 223-231, 233-237, their respective conservative variants (as that term is defined below), and the nucleotide and amino acid products encoded thereby. Another aspect of the invention is directed to a subset of the cell cycle genes and cell cycle gene products, namely SEQ ID NOs: 1-12, 14, 16-26, 30-37, 40-41, 43-76, 78-103, 106, 108-113, 116-121, 124-125, 128-147, 150-152, 154-155, 161-162, 164-172, 174, 177-183, 185-191, 193-197, 200-204, 208-213, 215-218, 220-221, 223-231, and 233-234 their respective conservative variants, and the nucleotide and amino acid products encoded thereby. A further aspect of the invention is directed to a subset of the cell cycle genes and cell cycle gene products, namely SEQ ID NOs: 1-12, 14, 16-26, 30-37, 40-41, 43-58, 60-62, 64-70, 72-75, 78-83, 85-86, 88-91, 93-103, 106, 108-113, 116-119, 121, 124-125, 128-130, 132-147, 150-152, 154-155, 161-162, 164-172, 174, 177-183, 185-191, 193-197, 200-204, 209-213, 215-218, 220-221, 223-231, and 233-234 their respective conservative variants, and the nucleotide and amino acid products encoded thereby.

›DETAILED DESCRIPTION · 2 of 14

The present invention also includes sequences that are complements, reverse sequences, or reverse complements to the nucleotide sequences disclosed herein.

The present invention also includes conservative variants of the sequences disclosed herein. The term “variant,” as used herein, refers to a nucleotide or amino acid sequence that differs in one or more nucleotide bases or amino acid residues from the reference sequence of which it is a variant.

Thus, in one aspect, the invention includes conservative variant polynucleotides. As used herein, the term “conservative variant polynucleotide” refers to a polynucleotide that hybridizes under stringent conditions to an oligonucleotide probe that, under comparable conditions, binds to the reference gene the conservative variant is a variant of. Thus, for example, a conservative variant of SEQ ID NO: 1 hybridizes under stringent conditions to an oligonucleotide probe that, under comparable conditions, binds to SEQ ID NO: 1. One aspect of the invention provides conservative variant polynucleotides that exhibit at least about 75% sequence identity to their respective reference sequences.

“Sequence identity” has an art-recognized meaning and can be calculated using published techniques. See C OMPUTATIONAL M OLECULAR B IOLOGY , Lesk, ed. (Oxford University Press, 1988), B IOCOMPUTING : I NFORMATICS A ND G ENOME P ROJECTS , Smith, ed. (Academic Press, 1993), C OMPUTER A NALYSIS O F S EQUENCE D ATA , P ART I, Griffin & Griffin, eds., (Humana Press, 1994), S EQUENCE A NALYSIS I N M OLECULAR B IOLOGY , Von Heinje ed., Academic Press (1987), S EQUENCE A NALYSIS P RIMER , Gribskov & Devereux, eds. (Macmillan Stockton Press, 1991), and Carillo & Lipton, SIAM J. Applied Math. 48: 1073 (1988). Methods commonly employed to determine identity or similarity between two sequences include but are not limited to those disclosed in G UIDE T O H UGE C OMPUTERS , Bishop, ed, (Academic Press, 1994) and Carillo & Lipton, supra. Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include but are not limited to the GCG program package (Devereux et al., Nucleic Acids Research 12: 387 (1984)), BLASTP, BLASTN, FASTA (Atschul et al., J. Mol. Biol. 215: 403 (1990)), and FASTDB (Brutlag et al., Comp. App. Biosci. 6: 237 (1990)).

The invention includes conservative variant polynucleotides having a sequence identity that is greater than or equal to 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, or 60% to any one of SEQ ID NOs: 1 to 237. In such variants, differences between the variant and the reference sequence can occur at the 5′ or 3′ terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

Additional conservative variant polynucleotides contemplated by and encompassed within the present invention include polynucleotides comprising sequences that differ from the polynucleotide sequences of SEQ ID NO: 1-237, or complements, reverse complements or reverse sequences thereof, as a result of deletions and/or insertions totaling less than 10% of the total sequence length.

The invention also includes conservative variant polynucleotides that, in addition to sharing a high degree of similarity in their primary structure (sequence) to SEQ ID NOs: 1 to 260, have at least one of the following features: (i) they contain an open reading frame or partial open reading frame encoding a polypeptide having substantially the same functional properties in the cell cycle as the polypeptide encoded by the reference polynucleotide, or (ii) they have nucleotide domains or encoded protein domains in common. The invention includes conservative variants of SEQ ID NOs: 1-260 that encode proteins having the enzyme or biological activity or binding properties of the protein encoded by the reference polynucleotide. Such conservative variants are functional variants, in that they have the enzymatic or binding activity of the protein encoded by the reference polynucleotide.

In accordance with the invention, polynucleotide variants can include a “shuffled gene” such as those described in e.g. U.S. Pat. Nos. 6,500,639, 6,500,617 6,436,675, 6,379,964, 6,352,859 6,335,198 6,326,204, and 6,287,862. A variant of a nucleotide sequence of the present invention also can be a polynucleotide modified as disclosed in U.S. Pat. No. 6,132,970, which is incorporated herein by reference.

In accordance with one embodiment, the invention provides a polynucleotide that encodes a cell cycle protein from one of the following families: cyclin, cyclin dependent kinase, cyclin dependent kinase inhibitor, histone acetyltransferase, histone deacetylase, peptidyl-prolyl cis-trans isomerase, retinoblastoma-related protein, WEE1-like protein, or WD40 repeat protein. SEQ ID NOs: 1-260 provide examples of such polynucleotides.

In accordance with another embodiment, a polynucelotide of the invention encodes the catalytic or protein binding domain of a polypeptide encoded by any of SEQ ID NOs: 1-260 or of a polypeptide comprising any of SEQ ID NOs: 261-520. The catalytic and protein binding domains of the cell cycle proteins of the invention are known in the art. The conserved sequences of these proteins are shown in Entries 1-248 as underlined, bold, and/or italicized text.

The invention also encompasses as conservative variants polynucleotides that differ from the sequences discussed above but that, as a consequence of the degeneracy of the genetic code, encode a polypeptide which is the same as that encoded by a polynucleotide of the present invention. The invention also includes as conservative variants polynucleotides comprising sequences that differ from the polynucleotide sequences discussed above as a result of substitutions that do not affect the amino acid sequence of the encoded polypeptide sequence, or that result in conservative substitutions in the encoded polypeptide sequence.

›DETAILED DESCRIPTION · 3 of 14

The present invention also includes an isolated polypeptide encoded by a polynucleotide comprising any of SEQ ID NOs: 1-260 or any of the conservative variants thereof discussed above. The invention also includes polypeptides comprising SEQ ID NOs: 261-520 and conservative variants of these polypeptides. Another aspect of the invention include polypeptides comprising SEQ ID NOs: 261-272, 274-318, 320-322, 324-330, 332-335, 337-343, 345-346, 348-351, 353-379, 381-390, 392-408, 410-416, 418-451, 453-467, 469-478, 480-481, 483-491, and 493-494 and conservative variants thereof. A further aspect of the invention includes polypeptides comprising SEQ ID NOs: 261-272, 274, 276-286, 289, 290-297, 300-301, 303-345, 347-363, 366, 368-373, 376-381, 384-385, 388-407, 410-412, 414-415, 420-422, 424-432, 434, 437-443, 445-451, 453-457, 460-464, 468-473, and 475-494 and conservative variants thereof. Another aspect of the invention includes polypeptides comprising SEQ ID NOs: 261-272, 274, 276-286, 290-297, 300-301, 303-318, 320-322, 324-330, 332-335, 337-343, 345, 348-351, 353-363, 366, 368-373, 376-381, 384-385, 388-390, 392-407, 410-412, 414-415, 421-422, 424-432, 434, 437-443, 445-451, 453-457, 460-464, 469-473, 475-478, 480-481, 483-491, and 493-494 and conservative variants thereof.

In accordance with the invention, a variant polypeptide or protein refers to an amino acid sequence that is altered by the addition, deletion or substitution of one or more amino acids.

The invention includes conservative variant polypeptides. As used herein, the term “conservative variant polypeptide” refers to a polypeptide that has similar structural, chemical or biological properties to the protein it is a conservative variant of. Guidance in determining which amino acid residues can be substituted, inserted, or deleted can be found using computer programs well known in the art such as Vector NTI Suite (InforMax, MD) software. In one embodiment of the invention, conservative variant polypeptides that exhibit at least about 75% sequence identity to their respective reference sequences.

Conservative variant protein includes an “isoform” or “analog” of the polypeptide. Polypeptide isoforms and analogs refers to proteins having the same physical and physiological properties and the same biological function, but whose amino acid sequences differs by one or more amino acids or whose sequence includes a non-natural amino acid.

Polypeptides comprising sequences that differ from the polypeptide sequences of SEQ ID NO: 261-520 as a result of amino acid substitutions, insertions, and/or deletions totaling less than 10% of the total sequence length are contemplated by and encompassed within the present invention.

One aspect of the invention provides conservative variant polypeptides that have the same function in the cell cycle as the proteins of which they are variants, as determined by one or more appropriate assays, such as those described below. The invention includes variant polypeptides that function as cell cycle proteins, such as those having the biological activity of cyclin, cyclin dependent kinase, cyclin dependent kinase inhibitor, histone acetyltransferase, histone deacetylase, peptidyl-prolyl cis-trans isomerase, retinoblastoma-related protein, WEE1-like protein, and WD40 repeat protein, and are thus capable of modulating the cell cycle in a plant. As discussed above, the invention includes variant polynucleotides that encode polypeptides that function as cell cycle proteins.

The activities and physical properties of cell cycle proteins can be examined using any method known in the art. The following examples of assay methods are not exhaustive and are included to provide some guidance in examining the activity and distinguishing protein characteristics of cell cycle protein variants.

CDK activity can be assessed using roscovitine as described in Yamaguchi et al., Proc. Natl. Acad. Sci. U.S.A. 100:8019 (2003). CDK histone kinase activity can be assayed using autoradiography to detect histone H1 phosphorylation by CDK as described in Joubes et al., Plant Physiol. 121:857 (1999).

CKI activity can be assayed using a variation of the method described in Zhou et al., Planta. 6:604 (2003). The modified method can employ co-transformation or subsequent transformations to identify the interaction of CKI and cyclins in vivo. For example, in the first transformation pine tissue can be transformed using the method described in U.S. Patent Application Publication No. 2002/0100083 using geneticin selection to obtain transgenic plants possessing cycD3 and cdc2a homologs. The second transformation can be performed using alpha-methyltryptophan as a selectable marker to obtain transformants having an ICK1 homologue as described in U.S. Provisional Application No. 60/476,189. Tissue capable of growing on both on geneticin and on alpha-methyltryptophan contains the ICK1 homologue and the cycD3 and cdc2a homologues. The CKI activity is determined by comparison of the phenotype of transformants having the cycD3 and cdc2a homologues to the transformants having ICK1 homologue and the cycD3 and cdc2a homologs.

Histone deacetylase activity can be assessed by complementation of the Arabidopsis mutants described in Tian et al., Genetics 165:399 (2003). Histone acetyltransferase activity can be assayed using anacardic acid as described in Balasubramanyam et al., J. Biol. Chem. 278:19134 (2003). Histone acetyltransferase also can be assayed using trichostatin A-treated plant lines as is described in Bhat et al., Plant J. 33:455 (2003). The plant lines described in Bhat et al., supra, also can be used to assay retinoblastoma-related proteins using the co-precipitation method described in Rossi et al., Plant Mol. Biol. 51:401 (2003).

Peptidyl-prolyl isomerase can be assayed as described in Edvardsson et al., FEBS Lett. 542:137 (2003). WD40 proteins can be evaluated based on the possession of the WD40 motif as well as their ability to interact with cdc2. WEE-1 can be assayed using any kinase activity assay known in the art.

›DETAILED DESCRIPTION · 4 of 14

2. Methods of Using Cell Cycle Genes, Polynucleotide and Polypeptide Sequences

The present invention provides methods of using plant cell cycle genes and conservative variants thereof. The invention includes methods and constructs for altering expression of plant cell cycle genes and/or gene products for purposes including, but not limited to (i) investigating function during the cell cycle and ultimate effect on plant phenotype and (ii) to effect a change in plant phenotype. For example, the invention includes methods and tools for modifying wood quality, fiber development, cell wall polysaccharide content, fruit ripening, and plant growth and yield by altering expression of one or more plant cell cycle genes.

The invention comprises methods of altering the expression of any of the cell cycle genes and variants discussed above. Thus, for example, the invention comprises altering expression of a cell cycle gene present in the genome of a wild-type plant of a species of Eucalyptus or Pinus . In one embodiment, the cell cycle gene comprises a nucleotide sequence selected from SEQ ID NOs: 1-260, from the subset thereof comprising SEQ ID NOs: 1-12, 14-58, 60-62, 64-70, 72-75, 77-83, 85-86, 88-91, 93-119, 121-130, 132-148, 150-156, 158-191, 193-207, 209-218, 220-221, 223-231, and 233 -237, from the subset thereof comprising SEQ ID NOs: 1-12, 14, 16-26, 30-37, 40-41, 43-76, 78-103, 106, 108-113, 116-121, 124-125, 128-147, 150-152, 154-155, 161-162, 164-172, 174, 177-183, 185-191, 193-197, 200-204, 208-213, and 215-234, from the subset thereof comprising SEQ ID NOs: 1-12, 14, 16-26, 30-37, 40-41, 43-58, 60-62, 64-70, 72-75, 78-83, 85-86, 88-91, 93-103, 106, 108-113, 116-119, 121, 124-125, 128-130, 132-147, 150-152, 154-155, 161-162, 164-172, 174, 177-183, 185-191, 193-197, 200-204, 209-213, 215-218, 220-221, 223-231, and 233-234, or the conservative variants thereof, as discussed above.

Techniques which can be employed in accordance with the present invention to alter gene expression, include, but are not limited to: (i) over-expressing a gene product, (ii) disrupting a gene's transcript, such as disrupting a gene's mRNA transcript; (iii) disrupting the function of a polypeptide encoded by a gene, or (iv) disrupting the gene itself. Over-expression of a gene product, the use of antisense RNAs, ribozymes, and the use of double-stranded RNA interference (dsRNAi) are valuable techniques for discovering the functional effects of a gene and for generating plants with a phenotype that is different from a wild-type plant of the same species.

Over-expression of a target gene often is accomplished by cloning the gene or cDNA into an expression vector and introducing the vector into recipient cells. Alternatively, over-expression can be accomplished by introducing exogenous promoters into cells to drive expression of genes residing in the genome. The effect of over-expression of a given gene on cell function, biochemical and/or physiological properties can then be evaluated by comparing plants transformed to over-express the gene to plants that have not been transformed to over-express the gene.

Antisense RNA, ribozyme, and dsRNAi technologies typically target RNA transcripts of genes, usually mRNA. Antisense RNA technology involves expressing in, or introducing into, a cell an RNA molecule (or RNA derivative) that is complementary to, or antisense to, sequences found in a particular mRNA in a cell. By associating with the mRNA, the antisense RNA can inhibit translation of the encoded gene product. The use of antisense technology to reduce or inhibit the expression of specific plant genes has been described, for example in European Patent Publication No. 271988, Smith et al., Nature, 334:724-726 (1988); Smith et. al., Plant Mol. Biol., 14:369-379 (1990)).

A ribozyme is an RNA that has both a catalytic domain and a sequence that is complementary to a particular mRNA. The ribozyme functions by associating with the mRNA (through the complementary domain of the ribozyme) and then cleaving (degrading) the message using the catalytic domain.

RNA interference (RNAi) involves a post-transcriptional gene silencing (PTGS) regulatory process:, in which the steady-state level of a specific mRNA is reduced by sequence-specific degradation of the transcribed, usually fully processed mRNA without an alteration in the rate of de novo transcription of the target gene itself. The RNAi technique is discussed, for example, in Elibashir, et al., Methods Enzymol. 26: 199 (2002); McManus & Sharp, Nature Rev. Genetics 3: 737 (2002); PCT application WO 01/75164; Martinez et al., Cell 110: 563 (2002); Elbashir et al., supra; Lagos-Quintana et al., Curr. Biol. 12: 735 (2002); Tuschl et al., Nat. Biotechnol. 20:446 (2002); Tuschl, Chembiochem. 2: 239 (2001); Harborth et al., J. Cell Sci. 114: 4557 (2001); et al, EMBO J. 20:6877 (2001); Lagos-Quintana et al., Science. 294: 8538 (2001); Hutvagner et al., loc cit, 834; Elbashir et al., Nature. 411: 494 (2001).

The present invention provides a DNA construct comprising at least one polynucleotide of SEQ ID NOs: 1-260 or conservative variants thereof, such as the conservative variants discussed above. Any method known in the art can be used to generate the DNA constructs of the present invention. See, e.g. Sambrook et al., supra.

The invention includes DNA constructs that optionally comprise a promoter. Any suitable promoter known in the art can be used. A promoter is a nucleic acid, preferably DNA, that binds RNA polymerase and/or other transcription regulatory elements. As with any promoter, the promoters of the invention facilitate or control the transcription of DNA or RNA to generate an mRNA molecule from a nucleic acid molecule that is operably linked to the promoter. The RNA can encode a protein or polypeptide or can encode an antisense RNA molecule or a molecule useful in RNAi. Promoters useful in the invention include constitutive promoters, inducible promoters, temporally regulated promoters and tissue-preferred promoters.

›DETAILED DESCRIPTION · 5 of 14

Examples of useful constitutive plant promoters include: the cauliflower mosaic virus (CaMV) 35S promoter, which confers constitutive, high-level expression in most plant tissues (Odel et al. Nature 313:810(1985)); the nopaline synthase promoter (An et al. Plant Physiol. 88:547 (1988)); and the octopine synthase promoter (Fromm et al., Plant Cell 1: 977 (1989)). It should be noted that, although the CaMV 35S promoter is commonly referred to as a constitutive promoter, some tissue preference can be seen. The use of CaMV 35S is envisioned by the present invention, regardless of any tissue preference which may be exhibited during use in the present invention.

Inducible promoters regulate gene expression in response to environmental, hormonal, or chemical signals. Examples of hormone inducible promoters include auxin-inducible promoters (Baumann et al. Plant Cell 11:323-334(1999)), cytokinin-inducible promoters (Guevara-Garcia, Plant Mol. Biol. 38:743-753(1998)), and gibberellin-responsive promoters (Shi et al. Plant Mol. Biol. 38:1053-1060(1998)). Additionally, promoters responsive to heat, light, wounding, pathogen resistance, and chemicals such as methyl jasmonate or salicylic acid, can be used in the DNA constructs and methods of the present invention.

Tissue-preferred promoters allow for preferred expression of polynucleotides of the invention in certain plant tissue. Tissue-preferred promoters are also useful for directing the expression of antisense RNA or siRNA in certain plant tissues, which can be useful for inhibiting or completely blocking the expression of targeted genes as discussed above. As used herein, vascular plant tissue refers to xylem, phloem or vascular cambium tissue. Other preferred tissue includes apical meristem, root, seed, and flower. In one aspect, the tissue-preferred promoters of the invention are either “xylem-preferred,” “cambium-preferred” or “phloem-preferred,” and preferentially direct expression of an operably linked nucleic acid sequence in the xylem, cambium or phloem, respectively. In another aspect, the DNA constructs of the invention comprise promoters that are tissue-specific for xylem, cambium or phloem, wherein the promoters are only active in the xylem, cambium or phloem.

A vascular-preferred promoter is preferentially active in any of the xylem, phloem or cambium tissues, or in at least two of the three tissue types. A vascular-specific promoter is specifically active in any of the xylem, phloem or cambium, or in at least two of the three. In other words, the promoters are only active in the xylem, cambium or phloem tissue of plants. Note, however, that because of solute transport in plants, a product that is specifically or preferentially expressed in a tissue may be found elsewhere in the plant after expression has occurred.

In another embodiment, the promoter is under temporal regulation, wherein the ability of the promoter to initiate expression is linked to factors such as the stage of the cell cycle or the stage of plant development. For example, the promoter of a cyclin D2 gene may be expressed only during the G1 and early S-phase, and the promoters of particular cyclin genes may be expressed only within the primary vascular poles of the developing seedling.

Additionally, the promoters of particular cell cycle genes may be expressed only within the cambium in developing secondary vasculature. Within the cambium, particular cell cycle gene promoters may be expressed exclusively in the stem or in the root. Moreover, the cell cycle promoters may be expressed only in the spring (for early wood formation) or only in the summer.

A promoter may be operably linked to the polynucleotide. As used in this context, operably linked refers to linking a polynucleotide encoding a structural gene to a promoter such that the promoter controls transcription of the structural gene. If the desired polynucleotide comprises a sequence encoding a protein product, the coding region can be operably linked to regulatory elements, such as to a promoter and a terminator, that bring about expression of an associated messenger RNA transcript and/or a protein product encoded by the desired polynucleotide. In this instance, the polynucleotide is operably linked in the 5′- to 3′-orientation to a promoter and, optionally, a terminator sequence.

Alternatively, the invention provides DNA constructs comprising a polynucleotide in an “antisense” orientation, the transcription of which produces nucleic acids that can form secondary structures that affect expression of an endogenous cell cycle gene in the plant cell. In another variation, the DNA construct may comprise a polynucleotide that yields a double-stranded RNA product upon transcription that initiates RNA interference of a cell cycle gene with which the polynucleotide is associated. A polynucleotide of the present invention can be positioned within a t-DNA, such that the left and right t-DNA border sequences flank or are on either side of the polynucleotide.

It should be understood that the invention includes DNA constructs comprising one or more of any of the polynucleotides discussed above. Thus, for example, a construct may comprise a t-DNA comprising one, two, three, four, five, six, seven, eight, nine, ten, or more polynucleotides.

The invention also includes DNA constructs comprising a promoter that includes one or more regulatory elements. Alternatively, the invention includes DNA constructs comprising a regulatory element that is separate from a promoter. Regulatory elements confer a number of important characteristics upon a promoter region. Some elements bind transcription factors that enhance the rate of transcription of the operably linked nucleic acid. Other elements bind repressors that inhibit transcription activity. The effect of transcription factors on promoter activity can determine whether the promoter activity is high or low, i.e. whether the promoter is “strong” or “weak.”

A DNA construct of the invention can include a nucleotide sequence that serves as a selectable marker useful in identifying and selecting transformed plant cells or plants. Examples of such markers include, but are not limited to, a neomycin phosphotransferase (nptII) gene (Potrykus et al., Mol. Gen. Genet. 199:183-188 (1985)), which confers kanamycin resistance. Cells expressing the nptII gene can be selected using an appropriate antibiotic such as kanamycin or G418. Other commonly used selectable markers include a mutant EPSP synthase gene (Hinchee et al., Bio/Technology 6:915-922 (1988)), which confers glyphosate resistance; and a mutant acetolactate synthase gene (ALS), which confers imidazolinone or sulphonylurea resistance (European Patent Application 154,204, 1985).

›DETAILED DESCRIPTION · 6 of 14

The present invention also includes vectors comprising the DNA constructs discussed above. The vectors can include an origin of replication (replicons) for a particular host cell. Various prokaryotic replicons are known to those skilled in the art, and function to direct autonomous replication and maintenance of a recombinant molecule in a prokaryotic host cell.

In one embodiment, the present invention utilizes a pWVR8 vector as described in U.S. Application No. 60/476,222, filed Jun. 6, 2003, or pART27 as described in Gleave, Plant Mol. Biol, 20:1203-27 (1992).

The invention also provides host cells which are transformed with the DNA constructs of the invention. As used herein, a host cell refers to the cell in which a polynucleotide of the invention is expressed. Accordingly, a host cell can be an individual cell, a cell culture or cells that are part of an organism. The host cell can also be a portion of an embryo, endosperm, sperm or egg cell, or a fertilized egg. In one embodiment, the host cell is a plant cell.

The present invention further provides transgenic plants comprising the DNA constructs of the invention. The invention includes transgenic plants that are angiosperms or gymnosperms. The DNA constructs of the present invention can be used to transform a variety of plants, both monocotyledonous (e.g grasses, corn, grains, oat, wheat and barley), dicotyledonous (e.g., Arabidopsis , tobacco, legumes, alfalfa, oaks, eucalyptus , maple), and Gymnosperms (e.g., Scots pine; see Aronen, Finnish Forest Res. Papers , Vol. 595, 1996), white spruce (Ellis et al., Biotechnology 11:84-89, 1993), and larch (Huang et al., In Vitro Cell 27:201-207, 1991).

The plants also include turfgrass, wheat, maize, rice, sugar beet, potato, tomato, lettuce, carrot, strawberry, cassava, sweet potato, geranium, soybean, and various types of woody plants. Woody plants include trees such as palm oak, pine, maple, fir, apple, fig, plum and acacia. Woody plants also include rose and grape vines.

In one embodiment, the DNA constructs of the invention are used to transform woody plants, i.e., trees or shrubs whose stems live for a number of years and increase in diameter each year by the addition of woody tissue. The invention includes methods of transforming plants including eucalyptus and pine species of significance in the commercial forestry industry such as plants selected from the group consisting of Eucalyptus grandis and its hybrids, and Pinus taeda , as well as the transformed plants and wood and wood pulp derived therefrom. Other examples of suitable plants include those selected from the group consisting of Pinus banksiana, Pinus brutia, Pinus caribaea, Pinus clausa, Pinus contorta, Pinus coulteri, Pinus echinata, Pinus eldarica, Pinus ellioti, Pinusjeffreyi, Pinus lambertiana, Pinus massoniana, Pinus monticola, Pinus nigra, Pinus palustris, Pinus pinaster, Pinus ponderosa, Pinus radiata, Pinus resinosa, Pinus rigida, Pinus serotina, Pinus strobus, Pinus sylvestris, Pinus taeda, Pinus virginiana, Abies amabilis, Abies balsamea, Abies concolor, Abies grandis, Abies lasiocarpa, Abies magnifica, Abies procera, Chamaecyparis lawsoniona, Chamaecyparis nootkatensis, Chamaecyparis thyoides, Juniperus virginiana, Larix decidua, Larix laricina, Larix leptolepis, Larix occidentalis, Larix siberica, Libocedrus decurrens, Picea abies, Picea engelmanni, Picea glauca, Picea mariana, Picea pungens, Picea rubens, Picea sitchensis, Pseudotsuga menziesii, Sequoia gigantea, Sequoia sempervirens, Taxodium distichum, Tsuga canadensis, Tsuga heterophylla, Tsuga mertensiana, Thuja occidentalis, Thuja plicata, Eucalyptus alba, Eucalyptus bancroflii, Eucalyptus botryoides, Eucalyptus bridgesiana, Eucalyptus calophylla, Eucalyptus camaldulensis, Eucalyptus citriodora, Eucalyptus cladocalyx, Eucalyptus coccifera, Eucalyptus curtisii, Eucalyptus dalrympleana, Eucalyptus deglupta, Eucalyptus delagatensis, Eucalyptus diversicolor, Eucalyptus dunnii, Eucalyptus ficifolia, Eucalyptus globulus, Eucalyptus gomphocephala, Eucalyptus gunnii, Eucalyptus henryi, Eucalyptus laevopinea, Eucalyptus macarthurii, Eucalyptus macrorhyncha, Eucalyptus maculata, Eucalyptus marginata, Eucalyptus megacarpa, Eucalyptus melliodora, Eucalyptus nicholii, Eucalyptus nitens, Eucalyptus nova-angelica, Eucalyptus obliqua, Eucalyptus occidentalis, Eucalyptus obtusiflora, Eucalyptus oreades, Eucalyptus pauciflora, Eucalyptus polybractea, Eucalyptus regnans, Eucalyptus resinifera, Eucalyptus robusta, Eucalyptus rudis, Eucalyptus saligna, Eucalyptus sideroxylon, Eucalyptus stuartiana, Eucalyptus tereticornis, Eucalyptus torelliana, Eucalyptus urnigera, Eucalyptus urophylla, Eucalyptus viminalis, Eucalyptus viridis, Eucalyptus wandoo, and Eucalyptus youmanni.

As used herein, the term “plant” also is intended to include the fruit, seeds, flower, strobilus, etc. of the plant. A transformed plant of the current invention can be a direct transfectant, meaning that the DNA construct was introduced directly into the plant, such as through Agrobacterium , or the plant can be the progeny of a transfected plant. The second or subsequent generation plant can be produced by sexual reproduction, i.e., fertilization. Furthermore, the plant can be a gametophyte (haploid stage) or a sporophyte (diploid stage).

As used herein, the term “plant tissue” encompasses any portion of a plant, including plant cells. Plant cells include suspension cultures, callus, embryos, meristematic regions, callus tissue, leaves, roots, shoots, gametophytes, sporophytes, pollen, seeds and microspores. Plant tissues can be grown in liquid or solid culture, or in soil or suitable media in pots, greenhouses or fields. As used herein, “plant tissue” also refers to a clone of a plant, seed, progeny, or propagule, whether generated sexually or asexually, and descendents of any of these, such as cuttings or seeds.

In accordance with one aspect of the invention, a transgenic plant that has been transformed with a DNA construct of the invention has a phenotype that is different from a plant that has not been transformed with the DNA construct.

›DETAILED DESCRIPTION · 7 of 14

As used herein, “phenotype” refers to a distinguishing feature or characteristic of a plant which can be altered according to the present invention by integrating one or more DNA constructs of the invention into the genome of at least one plant cell of a plant. The DNA construct can confer a change in the phenotype of a transformed plant by modifying any one or more of a number of genetic, molecular, biochemical, physiological, morphological, or agronomic characteristics or properties of the transformed plant cell or plant as a whole.

In one embodiment, transformation of a plant with a DNA construct of the present invention can yield a phenotype including, but not limited to any one or more of increased drought tolerance, herbicide resistance, reduced or increased height, reduced or increased branching, enhanced cold and frost tolerance, improved vigor, enhanced color, enhanced health and nutritional characteristics, improved storage, enhanced yield, enhanced salt tolerance, enhanced resistance of the wood to decay, enhanced resistance to fingal diseases, altered attractiveness to insect pests, enhanced heavy met al tolerance, increased disease tolerance, increased insect tolerance, increased water-stress tolerance, enhanced sweetness, improved texture, decreased phosphate content, increased germination, increased micronutrient uptake, improved starch composition, improved flower longevity, production of novel resins, and production of novel proteins or peptides.

In another embodiment, the affected phenotype includes one or more of the following traits: propensity to form reaction wood, a reduced period of juvenility, an increased period of juvenility, self-abscising branches, accelerated reproductive development or delayed reproductive development, as compared to a plant of the same species that has not been transformed with the DNA construct.

In a further embodiment, the phenotype that is different in the transgenic plant includes one or more of the following: lignin quality, lignin structure, wood composition, wood appearance, wood density, wood strength, wood stiffness, cellulose polymerization, fiber dimensions, lumen size, other plant components, plant cell division, plant cell development, number of cells per unit area, cell size, cell shape, cell wall composition, rate of wood formation, aesthetic appearance of wood, formation of stem defects, average microfibril angle, width of the S2 cell wall layer, rate of growth, rate of root formation ratio of root to branch vegetative development, leaf area index, and leaf shape.

Phenotype can be assessed by any suitable means. The plants can be evaluated based on their general morphology. Transgenic plants can be observed with the naked eye, can be weighed and their height measured. The plant can be examined by isolating individual layers of plant tissue, namely phloem and cambium, which is further sectioned into meristematic cells, early expansion, late expansion, secondary wall formation, and late cell maturation. See, e.g., Hertzberg, supra. The plants also can be assessed using microscopic analysis or chemical analysis.

Microscopic analysis includes examining cell types, stage of development, and stain uptake by tissues and cells. Fiber morphology, such as fiber wall thickness and microfibril angle of wood pulp fibers can be observed using, for example, microscopic transmission ellipsometry. See Ye and Sundström, Tappi J., 80:181 (1997). Wood strength, density, and grain slope in wet wood and standing trees can be determined by measuring the visible and near infrared spectral data in conjunction with multivariate analysis. See, U.S. Patent Application Publication Nos. 2002/0107644 and 2002/0113212. Lumen size can be measured using scanning electron microscopy. Lignin structure and chemical properties can be observed using nuclear magnetic resonance spectroscopy as described in Marita et al., J. Chem. Soc., Perkin Trans. I 2939 (2001).

The biochemical characteristic of lignin, cellulose, carbohydrates and other plant extracts can be evaluated by any standard analytical method known including spectrophotometry, fluorescence spectroscopy, HPLC, mass spectroscopy, and tissue staining methods.

As used herein, “transformation” refers to a process by which a nucleic acid is inserted into the genome of a plant cell. Such insertion encompasses stable introduction into the plant cell and transmission to progeny. Transformation also refers to transient insertion of a nucleic acid, wherein the resulting transformant transiently expresses the nucleic acid. Transformation can occur under natural or artificial conditions using various methods well known in the art. Transformation can be achieved by any known method for the insertion of nucleic acid sequences into a prokaryotic or eukaryotic host cell, including Agrobacterium -mediated transformation protocols, viral infection, whiskers, electroporation, microinjection, polyethylene glycol-treatment, heat shock, lipofection, and particle bombardment. Transformation can also be accomplished using chloroplast transformation as described in e.g. Svab et al., Proc. Natl Acad. Sci. 87:8526-30 (1990).

In accordance with one embodiment of the invention, transformation in Eucalyptus is performed as described in U.S. Patent Application No. 60/476,222 (supra) which is incorporated herein by reference in its entirety. In accordance with another embodiment, transformation of Pinus is accomplished using the methods described in U.S. Patent Application Publication No. 2002/0100083.

Another aspect of the invention provides methods of obtaining wood and/or making wood pulp from a plant transformed with a DNA construct of the invention. Methods of producing a transgenic plant are provided above and are known in the art. A transformed plant can be cultured or grown under any suitable conditions. For example, pine can be cultured and grown as described in U.S. Patent Application Publication No. 2002/0100083 . Eucalyptus can be cultured and grown as in, for example, Rydelius, et al., G ROWING E UCALYPTUS FOR P ULP AND E NERGY , presented at the Mechanization in Short Rotation, Intensive Culture Forestry Conference, Mobile, Ala., 1994. Wood and wood pulp can be obtained from the plant by any means known in the art.

›DETAILED DESCRIPTION · 8 of 14

As noted above, the wood or wood pulp obtained in accordance with this invention may demonstrate improved characteristics including, but not limited to any one or more of lignin composition, lignin structure, wood composition, cellulose polymerization, fiber dimensions, ratio of fibers to other plant components, plant cell division, plant cell development, number of cells per unit area, cell size, cell shape, cell wall composition, rate of wood formation, aesthetic appearance of wood, formation of stem defects, rate of growth, rate of root formation ratio of root to branch vegetative development, leaf area index, and leaf shape include increased or decreased lignin content, increased accessibility of lignin to chemical treatments, improved reactivity of lignin, increased or decreased cellulose content increased dimensional stability, increased tensile strength, increased shear strength, increased compression strength, increased shock resistance, increased stiffness, increased or decreased hardness, decreased spirality, decreased shrinkage, and differences in weight, density, and specific gravity.

B. Expression Profiling of Cell Cycle Genes

The present invention also provides methods and tools for performing expression profiling of cell cycle genes. Expression profiling is useful in determining whether genes are transcribed or translated, comparing transcript levels for particular genes in different tissues, genotyping, estimating DNA copy number, determining identity of descent, measuring mRNA decay rates, identifying protein binding sites, determining subcellular localization of gene products, correlating gene expression to a phenotype or other phenomenon, and determining the effect on other genes of the manipulation of a particular gene. Expression profiling is particularly useful for identifying gene expression in complex, multigenic events. For this reason, expression profiling is useful in correlating gene expression to plant phenotype and formation of plant tissues and the interconnection thereof to the cell cycle.

Only a small fraction of the genes of a plant's genome are expressed at a given time in a given tissue sample, and all of the expressed genes may not affect the plant phenotype. To identify genes capable of affecting a phenotype of interest, the present invention provides methods and tools for determining, for example, a gene expression profile at a given point in the cell cycle, a gene expression profile at a given point in plant development, and a gene expression profile a given tissue sample. The invention also provides methods and tools for identifying cell cycle genes whose expression can be manipulated to alter plant phenotype or to alter the biological activity of cell cycle gene products. In support of these methods, the invention also provides methods and tools that distinguish expression of different genes of the same family.

As used herein, “gene expression” refers to the process of transcription of a DNA sequence into an RNA sequence, followed by translation of the RNA into a protein, which may or may not undergo post-translational processing. Thus, the relationship between cell cycle stage and/or developmental stage and gene expression can be observed by detecting, quantitatively or qualitatively, changes in the level of an RNA or a protein. As used herein, the term “biological activity” includes, but is not limited to, the activity of a protein gene product, including enzyme activity.

The present invention provides oligonucleotides that are useful in these expression profiling methods. Each oligonucleotide is capable of hybridizing under a given set of conditions to a cell cycle gene or gene product. In one aspect of the invention, a plurality of oligonucleotides is provided, wherein each oligonucleotide hybridizes under a given set of conditions to a different cell cycle gene product. Examples of oligonucleotides of the present invention include SEQ ID NOs: 521-772. Each of the oligos of SEQ ID NOs 521-772 hybridizes under standard conditions to a different gene product of one of SEQ ID NOs: 1-260. The oligonucleotides of the invention are useful in determining the expression of one or more cell cycle genes in any of the above-described methods.

1. Cell, Tissue, Nucleic Acid, and Protein Samples

Samples for use in methods of the present invention may be derived from plant tissue. Suitable plant tissues include, but are not limited to, somatic embryos, pollen, leaves, stems, calli, stolons, microtubers, shoots, xylem, male strolbili, pollen cones, vascular tissue, apical meristem, vascular cambium, xylem, root, flower, and seed.

According to the present invention “plant tissue” is used as described previously herein. Plant tissue can be obtained from any of the plants types or species described supra.

In accordance with one aspect of the invention, samples are obtained from plant tissue at different stages of the cell cycle, from plant tissue at different developmental stages, from plant tissue at various times of the year (e.g. spring versus summer), from plant tissues subject to different environmental conditions (e.g. variations in light and temperature) and/or from different types of plant tissue and cells. In accordance with one embodiment, plant tissue is obtained during various stages of maturity and during different seasons of the year. For example, plant tissue can be collected from stem dividing cells, differentiating xylem, early developing wood cells, differentiated spring wood cells, and differentiated summer wood cells. As another example, gene expression in a sample obtained from a plant with developing wood can be compared to gene expression in a sample obtained from a plant which does not have developing wood.

Differentiating xylem includes samples obtained from compression wood, side-wood, and normal vertical xylem. Methods of obtaining samples for expression profiling from pine and eucalyptus are known. See, e.g., Allona et al., Proc. Nat'l Acad. Sci. 95:9693-8 (1998) and Whetton et al., Plant Mol. Biol. 47:275-91, and Kirst et al., I NT'L U NION OF F ORESTRY R ESEARCH O RGANIZATIONS B IENNIAL C ONFERENCE , S6.8 (June 2003, Umea, Sweden).

›DETAILED DESCRIPTION · 9 of 14

In one embodiment of the invention, gene expression in one type of tissue is compared to gene expression in, a different type of tissue or to gene expression in the same type of tissue in a difference stage of development. Gene expression can also be compared in one type of tissue which is sampled at various times during the year (different seasons). For example, gene expression in juvenile secondary xylem can be compared to gene expression in mature secondary xylem. Similarly, gene expression in cambium can be compared to gene expression in xylem. Furthermore, gene expression in apical meristems can be compared to gene expression in cambium.

In an alternative embodiment, differences in gene expression are determined as cells from different tissues advance during the cell cycle. In this method, the cells from the different tissues are synchronized and their gene expression is profiled. Methods of synchronizing the stage of cell cycle in a sample are known. These methods include, e.g., cold acclimation, photoperiod, and aphidicoline. See, e.g., Nagata et al., Int. Rev. Cytol. 132:1-30 (1992), Breyne and Zabeau, Curr. Opin. Plant Biol. 4:136-42, 140 (2001). A sample is obtained during a specific stage of the cell cycle and gene expression in that sample is compared to a sample obtained during a different stage of the cell cycle. For example, tissue can be examined in any of the phases of the cell cycle, such as mitosis, G1, G1, S, and G2. In particular, one can examine the changes in gene expression at the G1, G2, and metaphase checkpoints.

In another embodiment of the invention, a sample is obtained from a plant having a specific phenotype and gene expression in that sample is compared to a sample obtained from a plant of the same species that does not have that phenotype. For example, a sample can be obtained from a plant exhibiting a fast rate of growth and gene expression can be compared with that of a sample obtained from a plant exhibiting a normal or slow rate of growth. Differentially expressed genes identified from such a comparison can be correlated with growth rate and, therefore, useful for manipulating growth rate.

In a further embodiment, a sample is obtained from clonally propagated plants. In one embodiment the clonally propagated plants are of the species Pinus or Eucalyptus . Individual ramets from the same genotype can be sacrificed at different times of year. Thus, for any genotype there can be at least two genetically identical trees sacrificed, early in the season and late in the season. Each of these trees can be divided into juvenile (top) to mature (bottom) samples. Further, tissue samples can be divided into, for example, phloem to xylem, in at least 5 layers of peeling. Each of these samples can be evaluated for phenotype and gene expression. See Entry 196.

Where cellular components may interfere with an analytical technique, such as a hybridization assay, enzyme assay, a ligand binding assay, or a biological activity assay, it may be desirable to isolate the gene products from such cellular components. Gene products, including nucleic acid and amino acid gene products, can be isolated from cell fragments or lysates by any method known in the art.

Nucleic acids used in accordance with the invention can be prepared by any available method or process, or by other processes as they become known in the art. Conventional techniques for isolating nucleic acids are detailed, for example, in Tijssen, L ABORATORY T ECHNIQUES IN B IOCHEMISTRY AND M OLECULAR B IOLOGY : H YBRIDIZATION W ITH N UCLEIC A CID P ROBES , chapter 3 (Elsevier Press, 1993), Berger and Kimmel, Methods Enzymol. 152:1 (1987), and G IBCO BRL & L IFE T ECHNOLOGIES T RIZOL RNA I SOLATION P ROTOCOL , Form No. 3786 (2000). Techniques for preparing nucleic acid samples, and sequencing polynucleotides from pine and eucalyptus are known. See, e.g., Allona et al., supra and Whetton et al., supra, and U.S. Application No. 60/476,222.

A suitable nucleic acid sample can contain any type of nucleic acid derived from the transcript of a cell cycle gene, i.e., RNA or a subsequence thereof or a nucleic acid for which an mRNA transcribed from a cell cycle gene served as a template. Suitable nucleic acids include cDNA reverse-transcribed from a transcript, RNA transcribed from that cDNA, DNA amplified from the cDNA, and RNA transcribed from the amplified DNA. Detection of such products or derived products is indicative of the presence and/or abundance of the transcript in the sample. Thus, suitable samples include, but are not limited to, transcripts of the gene or genes, cDNA reverse-transcribed from the transcript, cRNA transcribed from the cDNA, DNA amplified from the genes, and RNA transcribed from amplified DNA. As used herein, the category of “transcripts” includes but is not limited to pre-mRNA nascent transcripts, transcript processing intermediates, and mature mRNAs and degradation products thereof.

It is not necessary to monitor all types of transcripts to practice the invention. For example, the expression profiling methods of the invention can be conducted by detecting only one type of transcript, such as mature mRNA levels only.

In one aspect of the invention, a chromosomal DNA or cDNA library (comprising, for example, fluorescently labeled cDNA synthesized from total cell mRNA) is prepared for use in hybridization methods according to recognized methods in the art. See Sambrook et al., supra.

In another aspect of the invention, mRNA is amplified using, e.g., the MessageAmp kit (Ambion). In a further aspect, the mRNA is labeled with a detectable label. For example, mRNA can be labeled with a fluorescent chromophore, such as CyDye (Amersham Biosciences).

In some applications, it may be desirable to inhibit or destroy RNase that often is present in homogenates or lysates, before use in hybridization techniques. Methods of inhibiting or destroying nucleases are well known. In one embodiment of the invention, cells or tissues are homogenized in the presence of chaotropic agents to inhibit nuclease. In another embodiment, RNase is inhibited or destroyed by heat treatment, followed by proteinase treatment.

›DETAILED DESCRIPTION · 10 of 14

Protein samples can be obtained by any means known in the art. Protein samples useful in the methods of the invention include crude cell lysates and crude tissue homogenates. Alternatively, protein samples can be purified. Various methods of protein purification well known in the art can be found in Marshak et al., S TRATEGIES FOR P ROTEIN P URIFICATION AND C HARACTERIZATION : A L ABORATORY C OURSE M ANUAL (Cold Spring Harbor Laboratory Press 1996).

2. Detecting Level of Gene Expression

For methods of the invention that comprise detecting a level of gene expression, any method for observing gene expression can be used, without limitation. Such methods include traditional nucleic acid hybridization techniques, polymerase chain reaction (PCR) based methods, and protein determination. The invention includes detection methods that use solid support-based assay formats as well as those that use solution-based assay formats.

Absolute measurements of the expression levels need not be made, although they can be made. The invention includes methods comprising comparisons of differences in expression levels between samples. Comparison of expression levels can be done visually or manually, or can be automated and done by a machine, using for example optical detection means. Subrahmanyam et al., Blood. 97: 2457 (2001); Prashar et al., Methods Enzymol. 303: 258 (1999). Hardware and software for analyzing differential expression of genes are available, and can be used in practicing the present invention. See, e.g., GenStat Software and GeneExpress® GX Explorer™ Training Manual, supra; Baxevanis & Francis-Ouellette, supra.

In accordance with one embodiment of the invention, nucleic acid hybridization techniques are used to observe gene expression. Exemplary hybridization techniques include Northern blotting, Southern blotting, solution hybridization, and S1 nuclease protection assays.

Nucleic acid hybridization typically involves contacting an oligonucleotide probe and a sample comprising nucleic acids under conditions where the probe can form stable hybrid duplexes with its complementary nucleic acid through complementary base pairing. For example, see PCT application WO 99/32660; Berger & Kimmel, Methods Enzymol. 152: 1 (1987). The nucleic acids that do not form hybrid duplexes are then washed away leaving the hybridized nucleic acids to be detected, typically through detection of an attached detectable label. The detectable label can be present on the probe, or on the nucleic acid sample. In one embodiment, the nucleic acids of the sample are detectably labeled polynucleotides representing the mRNA transcripts present in a plant tissue (e.g., a cDNA library). Detectable labels are commonly radioactive or fluorescent labels, but any label capable of detection can be used. Labels can be incorporated by several approached described, for instance, in WO 99/32660, supra. In one aspect RNA can be amplified using the MessageAmp kit (Ambion) with the addition of aminoallyl-UTP as well as free UTP. The aminoallyl groups incorporated into the amplified RNA can be reacted with a fluorescent chromophore, such as CyDye (Amersham Biosciences)

Duplexes of nucleic acids are destabilized by increasing the temperature or decreasing the salt concentration of the buffer containing the nucleic acids. Under low stringency conditions (e.g., low temperature and/or high salt) hybrid duplexes (e.g., DNA:DNA, RNA:RNA or RNA:DNA) will form even where the annealed sequences are not perfectly complementary. Thus, specificity of hybridization is reduced at lower stringency. Conversely, at higher stringency (e.g., higher temperature and/or lower salt and/or in the presence of destabilizing reagents) hybridization tolerates fewer mismatches.

Typically, stringent conditions for short probes (e.g., 10 to 50 nucleotide bases) will be those in which the salt concentration is at least about 0.01 to 1.0 M at pH 7.0 to 8.3 and the temperature is at least about 30° C. Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide.

Under some circumstances, it can be desirable to perform hybridization at conditions of low stringency, e.g., 6×SSPE-T (0.9 M NaCl, 60 mM NaH 2 PO 4 , pH 7.6, 6 mM EDTA, 0.005% Triton) at 37° C, to ensure hybridization. Subsequent washes can then be performed at higher stringency (e.g., 1×SSPE-T at 37° C.) to eliminate mismatched hybrid duplexes. Successive washes can be performed at increasingly higher stringency (e.g., down to as low as 0.25×SSPE-T at 37° C. to 50° C.) until a desired level of hybridization specificity is obtained.

In general, standard conditions for hybridization is a compromise between stringency (hybridization specificity) and signal intensity. Thus, in one embodiment of the invention, the hybridized nucleic acids are washed at successively higher stringency conditions and read between each wash. Analysis of the data sets produced in this manner will reveal a wash stringency above which the hybridization pattern is not appreciably altered and which provides adequate signal for the particular oligonucleotide probes of interest. For example, the final wash may be selected as that of the highest stringency that produces consistent results and that provides a signal intensity greater than approximately 10% of the background intensity.

a. Oligonucleotide Probes

Oligonucleotide probes useful in nucleic acid hybridization techniques employed in the present invention are capable of binding to a nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing via hydrogen bond formation. A probe can include natural bases (i.e., A, G, U, C or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the nucleotide bases in the probes can be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization. Thus, probes can be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages.

›DETAILED DESCRIPTION · 11 of 14

Oligonucleotide probes can be prepared by any means known in the art. Probes useful in the present invention are capable of hybridizing to a nucleotide product of cell cycle genes, such as one of SEQ ID NOs: 1-260. Probes useful in the invention can be generated using the nucleotide sequences disclosed in SEQ ID NOs: 1-260. The invention includes oligonucleotide probes having at least a 2, 10,15, 20, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 100 nucleotide fragment of a corresponding contiguous sequence of any one of SEQ liD NOs: 1-260. The invention includes oligonucleotides of less than 2, 1, 0.5, 0.1, or 0.05 kb in length. In one embodiment, the oligonucleotide is 60 nucleotides in length.

Oligonucleotide probes can be designed by any means known in the art. See, e.g., Li and Stormo, Bioinformatics 17: 1067-76 (2001). Oligonucleotide probe design can be effected using software. Exemplary software includes ArrayDesigner, GeneScan, and ProbeSelect. Probes complementary to a defined nucleic acid sequence can be synthesized chemically, generated from longer nucleotides using restriction enzymes, or can be obtained using techniques such as polymerase chain reaction (PCR). PCR methods are well known and are described, for example, in Innis et al. eds., PCR P ROTOCOLS : A G UIDE TO M ETHODS AND A PPLICATIONS , Academic Press Inc. San Diego, Calif. (1990). The probes can be labeled, for example, with a radioactive, biotinylated, or fluorescent tag. Optimally, the nucleic acids in the sample are labeled and the probes are not labeled. Oligonucleotide probes generated by the above methods can be used in solution or solid support-based methods.

The invention includes oligonucleotide probes that hybridize to a product of the coding region or a 3′ untranslated region (3′ UTR) of a cell cycle gene. In one embodiment, the oligonucleotide probe hybridizes to the 3′ UTR of any one of SEQ ID NOs: 1-260. The 3′ UTR is generally a unique region of the gene, even among members of the same family. Therefore, the probes capable of hybridizing to a product of the 3′ UTR can be useful for differentiating the expression of individual genes within a family where the coding region of the genes likely are highly homologous. This allows for the design of oligonucleotide probes to be used as members of a plurality of oligonucleotides, each capable of uniquely binding to a single gene. In another embodiment, the oligonucleotide probe comprises any one of SEQ ID NOs: 521-772. In another embodiment, the oligonucleotide probe consists of any one of SEQ ID NOs: 521-772.

b. Oligonucleotide Array Methods

One embodiment of the invention employs two or more oligonucleotide probes in combination to detect a level of expression of one or more cell cycle genes, such as the genes of SEQ ID NOs: 1-260. In one aspect of this embodiment, the level of expression of two or more different genes is detected. The two or more genes may be from the same or different cell cycle gene families discussed above. Each of the two or more oligonucleotides may hybridize to a different one of the genes.

One embodiment of the invention employs two or more oligonucleotide probes, each of which specifically hybridize to a polynucleotide derived from the transcript of a gene provided by SEQ ID NOs: 1-260. Another embodiment employs two or more oligonucleotide probes, at least one of which comprises a nucleic acid sequence of SEQ ID NOs: 521-772. Another embodiment employs two or more oligonucleotide probes, at least one of which consists of SEQ ID NOs: 521-772.

The oligonucleotide probes may comprise from about 5 to about 60, or from about 5 to about 500, nucleotide bases, such as from about 60 to about 100 nucleotide bases, including from about 15 to about 60 nucleotide bases.

One embodiment of the invention uses solid support-based oligonucleotide hybridization methods to detect gene expression. Solid support-based methods suitable for practicing the present invention are widely known and are described, for example, in PCT application WO 95/11755; Huber et al., Anal. Biochem. 299: 24 (2001); Meiyanto et al., Biotechniques. 31: 406 (2001); Relogio et al., Nucleic Acids Res. 30:e51 (2002). Any solid surface to which oligonucleotides can be bound, covalently or non-covalently, can be used. Such solid supports include filters, polyvinyl chloride dishes, silicon or glass based chips, etc.

One embodiment uses oligonucleotide arrays, i.e. microarrays, which can be used to simultaneously observe the expression of a number of genes or gene products. Oligonucleotide arrays comprise two or more oligonucleotide probes provided on a solid support, wherein each probe occupies a unique location on the support. The location of each probe may be predetermined, such that detection of a detectable signal at a given location is indicative of hybridization to an oligonucleotide probe of a known identity. Each predetermined location can contain more than one molecule of a probe, but each molecule within the predetermined location has an identical sequence. Such predetermined locations are termed features. There can be, for example, from 2, 10, 100, 1,000, 2,000 or 5,000 or more of such features on a single solid support. In one embodiment, each oligonucleotide is located at a unique position on an array at least 2, at least 3, at least 4, at least 5, at least 6, or at least 10 times.

Oligonucleotide probe arrays for detecting gene expression can be made and used according to conventional techniques described, for example, in Lockhart et al., Nat'l Biotech. 14: 1675 (1996), McGall et al., Proc. Nat'l Acad Sci. USA 93: 13555 (1996), and Hughes et al., Nature Biotechnol. 19:342 (2001). A variety of oligonucleotide array designs is suitable for the practice of this invention.

In one embodiment the one or more oligonucleotides include a plurality of oligonucleotides that each hybridize to a different gene expressed in a particular tissue type. For example, the tissue can be developing wood.

›DETAILED DESCRIPTION · 12 of 14

In one embodiment, a nucleic acid sample obtained from a plant can be amplified and, optionally labeled with a detectable label. Any method of nucleic acid amplification and any detectable label suitable for such purpose can be used. For example, amplification reactions can be performed using, e.g. Ambion's MessageAmp, which creates “antisense” RNA or “aRNA” (complementary in nucleic acid sequence to the RNA extracted from the sample tissue). The RNA can optionally be labeled using CyDye fluorescent labels. During the amplification step, aaUTP is incorporated into the resulting aRNA. The CyDye fluorescent labels are coupled to the aaUTPs in a non-enzymatic reaction. Subsequent to the amplification and labeling steps, labeled amplified antisense RNAs are precipitated and washed with appropriate buffer, and then assayed for purity. For example, purity can be assay using a NanoDrop spectrophotometer. The nucleic acid sample is then contacted with an oligonucleotide array having, attached to a solid substrate (a “microarray slide”), oligonucleotide sample probes capable of hybridizing to nucleic acids of interest which may be present in the sample. The step of contacting is performed under conditions where hybridization can occur between the nucleic acids of interest and the oligonucleotide probes present on the array. The array is then washed to remove non-specifically bound nucleic acids and the signals from the labeled molecules that remain hybridized to oligonucleotide probes on the solid substrate are detected. The step of detection can be accomplished using any method appropriate to the type of label used. For example, the step of detecting can accomplished using a laser scanner and detector. For example, on can use and Axon scanner which optionally uses GenePix Pro software to analyze the position of the signal on the microarray slide.

Data from one or more microarray slides can analyzed by any appropriate method known in the art.

Oligonucleotide probes used in the methods of the present invention, including microarray techniques, can be generated using PCR. PCR primers used in generating the probes are chosen, for example, based on the sequences of SEQ ID NOs: 1-260, to result in amplification of unique fragments of the cell cycle genes (i.e., fragments that hybridize to only one polynucleotide of any one of SEQ ID NOs: 1-260 under standard hybridization conditions). Computer programs are useful in the design of primers with the required specificity and optimal hybridization properties. For example, Li and Stormo, supra at 1075, discuss a method of probe selection using ProbeSelect which selects an optimum oligonucleotide probe based on the entire gene sequence as well as other gene sequences to be probed at the same time.

In one embodiment, oligonucleotide control probes also are used. Exemplary control probes can fall into at least one of three categories referred to herein as (1) normalization controls, (2) expression level controls and (3) negative controls. In microarray methods, one or more of these control probes may be provided on the array with the inventive cell cycle gene-related oligonucleotides.

Normalization controls correct for dye biases, tissue biases, dust, slide irregularities, malformed slide spots, etc. Normalization controls are oligonucleotide or other nucleic acid probes that are complementary to labeled reference oligonucleotides or other nucleic acid sequences that are added to the nucleic acid sample to be screened. The signals obtained from the normalization controls, after hybridization, provide a control for variations in hybridization conditions, label intensity, reading efficiency and other factors that can cause the signal of a perfect hybridization to vary between arrays. In one embodiment, signals (e.g., fluorescence intensity or radioactivity) read from all other probes used in the method are divided by the signal from the control probes, thereby normalizing the measurements.

Virtually any probe can serve as a normalization control. Hybridization efficiency varies, however, with base composition and probe length. Preferred normalization probes are selected to reflect the average length of the other probes being used, but they also can be selected to cover a range of lengths. Further, the normalization control(s) can be selected to reflect the average base composition of the other probes being used. In one embodiment, only one or a few normalization probes are used, and they are selected such that they hybridize well (i.e., without forming secondary structures) and do not match any test probes. In one embodiment, the normalization controls are mammalian genes.

Expression level controls probes hybridize specifically with constitutively expressed genes present in the biological sample. Virtually any constitutively expressed gene provides a suitable target for expression level control probes. Typically, expression level control probes have sequences complementary to subsequences of constitutively expressed “housekeeping genes” including, but not limited to certain photosynthesis genes.

“Negative control” probes are not complementary to any of the test oligonucleotides (i.e., the inventive cell cycle gene-related oligonucleotides), normalization controls, or expression controls. In one embodiment, the negative control is a mammalian gene which is not complementary to any other sequence in the sample.

The terms “background” and “background signal intensity” refer to hybridization signals resulting from non-specific binding or other interactions between the labeled target nucleic acids (i.e., mRNA present in the biological sample) and components of the oligonucleotide array. Background signals also can be produced by intrinsic fluorescence of the array components themselves.

A single background signal can be calculated for the entire array, or a different background signal can be calculated for each target nucleic acid. In a one embodiment, background is calculated as the average hybridization signal intensity for the lowest 5 to 10 percent of the oligonucleotide probes being used, or, where a different background signal is calculated for each target gene, for the lowest 5 to 10 percent of the probes for each gene. Where the oligonucleotide probes corresponding to a particular cell cycle gene hybridize well and, hence, appear to bind specifically to a target sequence, they should not be used in a background signal calculation. Alternatively, background can be calculated as the average hybridization signal intensity produced by hybridization to probes that are not complementary to any sequence found in the sample (e.g., probes directed to nucleic acids of the opposite sense or to genes not found in the sample). In microarray methods, background can be calculated as the average signal intensity produced by regions of the array that lack any oligonucleotides probes at all.

›DETAILED DESCRIPTION · 13 of 14

c. PCR-Based Methods

In another embodiment, PCR-based methods are used to detect gene expression. These methods include reverse-transcriptase-mediated polymerase chain reaction (RT-PCR) including real-time and endpoint quantitative reverse-transcriptase-mediated polymerase chain reaction (Q-RTPCR). These methods are well known in the art. For example, methods of quantitative PCR can be carried out using kits and methods that are commercially available from, for example, Applied BioSystems and Stratagene®. See also Kochanowski, Q UANTITATIVE PCR P ROTOCOLS (Humana Press, 1999); Innis et al., supra.; Vandesompele et al., Genome Biol. 3: RESEARCH0034 (2002); Stein, Cell Mol. Life Sci. 59: 1235 (2002).

Gene expression can also be observed in solution using Q-RTPCR. Q-RTPCR relies on detection of a fluorescent signal produced proportionally during amplification of a PCR product. See Innis et al., supra. Like the traditional PCR method, this technique employs PCR oligonucleotide primers, typically 15-30 bases long, that hybridize to opposite strands and regions flanking the DNA region of interest. Additionally, a probe (e.g., TaqMan®, Applied Biosystems) is designed to hybridize to the target sequence between the forward and reverse primers traditionally used in the PCR technique. The probe is labeled at the 5′ end with a reporter fluorophore, such as 6-carboxyfluorescein (6-FAM) and a quencher fluorophore like 6-carboxy-tetramethyl-rhodamine (TAMRA). As long as the probe is intact, fluorescent energy transfer occurs which results in the absorbance of the fluorescence emission of the reporter fluorophore by the quenching fluorophore. As Taq polymerase extends the primer, however, the intrinsic 5′ to 3′ nuclease activity of Taq degrades the probe, releasing the reporter fluorophore. The increase in the fluorescence signal detected during the amplification cycle is proportional to the amount of product generated in each cycle.

The forward and reverse amplification primers and internal hybridization probe is designed to hybridize specifically and uniquely with one nucleotide derived from the transcript of a target gene. In one embodiment, the selection criteria for primer and probe sequences incorporates constraints regarding nucleotide content and size to accommodate TaqMan® requirements.

SYBR Green® can be used as a probe-less Q-RTPCR alternative to the Taqman®-type assay, discussed above. ABI P RISM® 7900 S EQUENCE D ETECTION S YSTEM U SER G UIDE A PPLIED B IOSYSTEMS , chap. 1-8, App. A-F. (2002).

A device measures changes in fluorescence emission intensity during PCR amplification. The measurement is done in “real time,” that is, as the amplification product accumulates in the reaction. Other methods can be used to measure changes in fluorescence resulting from probe digestion. For example, fluorescence polarization can distinguish between large and small molecules based on molecular tumbling (see U.S. Pat. No. 5,593,867).

d. Protein Detection Methods

Proteins can be observed by any means known in the art, including immunological methods, enzyme assays and protein array/proteomics techniques.

Measurement of the translational state can be performed according to several protein methods. For example, whole genome monitoring of protein—the “proteome”—can be carried out by constructing a microarray in which binding sites comprise immobilized, preferably monoclonal, antibodies specific to a plurality of proteins having an amino acid sequence of any of SEQ ID NOs: 261-520 or proteins encoded by the genes of SEQ ID NOs: 1-260 or conservative variants thereof. See Wildt et al., Nature Biotechnol. 18: 989 (2000). Methods for making polyclonal and monoclonal antibodies are well known, as described, for instance, in Harlow & Lane, A NTIBODIES : A L ABORATORY M ANUAL (Cold Spring Harbor Laboratory Press, 1988).

Alternatively, proteins can be separated by two-dimensional gel electrophoresis systems. Two-dimensional gel electrophoresis is well-known in the art and typically involves isoelectric focusing along a first dimension followed by SDS-PAGE electrophoresis along a second dimension. See, e.g., Hames et al, , G EL E LECTROPHORESIS OF P ROTEINS : A P RACTICAL A PPROACH (IRL Press, 1990). The resulting electropherograms can be analyzed by numerous techniques, including mass spectrometric techniques, western blotting and immunoblot analysis using polyclonal and monoclonal antibodies, and internal and N-terminal micro-sequencing.

3. Correlating Gene Expression to Phenotype and Tissue Development

As discussed above, the invention provides methods and tools to correlate gene expression to plant phenotype. Gene expression may be examined in a plant having a phenotype of interest and compared to a plant that does not have the phenotype or has a different phenotype. Such a phenotype includes, but is not limited to, increased drought tolerance, herbicide resistance, reduced or increased height, reduced or increased branching, enhanced cold and frost tolerance, improved vigor, enhanced color, enhanced health and nutritional characteristics, improved storage, enhanced yield, enhanced salt tolerance, enhanced resistance of the wood to decay, enhanced resistance to fungal diseases, altered attractiveness to insect pests, enhanced heavy met al tolerance, increased disease tolerance, increased insect tolerance, increased water-stress tolerance, enhanced sweetness, improved texture, decreased phosphate content, increased germination, increased micronutrient uptake, improved starch composition, improved flower longevity, production of novel resins, and production of novel proteins or peptides.

In another embodiment, the phenotype includes one or more of the following traits: propensity to form reaction wood, a reduced period of juvenility, an increased period of juvenility, self-abscising branches, accelerated reproductive development or delayed reproductive development.

In a further embodiment, the phenotype that is differs in the plants compares includes one or more of the following: lignin quality, lignin structure, wood composition, wood appearance, wood density, wood strength, wood stiffness, cellulose polymerization, fiber dimensions, lumen size, other plant components, plant cell division, plant cell development, number of cells per unit area, cell size, cell shape, cell wall composition, rate of wood formation, aesthetic appearance of wood, formation of stem defects, average microfibril angle, width of the S2 cell wall layer, rate of growth, rate of root formation ratio of root to branch vegetative development, leaf area index, and leaf shape.

›DETAILED DESCRIPTION · 14 of 14

Phenotype can be assessed by any suitable means as discussed above.

In a further embodiment, gene expression can be correlated to a given point in the cell cycle, a given point in plant development, and in a given tissue sample. Plant tissue can be examined at different stages of the cell cycle, from plant tissue at different developmental stages, from plant tissue at various times of the year (e.g. spring versus summer), from plant tissues subject to different environmental conditions (e.g. variations in light and temperature) and/or from different types of plant tissue and cells. In accordance with one embodiment, plant tissue is obtained during various stages of maturity and during different seasons of the year. For example, plant tissue can be collected from stem dividing cells, differentiating xylem, early developing wood cells, differentiated spring wood cells, differentiated summer wood cells.

It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.

The following examples are given to illustrate the present invention. It should be understood, however, that the invention is not to be limited to the specific conditions or details described in these examples. Throughout the specification, any and all references to a publicly available document, including a U.S. patent, are specifically incorporated by reference.

EXAMPLES
›Examples33
›Example 1

Example 1 illustrates a procedure for RNA extraction and purification, which is particularly useful for RNA obtained from conifer needle, xylem, cambium, and phloem.

Tissue is obtained from conifer needle, xylem, cambium or phloem. The tissue is frozen in liquid nitrogen and ground. The total RNA is extracted using Concert Plant RNA reagent (Invitrogen). The resulting RNA sample is extracted into phenol:chloroform and treated with DNase. The RNA is then incubated at 65° C. for 2 minutes followed by centrifugation at 4° C. for 30 minutes. Following centrifugation, the RNA is extracted into phenol at least 10 times to remove contaminants.

The RNA is further cleaned using RNeasy columns (Qiagen). The purified RNA is quantified using RiboGreen reagent (Molecular Probes) and purity assessed by gel electrophoresis.

RNA is then amplified using MessageAmp (Ambion). Aminoallyl-UTP and free UTP are added to the in vitro transcription of the purified RNA at a ratio of 4:1 aminoallyl-UTP-to-UTP. The aminoallyl-UTP is incorporated into the new RNA strand as it is transcribed. The amino-allyl group is then reacted with Cy dyes to attach the calorimetric label to the resulting amplified RNA using the Amersham procedure modified for use with RNA. Unincorporated dye is removed by ethanol precipitation. The labeled RNA is quantified spectrophotometrically (NanoDrop). The labeled RNA is fragmented by heating to 95° C. as described in Hughes et al., Nature Biotechnol. 19:342 (2001).

›Example 2

Example 2 illustrates how cell cycle genes important for wood development in Pinus radiata can be determined and how oligonucleotides which uniquely bind to those genes can be designed and synthesized for use on a microarray.

Pine trees of the species Pinus radiata are grown under natural light conditions. Tissue samples are prepared as described in, e.g., Sterky et al., Proc. Nat'l Acad. Sci. 95:13330 (1998). Specifically, tissue samples are collected from woody trees having a height of 5 meters. Tissue samples of the woody trees are prepared by taking tangential sections through the cambial region of the stem. The stems are sectioned horizontally into sections ranging from juvenile (top) to mature (bottom). The stem sections separated by stage of development are further separated into 5 layers by peeling into sections of phloem, differentiating phloem, cambium, differentiating xylem, developing xylem, and mature xylem. Tissue samples, including leaves, buds, shoots, and roots are also prepared from seedlings of the species Pinus radiata.

RNA is isolated and ESTs generated as described in Example 1 or Sterky et al., supra. The nucleic acid sequences of ESTs derived from samples containing developing wood are compared with nucleic acid sequences of genes known to be involved in the plant cell cycle. ESTs from samples that do not contain developing wood are also compared with sequences of genes known to be involved in the plant cell cycle. An in silico hybridization analysis is performed using BLAST (NCBI). Sequences from among the known cell cycle genes that show hybridization in silico to ESTs made from samples containing developing wood, but that do not hybridize to ESTs from samples not containing developing wood are selected for further examination.

cDNA clones containing sequences that hybridize to the genes showing wood-preferred expression are selected from cDNA libraries using techniques well known in the art of molecular biology. Using the sequence information, oligonucleotides are designed such that each oligonucleotide is specific for only one cDNA sequence in the library. The oligonucleotide sequences are provided in Table 14. 60-mer oligonucleotide probes are designed using the method of Li and Stormo, supra or using software such as ArrayDesigner, GeneScan, and ProbeSelect.

The oligonucleotides are then synthesized in situ described in Hughes et al., Nature Biotechnol. 19:324 (2002) or as described in Kane et al., Nucleic Acids Res. 28:4552 (2000) and affixed to an activated glass slide (Sigma-Genosis, The Woodlands, Tex.) using a 5′ amino linker. The position of each oligonucleotide on the slide is known.

›Example 3

Example 3 illustrates how cell cycle genes important for wood development in Eucalyptus grandis can be determined and how oligonucleotides which uniquely bind to those genes can be designed and synthesized for use on a microarray.

Eucalyptus trees of the species Eucalyptus grandis are grown under natural light conditions. Tissue samples are prepared as described in, e.g., Sterky et al., Proc. Nat'l Acad. Sci. 95:13330 (1998). Specifically, tissue samples are collected from woody trees having a height of 5 meters. Tissue samples of the woody trees are prepared by taking tangential sections through the cambial region of the stem. The stems are sectioned horizontally into sections ranging from juvenile (top) to mature (bottom). The stem sections separated by stage of development are further separated into 5 layers by peeling into sections of phloem, differentiating phloem, cambium, differentiating xylem, developing xylem, and mature xylem. Tissue samples, including leaves, buds, shoots, and roots are also prepared from seedlings of the species Pinus radiata.

RNA is isolated and ESTs generated as described in Example 1 or Sterky et al., supra. The nucleic acid sequences of ESTs derived from samples containing developing wood are compared with nucleic acid sequences of genes known to be involved in the plant cell cycle. ESTs from samples that do not contain developing wood are also compared with sequences of genes known to be involved in the plant cell cycle. An in silico hybridization analysis is performed as described in, for example, Audic and Claverie, Genome Res. 7:986 (1997). Sequences from among the known cell cycle genes that show hybridization in silico to ESTs made from samples containing developing wood, but do not hybridize to ESTs from samples not containing developing wood are selected for further examination.

cDNA clones containing sequences that hybridize to the genes showing wood-preferred expression are selected from cDNA libraries using techniques well known in the art of molecular biology. Using the sequence information, oligonucleotides are designed such that each oligonucleotide is specific for only one cDNA sequence in the library. The oligonucleotide sequences are provided in Table 14. 60-mer oligonucleotide probes are designed using the method of Li and Stormo, supra or using software such as ArrayDesigner, GeneScan, and ProbeSelect.

The oligonucleotides are then synthesized in situ described in Hughes et al., Nature Biotechnol. 19:324 (2002) or as described in Kane et al., Nucleic Acids Res. 28:4552 (2000) and affixed to an activated glass slide (Sigma-Genosus, The Woodlands, Tex.) using a 5′ amino linker. The position of each oligonucleotide on the slide is known.

›Example 4

Example 4 illustrates how to detect expression of Pinus radiata cell cycle genes which are important in wood formation using an oligonucleotide microarray prepared as in Example 2. This is an example of a balanced incomplete block designed experiment carried out using aRNA samples prepared from mature-phase phloem (P), cambium (C), expanding xylem found in a layer below the cambium (X1) and differentiating, lignifying xylem cells found deeper in the same growth ring (X2). In this example, cell cycle gene expression is compared among the four samples, namely P, C, X1, and X2.

In the summer, plants of the species Pinus radiata are felled and the bark of the main stem is immediately pulled gently away to reveal the phloem and xylem. The phloem and xylem are then peeled with a scalpel into separate containers of liquid nitrogen. Needles (leaves) and buds from the trees are also harvested with a scalpel into separate containers of liquid nitrogen. RNA is subsequently isolated from the frozen tissue samples as described in Example 1. Equal microgram quantities of total RNA are purified from each sample using RNeasy Mini columns (Qiagen, Valencia, Calif.) according to the manufacturer's instructions.

Amplification reactions are carried out for each of the P, C, X1, and X2 tissue samples. Amplification reactions are performed using Ambion's MessageAmp kit, a T7-based amplification procedure, following the manufacturer's instructions, except that labeled aaUTP is added to the reagent mix during in the amplification step. aaUTP is incorporated into the resulting antisense RNA formed during this step. CyDye fluorescent labels are coupled to the aaUTPs in a non-enzymatic reaction as described in Example 1. Labeled amplified antisense RNAs are precipitated and washed, and then assayed for purity using a NanoDrop spectrophotometer. These labeled antisense RNAs, corresponding to the RNA isolated from the P, C, X1, and X2 tissue samples, constitute the sample nucleic acids, which are referred to as the P, C, X1, and X2 samples.

Normalization control samples of known nucleic acids are added to each sample in a dilution series of 500, 200, 100, 50, 25 and 10 pg/μl for quantitation of the signals. Positive controls corresponding to specific genes showing expression in all tissues of pine, such as housekeeping genes, are also added to the plant sample.

Each of four microarray slides is incubated with 125 μL of a P, C, X1 or X2 sample under a coverslip at 42° C. for 16-18 hours. The arrays are washed in 1×SSC, 0.1% SDS for 10 minutes and then in 0.1×SSC, 0.1% SDS for 10 minutes and the allowed to dry.

The array slides are scanned using an Axon laser scanner and analyzed using GenePix Pro software. Data from the microarray slides are subjected to microarray data analysis using GenStat SAS or Spotfire software. Outliers are removed and ratiometric data for each of the datasets are normalized using a global normalization which employs a cubic spline fit applied to correct for differential dye bias and spatial effects. A second transformation is performed to fit control signal ratios to a mean log 2 =0 (i.e. 1:1 ratio). Normalized data are then subjected to a variance analysis.

Mean signal intensity for each signal at any given position on the microarray slide is determined for each of three of P, C, X1, and X2 sample microarray slides. This mean signal/probe position is compared to the signal at the same position on sample slide which was not used for calculating the mean. For example, a mean signal at a given position is determined for P, C, and X1 and the signal at that position in the X2 microarray slide is compared to the P, C, and X1 mean signal value.

Table 1 shows genes having greater than doubled signal with any one sample as compared to the mean signal of the other three samples.

The data shows that WD40 repeat protein A encodes a WD40 repeat protein is less highly expressed in cambium than in developing xylem, while WD40 repeat protein B encodes a WD40 repeat protein that is more highly expressed in phloem than in the other tissues.

Signal data are then verified with RT-PCR to confirm gene expression in the target tissue of the genes corresponding to the unique oligonucleotides in the probe.

›Example 5

Example 5 demonstrates how one can correlate cell cycle gene expression with agronomically important wood phenotypes such as density, stiffness, strength, distance between branches, and spiral grain.

Mature clonally propagated pine trees are selected from among the progeny of known parent trees for superior growth characteristics and resistance to important fungal diseases. The bark is removed from a tangential section and the trees are examined for average wood density in the fifth annual ring at breast height, stiffness and strength of the wood, and spiral grain. The trees are also characterized by their height, mean distance between major branches, crown size, and forking.

To obtain seedling families that are segregating for major genes that affect density, stiffness, strength, distance between branches, spiral grain and other characteristics that may be linked to any of the genes affecting these characteristics, trees lacking common parents are chosen for specific crosses on the criterion that they exhibit the widest variation from each other with respect to the density, stiffness, strength, distance between branches, and spiral grain criteria. Thus, pollen from a plus tree exhibiting high density, low mean distance between major branches, and high spiral grain is used to pollinate cones from the unrelated plus tree among the selections exhibiting the lowest density, highest mean distance between major branches, and lowest spiral grain. It is useful to note that “plus trees” are crossed such that pollen from a plus tree exhibiting high density are used to pollinate developing cones from another plus tree exhibiting high density, for example, and pollen from a tree exhibiting low mean distance between major branches would be used to pollinate developing cones from another plus tree exhibiting low mean distance between major branches.

Seeds are collected from these controlled pollinations and grown such that the parental identity is maintained for each seed and used for vegetative propagation such that each genotype is represented by multiple ramets. Vegetative propagation is accomplished using micropropagation, hedging, or fascicle cuttings. Some ramets of each genotype are stored while vegetative propagules of each genotype are grown to sufficient size for establishment of a field planting. The genotypes are arrayed in a replicated design and grown under field conditions where the daily temperature and rainfall are measured and recorded.

The trees are measured at various ages to determine the expression and segregation of density, stiffness, strength, distance between branches, spiral grain, and any other observable characteristics that may be linked to any of the genes affecting these characteristics. Samples are harvested for characterization of cellulose content, lignin content, cellulose microfibril angle, density, strength, stiffness, tracheid morphology, ring width, and the like. Samples are also examined for gene expression as described in Example 4. Ramets of each genotype are compared to ramets of the same genotype at different ages to establish age:age correlations for these characteristics.

›Example 6

Example 6 demonstrates how the stage of plant development and responses to environmental conditions such as light and season can be correlated to cell cycle gene expression using microarrays prepared as in Example 4. In particular, the changes in gene expression associated with wood density are examined.

Trees of three different clonally propagated Eucalyptus grandis hybrid genotypes are grown on a site with a weather station that measures daily temperatures and rainfall. During the spring and subsequent summer, genetically identical ramets of the three different genotypes are first photographed with north-south orientation marks, using photography at sufficient resolution to show bark characteristics of juvenile and mature portions of the plant, and then felled as in Example 4. The age of the trees is determined by planting records and confirmed by a count of the annual rings. In each of these trees, mature wood is defined as the outermost rings of the tree below breast height, and juvenile wood as the innermost rings of the tree above breast height. Each tree is accordingly sectored as follows:

NM—NORTHSIDE MATURE SM—SOUTHSIDE MATURE NT—NORTHSIDE TRANSITION ST—SOUTHSIDE TRANSITION NJ—NORTHSIDE JUVENILE SJ—SOUTHSIDE JUVENILE

Tissue is harvested from the plant trunk as well as from juvenile and mature form leaves. Samples are prepared simultaneously for phenotype analysis, including plant morphology and biochemical characteristics, and gene expression analysis. The height and diameter of the tree at the point from which each sector was taken is recorded, and a soil sample from the base of the tree is taken for chemical assay. Samples prepared for gene expression analysis are weighed and placed into liquid nitrogen for subsequent preparation of RNA samples for use in the microarray experiment. The tissues are denoted as follows:

P—phloem C—cambium X1—expanding xylem X2—differentiating and lignifying xylem

Thin slices in tangential and radial sections from each of the sectors of the trunk are fixed as described in Ruzin, Plant Microtechnique and Microscopy, Oxford University Press, Inc., New York, N.Y. (1999) for anatomical examination and confirmation of wood developmental stage. Microfibril angle is examined at the different developmental stages of the wood, for example juvenile, transition and mature phases of Eucalyptus grandis wood. Other characteristics examined are the ratio of fibers to vessel elements and ray tissue in each sector. Additionally, the samples are examined for characteristics that change between juvenile and mature wood and between spring wood and summer wood, such as fiber morphology, lumen size, and width of the S2 (thickest) cell wall layer. Samples are further examined for measurements of density in the fifth ring and determination of modulus of elasticity using techniques well known to those skilled in the art of wood assays. See, e.g., Wang, et al., Non - destructive Evaluations of Trees , E XPERIMENTAL T ECHNIQUES , pp. 28-30 (2000).

For biochemical analysis, 50 grams from each of the harvest samples are freeze-dried and analyzed, using biochemical assays well known to those skilled in the art of plant biochemistry for quantities of simple sugars, amino acids, lipids, other extractives, lignin, and cellulose. See, e.g., Pettersen & Schwandt, J. Wood Chem . & Technol. 11:495 (1991).

In the present example, the phenotypes chosen for comparison are high density wood, average density wood, and low density wood. Nucleic acid samples are prepared as described in Example 3, from trees harvested in the spring and summer. Gene expression profiling by hybridization and data analysis is performed as described in Examples 3 and 4.

Using similar techniques and clonally propagated individuals one can examine cell cycle gene expression as it is related to other complex wood characteristics such as strength, stiffness and spirality.

›Example 7

Example 7 demonstrates the ability of the oligonucleotide probes of the invention to distinguish between highly homologous members of a family of cell cycle genes. Hybridization to a particular oligonucleotide on the array identifies a unique WD40 gene that is expressed more strongly in a genotype having a higher density wood than in observed in other genotypes examined. The WD40 gene is also expressed more strongly in mature wood than in juvenile wood and more strongly in summer wood than in spring wood. This gene is not found to be expressed at high levels either in leaves or buds.

The gene expression pattern is confirmed by RT-PCR. This gene, the putative “density-related” gene, is used for in situ hybridization of fixed radial sections. The density-related WD40 gene hybridizes most strongly to the vascular cambium in regions of the stem where the xylem is comprised primarily of fibers with few vessel elements and few xylem ray cells.

These results suggest that the WD40 gene product functions in radial cell division, which occurs in the cambium and results in diameter growth, rather than in axial cell division such as may be important in the apex or leaves. Such a gene would be difficult to identify by cDNA microarrays or other traditional hybridization means because the highly conserved regions present in the gene would result in confusing it with genes encoding enzymes having similar catalytic functions, but acting in axial or radial divisions. Furthermore, from the sequence similarity-based annotation suggesting a function of this gene product in cell division and the observation of this microarray hybridization pattern, confirmed by RT-PCR and in silico hybridization, this gene product functions specifically in developing secondary xylem to guide the cell division patterns of fibers, such that higher expression of this gene results in greater fiber production relative to vessel element or ray production. The fiber content is correlated with a principal components analysis (PCA) variable that accounts for at least 10% of the variation in basic density.

›Example 8

Example 8 demonstrates how the use of oligonucleotide probes of the invention can be used to identify one wood “density related” WD40 repeat protein gene and its promoter from among the family of homologous genes. Further, this example demonstrates how a promoter sequence identified using this method is used to transform other hardwood species to result in increased diameter growth rates as compared to wild-type plants of the same species.

The sequence of the WD40 gene is used to probe a Genome Walker library in order to isolate 5′ flanking sequences comprising a promoter region. The promoter region is then operably linked to a beta-glucuronidase reporter gene and cloned into a binary vector for transformation into Eucalyptus using the method described in U.S. Application Ser. No. 60/476,222. Regenerated transgenic tobacco and Eucalyptus plants are then sectioned and stained using X-gluc, demonstrating that the microarray data results in isolation of a promoter capable of highly cambial-specific expression solely in those portions of the stem that develop more fibers than vessel elements or xylem rays.

Using techniques well known to those skilled in the art of molecular biology, the promoter is then operably linked to a cell division promoting gene and this construct placed in a binary vector for transformation into hardwood plants such as Sweetgum and Populus, such that the cell division promoting gene is expressed more strongly than normally in the vascular cambium. This results in increased diameter growth rate in the transgenic hardwood plants relative to control hardwood plants.

›Example 9

Example 9 demonstrates how a density related polypeptide can be linked to a tissue-preferred promoter and expressed in pine resulting in a plant with increased wood density.

A density-related polypeptide, which is more highly expressed during the early spring, is identified by the method described in Example 7. A DNA construct having the density-related polypeptide operably linked to a promoter is placed into an appropriate binary vector and transformed into pine using the method of Connett et al. U.S. patent application Ser. Nos. 09/973,088 and 09/973,089). Pine plants are transformed as described in Connett et al., supra, and the transgenic pine plants are used to establish a forest planting. Increased density even in the spring wood (early wood) is observed in the transgenic pine plants relative to control pine plants which are not transformed with the density related DNA construct.

›Example 10

Using techniques well known to those skilled in the art of molecular biology, the sequence of the putative density-related gene isolated in Example 7 is analyzed in genomic DNA isolated from alfalfa. This enables the identification of an orthologue in alfalfa whose sequence is then used to create an RNAi knockout construct. This construct is then transformed into alfalfa. See, e.g., Austin et al., Euphytica 85, 381 1995. The regenerated transgenic plants show lower fiber content and increased ray cells content in the xylem. Such properties improved digestability which results in higher growth rates in cattle fed on this alfalfa as compared to wild-type alfalfa of the same species.

›Example 11

Example 11 demonstrates how gene expression analysis can be used to find gene variants which are present in mature plants having a desirable phenotype. The presence or absence of such a variant can be used to predict the phenotype of a mature plant, allowing screening of the plants at the seedling stage. Although this example employs eucalyptus, the method used herein is also useful in breeding programs for pine and other tree species.

The sequence of a putative density-related gene is used to probe genomic DNA isolated from Eucalyptus that vary in density as described in previous examples. Non-transgenically produced Eucalyptus hybrids of different wood phenotypes are examined. One hybrid exhibits high wood density and another hybrid exhibits lower wood density. A molecular marker in the 3′ portion of the coding region is found which distinguishes a high-density gene variant from a lower density gene variant.

This molecular marker enables tree breeders to assay non-transgenic Eucalyptus hybrids for likely density profiles while the trees are still at seedling stage, whereas in the absence of the marker, tree breeders must wait until the trees have grown for multiple years before density at harvest age can be reliably predicted. This enables selective outplanting of the best trees at seedling stage rather than an expensive culling operation and resultant erosion at thinning age. This molecular marker is further useful in the breeding program to determine which parents will give rise to high density outcross progeny.

Molecular markers found in the 3′ portion of the coding region of the gene that do not correspond to variants seen more frequently in higher or lower wood density non-transgenic Eucalyptus hybrid trees are also useful. These markers are found to be useful for fingerprinting different genotypes of Eucalyptus , for use in identity-tracking in the breeding program and in plantations.

›Example 12

This Example describes microarrays for identifying gene expression differences that contribute to the phenotypic characteristics that are important in commercial wood, namely wood appearance, stiffness, strength, density, fiber dimensions, coarseness, cellulose and lignin content, extractives content and the like.

As in Examples 2-4, woody trees of genera that produce commercially important wood products, in this case Pinus and Eucalyptus , are felled from various sites and at various times of year for the collection and isolation of RNA from developing xylem, cambium, phloem, leaves, buds, roots, and other tissues. RNA is also isolated from seedlings of the same genera.

All contigs are compared to both the ESTs made from RNA isolated from samples containing developing wood and the sequences of the ESTs made from RNA of various tissues that do not contain developing wood. Contigs containing primarily ESTs that show more hybridization in silico to ESTs made from RNA isolated from samples containing developing wood than to ESTs made from RNA isolated from samples not containing developing wood are determined to correspond to possible novel genes particularly expressed in developing wood. These contigs are then used for BLAST searches against public domain sequences. Those contigs that hybridize with high stringency to no known genes or genes annotated as having only a “hypothetical protein” are selected for the next step. These contigs are considered putative novel genes showing wood-preferred expression.

The longest cDNA clones containing sequences hybridizing to the putative novel genes showing wood-preferred expression are selected from cDNA libraries using techniques well known to those skilled in the art of molecular biology. The cDNAs are sequenced and full-length gene-coding sequences together with untranslated flanking sequences are obtained where possible. Stretches of 45-80 nucleotides (or oligonucleotides) are selected from each of the sequences of putative novel genes showing wood-preferred expression such that each oligonucleotide probe hybridizes at high stringency to only one sequence represented in the ESTs made from RNA isolated from trees or seedlings of the same genus.

Oligomers are then chemically synthesized and placed onto a microarray slide as described in Example 3. Each oligomer corresponds to a particular sequence of a putative novel gene showing wood-preferred expression and to no other gene whose sequence is represented among the ESTs made from RNA isolated from trees or seedlings of the same genus.

Sample preparation and hybridization are carried out as in Example 4. The technique used in this example is more effective than use of a microarray using cDNA probes because the presence of a signal represents significant evidence of the expression of a particular gene, rather than of any of a number of genes that may contain similarities to the cDNA due to conserved functional domains or common evolutionary history. Thus, it is possible to differentiate homologous genes, such as those in the same family, but which may have different functions in phenotype determination.

Thus hybridization data, gained using the method of Example 4, enable the user to identify which of the putative novel genes actually has a pattern of coordinate expression with known genes, a pattern of expression consistent with a particular developmental role, and/or a pattern of expression that suggests that the gene has a promoter that drives expression in a valuable way.

The hybridization data thus using this method can be used, for example, to identify a putative novel gene that shows an expression pattern particular to the tracheids with the lowest cellulose microfibril angle in developing spring wood (early wood). The promoter of this gene can also be isolated as in Example 8, and operably linked to a gene that has been shown as in Example 9 to be associated with late wood (summer wood). Transgenic pine plants containing this construct are generated using the methods of Example 9, and the early wood of these plants is then shown to display several characteristics of late wood, such as higher microfibril angle, higher density, smaller average lumen size, etc.

›Example 13

Example 13 demonstrates the use of a cambium-specific promoter functionally linked to a cell cycle gene for increased plant biomass.

Cambium-specific cell cycle transcripts are identified via array analyses of different secondary vasculature layers as described in Example 4. Candidate promoters linked to the genes corresponding to these transcripts are cloned from pine genomic DNA using, e.g., the BD Clontech GenomeWalker kit and tested in transgenic tobacco via a reporter assay(s) for cambium specificity/preference. The cambium-specific promoter overexpressing a cell cycle gene involved in secondary xylem cell division is used to increased wood biomass. A tandem cambium-specific promoter is constructed driving the cell cycle ORF. Boosted transcript levels of the candidate cell cycle gene result in an increased xylem biomass phenotype.

›Example 14

Isolation and Characterization of cDNA Clones from Eucalyptus grandis

Eucalyptus grandis cDNA expression libraries were prepared from mature shoot buds, early wood phloem, floral tissue, leaf tissue (two independent libraries), feeder roots, structural roots, xylem or early wood xylem and were constructed and screened as follows.

Total RNA was extracted from the plant tissue using the protocol of Chang et al. ( Plant Molecular Biology Reporter 11:113-116 (1993). mRNA was isolated from the total RNA preparation using either a Poly(A) Quik mRNA Isolation Kit (Stratagene, La Jolla, Calif.) or Dynal Beads Oligo (dT) 25 (Dynal, Skogen, Norway). A cDNA expression library was constructed from the purified mRNA by reverse transcriptase synthesis followed by insertion of the resulting cDNA clones in Lambda ZAP using a ZAP Express cDNA Synthesis Kit (Stratagene), according to the manufacturer's protocol. The resulting cDNAs were packaged using a Gigapack II Packaging Extract (Stratagene) using an aliquot (1-5 αl) from the 5 μl ligation reaction dependent upon the library. Mass excision of the library was done using XL1-Blue MRF′ cells and XLOLR cells (Stratagene) with ExAssist helper phage (Stratagene). The excised phagemids were diluted with NZY broth (Gibco BRL, Gaithersburg, Md.) and plated out onto LB-kanamycin agar plates containing X-gal and isopropylthio-beta-galactoside (IPTG).

Of the colonies plated and selected for DNA miniprep, 99% contained an insert suitable for sequencing. Positive colonies were cultured in NZY broth with kanamycin and cDNA was purified by means of alkaline lysis and polyethylene glycol (PEG) precipitation. Agarose gel at 1% was used to screen sequencing templates for chromosomal contamination. Dye primer sequences were prepared using a Turbo Catalyst 800 machine (Perkin Elmer/Applied Biosystems Division, Foster City, Calif.) according to the manufacturer's protocol.

DNA sequence for positive clones was obtained using a Perkin Elmer/Applied Biosystems Division Prism 377 sequencer. cDNA clones were sequenced first from the 5′ end and, in some cases, also from the 3′ end. For some clones, internal sequence was obtained using either Exonuclease III deletion analysis, yielding a library of differentially sized subdlones in pBK-CMV, or by direct sequencing using gene-specific primers designed to identified regions of the gene of interest.

The determined cDNA sequences were compared with known sequences in the EMBL database using the computer algorithms FASTA and/or BLASTN. Multiple alignments of redundant sequences were used to build reliable consensus sequences. Based on similarity to known sequences from other plant species, the isolated polynucleotide sequences were identified as encoding transcription factors, as detailed herein. The predicted polypeptide sequences corresponding to the polynucleotide sequences are also depicted therein.

›Example 15

Isolation and Characterization of cDNA Clones from Pinus radiata

Pinus radiata cDNA expression libraries (prepared from either shoot bud tissue, suspension cultured cells, early wood phloem (two independent libraries), fascicle meristem tissue, male strobilus, root (unknown lineage), feeder roots, structural roots, female strobilus, cone primordia, female receptive cones and xylem (two independent libraries) were constructed and screened as described above in Example 14.

DNA sequence for positive clones was obtained using forward and reverse primers on a Perkin Elmer/Applied Biosystems Division Prism 377 sequencer and the determined sequences were compared to known sequences in the database as described above.

Based on similarity to known sequences from other plant species, the isolated polynucleotide sequences were identified as encoding transcription factors, as detailed herein. The predicted polypeptide sequences corresponding to the polynucleotide sequences are also depicted therein.

›Example 16

5′ RACE Isolation

To identify additional sequence 5′ or 3′ of a partial cDNA sequence in a cDNA library, 5′ and 3′ rapid amplification of cDNA ends (RACE) was performed. using the SMART RACE cDNA amplification kit (Clontech Laboratories, Palo Alto, Calif.). Generally, the method entailed first isolating poly(A) mRNA, performing first and second strand cDNA synthesis to generate double stranded cDNA, blunting cDNA ends, and then ligating of the SMART RACE. Adaptor to the cDNA to form a library of adaptor-ligated ds cDNA. Gene-specific primers were designed to be used along with adaptor specific primers for both 5′ and 3′ RACE reactions. Using 5′ and 3′ RACE reactions, 5′ and 3′ RACE fragments were obtained, sequenced, and cloned. The process may be repeated until 5′ and 3′ ends of the full-length gene were identified. A full-length cDNA may generated by PCR using primers specific to 5′ and 3′ ends of the gene by end-to-end PCR.

For example, to amplify the missing 5′ region of a gene from first-strand cDNA, a primer was designed 5′→ 3 ′ from the opposite strand of the template sequence, and from the region between ˜100-200 bp of the template sequence. A successful amplification should give an overlap of ˜100 bp of DNA sequence between the 5′ end of the template and PCR product.

RNA was extracted from four pine tissues, namely seedling, xylem, phloem and structural root using the Concert Reagent Protocol (Invitrogen, Carlsbad, Calif.) and standard isolation and extraction procedures. The resulting RNA was then treated with DNase, using 10 U/ul DNase I (Roche Diagnostics, Basel, Switzerland). For 100 μg of RNA, 9 μl 10×DNase buffer (Invitrogen, Carlsbad, Calif.), 10 μl of Roche DNase I and 90 μl of Rnase-free water was used. The RNA was then incubated at room temperature for 15 minutes and 1/10 volume 25 mM EDTA is added. A RNeasy mini kit (Qiagen, Venlo, The Netherlands) was used for RNA clean up according to manufacturer's protocol.

To synthesize cDNA, the extracted RNA from xylem, phloem, seedling and root was used and the SMART RACE cDNA amplification kit (Clontech Laboratories Inc, Palo Alto, Calif.) was followed according to manufacturer's protocol. For the RACE PCR, the cDNA from the four tissue types was combined. The master mix for PCR was created by combining equal volumes of cDNA from xylem, phloem, root and seedling tissues. PCR reactions were performed in 96 well PCR plates, with 1 μl of primer from primer dilution plate (10 mM) to corresponding well positions. 49 μl of master mix is aliquoted into the PCR plate with primers. Thermal cycling commenced on a GeneAmp 9700 (Applied Biosystems, Foster City, Calif.) at the following parameters:

94° C. (5 sec), 72° C. (3 min), 5 cycles; 94° C. (5 sec), 70° C. (10 sec), 72° C. (3 min), 5 cycles; 94° C. (5 sec), 68° C. (10 sec), 72° C. (3min), 25 cycles.

cDNA was separated on an agarose gel following standard procedures. Gel fragments were excised and eluted from the gel by using the Qiagen 96-well Gel Elution kit, following the manufacturer's instructions.

PCR products were ligated into pGEMTeasy (Promega, Madison, Wis.) in a 96 well plate overnight according to the following specifications: 60-80 ng of DNA, 5 μl 2× rapid ligation buffer, 0.5 μl pGEMT easy vector, 0.1 μl DNA ligase, filled to 10 μl with water, and incubated overnight.

Each clone was transformed into E.coli following standard procedures and DNA was extracted from 12 clones picked by following standard protocols. DNA extraction and the DNA quality was verified on an 1% agarose gel. The presence of the correct size insert in each of the clones was determined by restriction digests, using the restriction endonuclease EcoRI, and gel electrophoresis, following standard laboratory procedures.

›Example 17

Curation of an EST Sequence.

During the production of cDNA libraries, the original transcripts or their DNA counterparts may have features that prevent them from coding for fimctional proteins. There may be insertions, deletions, base substitutions, or unspliced or improperly spliced introns. If such features exist, it is often possible to identify them so that they can be changed. Similar curation can be performed on any other sequences that have homology to sequences in the public databases.

After determination of the DNA sequence, BLAST analysis shows that it is related to an Arabidopsis gene on the publicly available Arabidopsis genome sequence). However, instead of coding for an approximately 240 amino acid polypeptide, the consensus being curated is predicted to code for a product of only 157 amino acid residues, suggesting an error in the DNA sequence. To identify where the genuine coding region might be, the DNA sequence to the end of each EST is translated in each of the three reading frames and the predicted sequences are aligned with the Arabidopsis gene's amino acid sequence. It is found that the DNA segment in one portion of the EST codes for a sequence with similarity to the carboxyl terminus of the Arabidopsis gene. Therefore, it appears that an unspliced intron is present in the EST.

Unspliced introns are a relatively minor issue with regard to use of a cloned sequence for overexpression of the gene of interest. The RNA resulting from transcription of the cDNA can be expected to undergo normal processing to remove the intron. Antisense and RNAi constructs are also expected to function to suppress the gene of interest. On other occasions, it may be desirable to identify the precise limits of the intron so that it can be removed. When the sequence in question has a published sequence that is highly similar, it may be possible to find the intron by aligning the two sequences and identifying the locations where the sequence identity falls off, aided by the knowledge that introns start with the sequence GT and end with the sequence AG.

When there is some doubt about the site of the intron because highly similar sequences are not available, the intron location can be verified experimentally. For example, DNA oligomers can be synthesized flanking the region where the suspected intron is located. RNA from the source species, either Pinus or Eucalyptus , is isolated and used as a template to make cDNA using reverse transcriptase. The selected primers are then used in a PCR reaction to amplify the correctly spliced DNA segment (predicted size of approximately 350 bp smaller than the corresponding segment of the original consensus) from the population of cDNAs. The amplified segment is then subjected to sequence analysis and compared to the consensus sequence to identify the differences.

The same procedure can be used when an alternate splicing event (partial intron remaining, or partial loss of an exon) is suspected. When an EST has a small change, such as insertion or deletion of a small number of bases, computer analysis of the EST sequence can still indicate its location when a translation product of the wrong size is predicted or if there is an obvious frameshift. Verification of the true sequence is done by synthesis of primers, production of new cDNA, and PCR amplification as described above.

›Example 18

Transformation of Populus deltoides with constructs containing cell cycle genes.

Constructs made as described in the preceding example and shown in Table 2 below were each inoculated into Agrobacterium cultures by standard techniques.

Table 2 identifes plasmid(s), genes, and Genesis ID numbers for constructions described in Example 17.

Populus deltoides stock plant cultures were maintained on DKW medium (Driver and Kuniyuki, 1984, McGranahan et al. 1987, available commercially from Sigma/Aldrich) with 2.5 uM zeatin in a growth room with a 16 h photoperiod. For transformation, petioles were excised aseptically using a sharp scalpel blade from the stock plants, cut into 4-6 mm lengths, placed on DKW medium with 1 ug/ml BAP and 1 ug/ml NAA immediately after harvest, and incubated in a dark growth chamber (28 degrees) for 24 hours.

Agrobacterium cultures containing the desired constructs were grown to log phase, indicated by an OD600 between 0.8-1.0 A, then pelleted and resuspended in an equal volume of Agrobacterium Induction Medium (AIM), which contains Woody Plant Medium salts (Lloyd, G., and McCown, B., 1981. Woody plant medium. Proc. Intern. Plant Prop. Soc. 30:421, available commercially from Sigma/Aldrich), 5 g/L glucose and 0.6 g/L MES at pH 5.8, with the addition of 1 ul of a 100 mM stock solution of acetosyringone per ml of AIM. The pellet was resuspended by vortexing. The bacterial cells were incubated for an hour in this medium at 28 degrees C. in an environmental chamber, shaking at 100 rpm.

After the induction period, Populus deltoides explants were exposed to the Agrobacterium mixture for 15 minutes. The explants were then lightly blotted on sterile paper towels, replaced onto the same plant medium and cultured in the dark at 18-20 degrees C. After a three-day co-cultivation period, the explants were transferred to DKW medium in which the NAA concentration was reduced to 0.1 ug/ml and to which was added 400 mg/L timentin to eradicate the Agrobacterium.

After 4 days on eradication medium, explants were transferred to small magenta boxes containing the same medium supplemented with timentin (400 mg/L) as well as the selection agent geneticin (50 mg/L). Explants were transferred every two weeks to fresh selection medium. Calli that grow in the presence of selection were isolated and sub-cultured to fresh selection medium every three weeks. Calli were observed for the production of adventitious shoots.

Adventitious shoots were normally observed within two months from the initiation of transformation. These shoot clusters were transferred to DKW medium to which no NAA was added, and in which the BAP concentration was reduced to 0.5 ug.ml, for shoot elongation, typically for about 14 weeks. Elongated shoots were excised and transferred to BTM medium (Chalupa, Communicationes Instituti Forestalis Checosloveniae 13:7-39, 1983, available commercially from Sigma/Aldrich) at pH5.8, containing 20 g/l sucrose and 5 g/l activated charcoal. See Table 3 below.

After development of roots, typically four weeks, transgenic plants were propagated in the greenhouse by rooted cutting methods, or in vitro through axillary shoot induction for four weeks on DKW medium containing 11.4 uM zeatin, after which the multiplied shoots were separated and transferred to root induction medium. Rooted plants were transferred to soil for evaluation of growth in glasshouse and field conditions.

›Example 19

Production of disproportionately large leaves mediated by ectopic expression of certain cyclin D genes

Approximately 100 explants of Populus deltoides per construct were transformed with pGRW16 and pGRW19, which contain genes that are normally show preferred expression in the vasculature, driven by a constitutive promoter (the Pinus radiata superubiquitin promoter). Upon regeneration, many of the ramets of many of the translines were observed to have disproportionately large leaves relative to control plants. The leaves were both longer and broader than those of control plants.

Disproportionately large leaves could be a very useful early indicator of growth potential. large leaf size and thus high growth potential. Lage leaf size can be a function of either increased numbers of leaf cells or increased leaf cell size or both.

›Example 20

Production of unusual vascular development mediated by ectopic expression of a cyclin D gene.

Approximately 100 explants of Populus deltoides per construct were transformed with pGRW18. Multiple transgenic lines regenerated from this experiment showed a very unique pleiotropic phenotype. Leaves of these transgenic lines symmetrically folded on both sides of the midrib down the entire length of the leaf. Many petioles of these lines spiraled, and in many cases turned 360 degrees, in a right-handed fashion towards the leaf. The stem showed some thickening and slight bending near the middle.

One ramet of the transgenic line TDL002534 showing these phenotypes was sacrificed to investigate these aberrancies at the tissue level. Transverse sections of a curling petiole stained with toluidine blue revealed retardation of vascular development, but the presence of additional vascular cylinders developing as indicated by the black arrows. The xylem and phloem within the vascular cylinders of the curling petiole appeared to be developmentally similar and spatially oriented correctly. Longitudinal sections of straight and curled petioles may offer an explanation for the spiraling phenomenon. Curled petioles showed more elongated cells on the outside turn of the curl and more compressed cells on the opposite side of the petiole.

Perhaps the most striking phenotype was identified in the leaves. As with the petioles, aberrant vascular development was noted, comprising additional forming vascular cylinders lateral to the larger midrib. In some sections almost fully-formed veins could be seen immediately adjacent to the midrib. In all instances where the folding phenotype was noted, this type of leaf configuration was associated with the phenotype.

The development of additional vascular cylinders in the space where normally a small number of vascular bundles or a single midrib are seen is indicative of unusual cell division activity at the level of early vascular development. Thus, this gene expressed under the control of a vascular-preferred promoter rather than a constitutive promoter could have utility in increasing cell division in later vascular development, creating additional wood.

›Example 21

This example illustrates how polynucleotides important for wood development in P. radiata can be determined and how oligonucleotides which uniquely bind to those genes can be designed and synthesized for use on a microarray.

Open pollinated trees of approximately 16 years of age are selected from plantation-grown sites, in the United States for loblolly pine, and in New Zealand for radiata pine. Trees are felled during the spring and summer seasons to compare the expression of genes associated with these different developmental stages of wood formation. Trees are felled individually and trunk sections are removed from the bottom area approximately one to two meters from the base and within one to two meters below the live crown. The section removed from the basal end of the trunk contains mature wood. The section removed from below the live crown contains juvenile wood. Samples collected during the spring season are termed earlywood or springwood, while samples collected during the summer season are considered latewood or summerwood (Larson et al., Gen. Tech. Rep. FPL-GTR-129. Madison, Wis.: U.S. Department of Agriculture, Forest Service, Forest Products Laboratory. p. 42).

Tissues are isolated from the trunk sections such that phloem, cambium, developing xylem, and maturing xylem are removed. These tissues are collected only from the current year's growth ring. Upon tissue removal in each case, the material is immediately plunged into liquid nitrogen to preserve the nucleic acids and other components. The bark is peeled from the section and phloem tissue removed from the inner face of the bark by scraping with a razor blade. Cambium tissue is isolated from the outer face of the peeled section by gentle scraping of the surface. Developing xylem and lignifying xylem are isolated by sequentially performing more vigorous scraping of the remaining tissue. Tissues are transferred from liquid nitrogen into containers for long term storage at −70 until RNA extraction and subsequent analysis is performed.

›Example 22

This example illustrates a procedure for RNA extraction and purification, which is particularly useful for RNA obtained from conifer needle, xylem, cambium, and phloem.

Tissue is obtained from conifer needle, xylem, cambium or phloem. The tissue is frozen in liquid nitrogen and ground. The total RNA is extracted using Concert Plant RNA reagent (Invitrogen). The resulting RNA sample is extracted into phenol:chloroform and treated with DNase. The RNA is then incubated at 65° C. for 2 minutes followed by centrifugation at 4° C. for 30 minutes. Following centrifugation, the RNA is extracted into phenol at least 10 times to remove contaminants.

The RNA is further cleaned using RNeasy columns (Qiagen). The purified RNA is quantified using RiboGreen reagent (Molecular Probes) and purity assessed by gel electrophoresis.

RNA is then amplified using MessageAmp (Ambion). Aminoallyl-UTP and free UTP are added to the in vitro transcription of the purified RNA at a ratio of 4:1 aminoallyl-UTP-to-UTP. The aminoallyl-UTP is incorporated into the new RNA strand as it is transcribed. The amino-allyl group is then reacted with Cy dyes to attach the colorimetric label to the resulting amplified RNA using the Amersham procedure modified for use with RNA. Unincorporated dye is removed by ethanol precipitation. The labeled RNA is quantified spectrophotometrically (NanoDrop). The labeled RNA is fragmented by heating to 95° C. as described in Hughes et al., Nature Biotechnol. 19:342 (2001).

›Example 23

This Example illustrates how genes important for wood development in P. radiata can be determined and how oligonucleotides which uniquely bind to those genes can be designed and synthesized for use on a microarray.

Pine trees of the species P. radiata are grown under natural light conditions. Tissue samples are prepared as described in, e.g., Sterky et al., Proc. Nat'l Acad. Sci. 95:13330 (1998). Specifically, tissue samples are collected from woody trees having a height of 5 meters. Tissue samples of the woody trees are prepared by taking tangential sections through the cambial region of the stem. The stems are sectioned horizontally into sections ranging from juvenile (top) to mature (bottom). The stem sections separated by stage of development are further separated into 5 layers by peeling into sections of phloem, differentiating phloem, cambium, differentiating xylem, developing xylem, and mature xylem. Tissue samples, including leaves, buds, shoots, and roots are also prepared from seedlings of the species P. radiata.

RNA is isolated and ESTs generated as described in the Example above or Sterky et al., supra. The nucleic acid sequences of ESTs derived from samples containing developing wood are compared with nucleic acid sequences of genes known to be involved in polysaccharide synthesis. ESTs from samples that do not contain developing wood are also compared with sequences of genes known to be involved in the plant cell cycle. An in silico hybridization analysis is performed using BLAST (NCBI) as follows.

›Example 24

Eucalyptus in Silico Data

In silico gene expression can be used to determine the membership of the consensi EST libraries. For each library, a consensus is determined from the number of ESTs in any tissue class divided by the total number of ESTs in a class multiplied by 1000. These values provide a normalized value that is not biased by the extent of sequencing from a library. Several libraries were sampled for a consensus value, including reproductive, bud reproductive, bud vegetative, fruit, leaf, phloem, cambium, xylem, root, stem, sap vegetative, whole plant libraries.

As shown below, a number of the inventive sequences exhibit vascular-preferred expression (more than 50% of the hits by these sequences if the databases were searched at random would be in libraries made from developing vascular tissue) and thus are likely to be involved in wood-related developmental processes. The data are shown in Table 12.

›Example 25

Pinus in Silico Data

In silico gene expression can be used to determine the membership of the consensi EST libraries. For each library, a consensus is determined from the number of ESTs in any tissue class divided by the total number of ESTs in a class multiplied by 1000. These values provide a normalized value that is not biased by the extent of sequencing from a library. Several libraries were sampled for a consensus value, including needles, phloem, cambium, xylem, root, stem and, whole plant libraries.

As shown below, a number of the inventive sequences exhibit vascular-preferred expression (more than 50% of the hits by these sequences if the databases were searched at random would be in libraries made from developing vascular tissue) and thus are likely to be involved in wood-related developmental processes. The data are shown in Table 13.

›Example 26

Sequences that show hybridization in silico to ESTs made from samples containing developing wood, but that do not hybridize to ESTs from samples not containing developing wood are selected for further examination.

cDNA clones containing sequences that hybridize to the genes showing wood-preferred expression are selected from cDNA libraries using techniques well known in the art of molecular biology. Using the sequence information, oligonucleotides are designed such that each oligonucleotide is specific for only one cDNA sequence in the library. The oligonucleotide sequences are provided in Table 14. 60-mer oligonucleotide probes are designed using the method of Li and Stormo, supra or using software such as ArrayDesigner, GeneScan, and ProbeSelect.

The oligonucleotides are then synthesized in situ described in Hughes et al., Nature Biotechnol. 19:324 (2002) or as described in Kane et al., Nucleic Acids Res. 28:4552 (2000) and affixed to an activated glass slide (Sigma-Genosis, The Woodlands, Tex.) using a 5′ amino linker. The position of each oligonucleotide on the slide is known.

›Example 27

This example illustrates how to detect expression of Pinus radiata genes of the instant application which are important in wood formation using an oligonucleotide microarray prepared as described above. This is an example of a balanced incomplete block designed experiment carried out using aRNA samples prepared from mature-phase phloem (P), cambium (C), expanding xylem found in a layer below the cambium (X1) and differentiating, lignifying xylem cells found deeper in the same growth ring (X2). In this example, cell cycle gene expression is compared among the four samples, namely P, C, X1, and X2.

In the summer, plants of the species Pinus radiata are felled and the bark of the main stem is immediately pulled gently away to reveal the phloem and xylem. The phloem and xylem are then peeled with a scalpel into separate containers of liquid nitrogen. Needles (leaves) and buds from the trees are also harvested with a scalpel into separate containers of liquid nitrogen. RNA is subsequently isolated from the frozen tissue samples as described in Example 1. Equal microgram quantities of total RNA are purified from each sample using RNeasy Mini columns (Qiagen, Valencia, Calif.) according to the manufacturer's instructions.

Amplification reactions are carried out for each of the P, C, X1, and X2 tissue samples. Amplification reactions are performed using Ambion's MessageAmp kit, a T7-based amplification procedure, following the manufacturer's instructions, except that labeled aaUTP is added to the reagent mix during in the amplification step. aaUTP is incorporated into the resulting antisense RNA formed during this step. CyDye fluorescent labels are coupled to the aaUTPs in a non-enzymatic reaction as described in Example 1. Labeled amplified antisense RNAs are precipitated and washed, and then assayed for purity using a NanoDrop spectrophotometer. These labeled antisense RNAs, corresponding to the RNA isolated from the P, C, X1, and X2 tissue samples, constitute the sample nucleic acids, which are referred to as the P, C, X1, and X2 samples.

Normalization control samples of known nucleic acids are added to each sample in a dilution series of 500, 200, 100, 50, 25 and 10 pg/μl for quantitation of the signals. Positive controls corresponding to specific genes showing expression in all tissues of pine, such as housekeeping genes, are also added to the plant sample.

Each of four microarray slides is incubated with 125 μL of a P, C, X1 or X2 sample under a coverslip at 42° C. for 16-18 hours. The arrays are washed in 1×SSC, 0.1% SDS for 10 minutes and then in 0.1×SSC, 0.1% SDS for 10 minutes and the allowed to dry.

The array slides are scanned using an Axon laser scanner and analyzed using GenePix Pro software. Data from the microarray slides are subjected to microarray data analysis using GenStat SAS or Spotfire software. Outliers are removed and ratiometric data for each of the datasets are normalized using a global normalization which employs a cubic spline fit applied to correct for differential dye bias and spatial effects. A second transformation is performed to fit control signal ratios to a mean log 2 =0 (i.e. 1:1 ratio). Normalized data are then subjected to a variance analysis.

Mean signal intensity for each signal at any given position on the microarray slide is determined for each of three of P, C, X1, and X2 sample microarray slides. This mean signal/probe position is compared to the signal at the same position on sample slide which was not used for calculating the mean. For example, a mean signal at a given position is determined for P, C, and X1 and the signal at that position in the X2 microarray slide is compared to the P, C, and X1 mean signal value.

Table 5 shows genes having greater than doubled signal with any one sample as compared to the mean signal of the other three samples.

The data shows that WD40 repeat protein A encodes a WD40 repeat protein is less highly expressed in cambium than in developing xylem, while WD40 repeat protein B encodes a WD40 repeat protein that is more highly expressed in phloem than in the other tissues.

Signal data are then verified with RT-PCR to confirm gene expression in the target tissue of the genes corresponding to the unique oligonucleotides in the probe.

›Example 28

This example illustrates how RNAs of tissues from multiple pine species, in this case both P. radiata and loblolly pine P. taeda trees, are selected for analysis of the pattern of gene expression associated with wood development in the juvenile wood and mature wood forming sections of the trees using the microarrays derived from P. radiata cDNA sequences described in Example 4.

Open pollinated trees of approximately 16 years of age are selected from plantation-grown sites, in the United States for loblolly pine, and in New Zealand for radiata pine. Trees are felled during the spring and summer seasons to compare the expression of genes associated with these different developmental stages of wood formation. Trees are felled individually and trunk sections are removed from the bottom area approximately one to two meters from the base and within one to two meters below the live crown. The section removed from the basal end of the trunk contains mature wood. The section removed from below the live crown contains juvenile wood. Samples collected during the spring season are termed earlywood or springwood, while samples collected during the summer season are considered latewood or summerwood. Larson et al., Gen. Tech. Rep . FPL-GTR-129. Madison, Wis.: U.S. Department of Agriculture, Forest Service, Forest Products Laboratory. p. 42.

Tissues are isolated from the trunk sections such that phloem, cambium, developing xylem, and maturing xylem are removed. These tissues are collected only from the current year's growth ring. Upon tissue removal in each case, the material is immediately plunged into liquid nitrogen to preserve the nucleic acids and other components. The bark is peeled from the section and pwloem tissue removed from the inner face of the bark by scraping with a razor blade. Cambium tissue is isolated from the outer face of the peeled section by gentle scraping of the surface. Developing xylem and lignifying xylem are isolated by sequentially performing more vigorous scraping of the remaining tissue. Tissues are transferred from liquid nitrogen into containers for long term storage at −70° C. until RNA extraction and subsequent analysis is performed.

›Example 29

This example illustrates procedures alternative to those used in the example above for RNA extraction and purification, particularly useful for RNA obtained from a variety of tissues of woody plants, and a procedure for hybridization and data analysis using the arrays described in Example 4.

RNA is isolated according to the protocol of Chang et al., Plant Mol. Biol. Rep. 11:113. DNA is removed using DNase I (Invitrogen, Carlsbad, Calif.) according to the manufacturer's recommendations. The integrity of the RNA samples is determined using the Agilent 2100 Bioanalyzer (Agilent Technologies, USA).

10 μg of total RNA from each tissue is reverse transcribed into cDNA using known methods.

In the case of Pinus radiata phloem tissue, it can be difficult to extract sufficient amounts of total RNA for normal labelling procedures. Total RNA is extracted and treated as previously described and 100 ng of total RNA is amplified using the Ovation™ Nanosample RNA Amplification system from NuGEN™ (NuGEN, Calif., USA). Similar amplification kits such as those manufactured by Ambion may alternatively be used. The amplified RNA is reverse transcribed into cDNA and labelled as described above.

Hybridization and stringency washes are performed using the protocol as described in the US patent application for “Methods and Kits for Labeling and Hybridizing cDNA for Microarray Analysis” (supra) at 42 C. The arrays (slides) are scanned using a ScanArray 4000 Microarray Analysis System (GSI Lumonics, Ottawa, ON, Canada). Raw, non-normalized intensity values are generated using QUANTARRAY software (GSI Lumonics, Ottawa, ON, Canada).

A fully balanced, incomplete block experimental design (Kerr and Churchill, Gen. Res. 123:123, 2001) is used in order to design an array experiment that would allow maximum statistical inferences from analyzed data.

Gene expression data is analyzed using the SAS® Microarray Solution software package (The SAS Institute, Cary, N.C., USA). Resulting data was then visualized using JMP® (The SAS Institute, Cary, N.C., USA).

Analysis done for this experiment is an ANOVA approach with mixed model specification (Wolfinger et al., J. Comp. Biol. 8:625-637). Two steps of linear mixed models are applied. The first one, normalization model, is applied for global normalization at slide-level. The second one, gene model, is applied for doing rigorous statistical inference on each gene. Both models are stated in Models (1) and (2).

log 2 ( Y ijkls )=θ ij +D k +S l DS kl +ω ijkls   (1)

R ijkls (g) =μ ij (g) +D k (g) +S l (g) +DS kl (g) +SS ls (g) +ε ijkls (g)   (2)

Y ijkls represents the intensity of the S th spot in the l th slide with the k th dye applying the j th treatment for the i th cell line. θ ij , D k , S l , and D Skl represent the mean effect of the jth treatment in the ith cell line, the kth dye effect, the lth slide random effect, and the random interaction effect of the k th dye in the l th slide. ω ijkls is the stochastic error term. represent the similar roles as θ ij , D k , S l , and D Skl except they are specific for the g th gene. R ijkls (g) represents the residual of the g th gene from model (1). μ ij (g) ,D k (g) ,S l (g) , and DS kl (g) represent the similar roles as θ ij , D k , S l , and DS kl except they are specific for the g th gene. SS ls (g) represent the spot by slide random effect for the g th gene. ε ijkls (g) represent the stochastic error term. All random terms are assumed to be normal distributed and mutually independent within each model.

According to the analysis described above, certain cDNAs, some of which are shown in Table 6 below, are found to be differentially expressed.

The involvement of these specific genes in wood development is inferred through the association of the up-regulation or down-regulation of genes to the particular stages of wood development. Both the spatial continuum of wood development across a section (phloem, cambium, developing xylem, maturing xylem) at a particular season and tree trunk position and the relationships of season and tree trunk position are considered when making associations of gene expression to the relevance in wood development.

›Example 30

This example demonstrates how one can correlate polysaccharide gene expression with agronomically important wood phenotypes such as density, stiffness, strength, distance between branches, and spiral grain.

Mature clonally propagated pine trees are selected from among the progeny of known parent trees for superior growth characteristics and resistance to important fuingal diseases. The bark is removed from a tangential section and the trees are examined for average wood density in the fifth annual ring at breast height, stiffness and strength of the wood, and spiral grain. The trees are also characterized by their height, mean distance between major branches, crown size, and forking.

To obtain seedling families that are segregating for major genes that affect density, stiffness, strength, distance between branches, spiral grain and other characteristics that may be linked to any of the genes affecting these characteristics, trees lacking common parents are chosen for specific crosses on the criterion that they exhibit the widest variation from each other with respect to the density, stiffness, strength, distance between branches, and spiral grain criteria. Thus, pollen from a tree exhibiting high density, low mean distance between major branches, and high spiral grain is used to pollinate cones from the unrelated plus tree among the selections exhibiting the lowest density, highest mean distance between major branches, and lowest spiral grain. It is useful to note that “plus trees” are crossed such that pollen from a plus tree exhibiting high density are used to pollinate developing cones from another plus tree exhibiting high density, for example, and pollen from a tree exhibiting low mean distance between major branches would be used to pollinate developing cones from another plus tree exhibiting low mean distance between major branches.

Seeds are collected from these controlled pollinations and grown such that the parental identity is maintained for each seed and used for vegetative propagation such that each genotype is represented by multiple ramets. Vegetative propagation is accomplished using micropropagation, hedging, or fascicle cuttings. Some ramets of each genotype are stored while vegetative propagules of each genotype are grown to sufficient size for establishment of a field planting. The genotypes are arrayed in a replicated design and grown under field conditions where the daily temperature and rainfall are measured and recorded.

The trees are measured at various ages to determine the expression and segregation of density, stiffness, strength, distance between branches, spiral grain, and any other observable characteristics that may be linked to any of the genes affecting these characteristics. Samples are harvested for characterization of cellulose content, lignin content, cellulose microfibril angle, density, strength, stiffness, tracheid morphology, ring width, and the like. RNA is then collected from replicated samples of trees showing divergent stiffness and density, or other characteristics, from genotypes that are otherwise as similar as possible in growth habit, in spring and fall so that early and late wood development is assayed. These samples are examined for gene expression similarly as described in above examples.

Ramets of each genotype are compared to ramets of the same genotype at different ages to establish age:age correlations for these characteristics.

›Example 31

Example 8 demonstrates how responses to environmental conditions such as light and season alter plant phenotype and can be correlated to polysaccharide synthesis gene expression using microarrays. In particular, the changes in gene expression associated with wood density are examined.

Trees of three different clonally propagated E. grandis hybrid genotypes are grown on a site with a weather station that measures daily temperatures and rainfall. During the spring and subsequent summer, genetically identical ramets of the three different genotypes are first photographed with north-south orientation marks, using photography at sufficient resolution to show bark characteristics of juvenile and mature portions of the plant, and then felled. The age of the trees is determined by planting records and confirmed by a count of the annual rings. In each of these trees, mature wood is defined as the outermost rings of the tree below breast height, and juvenile wood as the innermost rings of the tree above breast height. Each tree is accordingly sectored as follows:

NM—NORTHSIDE MATURE SM—SOUTHSIDE MATURE NT—NORTHSIDE TRANSITION ST—SOUTHSIDE TRANSITION NJ—NORTHSIDE JUVENILE SJ—SOUTHSIDE JUVENILE

Tissue is harvested from the plant trunk as well as from juvenile and mature form leaves. Samples are prepared simultaneously for phenotype analysis, including plant morphology and biochemical characteristics, and gene expression analysis. The height and diameter of the tree at the point from which each sector was taken is recorded, and a soil sample from the base of the tree is taken for chemical assay. Samples prepared for gene expression analysis are weighed and placed into liquid nitrogen for subsequent preparation of RNA samples for use in the microarray experiment. The tissues are denoted as follows:

P—phloem C—cambium X1—expanding xylem X2—differentiating and lignifying xylem

Thin slices in tangential and radial sections from each of the sectors of the trunk are fixed as described in Ruzin, P LANT M ICROTECHNIQUE AND M ICROSCOPY , Oxford University Press, Inc., New York, N.Y. (1999) for anatomical examination and confirmation of wood developmental stage. Microfibril angle is examined at the different developmental stages of the wood, for example juvenile, transition and mature phases of Eucalyptus grandis wood. Other characteristics examined are the ratio of fibers to vessel elements and ray tissue in each sector. Additionally, the samples are examined for characteristics that change between juvenile and mature wood and between spring wood and summer wood, such as fiber morphology, lumen size, and width of the S2 (thickest) cell wall layer. Samples are further examined for measurements of density in the fifth ring and determination of modulus of elasticity using techniques well known to those skilled in the art of wood assays. See, e.g., Wang, et al., Non - destructive Evaluations of Trees , E XPERIMENTAL T ECHNIQUES , pp. 28-30 (2000).

For biochemical analysis, 50 grams from each of the harvest samples are freeze-dried and analyzed, using biochemical assays well known to those skilled in the art of plant biochemistry for quantities of simple sugars, amino acids, lipids, other extractives, lignin, and cellulose. See, e.g., Pettersen & Schwandt, J. Wood Chem . & Technol. 11:495 (1991).

In the present example, the phenotypes chosen for comparison are high density wood, average density wood, and low density wood. Nucleic acid samples are prepared as described in Example 3, from trees harvested in the spring and summer. Gene expression profiling by hybridization and data analysis is performed as described above.

Using similar techniques and clonally propagated individuals one can examine polysaccharide gene expression as it is related to other complex wood characteristics such as strength, stiffness and spirality.

›Example 32

Example 32 demonstrates the use of a vascular-preferred promoter functionally linked to one of the genes of the instant application.

A vascular-preferred promoter is then linked to one of the genes in the instant application and used to transform tree species. Boosted transcript levels of the candidate gene in the xylem of the transformants results in an increased xylem biomass phenotype.

In another example, a vascular-preferred promoter such as any of those in ArborGen's November 2003 patent applications is then linked to an RNAi construct containing sequences from one of the genes in the instant application and used to transform a tree of the genus from which the gene was isolated. Reduced transcript levels of the candidate gene in the xylem of the transformants results in an increased xylem biomass phenotype.

›Example 33

The vector pARB476 was developed using the following steps. The Bluescript vector (Stratagene, La Jolla, Calif.) was modified by adding the Superubiquitin 3′UTR and nos 3′terminator sequence at the KpnI and ClaI sites to produce the vector pARB005 (SEQ ID NO. 773). To this vector the P. radiata superubiquitin promoter with intron was added. The promoter/intron sequence was first amplified from the P. radiata superubiquitin sequence identifed in U.S. Pat. No. 6,380,459 using standard PCR techniques and the primers of SEQ ID NOS 774 and 775. The amplified fragment was then ligated into pARB005 using XbaI and PstI restriction digestion to produce the vector pARB119 (SEQ ID NO. 776).

The poplus tremuloises UDB Glucose binding domain gene (patent W0 OO71670, ptCelA Genbank number AF07213 1) was amplified using standard PCR techniques and primers including and ATG and a Clal site as part of the 5′ primer and a TGA and a ClaI site as part of the 3′ primer. The amplified fragment was then cloned into the Clal site of pARB119 to produce the vector pARB476 (SEQ ID NO. 777).

The NotI cassette containing the P. radiata superubiquitin promoter with intron::UDP Glucose Binding domain::3′UTR: nos terminator from pARB476 was removed and cloned into the NotI site of pART29 to produce the vector pARB483. The binary vector pART29 is a modified pART27 vector (Gleave, Plant Mol. Biol. 20:1203-1207, 1992) that contains the Arabidopsis thaliana ubiquitin 3 (UBQ3) promoter instead of the nos5′ promoter and no lacZ sequences.

To make the growth100 plasmids, an acceptor vector (pWVK202) was built by first inserting the NotI-SUBIN::UDPGBD::nos term-NotI cassette from pARB483a into plasmid pWVK147 at NotI. Next, the UDPGBD gene was removed using restriction sites PstI and ClaI. A polylinker containing the restriction sites PstI, NHeI, AvrII, ScaI, and ClaI was inserted in place of the UDPGBD gene. Sites AvrII and NheI are both compatible with SpeI, a site found often in the plasmids provided by Genesis. ScaI is blunt, so any fragment can be blunted and then inserted at that position into the acceptor vector. Plasmids were received from Genesis and analyzed to determine which restriction sites would be most suitable for subcloning into the acceptor vector pWVK202. After the ligations were performed, the resulting products were checked by extensive restriction digest analysis to make sure that the desired plasmid had been created.

›Tables in the description — 13
TABLE 2
Plasmid(s)GeneGenesis ID
pGrw14Cyclin Aprga001823
pGrw15Cyclin Aprpe001264
pGrw16Cyclin Dprxa004540
pGrw18Cyclin Dprxl006271
PGrw19Cyclin Dprpb019661
PGrw20WEE1-like proteinprrd041233
TABLE 3 — Rooting medium for Populus deltoids .
BTM-1 Media Componentsmg/L
NH 4 NO 3412
KNO 3475
Ca(NO 3 ) 2 •4H 2 O640
CaCl 2 •2H 2 O440*
MgSO 4 •7H 2 O370
KH 2 PO 4170
MnSO 4 •H 2 O2.3
ZnSO 4 •7H 2 O8.6
CuSO 4 •5H 2 O0.25
CoCl 2 •6H 2 O0.02
KI0.15
H 3 BO 36.2
Na 2 MoO 4 •2H 2 O0.25
FeSO 4 •7H 2 O27.8
Na 2 EDTA•2H 2 O37.3
Myo-inositol100
Nicotinic acid0.5
Pyridoxine HCl0.5
Thiamine HCl1
Glycine2
Sucrose20000
Activated Carbon5000
TABLE 6 — Gene corre- sponding
to SEQ IDOligo IDGene_FamilyExpression
162Pra_000171_O_2Peptidylprolylsteady state RNA
isomerasehigher in xylem than
cambium
164Pra_001480_O_3Peptidylprolylsteady state RNA
isomeraselower in xylem than
cambium
controlPra_000218_O_2RIBO-steady state RNA
NUCLEOSIDE-lower in xylem than
DIPHOSPHATEcambium
REDUCTASE
LARGE CHAIN
(EC1.17.4.1).
controlPra_000193_O_2PUTATIVEsteady state RNA
SURFACElower in xylem than
PROTEIN.cambium
TABLE 7 — Concensus ID Information.
Patent appSEQ IDGene FamilyConsensus_IDExpression
—controlRibonucleoside-pinusRadiata_000218up in early spring
diphosphate reductasexylem vs late
summer xylem
Cell Cycle168PeptidylprolylpinusRadiata_001692up in juvenile
isomerasedeveloping wood vs
mature developing
xylem
—controlNitrite transporterpinusRadiata_016801up mature
developing xylem
vs juvenile
cambium
TABLE 8 — pGrowth Information.
CW ARPlasmid(s)PromoterGeneGenesis ID
88pGrowth14SUBINCyclin Aprga001823
88pGrowth15SUBINCyclin Aprpe001264
88pGrowth16SUBINCyclin Dprxa004540
88pGrowth18SUBINCyclin Dprx1006271
88pGrowth19SUBINCyclin Dprpb019661
88pGrowth20SUBINWEE1-like proteinprrd041233
TABLE 9 — Eucalyptus grandis Cell Cycle Genes and Proteins.
DNAPatentPatent
SEQ IDProteinORFORF
NOSEQ ID NOSequence Identifierstartstop
1261eucalyptusSpp_0039103871820
2262eucalyptusSpp_019213991007
3263eucalyptusSpp_0368001201004
4264eucalyptusSpp_04026023937
5265eucalyptusSpp_0419651491033
6266eucalyptusSpp_0029061991116
7267eucalyptusSpp_00151841982
8268eucalyptusSpp_0080782912042
9269eucalyptusSpp_0098261072236
10270eucalyptusSpp_010364821749
11271eucalyptusSpp_0115231511560
12272eucalyptusSpp_024358821644
13273eucalyptusSpp_0391256262782
14274eucalyptusSpp_005362131467
15275eucalyptusSpp_0448571131558
16276eucalyptusSpp_0017431871686
17277eucalyptusSpp_0124052381653
18278eucalyptusSpp_0037392351539
19279eucalyptusSpp_0223381581618
20280eucalyptusSpp_0286052051530
21281eucalyptusSpp_0410061741499
22282eucalyptusSpp_006643941332
23283eucalyptusSpp_0453381761342
24284eucalyptusSpp_0464861501283
25285eucalyptusSpp_012070101367
26286eucalyptusSpp_00661791352
27287eucalyptusSpp_007827891486
28288eucalyptusSpp_008036801477
29289eucalyptusSpp_0015971601062
30290eucalyptusSpp_0015961721077
31291eucalyptusSpp_00587066989
32292eucalyptusSpp_0069011111541
33293eucalyptusSpp_0069021161615
34294eucalyptusSpp_0074401551453
35295eucalyptusSpp_0089942282033
36296eucalyptusSpp_0245801101258
37297eucalyptusSpp_037831501462
38298eucalyptusSpp_034958176739
39299eucalyptusSpp_0229671501529
40300eucalyptusSpp_0085992471971
41301eucalyptusSpp_0099191361644
42302eucalyptusSpp_01582048836
43303eucalyptusSpp_00832749822
44304eucalyptusSpp_004604185751
45305eucalyptusSpp_000966103621
46306eucalyptusSpp_00103741559
47307eucalyptusSpp_004603127693
48308eucalyptusSpp_00546528639
49309eucalyptusSpp_006571135812
50310eucalyptusSpp_006786119613
51311eucalyptusSpp_00705738562
52312eucalyptusSpp_0086701091872
53313eucalyptusSpp_009137741159
54314eucalyptusSpp_010285542045
55315eucalyptusSpp_010600531879
56316eucalyptusSpp_0115517690
57317eucalyptusSpp_02074383601
58318eucalyptusSpp_023739125535
59319eucalyptusSpp_02410355573
60320eucalyptusSpp_031985147842
61321eucalyptusSpp_032025167487
62322eucalyptusSpp_032173195890
63323eucalyptusSpp_03334068586
64324eucalyptusSpp_0091431823265
65325eucalyptusSpp_0003491651145
66326eucalyptusSpp_0005755291569
67327eucalyptusSpp_0008041561136
68328eucalyptusSpp_000805901073
69329eucalyptusSpp_000806661049
70330eucalyptusSpp_0022482771512
71331eucalyptusSpp_003203331076
72332eucalyptusSpp_00320965973
73333eucalyptusSpp_004429821047
74334eucalyptusSpp_004607431101
75335eucalyptusSpp_0046821421095
76336eucalyptusSpp_005786611257
77337eucalyptusSpp_0058871931527
78338eucalyptusSpp_0059811091155
79339eucalyptusSpp_006766711213
80340eucalyptusSpp_0067691091785
81341eucalyptusSpp_0069073642685
82342eucalyptusSpp_007518961412
83343eucalyptusSpp_0077171161702
84344eucalyptusSpp_007718461101
85345eucalyptusSpp_007741231258
86346eucalyptusSpp_0078844042644
87347eucalyptusSpp_0082581072383
88348eucalyptusSpp_0084652431625
89349eucalyptusSpp_0086161261127
90350eucalyptusSpp_0086902571390
91351eucalyptusSpp_0087081781632
92352eucalyptusSpp_0088502902917
93353eucalyptusSpp_0090721481197
94354eucalyptusSpp_0094651401567
95355eucalyptusSpp_0094723761737
96356eucalyptusSpp_009550691010
97357eucalyptusSpp_0102841491423
98358eucalyptusSpp_0105953652677
99369eucalyptusSpp_01065724923
100360eucalyptusSpp_0126362213598
101361eucalyptusSpp_012748441447
102362eucalyptusSpp_0128791961314
103363eucalyptusSpp_0155151931668
104364eucalyptusSpp_015724781634
105365eucalyptusSpp_016167852826
106366eucalyptusSpp_016633741246
107367eucalyptusSpp_0174851004377
108368eucalyptusSpp_018007582439
109369eucalyptusSpp_0207751591064
110370eucalyptusSpp_0231321181665
111371eucalyptusSpp_023569571628
112372eucalyptusSpp_0236112501566
113373eucalyptusSpp_0249341061434
114374eucalyptusSpp_0255461901917
115375eucalyptusSpp_0301341022942
116376eucalyptusSpp_031787751079
117377eucalyptusSpp_034435991148
118378eucalyptusSpp_0344522321806
119379eucalyptusSpp_035789721124
120380eucalyptusSpp_0358043152069
121381eucalyptusSpp_0430571451968
122382eucalyptusSpp_0467411301488
123383eucalyptusSpp_0471612691693
235495eucalyptusSpp_0063661171580
236496eucalyptusSpp_0173781111700
252512eucalyptusSpp_0454142381648
253513eucalyptusSpp_04432859859
254514eucalyptusSpp_015615441829
255515eucalyptusSpp_0172391091866
256516eucalyptusSpp_0186432121815
257517eucalyptusSpp_0191272071193
258518eucalyptusSpp_02262462786
259519eucalyptusSpp_0324242131726
260520eucalyptusSpp_0374721012110
TABLE 10 — Pinus radiata cell cycle genes and proteins.
DNAPatentPatent
SEQ IDProtein SEQORFORF
NOID NOSequence Identifierstartstop
124384pinusRadiata_00176611632545
125384pinusRadiata_0029271521582
126385pinusRadiata_0076423891297
127386pinusRadiata_01371438946
128387pinusRadiata_0163321801088
129388pinusRadiata_02167740948
130389pinusRadiata_0275622291134
131390pinusRadiata_0015041052642
132391pinusRadiata_0152111872580
133392pinusRadiata_0204212201749
134393pinusRadiata_0031874381748
135394pinusRadiata_0156612401631
136395pinusRadiata_0138742521604
137396pinusRadiata_0146152611817
138397pinusRadiata_0045781671576
139398pinusRadiata_0233871831598
140399pinusRadiata_006970981126
141400pinusRadiata_010322148894
142401pinusRadiata_0227212871363
143402pinusRadiata_0234072511348
144403pinusRadiata_001945229510
145404pinusRadiata_00823392409
146405pinusRadiata_00823464381
147406pinusRadiata_02205468349
148407pinusRadiata_0121371251849
149408pinusRadiata_012582701602
150409pinusRadiata_0152851401465
151410pinusRadiata_0172296282565
152411pinusRadiata_020724551818
153412pinusRadiata_0045552591710
154413pinusRadiata_0045563561807
155414pinusRadiata_0057292611298
156415pinusRadiata_0073953652251
157416pinusRadiata_0095031561454
158417pinusRadiata_0112832031348
159418pinusRadiata_0123222291644
160419pinusRadiata_0186711561454
161420pinusRadiata_023236272222
162421pinusRadiata_000171711759
163422pinusRadiata_0001723582040
164423pinusRadiata_001480238756
165424pinusRadiata_001481285803
166425pinusRadiata_001483190708
167426pinusRadiata_001484156674
168427pinusRadiata_0016921761912
169428pinusRadiata_00531364765
170429pinusRadiata_00636293881
171430pinusRadiata_0064933721070
172431pinusRadiata_00698328594
173432pinusRadiata_00698434648
174433pinusRadiata_0076654811611
175434pinusRadiata_01219693584
176435pinusRadiata_0133822501869
177436pinusRadiata_01646184422
178437pinusRadiata_0176111281213
179438pinusRadiata_019776265837
180439pinusRadiata_02065938781
181440pinusRadiata_02255938526
182441pinusRadiata_024188371158
183442pinusRadiata_02797361768
184443pinusRadiata_0013534212172
185444pinusRadiata_0019781631647
186445pinusRadiata_0028101921172
187446pinusRadiata_0028111311111
188447pinusRadiata_0028121491726
189448pinusRadiata_0035149482228
190449pinusRadiata_0041043321465
191450pinusRadiata_0055952321590
192451pinusRadiata_0057542071550
193452pinusRadiata_0064632211171
194454pinusRadiata_0066652213679
195455pinusRadiata_0067502691252
196456pinusRadiata_0070302141242
197457pinusRadiata_0078541192065
198458pinusRadiata_0079171861550
199459pinusRadiata_0079892443671
200460pinusRadiata_0085061631431
201461pinusRadiata_0086921551081
202462pinusRadiata_0086935371463
203463pinusRadiata_0091702841909
204464pinusRadiata_0094086101659
205465pinusRadiata_0095222411452
206466pinusRadiata_0097342231173
207467pinusRadiata_0098152511777
208468pinusRadiata_0106703671419
209469pinusRadiata_0112972841303
210470pinusRadiata_0130986841784
211471pinusRadiata_0131723362738
212472pinusRadiata_013589811622
213473pinusRadiata_0136083991460
214474pinusRadiata_0142992071673
215475pinusRadiata_0144982631309
216476pinusRadiata_0145482322529
217477pinusRadiata_014610562950
218478pinusRadiata_0160901932577
219479pinusRadiata_0167221871233
220480pinusRadiata_016785511436
221481pinusRadiata_0170945252351
222482pinusRadiata_0175271521099
223483pinusRadiata_0175914704114
224484pinusRadiata_0177691962007
225485pinusRadiata_0180472141323
226486pinusRadiata_018414682146
227487pinusRadiata_0189868743705
228488pinusRadiata_0194793601754
229489pinusRadiata_0201441851384
230490pinusRadiata_0224802411533
231491pinusRadiata_0230792301435
232492pinusRadiata_0267391012857
233493pinusRadiata_026951431548
234494pinusRadiata_0265292061657
237497pinusRadiata_0008881441412
238498pinusRadiata_0141667931683
239499pinusRadiata_0031894152196
240500pinusRadiata_0093561091653
241501pinusRadiata_0000653431023
242502pinusRadiata_0141974172351
243503pinusRadiata_00908169641
244504pinusRadiata_0134171721623
245505pinusRadiata_0057552311768
246506pinusRadiata_0066703762943
247507pinusRadiata_0070271071498
248508pinusRadiata_0072761181425
249509pinusRadiata_007390186797
250510pinusRadiata_0126483872456
251511pinusRadiata_0131713592761
TABLE 11 — Annotated Peptide Sequences of the Present Invention.
EntrySequence DescriptionAnnotated Peptide Sequence
1The amino acid sequence of SEQ IDMGDGSLGSGGRGNSGGGGGGGSRPEWLQQ YDLIGKIGEG
261. The conserved eukaryotic
TYGLVFLARIKHPSTNRGKYIAIKKFKQSKDGDGVSPTA
protein kinase domain is
IREIMLLREISHENVVKLVNVHINPVDMSLYLAFDYADH
underlined and the
DLYEIIRHHRDKVNQAINPYTVKSLLWQLLNGLNYLHSN
serine/threonine protein kinases
WIIHRDLKPSNILV MGEGEEQGVVKIADFGLARVYQAPL
active-site signature is in bold.
KPLSDNGVVVTIWYRAPELLLGAKHYTSAVDMWAVGCIF
AELLTLKPLFQGQEVKANPNPFQLDQLDKIFKVLGHPTQ
EKWPMLVNLPHWQSDVQHIQRHKYDDNALGNVVRLSSKN
ATFDLLSKMLEYDPQKRITAAQALEHEYF RMEPLPGRNA
LVPSSPGDKVNYPTRPVDTTTDIEGTTSLQPSQSASSGN
AVPGNMPGPHVVTNRPMPRPMEMVGMQRVPASGMAGYNL
NPSGMGGGMNPSGIPMQRGVANQAQQSRRKDPGMGMGGY
PPQQKQRRF
2The amino acid sequence of SEQ IDMEK YQQLAK IGEGTYGIVYKAKDKKSGELIALKKI RLEA
262. The conserved eukaryotic
EDECIPSTAIREISLLRQLQHPNIVRLYDVVHTEKKLTL
protein kinase domain is
VFEFLDQDLKKYLDACGDNGLEPYTVKSFLYQLLQGIAF
underlined and the protein kinases
CHEHR VLHEDLKPQNLLI NMEGELKLADFGLAPAFGIPV
ATP-binding region and
RNYTHEVVTLWYRAPDVLMGSRKYSTQVDIWSVGCIFAE
serine/threonine protein kinases
MVNGRPLFPGSSEQDQLLRIFKTLGTPSLKTWPGMAELP
active-site signatures are in
DFKDNFPKYVVQSFKKICPKKLDKTGLDLLSRMLQYDPA
bold.KRISAEQAMGHPYF KDLKLRKPKAAGPGP
3The amino acid sequence of SEQ IDMDQ YEKIEK IGEGTYGVVYKAIDRSTNKTIALKK IRLEQ
263. The conserved eukaryotic
EDEGVPSTAIREISLLKEMQHGNIVKLQDVVHSERRLYL
protein kinase domain is
VFEYLDLDLKKHNDSCPEFSKDTHTIKNFLYQILRGISY
underlined and the protein kinases
CHSHRV LHEDLKPQNLLL DRRTNSLKLADFGLARAFGIP
ATP-binding region and
VRTFTHEVVTLWYRAPEILLGSRHYSTPVDVWSVGCIFA
serine/threonine protein kinases
EMVNRRPLFPGDSEIDELFKIFRIMGTPNEDSWPGVTSL
active-site signatures are in
PDFKSTFPKWASQDLKTVTPTVDPAGIDLLSKNLCMDPR
bold.RRITAKVALEHEYF KDVGVIP
4The amino acid sequence of SEQ IDMVNKSKLDK YEKLEK IGEGTYGVVYKAQDKTTKEIYALK
264. The conserved eukaryotic
KIRLESEDEGIPSTAIREIALLKELQHPNVVRIHDVIHT
protein kinase domain is
NKKLILVFEFVDYDLKKFLHNFDKGIDPKIVKSLLYQLV
underlined and the protein kinases
RGVAHCHQQKV LHEDLKPQNLL VSQEGILKLGDFGLARA
ATP-binding region and
FGIPVKNYTNEVVTLWYRAPDILLGSKNYSTSVDIWSIG
serine/threonine protein kinases
CIFVEMLNQRPLFPGSSEQDQLKKIFKIMGTPDATKWPG
active-site signatures are in
IAELPDWKPENFEKYPGEPLNKVCPRMDPDGLDLLDKML
bold.KCNPSERIAAKNANSHPYF KDIPDNLKKLYN
5The amino acid sequence of SEQ IDMDQ YEKVEK IGEGTYCVVYKAIDRLTNETIALK KIRLEQ
265. The conserved eukaryotic
EDEGVPSTAIREISLLKEMQHGNIVRLQDVVHSENRLYL
protein kinase domain is
VFEYLDLDLKKHMDSSPDFAKDPRLVKIFLYQILRGIAY
underlined and the protein kinases
CHSHR VLHRDLKPQNLLI DRRTNALRLADFGLARAFGIP
ATP-binding region and
VRTFTHEVVTLWYRAPEILLGSRHYSTPVDVWSVGCIFA
serine/threonine protein kinases
EMVNQRPLFPGDSEIDELFKIFRILGTPNEDTWPGVTAL
active-site signatures are in
PDFKSAFPKWPAKNLQDMVPGLNSAGIDLLSKMLCLDPS
bold.KRITARSALEHEYF KDIGFVP
6The amino acid sequence of SEQ IDMEK YEKLEK VGEGTYGKVYKAKDKATGQLVALKK TRLEM
266. The conserved eukaryotic
DEEGVPPTALREVSLLQLLSQSLYVVRLLSVEHVDGGSK
protein kinase domain is
RKAAAAAAAEGGGGEAHGGGAVGGGKPMLYLVFEYLDTD
underlined and the protein kinases
LKKFIDSHRKGPNPRPVPAATVQNFLYQLLKGVAHCHSH
ATP-binding region and
G VLHRDLKPQNLLV DKEKGILKIADLGLGRAFTVPLKSY
serine/threonine protein kinases
THEVFAFLAILLWRSEGESAADFDSXFRVSPVQVVTLWY
active-site signatures are in
RAPEVLLGSAHYSIGVDMWSVGCIFAENVRRQALFPGDS
bold.
EFQQLLHIFRLLGTPTEKQWPGVTTLRDWHVYPQWEPQN
LARAVPSLGPDGVDLLSKMLKYDPAERISAKAALDHPFF
DSLDKSQF
7The amino acid sequence of SEQ IDMERPATAAVSAMEA FEKLEKVGEGTYGKVYRAPEKATGK
267. The conserved eukaryotic
IVALKKTRLHEDEEGVPPTTLREISILRMLSRDPHIVRL
protein kinase domain is
MDVKQGQNKEGKTVLYLVFEYMETDLKKYIRGFRSSGES
underlined and the protein kinases
IPVNIVKSLMYQLCKGVAFCHGHGV LHRDLKPHNLIM DK
ATP-binding region and
KTLTLKIADLGLARAFTVPIKKYTHEILTLWYRAPEVLL
serine/threonine protein kinases
GATHYSTAVDMWSVGCIEAELVTKQALFPGDSELQQLLH
active-site signatures are in
IFRLLGTPNEKNWPGVSSLMNWHEYPQWKPQSLSTAVPN
bold.LDKDGLDLLSQMLHYEPSRRISAKAAMEHPYF DDVNKTC
L
8The amino acid sequence of SEQ IDMGCVLGREVSSGIVTESKGRDSSEVETSKRDDSVAAKVE
268. The conserved eukaryoticGEGKAEEVRTEETQKKEKVEDDQQSREQRRRSKPSTKLG
protein kinase domain isNLPKHIRGEQVAAGWPSWLSDICGEALNGWIPRRANT FE
underlined and the
KIDKIGQGTYSNVYKAKDLLTGKIVALKKVRFDNLEPES
serine/threonine protein kinases
VRFMAREILILRHLDHPNVVKLEGLVTSRMSCSLYLVFE
active-site signature is in bold.
YMEHDLAGLAASPAIKFTEPQVKCYMHQLLSGLEHCHNR
R VLHRDIKGSNLLI DNGGVLKIGDFGLASFYDPDHKHRN
TSRVVTLWYRPPELLLGANDYGVGIDLWSAGCILAELLA
GKPIMPGRTEVEQLHKIYKLCGSPSEEYWKKYKLPNATL
FKPREPYRRCIRETFKDFPPSSLPLIETLLAIDPAERGT
ATDALQSEFF RTEPYACEPSSLPQYPPSKEMDAKKRDDE
ARRLRAASKGQADGSKKERTRDRRVRAVPAPEANAELQH
NIDRRRLISHANAKSKSEKFPPPHQDGALGFPLGASHRF
DPAVVPPDVPFTSTSFTSSKEEDQTWSGFLVDPPGAPRR
KKHSAGGQRESSKLSMGTNKGRRADSHLKAYESKSIA
9The amino acid sequence of SEQ IDMYSKSSAVDDSRESPKDRVSSSRRLSEVKTSRLDSSRRE
269. The conserved eukaryoticNGFRARDKVGDVSVMLIDKKVNGSARFCDDQIEKKSDRL
protein kinase domain isQKQRRERAEAAAAADHPGAGRVPKAVEGEQVAAGWPVWL
underlined and theSAVAGEAIRGWLPRRADT FEKLDKIGQGTYSSVYKARDV
serine/threonine protein kinase
TNNKIVALKRVRFDNLDTESVKFMAREIHILRMLDHPNV
active-site signature is in bold.
IKLEGLITSRMSCSLYLVFEYMEHDLTGLASRPDVKFSE
PQIKCYMKQLLSGLDNCHKHG VLHRDIKGSNLL IDNNGI
LKIADFGLASVFDPHQTAPLTSRVVTLWYRPPELLLGAS
RYGVEVDLWSTGCILGELYTGKPILPGKTEVEQLHKIFK
LCGSPSDDYWRRLHLPRAAVFKPPQPYRRCVAEIFKELP
PVALGLLETLISVDPSQRGTAAFALRSEFF TASPLPCDP
SSLPKYPPSKEIDMKLREEEARRRGAAGGKNELEKRGTK
DSRTNSAYYPNAGQLQVKQCHSNANGRSEIFGPYQEKTV
SGFLVAPPKQARVSKETRKDYAEQPDRASFSGFLVPGPG
FSKAGKELGHSITVSRNTNLSTLSSLVTSRTGDNKQKSG
PLVSESANQASRYSGPIREMEPARKQDRRSHVRTNIDYR
SREDGNSSTKEPALYGRGSAGNKIYVSGPLLVSSNNVDQ
MLKEHDRRIQEHARRARFDKARVGNNHPQAAVDSKLVSV
HDAG
10The amino acid sequence of SEQ ID MGCIPTIISDGRRRSAAPDKRRPRPRRSSSEGEAPPHAT
270. The conserved eukaryoticAAGSEGGESARGAPGKERPEPAPRFVVRSPQGWPPWLVA
protein kinase domain isAVGRAIGEFVPRCADS FRKLAKIGEGTYSNVYKARDLVT
underlined and the
GKTVALKKVRFDNLEAESIKFMAREILVLTRLNHPNVIK
serine/threonine protein kinase
LEGPVTSRMSSGLYLAFEYMEHDLSGIAARQNGKFTEPQ
active-site is in bold
VKCFMRQLLSGLEHCHNHD VLHRDIKCSNLLIDNEGNLK
IADFGLATFYDPERKQVMTNRVVTLWYRAPELLLGATSY
GIGIDLWSAGCILAELLYGKPIMPGRTEVEQLHKIFKLC
GSPSEAYWNKFKLPNANIFKPPQPYARCIAETFKDFPPS
ALPLLETLLSIDPDERGTATTALNSEFF AAEPHACEPSS
LPKYPPSKEMDLKLIKEKTRRDSSKRPSAIHGSRRDGIH
DRAGRVIPAPEATAENQATLHRPRAMKKANPMSRSEKFP
PAMMOGVVGSSANAWLSGPASNAAPDSRRHRSLNQNPSS
SVGKASTGSSTTQETLKVAPELLQVGSSSLHPCHRMLVY
GSNLTIRSK
11The amino acid sequence of SEQ IDMGCICAKQADRGPASPGSGILTGAGTGTGTRSSKIPSGL
271. The conserved protein kinaseFEFEKSGVKEHGGRSGELRKLEEKGSLSKRLRLELGFSH
family domain is underlined, andRYVEAEQAAAGWPSWLTAVAGDAIQGLVPLKADS FEKLE
the serine/threonine protein
KIGQGTYSSVFRARELANGRNVALKKVRFDNFQPESIQF
kinases active-site signature is
MAREISILRRLDHPNIMKLEGIITSRNSNSIYLVFEYME
in bold
HDLYGLISSPQVKFSDAQVKCYMKQLLSGIEHCHQHG VI
HRDVKSSNILV NNEGILRIGDFGLANILNPKDRQQLTSH
VVTLWYRPPELLMGSTSYGVTVDLWSVGCVFAELMFRKP
ILRGRTEVEQLHKIFKLCGSPPDGYWKNCKVPQATMFRP
RHAYECTLRERCKGIATSAMKLMETFLSIEPHKRGTASS
ALISEYF RTVPYACDPSSLPKYPPNKEIDAKHREEARRK
KARSRVREAEVGKRPTRIHRASQEQGFSSNIAPKEKRSY
A
12The amino acid sequence of SEQ IDMAVAAPGHLNVNESPSWGSRSVDC FEKLEQ IGEGTYGQV
272. The conserved eukaryotic
YMAKEKKTGEIVALKKIRMDNEREGFPITAIREIKILEK
protein kinase domain is
LHHENVIKLKEIVTSPGPEKDEQGRPEGNKYKGGIYMVF
underlined and the protein kinases
EYMDHDLTGLADRPGMRFSVPQIKCYMRQLLTGLHYCHI
ATP-binding region and
NQV LHRDIKGSNLL IDNEGNLKLADFGLARSFSNDHNAN
serine/threonine protein kinases
LTNRVITLWYRPPELLLGATKYGPAVDMWSVGCIFAELL
active-site signatures are in
HGKPIFPGKDEPEQLNKIFELCGAPDEINWPGVSKIPWY
bold.
NNFKPTRPMKRRLREVFRHFDRHALELLERMLTLDPSQR
ISAKDALDAEYFW ADPLPCDPKSLPKYESSHEFQTKKKR
QQQRQHEETAKRQKLQHPFQHPRLPPVQQSGQAHAQMRP
GPNQLMHGSQPPVATGPPGHHYGKPRGPSGGAGRYPSSG
NPGGGYNHPSRGGQGGSGGYNSGPYPPQGRAPPYGSSGM
PGAGPRGGGGNNYGVGPSNYPQGGGGPYGGSGAGRGSNM
MGGNRNQQYGWQQ
13The amino acid sequence of SEQ IDMGCICTKGILPAHYRIKDGGLKLSKSSKRSVGSLRRDEL
273. The conservedAVSANGGGNDAADRLISSPHEVENEVEDRKNVDFNEKLS
serine/threonine protein kinaseKSLQRRATMDVASGGHTQAQLKVGKVGGFPLGERGAQVV
domain is underlined, and theAGWPSWLTAVAGEAINGWVPRRADS FEKLEKIGQGTYSS
serine/threonine protein kinase
VYPARDLETNTIVALKKVRFANMDPESVRFMAREIIIMR
active-site signature is in bold.
KLDHPNVMKLEGLITSRVSGSLYLVFEYMDHDLAGLAAT
PSIKLTESQIKCYMQQLLRGLEYCHSHG VLHRDIKGSNL
LV DNNGNLKIGDFGLATFFRTNQKQPLTSRVVTLWYRPP
ELLLGSSDYGASVDLWSSGCILAELFAGKPIMPGRTEVE
QLHKIFKLCGSPSEEYWKKSKLPHATIFKPQQPYKRCLL
ETFKDFPSSALGLLDVLLAVEPECRGTASSALQNEFF TS
NPLPSDPSSLPKYPSSKEFDARLRDEEARKHKATAGKAR
GLESIRKGSKESKVVPTSNANADLKASIQKRQEQSNPRS
TGEKPGGTTQNNFILSGQSAKPSLNGSTQIGNANEVEAL
IVPDRELDSPRGGAELRRQRSFMQRRASQLSRFSNSVAV
GGDSHLDCSREKGANTQWRDEGFVARCSHPDGGELAGKH
DWSHHLLHRPISLFKKGGEHSRRDSIASYSPKKGRIHYS
GPLLPSGDNLDEMLKEHERQIQNAVRKARLDKVKTKREY
ADHGQTESLLCWANGR
14The amino acid sequence of SEQ IDMDPDPSPDPDPPKSWSIHTRREIIAR YEILERVGSGAYS
274. The conserved protein kinase
DVYRGRRLSDGLAVALKEVHDYQSAFREIEALQILRGSP
family domain is underlined and
HVVLLHEYFWREDEDAVLVLEFLRSDLAAVIADASRRPR
the serine/threonine protein
DGGGGGAAALRAGEVKRWMLQVLEGVDACHRNS IVHRDL
kinases active-site signature is
KPGNLLI SEEGVLKIADFGQARILLDDGNVAPDYEPESF
in bold.
EERSSEQADILQQPETMEADTTCPEGQEQGAITREAYLR
EVDEFKAKNPRHEIDKETSIFDGDTSCLATCTTSDIGED
PFKGSYVYGAEEAGEDAQGCLTSCVGTRWFRAPELLYGS
TDYGLEVDLWSLGCIFAELLTLEPLEPGISDIDQLSRIF
NVLGNLSEEVWPGCTKLPDYRTISFCKIENPIGLESCLP
NCSSDEVSLVRRLLCYDPAARATPMELLQDKYF TEEPLP
VPISALQVPQSKNSHDEDSAGGWYDYNDMDSDSDFEDFG
PLKFTPTSTGFSIQFP
15The amino acid sequence of SEQ IDMDPDPSPSPDPPKSWSIHTRREIIAR YEILERVGSGAYS
275. The conserved
DVYRGRRLSDGLAVALKEVHDYQSAFREIEALQILRGSP
serine/threonine protein kinase
HVVLLHEYFWREDEDAVLVLEFLRSDLAAVIADASRRPR
domain is underlined, and the
GGGVAPLRAGEGKRWMLQVLEGVDACHRNS IVHRDLKPG
serine/threonine protein kinase
NLLI SEEGVLKIADFGQARILLDDGNVAPDYEPESFEER
active-site signature is in bold.
SSEQADILQQPETMEADTTCPEGQEQGAITREAYLREVD
EFKAKNPRHEIDKETSIYDGDTSCLATCTTSDIGEDPFK
GSYVYGAEEAGEDAQGSLTSCVGTRWFRAPELLYGSTDY
GLEVDLWSLGCIFAELLTLEPLFPGISDIDQLSRIFNVL
GNLSEEVWPGCTKLPDYRTISFCKIENPIGLESCLPNCS
SDEVSLVRRLLCYDPAARATPMELLQDKYF TEEPLPVPI
SALQVPQSKNSHDEDSAGGWYDYNDMDSDSDFEDFGPLK
FTPTSTGFSIQFP
16The amino acid sequence of SEQ IDMSNQHRRSSFSSSTTSSLAKRHASSSSSSLENAGEAFAA
276. The conserved cyclin andAAVPSHLARKRAPLGNLTNLKAGDGNSRSSSAPSTLVAN
cyclin C-terminal domains areATKLAKTRKGSSTSSSIMGLSGSALPRYASTKPSGVLPS
underlined and the cyclinsVNPSIPRIEIAVDPNSCSMVVSPSRSDMQSVSLDESMST
signature is in bold.CESFKSPDVEYIDNEDVSAVDSIDRRTFSNLYISDAAAK
TAVNICERDVLMEMETDEKIVNVDDNYSDPQLCATIAC D
IYQHLRASEAKRRPSTDFMDRVQKDITASM RAILIDWLV
EVAEEYRLVPDTLYLTVNYIDRY LSGNVMNRQRLQLLGV
ACMMIAAKYEEICAPQVEEFCYITDNTYFKEEVLQMESS
VLNYLKFEMTAPTVKCFLRRFVRAAQGVNEVPSLQLECM
ANYIAELSLLEYDNLCYAPSLVAASAIFLARFVITPSKR
PWDPTLQHYTLYQPSDLGNCVKDLHRLCFNNHGSTLPAI
REKYSQNKYRYVAKKYCPPSIP PEFFHNLVY
17The amino acid sequence of SEQ IDMNKENAVGTRSEAPTIRITRSRSRALGTSTGMLPSSRPS
277. The conserved cyclin andFKQEQKRTVRANAKRSASDENKGTMVGNASKQHKKRTVL
cyclin C-terminal domains areNDVTNIFCENSYSNCLNAAEAQTSRQGRRWSMKKDRDVH
underlined.QSGAVQIMQEDVQAQFVEESSKIKVAESMEITIPDKWAK
RENSENSISMKDTVAESSRKPQEFICGEKSAALVQPSIV
DIDSKLEDPQACTPYAL DIYNYKRSTELERRPSTIYMET
LQKDVTPNMRGILVDWLVEVSEEYKLVPDTLYLTVNLID
RSLSQKFIEKQRLQLLGVTCMLIASKYEEICPPRVEEEC
FITDNTYTSLEVLKMESRVLNLLHFQLSVPTVKTFLRRF
VQAAQVSSEVPSVELEYLANYLAELTLVEYSFLRFLPSL
MAASAVLLARWTLNQSDNPWNLTLEHYTKYKASELKAAV
LALEDLQLNTSGSTLNAIREKYRQQKVNYSLLIHSKANH
EIL
18The amino acid sequence of SEQ IDMAGSDENNPGVVGGAHVQEGLRVGAGKMGAGNVQQRRAL
278. The conserved cyclin N- andSNINSNIIGAPPYPCAVNKRVLSEKNVNSENDLLNAAHR
c-terminal family domains arePITRQFAAQMAYKQQLRPEENKRTTQSVSNPSRSEDCAI
underlined end the cyclinsLDVDDDRMADDFPVPMFVQHTEAMLEEIDRMEEVEMEDV
signature is in bold.AEEPVTDIDSGDRENQLAVVEYID DLYMFYQKAEASSCV
PPNYMDRQQDINERM RGILIDWLIEVHYKFELMDETLYL
TVNLIDRF LAVQPVVKKKLQLVGVTAMLLACKYEEVSVP
VVEDLILISDRAYSRKEVLEMERLMVNTLHFNMSVPTPY
VFMRRFLKAAQSDRKLELLSFFIIELSLVEYDMLKFPPS
LLAASAIYTALSTITRTRQWSTTCEWHTSYSEEQLLECA
RLMVTFHQRAGSGKLTGVHRKYSTSKFGHAARTEPANFL
LDFRL
19The amino acid sequence of SEQ IDMASRPIVPVQARGEAAIGGGAGKAAIGGGAGKQQKKNGA
279. The conserved cyclin andAEGRNRKALGDIGNLVTVRGIEGRVQPHRPITRSFCAQL
cyclin C-terminal domains areLANAQAAAAAENNKKQAVVNVNGAPSILDVPGAGKRAEP
underlined.AAAAAAAVAKAAQRKVVKPKQKAEVIDLTSDSEERSRPR
RSN NIMSLRRRKERNHREGICPLSLRSSLLEARLVDWLI
EIHNRFDLMPETLYLTINIIDRFLSVKAVPRRELQLLGM
GALFTASKYEEIWAPEVNDLVCIADRAYSHEQVLANEKT
ILGKLEWTLTVPTHYVFLVRFIRASLGDRKLENMVYFLA
ELGVMNYATLTYCPSMVAASAVYAARCTLGLTPLWNDTL
KLHTGFSESQLMDCARLLVGYHAKAKENKLQVVYKKYSS
SQREGVALIPPAKALL CEGGGLSSSSSLASSS
20The amino acid sequence of SEQ IDMGLPDENNAALSKPTNLQVGGLEIGGRKFGQEIRQTRRA
280. The conserved cyclin andLSVINQNLVGDRAYPCHVVNKRGNSKRDAVCGKDQVDPV
cyclin C-terminal domains areHRPLTRKFAAQTASTQQHCIEEAKKPRTAVQERNEFGDC
underlined and the cyclinsIFVDVEDCQPSSENQPVPMFLEIPESRLDDDMEEVEMED
signature is in bold.IVEEEEEEPIMDIDGRDKKNPLAVVDYIE DIYANYRRTE
NCSCVSANYMAQQADINEK MRSILIDWLIEVHDKFDLMH
ETLFLTVNL IDRFLARQSVVRKKLQLVGLVAMLLACKYE
EVSVPVVGDLILISDKAYTRKEVLEMESLMLNSLQFNMS
VPTPYVMFRRFLKAAESDKKLEVLSFFLIELSLVEYEMV
RFPPSLLAAAAIFTAQCTLYGFKQWTKTCEWHSNYTEDQ
LLECARMMVGFHQKAATGKLTGVNRKYGTSKFGYTSKCE
PANFL LGEMKNP
21The amino acid sequence of SEQ IDMGLPDENNAALSKPTNLQVGGLEIGGRKFGQEIRQTRRA
281. The conserved cyclin andLSVINQNLVGDRAYPCHVVNKRGHSKRDAVCGKDQVDPV
cyclin C-terminal domains areHRPLTRKFAAQTASTQQHCIEEAKKPRTAVQERNEFGDC
underlined and the cyclinsIFVDVEDCQPSSENQPVPMFLEIPESRLDDDMEEVEMED
signature is in bold.IVEEEEEEPIMDIDGRDRKNPLAVVDYIED IYANYRRTE
NCSCVSANYMAQQADINEKMRSILIDWLIEVHDKFDLWI
ETLFLTVNLIDRPLARQSVVRKKLQLVGLVAMLLACEYE
EVSVPVVGDLILISDKAYTRKEVLEMEKLMLNSLQFNMS
VPTPYVFNRRFLKAAESDKKLEVLSFFLIELSLVEYEMV
KFPPSLLAAAAIFTAQCTLYGFKQWTKTCEWHSNYTEDQ
LLECARNMVGFHQKAATGKLTGVHRKYGTSKFGYTSKCE
PANFLL GEMKNP
22The amino acid sequence of SEQ IDMAMVQRQGHDPSSPQEQEDGPSSFLSDDALYCEEGRFEE
282. The conserved cyclin N- andDDGGGGGQVDGIPLFPSQPADRQQDSPWADEDGEEKEEE
C-terminal family domains areEAELQSLFSKERGARPELAKDDGGAVAARREAV EWMLMV
underlined.
RGVYGFSALTAVLAVDYLDRFLAGFRLQRDNRPWMTQLV
AVACLALAAKVEETDVPLLVELQEVGDARYVFEAKTVQR
MELLVLSTLGWEMHPVTPLSFVHHVARRLGASPHHGEFT
HWAFLRRCERLLVAAVSDARSLKHLPSVLAAAAMLRVIE
EVEPFRSSEYKAQLLSALHMSQEMVEDCCRFILGIAETA
GDAVTSSLDSFLKRKRRCGHLSPRSPSGVIDASFSCDDE
SNDSWATDPPSDPDDNDDLNPLPKKSRSSSPSSSPSSVP
DRVLDLPFMNRIFEGIVNGSPI
23The amino acid sequence of SEQ IDMEASYQPHHHGHLRQHDPSSSQQEEQVPFDALYCSEEHW
283. The conserved cyclin andGEEDEEEGLASDGLLSEERDHRLLSPRALLDQDLLWED E
cyclin C-terminal domains are
ELASLFSKEEPGGMRLNLENDPSLADARREAVEWIMRVN
underlined.
AHYAFSALTALLAVNYWDRFTCSFALQEDKPWMTQLSAV
ACLSLAAKVEETQVPLLIDFQVEDSSPVFEAKNIQRMEL
LVLSSLEWKMNPVTPLSFLDYMTRRLGLTGHLCWEFLRR
CENVLLSVISDCRFTCYLPSVIAASTMLHVINGLKPRLD
VEDQTQLLGILAMGMDKIDACYKLIDDDHALRSQRYSHN
KRKFGSVPGSPRGVMELCFSSDGSNDSWSVAASVSSSPE
PHSKKSRAGEEAEDRLLRGLEGEEDDPASADIFSFPH
24The amino acid sequence of SEQ IDMALQEEDTRRHYPTAPPFSPDGLYCEDETFGEDLADNAC
284. The conserved cyclin andEYAGGGARDGLCEIKDPTLPPSLLGQDLFWED GELASLV
cyclin C-terminal domains are
SRETGTHPCWDELISDGSVALARKDAVGWILRVHGHYGF
underlined.
RPLTAMLAVNYLDRFFLSRSYQRDRPWISQLVAVACLSV
AAKVEETQVPILLDLQVANAKFVFESRTIQRMELLLMST
LDWRMNSVTPISFFDHILRRFGLTTNLHRQFFWNCERLL
LSVVADVRLASFLPSVVATAANLYVNKEIEPCICSEFLD
QLLSLLKINEDRVNECYELILELSIDHPEILNYKHKRKR
GSVPSSPSGVIDTSFSCDSSNDSW GVASSVSSSLEPRFK
RSRFQDQQMGLPSVNVSSMGVLNSSY
25The amino acid sequence of SEQ ID
MGQIQ YSEKYFDDTYEYRHVVLPP DVAKLLPKNRLLSEN
285. The conserved cyclin-EWRAIGVQQSRGWVHYAIHRPEPHIMLFRRPLN YQQQQE
dependent kinases regulatoryNQAQQNMLAK
subunit domain is underlined and
the cyclin-dependent kinases
regulatory subunits signature 1 is
in bold.
26The amino acid sequence of SEQ IDMGSIDPPKAEQNGTAAAAVADPGQKPGAGDAMPPPPPVW
286. The conserved chromo domainHSNGTAAEPDVATKRRRMSVLPLEVGTRVMCRWRDG KYH
is underlined and the MOZ/SAS-like
PVKVIERRKLNPGDPNDYEYYVHYTEFNRRLDEWVKLEQ
protein domain is in bold/italics.LDLNSVETVVDEKVEDKV TGLKMTRHQKRKIDETHVEGH
EELDAASLREHEEFTKVKNIATIELGRYEIETWYFSPFP
PEYNDCSKLYFCEFCLNFMKRKEQLQRHMKKCD
DPKVLDRHLKAA
GRGGLEVDVSKLIWTPYREQG
27The amino acid sequence of SEQ IDMDTGGNSLPSGPDGVK RKVCYFYDPEVGNYYLLQHMQVL
292. The conserved histone
KPVPARDRDLCRFHADDYVAELRSITPETQQDQLRQLKR
deacetylase family domain is
FNVGEDCPVFDGLHSFCQTYAGGSVGGAVKLNHGLCDIA
underlined.
INWAGGLHHAKKCEASGFCYVNDIVLGILELLKQHERVL
YVDIDIHHGDGVEEAFYTTDRVMTVSFHKFGDYFPGTGD
IRDIGYGKGKYYSLNVPLDDGIDDESYHSLFKPIIGKVM
EVFKPGAVVLQCGADSLSGDRLGCFNLSIKGHAECVRYM
RSFNVPVLLLGGGGYTIRNVARCWCYETGVALGLEVDDK
MPQHEYYEYFGPDYTLHVAPSNMENKNSRQLLEEIRSKL
LENLSKLQHAPSVPFQERPPDTELPEADEDQEDPDERWD
PDSDMDVDEDRKPLPSRVKRELIVEPEVKDQDSQKASID
HGRGLDTTQEDNASIKVSDMNSMITDEQSVKMEQDNVNK
PSEQIFPK
28The amino acid sequence of SEQ IDMDTGGNSLPSGPDGVK RKVCYFYDPEVGNYYYGQGHPMK
293. The conserved histone
PHRIRMTHALLAHYGLLQHNQVLKPVPARDRDLCRFHAD
deacetylase family domain is
DYVAFLRSITPETQQDQLRQLKRFNVGEDCPVFDGLHSF
underlined.
CQTYAGGSVGGAVKLNHGLCDIAINWAGGLHHAKKCEAS
GFCYVNDIVLGILELLKQHERVLYVDIDIHHGDGVEEAF
YTTDRVMTVSFHKFGDYFPGTGDIRDIGYGKGKYYSLNV
PLDDGIDDESYHSLFKPIIGKVMEVFKPGAVVLQCGADS
LSGDRLGCFNLSIKGHAECVRYMRSFNVPVLLLGGGGYT
IRNVARCWCYETG VALGLEVDDKMPQHEYYEYFGPDYTL
HVAPSNNENKNSPQLLEDIRSKLLENLSKLQHAPSVPFQ
ERPPDTELPEADEDQEDPDERWDPQSDMDVDEQRKPLPS
RVKRELIVEPEVKDQDSQKASIDHGRGLDTTQEDNASIK
VSDMNSMITDEQSVKMEQDNVNRPSEQIFPK
29The amino acid sequence of SEQ IDMRPK DRISYFYDGDVGSVYFGPNHPMKPHRLCMTHHLVL
294. The conserved histone
SYELHTKMEIYRPHKAYPAELAQEHSPDYVEFLHRITPD
deacetylase domain is underlined.
TQHLFPNDLAKYNLGEDCPVFENLFEFCQIYAGGTIDAA
RRLNNQLCDIAINWAGGLHHAKKCEASGFCYINDLVLGI
LELLRYHARVLYIDIDVHHGDGVEEAFYFTDRVMTVSFH
KFGDMFFPGTGDVKEIGGKEGKFYAINVPLKDGIDDTSF
TRLFKAIISKVVETYQPGAIVLQCGADSLAGDRLGCFNL
SIDGHSECVRFVKKFNLPLLVTGGGGYTKENVARCWVVE
TGVLLD TELPNEIPENEYFKYFAPDYSLKIPRGNIVLEN
LNSKSYLSAIKVQVLENLRNIQHAPSVQMQEVPPDFYIP
DFDEDEQNPDERMDQHTQDKQIQRDDEYYDGDNDNDHNM
DD
30The amino acid sequence of SEQ IDMTVAEDFHVNNRSKMVSQATPESRLTGGEDDNSLHNQVD
295. The conserved histoneELLCQELPERQVILEFEGTRPKPYFSDHNGGENSALGVR
deacetylase family domain isATEQDLNSDVEAEEKQKEMTLEDMYKNDGTLYQDDEDQS
underlined and the Zinc fingerDWEPVKRQVELMR WFCTNCTMVNVEDVFLCDIC GEHRDS
RanBP2-type profile is in bold.GILRHGFYASPFMQDVGAPSVEAEVQESREDHARSSPPS
SSTVVGFOEKMLLHSEVEMKSHPHPERAORLQAIAASLA
TAGIFPGRCRSLPVREITKEELQMVHSSEHVDAVEMTSH
MFSSYFTPDTYANEHSARAARIAAGLCADLASTIISGRS
KNGFALVRPPGHHAGIKHAMGFCLHNNAAVAALAAQGAG
AKKVLIVDWQVHHGNGTQEIFQGNKSVLYISLHRHEGGN
FYPGTGAAHEVGTMGAEGYCVNIPWSRRGVGDNDYVFAF
HHIVLPIASAFAPDFTIISAGFDAARGDPLGCCDVTPAG
YAQMTHMLSALSGGKLLVILEGGYNLRSISSSAVAVIKV
LLG DSPISEIADAVPSKAGLRTVLEVLKIQRSYWPSLES
IFWELQSQWGMFLVONRRKQIRKRRRVLVPIWWKWGRKS
VLYHLLNGHLHVKTKR
31The amino acid sequence of SEQ ID
MAAAPSSPPTNRVDVFWHDGMLSHDTGRGVFDTGSDPGF
296. The conserved histone
LDVLEKHPENPDRVRNMVSILKRGPISPFISWETATFAL
deacetylase family domain is
ISQLLSFHSPEYINELVEADKNGGKVLCAGTFLNPGSWD
underlined.
AALLAAGNTLSAMKYVLDGKGRIAYALVRPPGHHAQPSQ
ADGYCFLNNAGLAVRLALDSGCKRVVVVDIDVHYGNGTA
EGFYQSSDVLTISLHINHGSWGPSHPQSGSVDELGEDEG
YGYIINIPLPNGTGDRGYEYAVTELVVPAVESFKPEMV V
LVVGQDSSAFDPNGRQCLTMDGYRAIGRTIRGLADRHSG
GRILIVQEGGYHVTYSAYCLHATVEGILDLPDPLLADPI
AYYPEDEAFPVKVVDSIKRYLVDKVPFLKEH
32The amino acid sequence of SEQ IDMVESSGGASLPSVGQDARK RRVSYFYEPTIGDYYYGQGH
297. The conserved histone
PMKPHRIRMAHNLIVHYYLHRRMEISRPFPAATTDIRRF
deacetylase family domain is
HSEDYVTFISSVTPETVSDPAFSRQLKRFNVGEDCPVFD
underlined.
GIFGFCQASAGGSMGAAVKLNRGDSDIALNWAGGLHHAK
KSEASGFCYVNDIVLGILELLKVHKRVLYVDIDVHHGDG
VEEAFYTTDRVMTVSFHKFGDFFPGSGHIKDTGAGPGKN
YALNVPLNDGIDDESFRGMFRPIIQKVMEVYQPDAVVLQ
CGADSLSGDRLGCFNLSVKGHADCLRFLRSFNVPLMVLG
GGGYTMRNVARCWCYETAVAVG VEPENDLPYNEYYEYFG
PDYTLHVEPCSMENLNAPRDLERIRNNLLEQLSRIPHAP
SVPFQMTPPITQEPEEAEEDMDERPKPRIWNGEDYESDA
EEDKSQHRSSNADALHDENVEMRDSVGENSGDKTREDRS
PS
33The amino acid sequence of SEQ IDMAAIISCHHYHSCCSSLIASKWVGARIPTSCFGRSSTQS
299. The conserved cyclophilin-NNAASVRQFVTRCSSSPSSRGQWQPHQNGEKGRSFSLRE
type peptidyl-prolyl cis-transCAISIALAVGLVTGVPSLDMSTGNAYAASPALPDLSVLI
isomerase family domain isSGPPIKDPEALLRYALPINNKAIREVQKPLEDITDSLKV
underlined.AGLRALDSVERHVRQASRVLKQGKNLIVSGLAESKKDHG
VELLDKLEAGMDELQQIVEDGNRDAVAGKQRELLNYVGG
VEEDMVDGEPYEVPEEYKNMPLLKGRAAVDMKVKVKDNP
NLEECVFRIVLDGYNAPVTAGNFVDLVERHFYDGMEIQR
ADGFVVQTGDPEGPAESFIDPSTEKPRTIPLEIDMDGEK
APVYGATLEELGLYKAQTKLPFNAFGTMAMARDEFEDNS
ASSQIFWLLKESELTPSNANILDGRYAVFGYVTENQDFL
ADLKVGDVIESVQVVS GLDNLANPSYKIAG
34The amino acid sequence of SEQ IDMAGEDFDIPPADEMNEDFDLPDDDDDAPVMKAGDEKEIG
300. The conserved FKBP-typeKQGLKRKLVKEGDAWETPDN GDEVE VHYTGTLLDGTQFD
peptidylprolyl isonerase domains
SSRDRGTPFKFTLGQGQ VIKGWDQGIKTMKKGENAIFTI
are underlined. The FKBP-typePPELAYGEAGSPPTIPPNATLQFDVELL SWTSVKDICKD
peptidyl-prolyl cis-transGGIFKKILVE GEKWENPKDLDEVLVRYEFQLEDGTTIAR
isomerase signature 1 is in bold
SDGVEFTVKEGHFCPAVAKAVKTMKKGEKVLLTVKPQYG
and the FKBP-type peptidyl-prolylFGEKGKPASGDEGAVPPNATLQITLELV SWKTVSEVTDD
cis-trans isonerase signature 2 isKKVIKKILKE GEGYERPNEGAVVEVKLIGKLQDGTVFVK
in bold/italics.
KGHDDCEELFKFKIDEEQ VVDGLDKAVMNMKKGEVALLT
VAPEYAFGSSESKQDLAVVPPSSTVYYEVELV SFVKDKE
SWDMNTEEKIEAAGKKKEEGNVIFKAGKYAKASKRYEKA
VKYIEYDTSFSEDEKKQAKALKVACNLNDAACKLKLKDY
NQAEKLCTKVLELDSRNVKALYRRAQAYIELSDLDLAEF
DIKKALEIDPHNRDVKLEYKVLKEKVKEFNKKDAKFYGN
MFAKMSKLEPVEKTAAKEPEPMSIDSKA
35The amino acid sequence of SEQ IDMSTVYVLEPPTKG KVVLNTTHGPLQVELWPKEAPRAVRN
301. The conserved cyclophilin-
FVQLCLSGY YDNTIFHRIIKDFLVQGG DPTGSGTGGESI
type peptidyl-prolyl cis-trans
YGDAFSDEFHSRLRFKHRGLVACANAGSPHSNGSQFFIT
isomerase family domain is
LDRCDWLDRKNTIFGKITGDSIYNLSGLAEVETDKSDRP
underlined and the cyclophilin-LDPPPKIISVEVLW NPFEDIVPRAPVRSLVPTVPDVQNK
type peptidyl-prolyl cis-transEPKKKAVKKLNLLSFGEEAEEEEKALVVVKQKIKSSHDV
isomerase signature is in bold.LDDPRLLKEHIPSKQVDSYDSKTARDVQSVREALSSKKQ
ELQKESGAEFSNSFREIADDEDDDDDDASFDARMRRQIL
QKRKELGDLPPKPKPKSRDGISARKERETSISRDKDDDD
DDDQPRVEKLSLKKKGIGSEARGERMANADADLQLLNDA
ERGRQLQKQKKHRLRGREDEVLTKLETFKASVFGKPLAS
SAKVGDGDGDLSDWRSVKLKFAPEPGKDHMTRNEDPNDY
VVVDPLLERGKEKFNRMQAKEKRRGREWAGKSLT
36The amino acid sequence of SEQ IDMASAISMHSSGLLLLQGTNGKDVTEMGKAPASSRVANNQ
302. The conserved cyclophilin-QRKYGATCCVARGLTSRSHYASSLAFKQFSKTPSIKYDR
type peptidyl-prolyl cis-transMVEIKAMATDLGLQAKVTN KCFTDVEIGGEPAGRIVIGL
isomerase family domain is
FGDDVPKTVENFRALCTGEKGFGYKGCSFHRIIKDFMIQ
underlined and the cyclophilin-
GGDFTRGNGTGGKSIYGSTFEDENFALKHVGPGVLSMAN
type peptidyl-prolyl cis-trans
AGPSTNGSQFFICTVRTPWLDNRHVVFGQVVDGMDVVQK
isomerase signature is in bold.LESQETSRSDVPRQPCRIVNCGELP LDG
37The amino acid sequence of SEQ IDMAASFTALSNVGSLSSPRNGSEIRRFRPSCNVAASVRPP
303. The conserved cyclophilin-PLKAGLSASSSSSFSGSLRLIPLSSSPQRKSRPCSVRAS
type peptidyl-prolyl cis-transAEAAAAQSKVTN KVYLDISIGNPVGKLVGRIVIGLYGDD
isomerase signature is underlined.
VPQTAENFRALCTGEKGFGYKGSTVHRVIKDFMIQGGDF
DKGNGTGGKSIYGRTFKDENFKLSHVGPGVVSMANAGPN
TNGSQFFICTVKTPWLDQRHVVFGQVLEGMDIVRLIESQ
ETDRGDRPRKRVVVSDCGELPVV
38The amino acid sequence of SEQ ID
MAEAIDLTGDGGVMKTIVRRAKPDAVSPSETLPLVDVRY
304. The conserved FKBP-type
EGVLAETGEVFDSTHEDNTLFSFEIGKGS VISAWDTALR
peptidyl-prolyl cis-trans
TMKVGEVAKITCKPEYAYG STGSPPDIPPDATLIFEVEL
isomerase signature is underlinedV ACKPCKGFSVTSVTEDKARLEELKKQREIAAATKEEEK
and the FKBP-type peptidyl-prolylKRREEAKAAAAARVQAKLDAKKGHGKGKGKAK
cis-trans isomerase signature 2 is
in bold.
39The amino acid sequence of SEQ IDMGNP KVFFDMSIGGQPAGRIVMELYADVVPRTAENFRAL
305. The conserved cyclophilin-
CTGEKGAGRSGKPLHY KGSSFHRVIPGFMCQGG DFTAGN
type peptidyl-prolyl cis-trans
GTGGESIYGSKFADENFVKKNTGPGVLSMANAGPGTNGS
isomerase family domain is
QFFVCTAKTEWLDGKHVVFGQIVDGMDVVKAIEKVGSSS
underlined and the cyclophilin-
GRTSKPVVVADCGQLS
type peptidyl-prolyl cis-trans
isomerase signature is in bold.
40The amino acid sequence of SEQ IDMPNP KVFFDMTIGGAAAGRVVMELYADTTPRTAENFRAL
306. The conserved cyclophilin-
CTGEKGVGRSKKPLH YKGSKFHRVIPSFMCQGG DFTAGN
type peptidyl-prolyl cis-trans
GTGGESIYGVKFADENFIKKHTGPGILSMANAGPGTNGS
isomerase signature is underlined
QFFICTTKTEWLDGKHVVFGKVVEGMEVVKAIEKVGSSS
and the cyclophilin-type peptidyl-
GRTSKPVVVADCGQLP
prolyl cis-trans isomerase
signature is in bold.
41The amino acid sequence of SEQ IDMAEAIDLTGDGGVMKTIVRRAKPDAVS PSETLPLVDVRY
301. The conserved FKBP-type
EGVLAETGEVFDSTHEDNTLFSFEIGRGSV ISAWDTALR
peptidyl-prolyl cis-trans
TMKVGEVAKITCKPEYAYG STGSPPDIPPDATLIFEVEL
isomerase signature is underlinedV ACKPCKGFSVTSVTEDKARLEELKKQREIAAATKEEEK
and the FKBP-type peptidyl-prolylKRREEAKAAAAARVQAKLDAKKGHGKGKGKAK
cis-trans isomerase signature 2 is
in bold.
42The amino acid sequence of SEQ IDMATARSFFLCALLLLATLYLAQAKKSEDLKEVTH KVYFD
308. The conserved cyclophilin-
VEIAGKPAGRIVMGLYGKAVPKTAENFRALCTGEKGTGK
type peptidyl-prolyl cistrans
SGKPLH YKGSSFHRIIPSFMLQGG DFTLGDGRGGESIYG
isomerase signature is underlined
EKFADENFKLKHTGPGLLSMANAGPDTNGSQFFITTVTT
and the cyclophil in-type peptidyl
SWLDGRHVVFGKVLSGNDVVYKVEAEGRQSGTPKSKVVI
prolyl cis-trans isomeraseADSGELP L
signature is in bold.
43The amino acid sequence of SEQ IDMMRREISVLLQPRFVLAFLALAVLLLVFAFPFSRQRGDQ
309. The conserved cyclophilin-VEEEPEITH RVYLDVDIDGQHLGRIVIGLYGEVVPRTVE
type peptidyl-prolyl cistrans
NFRALCTGEKGKSANGKKLHYKGTPFHRIISGFMIQCGD
isomerase family domain is
VIYGDGKGYESIYGGTFADENFRIKHSHAGIISMVNSGP
underlined and the cyclophilin-
DSNGSQFFITTVKASWLDGEHVVFGRVIQGHDTVYAIEG
type peptidyl-prolyl cis-transGAGTYNGKPRKKVIIADSGEIP KSKWDEER
isomerase signature is in bold.
44The amino acid sequence of SEQ IDMWATAEGGPPE VTLETSMGSFTVELYFKHAPRTSRNFIE
310. The conserved cyclophilin-
LSRRGY YDNVKFHRIIKDFIVQGG DPTGTGRGGESIYGK
type peptidyl-prolyl cis-trans
KFEDEIRPELKHTGAGILSMANAGPNTNGSQFFITLAPC
isomerase family domain is
PSLDGKHTIFGRVCRGMEIIKRLGSVQTDNNDRPIHDVR
underlined and the cyclophilin-
ILRTSVKD
type peptidyl-prolyl cis-trans
isomerase signature is in bold.
45The amino acid sequence of SEQ IDMSNP KVFFDILIGKMKAGRVVMELFADVTPKTAENFRAL
311. The conserved cyclophilin-
CTGEKGIGRSGKPLH YKGSTFHRIIPNFMCQGG DFTRGN
type peptidyl-prolyl cis-trans
GTGGESIYGMKFADENFKIKHTGLGVLSMANAGPDTNGS
isomerase family domain is
QFFICTEKTPWLDGKHVVFGKVIDGYNVVKEMESVGSDS
underlined and the cyclophilin-GSTRETVAIEDCGQLS EN
type peptidyl-prolyl cis-trans
isomerase signature is in bold.
46The amino acid sequence of SEQ IDMDDDFEFPASSNVENDDDDGNDNDDNGGDVPEEEDPVAS
312. The conserved FKBP-typePAVLKVGEEREIGKAGFKKKLVKE GEGWETPSSGDEVE V
peptidylprolyl isomerase domains
HYTGTLLDGTKFDSS RDRGTPFKFKLGRGQ
are underlined. The FKBP-type
ESGSPPTIPPNATLQFDVE
peptidyl-prolyl cis-transLL SWSSVKDICKDGGILKKVLVE GEKWDNPKDLDEVFVK
isomerase signature 1 is in bold
YEASLEDGTLISKSDGVEFTVGDGYFCAALAKAVKTMKK
and the FKBP-type peptidyl-prolyl
GEKVLLTVNPQYAFGETGRPASGDEAAVPPDASLQIMLE
cis-trans isomerase signature 2 isLV SWKTVSDVTKDKKVLKKTLKE GEGYERPNDGAAVQVR
in bold/italics. The TPR repeat
LCGKLQDGTVFVKKDDEEPFEFKIDEEQ
is in italics.
PTESQQDLAVVPANSTVYYEV
ELL SFVKEKESWEMNNQEKIEAAARKKEEGNAAFKAGKY
VRASKRYEKAVRFIEYDSSFSDEEKQQAKTLKNTCNLND
AACKLKLKDFKEAEKLCTKVLEGDGKNVKALYRRAQAYI
QLVDLDLAEQDIKKALEIDPNNRDVKLEYKILKEKVREY
NKRDAQFYGNMFAKMNKLEHSRTAGMGAKHEAAPMTIDS
KA
47The amino acid sequence of SEQ IDMAK PRCFMDISIGGELEGRIVGELYTDVAPKTAENFRAL
313. The conserved cyclophilin-
CTGEKGIGPHTGAPLH YKCVPFHRVIKGFMVQGG DISAG
type peptidyl-prolyl cis-trans
DGTGGESIYGLKFEDENFDLKHERKGNLSMANSGPNTNG
isomerase family domain is
SQFFITTTRTSHLDGKHVVFGRVVKGNGVVRSVEHVTTA
underlined and the cyclophilin-AGDCPTVDVVIADCGEIP AGADDGIRNFFKDGDTYPDWP
type peptidyl-prolyl cis-transADLDESPAELSWWMDAVDSIKAFGNGSYKKQDYKNALRK
isomerase signature is in bold.YRKALRYLDICWEKEGIDEVESSSLRKTKSQIFTNSSAC
The TPR repeat is in bold/italics.KLKLCDLKGALLDAEFAVRDGENN
VGIKKELNAAKKKIFERREQ
EKRAYRKNFL
48The amino acid sequence of SEQ IDMTKRKNP LVFLDVSIDGDPVERIVIELFADTVPRTAENF
314. The conserved cyclophilin-
RSLCTGEKGVGKTTGKPLHYKGSYFHRIIK GFMAQGG DF
type peptidyl-prolyl cis-trans
SNGNGTGGESIYGGKFADENFKLAHDGPGLLSMANGGPN
isomerase signature is underlined
TNGSQFFIIFKRQPHLDGKHVVFGKVMRGMEVVKKIEQV
and the cyclophilin-type peptidyl-GSANGKPLQPVKIVDCGETS ETGTQDAVVEEKSKSATLK
prolyl cis-trans isomeraseAKKKRSARDSSSESRGKRRQRKSRKERTRKRRRYSSSDS
signature is in bold.YSSESSDSDSESYSSDTESESKSHSESSVSDSSSSDGRR
RKRKSTKREKLRRQRGKDSRGEQKSARYDKKSRHKSADS
SSDSESESSSRSRSRDDKKKSSRRESARSVSKLKDAEAN
SPENLESPRDREIKKVEDNSSHEEGEFSPKNDVQHNGHG
TDAKFGKYDDQRPRSDGSKKSSGSNRDSPKRLANSVPQG
SPSSSPAHKASEPSSSIRARNPSRSPAPDGNSKRIRKGR
GFTERFSYARRYRTPSPEDVTYRPYHYGRRNFEDRRNDR
YSNYRSYSERSPHRRYRSPPRGRSPPRYQRRRSRSRSVS
RSPGGNKGRYRGRDQSRSRSRSRSRSPRRGSSPANKQLP
LSERLKSRLGTRVDEHSPRRRRSSSRSEDSSRSRSPDEV
PDKHEGKAAPVSPARSRSSSPSGRGLVSYGDASPDSGIN
49The amino acid sequence of SEQ ID
MSVLLVTSLGDIVVDLHADRCPLTCKNFLKLCRIKYYNG
315. The conserved cyclophilin-
CVFHTVQKDFTAQTGDPTGTGTGGDSVYKFLYGDQARFF
type peptidyl-prolyl cis-trans
MDEIHLDLKHSKTGTVAMASGGENLNASQFYFTLRDDLD
isomerase signature is underlined.
YLDGKHTVFGEVAEGLETLTRINEAYVDEKGRPYKNIRI
The CCHC type zinc finger is inRHTYILD DPFDDPPQLAELIPDASPEGKPKDEVVDDVRL
bold and the RNA-binding regionEDDWVPLDEQLGPAQLEEAIRAKEAHSRAVVLESIGDIP
RNP-1 (RNA recognition motif) isDAEIKPPDNV
in bold/italics.
DFSQSVAKLWSQFKRKDSQAAKG KGCFKCGAPDHM
APECPGSSTRQPLSKYILKEDNAQRGGDDSRYEMVFDED
APESPSHGKKRRGRDDRDDRHKNSRQSVEETKFNDREGG
HSVDKHRQSERSKHREDEMSRDSKASEAGRRRIDRDFPE
EERDGEKYTESHRDRDGKRGDYRDYRKGRADVQTHGDRR
GDENYRRKSAAYDDGHEGAGAARRKDSNDDHHAYRRGYG
DSRKGTRDEDDDGRGRRDDPSYRRSSGHKDSSNGGREEQ
KYRSGETDGKSHPERSHRGDRRR
50The amino acid sequence of SEQ IDMRPFNGGSSIACLVLVIAAGALAESQGPHLGSA RVVFQT
316. The conserved cyclophilin-
NYGDIEFGFFPGVAPRTVDHIFRLVRLGCYNTNHFFRVD
type peptidyl-prolyl cis-trans
KGFVAQVADVANGRTAPMNDEQRTEAEKTIVGEFSNVKH
isomerase signature is underlined.
VRGILSMGRYDDPDSAQSSFSILLGDAPHLDGKYAIFGR
VTKGDETLKKLEQLPTRREGMFVMPTERITILSSYYYD T
GAESCEEENSTLRRRLAASAVEVERQRNKCFP
51The amino acid sequence of SEQ IDMPNP KVFFDMQVGGAPAGRIVMELYADVVPKTAENFRAL
317. The conserved cyclophilin-
CTGEKGTGRSGKPLH FKCSSFHRVIPGFMCQGG DFTRGN
type peptidyl-prolyl cis-trans
GTGGESIYGEKFADENFVKKHTGPGILSMANAGPNTNGS
isomerase signature is underlined
QFFICTAQTSWLDGKHVVFGQVVEGLEVVRDIEKVGSGS
and the cyclophilin-type peptidyl-
GRTSKPVVIADSGQLA
prolyl cis-trans isomerase
signature is in bold.
52The amino acid sequence of SEQ IDMRFTSITSAIALFAAAASALDKPLDIKVDKAV ECSRKTK
318. The conserved FKBP-type
AGDKIQVHYRGTLEADGSEFDASYRRGQPLSFHVGKGQ V
peptidyl-prolyl cis-trans
IKGWDQGLLDMCPGEKRTLTIQPDWGYGSRGMGPIPANS
isomerase signature is underlinedVLIFETELV EIAGVAREEL
and the FKBP-type peptidyl-prolyl
cis-trans isomerase signature 2 is
in bold.
53The amino acid sequence of SEQ IDMGNP KVFFDMSIGGQPAGRIVMELYADVVPRTAENFRAL
319. The conserved cyclophilin-
CTGEKGAGRSGKPLH YKGSSFHRVIPGFMCQGG DFTAGN
type peptidyl-prolyl cis-trans
GTGGESIYGSKFADENFVKKHTGPGVLSMANAGPGTNGS
isomerase signature is underlined
QFFVCTAKTEWLDGKHVVFGQIVDGMDVVKAIEKVGSSS
and The cyclophilin-type peptidyl-
GRTSKPVVVADCGQLS
prolyl cis-trans isomerase
signature 2 is in bold.
54The amino acid sequence of SEQ IDMAVATRSRWVAMSVAWILVLFGTLALIQNRLSDTGASSD
320. The conserved FKBP-typePKLVHRKVGEEKKKPDDLEEVTH KVFFDVEIGGKPAGRI
peptidyl-prolyl cis-trans
VMGLFGKTVPKTVENFRALCTGEKGIGKSGKPLNYKGSQ
isomerase signature is underlined
FHRIIPKFHIQGG DFTLGDGRGGESIYGNKFSDENFKLK
and the Cyclophilin-type peptidyl-
HTDAGRLSMTNAGPDTNGSQFFITTVTTSWLDGRHVVFG
prolyl cis-trans isomeraseKVLSGMDVVHKIEAEGGQSGQPKSIVVISDSGELD L
signature is in bold.
55The amino acid sequence of SEQ ID
MAVTLHTNLGDIKCEIFCDEVPKAAEHNARGILSMANSG
321. The conserved cyclophilin-
PNTNGSQFFIAYAKQPHLNGLYTIFGRVIHGFEVLDIME
type peptidyl-prolyl cis-transKTQTGPGDRPLAEIRLNRVTIHA NPLAG
isomerase domain is underlined
56The amino acid sequence of SEQ IDMAVATRSRWVAMSVAWILVLFGTLALIQNRLSDTGASSD
322. The conserved FKBP-typePKLVHRKVGEEKKKPDDLEEVTH KVFFDVEIGGKPAGRI
peptidyl-prolyl cistrans
VMGLFGKTVPKTVENFRALCTGEKGIGKSGKPLNYKGSQ
isomerase signature is underlined
FHRIIPKFMIQGG DFTLGDGRGGESIYGNRFSDENFKLK
and the Cyclophilin-type peptidyl-
HTDAGRLSMANAGPDTNGSQFFITTVTTSWLDGRHVVFG
prolyl cis-trans isomeraseKVLSGMDVVHKIEAEGGQSGQPKSIVVISDSGELD L
signature is in bold.
57The amino acid sequence of SEQ IDMGNP KVFFDMSIGGQPAGRIVMELYADVVPRTAENFRAL
323. The conserved cyclophilin-
CTGEKGAGRSGKPLH YKGSSFHRVIPGEHCQGG DFTAGN
type peptidyl-prolyl cis-trans
GTGGESIYGSKFADENFVKKNTGPGVLSMANAGPGTNGS
isomerase signature is underlined
QFFVCTAKTEWLDGKHVVFGQIVDGMDVVKAIEKVGSSS
andThe cyclophilin-type peptidyl-
GRTSKPVVVADCGQLS
prolyl cis-trans isomerase
signature 2 is in bold.
58The amino acid sequence of SEQ IDMSPVAANAMEEAA EPEVPAPVTPSRDDADTDAAVSRFLG
324. The conserved A-box of the
FCRSKLGLAEGNCVQSSTLLRKTAHVLRSSGTVIGTGTA
Retinoblastoma-associated protein
EEAERYWFAFVLYTVRRVGERKAEDEQNGSDETEVPLSR
is underlined and the B-box of the
ILKASVLNLIDFFKEIPQFVIKAGAIVSGIYGANWDSRL
Retinoblastoma-associated protein
EAREMQTNYVELCILCKFYKRICGEFFILNDAKDDMKSA
is in bold.DSSTSDPVIMYQPFGWLL FLALRIHALSRFKDLVSSTNA
LVSVLAILIIHLPTRFRKFSISDSSQLVKRSEKGVDLVG
SLAYRYDTSEDEIKRTLEKANNVIAEILGITPPPASECK
AENLENVDTDGLIYFGNLMEETSLSSILSTLEKIYEDAT
RNDSEFDERVFINDDDSLLVSGSLSGAAINLTGAKRKYD
SFASPAKTITRPLSPSRSPASHINGIIGGTNLRITATPV
ATAMTTAKWLRTFVSPLPSKPSTDLQGFLASCDRDVTSD
VIRRANIILEAIFPNSPIGERTVTGGLQNANLMDNMWAE
QRRLEALRLYYRVLEAMCRAEAQILHSNNLTSLLTNERF
HRCMLACSAELVLATHRTVTMLFPAVLERTGITAFDLSK
VIESFVRHEETLPRELRRHLNTLEERLLENMVWERGSSM
YNSLVVARPALAPEINRLGLLPEPMPSLDAIALLINFSS
SGLPQSPVQKHEASPGQNGDIRSPKRISTEYRSVLVERN
FTSPVKDRLLALSNIKSKLPPPPLQSAFASPTRPHPGGG
GETCAETAIHIFFSKITRLAAVRINANLERLQLSQQIKE
GVYCLFQQILSQRTNLFFNRHIDQVILCCFYGVAKINQI
NLTFREIIYNYRKQPQCKPQVFRNVEVDWSTRRNGKAGN
EHVDIISFYNEIFIPSVKPLLVELGP TGATTRTNRTSEV
GNKNDAQCPGSPKISSFPTLPDMSPKKVSASHNVYVSPL
RSSKNDASISHSSRSYYACVGESTHAYQSPSKDLVAINS
RLNGNRKVRGTLNFDDVDAGLVSDSMVANSLYLQNGSSM
SSSTAKSSEK
59The amino acid sequence of SEQ IDMRPILMKGHERPLTFLKYNREGDLLFSCAKDHTPTVWFA
325. The conserved G-protein betaDNGE RLGTYRGHNGAVWCCDVSRDSMRLITGSADTTAKL
WD-40 repeat domains areWS VQNGTQLFTFNFDSPARSVDFSIGDRLAVITTDPFME
underlined.LPSAIHVRRIARDPADQASESVLVLRGHQGRIARAVWGP
LNKTIISAGEDAVIRIWDSETGRLLR ESDKETGHRKAVT
SLMKSVDGSHFVTGSQDKSAKLWD IRTLTLIKTYVTERP
VNAVTMSPLLDHVVLGGGQDASAVTHTDHRAGKFEAKFF
DKILQE EIGGVKGHFGPINALAFNPDGKSFSSGGEDGYV
RLHHFDPDYFNIKI
60The amino acid sequence of SEQ IDMDKKR TVVPLVCHGHSRPVVDLFYSPITPDGFFLISASK
326. The conserved G-protein beta
DSSPMLRN GET GDWIGTPEGHKCAVWSCCLDTNALRAAS
domain is underlined and the WD-40
GSADFSAKLWD ALS GDELHSFEHKHIVRSCAFSEDTHLL
repeat domains are in bold
LTGGVEKILPIFD LNRP DAPPREVDNSPGSIRTVAWLHS
DQTILSSCTDIGGVRLWD VRS GKIVQTLETKSPVTSSEV
SQDGRYITTADCSTVKFWD ANHFGLVKSYNMPCNIESAS
LEPKLGNKFIAGGEDNWVHIFDFHT GEEIGCNKGHHGPV
HCVRFSPGGESYASCSEDGTIPIWQ TGPANNVEGDANPS
NGPVTGKAKVGADEVTRKVEDLQIGKEGRDWREG
61The amino acid sequence of SEQ IDMAEGLI LKGTMRAHTDMVTAIAIPIDNSDMVVTSSRDKS
327. The conserved G-protein betaIILWH LTKEEKVYGV PRRRLTGHSHFVQDVVLSSDGQFA
WD-40 repeat domains areLSGSWDGELRLWD LATG VSARRFVGHTKDVLSVAFSIDN
underlined.RQIVSASRDRTIKLWN TLGECKY TIQEGEAHTDWVSCVR
FSPNTLQPTIVSASWDRTIKVWN LTNCK LRNTLAGHNGY
VNTVAVSPDGSLCASGGKDGVILLWD LAEGKRLYNLEAG
AIIHSLCFSPNRYWLCAATENSIKIWDLESKSIVEDLRV
DLKNEADKTDGTTTAASNKKVIYCTSLNWSADGSTLFSG
YNDGVIRVWGTGRY
62The amino acid sequence of SEQ IDMAEGLHLKGTMKAHTDMVTAIAVPIDNADMIVTSSRDKS
328. The conserved G-protein betaIILWHLTKEDK VYGVPRRRLTGHSHFVQDVVLSSDGQFA
WD-40 repeat domains areLSGSWDGELRLWD LA TGVSARRFVGNTKDVLSVAFSIDN
underlined.RQIVSASRDRTIKLWN T LGECKYTIQEGEAHNDWVSCVR
FSPNTLQPTIVSASWDRTVKVWN L TNCKLRNTLQGHSGY
VNTVAVSPDGSLCASGGKDGVILLWD LAEGKKLYSLEAG
AIIHSLCFSPNRYWLCAATENSIKIWDLESKSIVEDLRV
DLKNEADMSDGTTGAMSSNKKVIYCTSLNWSADGSTLFS
GYNDGVIRVWGIGRY
63The amino acid sequence of SEQ IDMAEGL HLKGTMKAHTDMVTAIAVPIDNADMIVTSSRDKS
329. The conserved G-protein betaIILWH LTKEDKVY GVPRRRLTGHSHFVQDVVLSSDGQFA
WD-40 repeat domains areLSGSWDGELRLWD LAT GVSARRFVGHTKDVLSVAFSIDN
underlined and the Trp-Asp (WD)RQ IVSASRDRTIKLWN T LGEC KYTIQEGEAHNDWVSCVR
repeats signature is in bold.FSPNTLQPT IVSASWDRTVKVWN L TN CKLRNTLQGHSGY
VNTVAVSPDGSLCASGGKDGVILLWD LAE GKKLYSLEAG
AIIHSLCFSPNRYWLCAATENSIRIWD LESKSIVEDLRV
DLKNEADMSDG TTGAMSSNKKVIYCTSLNWSADGSTLFS
GYNDGVIRVWG IGRY
64The amino acid sequence of SEQ IDMSGVPAPPFATTTPENGTMSSNSPAFHRDSDDDDDQGEV
330. The conserved G-protein betaFLDDSDIIHEVAVDDEDLPDADDEADEAEEADD SLHIFT
WD-40 repeat domains areGHNGEVYSLACSPTDATLVATGAGDDKGFLWR IGHGD WA
underlined.VELQGHKDSISSLAFSLDGQLLASGSLDGVIQIWD VPSG
N LKGTLDGPGGGIEWIRWHPKGHIILAGSEDSTVWMWN A
DKMA YLNMFSGHGNSVTCGDFTPDGKTICTGSDDATLRI
WN PKSGENIH VVKGHPYHAEGLTSMAISSDSGLAITGAK
DGSVRIVN ISSGR VVSSLDAHADSVEFVGLALSSPWAAT
GSLDQKLIIWD LQHS SPRATCDHEDGVTCLSWVGASRFL
ASGCVDGKVRVWD SLSGD CVRTFHGHSDAIQSLSVSANE
EFLVSVSIDGTARVFEIAEFH
65The amino acid sequence of SEQ IDMGTSQHQLSSCLQLLPRRRGNKNLIFRRTMASGGAAAVA
331. The conserved G-protein betaPPPGYKPYR HLKTLTGHVAAVSCVKFSNDGTLLASASLD
WD-40 repeat domains areKTLIIWS SAALS LLHRLVGHSEGVSDLAWSSDSHYICSA
underlined.SDDRTLRIWS SRSPFD CLKTLRGHTDFVFCVNFNPQSSL
IVSGSFDETIRIWE VKTGR CLNVIRAHSMPVTSVHFNRD
GSLIVSGSHDGSCKIWD TKNGAC LKTLIDDTVPAVSFAK
FSPNGKFILVATLNDTLKLWN YATGK FLKIYTGHKNSVY
CLTSTFSVTNGKYIVSGSEDRCICIWD LQGKN LIQKLEG
HSDTVISVTCHPSENKIASAGLDSDRTVRIWL QDA
66The amino acid sequence of SEQ IDMP SQKIETGHQDIVHDVAMDYYGKRVATASSDTTIKIIG
332. The conserved G-protein betaVSNSSGSQ HLASLSGHKGPVWQVAWAHPKFGSILASCSY
WD-40 repeat domains areDGQVILWK EGNQNDWA QAHVFNDHKSSVNSIAWAPHELG
underlined.LCLACGSSDGNISVFT ARPDGGWD TTRIEQAHPVGVTSV
SWAPSMAPGALVGSGLLDPVQKLASGGCDNTVKVWK LYN
GTWKMD CFPALQMHSDWVRDVAWAPNLGLPKSTIASASQ
DGTVVIWT VAKEGEQW QGKVLKDFKTPVWRVSWSLTGNL
LAVADGNNNVTLWN EAVDGEWQQVTTVEP
67The amino acid sequence of SEQ ID
MKIAGLKSVENAHDESVWAAAWVPATESRPALLLTGSLD
333. The conserved G-protein betaETVKLWR PDELA LERTNAGHFLGVVSVAAHPSGVIAASA
WD-40 repeat domains areSIDSFVRVFD VDTNA TIATLEAPPSEVWQMQFDPKGTTL
underlined and the Trp-Asp (WD)AVAGGGSASIKLWD TATWELNATLSIPRPEQPKPSEKGN
repeats signature is in bold.KKFVLSVAWSPDGRRLACGSMDGTISIFDVARAK FLHHL
EGHFMPVRSLVFSPVEPRLLFSASDDAHVHMYD SEGRS L
VGSMSGHASWVLSVDVSPDGAALATGSSDRTVRLWD LSM
RA AVQTMSNHSDQVWGVAFRPMAGAGVRAGGRLASVSDQ
KSISLYD YS
68The amino acid sequence of SEQ IDMEIDLGNLAFDVDFHPSEQLVASGLITGDLLLYRYGDGS
334. The conserved G-protein beta
SPEKLLEVRAHGESCRAVRFINDGKAILTGSPDCSILAT
WD-40 repeat domains areD VET GSVVARVENAHEAAVNRLVNLTESTIATGDDNGCI
underlined and the Trp-Asp (WD)KVWD TRQ RSCCNTFSAHEDFISDMTFASDSMKLVVTSGD
repeats signature is in bold.GTLSVCN LR SNKVQTRSEFSEDELLSVVIMKNGRKVVCG
TQSGTLLLYS WGFFKDCSDRFVDLSPSSVDALLKLDEDR
IIAGTENGLISLIGILP NRIIQPIAEHSDHPIERLAFSH
DKK FLGSISHDQTLKLWD LNDILGSEDSPSSQAAIDDSD
SDEMOVDANPPDSSKGNKKKHSGKGNDVGNANNFFADLG
D
69The amino acid sequence of SEQ IDMSQQPSVILATASYDHTIRFWEAKSGR CYRTIQYPDSQV
335. The conserved G-protein betaNRLEITPHKRYLAVAGNPSIRLFD VNSNTPQ PVMSFDSH
WD-40 repeat domains areTNNVMAVGFQYDGNWMYSGSEDGTVRIWD LRARG CQREY
underlined and the Trp-Asp (WD)ESRGAVNTVVLHPNQTELISGDQNGNIRVWD LTANSCS C
repeats signature is in bold.ELVPEVDTAVRSLTVMWDGSLVVAANNNGTCYVWR LLRG
SQTMTNFE PLHKLQAHNGYILKCLLSPEFCEPHRY LATA
SSDHTVKIWN VEGFT LEKTLIGHQRWVWDCVFSVDGAYL
ITASSDTTARLWS MSTGQDIRVYQGHHKATTCCALHDGA
EGSPG
70The amino acid sequence of SEQ IDMEDANDMEVEVEVEAEEHSPSSSNPSGSSFRRFGLKNSI
336. The conserved G-protein betaQTNFGSDYVFEITPKFDWSLMGVSLSSNAVKLYSPTT GQ
WD-40 repeat domains are
YCGECRGHSDTVNGISFSGPSSPHVLHSCSSDGTIRAWD
underlined.TRSF KEVSCISAGPSQEIFSFSFGGSSDSLLSAGCKSQI
LFWDWRN RKQVACLEDSHVDDVTQVCFVPHHQNKLISAS
VDGLICIFDTAGDINDDEHMESVINVGTSIGKVGIFGQT
FEKLWCLTHIETLSVWDWKEGTNEANFEDARKLASDSWS
LDHIDYFVDCHSAEEGEGLWVIGGTNAGTLGYFPVKYKG
GAAI GSPEAVLGGGHSDVVRSVLPMSGMAGTTSKTRGIF
GWTGGEDGRLCCWL SDDSSATSRSWMSSNLVLKSSRSHR
KKNRHQPY
71The amino acid sequence of SEQ IDMSQHQEYPMEYAADDYDVGEVEDDMYFHERVMGDSDTDE
337. The conserved G-protein betaDEEYDHLDNKITDTSAADARRGKDIQGIPWERLSVTREK
domain is underlined and the WD-40YRRTRIEQYKNYENVPQSGESSEKDCKPTRKGGNYYEFW
repeat domains are in boldRNTRSVKSTILHFQLRNLVWSTTKHDVYLMSHFSIIHWS
SLTCKKTEVLDVYGHVAPREKHPGSLLEGFTQTQVSTLA
VRDKLLIAGGFQGELICKNLDRPGVSYCCRTTYDDNAIT
NAVEIYDYPSGAVHFMASNNDCGVRDFDMEKFELSRHFT
FPWPVNHTSLSPDGKLLVIVGDNPEGIVVDSQR GKTIRP
LQGHLDFSFASAWHPDGHIFATGNQDKTCRIWD IRNLSK
SVAVLKGNLGAIRSIRFTSDGRFMANAEPADFVHVYD VK
SGYEKEQEIDFFGEISGVSFSPDTESLFVGVWDRTYGSL
LQYNRCRNYSYLDSM
72The amino acid sequence of SEQ IDMGASSDPNPDVSDEHQKRSEIYTYEAPWHIYANNWSVRR
338. The conserved G-protein betaDKKYRLAIASLLDHPAAAAAVPNRVEIVQLDDSTGEIRA
WD-40 repeat domains areDPNLSFDHPYPATKAAFVPDKDCQRADLLATSSDFLRIW
underlined.RIADDSSRVDLRSFL NGNKNSEFCRPLTSFDWNEAEPKR
IGTSSIDTTCTIWD IERET VDTQLIAHDKEVYDIAWGGV
SVFASVSADGSVRVFD LRDKEHSTIIYESSEPDTPLVRL
GWNKQDPRYMATIIMDSAKVVVLDIRYPTMP VVELQRRQ
ASVNAIAWAPHSSCHICTAGDDSQALIWD LSSMAQPVEG
GLDPILAYTAGAEIEQLQWSSSQPDWVAIAFSLKLQ
73The amino acid sequence of SEQ IDMRGGGGGGDATGWDEDAYRES VLKEREVQTRTVFRAAFA
339. The conserved G-protein betaPSPSPSPSPDAVVVASSDGSVASYSIS ACLSDRRLQSLR
WD-40 repeat domains areFADAKSQNVLEAE PACFLQGHDGPAYDVKFYGEGEDSLL
underlined.LSCGDDGRIRGWM WRDITSSEAHDHSQGNSAKPVLDLVN
PQSRGPWGALSPIPENNALAVDVKRGSIYAAAGDSCAYC
WDVECGK IKTVFKGHSDYLHCIAARNSSSQIITGSEDGT
ARIWD CRSGKCVQVIDP DKDHKKGFFASVSCLALDASES
WLVCGRGRDLSVWS ISASQCIAKISTNAPAQDVLFDDNQ
ILLVGAEPLISRLDMNGAVLSQIHCAPQSVFSVSLHQSG
VTAVGGYGGLVDVISQFGSHLCTFRCKCI
74The amino acid sequence of SEQ IDMEAPIIDPLQGDFPE VIEEYLEHGIMKCIAFNRRGTLLA
340. The conserved G-protein betaAGCTDGSCIIWD FETRGVA KELRDKECTAAITSVCWSKY
WD-40 repeat domains areGHRILVSASDKSLILWD VLSGEKIAHTTLQHTVLQACLH
underlined.PGSSTPSICLACPFSSAPMIVDLNTGSTTALPVLTADVS
NGATPLSRNKTSDTSVTYSPCNACFNKHGDLVYAGTSKG
EILIIDHKNVRV CAIVLVSGGAVIKNVVFSRNGQYMLTN
SMDRLIRIYK NLLPPKDGLKNLDELNESFNESDDVEKLK
AIGSKCLELLHEFQDSITRVQWKAPCFSGDGEWVIGGAA
SRGEHKIYIWDRAGH LVKILEGPKEALMDLAWHPVHPII
ISVSLTGLVYIWA KDYTENWSAFAPDFKELEENEEYVER
EDEFQLVPETEEVKGLDVHEDDEVDVLTVERDSVFSDSD
MSQEELCFLPAVPCLDIPEQQDKCVGSCSKLPDGNHSGS
PLSVEAGQNGNASNHNSSPLEPMENSTADDTDGVRLKRK
RKPSEKGLELQAEKVKEPVKPLKSSGRLSKTHKPVIDPD
SSNGVYGDDGSD
75The amino acid sequence of SEQ IDMRGVSWPEDGNNPSTSSSSQRNQQQAHAPRAVSGHAASH
341. The conserved G-protein betaPSASNIFKLLVQREVSPRSKHSSKKLWREASKCQPYPFQ
WD-40 repeat domains areQSCEAVRDVRQGLISWVESASLRHL SAKYCPLVPPPRST
underlined.IAAAFSPDGKILASTHGDHTVKLID SQT GSCLKVLRGHR
RTPWVVRFHPLYPEILASGSLDHEVRLWD ANT AECIGSR
NFYRPIASIAFHARGELLAVASGHKLYIWH YNRRGETSS
PTIVLRTQRSLRAVHFHPHAAPFLLTAEVNDLDSADSAH
TLATSPGYLHYPPPTVYFADAHSHERSRLADELPLNPLP
LLMWPSFTRDDGRVPLQRIDGDVGLNGQQRVDSSSSVRL
WTYSTPSGQYELLLSPVESGNSPSMPEETGNNAFSSAVE
AEVSQSAMDTVEDHEVQPEERNTQFFSFSDPRFWELPLL
HGWLVGQTQAGPRSVRQSSPGDIETQSAFGEVASVSPIT
SGVMPVSMDPSRFGGRSGSRYRSPGSRGVHVTGPNNDGP
RDENDPQSVVSKLRSELAASLAAAASTELPCTVKLRIWP
HDVKDPCAQLDLESCRLTIPHAVLCSEMGAHFSPCGRFL
AACVACVLPHLESDPGLHGQVNQDVTGVATSPTRHPISA
HQIMYELRIYSLEEATFGIVLASRPVRAAHCLTSIQFSP
TSEHLLLAYGRRHSSLLKSIVIDGENTVPIYTILEVYRV
SD MELVRVLPSAEDEVNVACFHPSVGGGLIYGTKEGKLR
ILH YDSSHGLNLKSSGFLDENVPEVQTYALEC
76The amino acid sequence of SEQ IDMDSAVAIAALSLVVGAAIALLFFGNYFRKRRSEVVAMAE
342. The conserved G-protein betaADLQPHPKNPSRPPPQPAAKKVHAKSHAHGADKDKNKRH
WD-40 repeat domains areHPL DLNTLKGHGDSVTGLCFASDGRSLATACADGVVRVF
underlined and the Trp-Asp (WD)K LDDASNKSFKFLRINLPAGGHPTAVAFGDGVSSVIVAS
repeats signature is in bold.QHLSGCSLYMYGEEKPTNLDSNKQQTKLPMPEIKWEHH K
VHEQKAILTLSGAAANYDSGDGSTIIASCSEGTDIIIWH
AKTGR ILGNVDTNQLKNTMSAISPNGRFIAAAAFTADVK
VWE IVYSRDGSVKGVT KVMQLKGHKSAVTWLCFTPNSEQ
IVTASKDGSIRIWN INVRYHLDEDTKTLKVFPIPLQDSS
GTTLHYERLSLSPDGKILAATHGSMLQWLCIETGKV LDT
AEKAHDGDITCMSWAPQSIPTGDKKVNVLATASGDKKVK
LWA APPLPS
77The amino acid sequence of SEQ IDMEVEPKKASKTFPVKPKLKPKPRTPSGKTPESKYWSS FK
343. The conserved G-protein beta
TTHPLDNLSFSVPSLAFSPSPPHLLAAAHSATVSLFSPH
WD-40 repeat domains areRTTISSFSDVVSSLSFRSDGQLLAASDLSGLIQVFD VRS
underlined.
RTPLRRLRSHARPVRFVRYPVLDKLHLVSGGDDALVKYW
D VAG ESVVSELRGHKDYVRCGDCSPADANCFVTGSYDHV
VKLWD VRVRD GNRAATEVNHGSPVQDVIFLPSGSLVATA
GGNSVKIWD LIGG GRMVYSNESHNKTVTSICVGTNGAQQ
SGEEGVQLRILSVGLDGYMKVFD YSRMKVTHSMRFPAPL
LSIGFSPDSNVRAIGTSNGILYVGKRKAKENAEGGANGI
LGLGSVEEPRRRVLKPSFYRYFHRGQSEKPSEGDYLVMR
PKKVKLAEHDKLLKKFQHKNALISVLGGNDPEKVVAVME
ELVARRALLKCVLNLDADELGLILTFLHKNSTVPRYSSL
LLGLAKKVIDLRLEDIRASDALKGHIRNLKRSVDEEIRI
QEGLQEIQGMVSPLLRIAGRR
78The amino acid sequence of SEQ IDMQGGSSGVGYGLKYQARCISDVKADTDHTSFLTGTLSLK
344. The conserved G-protein betaEENEVHLLRLSSGGTELICEGLFSHPSEIWDLSSCPFDQ
WD-40 repeat domains areRIFSTVFSTGESYGAAVWQIPELYGQLNSPQ LEKIASLD
underlined.
AHSRKISCVLWWPSGRHDKLVSIDEENIFLWGLDCSKKS
AQVQSQESAGMLHNLSGGAWDPHDVNTVAATCESSIQFW
D LRTMKKANSLESVHARDLDYDMRKKHLLVTSEDESGVR
VWDLRMP KAPIQEFPGHTHWTWAVRCNPDYEGLILSAGT
DSAVNLWW SSTASSDELISERLIDSPTRKL DPLLHSYND
YEDSVYGLAWSSREPWIFASLSYDGRVVVES VKPFLSRK
79The amino acid sequence of SEQ IDMAEEEGSAELEQQLEEEFAVWKKNTPILYDLLISHALEW
345. The conserved G-protein betaPSLTVHWAPLLPQPSSSAAAAAGDPSLAAHRLVLGTHTS
WD-40 repeat domains areDGAPNFLILADALLPSSESDHCGDDAVLPKVEISQKIRV
underlined.DGEVNRARFMPQNHNIVGAKTNGCEVYVFDCSKQAAKQH
DGGFDPDLRLTGHDGEGYGLSWSPLKENYLLSASHDKKI
CLWDISAAAQDKV LGAMHVFEAHEGAVGDASWHSKNDNL
FGSAGDDCQLMIWD LRT NKAQQCVKAHEKEVNSVSFNSY
NDWILATASSDTTVGLFD MRKL TTPLHVFSSHEGEVLQV
EWDPNHEAVLASSSEDRRVMVWD LNRIGDEQQEGDASDG
P AELLFSHGGHKAKISDFSWNKNEPWVISSVAEDNSVQV
WQ MAESICGDDDDMQAMEGYI
80The amino acid sequence of SEQ IDMGNYGEEDEDQYFDALEETASVSDRGSNSSDCCSSGSGL
346. The conserved G-protein betaDENVLDSLGFEFWTKFPESVRARRNRFLNLTGLGIEANS
WD-40 repeat domains areVDKEDAFPPSCNEIEVYTCKVTRDDGAVQRSLDSYNCIS
underlined.LLQSSTSIRSNQEVESLRGDSLLSSFRGRSKESDDLTEL
CGMGCPESKRNAVSEFGSVSQGSIEELRRIVASSPLVHP
LLHRKLEYERELIETKQKMGAGWLRKFGSATCISGRQGD
TWSDPDDLEITAGMKMRRVRAHSSKKKYKELSSLYAAQE
FLAHEGSISTMKFSMDGQY LASAGEDTVVRVWKV TEEDR
SERVNVTVDPSCLYFALNESTQLASLNTNKEHIGKAKTF
QRSSDSSCVILPLKVFQITEKPWHEFKGHNGEVLDLSWS
SKGY LLSSSTDKTVRLWRV GCDRCQRVYSHNDYVTCISF
NPVNENF FISGSIDGKVRIWN VFGGQVVAYIDCREIVSA
VCYRSDGKGAIVGTMTGNCLFYSIKDNHLQMDAQVYLHG
KKKSPGKRITGFQFPPNDPGKLNITSADSVIRVLSGLDV
VCKLKGPRNSGGPMIATFTSDGKHVISASEDSNVYIWNY
AGQDKTSSRVKKIWSCESFWSSNASVALPWCGIRTVPEA
LAPPSRSEERRASCAENGENHHMLEEYFQKMPPYSPDCF
SLSRGFFLELLPKGSATWPEEKLSDTSPPTVSSQAISKL
EYKFLKSACHSVLSSAHMWGLVIVTAGWDGRIRTYHNYG
LPVRS
81The amino acid sequence of SEQ IDMDIDFKEYR LRCELRGHEDDVRGVCVCGDGSIGTSSRDR
347. The conserved G-protein betaTVRLWA PSAGERRKYE VARVLLGHKSFVGPLAWVPPSEE
WD-40 repeat domains areLPEGGIVSGGMDTLVMAWD LRMG EAQTLKGHQLQVTGIV
underlined.LDGGDIVSASVDCTLIRWK NGQ LTEHWEAHKAPIQAVIR
LPSGELVTGSSDTTLKLWR GKT CTQTFVGHTDTVRGLAV
MPDLGILSASHDGSIRLWA VSGE CLMEMVDHTSIVYSVD
SHASGLIVSGSEDRFAKIWK DGV CFQSIEHPGCVWDVKF
LEDGDIVTACSDGTIRIWT NQEDRMANSTELELFDLELS
SYKRSRKRVGGLKLEELPGLEALQVPGTSDGQTKVIREG
DNGVAYAWNSTELKWDKIGEVVDGPEDSMNRPALDGVQY
DYVFDVDIGDGEPTRKLPYNRSDNPYDTADKWLLKENLP
LSYRQQIVEFILANSGQRDFNLDPSFRDPYTGSSAYVPG
APSQLAAKQARPTFKHIPKKGMLVFDAAQFDGILKKINE
FNNTLLSNQEKKNLSLTDIEISRLGAVVKILRDTSHYHS
SKFADADFDLMLKLLESWPYEMMFPVIDIFRMVILHPDG
ADGLLRHQEDKKDVLMESIKRATGNPSVPANFLTSIRAV
TNLFKNSAYYSWLQKHRSEMLDAFSSCSSSSNKNLQLSY
ATLLLNYAVLLIEKKDEEGQSQVLSAALELAENESLEVD
ARYRALVAIGSLMLDGLVKRIALDFDVEHIAKAARTSKE
AKIAEVGADIELLIKQS
82The amino acid sequence of SEQ IDMEFTEAYKQSGPCCESPNARFIAVAVDYRLVIRDTLSLK
348. The conserved G-protein betaVVQLFSCLDKISYIEWALDSEYILCGLYKRPMIQAWSLI
domain is underlined and the WD-40QPEWTCKIDEGPAGIAYARWSPDSRHILTTSDFQLRLTV
repeat domains are in boldWSLVNTACVHVQWPKHASKGVSFTRDGKFAAICTRHDCK
DYINLLSCHNWEIMGVFAVDTLDLADIQWSPDDSAIVIW
DSPLEYKVLVYSPDGR CLFKYQAYESGLGVKSVSWSPCG
QFLAVGSYDQMLRVLS HLTWKTFAEFTHLSNVRAPCCAA
IFREVDEPLQIDMSELSLSDDYMQGNSGDAPEGHYRVRY
DVTEVPITLPCQKPPADRPNPKQGIGLMSWSNDSQYICT
RNDSNPTILWIWDMRH LELAAILVQKDPIRAAVWDPTGT
RLVLCTGSSHLYHWT PSGAYCVSVPLSQFNITDLKWNSD
GSCLLLKDKESFCCAAAPLPPDESSDYSSDD
83The amino acid sequence of SEQ IDMATIAALDDDMVRSMSI GAVFSDFVGKLNSLDFHRKDDI
349. The conserved G-protein betaLVTAGEDDSVRLYD IANARLLKTTFHKKHGTDRVCFTHH
WD-40 repeat domains arePNSLICSSTKNLDTGESLRYISMYDNR SLRYFKGHKQRV
underlined.VSLCMSPINDSFMSGSLDHSVRMWD LRVNACQGILRLRG
RPTVAYDQQGLVFAVANEGGAIKLFDSRSYDKGPFD AFL
VGGDTSEVCDIKFSNDGKSVLLSTTNNNIYVLD AYAGDK
QC GFNLEPSPSTPIEASFSPDGQYVVSGSGDGTLHAWN I
SRRNEVACWNSHIGVASCLKWAPRRANFVAASTVLTFWI
PNSEPELASAKGEAGVPPEQV
84The amino acid sequence of SEQ IDMSVAELKERHRAATETVNSLRERLKQKRVQLLDTDVAGY
350. The conserved G-protein betaARTQGKTPVTFGATDLV CCRTLQGHTGKVYSLDWTPERN
WD-40 repeat domains areRIVSVSQDGRFIVWN ALTSQ KTHAIRLPCAWVMTCAFA P
underlined and the beta G-proteinNGQSVACGGLDSVCSIF N LNSPVDRDGNLP VSRMLSGHK
(transducin) is in bold.GYVSSCQYVPDGDAHLITGSGDQTCVLWD ITTGLRTSVF
GGEFQSGHTADVLSVSINGSSPRIFVSGSCDSTARMWD T
RVASR AVHTYHGHEGDVNAVKFFPDGNRFGTGSDDGTCR
LFD IRTGHELQVY YQQRGIDEIPHVTSIAFSISGRLLIA
GYSNGDCFVWD TLLAQVVLN LGSLQNSHEGRISCLGVSA
DGSALCTGSWDTNLKIWA FGGIRRVT
85The amino acid sequence of SEQ IDMKKRPRGASLDQAVVDIRRREVGGLSGLSFARRLAASEG
351. The conserved G-protein betaLVLR LDIYNKLKGHRGCVNTVGFNLDGDIVISGSDDEHV
domain is underlined and the WD-40
KLWDWQTGKVKLSFDSGHLSNVFQAKIMPYTDDRSIVTC
repeat domains are in bold
AADGQARHAQILEGGQVQTMLLAKHRGRAHKLAIDPGSP
HIVYTCGEDGLVQRLDLRSNTARELFTCEEVYGTHVEVV
HLNAIAIDPRNPNLFVIGGSDEYARVYDIRNYKWNGSHN
FGRSANYFCPSHLIGEAHVGITGLAFSCQSELLVSYNDE
SIYLFTQEMGLGPDPLSASTKSVDSNSSEVTSPTAVNVD
DNVTPQVYKGHRNCETVKCVGFFGPKCEYVVSGSDCGRI
FIWK KKG GQLIRVMAADKIWVNCIEPHPHIPALASSGIE
NDIKIWT PKAIERATLPMNVEQLKPKARGWMNRISSPRQ
LLLQLYSLERWPEEGGETSSGLAAGQEELTELFFALSAN
GNGSPDGGGDPSGPLL
86The amino acid sequence of SEQ IDMSKR GYKLQEFVAHSSNVNCLSIGKKACRLFLTGGDDCK
352. The conserved G-protein betaVNLWA IGK PNSLNSLCGETNAVESVAFDSAEVLVLAGAS
WD-40 repeat domains areSGVIRLWD VEE AKLVRGLTGHRSNCTAMEFHPFGEFFAS
underlined and the Trp-Asp (WD)GSTDTNLKIWD IRK KGCIHTYKGHTRGISTIRFSPDGRW
repeats signature is inbold.VVSGGNDNVVKVWD LTA GKLLHDFKFHENHIRSIDFHPL
EFL LATGSADRTVKFWD L ET FELIGSSRPEAAGVRAIAF
HPDGRTLFCGLEDSLKVYS WEPVICHDGVDNGWSTLADL
CIHDGKLLGCSYYQSSVGVWVADASLIEPYGTNVKPQQK
DSGDDEIEHQESRPSAKVGTTIRSTSIMRCASPDYETKD
IKNIYVDTASGNPVSSQRVGTTNFAKVTQPLDFNDTPNL
TLRRQGLVTETPDGLSGHVPSKSITQPKVVSRDSPDGKD
SSRRESITFSRTKPGMLLRPAHSRRPSSTKYDVDRLSAC
AEIGVLSSAKSGSESLVDSFLNIKVAPEDGARNGCEDNH
SSVKNVSVESEKVLPLQTPKTEKCDQTVGFKEEINSVKF
VNGVAVVPGRTRTLVEKFEKREKLNSTEDQTINTPENPT
LDKTPPPSLAENEEKSDRLNIVERKATRMSSHMVTAEDR
TPVTLVGSPEDQSTVMAPQRELFADESSKTPPLPVEDLE
IHHGSNVSEDKATILSSQTVSEEDSKRSTLIRNFRRRDR
FKSTEGRSPVMATQRKLPTDESGKTSSLPMEDLEIKGGL
NVSEDKATSFSSRAPPREDRAHSALVRNVRKRDKFKSTN
DTITVMVHQRGLSTDEASTVSVERVERRQLSNNVENPLN
NLPPHSVPPTTTRGEPQYVGSESDSVNHEDVTELLLGNH
EVFLSTLRSRLTKLQVV
87The amino acid sequence of SEQ IDMSTFLTGTALSNPNPNK SYEVVQPPNDSVSSLSFNPKAN
353. The conserved G-protein betaFLVATSWDNQVRCWE IVRSGTSLGT TPKASISHDQPVLC
WD-40 repeat domains areSTWKDDGTTVFSGGCDKQVKNWP LSGG QPMTVAMHDAPI
underlined.KEISWIPEMNLLVTGSWDRTLRYWD TRQAN PVHIQQLPE
RCYALTVRHPLMVVGTADRNLIIYN LQSPQTEFKRISSP
LKYQTRCLAAFPDQQGFLVGSIEGRVGVHHLDDSQQSKN
FTFK CHREGSEIYSVNSLNFHPVHHTFATAGSDGAFNFW
D KDSRQRLKAMSRCSQPIPCSTFNNDGSIFAYSACYDWS
KGAENHNPATAKTYIFLHLPQESEVKGKPRLGTTGRK
88The amino acid sequence of SEQ IDMEVEAQQRDVNNVNCQLVDPEGTTLGPPMYLPQDVGPQQ
354. The conserved G-protein betaLQQMVNKLLSNEDKLPYTFYISDQELVVPLESYLQKNKV
WD-40 repeat domains areSVEKVLSIVYQPQAIFRIRPVNRC SATIAGHSEAVLSVA
underlined and the Trp-Asp (WD)FSPDGKQ LASGSGDTTVRLWD LSTQTP MFTCRGHKNWVL
repeats signatures are in bold.SIAWSPDGKHLVSGSKAGEIQCWD PLTGQP SGNPLVGHK
KWITGISWEPVHLSSPCRRFVSSSKDGDARIWD VTLRRC
VICLSGHTLAVTCVKWGGDGVIYTGSQDCTIKVW ETSQG
K LIRELKGHGHWVNSLALSTEYVLRTGAFDHTGKQYS SA
EEMKQVALERYKMKKGNAPERLVSGSDDFTMFLWEPSVS
KH PKTRMTGHQQLVNHVYFSPDGQ WVASASFDKSVKLWN
GITGK FVAAFRGHVGPVYQISWSADSR LLLSGSKDSTLK
IWD IRTKK LKRDLPGHADEVFAVDWSPDGEKVVSGGKDK
VLKLWM G
89The amino acid sequence of SEQ IDMDAGSAHSSSNNKTQSRSPLQEQFLQRRNSRENLDRFIP
355. The conserved G-protein betaNRSAMDFDYAHYMLTEGRKGKENPAVSSPSREAYRKQLA
WD-40 repeat domains areETLNMNRTRILAFKNKPPTPVELIPHELTSAQPAKPTKT
underlined.RRYIPQTSERTLDAPDLLDDYYLNLLDWGSSNVLSIALG
NTVYLWNASDGSTS ELVTIDDETGPVTSVSWAPDGRHIA
VGLNNSDVQLWDS ADNRL LRTLRGGHRSRVGSLAWNNHI
LTTGGMDGLIVNND VRVRSH IVDTYRGHTQEVCGLKWSA
SGQQLASGGNDNILHIWD RSTASSNSPTQ WLHRLEEHTA
AVKALAWCPFQGNLLASGGGGGDRTIKFWN THTGACLNS
VDTGSQVCALLWNKNERELLSSHGFTQNQLTLWKYPSHV
KIAELTGHTSRVLFMAQSPDGCTVASAAGDETLRFWN VF
GVPEVAKPAPKANPEPFAHLNRIR
90The amino acid sequence of SEQ IDMEEAIPFK NLPSREYQGHKKKVHSVAWNCTGTKLASGSV
356. The conserved G-protein betaDQTARVWH IEPHGHG KVKDIELKGHTDSVDQLCWDPKHA
WD-40 repeat domains areDL IATASGDKTVELWD ARSGKCSQQAELSGENINITYKP
underlined and the Trp-Asp (WD)DGTHVAVGNRDDELTILDVRKFKPIHKRKFNYEVNEIAW
repeats signature is in bold.NMSGEMFFLTTGNGTVEVLAYPS LRPVDTLMAHTAGCYC
IAIDPVGRYFAVGSADSLVSLWD ISE MLCVRTFTKLEWP
VRTISFNHTGDYVASASEDLFIDISN VQTGRTVHQIPCR
AAMNSVEWNPKYNLLAYAGDDKNKYQADEGVFRIFGFES
A
91The amino acid sequence of SEQ IDMGKDEEEMRGEIEERLINEEYKVWKKNTPFLYDLVITHA
357. The conserved G-protein betaLEWPSLTVEWLPDREEPPGKDYSVQKLVLGTHTSENEPN
WD-40 repeat domains areYLMLAQVQLPLEDAENDARHYDDDRADVGGWGCANGKVQ
underlinedIIQQINHDGEVNRARYMPQNSFIIATKTVSAEVYVFDYS
KHPSEPPLDGA CSPDLRLRGHSTEGYGLSWSKFKQGHLL
SGSDDAQICLWD INATPKNKS LDAMQIFKVHEGVVEDVA
WHLRHEYLFGSVGDDQYLLIWD LRTPSV TKPVQSVVAHQ
SEVNCLAFNPFNEWVVATGSTDKTVKLFD LRKI STALHT
FDAHKEEVFQVGWNPENETILASCCLGRRLMVWD LSRID
EEQTPEDAEDGP PELLFIHGGHTSKISDFSWNTCEDWVV
ASVAEDNILQIWQ MAENIYHDEDDVPGEESNKGS
92The amino acid sequence of SEQ IDMMRGFSCTEDGDAPSTSSTSPPPPPPPPHRQQMQAPRAS
358. The conserved G-protein betaSSSSGQPTSRRSTGNVFKLLARREVSPRSKHSLKKFWGE
WD-40 repeat domains areASECQLCPFQQSYEAVRDVRRSLISWVEAFSLQHLS AKY
underlined.CPLMPPPRSTIAAAFSPDGKILASTHGDHTVKLID SQT G
SCLKVLRGHRRTPWVVRFHPLYPEILASGSLDHEVHLWD
ANT AECIGSRNFYRPIASIAFHAQGDLLAVASGHKLYIW
H YNRSGETSSPTIVLRTPRSLRAVHFHPHAAPFLLTAEV
NDLDLTDSAMTLATSPGYLHYPPPTIYLADAHSNERSRL
EDELPLMPSPLLMWPSFTRDDGRATLPHIGGDVGLSGQQ
RVDSLSSGQYEFHPSPIEPSSSTSMHEEMGTDPFSSVRE
SEVTQSAMNIVDNTEVQPEERSTYSFSFSDPRFWELPSV
YGWLVGQTQAAPRTAPSPGALETASALGEVASVSPVRSE
FMPGGMDQPRLGGRSGSGCRSSGSRMMRTAGLNDHPHDE
NYPQSVVSKLRSELEASLAAAASTELPCTVKLRVWPYDM
KDPCALFRSESCRLTIPHAVLCSEMGAHFSPCGRFFAAC
VACVLPQLEADPVLHGQVDPDVTGVATSPTRHPVSAYQI
MYELRIYSLEEATFGMVLASRSIRAAHCLTSIQFSPTSE
HLLLAYGRRHNSLLKSIVIDGENTVPIYSILEVYRVSD M
ELVRVLPSAEDEVNVACFHPSVGGGLVYGTKEGKLRILQ
IDSSGGLNPKSTGFLDENMAEVPTYALEC
93The amino acid sequence of SEQ IDMGEGDLPR TEAGVLRGHEGAVLAARFNGDGNYCLSCGKD
359. The conserved G-protein betaRTIRLWN PHRGI HIKTYKSHGREVRDVECTSDNSKLISC
WD-40 repeat domains areGGDRQIFYWD VSTGR VIRRFRGHDSEVNAVKFNDYASVV
underlined.VSAGYDRSVRAWD CRSHSTE PIQIINTFQDSVMSVCLTK
TEIIGGSVDGTVRTFD IRIGR EISDDLGQPVNCISMSND
GNCILASCLDSTLRLVD RSAGE LLQEYKGHTCKSYKLDC
CLTNTDAHVAGGSEDGYVFFWD LVDAS VISKFRAHSSVV
TSVSYHPKEDCMITASVDGTIKVWK T
94The amino acid sequence of SEQ IDMACIKGVGRSASVAMAPDGGYLATGTMAGTVDLSFSSSA
360. The conserved G-protein betaSLEIFGLDFQSDDRDLPLIAESPSSERFNRLSWGKNGSG
WD-40 repeat domains areSDEFSLGLIAGGLVDGTIGLWNPLSLIRSEAGD KAIVGH
underlinedLSRHKGPVRGLEFNVIAPNLLASGADDGEICIWD LAAPR
EPSHF PPLRGSGSAAQGEISFLSWNSKVQHILASTSYNG
TTVVWD LKKQKPVISFSDSVRRRCSVLQWNPDLATQLVV
ASDEDSSPTLRLWDMRNI MSPVKEFAGHTRGVIAMSWCP
NDSSYLVTCAKDNRTICWD TVT GEIVCELPAGSNWNFDV
HWYPKIPGVISASSFDGKIGIYN VEGCSRYGVRENEFGA
ATLRAPKWFKRPVGASFGFGGKVVSFHTRSTGGPSVNSS
EVFVHDIITEQTLVSRSSEFEAAIQSGDRPSLRALCERK
SQHCESTDDQETWGFLKVLLEDDGTARSKLLAHLGFDIP
TETNDGSQEDLSQQVNALGLEDVTADKVVQEDNNESMVF
PTDNGEDFFNNLPSPRADTPVSTSADGFPTVNAAVEPSQ
DEVDGLEESSDPSFDDSVQRALVVGDYKAAVALCMSANK
LADALVIAHVGGASLWESTRDKYLKNSRLPYLKVVFAMV
NNDLQSLVDTRPLKFWKETLAILCSFAQGEEWAMLCNSL
ASKLMAAGNMLAATLCFICAGNIDKTVEIWSRSLATEHD
GMSYMDLLQDLMEKTIVLALASGQKQFSASVCKLVEKYA
EILASQGLLTTAMDYLKLLGTDDLSPELAVLRDRIAFSV
EAEKGANISAFNGSQDPRGAVYGVDQSNYGMVDTSQHYY
PEAAQPQVPHTVPGSPYGENYQQPFGSSFGKGYNTPMQY
QAPSQASMFVPSEPPQNAQPSFVPTPVTSQPTTRSQFIP
APPLALRNPEQYQQPTLGSHLYPGSVNPTFQPLPHAPGP
VAPVPPQVSSVPGQNMPQAVAPTQNRGFMPVTNPGVVQN
PGPISMQPATPIESAAAQPVVSPAAPPPTVQTADTSNVP
APQKPVIATL
95The amino acid sequence of SEQ IDMKERGKGAGRSVDERYTQWKSLVPVLYDWLANHNLVWPS
361. The conserved G-protein betaLSCRWGPQLEQATYKNRQRLYLSEQTDGSVPNTLVIANV
WD-40 repeat domains areEVVKPRVAAAEHISQFNEEARSPFVKKFKTIIHPGEVNR
underlined.IRELPQNSKIVATHTDSPDVLIWDVETQPNRHAVLGAST
SRP DLILTGHKDNAEFALAMSPTEPFVLSGGKDRYVVLW
S IQDHISTLAADPGSAKSPGSAGTNNKQSSKAAGGNDKT
GDSPSIE PRGVYLGHGDTVEDVTFCPSSAQEFCSVGDDS
CLILWD ARTGSSP AIKVEKAHHADLHCVDWNPHDVNLIL
TGSADNTVRMFD RRNLTSGGVGS PVHTFEGHNAAVLCVQ
WSPDKSSVFGSSAEDGILNIWD HEKIGRKIETVGSKVPN
SPPG LFFRHAGHRDKVVDFHWNSSDPWTIVSVSDDGEST
GGGGTLQIWR MIDLIYRPEEEVLAELDKFKSHILSCTS
96The amino acid sequence of SEQ IDMAKIAPGCEPVAGTLTPSEKREYRVTNRLQEGKRPLYAV
362. The conserved G-protein betaVFNFIDSRYFNVFATVGGNRVTVYQCLEGGVIAVL QSYI
WD-40 repeat domains areDEDKDESFYTVSWACNIDRTPFVVAGGINGIIRVID AGN
underlined and the Trp-Asp (WD)EK IHRSFVGHGDSINEIRTQPLNPSL IVSASKDESVRLW
repeats signature is in bold.N VHTGICIL IFAGAGGHRNEVLSVDFHPSDKYRIASCGM
DNTVKIWS MKEFWTYVEKSFTWTDLPSKFPTKYVQF PVF
IAPVHSNYVDCMRWLGDFVLSKSVDNEIVLWE PKMKEQS
PGEGSVD ILQKYPVPECDIWFIKFSCDFHYHSIAIGNRE
GKIYVWE LQSS PPVLIAKLSHPQSKSPIRQTAMSFDGST
ILSCCEDGTIWRWD AITASTS
97The amino acid sequence of SEQ IDMNTAMHFGAGWRSIAEMGYTMSRLEIEPESCEDEKSLDG
363. The conserved G-protein betaVGNSQGPNELPRCLDHELAHLTNLKSRPHEHLIRDFPGR
WD-40 repeat domains areRALPVSTVKMLAGRECNYSRRGRFSSADCCHMLSRYVPV
underlined.NGPSPLDQMNSRAYVSQFSADGSLFVAGFQGSHIRIYNV
DKGWKCQKNILTKSLRWTITDTSLSPDQRYLVYASMSPI
VHIVDIGSAAMDSLANITEIHEGLDF SADSGPYSFGIFS
VKFSTDGREVVAGSSDDSIYVYDL VANK LSLRIPAHESD
VNTVCFADESGHIIYSGSDDTYCKVWD RRCLSARNK PAG
VLMGHLEGITFIDSRGDGRYFISNGKDQTIKLWD IRKMG
SDICRRGFRNFEWDYRWMDYPPRARDSKHPFDL SVATYK
GHSVLRTLIRCYFSPVHSTGQKYIYTGSHDSCVYIYD VV
TGA QVAALKHHKSPVRDCSWHPEYPMIVSSSWDGDIVKW
E FFGNGETEIPAMKKRIRRRHLY
98The amino acid sequence of SEQ IDMEPQPQAPKKRGRKPKPKEDEKEEQLHQPPPPPPPQQQA
364. The conserved G-protein betaAPAPAPAATRSSTSGSAGGRDRRPQQQHAVDEKYARWKS
WD-40 repeat domains areLVPVLYDWLANHNLLWPSLSCRWGPQLEQATYKNRQRLY
underlined.ISEQTDGSVPNTLVIANCEVVKPRVAAAEHVSQFNEEAR
SPFIRKYKTIIHPGEVNRVRELPQNPNIVATHTDSPDVL
IWDVESQPNRHAVYGATASRPNLILTGHQENAEFALANC
PAEPFVLSGGKDKTVVLWSIQDHITASATDQTTNKSPGS
GGSIIRKTGEGNEETGNGPSV GPRGIYCGHEDTVEDVAF
CPSTAQEFCSVGDDSCLILWD ARVGT NPVAKVEKAHNGD
LHCVDWNPHDNNLILTGSADNSVNMFD RRNLTSNGV GSP
VYKFEGHKAAVLCVQWSPDKPSVFGSSAEDGLLNIWD YE
RVDKKVDRAPNAPAGLFFQHAGHRDKIVDFHWNAADPWT
MVSVSDDCDTAGGGGTLQIWRNSDLIYRPEEEVLAELEN
FKAHVLECSKA
99The amino acid sequence of SEQ IDMGIFEPYRAVGYITTGVPFSVQRLGTETFVTVSVGKAFQ
365. The conserved G-protein betaVYNCAKLSLVLVGPQLPKKIRALASYREYTFAAYGSDIG
WD-40 repeat domains areIFKRAHQLATWSGHTAKVCLLLLEGEHILSVDVDGNAYI
underlined and the Trp-Asp (WD)WAFKGMNYNLSPVGHILLDSNFTPSCIMHPDTYLWKVIL
repeats signature is in bold. TheGSQEGPLQLWNISTKTKLYEFKGWNSSVSSCVSSPALDV
Utp21 specific WD4O associatedVAVGCADGKIHVHMIRYD EELVTFSHSMRGSVTALSFST
putative domain is in italics.DGQPLLASGSSSGVVSIWN LDKRRLQSVIRDAHDGSIIS
LHFFANEPVLMSSSADNSIKMWIFDTSDGDPRLLRFRSG
HSAPPLCIRFYANGRHILSAGQDRAFRLFSVVQDQQSRE
LSQRHVSKRAKKLKLKEEEIKLKPVIAFDVAEIRERDWC
NVVTSHMDTPQAYVWRLQNFVIGEHILRPCPNKPTPVKA
CMISACGNFAILGTAGGWIERFNLQSGISRGSYIDQLEG
TNSAHDGEVVGVACDATNTLMISAGYAGDIKVWDFKGRE
LKSRWEIGSSLVKISYHRLNGLLATVADDFIIRLFDAVA
LRMVRKFEGHTDRITDLCFSEDGK WLLSSSMDGSLRIWD
IILARQVDAVFVDVSITALSLSPNMDILATTHVDQNGVF
LWVNQSMFSGDSDINLYASGKEVVTVKLPSVSSVEGS QV
EESNEPTIRHSESKDVPSFRPSLEQIPDLVTLSLLPKSQ
WQSLINLDIIKVRNKPVEPPKKPEKAPFFLPSIPSLSGE
ILFKPSEMSDKGDMKADEDKSKITPEVPSSRFLQLLHSC
SEAKNFSPFTTYIKGLSPSTLDLELRMLQIIDDDAVDAD
ADDPQDVDKRQELLSIELLMDYFIHEISCRSNFEEVQAL
VRLFLKIHGETIRRQSVLQNKAKVLLETQCSVWQRVDKL
FQGARCMVAFLSNSQF
100The amino acid sequence of SEQ IDMEETKVTCGSWIRRPENVNLAVLGRSPRRRGSAALEIFA
366. The conserved G-protein betaFDPKSTSLSSSPLVAHVIEEIEGDPLAIAVHPNGEDIVC
WD-40 repeat domains areFASSGSCLSFELSGQESNLKLLTK ELPPLRGIGPQKCMA
underlined.FSVDGSRFATGGVDGRLRILE WPSLRI ILDEPKAHKSIR
DLDFSLDSEFLATTSTDGSARIWK AEDGLPCTTLTRRSD
EKIELCRFSKDGTKPFLFCTVQRGDKAVTGVWDISTWNK
IG HKRLLRKPAVVMSISLDGKYLAQGSKDGDMCVVE VKK
MEVSHWSKRLHLGTSLTSLEFCPIERVVITTSDEWGVLV
TKLNVPADWKAWQVYLLLLGLFLASLVAFYIFYENSDSF
WGFPLGKDQPARPKIGSVLGDPKSADDQNMWGEFGPLDM
101The amino acid sequence of SEQ IDMADPVEHQHQQHQQHQLQQQRRRGWRIQGGQYLGEISAL
367. The conserved G-protein betaCFLHLPPPPLSLSSSPVLSLSSGLDSESRDRPACSFRFP
WD-40 repeat domains areSAGSGSQVSLFDLASGAMVRTFYVFRGIRVHGIVLGCAD
underlined.FPGGSSSSSSTLDYVIAVYGERRVKLFRLSVRLGRGAGE
GSGTVLSADLELVSAAPRLSHWVMDVRFLKENGTSEDEL
QRCLTVAIGCSDNSIRLWDVDKCSFVLAVSSPERCLLYS
MRLWGDNLEDLQVASGTIYNEILIWKVVPNHDAPSSNEL
TEEGLTNSCAGNSVHECLRYE AYHICRLVGHEGSIFRIA
WSSDGSKLVSVSDDRSARIWE VHCKVQYSEDA GEVGLLF
GHSARVWDCYISQNLIVTAGEDCSCRVWG LDGQQHDVIK
EHIGRGIWRCLYDPWSSLLVTGGFDSAIRVHKLDASLAE
ASAKQSNIKDLSDGTELFTTHLPNSSGHSGHMDSKSEYV
RCLSFSCEDVMYIATNHGYLYHAKLCNDGDLRWTELAQV
SNEVQIICMELLPSNPYDPRIDADDWVAVGDGKGWTTVV
RVVKNSDSPKVSTSFSWAAEMDRQLLGIHWCKSLGHRFI
FTADPRGALKLWRFFEVSQSSSLYPENSPRISLIAEFKS
DLGARIMCLDVAFESELLICGDLRGNLVLFPLLKDLLLD
TFVVSAAKISPVNHFKGAHGISAVSSISVAHMSFNHIEL
RSTGADGCICYNEYDKGLQSLNFVGNKQVKELSMIESVS
TENESTGYRTSGSYASGFASTDFIIWNLVTEAKVLQVSC
GGWRRPHSYYLGDVPEMKNCFAYVKDDIIYIRREWIKDS
KQKILPQNLRLQFHGREVHSLCFVTGDFQLRKNKQSSWI
VTGCEDGTVRLTRYTQCTDNWSSSKLLGEHVGGSAVRSI
CCVSNIHTTSSGTSVSDVKGIENLPKDIKGTLMEDECNP
SLLISVGAKRVLTSWLLRRRKQDGKEDDVTDLQEAENSS
LPSSAGSSTFSFQWLSTDMPVKYSVPSKKSGSIKKLIGV
SDTNVRCKSL
102The amino acid sequence of SEQ IDMPYK LSATLSNHSSDVRAVASPSDDLILSASRDSTAISW
368. The conserved G-protein betaF RQSPSSFT PASVIRAGSRFVNAIAYLPPTPRAPQGYAV
WD-40 repeat domains areVGGQDTVVNVFA LGPGDKEE PEYTLVGHTDNVCALSVNS
underlined.DDTIISGSWDKTAKVWK DFALVYD LKGHQQSVWAVLAMN
EKEFLTASADRTIKYWV QHK TMQTYEGHRDAVRGLALIP
DIGFASCSNDSEIRVWT MGGD VVYTLSGHTSFVYSLSVL
PNGDLVSAGEDRSVRVWR DGE CSQVIVHPAISVWAVSTM
PNGDIISGSSDGVVRVFS ESEKRWATASELKALEDQIAS
QSLPSQQVGDVKKTDLPGPEALSVPGKKAGEVKMIRSGD
VVEAHQWDSLASSWQKIGEVVDAIGSGRKQLHDGKEYDY
VFDVDIQEGAPPLKLPYNVSENPYTAAQRFLEQNDLPTG
YLDQVVKFIEQNTAGVKLGNDGYVDPFTGASRYQPATQS
TSNTASSSYNDPFTGGSRHIAESAPSNVPQGSHATGIIP
FSKPIFFKLANVSAMQAKMFQFDEVLRNEISTATLAMRP
DEVINVNETFTYLSKVVTSTSSARTSLGWIHIETIMQIL
DRWPVPQRFPVIDLGRLVTAYCMNAFSGPGDLEKFFSCL
FRTSEWTSITSGSKALTKAQETNVLLLFRTIANSLDGAP
LNDNEWIKQIFRELAQTPQLVLNKSHRLALASVLFNFSC
IGLKGPVPADVRTLHLTIILQVLRSPNDDPEVAYRTCVA
LGNMLYSDKTRGTPRDAQSPSPTELKSAVAAIKGGFSDP
RINDVHREIMSLI
103The amino acid sequence of SEQ ID
MPPQKIESGHKDTVHDLAMDYYGKRLATASSDHTINVVG
369. The conserved G-protein beta
VSSSGSQHLATLIGHQGPVWQISWAHPKFGSLLASCSYD
domain is underlined and the WD-40
GRVIIWREGNPNEWTQAQVFEEHKSSVNSVAWAPHELGL
repeat domains are in bold
CLACGSSDGNISVFTARQDGGWDTSRIDQAHPVCVTSVS
WAPSTAPGALVGSRGMMEPVQKCSGGCDNTVKVWKLYNR
VWKLDCFPVLQMHTDWVRDVAWAPNLGLPKSTIASASQD
GRVIIWTLAKEGDQWQCKVLYDFRTPVWRVSWSLTGNIL
AVADGNNNVSLWN EAVDGEWIQVSTVEP
104The amino acid sequence of SEQ IDMSAPMLEIEARDVVKIVLQFCKENSLHQTFQTLQSECQV
370. The conserved G-protein betaSLNTVDSIETFVADINSGRWDAILPQVAQLKLPRNTLED
WD-40 repeat domains areLYEQIVLEMIELRELDTARAILRQTQAMGVMKQEQPERY
underlined and the Trp-Asp (WD)LRLEHLLVRTYFDPNEAYQDSTKEKRRAQIAQALAAEVT
repeats signature is in bold.VVPPSRLMALVGQALKWQQHQGLLPPGTQFDLFRGTAAN
KQDVDDMY PTTLSHTIKFGTKSHAECARFSPDGQFLVS C
SVDGFIEVWD YNSGKLKKDLQ YQADETFMMHDDPVLCVD
FSRDSEMLASGSQDGKIKVWR IR TGQCLRRLERAHSQGV
TSVLFSRDGSQLLSTSFDGSARIHG LK SGRQLREFRGHS
SYVNDAIFSNDGSR VITASSDCTVKVWD VK TSDCLQTFK
PPPPLRGGDASVNSVHLFPKNADHIVVCNKTSSIYIMT L
QGQVVKSLSSGKREGGDFVAACVSPKGEWIYCVGEDRNL
YCFS CQ SGKLEHLMKVHERDVIGVTHHPHRNLVATYSED
STMRLWK P
105The amino acid sequence of SEQ IDMDLLQSYAEQNDGDLGRHSSPEPSPPRLLPSKSAAPKVD
371. The conserved G-protein betaDTTLALTVAQTNQTLARPIDPSQHAVAFNPTYDQLWAPI
WD-40 repeat domains areCGPAHPYAKDGIAQGMRNHKLGFVEDAAIGSFLFDEQYN
underlined.TFQRYGYAADPCASTGNEYVGDLDALKQNDGISVYNIRQ
QEQKRYAEEYAKKKGEERGEGGREKAEVVSDKSTFHGKE
ERDYQGRSWIAPPKDAKATNDHCYIPKR LVHTWSGNTKG
VSAIRFFPKHGHLILSAGMDTKVKIWD VFNSGK CNRTYM
GHSRAVRDISFCNDGTKFLTAGYDKNIKYWD TETGK VIS
TFSTGRIPYVVKLHPDDEKQNILLAGMSDKKIVQWD MNT
GQ ITQEYDQHLGAVNTITFVDDNRRFVTSSDDKSLRVWE
FGIPV VIKYISEPHMHSMPSISLHPNTNWLAAQSLDNQI
LIYS TRERFQLN KKKRFAGHIVAGYACQVNFSPDGRFVM
SGDGEGRCWFWD WKSCR VFRTLKCHEGVCIGCEWHPLEQ
SKVATCGWDGLIKYWD
106The amino acid sequence of SEQ IDMESNGNLEQTLQDGRIYRQLNSLIVAHLRDHNFPQAASA
372. The conserved G-protein betaVALATMTPLNVEAPRNRLLELVAKGLAVEKGELLRGVSH
WD-40 repeat domains areAGTNDLGGSIPASYGLVPAPWTAIDFSSLRDTKGNSKSF
underlined.
TKHETRHLSDHKNVARCARFSTDGRFFATGSADTSIKLF
E VSKIKQMMLPDSTDGA IRAVIRTFYDHTHPVNDLDFHP
QNTVLISAAKDHTVKFFD YSKAT AKRAFRVIQDTNNVRS
VAFHPSGDFLLAGTDNPIPHLYD VN TFQCYLSANVPEFA
VNAAINQVRYSSSGGMYVTASKDGTIRFWD GA SANCVRS
IAGAHGAAEVTSANFTKDQRYVLSCGKDSTVKLWE VGTG
RLVKQYLGATHNQLRCQAVFNNTEEFVLSIDEPSNEIVV
WDAM TAEKVARWPSNHNGPPRWIEHSPTEAAFVSCGTDR
SIRFWK ETH
107The amino acid sequence of SEQ IDMSNFQGEDGEYVADDFEAEDGDEELHGRESADPESDVDE
373. The conserved G-protein betaIDTPSNRFTDTTADQARRGRDIQGIPWERLSITREKYRR
WD-40 repeat domains areTRLEQYRNYENVPQSGERSGRDCTVTERGNSFYEFRRNS
underlined.RSVKSTILHFQLRNLVWATSKHDVYLNSNYSVVHWSSLT
GRRSEVLNLAGHVAPNEKHPGSLLEGFTQTQVSTLAVKD
RFLVAGGFQGELICRFLDRPGISFCSRTTYDDNAITNAV
EIYVSPSGGIHFIASNNDCGVRDFDME NFELSKHFRFPW
PVNHTSLSPDGRLLVIVGDDPEGILVD AK TGRTIMPLRG
HLDFSRASEWHPDGVTFATGNQDKTCRIWD IRN LSKSIA
VLKGNLGAIRSIRYTSDGRYMAIAEPADFVHVYD TKTGY
KKEQEIDFFGEISGNSFSPDTESLFIGVWDRTYGSLLEY
GRRRNFSYLDCLV
108The amino acid sequence of SEQ IDMGVEEDLEDLNALAESTDAAVDGQAALASAVDSVTLQPA
374. The conserved G-protein betaPPILPPVIPPPAVPVVAPVPTIPPVLRPLAPLPIRPPVL
WD-40 repeat domains areRPPAPRRDEAGSSDSDSDHDGTAAGSTAEYEITEESRLV
underlined and the splicing factorRERHERANQDLMMRRRGAALAVP TNDKAVEARLRRLGEP
motif is in bold.MTLFGEREMERRPDRLRMLMAKDAEGQLEKUORAHEDE E
AAASAAPEDVEEEMLQYPFYTEGSRALFNARIDIARFSI
TRAALRLERARRRRDDPDEDVDAEIDWALKKAESLSLHC
SEIGDDRPLSGCSFSHDGRLLATCSNSGVAKLWDTCRNP
QVNRVLTLKGHTERATDVAFSPVQNH IATASADRTAKLW
NT EGTILKTFEGHLDRLGRIAFHPSGKY LGTTSFDKTWR
LWD IESGEELLLQEGHSRSIYGIDFHRDGSLVASCGLDA
LARVWDLRTGRSILALEGHVKPVLGVSFSPNGYH LATGG
EDNTCRIWDL RKKKSLYTIPAHANLISEVKFEPQEGYFL
VTASYDTTAKVWSARDFKPVKTLSVHEAKITSVDITADA
SHIVTVSHDRTIKLWTSNDDVKEQAMDVD
109The amino acid sequence of SEQ IDMVKAYLRYEPAAAFGVIASVESNIAYDASGKHLLAPALE
375. The conserved G-protein betaKVGVWHVRQGVCTKALAPSASSAAGPSLAVTAIASSPSS
WD-40 repeat domains areL IASGYADGSIRIWDF EKGSCETTLNGHKGAVSVLRYGK
underlined, and the conservedLGSL LASGSKDNDIILWDV VGETGLYRLRGHRDQVTDLV
Dip2/Utp12 domain is in bold.FLDSDKK LVSSSKDKYLRVWDL ETQHCMQIVGGHHSEIW
SLDTDPEERYLVTGSADPELRFYTVRNDSSDERSEADAS
GGVGNGDLASHNKWDVLKQFGEIQRQSKDRVATVRFNKN
GNLLACQAAGKLVEVFRVLDEAEAKRKAKRRLHRKREKK
GADVNENGDSSRGIGEGHDTMVTVADVFKLLQTIRASKK
ICSISFCPVAPKSSLATLALSLNNNLLEFHSIEADKTSK
MLTIELQGHRSDVRSVTLSSDNTLLMSTSHNSVKIWNPS
TGSCLRTIDSGYGLCGLIVPQNKHALIGTKDGAIEIFDV
GSGTCIEVVEAHGGSIRSIVAIPNQNGFVTGSADHDIKF
WEYGMKQKPGDNSKHLTVSNVRTLRMNDDVLVVAVSPDA
QKIAVALLDCTVKVFFNDSLKLMHSLYGHRLPVLCLDIS
SDGDLIVTGSADKNLMIWGLDFGDRHKSIFAHGDSIMAV
QFVGHTHYNFSVGKDRLVKYWDADKFELLLTLEGHHADI
WCLAISNRGDFLVTGSHDRSIRRWDRTEEPFFIEEEKEK
RLE EMESDLDNAPGNKYVPKflEIPEEGAVALAGKKTQE
TLSATDSIIEALDIAEELKRIAEHEEEIQINGKTAEFHP
NYVNLGLSPSDFILRALSNVQTNDLEQTLLALPFSQALK
LLSYLKDWTTYPDKVELVSRIATVLLQTHYNQLVSTPAA
RPLLTTLKDILHKKVKECKDTIGFNLAANDHLKQLMALR
SDALPQDAKVKLLEIRSQLSKRLEERTDPREAKRRKKKQ
KKS TNMHAWP
110The amino acid sequence of SEQ IDMGGVQAEREDKDKVSLELTEEILQ SMEVGMTFRDYSGRI
376. The conserved G-protein betaSSMDFHRASSYLVTASDDESIRLYD VASATCLKTINSKK
WD-40 repeat domains areYGVDLVSFTSHPMTVIYSSKNGWDESLRLLSLH DNKYLR
underlined.YFRGHHDRVVSLSLCPRNECFISGSLDRTVLLWD QRAEK
CQGLLRVQGRPATAYDDPGLVFAIAFGGCVRMFDARKYE
K GPFEIFSVGGDVSDANVVKFSNDGRLMLLTTTDGHIHV
LD SF RGTLLYTFNVKPTSSKSTLEASFSPEGMFVISGSG
DGSVYAWS VRGGKEVASWLSTDTEPPVIKWAPGRLMFAT
GSSELSFWIPDLSKLGAYVGRK
111The amino acid sequence of SEQ IDMAAFGAAPAGNHN PNKSSEVIQPPSDSVSSLCFSPRANH
377. The conserved G-protein betaLVATSWDNQVRCWE LTKNGASV TSVPKASMSHDQPVLCS
WD-40 repeat domains areAWKDDGTTVFSGGCDKQAKMWS LMS GGQPVTVAMHDAPI
underlined.KEIAWIPEMNVLVTGSWDKTLKYWD TRQSNPVHTQQLPE
RCYAMTVRYPLMVVGTADRNLIVFN LQNPQAEFKRFSSP
LKYQTRCVAAFPDQQGFLVGSIEGRVGVHH LDDS QISKN
FTEKCHRDNNDIYSVNSLNFHPVHHTFATAGSDGTFNFW
D KDSKQRLKAMSRCSQPIPCSTFNNDGTIYAYSVCYDWS
KGAENHNPATAKTYIFLHLPQESEVKAKPRVGTTNRK
112The amino acid sequence of SEQ IDMNCSISGEVPEEPVVSTKSGHVFERRLIERYVSDYGKCP
378. The conserved G-protein betaVSGEPLTMDDVLPVKMGKIVKPRPLQAASIPGLLSIFQN
WD-40 repeat domains areEWDSLMLSNFALEQQLHTARQELSHALYQHDAACRVIAR
underlined.LKKERDEARSLLALAERQIPMTASSDIAVNAPAMSNGRK
ASLDEEPGYAGKKMRPGISASIIAEITDCNLALSQQRKK
RQIPSTLAPVEDLE RYTQLSSYPLHKTGKPGITSLDICH
SKDIIATGGIDTSAVLFD RS SGQIMSTLSGHSKKVTSVN
FDAQGDMVLTGSADKTVRIWQ GSEDG SYNCRHILKDHTA
EVQAITVHATNNYFATASLDNTWCFYE FS TGLCLTQVEG
ASGSEGYTSAAFHPDGLILGTGTSNADVKIWD VK TQANV
TTFSGHTGAITAISFSENGYFLATAAQDGVKLWD LR KLK
NFRTFSAYDKDTGTNSVEFDHSGCYLGLAGSDIRVYQ VA
SVKS EWNCVKTFPDLSGTGKVTCVKFGPDSKYIAVGSMD
HNLRIFG LPSEDGAMES
113The amino acid sequence of SEQ IDMAAPGVETLKKEIKELKEKIAQHRLDTDGEQPLPAAAKS
379. The conserved G-protein betaKSVPEVSA ALKQRRILKGHFGKIYALHWSADSRHLVSAS
domain is underlined and the WD-40
QDQIRIIWN GFT TNKVHAIPLRSSWVMTCAYSPSGNLVA
repeat domains are in bold
CGGLDNLCSVYKV PHGGNKESSSA QKTYCELAQHEGYLS
CCRPIIRNEIVTSSGDSTCILWD VET KTPKAIFNDHTGD
VMSLAVFDDKGVFVSGSCDATAKLWD HRVH KQCVHTFQG
HESDINSVQFFPDGDAFGTGSDDSSCRLPD IRAY QQINK
YSSDKILCGITSVAFSKTGKSLFACYDDYNTYVWD TLS G
NQVEVLTGHENRVSCLGVSEDGKALATGSWDTLLKIWA
114The amino acid sequence of SEQ IDMGGVEDESEPASKRMKLSSRVLRGLANGSSRTEPAAGSS
380. The conserved G-protein betaLDLMARPLPIEGDEEVIGSKGVIKRVEFVRLIAKALYSL
WD-40 repeat domains areGYEKSGARLEEESGIPLQSSVVNLFMQQISDGLWDESVV
underlined.TLHKIGLSDENLVKSASFLILEQKFLELLDQEKANDALK
TLRTEITPLCIKNSRVRELSSCIISPSSCGLLNQNKRNS
TRARSRSELLEELQKLLPPAVIIPERRLEHLVEQALVLQ
TDACMLHNSIDMEMSLYTDHQCGKEHI PCRTLQILQSHN
DEVWLVQFSHNGKYLASASNDRSAIIWE VDENG SVSLKH
KLTGHQKPISSVCWSPDDRQLLTCGVGETVRRWD VS SGE
CLRVYEKAGHGLISCAWFPDGKWICYGVSDRSICMCD L E
GKEIECWKGQRTLSISDLEITSDGKQIISICRETAILLL
D R EARYERNIEENQTITSRSLSKDNRYLLVNLLNQEIHL
WD IKG DFRLVAKYKGLKRSRFVIRSCFGGLKQAFVASGS
EDSQVYIWH KG SGELIEPLPGHSGAVNCVSWNPANHHML
ASASDDRTIRIWG LNELNTRHKGARPNGVHYCNGNGTS
115The amino acid sequence of SEQ IDMTQLAETYACMPSTERGRGILIAGNPKPGSNSVLYTNGR
381. The conserved G-protein betaSVVILNLD NPLDISVYAEHAYPATVARFSPNGEWVASAD
WD-40 repeat domains areSSGAVRIWG AYNDHVLKKEFKVLSGRIDDLQWSPDGLRI
underlined.VASGDGKGKSLVRAFMWD SGTNVGEFDGHSRRVLSCAFK
PTRPFRIVTCGEDFLVNFYE GP PFKFKLSRRDHSRFVNC
LRFSPDGNRFISVSSDKKGIIYD GK TGEKIGELSSDGGH
TGSIYAVSWSPDSKQVITVSADKSAKIWD ISEDGSGNLR
KTLTSSGSGGVDDMLVGCLWQNNHLVTVSLGGTISIYTA
GD LDKAPVSFSGHMKNVSSLSVLKGDPKVILSSSYDGLI
IKWI QGIGFSGRVQRKESTQIKCLAAVDEEIVTSGYDNK
VCRVSGSGDAEFIDIGCQPKDLSLALQCPEFALVSTDTG
VVLLR GAKIVSTINLGFAVTASTVAPDGTEAIIGAQDGK
LRIYS ISGD TLTEEAVLEKHRGAISVIHYSPDLSMFASG
DLNREAVVWD RASR EVRLKNILYHTARINCLAWSPDSST
VATGSLDTCVIIYE VDK PASNRLTIKGAHLGGVYGLAFT
DDFSVVSSGEDACIRVWKINRQ
116The amino acid sequence of SEQ IDMKVKVISRSTDEFTRERSQDLQRVFRNFDPNLRTQEKAV
382. The conserved G-protein betaEYVRALNAAKLDKVFA RPFVGANDGHVDSVSCMAKNPNY
WD-40 repeat domains areLKGIFSGSMDGDIRLWD IAS RRTVCQFPGHQGPVRGLAA
underlined and the SOF1 proteinSTDGQILVSCGIDSTVRLWN VPVATLGESDGTHENLAKP
domain is in bold.LAVYVWKNAFWAVDHQWDGELFATAGAQVDIWNQNR SQP
ISSFEWGTDTVISVRFNPGEPNVLATSGSDRSITLYD LR
MSSPTRKVIMRTKTNAISWNPMEPMNFTAANEDCNCYSY
DARKL EEAKCVHKDHVSAVMDIDYSPTGREFVTGSYDRT
VRIFQ YNGGH SREVYHTKRMQRVFCVKFSCDASYVISGS
DDTNLRLWKAKASEQLGVVLPRERRKHEYHEAVKSRYKH
LPEVKRIVRHEHLPKPIYKAGILRRTVNEADERKEERPK
AHSAPGSSSAEPLRKRRIIKEIE
117The amino acid sequence of SEQ IDMVRSIENPKKAKRRNKGSKNGDGSSSSSSIPSMPTKVWQ
383. The conserved G-protein betaPGVDKLEEGEELQCDPSAYNSLHAFHIGWPCLSFDIVRD
WD-40 repeat domains areTLGLVRTEFPHQVYFVAGTQAERPTWNSIGIFKVSNITG
underlined.KRRELVPSKPTDDADEESDSSDSDEDSDDEVGGSGTPIL
QLRKVGHEGCVNRIRAMNQWPHICASWGDSGHVQIWDFS
SHLNALAESEADVSQGASSVFNQAPLVKFGGHKDEGYAL
DWSPLVPGRLVSGDCKNSIHLWEPTSGSTW NVDSTPFIG
HAASVEDLQWSPTEENVFASCSVDGTIAIWD TRLG KTPA
ASFKAHDADVNVISWNRLATCMLASGCDDGTFSIHD LRL
LKEG DSVVAHFEYHKHPVTSIEWSPHEASTLAVSSADCQ
LTIWD LSLEKDEEEEAEFKAKTKEQVNAPEDLPPQLLFV
HQGQKDLKELHWHAQIPGMIVSTAADGFNILMPSNIQST
LPSDGA
118The amino acid sequence of SEQ IDMERY KVIKE LGDCTYGSVWKALNQQTHEIVAIKK MKRKY
384. The conserved eukaryotic
YIWEECINLREVKSLRKLNHPNIIKLKEVIRENNELFFI
protein kinase domain is
FEYMECNLYQIMKERSTFFSETAIIKFCYQILQGLSYMH
underlined and the protein kinases
RNGY FHRDLKPENLLV TSDLIKIADFGLAREVLTSPPYT
ATP-binding region and
DYVSTRWYRAPEVLLQSPTYTTAIDMWAVGAILAELFTL
serine/threonine protein kinases
HPLFPGESELDEIYRICGVLGTPDYETWPDGMQLAAFRN
active-site signatures are in
FIFPQFLPVNLSVLIPHASPEAIDLITRLCSWDPQKRPT
bold.AEQALHHPFF RIGMSIPLSLGGHFQDNTCAAEVDTKFHS
KKACKAWNGEKESSLECFLGLSLGLKPSLGHLGAMGSQG
VGAVKQEVGSSPGCQSNPKQSLFQVLNSRAILPLFSSSP
NLNVVPVKSSLPSAYTVNSQVMWPTIAGPPAAAVTVSTL
QPSILGDFKIFGKSMGLASQYAGKEASPFS
119The amino acid sequence of SEQ IDMGEMGRGINNSSNNNNSNRPAWLQH YDLVGKIGEGTYGL
385. The conserved eukaryotic
VFLARSKLPNNRGLRIAIKK FKQSKDGDGVSPTAIREIM
protein kinase domain is LLREFSHENVVKLVNVHINHVDMSLYLAFDYAEHDLYEI
underlined and the protein kinases
IRHHREKLNHHNINQYTVKSLLWQLLNGLNYLHSNWIVH
ATP-binding region and
RDLKPSNI LVNGEGEEHGVVKIADFGLARIYQAPLKPLS
serine/threonine protein kinases
DNGVVVTIWYRAPELLLGAKHYTSAVDMWAVGCIFAELI
active-site signatures are boxed
TLKPLFQGVEVKASPNPFQLDQLDKIFKVLGHPTIEKWP
in bold.
TLMNLPHWSKNLQQIQQHKYDNAGLHIGPIPAKSPAYDL
LSKMLEYDPRKRITAAQALEHEYF RIDPQPGRNALVPSQ
PGEKAINYPPRLVDANTDFDGTIAPQPSQVSSGNAPSGS
IASAAVPAVRPLPQQMQLMGMQRMQNPGMAAFNLGAQAS
MSGLNHNNIALQRGSSQQQAHQQVRRKEPNSGFPNTGYP
PPPKSRRL
120The amino acid sequence of SEQ IDMDK YEKLEK VGECTYGKVYKARDKMTGQLVALKK TRLEM
386. The conserved protein kinase
DEEGVPPSSLREISLLQMLSQSIYVVRLLCVEHVTKKGK
family domain is underlined. The
PLLYLVFEYLDTDLKKFIDYRRSVNAGPLPQNVIQSFMY
protein kinases ATP-binding region
QLLKGVAHCHSHGV LHRDLKPQNLLV DKSKGLLKVGDLG
is in bold and the
LGRAFTVPLKCYTHEVVTLWYRAPEVLLGSTHYSTPVDI
serine/threonine protein kinases
WSVGCIFAEMVRRQPLFPGDCEIQQLLHIFTLLGTPTEE
active-site signature is in
MWPGVKRLRDWHEYPQWKPENLARAVPNLSPTGLDLISK
bold/italics.MLQCDPARRISAKAAMNHPYF DDLDKSQF
121The amino acid sequence of SEQ IDMDG YEKNDK VGEGTYGKVYMAPDKKTGQLVALK KTRLEN
387. The conserved protein kinase
DGEGIPPTALREISLLQMLSQDIYIVRLLDVKHTENKLG
family domain is underlined. The
KPLLYLVFEYMESDLKKYIDSYRRSHTKNPPSMIKSFMY
protein kinases ATP-binding region
QLCRGVAYCHSRGDKEKGVLKIADLG
is in bold and the
LSRAFTVPVKKYTHEIVTLWYRAPEVLLGATHYSLPVDI
serine/threonine protein kinases
WSVGCIFAEMSRMQALFTGDSEVQQLMNIFRFLGTPNEE
active-site signature is in
VWPGVTKLKDWHIYPEWKPQDISHAVPDLEPSGLDLLSQ
bold/italics.MLVYEPSKRISAKKALEHPYF DDLDKSQF
122The amino acid sequence of SEQ IDMDA YEKLEK VQEGTYGKVYKAKDKNTGQLVALK KTRLES
388. The conserved eukaryotic
DDEGIPPTALREISLLQMLSQDIHIVRLLDVEHTENKNG
protein kinase domain is
KPLLYLVFEYMDSDLKKYIDGYRRSHTRVPPNIIKSFMY
underlined and the protein kinases
QLCQGVAYCHSRG VMHRDLKPHNLL VDKQRGVVKIADLG
ATP-binding region and
LGRAFTIFIKKYTHEIVTLWYRAPEVLLGATHYSTPVDI
serine/threonine protein kinases
WSVGCIFAEMVRLQALFIGDSEVQQLFKIFSFLGTPNEE
active-site signatures are in
IWPGVTKFRDWHIYPQWKPQDISSAVPDLEPSGVDLLSK
bold.MLVYEPSKRISAKKALEHPYF DDLDKSQF
123The amino acid sequence of SEQ IDMDS YEKLEKVGEGTYGKVYKAKDKKTGKLVALKKTRLEN
389. The conserved protein kinase
DGEGIPPTALREISLLQMLSQDMNIVRLLDVEHTENKNG
family domain is underlined. The
KPLLYLVFEYMDSDLKKYVDGYRRSHTKMPPKIIKSFMY
protein kinases ATP-binding region
QLCQGVAYCHSRG DKQRGVLKIADLG
is in bold and the
LGRAFTVPIKKYTHEIVTLWYRAPEVLLGATHYSTPVDI
serine/threonine protein kinases
WSVGCIEAEMSRMHALFCGDSEVQQLMSIFKFLGTPNEG
active-site signature is in
VWPGVTKLKDWHIYPEWRPQDLSRAVPDLEPSGVDLLTK
bold/italics.MLVYEPSKRISAKKALQHPYF DDLDRSQF
124The amino acid sequence of SEQ IDMEK YEKLEKVGEGTYGKVYKGRDKRTGRLVALKKTPFHQ
390. The conserved eukaryotic
EEGIPPTAIREISLLKSLSQCIYIVKLLDVKASFNGKGK
protein kinase domain is
HVLFMVFEYADSDLKKHIDAHRQCNTKLSPRSIQSYMFQ
underlined and the protein kinasas
LCKGIAYCHSHGVLHRDLKPQNILVDQKIGLLKIADLGL
ATP-binding region and
GRACTVPIKSYTFEVVTLWYRAPEVLLGAKRYSMALDIW
serine/threonine protein kinases
SLGCIFAELCNLQALFAGDSQIQQLINIFRLLGTPNEQL
active-site signatures are in
WPGVTQLSDWHEFPQWRPQDLSKVVFNLDPNGVDLLSKM
bold.LQYDPARRISAKEALDHPYF DSLDKSQF
125The amino acid sequence of SEQ IDMGCVCGKPSARAADYVESPAEKGASSNSRSSSMASRRLV
391. The conserved eukaryoticAPAVMDQGIDAENGHEGDYRTKLRGKQSNGADPVSLLSD
protein kinase domain isDAEKQRHSRHHQHQQHHPIRPHHLRPQGEFVPNANSNPR
underlined and theFGNPPRHIEGEQVAAGWPAWLTAVAGEAIKGWIPRRADS
serine/threonine protein kinases
FEKLDKIGQGTYSNVYKARDLDTGKIVALKKVRFDNLEP
active-site signatures are in
ESVRFMAREIQVLRRLDHPNVVKLEGLVTSRMSCSLYLV
bold.
FEYMDHDLAGLAACPGIKFTEPQVKCYMQQLLRGLDHCH
SRGV LHPDIKGSNLL IDNGGILKIADFGLATFFHPDQRQ
PLTSRVVTLWYRPPELLLGATEYGVAVDLWSTGCILAEL
LAGKPIMPGRTEVEQLHKIFKLCGSPSEDYWKKSKLPHA
TIFKPQQPYKRCVAETFKDFPPSALALMEVLLAIEPADR
GTATSALKSDFF TTKPLACDPSSLPKYPPSKEFDAKIRD
EEARRQRAAGGRGRDAARRPSRESRAIPAPEANAELAIS
IQKRRLSSQGPSKSKSEKFNPQQEDGAVGFPIEPPRPMH
IGIDAGATSRMYSQQFGPSHSGPLSNQISSSIWGKNQKE
DEIQMAPGRPSRSSKATISDFRKPGACAPQPGADLSHLS
SLVATARSNAGIDTHKDRSGMWQHNRIDAIDGVHNNGKH
EFLEVPEHPNRQDWTRFQQPESFKGLDNYHLQDLPATHH
RKDERVASKEATMNWQGYGGQGGDKIHYSGPLLPPSGNI
DEILKEHERHIQHAVRRARQDKGRPQRSNLSQNERKAFE
HRSFVSGVNGNAGYSDLVNELPISVGSNRLKVSKTRGTE
EIVELRELEREPLSSVMEKYEREHEM
126The amino acid sequence of SEQ IDMGCVCAKQSDILGEPESPKVKGSNLASSRWSVSSETKQL
392. The conserved eukaryoticPQHSDSGILHHQHYYHPRDESDEAKLKESNYGGSKRRTR
protein kinase domain isQGRDPADLDMGIFVRTPSSQSEAELVAAGWPAWMAAFAG
underlined and serine/threonineEAIHGWIPRRAES FEKLYKIGQGTYSNVYKARDLDNGKI
protein kinases active-site
VALKKVRFDSLDAESVRFMAREILVLRKLDHPNIVKLEG
signatures is in bold.
LVTSEVSSSLYLVFEYMEHDLAGLAACPGIKFTEPQVKC
YMQQLLQGLDHCHRHG VLHRDIKGSNLLI DNGGILKIAD
FGLATFFYPDQKQLLTSRVVTLWYRPPELLLGATDYGVA
VDIWSAGCILAELLAGKPILPGRTEVEQLHKIFKLCGSP
SEDYWKESKLPHATIFKPQHPYKSCIAEAFKDFSPSALA
LLETLLAIEPGHRGEASGALKSEFF TTEPLSCDPSSLPK
YPPSKEFDAKLRAQETRRQRDVGVRGHGSEAARRTSRLS
RAGPTPNEGAELTALTQKQHSTSHATSNIGSEKPSTKKE
DYTAGLHIDPPRPVNHSYETTGVSRAYDAIRGVAYSGPL
SQTHVSGSTSGKKPKRDHVKGLSGQSSLQPSKPFIVSDS
RSERIYEKSHVTDLSNHSRLAVGRNRDTTDPHKSLSTLM
QQIQDGTLDGIDIGTHEYARAPVSSTKQRSAQLQRPSAL
KYVDNVQLQNTRVGSRQSDERPANKESDMVSHRQGQRIN
CSGPLLHPSANIEDLLQKHEQQIQQAVRRAHHGKREALS
NKSSLPGKKPVDHRAWVSSGKGNKESPYFKGKGNKELSD
LKGGPTAKVTNFRQKVM
127The amino acid sequence of SEQ IDMAVANPGQLNLQEAPSWGSRSVNC FEKLEQ IGEGTYGQV
393. The conserved protein kinase
YMAKEIETGEIVALK KIRMDNEREGFPITAIREIKLLKK
family domain is underlined. The
LQHENVIKLKEIVTSPGPEKDEQGKSDGNKYNGSIYMVF
protein kinasas ATP-binding region
EYMDHDLTGLAERPGMRFSVPQIKCYMKQLLIGLHYCHI
is in bold and the
NQ NNGILKLADFGLARSFCSDQNGN
serine/threonine protein kinasas
LTNRVITLWYRPPELLLGSTKYGPAVDMWSVGCIFAELL
active-site signature is in
YGKPILPGKNEPEQLTKIFELCGSPDESNWPGVSKLPWY
bold/italics.
SNFKPQRQMKRRVRESFKNFDRHALDLVEKMLTLDPSQR
ISAKDALDAEYF WTDPVPCAPSSLPRYEPSHDFQTKRKR
QQQRQHDEMTKRQKISQHPPQQHVRLPPIQNAGQGHLPL
RPGPNPTMHNPPPQFPVGPSHYTGGPRGAGGQNRHPQNI
RPLHAAQGGGYNANRGYGGPPQQQGGGYPPHGMGNQGPR
GGQFGGRGAGYSQGGPYGGPVGGRGPNVGGGNRGPQFWS
EQ
128The amino acid sequence of SEQ IDMQNMEDNVQSSWSLHGNKEICARYEILERVGSGTYSDVY
394. The conserved eukaryoticRGRRKADGLIVALKEVHDYQSSWREIEALQRLCGCPNVV
protein kinase domain isRLYEWFWRENEDAVLVLEFLPSDLYSVIKSGKNKGENGI
underlined and thePEAEVKAWMIQILQGLADCHANWVIHRDLEPSNLLISAD
serine/threonine protein kinasasGILKLADFGQARILEEPEAIYEVEYELPQEDIVADAPGE
active-site signature is in bold.RLMEEDDSVKGVRNEGEEDSSTAVETNFGDMAETANLDL
SWKNEGDMVMQGFTSGVGTRWYRAPELLYGATIYGKEID
LWSLGCILGELLILEPLFSGTSDIDQLSRLVKVLGTPTE
ENWPGCSNLPDYRKLCFPGDGSPVGLKNHVPSCSDSVFS
ILERLVCYDPAARLNAKEVLENKYFVEDPYPVLTHELRV
PSPLREENNFSEDWAKWKDMEADSDLENIDEFNVVHSSD
GFCIKFS
129The amino acid sequence of SEQ IDMDLNQYPEDLNPELPEGTDNVDNPDNNKGSPVPSPHPPL
395. The conserved eukaryoticKPLDPSER YRKGIT LGQGTYGIVYKAFDTVTNKTVAVKK
protein kinase domain is
IHLGKAKEGVNVTALREIKLLKELSHPNIIQLIDAYPHK
underlined and the protein kinases
QNLHIVFEFNETDLEAVIKDRNLVFSPADIKSYLQMTLK
ATP-binding region and
GLAVCHRK WVLHPDMKPMNLLI AADGQLKLGDFGLARLF
serine/threonine protein kinases
GSPDRKFTHQVFAVWYRAPELLFGAKQYGPAVDIWATGC
active-site signatures are in
IFAELLLRKPFLQGVSDLDQIGKIFAAFGTPRQSQWPDV
bold.
ASLPDFVEFQFVPAPSLRSLFPMASEDALDLLSKMFTLD
PKNRITAQQALEHRYF SSVPAPTRPDLLPKPSKVDSSRP
PKHASPDGPVVLSPSKARRVMLFPNNLAGILPKQVSQST
TGGTPIEFDMPTQKLREVCPRSRITESGKKNLKRKTMDM
SAALDECAREQEGQEGKTILDPDHQRSAKKEKHM
130The amino acid sequence of SEQ IDMAGGQENCVRITRARAACVSKASAPVIQSQVDEKKSRKR
396. The conserved cyclin N- andAPKRAAVDDLAANASGSQPKRRAVLGDVTNLHAAATDCL
C-terminal family domains areSTAEDQVDAPNPSIKGRARNKKKEARTSTKVVKDEIHPE
underlined.SNPLADHSSNLSECQKPPAAKLAEQRSLRGVPSKAKQGG
SSNSQSCSKHTDIDKDHTDPQMCTTYVE DIYEYLRNAEL
KNRPSANFMETAQNDITPNMRAILVDWLVEVSEEYKLVP
DTLYLTVSYIDRYLSANPTSRHKLQLLGVSCMLIASKYE
EVCPPHVEEFCYITDNTYTRDENLSMERKILIFLNFEMT
K PTTKSFLRRFVRASQAGNKAPSLHMEFLANYLAELTLM
ECSFLQYLPSLIAASTVFLSRLTLDFLTNPWNPTLAHYT
GYKASQLKDCVMAIYNVQMNRKGSTLVAIREKYQQHKFK
CVASLPPPPFIA ERFFEDTPN
131The amino acid sequence of SEQ IDMTGTQASNVRITRARAAKSTLNNALPPLPPAQGKPRGKR
397. The conserved cyclin andAATESNISGFSVAAEPLKRRAVLSDVSNICKEAAAVDCL
cyclin C-terminal domains areKKPKAVKVVSQNANAKGRGRGIPRNNKKITQEAEIKKET
underlined and the cyclinsSPAICNVDDASAGNAIGDDKQNNNVNPLKEVQDNPKELN
signature is in bold.PIAEQISVHPHCEQSVEKPNEKEIVVSDNKAAIASLKQQ
STLQSLRIPKQPKYSLKQGNPVPLANLHEDVGRSSCSDF
IDIDSEYKDPQMCTAYVT DIYANMRVVELKRRPLPNFME
TTQRDINANM RSVLIDWLVEVSEEYIRVPDTLYLTVSYI
DRF LSANVVNRQRLQLLGVSCMLVASKYEEICAPPVEEF
CYITDNTYKKEEVLEMEISVLNRLQYDLT T PTTKTFLRR
FIRAAQASCKVSSLHLEFMGNYLAELTLVEYDFLKYLPS
LIAAAAVFVARNTLDPNVHPWNSTLQHYTGYKVSDMRDC
ICAIHDLQLNRKGCTLAAIREKYNQPKFKCVANLFPPPI
IS PQFLIDNEV
132The amino acid sequence of SEQ IDMAAPNQNALLINNNNRRPLVDIGNLVGALNAQCNISKNG
398. The conserved cyclin andARKRAFGDIGNLVEDLDAKCTISKYWVRKRPRTNFGVNA
cyclin C-terminal domains areNKGASSSTQGQGIVVRGEQKAWDRIVWGNKQSCAIKMNA
underlined and the cyclinsQHVTATQRGTAISISDIIDSSVQDGGIKAPSQLKARKQT
signature is in bold.VRTVTATLTARSEDSLRDVLEVPPGIDDGDRDNPLAVVE
YVE DIYHFYRKIEVRSCVPPDYMTRQLEIKDSNRG VIID
WLIEVHRTFLLMPETLYLTVNIIDRY LSIQSVTRNELQL
MGITANFIASKYEEISPPKINDLVYITKDAYTSKQIVNM
EHTILNRLRFKLT V PTPYVFLVRFLKAAGPDKVMKNLAF
FLVDLCLLHYKMIKYSPSMLAAAAVYTAQCTLKKHPYWN
ETLILHIGYSEAHLRECAHLMADLHLKAEGSNLKSVYKK
YSYPIFGSVAFLSPAKIPA GTVAAPAIDKCAHQIYLRNL
R
133The amino acid sequence of SEQ IDMFPNKQTQGLVQNKKMASKAAQPKAMVPPQRVPPAANNR
399. The conserved cyclin N- andRALGDIGNIVADVGGKCNVTKDGVNGKPLAQVSRPITRS
C-terminal family domains areFGAQLLAQAAANKGISAANNQTQVPVVIPKADVRGNRQR
underlined.RTSKSKDIPPTTVVTNESDDCVIIEQAQRIKPTCNHNVG
AVGNKEKPQLLTAKPKSLTASLTSRSAVALRGFRFDDEM
TEAEEDPLPNIDVGDRDNQLAVVEYVE DIYKFYRRTEQM
SCVPDYMPRQQEINPKMRAVLINWLIEVHYRFGLNPETL
YLTTNLIDRYLATQLVSRSNYQLVGATANLLASKYEEIW
APEMNDFLDILENKFERKHVLVNEKANLNKLKFHLT V PT
PYVFLVRFLKAAASDEEMENLVFFLMELSLMQYVMIKFP
PSMLAAAAVYTAQITLKKTTVWNDVLKRHTGYSEIDLKE
CTRLMVAFHQSSEESKLNVVFKKYSMPEYDSVALIKPAK
LP A
134The amino acid sequence of SEQ IDMAPSFDCVANAYIESCEDQEKLRQNAQILAQSGENDVD E
400. The conserved cyclin and
PVSMLVQRETHYMLPEDYLQRLRNRTLDVNVRREAVGWI
cyclin C-terminal domains are
LKVHSFYNFGAPTAYLAVNYLDRFLSRHRMPQGVKAWMI
underlined
QLMAVACLSLAAKMEETQVPLPSDLQREDARFIEDARTI
QRMELLILSTLQWGMR S ITPFSFIDYFAYRAVQGHGHGH
DATPKAVMSRAIELILSTTEEIDFMEYRPSAIAAAALLC
AAEEVVPLQAVHYKRALSSSITDVDKDKNFGCYNLIQET
IIEGGCYWTPMSLQSTEKTPVGVLDAAACLSNTPTSS YS
VKPYASVTAAKRRKLNEICSALLVSQAHPC
135The amino acid sequence of SEQ IDMAANFWTSSHCKELLDAEKVGIVHPLDRDQGLTQEDVKI
401. The conserved cyclin andIKINMS NCIRTLAQYVKLRQRVVATAITYCRRVYTRKSF
cyclin C-terminal domains are
TEYDPQLVAPTCLYLASKAEESTVQAKLVIFYMKKYSKH
underlined.RYEIKDMLEMEMKLLE ALDYYLVIYHPY RPLIQFLQDAG
LNDLKVTAWALVNDTYRTDLILTYPPYMIALACIYFACI
MEEKDAQAWFEELRVDMNEIKNISMEIVD YYDNYRVIPD
EKNNSALNKLPHRF
136The amino acid sequence of SEQ IDMAPALSSSYECLSHLLCAEDASNVVGCWDEDESKIFCEE
402. The conserved cyclin domainEEGFGIQHFPDFPVPDD DEIRVLVRKESQYMPGKSYVQS
is underlined.
YQNLGLOFTARQNAIGWILKVHGSYNFGPLTAYLSINYL
DRFLSRNPLPEAKVWMLQLLSVACLSLAAKMEETQVPLL
LDLQAEEPDFLFEPRTIQRMELLVLSTLEWRML SVTPFS
FVDYFLQGGGGRKPPPRAMVARANELIFNTHTVLDFLEH
RPSAIAAAAVICAAEEVLPLEAAQYKETILSCSLVDKEW
VFGSYNLIQEVLIEKFSTPKKAKSASSSIPQSPVGVLDA
FCLSNNSNNTSLEASLSVNLYASVAAKRRKLNDYCNTWR
MFQHSTC
137The amino acid sequence of SEQ IDMAPNCIDCAPSDLFCAEDAFGVVEWGDAETGSLYGDEDQ
403. The conserved cyclin domainLHYNLDICDQHDEHLWDDG ELVAFAEKETLYVPNPVEKN
is underlined.
SAEAKARQDAVDWILKVHAHYGFGPVTAVLSINYLDRFL
SANQLQQDKPWMTQLAAVACLSLAAKNDETEVPLLLDFQ
VEEAKYIFESRTIQRMELLVLSTLEWRMS PVTPLSYIDH
ASRMIGLENHHCWIFTMRCKEILLNTLRDAKFLGLLPSV
VAAAIMLHVIKETELVNPCEYENRLLSAMKVNRDMCERC
IGLLIAPESSSLGSFSLGLKRKSSTINIPVPGSPDGVLD
ATFSCSSSSCGSGQSTPGSYDSNNSSILCISPAVIKKRK
LNYEFCSDLHCLED
138The amino acid sequence of SEQ ID
MPQIQ YSEKYTDDTYEYRWJVLPP ETAKLLPKNRLLNEN
404. The conserved cyclin-EWRAIGVQQSRGWVHYAIHRPEPHIMLFRRPLN YQQNQQ
dependent kinasas regulatoryQQAGAQSQPMGLKAQ
subunit domain is underlined and
the cyclin-dependent kinases
regulatory subunits signature 1 is
in bold.
139The amino acid sequence of SEQ ID
MDQIE YSEKYYDDTYEYRHVELPP DVARLLPKNRLLTEN
405. The conserved cyclin-EWRGIGVQQSRGWVHYAIHCSEPHIMLFRRPLN YEQNHQ
dependent kinases regulatoryHPEPHIMLFRRPLNCQPNHQPQAHHPT
subunit domain is underlined and
the cyclin-dependent kinases
regulatory subunits signature 1 is
in bold.
140The amino acid sequence of SEQ ID
MDQIEY SEKYYDDTYEYRHVELPP DVARLLPKNRLLTEN
406. The conserved cyclin-EWRGIGVQQSRGWVHYAIHCSEPHIMLFRRPLN YEQNHQ
dependent kinases regulatoryHPEPNIMLFRRPLNCQPNHQPQAHHPT
subunit domain is underlined and
the cyclin-dependent kinases
regulatory subunits signature 1 is
in bold.
141The amino acid sequence of SEQ ID
MPQIQ YSEKYYDDTYEYRHVVLPP DVARLLPKNRLLNEN
407. The conserved cyclin-EWRGIGVQQSRGWVHYAIHRPEPHIMLFRRHLN YQQNQQ
dependent kinases regulatoryQQAQQQPAQAMGLQA
subunit domain is underlined and
the cyclin-dependent kinasas
regulatory subunits signature 1 is
in bold.
142The amino acid sequence of SEQ IDMALVETEPVTLIHPEEPRKFKKKPTPGRGGVISHGLTEE
408. The conserved GCN5-related N-EARVKAIAEIVGANVEGCRKGEDVDLNALKAAACRRYGL
acetyltransferase family domain isSRAPRLVEMIAALPDGERAAVLPRLKARPVRTASGIAVV
underlined and the radical SAMAV MSKPHRCPHIATTGNICVYCPGGPDSDFEYSTQSYTG
family domain is in bold.
YEPTSMRAIRARYNPYVQTRSRIDQLKRLGHTVDKVEFI
LMGGTFMSLPADYPDYFIENLHDALSGHTSSNVEEAVCY
SEHSATKCIGLTIETRPDYCLGPHLRQMLSYGCTPLEIG
VQSTYEDVARDTNRGHTVAAVADCFCLAIWAGFKVVAHM
MPDLPNVGVERDDNSFREFF ENPAFRADGLRIYPTLVIR
GTGLYELWKTGRYRNYPPEQLVDIIARVLALVPPWTRVY
RVQRDIPMPLVTSGVERGNLRELALARMDDLGLKCRDVR
TREAGIQDIHHKIRPEVVELVRRDYCANEGWETFLS YED
TRQDILVGLLRLRKCGHNTTCPELRGRCSIVRELHVYGT
AVPVHGRDADRLQHQGYGTLLMEQAERIAWREHRSIKIA
VISGVGTRHYYRKLGYE LEGPYNMKYLN
143The amino acid sequence of SEQ IDMLGFRDLYTSICEHLQRASGRLPIIAAATSLISTPEIAA
409. The conserved chromo domainVERENKAPNSVDEMGMGSADESGRFSTSNGQFMNMNNGV
is underlined and the MOZ/SAS-likeVKEEWRGGVPVVPSAPTTVPVITNVKLETPSSPDHDMAR
protein domain is in bold.KRKLGFLPLEVGTRVLCKWRDG KFHPVRIIERRKLPNGA
TNDYEYYVHYTEFNRRLDEWVKLEQLELDSVETDADERV
DDKA GSLENTRHQKRKIDETHVEGNEELDAASLREHEEF
TKVRNITRIELGRYEIETWYFSPFPSEYNNCEKLYFCEF
CLNFMRRREQLQRHMRKCD LKHPPGDEIYRSGTLSMFEV
DGKKNKVYAQNLCYLAKLFLDHKTLYYDVDLFLFYILCE
CDERGCNMVGYFSKEKHSEESYNLACILTLPPYQRKGYG
KFLISFSYELSKKEGKVGTPERPLSDLGLLBYRGYWTRV
LLDILKKHKSNISIKELSDMTAIKADDVLSTLQGLDLIQ
YRKGQHAICAD PKVLDRHLKAVGRGGLEVDVCKLIWTPY
KEQ
144The amino acid sequence of SEQ IDMGSLDESTCSEEIRDEGRDSIRTKFKVESTVNNAQNGGN
410. The conserved MOZ/SAS-likeDNSRRKRAAGLPLEVGIRLLCRWRDSKLHFVRIIERREL
protein domain is underlined.PNGFPQDYEYYVHYTEFNRRLDEWVKLEQFELDSVETDA
DEKIEDKGGSLKNTRHQKRKIDEIHVEEGQGHEDFDPAS
LREHEEFTKVRNIAKVELGRYEIETWYFSPFPPEYSHCE
KLFFCEFCLNFMKRKEQLQRHNRKCD LKHPPGDEIYRNG
TLSMFEVDGKKNKIYGQNLCYLAKLFLDHKTLYYDVDLF
LFYVLCECDDRGCHVVGYFSKEKHSDEAYNLACILTLPP
YQRKGYGKFLIAFSYELSKKEGKVGTFERPLSDLGLLSY
RGYWTRILLDILKKQRGNISIKELSDMTAIKVEDVISTL
QVLDLIQYRKGQHVICAD PKVLDRHLKAAGIAGLEVDVS
KLIWTPYKEQCG
145The amino acid sequence of SEQ IDMASAFMVGCDDSRDKHRWVESKVYMRKGHGKGSKGNAGF
411. The conserved bromo familyNAQNSTAQVRRENDNMGNSIADNGKSEAASEGLSSLSRK
domain is underlined.QITVNQDHPPNETSSMPAVGGLQNIDTHVTFKLEGCSKQ
EIWELRKKLTNELEQVRGTFKKLEARELQLRGYSVSAGV
NTSYSASQFSGNDMRNNGGKEVTSEVASGGAITPKQAQR
ESNPPRQLSISLNENNQAASDMGEKGKRTPRANQYYRNS
EFVLGKDKFPPAESKKSKSTGNKKISQSKVFSKETMQVG
KEFNFQKSVN EVFKQCSLLLTKLMKHKYGWVFNLPVDAQ
ALGLHDYHTIIKRPNDLGTVKSKLEKNLYNSPASFAEDV
KLTFSNAMTYNPKGHEVHTMAEQ LLQLFEERWKTIYEEH
LDGKMRFGSGQGLGASSSTKKLPFQDSKKNIKKSEPAGG
PSPPKPKSTNHHASRTPSAKKPKAKDPHKRDMTYEEKQR
LSTNLQNLPQERLELIVQIIKKRNPSLCQHDEEIEVDID
SFDTETLWELDRFVTNYKKSLSRNKKKALLADQAKRASE
HGSARNKHPMIGRELPNNNRKGEQGEKVVEIDHMPPVNP
PVVEVEKDGVYARRSSSSSSSSSDSGSSSSDSDSGSSSG
SESDAYAATSPPAGSNTSARG
146The amino acid sequence of SEQ IDMEGHSGALGFGQGFSRSSQSPNLSPSPSHSASASVTSSG
412. The conserved GCN5-related NQKRKRNEVEHAGVASNSTGMFAVPPSHIYSHLHPNSMSN
acetyltransferase family domain isPNPMHNSHPSSLSESRDGALTSNDDDDNLTGGNQSQLDS
underlined and the bromodomain isMSAGNTDGREDFDDEDDDDDDEEDDDEVEGDEEDQDHDP
in bold.DADDDSDDGHDSMRTFTAARLDNGAPNSRNLKPKADAAG
VAIAPTVKTEPILDTVKEEKVSGNNNNNSVSANNAQVAP
SGSAVLLSAVKEEANKFTSTDHIQTSGAYCAREESLKRE
EDADRLRFVCFGNDGIDQHMIWLIGLKNIFARQLPNNPK
EYIVRLVMDRSHKS VMIIKQNQVVGGITYRPYLSQKFGE
IAFCAITADEQVKGYGTRLMNHLKQHARDVDGLTHFLTY
ADNNAVGYFIKQDFT KEIKLEKERWHGYIKDYDGGILME
CKIDPKLPYTDLPANIRWQRQTIDEKIRELSNCHIVYSG
IDIQRKEAGIPRKPIKVEDIPGLKEAGWTTDOWGNSRFR
LLNSPSEGLPNRQ VLHAFMRSLHKAMVEHADAWPFKEPV
DPRDVPDYYDIIKDPMDVKRMFTNARTYNTHETIYYKCA
NR
147The amino acid sequence of SEQ IDMEESGNSLTSGPDGSK RRVSYFYDSDIGNYYYSQGHPMK
413. The conserved histome
PHRTRMAHSLIVHYALDEKNEVCRFNLLQSRELRVFHAD
deacetylase family domain is
DYISFLQSVTFETQHEQLRQLKRFNVGEDCFVFDGLYNF
underlined.
CQTYAGGSVGAAIKLNNKEADIAINWSGGLHHAKKCEAS
GFCYVNDIVLAILELLKVHQRVLYIDIDIHHGDGVEEAF
YSTDRVMSVSFHKFGDYFFGTGHLKDVGYGKGKYYSLNV
PLNDGIDDESYKNLFRFIIQKVMEIYQFEAVVLQCGADS
LSGDRLGCFNLSVKGHADCVRFLRSFNVFLVLVGGGGYT
IRNVARCWCYETAVAVG VEFQDKLFYNEYYEYFGFDYTL
HVAFSNMENQNSAKELAKIRNTLLEQLKRIQHVFSVFFQ
ERFFDTKFFEEDEEDYEKRFKGHKWGGEYFGSESDEEQK
FQNRDIDISDKFGIRRQSFFNVEAAKKIKVEEEDGDIGI
VNENDGAKWFLGEAG
148The amino acid sequence of SEQ IDMEESGNSLTSGFDGSK RRVSYFYDSDIGNYYYSQGHFMK
414. The conserve histone
PHRIRMAHSLIVHYALDEKNEVCRFNLLQSRELRVFHAD
deacetylase domain is underlined.
DYTSFLQSVTFETQHEQLRQLKRFNVGEDCFVFDGLYNF
CQTYAGGSVGAAIKLNNKEADIAINWSGGLHHAKKCEAS
GFCYVNDIVLAILELLKVHQRVLYIDIDIHHGDGVEEAF
YSTDRVNSVSFHKFGDYFFGTGHLKDVGYGKGKYYSLNV
PLNDGIDDESYKNLFRFIIQKVMEIYQFEAVVLQCGADS
LSGDRLGCFNLSVKGHADCVRFLRSFNVFLVLVGGGGYT
IRNVARCWCYETAVAVG VEFQDKLFYNEYYEYFGFDYTL
HVAFSNMENQNSAKELAKIRNTLLEQLKRIQHVFSVFFQ
ERPFDTKFFEEDEEDYEKRFKGHKWGGEYFGSESDEEQK
FQNRDIDISDKFGIRRQSFFNVEAAKKIKVEEEDGDIGI
VNENDGAKWFLGEAG
149The amino acid sequence of SEQ IDMMETGGNSLFSGFDGVK RKVAYFYDFEVGNYYYGQGHPN
416. The conserved histone
KPHRIRMTHALLVQYGLHKEMQILKFYFARDRDLCRFHA
deacetylase family domain is
DDYVAFLRGITFETIQDQVKALKRFNVGDDCFVFDGLYQ
underlined.
YCQTYAGGSVGGAVKLNHKLCDIAINWAGGLHHAKKCEA
SGFCYVNDIVLAILELLKYHKRVLYVDIDIHHGDGVEEA
FYTTDRVNTVSFHKFGDYFFGTGDIRDIGCGKGKYYAVN
VPLDDGIDDESFQSLFKFIIQQVMLVYNFEAIVLQCGAD
SLSGDRLGCFNLSVKGHAECVRYMRSFNVFLLMVGGGGY
TVRNVARCWCYETGVAVG VEIDDKNFQHEYYEYFGFDYT
VHVAFSNMENKNTKQYLDKIRSKILENINSLFCAFSAQF
QVQFFDTDFFELEEEDYDERTRSHKWDGASCDSDSENGD
LKHRNHDVEESAFFRHNLANISYNTRIKLEGVGTGGLDM
AAGTDTKKNDESFEAMDYESGEELRQDHFASTINASQFC
DFALLTGVQNQLQSTDTVKFIEQSGNAFGIPPPSVATVS
TGTRFSSISRTSSLNSMSSVKQGSILGFNPPQGLNASGL
QFFVFTSNSFIRQGGSYSITVQAFDKQGLQNHMRGFQNN
PGNS
150The amino acid sequence of SEQ IDMPPK DRVAYFYDGDVGSVYFGPNHPMKPHRLCMTHHLVL
417. The conserved histone
SYELHKKMEIYRPHKAYPVELAQFHSADYVEFLHRITPD
deacetylase family domain is
TQHLFTKELVKYNMGEDCPVFENLFEFCQIYAGGTIDAA
underlined.
HRLNNQICDIAINWSGGLHHAKKCEASGFCYINDLVLGI
LELLKHHARVLYVDIDVHHGDGVEEAFYFTDRVMTVSFH
KYGDMFFPGTGDVKEVGEREGKYYAINVPLKDGIDDASF
TRLFKTIITKVVDIYQPGAIVLQCGADSLAGDRLGCFNL
SIDGHAQCVRIVKRFNLPLLVTGGGGYTKENVARCWSVE
TGVLLD TELPNEIPDNDYIRYFAPDYSLKINTAGNMENL
NSKTYLSAIKVQVMENLRAIQHAPSVQMHEVPPDFYIPD
IDEDELNPDERMDQHTQDRQIQRDDEYYDGDNDIDHDME
EAS
151The amino acid sequence of SEQ IDMDSSKSEEANILHVFWHEGMLNHD LGTGVFDTLEDPGFL
418. The conserved histone
EVLERHPENADRVRNMLSILRKGPIAPYTEWHTGRAAYL
deacetylase family domain is
SELYSFHRPDYVQMLARTSTAGGKTLCHGTRLNPGSWEA
underlined.
ALLAAGTTLEAMRYILDGHGKLSYALVRPPGHHAQPTQA
DGYCFLNNAGLAVELAVASGCKRVAVVDIDVHYGNGTAE
GFYERDDVLTISLHMMHGSWGPSHPQTGFHDEVGRGKGL
GFNLNVPLPNGTGDKGYEHAMHELVVPAISKFMPEMIVL
VIGQDSSAFDPNGRECLTMEGYRKIGQIMRQQADQFSGG
RLVVVQEGGYHITYAAYCLHATLEGVLC LPHPLLSDPIA
YYPEHDIYSERVTFIKNYWQGIISTTDKRN
152The amino acid sequence of SEQ IDMEESGNALVSGPDGSK RRVTYFYDADIGNYYYGQGHPMK
419. The conserved histone
PHRMRMAHNLIVHYGLHQRNEVCRPHLAQSEDIRAFHTD
deacetylase family domain is
DYIHFLSSVAPDTQQEQLRQLKRFMVGEDCPVFDGLENF
underlined.
CQSSAGGSIGAALKLMRKDADIAINWAGGLHHAKKCEAS
GFCYVNDIVLGILELLKVHQRVLYIDIDIHHGDGVEEAF
YTTDRVMTVSFHKFGDYFPGTGHIKDVGYGKGKYYALMV
PLNDGIDDESYKHLFRPIIQKVMEVYQPEAVVLQCGADS
LSGDRLGCFNLSVKGHADCVRFVRSFNIPLMLVGGGGYT
IRNVARCWCYETAVAVG VEPQDKLPYNEYYEYFGPDYTL
YVAPSNMEMLNTEKDLERMRNVLLEQLSKIQHTPSVPFQ
ERPPDTEFNDEEEEDMEKRSKCRIWDGEYVGSEPEEDGK
LPRFDADTYERSVLKHENKRLVPVSNVEPLKRIKQEEDG
AAV
153The amino acid sequence of SEQ IDMDLNLVSHGEEEEGVRR RKVGIVYDERNCKHATPEDQPH
421. The conserved histone
PEQPDRIRVIWDKLNSAGVLHKCVMVEAKEASEEQLAGV
deacetylase family domain is
HSRKHIEVMKSIGTARYNKKKRDKLAASYSSIYWSQGSS
underlined.
EAALLAAGSVVEISEKVASGELDAGVAIVRPPGHHAEAD
KAMGFCLFNNIAIAARHLVHERPELGVQKVLIVDWDVHH
GNGTQHMFWTDPHVLYFSVHRFDAGTFYPGGDDGFYDKI
GEGKGAGYNINVPWEQGKCGDADYLAVWDHVLVPVAKSY
DPDMVLISGGFDAALGDPLGGCRLTPYGYSLMTKKLMEF
AGGKIVLALEGGYNLKSLADSFLACVEALLK DGPSRSSV
LTHPFGSTWRVIQAVRKELSSFWPALMEELQLPRLLKDA
SESFDKLSSSSSDESSASEDEKKFAEVTSIMEVSPDPSS
ILALTAEDIAQPLAGLKIEEAGTDSQRSSDHTLLDLTND
DTQKLKQFEGEIFVMIGDEESVPSASSSKDQNESTVVLS
KSNIKAHSWRLTFSSIYVWYASYGSNMWNPRFLCYIEGG
QVEGMAKRCCGSEDKLLLKGYSGKLFLIECFLGDHTQIH
GVQEECPFLIQIVVIRVKRNSACIK
154The amino acid sequence of SEQ IDMADEDLDLSDVGEVEDEPGEEIESTPPLAVGQEKEINSL
422. The conserved FKBP-typeALKKKLLKV GTRWETPENGDEVT VHYTGTLPDGTKFDSS
peptidyl-prolyl cis-trans
RDRGEPFTFKLGQGQ VIKGWDQGIVTMKKGERALFTIPP
isomerase signature is underlinedELAY GSSGVRPTIPPNATLQFDVELL SWTNIVDVCNDGG
and the FKBP-type peptidyl-prolylILKRIISE GEKYERPKDPDEVTVKYEAKLEDGTLVAKSP
cis-trans isomerase signatures 1
EEGVEFYVNDGHFCPAIAKAVKTMKRGESVILTIKPTYA
and 2 are in bold.FGERGKDAEEGFAAIPPNATLTTSLELV SFKAVIAVTED
KKVIKKILKE ADGYDKPSDGTVVQIRYTAKLQDGTIFEK
KGYEGEEPFQFVVDEEQVIAGLDKAVETMKTGEIALITI
GAEYGFGNFETQRDLAVIPPNSTLIYEVEMI SFTKEKES
WDMDTTEKIEASKQKKEQGNSLFKVGKYQRAAKKYEKAA
KYIEHDSSFSAEEKRQSKVLKVSCNLNHAACRLKLKDFK
EAVKLCSKVLELESQNVKALYRRAQAYIETADLDLAEFD
IKKALEIEPQMREVQLEYKILKQKQIEYNKKDAKLYGNN
FAKLNKLEAFEGKVLS
155The amino acid sequence of SEQ IDMADEGLELSDVAEVEDEPGEEFESAPPLVVGQEKELNSS
423. The conserved FKBP-typeGLKKRLLEAG TRCETPENGDEVT VHYTGTLLDGTKF DSS
peptidyl-prolyl cis-trans
RDRGEPFTFNIGQGQVIKGWDQGIVTMKKREHALFTIPP
isomerase family domains areELAYGASGMPPTIPPNATLQFDVELL SWTNIVDVCRDGG
underlined. The FKBP-typeILKRIISD GEKYERPKDPDEVTVKYEAKLEDGMLVAKSP
peptidyl-prolyl cis-trans
EEGVEFYVNDGNFCPAIVKAVKTMKKGENVTLTIKPAYA
isomerase signatures 1 and 2 areFGEQGKDAEEGFAAIPPNATITINLQLV SFKAVKEVTED
in bold. The TPR repeat is inKKVIKKILKE ADGYDKPSDGTVVQIRYTAKLQDGTIFEK
bold/italics.
KGYAGEEPFQFVVDEEQ VIAGLDKAVETMKTGEVALITI
GPEYGFG NIETQRDLAVIPPYSTLIYEVEMV SFTKEKES
WDMNTTENIEASKQKKEQGNSLFKVGKYLRAAKKYDKAA
KYIEHDNSFSAEEKKQSKVLKVSCNLNHAACCLKLKDFK
KAVKLCSEVLELESQN
REVRLEYLILKQKQIEYNKKDAKLYGNM
FARQNKLEAIEGKD
156The amino acid sequence of SEQ IDMPNP KVFFDMQVGGAPAGRIVMELYADVVPKTAENFRAL
424. The conserved cyclophilin-
CTGEKGTGRSGKPLH FKGSSFHRVIPCFMCQGG DFTRGN
type peptidyl-prolyl cis-trans
GTGGESIYGEKFADENFVKKHTGPGILSMANAGPNTNGS
isomerase signature is underlined
QFFICTAQTSWLDGKHVVFGQVVEGLEVVRDIEKVGSGS
and the cyclophilin-type peptidyl-
GRTSKPVVIADSGQLA
prolyl cis-trans isomerase
signature 2 is in bold.
157The amino acid sequence of SEQ IDMPNP KVFFDMQVGGAPAGRIVMELYADVVPKTAENFRAL
425. The conserved cyclophilin-
CTGERGNGRSGKPLH FKGSSFHRVIPGFMCQGG DFTRGN
type peptidyl-prolyl cis-trans
GTGGESIYGEKFADENFVKKHTGPGILSMANAGPNTNGS
isomerase signature is underlined
QFFICTAQTSWLDGKHVVFGQVVEGLEVVRDIEKVGSGS
andThe cyclophilin-type peptidyl-
GRTSKPVVIADSGQLA
prolyl cis-trans isomerase
signature 2 is in bold.
158The amino acid sequence of SEQ IDMPNP KVFFDMQVGGAPAGRIVMELYADVVPRTAENFRAL
426. The conserved cyclophilin-
CTGEKGTGRSGKPLHFKGSSFHRVIPGFMCQGGDFTRGN
type peptidyl-prolyl cis-trans
GTGGESIYGEKFADENFVKKHTGPGILSMANAGPNTNGS
isomerase signature is underlined
QFFICTAQTSWLDGKHVVFGQVVEGLEVVRDIEKVGSGS
andThe cyclophilin-type peptidyl-
GRTSKPVVIADSGQLA
prolyl cis-trans isomerase
signature 2 is in bold.
159The amino acid sequence of SEQ IDMPNP KVFFDMQVGGAPAGRIVMELYADVVPKTAENFRAL
427. The conserved cyclophilin-
CTGEKGTGRSGKPLH FKGSSFHRVIPGFMCQGG DFTRGN
type peptidyl-prolyl cis-trans
GTGGESIYGERFADENFVKKHTGPGILSMANAGPNTNGS
isomerase signature is underlined
QFFICTAQTSWLDGKHVVFGQVVEGLEVVRDIEKVGSGS
and The cyclophilin-type peptidyl-
GRTSKPVVIADSGQLA
prolyl cis-trans isomerase
signature 2 is in bold.
160The amino acid sequence of SEQ IDMADDFELPESAGMHENEDFGDTVFKVGEEKEIGKQGLKK
428. The conserved FKBP-typeLLVKE GGSWETPETGDEVEVHYTGTLLDGTKFDSSRDRG
peptidyl-prolyl cis-trans
TPFKFKLGQGQVIKGWDQGIATMKKGENAVFTIPPDLAY
isomerase signature is underlinedGESGSQPTIPPNATLKFDVELL SWASVKDICKDGGIFKK
and the FKBP-type peptidyl-prolylIIKE GEKWEHPKEADEVLVRYEARLEDGTVVSKSEEGVE
cis-trans isomerase signature 1 is
FYVKDGYFCPAFAIAVKTMKKGEKVLLTVKPQYGFGHQG
in bold and underlined. The TPRREAIGNDVARSTNATLLVDLELV SWKVVDEVTDDRKVLK
repeat is in bold/italics.KILKQ GEGYERPNDGAVVKVKYTGKLEDGTIFEEKGSDE
EPFEFMAGEEQVVDGLDRAVMTMKKGEVALVSVAAEYGY
QTEIKTDLAVVPPRSTLIYEVELV SFVKEKESWDMNTAE
KIEAAGKKKEEGNALFKVGKYFBASKKYEKATKYIEYDT
SFSEEEKKQSKPLK
RDVKLEYBALKEKQKEYNKKEAKFYGNMFARMSKL
EELESRKSGSQKVETANREEGSDAMAVDGESA
161The amino acid sequence of SEQ IDMAASLTPLGAGLAYATIYDQAKVRKLEPTKRSLIALCQH
429. The conserved FKBP-typeSDSQHRRFITRKYHVNVQILNRRDAIRLIGLAAGLCIDL
peptidylprolyl isomerase domain isSLMYDARGAGLPPQENAKLCDTTCEKELENAPMITTESG
underlined.LQYKDIKI GNGPSPPIGFQVAANYVAMVPSGQVFDSSLD
KGQPYIFRVGSGQVIKGLDEGLLSMKVGGRRRLYIPGPL
AFPKGLNSAPGRPRVAPSSPVIFDVSLE FIPGLESEEE
162The amino acid sequence of SEQ IDMSAASLSADMAIRGTILGKTALHVLGPQVVSQCRQPVMF
430. The conserved FKBP-typeKCPPHTLRKMRFSAQDLQSKNFYSGFTPFKSVFISTSKR
peptidylprolyl isomerase domain isSWQAGSARAMSQDAAFQSKVTT KCFLDIEIGGDPAGRIV
underlined and the Cyclophilin-
LGLFGEDVPKTAENFRALCTGEKGFG YKGSSFHRIIKDF
type peptidyl-prolyl cistrans
MLQGG DFDRGDGTGGKSIYGRTFEDENFKLAHVGPGVLS
isomerase signature is in bold.
MANAGPNTNGSQFFICTVRTPWLDKRHVVFGQVIEGMEI
VKKLESEETNRTDRPKRPCRIVDCGELP
163The amino acid sequence of SEQ IDMGRIKPQTLLQQSKKKKVPGRISVSTIIVCNLIIIFLMF
431. The conserved FKBP-typeSLVGIYRQRAKRNRATSRSDGDEEMENFGRSKINSVP HQ
peptidylprolyl isomerase domain is
AIVNTTRGLITLELFGKSSAHTVEKFVEWSERGYFNGLP
underlined.
FYRVIKHFVIQVGDPKFAGNREDWTVGGQLNVQLEFSPK
HEAFNLGTSKLEDQGDGFELFITTAPIPDLNDKLNVFGR
VIKGQDVVQEIEEVDTDEHFQPKSPIIINDVRLKD EL
164The amino acid sequence of SEQ IDMARQSTLLLFWSLVFLGAIVFTQARHEELEEVTH KVYFD
432. The conserved cyclophilin-
VDIAGKPAGRVVIGLFGKAVPKTVENFRALCTGEKGVGK
type peptidyl-prolyl cis-trans
SGKPLH YKGSFFHRIIPSFMIQGG DFTLGDGRGGESIYG
isomerase signature is underlined
TKFADENFKLKHTGPVFITTVTTDWLDGRHVVFGRIISG
and the cyclophilin-type peptidyl-MDVVYKVEAEGRQSGQPKRKVKIADSGELS MD
prolyl cis-trans isomerase
signature is in bold.
165The amino acid sequence of SEQ IDMEMDEIQEQSQPQSSERQDISQESDTGNDKTINAEKITS
434. The conserved FKBP-typeENAEVEEDDMLPPKVNTEVEVLHDKVTKQIIKE GSGNKP
peptidyl-prolyl cis-trans
SRNSTCFLHYRAWAESTMHKFQDTWQEQQPLELVLGREK
isomerase signature is underlined
KELSGFAIGVAGMKAGERALLHVDWQLGYGEEGNFSFPN
and the TPR repeat is in bold.VPPRANLIYEAELI GFEEAKEGKARSDMTVEERIEAADR
RRQQGNELFKEDKLAEAMQQYEMALAYNGDDFMFQLFGK
YKDMANAVKNPCHLNMAQCLLKLNRYEEAIGQCNMVLAE
DEKNIKALFRRGKARATLGQTDDAREDFQKVEKFSPEDR
AVIRELRLLAEHDKQVYQKQKEMFKGLFGQKPEQKPKKL
HWFVVFWQWLLSNIRTIFRMRSKTD
166The amino acid sequence of SEQ IDMAGAGEG TPEVTLETSMGPITVELYHKHAPKTCRNFLEL
435. The conserved cyclophilin-
SRRGY YNNVKFHRVIKDFMVQGG DPTGTGRGGESIYGPR
type peptidyl-prolyl cis-trans
FEDEITRDLKHTGAGILSMANAGPNTNGSQREISLAPTP
isomerase signature is underlined
WLDEKHTIFGRVCKGMDVVKRLGNVQTDKNDRPIHDVKI
and the cyclophilin-type peptidyl-
LRTTVKD
prolyl cis-trans isomerase
signature is in bold.
167The amino acid sequence of SEQ IDMMDPELMRLAQEQNSKISPDELMKMQRQIMANPDLMRMA
436. The conserved TPR repeatSENMKNLKPEDIRFAAEQMKNVRKEEMAEISERISRASP
domain is underlined.EEIEAMKARANLQSAYQLQVAQNLKDQGNQLHARMKYSE
AAEKYLQARNNLTGIPFSEAKSLLLASSSNLMSCYLKTG
QYEECVQTGSEVLAYDAMN VKALYRRGQAYKQIGKLELA
VADLRKAVEVSPED ETIAQALREASTELMEKGGTQDQNG
PRIEEIIEEEAVQPTAEKYPQSAPMVTSVTEDVSDDEQG
SEDQNGFSRDSFQATNAPDGQMYAESLRNLTENPDMLRT
MQSLMKNVDPDSLVALSGGKLSPDNVKTVSGNFGRMSPE
EIQNMMKNSSTLSRQNPSTSSRFDDITRGHSNNDSSPQS
VSVDNDLFEENQNRVGESSTNLSSSAAFSGMPNFSAENQ
EQVRNQMNDPATRQMFTSMIQNMSPEMMASMSEQFGVKL
SPEDAVKAQNAMASLSPNDLDRLMNWATRLQTAIDYARK
IKNWILGRPGLIFAISNLLLAIILHRFGYIGD
168The amino acid sequence of SEQ IDMGVEKEILRP GNGPKPRPGQSVTVHCTGYGKNEDLSQKF
437. The conserved FKBP-type
WSTKDPGQKPFTFTIGQGR VIKGWDEGVLDMQLGEIPKL
peptidylprolyl isomerase domain isRCSPDYGYGSNGFPAWGIRPNSVLVFEIEVLSVN
underlined and the Cyclophilin-
type peptidyl-prolyl cis-trans
isomerase signature is in bold.
169The amino acid sequence of SEQ IDMPNP RCYLDITIGEELEGRILVELYSDVVPRTAENFRAL
438. The conserved cyclophilin-
CTGEKGIGPHTGVPLH YKGLPFHRVIKGFKIQGG DISAQ
type peptidyl-prolyl cis-trans
NGTGGESIYGLKFDDENFQLKHERRGMLSMANSGPNTNG
isomerase family domain is
SQFFITTTRTSHLDGKHVVFGRVIRGMGVVRGIEHTPTE
underlined and the cyclophilin-SNDRPSLDVVISDCGEIP EGSDDGIANFFKDGDLYPDWP
type peptidyl-prolyl cis-transADLDEKSAEISWWMNAVDSARCFGNENYKKGDYKMALRK
isomerase signature is in bold.YRKALRYLDICWEKEEIDEEKSNHLRKTRSQIFTNSSAC
KLRLGDLKGALLDTEFAMRDGEDNVKALFRQGQAYMALK
DVDSAVASFRKALQLEPNDAGIRKELAVATKMINDRRDQ
ERRAYARMFQ
170The amino acid sequence of SEQ IDMGDVIDLNGDGGVLKTIIRSAKP GAMQPTEDLPNVDVHY
439. The conserved FKBP-type
EGTLADTGEVFDTTREDNTLFSFELGKGT VIKAWDIAVK
peptidylprolyl isomerase domain is
TMKVGEVAAITCKPEYAY GSAGSPPDIPENATLIFEVEL
underlined and the Cyclophilin-V ACRPRKGSTFGSVSDEKARLEELKRQREIAAASREEEK
type peptidyl-prolyl cis-transKRREEARATAAARVQARLEAKKGQGRGKGKSKGK
isomerase signature is in bold.
171The amino acid sequence of SEQ IDMGLGLRIASASFLPIFNIMATRSLCILLVCFIPVLAHVL
440. The conserved cyclophilin-SLQDPELGTV RVYFQTTYGDIEFGFFPHVAPKTVEHIYK
type peptidyl-prolyl cis-trans
LVRLGCYNSNNFFRVDKGFVAQVADVVGGREVPLNSEQR
isomerase signature is underlined.
KEGEKTIVGEFSEVKHVRGILSMGRYSDPDSASSSFSIL
LGNAPHLDGQYAVFGKVTKGDDTLKRLEEVPTRQEGIFV
MPLERIRILSTYYYD TNERESNLTCDHEVSILRRRLVES
AYEIEYQRRKCLP
172The amino acid sequence of SEQ IDMASKRSLRTMNVWPTLPPLVLLLLLCFSSMSSSVVAKRS
441. The conserved FKBP-typeDVSELQIGVRHKP KSCDIQAHKGDRIK VHYRGSLTDGTV
peptidylprolyl isomerase domain is
FDSS FERGDPIEFELGSGQ VIKGWDQGLLGMCVGEKRKL
underlined and the Cyclophilan-RIPSKLGYGAQGSPPRIPGGATLIFDTELV AVNGRGISN
type peptidyl-prolyl cis-transDGDSDL
isomerase signatures are in bold.
173The amino acid sequence of SEQ IDMSGAPAERP ISYFDITIGGKPIGRIVFSLYADLVPRTAE
442. The conserved FKBP-type
NFRALCTGEKGIGKSGKPLC YAGSGFHRVIKGFMCQGG D
peptidylprolyl isomerase domain is
FTAGNGTGGESIYGERFEDEAFPVEHTKPFLLSMANAGK
underlined andthe Cyclophilin-
DTNGSQFFITVSQTPHLDDKHVVFGEVIKGKSIVRAIEN
type peptidyl-prolyl cis-transYPTASGDVPTSPIIISACGVLS PDDPSLAASEETIGDSY
isomerase signatures are in bold.EDYPEDDDSDVQNPEVALDIARRIRELGNKLFKEGQIEL
ALRKYLKSIRYLDVHPVLPDDSPPELKDSYDALLAPLLL
NSALAALRTQPADAQTAVKNATRALERLELSDADRARAL
YRBASAHVILKQEDEAEEDLVAASQLSPEDMAISSRLKE
VKDEKKKRREKERKAFKKNFSS
174The amino acid sequence of SEQ IDMASSLRSSLFSSWALDSKSVCSLFNLNPGRMGLPSISTP
443. The conserved FRBP-typeLNWRTCCCSHSSELLELNEGLQSSRRKTVMGLSTVIALS
peptidylprolyl isomerase domain isLVYCDEVGAVSTSRRALRSQKVPEDEYTTLPNGLRYYDL
underlined.KV GSGTEAVRGSRVAVHYVARWKGITFMTSRQGMGITGG
TPYGFDVGASERGAVLKGLDLGVQGMRVGGQRILIVPPE
LAYGNTGIQEIPPNATLEFDVELI SIKQSPFGSSVKIVE
G
175The amino acid sequence of SEQ IDMGAIEDEEPPLKRLRVSSPGLRRGLEEEAPSLSVGSVSI
444. The conserved G-protein betaLMAKSLSLEEGETVGSRGLIRRVEFVRIITQALYSLGYQ
WD-40 repeat domains areRAGALLEEESGILLQSSNVALFRKQILDGRWDESVVTLR
underlined.GIDQVEVEGNTLKAASFLILQQKFFELLDKGNIPEANET
LRLEISPMQLNTKRVHELASCIVFPSRCEELGYSKQGNP
KSSQRNKVLQEIQQLLPPSIMIPERRLERLVEQALNVQR
EACIFHNSLDPALSLYTDHQCGRDQIP TTTLQVLESHKN
EVWFLQFSNNGKYLASASRDCSAIIWE ITEGDS FSMRHR
LSAHQRPVSFVAWSPDDKLLLTCGIEEVVKLWN VET GEC
KLTYDKANSGFTSCGWFPDGERFISGGVDKCIYIWD LEG
KELDSWRGQGMPKISDLAVTSDGREIISICGDNAIVMYN
LDTKTERLIEEESGITSLCVSKDSRFLLLNLANQEIHLW
DIGARSKLLLKYRGHRQGRYVIRSCFGGSDLAFVVSGSE
DSQVYIWHRGN GELLAVLPGHSGTVNCVSWNPVNPHVFA
SASDDYTIRIWG VNRNTFRSKNASSSNGVVHLANGGP
176The amino acid sequence of SEQ IDMPGTTAGAGIEPIEPQSLKKLSLKSLKRSFDLFASLHGE
445. The conserved G-protein betaPQPPDQRSQRIRIACKVPAEYEVVKNLPTLPQREVGSSV
WD-40 repeat domains areSNSNVGETHSSLTTNQAQGFPTDTSGDLSKDEGKEITSI
underlined and the Trp-Asp (WD)AVHLQPQTGLIDGKAGAIAGTSTAISSVGSSDRYQPSAA
repeats signature is in bold.IMKRLPSKWPRPIWHPPWK NYRVISGHLGWVRSVAFDPG
NEWFCTGSADRTIKIWE VATGKL KLTLTGHIEQIRGLAV
SSRHPYLFSAGDDKQVKCWD LEYNK AIRSYHGHLSGVYC
LALRPTLDILCTGGRDSVCRVWD IRTKA QIFALSGHENT
VCSVFTQAIDPQVVTGSHDTTIKLWD LAAGK TMSTLTYH
KKSVRAIAKHPFEHTFASASADNIKKFK LPKGEF LHNML
SQQKTIVNAMAINEDNVLVSAGDNGSLWFWD WKSGHNFQ
QAQTIV QPGSLDSEAGIYALQYDITGSRLVSCEADKTIK
MWK EDETATPESHPINFKAPKDIRRF
177The amino acid sequence of SEQ IDM RPILMKGHERPLTFLKYNRDGDLLFSCAKDHTPTVWY G
446. The conserved G-protein betaHNGE RLGTYRGHNGAVWCCDVSRDSTRLITSSADQTAKL
WD-40 repeat domains areWN VETGAQLFSFNFESPARAVDLAIGDKLVVITTDPFME
underlined.LPSAIHIKRIEKDLSKQTAD SVLTITGIKGRINRAVWGP
LNSTIISGGEDSVVRIWD SETGKLLR ESDKETGHQKPIT
SLCKSADGSHFLTGSLDKSARLWD IRTLTLIKTYVTERP
VNAVAISPLLDHVVIGGGQEASHVTTTDRRAGKFEAKFF
HKILEE EIGGVKGHFGPINSLAFNPDGRSFASGGEDGYV
RLHH FDPDYFHIKM
178The amino acid sequence of SEQ IDM RPILMKGHERPLTFLKYNRDGDLLFSCAKDHTPTVWY G
447. The conserved G-protein betaHNGE RLGTYRGHNGAVWCCDVSRDSTRLITSSADQTAKL
WD-40 repeat domains areWN VETGNQLFSFNFESPARAVDLAIGDKLVVITTDPFME
underlined.LPSAIHIKRIEKDLSKQTAD SVLTITGIKGRINRAVWGP
LNSTIISGGEDSVVRIWD SETGKLLR ESDKETGHQKAIT
SLCKSADGSHFLTGSLDKSARLWD IRTLTLIKTYVTERP
VNAVAISPLLDHVVIGGGQEASHVTTTDRRAGKFEAKFF
HKILEE EIGGVKGHFGPINSLAFNPDGRSFASGGEDGYV
RLHH FDPDYFHIKM
179The amino acid sequence of SEQ IDMAENNVGDFIPLDRQEYPSKPAPGAVDSSFWKSF KKKEV
448. The conserved G-protein betaSRQIAGVTCINFCPEPPHDFAVTSSTRVHIYD GKSCE LK
WD-40 repeat domains areKTITKFKDVAYSGVFRSDGQIIAAGGETGVIQVFN AKSQ
underlined.M VLRQLKGHGRPVRVVRYSPQDKLHLLSGGDDSMVKWWD
ITTQE ELLNLEGHKDYVRCGAASPSSVNLWATGSYDHTV
RLWD LRNS KTVLQLKHGKPLEDVLFFPSGGLLATAGGNV
VKVWD ILGGGR PIHTMETHQKTVMAMCISKVPRSGQALG
DAPSRLVTASLDGYNKVFD LDHFKVTHSARYPAPILSMG
ISSLCRTMAVGTSSGLLFIRQRKGQIEDKIHSDSSGLQV
NPVNDEKDSAVLKPNQYRYYLRGRSEKPSEGDYVVKRMA
KVYFQEYDKDLRHFNHSKALVSALKAADSKGTVAVIEEL
VARKRLIQTLSILNLDELELLINFLSRFILVPKYSRFLI
SLTDRVLDARAVDLGKSENLKKQIADLKGIVVQELRVQQ
SMQELQGIIEPLIRASAR
180The amino acid sequence of SEQ IDMDVETSGKPTGNKRTYTRLPRQVCVFWQEGRCTRESCMF
449. The conserved C-x8-C-x5-C-x3-LHVDEPGSVKRGGATNGFAPKRSYNGSDERDTLAAGPPG
H type zinc finger is underlinedGSRRNISARWGRGRGGIFISDERQKI RNKVCNYWLAGNC
and in italics and the conservedQRGEECKYLHSF VMGS DVKFLTQLSGHVKAIRGIAFPSD
Cys and His residues in bold, TheSGKLYSGGQDKKVIVWD CQTGQGTDIPLNDEVGCLMSEG
conserved G-protein beta WD-40PWIFVGLPNAVKAWN ILTSTELSLVGPRGQVHALAVGNG
repeat domains are underlined andMLFAGTHDGSILAW KFSPAS NTFEPAASLVGHTQAVVSL
the Trp-Asp (WD) repeats signature
VSGADRLY SGSMDKTIRVWDLGTFQCLQTLRDHTSVVMS
is in bold (non-italics).LLCWDQFLLSCSLDNTVKVW VAT SSGALEVTYTHNEEHG
VLALCGMNDEQAKPVLLCSCNDNTVRLY DL PSFSERGRI
FSRNEVRTFQIAPGGLFFTGDATGELKVW NWATQKS
181The amino acid sequence of SEQ IDMSVQELRERHAAATAKVNALRERIKAKRLQLLDTDVATY
450. The conserved G-protein betaASSNGRTPISFSFTDLV CCRTLQGHTGKVYSLDWTSEKN
WD-40 repeat domains areRIVSASQDGRLIVWN ALTSQ KTHAIKLPCAWVMTCAFSP
underlined.SGQAVACGGLDSVCSIFQ LNNQLDRDGHLP VSRILSGHR
SYVSSCQYVPDGDTHVITGSGDRTCIQWD VTTGQRIAIF
GGEFPLGHTADVMSVSISAANPKEFVSGSCDTTTRLWD T
RIAS RAIRTFHGHEADVNTVKFFPDGLRFGSGSDDGTCR
LFD IRTGHQLQVY RQPPRENQSPTVTAIAFSFSGRLLFA
GYSNGDCFVWD TILEKVVLN LGELQNTHNGRISCLGLSA
DGSALCTGSWDKNLKIWA FGGHRKIV
182The amino acid sequence of SEQ IDMKVKIISRSTDEFTRERSNDLQRVFRNFDPNLHTQARAQ
451. The conserved G-protein betaEYVRALNAAKLDKIF AKPFLAAMSGHIDGISAMAKSPRH
WD-40 repeat domains areLKSIFSGSVDGDIRLWD IA ARRTVQQFPGHRGAVRGLTV
underlined.STEGGRLISCGDDCTVRLWD IPVAGIGESSYGSEN VQKP
LATYVGKNSFRAVDYQWDSNVFATGGAQVDIWD HD RSEP
TNSFAWGSDTVISVRFNPAEKDIFATTASDRSIVLYDLR
MAS PLNKLIMQTRNNAIAWNPREPMNFTAANEDCNCYSY
DMRR MNISTCVHQDHVSAVMDIDYSPSGREFVTGSYDRT
VRIFP Y NAGHSREIYHTKRMQRVFCVKFSGDATYVVSGS
DDANIRLWK AKASEQLGVLLPRERKRHEYLDAVKERFKH
LPEIKRIERHRHLPKPIYKAALLRHTVNAAAKRKEERKR
AHSAPGSVVTNPLRKKRIVAQLE
183The amino acid sequence of SEQ IDMDHYYQDDFDYLVDDEMVDFADDVEDDVRTRRRSDIDSD
452. The conserved G-protein betaSENDFDLNNKSPDTTALQAKRGKDIQGIPWNRLNFTREK
WD-40 repeat domains areYRETRLQQYKNYENLPRPRRSRNLDKECTNFERGSSFYD
underlined.FRHNTRSVKATIVHFQLRNLVWATSKHNVYLMQNYSIMH
WSSLKQKGEEVLNVAGPIVPSVKHPGSSPQGLTRVQVSA
MSVKDNLVVAGGFQGELICKYLDKPGVSFCTKISHDENG
ITNAVEIYNDASGATRLMTANNDLAVRVFDTEKFTVLER
FSFPWSVNHTSVSPDGKLVAVLGDNADCLLADCKT GKTV
GTLRGHLDYSFAAAWHPDGYILATGNQDTTCRLWD VRKL
SSSLAVLKGRNGAIRSIRFSSDGRFMAMAEPADFVHLYD
TRQNYTESQEIDLFGEIAGISFSPDTEAFFVGVADRTYG
SLLEFNRRRMNYYLDSIL
184The amino acid sequence of SEQ IDMAE ALVLRGTMEGHTDAVTAIATPIDNSDM IVSSSRDKS
453. The conserved G-protein betaILLWN L TKEPEK YGVPRRRLTGHSHFVQDVVISSDGQFA
WD-40 repeat domains areLSGSWDSELRLWD LN TGLTTRRFVGHTKDVLSVAFSIDN
underlined and the Trp-Asp (WD)
RQ IVSASRDRTIIRWNTLGECKYTIQPDAEGHSNWISCV
repeats signatures are in bold.RFSPSATNPT IVSCSWDRTVKVWN L T NCKLRNTLVGHGG
YVNTAAVSPDGSLCASGGKDGVTMLWD LA EGKRLYSLDA
GDIIYALCFSPNRYWLCAATQQCVKIWD LESKSIVADLR
PDF IPNKKAQIPYCTSLSWSADGSTLFSGYTDGKIRVWG
IGHV
185The amino acid sequence of SEQ IDMAAIKSTSRSASVAFAPDAPLLAAGTMAGAIDLSFSSLA
454. The conserved G-protein betaNLEIFKLDFQSDDP ELPVVGECPSNERLNRLSWGSAGGS
WD-40 repeat domains areFGIIAGGLVDGTINIWN PATLINSEDN GDALIARLEQHT
underlined.GPVRGLEFNTISTNLLASGAEDGELCIWD LANPTAPTH F
PPLKGVGSGAQGEISFLAWNRKVQHILASTSYSGTTVVW
D LR RQKPIISFPDATRRRCSVLQWNPDASTQLIVASDDD
NSPTLRAWD LRN TISPYKEFVGHSRGVIAMSWCPSDSLF
LLTCAKDNRTLCWD TG SGEIVCELPAGANWNFDVQWSPK
IPGILSTSSFDGKIGIHN IEACSRNVSGEVEFGGAIVRG
GPSALLKAPKWLERPAGVSFGFGGKLASFRPSTVAQAAD
HRHSEVFIHNLVTEDNLVIRSTEFEAAIADGEKVSLRAL
CDRRAEESQSDEEKETWNFLRVNFEDEGTARTKLLEHLG
FKVQSEENGDLQETHSSKIDDIGSEIGKTLTLDDKTEED
VLPQLKGGQDAAIPQDNGEDFFDNLHSPKEEVSLSHVGN
DFVGEKDKDMVVNGAEIEHETEDLTEYSDWNEAIQHSLV
VGDYKGAVLQCLSANRMADALIIAHLGGNSLWEKTRDEY
LKKAKSSYLKVVSANVNNDLTGLVNSRPLKSWKETLANL
CTYSQREEWTVLCDMLASRLIAAGNVMAATLCYICAGNI
EKTVEIWSRSLKYDYDGRSFVDHLQDVNEKTVVLALATG
QKRVSPSLSKLVENYAELLASQGLLTTAMEYLKLLGTEE
SSNELSILRDRLYLSGTDNKVEASSFPFETRQDLTESQY
NMHQTGFGAPETQENYQENVHQVLPSGSYTDNYQPTANT
HYIAGYQPAPQQQPSFQNYFTPASYQPAPSPNVFYPSQV
SQAEQSNFAPPVNQPPMKTFVPSTPPILRNVDQYQTPSL
NPQLYQGVSSATVETHPYQTGAPASVSVGTTPGQPSVVP
NFMVPGPVTAPTVTPRGFMPVTTPTQHPLGSANPPVQPQ
SPQSSQVQSV
186The amino acid sequence of SEQ IDMAGAADSQLQTLSERDSTPNF KNLHTREYAAHRKKVHSV
455. The conserved G-protein betaAWNCTGTKLASGSVDQTARVWN IEPHGH SKTKDLELKGH
WD-40 repeat domains areADSVDQLCWDPKHSEL LATASGDRTVRLWD A R SGKCSQQ
underlined and the Trp-Asp (WD)VELSGENINITFKPDGTHIAVGNRDDELTIID VR KFKPL
repeats signature is in bold.HKRKFSYEVNEIAWNTTGELFFLTTGNGTVEVLS YP SLQ
VLHTLVAHTAGCYCIAIDPIGRYFAVGSADALVSLWD LS
EMLCVRTFTKLEWPVRTISFNHDGQYIASASEDLFIDIA
D VQ TGRTVHQISCPAAMNSVEWNPKYNLLAFAGDDRNKY
MQD EGVFRVFGFETP
187The amino acid sequence of SEQ IDMAATSPVGAG SGRELANPPTDGISNLRFSNHSDHLLVSS
456. The conserved G-protein betaWDRKVRLYD AS ANSLKGQFVHGGPVLDCCFHDDASGFSG
WD-40 repeat domains areSADNTVRRYD F STRKEDILGRHEAPVRCVEYSYAAGQVI
underlined.TGSWDKTLKCWD PRGASGQEKTLVGTYSOLERVYSMSLV
GHRLVVATAGRHINVYDLRNMSQPEQRRESSLKYQTRCV
RCYPNGTGFALSSVEGRVAMEFFDLSEAGQAKKY AFKCH
RKSEAGRDTVYPVNAIAFHPIYGTFATGGCDGYVNVWD G
NNKKRLYQYSKYPTSIAALSFSRDGRLLAVASSYTFEEG
EKPHEPDAVFVRSVNEAEVKPKPKVYAAPP
188The amino acid sequence of SEQ IDMASDDEEGFKNEEAPGVVDEAEVQEGLRACFPLSFGKQE
457. The conserved G-protein betaKKQAPLESIHSATKRPEDPRPRRQLGPPRPPPSILAEQE
WD-40 repeat domains areDSDRFVGPPRPPQFVRDDNDDGEAEIMIGPPRPPAQYSD
underlined and the Trp-Asp (WD)DHDNEETIGPPRPSYLEKGEETDQMVGPSKRGSDDETSG
repeats signature is in bold.DSDDGDDAVDFRV PLSNEIVLRGHTKVVSALAIDQTGSR
VLTGSYDYSVRMYD FQGMTS QLKSFRQLEPAEGHQVRSL
SWSPTSDRFLCVTGSAQAKIFD RDGLTLGEFVK GDMYLR
DLKNTKGHISGLTCGEWHPKEKQT ILTCSEDGSLRIWDV
ND FNTQKQVIKPKLAKPGRVPVTACAWGRDGRCIAGGVG
DGSIQVWN LKPGWG SRPDLYVAKGHDDDITGLQFSADGN
ILLTRSTDETLRVWD LREAITPLQVFRDLPNNYAQTNVA
FSPDERLIFTGTSVERDGNSGGLLCFYDRQTLELVLRIG
VSPVHSVVRCTWHPRHNQVFATVGDKKEGGAHILYDPAL
SERGALVCVARAPRKKSLDDFEAKPVIHNPHALPLFRDE
PSRKRQREKARMDPMKSQRPDLPVTGPGFGGRVGSTKGS
LLTQYLLKEGGLIKETWMEEDPREAILKYADVAAKDPKF
IAPAYAQTQPETVFAETDSEEEQK
189The amino acid sequence of SEQ IDMKERGQSHAGQPSVDERYTQWKSLVPVLYDWLAMHMLVW
458. The conserved G-protein betaPSLSCRWGPQMHQATYKNSQRLYLSEQTDGTVPNTLVIA
WD-40 repeat domains areTCEVVKPRVAAAEHISQFNEEARSPRVKKFKTIIHPGEV
underlined.NRIRELPQNSKIVATHTDGPDVLIWDVDTQPNRQATLGA
ADSRPDLVLTGHKDNAEFALAMSPSAPFVLSGGKDKCVL
LWSIQDHISAATEPSSAKASKTPSSAHGEKVPKIP SIGP
RGVYKGHKDTVEDVQFCPSNAQEFCSVGDDSALILWD AR
NGN EPVIKVEKAHNADLHCVDWNPNDENLILTGSADNSV
RMFD RRNLTSSGV GSPVEKFEGHSAPVLCVQWCPDEASV
FGSAAEDSYLNVWD YEKVGKNVGKKTPPGLFFQHAGHRD
KVVDFHWNSFDPWTIVSVSDDGESTGGGGTLQIWRNSDL
IYRPEDEVLAELERFRAHILSCQNR
190The amino acid sequence of SEQ IDMSS LSRELVFLILQFLDEEKFKESVHKLEQESGFFF NMK
459. The conserved G-protein beta
YFDEKAQAGEWDEVERYLSGFTKVDDNRYSMKIFFEIRK
WD-40 repeat domains areQKYLEALDRQDRAK AVDILVKDLKVFSTFNEELYKEITQ
underlined. The LissencephalyLLTLDNFRENEQLSKYGDTKSARTIMMSELKKLIEANPL
type-1-like homology motif is inFRERLIYPNLKASRLRTLINQSLNWQHQLCKNPRPNPDI
bold and the CTLH, C-terminal toRTLFTDHACGPPNGARTPTQPTASLGVLPKATTFTPIGP
LisH motif is in italics.HGPFPSSSTATSGLASWMSMPNMVTSPQAPVAVGPSVPV
PPNQATLLKRPRTPPGSSSVVDYQTADSEQLIKRLRPVS
QSIDEATYPGPTLRVPWSTDDLP KTLARALNEPYPVTSI
DFHPSQQTFLLVGTKNGEITLWE VGSREKLATRSFKIWD
NANCSNHLEAAFVKDSSVSINRVLWSPDGTLIGIAFTKH
LVHTYTFQGLD LRQHLEIDAHVGGVNDLAFSHPNKQLCV
VTCGDDKNIKVWD AVT GRKLYNFEGHDAPVYSVCPHHKE
NIQFIFSTAVDGKIKAWL YDHLGSRVDYDAPGHSCTTMM
YSADGTRLFSCGTSKEGESFLVEWNESEGAIKRTYSGLR
KKGSGVVQFDTTQNHFLAVGDEHLIKFWDMDSTNMLTSC
DAEGGLLNLPRLRFNKEGSLLAVTTVNGIKILANADGQK
LLRTMENRTFDLPSRAHIDAASATSSPATGRMERIERTS
SANTVSGINGVDPAQSSEKLRLSDDLSEKTKIWKLTEIT
DSIQCRCITLPENAAEPASKVSRLLYTNSGVGLLALGSN
AVHKLWEWNRSEQNPSGEATASVHPQRWQPTSGLL MTND
ITDINPEEAVPCIALSKNDSYVMSASGGKVSLFN MMT FK
VMTTFMPPPPASTFLAFHPQDNNIIAIGMEDSTIHIYN V
RV DEVKTKLRGHQKRITGLAFSSTQNILVSSGADAQLCV
WN TETWEKRKSKTIQMPVGKTVSGDTRVQFHSDQLHILV
VHETQLAIYDAYKLERQYQWVPQDALSAPILYATYSCNR
QLIYATFSDG
191The amino acid sequence of SEQ IDMAKDEEEFRGEMEERLVNEEYKIWKKNTPFLYDLVITHA
460. The conserved G-protein betaLEWPSLTVQWLPDREEPPGKDYSVQKNILGTHTSDNEPN
WD-40 repeat domains areYLNLAQVQLPLEDAENDARQYDDERGEIGGFGCANGKVQ
underlined.VIQQINHDGEVNRARYNPQNPFIIATKTVSAEVYVFDYS
KHPSKPPQDGGCH PDLRLRGHNTEGYGLSWSPFKHGHLL
SGSDDAQICLWD INVPAKNKVLE AQQIFKVHEGVVEDVA
WHLRHEYLFGSVGDDRHLLIWD LRTSATNK PLHSVVAEQ
GEVNCLAFNPFNEWVLATGSADRTVKLFD LRKISS ALHT
FSCHKEEVFQIGWSPKNETILASCSADRRLMVWD LSRID
EFQTPEDALDGPPE LLFIHGGHTSKISDFSWNPCEDWVI
ASVAEDNILQIWQ MAENIYHDEEDDMPPEEVV
192The amino acid sequence of SEQ IDMSPGV KQTGSQKFESGHQDVVHDVTMDYYGKRIATCSAD
461. The conserved G-protein betaRTIKLFG LNASD TPSLLASLTGHEGPVWQVAWAHPKFGS
WD-40 repeat domains areMLASCSYDGRVIIWR EGQQEN EWSQVQVFKEHEASVNSI
underlined.SWAPNELGLCLACGSSDGSITVFT CREDG SWDKTKIDQA
HQVGVTAVSWAPASAPGSLVGQPSDPIQKLVSGGCDNTA
KVWK FYNGSW KLDCFPPLQMHTDWVRDVAWAPNLGLPKS
TIASCSQDGKVVIWT QGKEG DKWEGRILNDFKIPVWRVN
WSLTGNILAVADGNNSVTLWK EAVDGDWNQVTTVQ
193The amino acid sequence of SEQ IDMSSGVK QTGSQRFESGHQDVVHDVTMDYYGKRIATCSAD
462. The conserved G-protein betaRTIRLFG MNTSDT PTLLASLTGHEGPVWQVAWAHPKFGS
WD-40 repeat domains areMLASCSYDRRVIIWR EGQQENE WSQVQVFKEHEASVNSI
underlined.SWAPHELGLCLACGSSDGSITVFT GREDGS WDKTKIDQA
HQVGVTAVSWAPASAPGSLVGQPSDPVQKLVSGGCDNTA
KVWK FYNGSWK LDCFPPLQMHTDWVRDVAWAPNLGLPKS
TIASCSQDGRVVIWT QGKEGD KWEGKILNDFKTPVWRIS
WSLTGNILAVADGNNNVTLWK EAVDGEWNQVTTVQ
194The amino acid sequence of SEQ IDMKKRSRPSNGHLSTAAKNKSRKTAPITKD2FFDSAHNRN
463. The conserved G-protein betaKSKGKGKSRGKGEEIFSSDEDDDAIGRDAPAEEEEEIAE
WD-40 repeat domains areEERETADEKRLRVAKAYLDEIRAITKANEEDNEEEAGED
underlined.EETEAERRGKRDSLVAEILQQEQLEESGRVQRQLASRVV
TPSKLVECRVVKRHKQSVTAVALTEDDLRGFSASKDGTI
IHWDVETGASEKYEWPSQAVSVSSSNEVSKT QKGKGSKK
QGSKHVLSMAVSSDGRYLATGGLDRYIHLWD TRT QKHIQ
AFRGHRGAVSCLAFRQGTQQLISGSFDRTIKLWS AEDRA
YMDTLYGHQSEILAVDCLRKERVLSVGRDHTLRLWKVP E
ETQLVFRGRAASLECCCFINNEDFLSGSDDGSIELWS ML
RKKPVFMAKNAHGHAIVENLSEDTSTREEPDEEVTTRQL
PNGNSIGNGMTNQMGITPSVESWVGAVTVCRGTDLAASG
AGNGVVRLWAIENSSKSLRALHDIPLTGFVNSLTFARSG
RFLIAGVGQEPRLGRWGRIQAARNGVTLCPIELS
195The amino acid sequence of SEQ IDMAATFGTINTATSPHN PNKSFEIVQPPNDSISSLSFSPK
464. The conserved G-protein betaANYLVATSWDNQVRCWE VLQTG ASMPKAANSHDQPVLCS
WD-40 repeat domains areTWKDDGTAVFSAGCDKQAKMWP LLT GGQPVTVAMHDAPI
underlined.KDIAWIPEMNLLATGSWDKTLKYWD TR QSNPVHTQQLPE
RCFALSVRHPLMVVGTADRNLIIFN LQN PQTEFKRISSP
LKYQTRCVAAFPDKQGFLVGSIEGRVGVHH VEEA QQSKN
FTFKCHRDSNDIYAVNSLNFHPVHQTFATAGSDGAFNFW
D KDSKQRLKAMARSNQPIPCSTFNSDGSLYAYAVSYDWS
KGAENHNPATAKHHILLHVPQESEIKGKPRVTTSGRK
196The amino acid sequence of SEQ IDMVVMDKGTHQTNEDESESEFIDEDDVIDEISIDEEDLPD
465. The conserved G-protein betaADVEGEDVQEDNKRSEPDENSSSLDDAIHTFEGHEDTLF
WD-40 repeat domains areAVACSPVDATWVASGGGDDKAFMWRIGH ATPFFELKGHT
underlined.DSVVALSFSNDGLLLASGGLDGVVRIWD AST GNLIHVLD
GPGGGIEWVRWHPKGHLVLAGSEDYSTWMWN ADL GKCLS
VYTGHCESVTCGDFTPDGKAICTGSADGSLRVWN PQTQE
S KLTVKGYPYHTEGLTCLSISSDSTLVVSGSTDGSVHVV
N IKN GKVVASLVGHSGSIECVRFSPSLTWVATGGMDKKL
MIWE LQ SSSLRCTCQHEEGVMRLSWSLSSQHIITSSLDG
IVRLWD SRS GVCERVFEGHNDSIQDMVVTVDQRFILTGS
DDTTARVFE IGAF
197The amino acid sequence of SEQ IDMPVFRTAFNGYAVKFSPFVETRLAVATAQNFGIIGNG RQ
466. The conserved G-protein beta
HVLELTPNGIVEVCAFDSSDGLYDCTWSEANENL VVSAS
WD-40 repeat domains areGDGSVKIWD I ALPPV ANPIRSLEEHAREVYSVDWNLVRK
underlined and the Trp-Asp (WD)DCFLSASWDDTIRLWT IDR PQSMRLFKEHTYCIYAAVWN
repeats signature is in bold.PRHADVFASASGDCTVRIWD VRE PNATIIIPAHEHEILS
CDWNKYNDCMLVTGSVDKLIKVWD IRTY RTPMTVLEGHT
YAIRRVKFSPHQESLIASCSYDMTTCMWD YRAP EDALLA
RYDHHTEFAVGIDISVLVEGLLASTGWDETVYVWQ HGMD
PRAC
198The amino acid sequence of SEQ IDMDSRNRRSRLNLPPGMSPSSLHLETTAGSPGLSRVNSSP
467. The conserved G-protein betaSTPSPSRTTTYSDRFIPSRTGSRLNGFALIDKQPQPLPS
WD-40 repeat domains arePTRSAAEGRDDASSSSASAYSTLLRNELFGEDVVGPATP
underlined.ATPEKSTGLYGGSRDSIKSPMSPSRNLFRFKNDHGGNSP
GSPYSASTVGSEGLFSSNVGTPPKPARKITRSPYKVLDA
PALQDDFYLNLVDWSSNNVLAVGLGTCVYLWSACTSKVT
RLCDLGVNDSVCSVGWTPQGTHLAVGTNIGEVQIWDTSR
CKKVRTMGGHCTRAGALAWSSYILSSGSRDRNILHRDIR
VQ DDFIRKLVGHKSEVCGLKWSYDDRELASGGNDNQLLV
WN QQSAQPLLRFNEHTAAVKAIAWSPHQHGILASGGGTA
DRCLRFWHTATDTRLNCVDTGSQVCNLVWCKNVNELVST
HGYSQNQIMVWRYPS MSKLATLTGHTLRVLYLAISPDGQ
TIVTGAGDETLRFWS IFPSPKSQSAVHDSGLWSLGRTHI
R
199The amino acid sequence of SEQ IDMEKK KVVVPIVCHGHSRPIVDLFYSPVTPDGLFLISASK
468. The conserved G-protein betaDSSTMLRN GE TGDWIGTFEGHKGAVWSCCLDWRALRAAS
WD-40 repeat domains areGSADFSAKIWD AL TGDELHCFVHKHIVRACAFSESTSLL
underlined.LTGGHEKILRIFD LNR PDAPPKEVDNSPGSIRTVAWLHS
DQTILSSNSDAGGVRLWD LR TEKIVRVLETKSPVTSAEV
SQDGRYITTADGNSVKFWD AN HFGMVKSYTHPCMVESAS
LEPTMGNNFVAGGEDMWVRLFD FH TGEEIACNKGHHGPV
HCVRFAPGGESYSSGSEDGTIRIWQ TLNMNSEENESYGV
HGLSGRVRVGVDDVVQKVEGFQITADGHLNDKPEKPNP
200The amino acid sequence of SEQ IDMERYSQGTQKKSEIYTYEAPWQIYGMNWSVRKDKRFRLG
469. The conserved G-protein betaIGSFLEEYNNRVEIIELDEESGEFKSDPRLAFDHPYPTT
WD-40 repeat domains areKIMFVPDKECQRPDLLATTGDYLRIWQVCEDRVEP KSLL
underlined.NNNKNSEFCAPLTSFDWNDADPKRIGTSSIDTTCTIWD I
E KEVVDTQLIAHDKEVYDIAWGEVGVFASVSADGSVRVF
D LRDKEHSTIIYESSQPETPLLRLGWNKQDPRFIATILM
DSCKVVILDIRF PTLPVAELQRHQASVNTIAWAPHSPCH
ICTAGDDSQALIWE LSSVSQPLVEGGGLDPILAYTAAAE
INQLQWSSMQPDWVAIAFSUEVQILRV
201The amino acid sequence of SEQ IDMQSENNLDESL HLREVQELQGHTDTVWAVAWNPVTGIDG
470. The conserved G-protein betaAPSMLASCSGDKTVRIWE NTHTLNSTSP SWACKAVLEET
WD-40 repeat domains areHTRTVRSCAWSPNGKLLATASFDATTAIWE NVGG EFECI
underlined.ASLEGHENEVKSVSWSASGMLLATCGRDKSVWIWD VQPG
NE FECVSVLQGHTQDVKMVQWHPNRDILVSASYDNSIKV
WA EDGDGD DWACMQTLGNSVSGHTSTVWAVSFNSSGDRM
VSCSDDLTLMVWD TSINPAERSGNAG PWKHLCTISGYHD
RTIFSVHWSRSGLIASGASDDCIRLFS
202The amino acid sequence of SEQ IDMK RAYKLQEFVAHASNVNCLKIGKKSSRVLVTGGEDHKV
471. The conserved G-protein betaNMWA IGK PNAILSLSGHSSAVESVTFDSAEALVVAGAAS
WD-40 repeat domains areGTIKLWD LE EAKIVRTLTGHRSNCISVDFHPFGEFFASG
underlined and the Trp-Asp (WD)SLDTNLKIWD IR RKGCIHTYKGHTRGVNSIRFSPDGRWV
repeats signature is in bold.VSGGEDNIVKLWD LT AGKLMHDFKCHEGQIQCMDFHPQE
FLL ATGSADRTVKFWD L E TFELIGSAGPETTGVRAMIFN
PDGRTLLTGLHESLKVFS WEPLRCYDAVQVGWSKLADLN
IHEGKLLGCSYNQSCVGVWVVDISRVGPYAAGNVSRTNG
HNEAKLASSGHPSVQQLDNNLKTNMARLSLSHSTESGIK
EPKTTTSLTTTEGLSSTPQRAGIAFSSKNLPASSGPPSY
VSTPKRNSTSRVQPTTNFQTLSRPDIVPVIVPRSNSLRP
ETTSDVKKEMNNFGRVVPSTVSTKSTDVIKSGSNRDESD
KIDSINQKRNTGNDKTDLNIARAEQHVSSRLDNTNTSSV
VCDGNQPAARWIGAAKFRRNSPVDPVVSPHDRSPTFPWS
ATDDGVTCQPDRQVTAPELSKRVVEPGRARALVASWETR
EKALTADTPVLVSGRPPTSPGVDMNSRIPRGSHGTSESD
LTVSDDNSAIEELMQQHNAFTSILQARLTKLQVIRRFWQ
RNDLKGAIDATGKNGDHSVSADVISVLIERSEIFTLDIC
TVILPLLTRLLQSETDRHLTVAMETLLVLVKTFGDVIRA
TISATPTIGVDLQAEQRLERCNLCYVELENIKQILVPLI
RRGGAVAKSAQELSLALQEV
203The amino acid sequence of SEQ IDMSTLEIEARDVIKIVLQFCKENSLHQTFQTLQNECQVSL
472. The conserved G-protein betaNTVDSLETFVADINSGRWDVILPQVAQLKLPRKKLEDLY
WD-40 repeat domains areEQIVLEMIELRELDTARAILRQTQANGFMKQEQPERYLR
underlined and the Trp-Asp (WD)LEHLLVRTYFDPREAYHESSKEKRRSQIAQALASEVTVV
repeats signature is in bold.PPSRLMALIGQSLKWQQHQGLLPPGTQFDLFRGTAAVKA
DEEEMY PTTLAHTIKFGKQSHPECARFSPDGQYLVSCSV
DGFIEVWD YISGKLKKDL QYQADDSFNMHDDAVLCVDFS
RDSEMLASGSQDGKIKVWR IR TGQCLRRLERAHSQGVTS
LSFSRDGSQLLSTSFDSTARIHG LK SGKALKEFRGHTSY
VNDAIFTSDGGR VITASSDCTVKVWD V K TTDCIQTFKPP
PPLKGGDVSVNSVHLFPKNSEHIVVCNKASSIYINT L QG
QVVKSFSSGKREGGDFVAACISPKGEWIYCVGEDRNIYC
FS QQ SGKLEHLMKAHDKDIIGVTPHPHRNLLVTYSEDST
MKIWK P
204The amino acid sequence of SEQ IDMDIELEDQPFDLDFHPSAPIVAVALITGRLQLFRYVDIS
473. The conserved G-protein betaS EPERLWTVTAHTESCRAARFINAGSSVLTASPDCSILA
WD-40 repeat domains areTN VE TGQPVARLDNAHGAAINCLTNLTESTIASGDENGI
underlined.IKVWD TR QNSCCNKFKAHEDYISDMEFVPDTMQLLGTSG
DGTLSVCN LR KNKVHARSEFSEDELLSVALMKNGKKVVC
GSQEGVLLLYS WGY FKDCSDRFVGHPHSVDALLKLDEDT
VLTGSSDGIIRVVS IL PNKMIGVIGEHSSYPIERLAFSH
DRNVLGSASHDQILKLWD IHYLHEDDEPETNKQEAVNDE
NVDMDLDVDTEKRPRGSKRKKRAEKGQTSSQKQSSQFFA
DI
205The amino acid sequence of SEQ IDMDRIQQIPHTCVARKINLPLGMSKESLALNLPANLAPTM
474. The conserved G-protein betaSPPSITYSDRFIPSRKASNFEEFALPDKTSPSPNSAGGQ
WD-40 repeat domains areSSSTNGEGRDDACAAYSALLRTELFPATPDKTEGCRRPV
underlined.IGSPSGNVFRFKSQQCKSQSPFSLCPVGEDGDLSETGAV
ARKTTRKIPRSPFKVLDAPALQDDFYLNLVDWSSHNILA
VGLSACVYLWSASSSKVTKLCDLGLDDNVCSVAWTQRGT
YLAVGTNNGGVQIWDAAHCKQVRTMEGHCTRVGTLAWNS
HILSSGGRDRNILQRDIRAQ DDFVSKFSGHKSEVCGLKW
SYDNRELASGGNDNQLFVWN QQSQQPVLKYNEHTAAVKA
IAWSPHQHGLLASGGGTADRCIRFWNTATNTSLNCVDTG
SQVCNLVWSKNVNELVSTHGYSQNQIIVWRYPT MSKLAT
LTGHTLRVLYLAISPDGQTIVTGAGDETLRFWN VFPSSK
TQQNTIRDMGVWSSGRTHIR
206The amino acid sequence of SEQ IDMAGGQGEGEEKVDKLSMELTEDVMK SMEIGAVFKDYNGK
475. The conserved G-protein betaINSLDFHRTNNYLVTASDDEAIRLFD TASATWQKTSYSK
WD-40 repeat domains areKYGVDLICFTNHQTSVLYSSKNGWDESLRHLSLN DNKYL
underlined.RYFKGHHDRVVSLCMSPKGECFMSGSLDRTVLLWD LRID
KCQGLIRVRGRPAVAYDEQGLVFAISNEGGLIKMFDARL
YDK GPFDTFVVEGDKSEASGIKFSNDGKLILLSTMDSNI
HVLD AY QGTTVHSFSVEAVPNGGEAVPNGGTLEASFSPD
GKFVISGSGNGNIHAWS VNSGKEVACWTTEGVIPAVVKW
APRRLMFASGSSVLSLWVPDLSKLASLTGSNSNSAY
207The amino acid sequence of SEQ IDMHRVGSTGNTSNSSRPRR EKRLTYVLNDANDSRHCSGIN
476. The conserved G-protein betaCLVISKLSLLGGNDYLFSGSRDGTLKRWE LADD SAVCSA
WD-40 repeat domains areTFESHVDWVNDAVLTGETLVSCSSDTTLKTWR PFS DGVC
underlined.TRTLRQHSDYVTCLAAASKNSNIVASGGLGREVFIWD IE
AAMAPVSRTSEAMDDDTSNGVLSSGNSVLSTTVRSTNAT
NSASLHTSQL QGYTPIAAKGHKESVYALAMNDVGTLLVS
GGTEKVVRVWD PR SGAKQMKLRGHTDNVRALILDSTGRF
CLSGSSDSIIRLWD LG QQRCVHSYAVHTDSVWALASTPN
FSHVYSGGRDLSLYLTD LTTRESLLLCMEKHPLLRLTLQ
DDSIWVATTDSSLHRWPAEGQNPPKMFQRGGSFLAGNLS
FTRARACLEGSAPVPVNTQPSFVIPGSPGIVQHEILNNR
RHVLTKDAEGTVKLWEITRGAVLDDYGKVSFEEKKEELF
EMVSIPAWFTMDTRLGSMSVHLDTPQCFTAEMYAVDLRV
PDAPEEQKINLAQETLRGLLAHWLSRRRQRLATQASANG
DFPAGQENALRNHISSRIDVHDDAETHIAGILPAFDFST
TSPPSIITEGSQGGPWRKKITDLDGTEDEKDFPWWCLEC
VLHGRLSPRESLKCSFYLHPYEGTTVQVLTQGKLSAPRI
LRIQKVINYVLEKMVLDRPLDSSNSETTFTPGLSGNQSH
AAVVGDGSLRSGARVWQQKAKPLVEILCNNQVLSPDMSL
ATVRTYIWKKPDDLYLYYRLVQNR
208The amino acid sequence of SEQ IDMM KGKTIQMQAAHQNHDGETSVACVLWDWHAKHLITAGA
477. The conserved G-protein betaDNTILIHS YPSSS SSKPITLRHHKNAVTALAINSNVRSL
WD-40 repeat domains areASGSVDHSVKLYS YP GGEFQSNVTRFTLPIRSLAFNKSG
underlined.ELLAAAGDDEGIKLIS TI DNSIARVLKGHRGPVTSISFD
PKNEFLASSDSDGTVIYWE LS TGKPVHTLKKIAPNTTSN
PTSLNQISWRPDGENLAVPGRKSEVSMYD RDTAEKLFSL
KGGHSDTICSLAWSPNGKYIATAGTDRQVMVWDADRRQD
IDKQRFDNPICSVAWKPSDNALAVIDVLGRFGVWESPIA
SHMKSPADGAERYDNMEDEEPLMARYEEELEDSVSGSLN
EIINDDDDDDEMGKIPRKILQKKPSVKVEKGKEESNAKA
FKSGQDSFKLKSAMQEAFQPGATQRQSGKRNFLAYNMLG
SVITFDNDGFSHIEVDFHDIGKGCRVPSMTDYFGFTMAS
LSESGSVFGSPQKGEKNPSTLMYRPFSSWANNSEWSMRF
PMGEEVKAVALGSGWVAAVTSLNFLRVFSEGGLQKFVLS
MDGPVVTAAGYENLLVVVSHASNPLLSGDQVLSFTVYDI
SQKTCPLSGRLPLSPGSHLTWLGFSEEGLLSSYDSEGNL
RVFTNDYNGCWVPIFSAARERKSETESIWMVGLNSTQVF
CVVCKLPDTYPQVAPKPVLSVLNLSLPLACSDLGADDLE
NEYLRGSLLLSQMQKKAEDAVACGRESNMEEDSIFKNEA
ALDRCLLRLIANCCKGDKLVRATELARLLSLEKSLQGAI
KLVSAMKLPMLAERFNTILEEKILQENNETISCRRLTSE
AQDMDTPISISVKQVSYGANLGDSPFLPNRQVEPKHSTP
VFSKPDTRIEVDTSEAIAKGCDAQNGNIKSGDAEVQPAS
HNDSIQKPSNPFAKASNTSANQAVQRNASLLSSIKQMKT
ATENEGKRKERARSGSLPQKPAKQSKIS
209The amino acid sequence of SEQ IDMKQKRKGHQVDDPKYSVQTPQEDDTPNESGPASEEVESS
478. The conserved G-protein betaDEEGGNSSNIEDDIIYSSSEEDPVVSSDYEEDEDAESDA
WD-40 repeat domains areEGVTAEQELEGDIDNALQNYNGTLTVLSNFHGENLKNAE
underlined.GEDTSGDDDDEEEMPKRAEESDSPEDENDERPKRAEESD
FSEDEDEERPKRAEESDSSEDEVPSRNTVGDVPLRWYKD
EQHIGYDIKGKKIKKQPKKDQLDSFLASTDDSSDWRKVY
DEYNDEEVELTKDEIKFISRLRKGTIPHADVNPYEPYVD
WFDWKDKGHPLSNAPEPKRRFIPSKWEAKKVVKLVRAIR
KGWITFQKAEEKPRFYLMWGDDLKPSEKMANGLSYIPAP
KPKLPGHEESYNPPPEYIPTQEEINSYQLMYEEDRPKFI
PKRFDSLRNVPAYDRFLSEIFERCLDLYLCPRTRKKRIN
IDPESLIPKLPKPKDLQPF PSICFLEYKGHTGAVSCISP
ESSGQWLASGSKDGTVRIWE VETARCLKVWDIGRPIQHI
AWNPVSQLSILAVAVDEEVLVLNTGLGSEDSQEKVAELL
HVKSKPVSADDLGDNTSLTKWIKHEKFDGIKLTHLKPVH
LISWHHKGDYFATVAPDGNTRAVLVHQLSKQQTQNPFKK
MQGRVVHVLFHPSRAIFFVATKTHVRVYDLVKQQLVKRL
VTGLHEVSSMAVHHKGDNLLVGSEEGKVCWFDNDL STQP
YKTLKNHSKDIHSVAFHDSYPLFASCSDDCKAYVFY GLV
YSDLLQNPLIVPLKVLQGHQSVNGMGVLDCQFHPKQPWL
FTAGADSVVKLYCN
210The amino acid sequence of SEQ IDMMSLKRGFEESLVPAKRQKTELSTVTYGDGPRRTSSL ES
479. The conserved G-protein betaPIMLLTGHHAAIYTMKFNPTGTVIASGSHEREIFLWN VH
WD-40 repeat domains areGD CKNFMVLKGHKNAVLDLHWTTDGCQIISASPDKTLRA
underlined.WD VET GKQIKKMAEHSSFVNSCCPSRRGPPLVVSGSDDG
TAKLWD LRH RGAIQTFPDKYQITAVGFSDAADKIYSGGI
DNEIKVWD LRR GEVTMRLQGHTDTITGNQLSSDGSYLLT
NSMDCSLRIWD MRPYAPQNRCVKILTGHQHNFEKNLLKC
SWSSDGSKVTAGSADRNVYIWDTTTRRILYKLPGHTGSV
NETGFHPTQPIIGSCSSDKQIYLGEIEPNVGYQAVI
211The amino acid sequence of SEQ IDMEFSDTYKHTGPCCFSPDARYLAIAVDYRLVIRDVVTLR
480. The conserved G-protein betaVVQLYSCMDKISNIEWALOSEYILCGLYKRANVQAWS LS
WD-40 repeat domains are
QPEWTCKIDEGPAGIAHARWSPDSRHIITTSDFQLRLTV
underlined.WS LVNTACIHIQWPKHASKGVSFTQDGKFAAIATRRDCK
DYVNLLSCHTWEVMGTFTVDTIDLADLEWSPNDSAIVVW
DSPLEYKVLIYSP DGRCLFKYQAYDSWLGVKTVAWSPCS
QFLAVGSYDQTLRTLN HLTWKPFAEFVHVSTVRGPASAV
VFKEVEEPWNLDVSGLHLNDDNAHDIQDGKPAEGHSRVR
YKVVEFPVNVSSQKHPVDKPNPKQGIGLLAWSRDSQYLF
TRNDNNPTALWIWDIC RLELAALLIQKEPIRAAAWDPVY
PRVALCTGSSHLYMWT PSGACCVNIPLPQFVVSDLKWNP
DGTSMLLKDRESFCCTFVPMLPEFNDDETNEE
212The amino acid sequence of SEQ IDMAKLIETHSCVPSTERGRGILIAGDAKTNSIIYCNGRSV
481. The conserved G-protein betaIMRNLD NPLEASVYGEHSYPATVARFSPNGEWVASGDTS
WD-40 repeat domains areGTVRIWG RGS DHTLKYEYKALAGRIDDLEWSADGQRIVV
underlined.
CGDSKGKSMVRAFMWDSGTNVGEFDGHSRRVLSCSFKPT
RPFRVATCGEDFLVNFYE GP PFRFKTSHRDHSNYVNCVR
FAPDGSKFITVGSDRKGVIFD GK MGEKIGELSKEGGHTG
SIYAASWSPDSKQVLTVSADKSAKIWE ISETGNGTVKKT
LTFGSQGGADDMLVGCLWLNDYLITVSLGGIVSLLSAVD
PDKPPKTISGHMKSINAIALSLQSGQSEVCSSSYDGVIV
RWI LGVGYAGRVERKDSTQIKCLATIEGELVTCGFDNKV
RRVPLLSEQHKESEPIDIGAQPKDLDVAVGCPELTFVST
DAGIIIIR ASKIVSTTNVGYAVTAAAISPDGTEAVVGGQ
DGKLRVYS IKGD TLLEESVLERHRGPINAIRFSPDGSMF
ASGDLNREAVVWD RITR EVKLKNNVYHTARINCIAWSPD
SSKVATGSLDTCILIYE VGK PASSRITIKGAHLGGVYGL
AFSDQSTVISAGEDACVRVWS LP
213The amino acid sequence of SEQ IDMPQPSVILATAGYDHTVRFWEAT SGRCYRTLQYPDSQVN
482. The conserved G-protein betaHLEITPDKQYLAAAGNPHIRLFE VNSN NPQPVISYDSHT
WD-40 repeat domains areNNVTAVGFQCDGKWMYSGSEDGTVRIWD LR APGFQREYE
underlined and the Trp-Asp (WD)SRAAVNTVVLHPNQTELISGDQNGNIRVWD LN ANSCSCE
repeats signature is in bold.LVPEDTAVRSLTVNWDGSLVVAANNHGTCYVWR LMRGTQ
TMT NFEPLHKLQAHNSYILKCLLSPEFCEHHRY LATTSS
DQTVKIWN V D GFTLERTLTGHQRWVWDCVFSVDGAFLVT
ASSDSTARLWD LSTGEAIRTYQGHHKATVCCALHDGTDG
ASC
214The amino acid sequence of SEQ IDMLTKFETKSNRVKGLSFHPKRPWILASLHSGVIQLWDYR
483. The conserved G-protein betaM GTLIDKFDEHDGPVRGVHFHKTQPLFVSGGDDYKIKVW
WD-40 repeat domains areN YKM RQCLFTFVGHLDYIRTVHFENEYPWIVSASDDQTI
underlined and the Trp-Asp (WD)RLWN WQS RVCISVLTGHNHYVMSASFHPKEDL VVSASLD
repeats signature is in bold. TheQTVRVWD I SGLRKKTVSPADDLSRLAQMNTDLFGGGD VV
coatomer WD associated region isVKYVLEGHDRGVNWAAFHTSLPLIVSGADDRQVKLWR MN
in bold/italics.DTK AWEVDTLRGHTNNVSCVIFHARQDIIVSNSEDKSIR
VWD MSKRTSVQTFRREHDRFWILAAHPEMNLLAAGHDSG
MIVFKLERERPAYVVYGGSLLYVK
IPVLPPGKKSSLLMPPAPILHGGDWPLLRVTRGIFE
GGLENSTSAAYEEEDEEAAADWGEDIDIENIEGENGEAT
VLDDQEVKGGEDDEGGWDMEDLELPPDVAAANVGTNQKT
LFVAPTLGMPVSQIWMQKSSLAGEHAAAGNFETALRLLT
RQLGIKNFSPLKPLFLELYMGSHTFLPSFASVPAFSLAL
QRGWSESASPNIRGPPALVYRLSVLEEKLTVAYRATTEG
RFSEALRLFL
215The amino acid sequence of SEQ IDMDLLQNYQDDSEDSNPELRNHPPLEDATATSAPAGVENE
484. The conservedG-protein betaTSSSPDSSPLRLALPAKSCAPDVDETLMALGVPGSEKKN
WD-40 repeat domains areNHNKPIDPTQHSVTFNPSYDQLWAPLYGPAHPYAKDGIA
underlined.QGMRNHKLGFVEDSAIEPFMFDEQYNTFHRYGYAADPSA
SLGSHIVGDLESLKKNDGASVYNLPKREHKRQKLEKKMI
QKDENEEEEKEVGEEVDNPSTEEWLKKNRKSPWAGKKEG
LQTELTEEQKKYAQEHAEKKGDRERGEKVEIVDKTTFHG
KEERDYQGRSWIDPPKDAKATNDHCYIP KRWVHTWSGHT
KGVSAIRFFPKYGHLLLSAGMDTKVRIWD VFNS GKCMRT
YMGHSKAVRDISFSNDGSRFLSAGYDRNIRLWD TET GKV
ISTFSTGKIPYVVKLHPDEDKQNVLLAGMSDKKIVQWD M
NS GEITQEYDQHLGAVNTITFVDNNRRFVTSSDDKSLRV
WE FGIP VVIKYISEPHMHSMPSISLHPNTNWLAAQSLDN
QILIYS TRERFQ LNKKKRFAGHIAAGYACQVNFSPDGRF
VMSGDGEGRCWFWD WKT CKVFRTLKCHDNVCIGCEWHPL
EQSKVATCGWDGMIKYWD
216The amino acid sequence of SEQ IDMARKGLGTDPAIGSLMSSKKRKEYKVTNRFQEGKRPLYA
485. The conserved G-protein betaIAFNFIDARYHNIFATAGGTRVTIYQCLEGGAISVLQAY
WD-40 repeat domains areVDDD KDESFYTLSWACDVNGSPLLVAGGHNGIIRVLD VA
underlined and the Trp-Asp (WD)
NEKVHKSFVGHGDSVNEIRTQALKPSL ILSASIWESVRL
repeats signature is in bold.WN V Q TGICILIFAGAGGHRNEVLSVDFHPSDVYRIASCG
MDNTVKIWS MKEFWTYVEKSFTWTDLPSKFPTKY VQFPV
FIAAVHSNYVDCTRWLGNFILSKSVDNEVVLWE PYSKEQ
STSDG VVDILQKYPVPECDIWFIKFSCDFHYNSMAVGNR
EGKVYVWE LQSS PPNLIARLSHAHCKNPIRQTAISHDGS
TILCCCDDGSMWRWD VVQ
217The amino acid sequence of SEQ IDMESGAGGSVGARVPSAKPEMLQQPPYSNGDDDNDMERGT
486. The conserved G-protein betaAPVPSSNPNTVSKWELDKDFLCPICMQTMKDAFLTACGH
WD-40 repeat domains areSFCYMCIMTHLNNKSNCPCCSLYLTNNOLFPNFLLNKLL
underlined and the Trp-Asp (WD)KKTSACQMASTASPVENLCLSLQOGAEVSVKELDFLLTL
repeats signature is in bold.LAEKKRKMEQEEAETNMEILLDFLQRLRQQKQAELNEVQ
ADLHYIKDDILALEKRRLELSRARERYSRKLHMLLDDPM
DTTLGHAAIDDGNNVRTAFVRGGQGDAISGRFQQKKAEI
KAQASSQGMQKRANFCHSDSQVLPTLSGLTIARKRRVLA
QFDDLQECYLQKRRRWATOLRKQCDGGLRKERDGNSISR
EGYHAGLEEFQSILTTFTRYS RLRVISELRHGDLFHSAN
IVSSIEFDRDDELFATAGVSRRIKVFD FATVVNEPAD VH
CPVVEMSTRSKLSCLSWNKCIKSQIASSDYEGIVTVWD V
N TRQSVNMYEEHEKRAWSVDFSRTEPTRLISGSDDGKVK
VWCTRQETSVLNIDMKANICCVKYNPGSSYYVAVGSADH
HIHYYD LRN PSVPLYEFNGHRKTVSYVKFISTNE LASAS
TDSTLRLWD V R DNCLVRTFKGHTNEKNFVGLTVNSEYIA
CGSETNGVFVYH KAISKPAAWHQFGSPDLDDSDDDTSHF
ISAVCWRSESPTMLAANSQGTIKVLVLAP
218The amino acid sequence of SEQ IDMANYVDSRKNFKCVPALQQFYTGGPFRLSSDGSFLVCAC
487. The conserved G-protein betaNDEVKVVDLAT GSVKNTLEGDSELIVALALTPDNKYLFS
WD-40 repeat domains areASRSTQIKFWD LSS ATCKRTWKAHNGPVADMACDASGGL
underlined.LATAGADRSILVWD VDG GYCTHSFRGHQGVVTTVIFHPD
PHCLLLFSGSDDATVRIWD LVA KKCISVLEKHFSTVTSL
AISENGWNLLSAGRDKVVNIWD LRDYHCRATIPTYEPLE
AVCVLPTGSRLVSVMNQSRALPENRKKSGAAPVYFLTVG
ERGIVRIWYSEGALCLYEQKSSDAIISSDKDELKGGFVS
AVLLPLTQGVHCVTADQRFLFYNLDESDEGKCDLKVSKR
LIGYNEEIVDLKFLGDEEKFLAVATNLEQVRMYDLSS MT
CVYELSGHTDIVLCLDTVVFSGHSLLASGSKDHTVRIWD
TES KSCICVAAGHMGAVGAVAFSKKAKNFFVSGSSDRTI
KVWS FASVLDFGGISKSIK LSSQAAVAAHDKDINSVAVA
PNDSLICTGSQDRTARIWR LPD LVPVLVLRGHKRGVWCV
EFSPVDQCVMTASGDKTIKIWA LSD GSCLKTFEGHTASV
LRASFLTRGTQFVSSGADGLLKLWT IKS NECIATFDQHE
DKIWAMAVGKKTEMLATGGSDSLVNLWH DCTTTDEEEAL
LKEEEAALKDQELLNALADTDYVKAIQLAFELRRPYKLL
NVFTELYSKGHAQDQIQKVIRELGNEELRLLLEYVREWN
TKPKFAHVAQFVLFQLFNVLPPKEIIEVQGISELLEGLI
PYAQRHYSRIDRLMRSTFLLDYTLSSMSVLSPTETDLSS
SNLLARTADPLHAQIDQFHPTHFPEPNLTPIQSLLDSGN
TDSVEVTARRAKKKRVSGNDSEKTTVAEVKIGDMENAFD
EPDVADQGSSRKHKPASSKKRKSIAVGNASIKRIASGNA
VTIALQV
219The amino acid sequence of SEQ IDMESSCSSMNSNRHSTEKRCLRPLQKQGASMNKHSSDRFI
488. The conserved G-protein betaPARGSIDLDVARFMVTQKQKDNNDIHALSPSPSPSKKAY
WD-40 repeat domains areQKEMADTLLKNAGAADNNCRILSFNGKSSTVSQGSQENV
underlined.LANLSISRRARRYI PQSADRTLDAPDLLDDYYLNLLDWS
STNVLSTALGNTVYLWD ASNS SISELLIADEEEGPVTSV
SWAPDGSQIAVGLNNSVVQLWD SQ SNKKLRALKGHHDRV
GALSWNGPILTTGGLDGIIINHD VRT RDHIVQTYKGHTQ
EVCGLKWSPSGQQLASGGNDNLLYIWD KSMASHNPS SQY
FHQLDEHCAAVKALAWCPFQTNLLASGGGTSDGSIKFWN
TQ TGACLNTVDTHSQVCSLLWNRHERELLSSHGLRQNQL
TLWK YP SMVKITELTGHTARVLHMAQSPDGYTVASAAAD
ETLKFWQ VFGAPDASKKTRTKDTKGAFNMFHMHIR
220The amino acid sequence of SEQ IDMLDEIVADEEEEFNIWKKNTPLLYDVVITHALEWPSLTV
489. The conserved G-protein betaQWLPDRHQSPTKDYSLQKMIVGTHTSGDEPNYLMIAEVQ
WD-40 repeat domains areMPLQYSEDGNVGGFESTEAKVHIIQQINHEGEVNRAQYM
underlined.PQNSFIIATKTVSSDVYVFDYTKHSSNAPQERVCN PELI
LKGHTNEGYSLSWSPLKEGQLLSGSNDAQICFWD INAAS
GRKVVE AKQIFKVHEGAVEDVSWHLKHEYLFGSVGDDCH
LLIWD TRTAAPNK PQHSVVAHESEVNSLAFNPFNEWLLA
TGSADKTVKLFD LRKLSC SLHTFSNHTEEVFQIEWSPMN
ETILASSGGDRRLMVWD LRRIGDEQTSEDAEDGPPE LIF
IHGGHTSKISDFSWNLHDDWLIASVAEDNILQIWQ MAEN
IYNDQADIL
221The amino acid sequence of SEQ IDMTKEDHGESRDEMGERMVNEEYKLWKKNTPFLYDLVITH
490. The conserved G-protein betaALEWPSLTVQWLPPSCKQQQDIIKDDDIDHPNTQMVILG
WD-40 repeat domains areTHTSDNEPNYLILAEVQLHDGTEDEDGQGDVKRPQDKMK
underlined.PGTSGGANGKVRILQQINHQKEVNRARYMPQKPTIIATK
TVNADVYVFDYSKHPSKPPQEGR CNPELRLQGHESEGYG
LSWSPLKEGHLLSASDDAQICLWD ITAATKAPKV VEANQ
IFRYHDGPVEDVAWHAIHDHLFGSVGDDHHLLLWD IRND
S EKPLHIVEAHQAEVNCLAFNPFNEWIVATGSADRTVAL
HD IRK LDKVLHTCAHHMEEVFQIGWSPQNGAILASCGSD
RRLMVWD LSRIGDEQNPEDAEEAP PELLFIHGGHTSKIS
DFSWNPAEEWVIASVAEDNILQVWQ MSEHIYNDDNDSPT
A
222The amino acid sequence of SEQ IDMAMAMGDENAADPVEEFNIWKKNTPFLYDLVITHALEWP
491. The conserved G-protein betaSLTVQWLPDRHQSSTADYSLQKMIVGTHTSEDEPNYLMI
WD-40 repeat domains areAEVQIPLQNSEDNIIGGFESTEA KVQIIQKINHEGEVNK
underlined.ARYMPQNSFVIATKTVSSDVYVFD YSKHPSKAPQER VCN
PELILKGHSNEGYGLSWSPLKEGYLLSGSNDAQICLWD I
NAAFGKK VLEANQIFKVHEGAVGDVSWHLKHEYLFGSVG
DDCHLLIWD MRTAA PNKPQQSVIAHQSEVNSLAFNPFNE
WLLATGSMDKTVKLFD LRK LSCSLHTFSNHTDQVFQIEW
SPMNETILASSGADRRLMVWD LARIGETPEDEEDG PPEL
LFVHGGHTSKISDFSWNLNDDRVIASVAEDNILQIWQ MA
ENIYHDDEDML
223The amimo acid sequence of SEQ IDMGLFEPFRALGYITDGVPFAVQRRGIETFVTLSVGKAWQ
492. The conserved G-protein betaIYNCAKLIPVLVGPQMDKKIRALACWRDFTFAATGHDIA
WD-40 repeat domains areVFRRAHQVATWSGHKAKVTLLLSFGQHVLSVDLEGCLFI
underlined and the Trp-Asp (WD)WAVAEVNQN KPPIGQIQLGEKFSPSCIMHPDTYLNKVLI
repeats signature is in bold.GSEEGTLQLWN VNT RKKLYEFKGWGSSIRCCVSSPALDV
VGIGCSDGKIHVHN LRYD EEIVTFMHSTRGAVTALSFRT
DGQPLLAAGGSSGVISIWN LEKK KLQSVIKDAHDSSVCS
LHFFANEPVLMSSATDNSIKMWI FDTTDGE ARLLKYRSG
HSAPPMCIRYYGKGRHILSAGQDRAFRIFS VIQDQQSRE
LSQGHVGKRAKKLKVKDEEIKLPPVIAFDAAEIRERDWC
NVVTCHLDDPCAYTWRLQNFVIGEHILKPCLEDPTPVKS
CSISACGNFAVLGTEGGWLERFNLQSGISRGTYI DIGEK
RQCAHNGAVVGLACDATNTLLISGGYNGDIKVWD FK GRE
LKFRWEIEVPLIKIVYHPGNGILATAADDMILRLFD VTA
MRLVRIFVGHMDRVTDLCFSGDGKW LLSSSMDGTIRVWD
I ISSRQLNAMHMDSAVTALSLSPGMDMLATTHVGHNGIY
LWANRMIYSKATDIEPFISGKQVVKVSMPTVSSKRESEE
GDEKRTIVAESNVNKSDVSGSLIGDSYSAQLTPELVTLA
LLPKAQWQSLVNLDIIKNRNKPIEPPKKPEKAPFFLPSL
PTLSGERIFIPSSMNGDGDQDETRNDKTVFEARGKKLGG
ESLSFMQLLQSCAKIKDFTTFTNYLKGLSPSAVDMELRL
LQIVDNENISETEHSVELQGIGMLLDYFVNEVSCNNNFE
FVQALIRLFLKIHGETIRCQVSLQEKARKLLEIQSSTWE
RLDTSFQNARCMITBLSSSQF
224The amino acid sequence of SEQ IDMIAAVCWVPKGVAKVLPDSAEPPTQEEIQELLKCNVVAE
493. The conserved G-protein betaSDDNEDSDEESEEMDTETDKNTDAVAKALAAANALGSQS
WD-40 repeat domains areSDFQRQHKVDDIANGLKELDMDHYDDEDEGIDIFGSGSL
underlined and the Trp-Asp (WD)GNCYYPANDMDPYLVEQDDDDEDEIEDMTIRPSDLIILS
repeats signature is in bold.ARNEDDVSHLEVWIYEEETEEGGSNMYVHHDIILPAFPL
SLAWLDCNLKGGEKGNFVAVGTMQPEIELWDLDVLDEVE
PAVVLGGAVKDEASGKTTKLKKKKKNK QAVNFKEGSHTD
AVLGLAWNMEYRNV LASASADKSVKIWD I VA EKCEHTMQ
PHTDKVQAVAWNPNQATVLLSGSFDRSVIMMD MRA PTHS
GIRWPVPADVESLAWDPHTDHSFNVSAEDGTVRGFD IRA
AASTADFD GKPMFILHAHDKAVCAISYNPAAPSLLTTGS
TDKMVKLWD ITNNQ PSCIASTNPNVGAVFSAAFSKNSPF
LLATGGSKGILHVWD TLDNSEVARRFGKFRPQN
225The amino acid sequence of SEQ IDMIMDENEFCDIFSLRKRLCLLSSQEGEEEEELEAMSQLD
494. The conserved eukaryoticAGEFTVTGNEEVVAIAEDDVNTGILSQDLFSSQDYCTPS
protein kinase domain isQPQDSTDLDSKDKAPCPLSPVKSTIQRKRCRPELLSNPP
underlined.DSIQFSFQRLERVRSEESIQSSSQQLARVRSEVSSSDDF
KTPKITASGQKNYVSQSALALRARVNSPPCIKNPYLDEN
EELNEKIQRSTRRSPACVTPIQSGACLSRYRADF HELEE
IGRGNFSRVYKALNRLDGCCYAVKCSQSELRLDTERKVA
LMEVQSLAALGPHKNIVGYHTAWFENDHLYIQMELCDHN
LTTANDRGILRTDTDFLEAVYQIAQALEFIHGRGVAHLD
VKPENIYVRDGTYKLGDFGRATLINGTLHVEEGDARYMS
REILNDNYEHLDKVDMFSLGATFFELLMRKQYPGSGKRI
DRDTEIEIPILPGFSIYFQELLQDLVSNDPGERPSAEDV
LENPIF NEVRGAEEV
226The amino acid sequence of SEQ IDMLAPALEMEPVEPQSLEELSFESLERALDLFSPVHGQIA
495. The conserved G-protein betaPPDPESEEMRISYELNFEYGGGSGSEDQVPEREESGAAQ
WD-40 repeat domains areNQGQQAAGASNALALPGPEGSEIPPMEESQNALTVGPSL
underlined and the Trp-Asp (WD)RPQGLNDVGLHGEGTAIISASGSSDRNLSTSAIMERLPS
repeats signature is in bold.RWPRPVWHPP WENYRVISGHLGWVRSIAFDPSNQWFCTG
SADRTIEIWD LAS GRLELTLTGHIEQIRGLAVSSKHTYM
FSAGDDKQVECWD LEQ NKVIRSYHGHLSGVYCLALHPTI
DILLTGGRDSVCRVWD IRS KMQIFALSGHDNTVCSVFAR
PTDPQ VVTGSHDTTIKFWD L RH GETMTTLTNHEESVRAM
AQHPEENCFASASADNIEEFQ LPR GEFLHNMLSQQETII
NTMAVNEEGVMATGGDNGSLWFWD WKSGHNFQQAHT IVQ
PGSLESEAGIYALSYDLTGSRLVSCEADETIEMWK EDEL
ATPETHPLNFEPPEDIRRF
227The amino acid sequence of SEQ IDMEEAAKEQSAGSGEPELLRYGLRSAAEPKEDEKEEQLHQ
496. The conserved G-protein betaPPPPPPPQQQAAPAPAPAATRSSTSGSAGGRDRRPQQQH
WD-40 repeat domains areAVDEEYARWESLVPVLYDWLANHNLLWPSLSCRWGPQLE
underlined.QATYENRQRLYISEQTDGSVPNTLVIANCEVVEPRVAAA
EHVSQFNEEARSPFIREYETIIHPGEVNRIRELPQNPNI
VATNTDSPDVLIWDVESQPNRHAVYGATASRPNLILTGH
QENAEFALAMCPAEPFVLSGGEDETVVLWSIQDHITASA
TDQTTNESPGSGGSIIEETGEGNEETGNGPS VGPRGIYC
GHEDTVEDVAFCPSTAQEFCSVGDDSCLILWD ARIGT NP
VAKVEKAHNGDLHCVDWNPHDNNLILTGSADNSVNMFD R
RNLTSNGV GSPVYEFEGHEAAVLCVQWSPDEPSVFGSSA
EDGLLNIWD YERVDEEVDRAPNAPAGLFFQHAGHRDEIV
DFHWNTADPWTMVSVSDDCDTAGGGGTLQIWRMSDLIYR
PEEEVLAELENFEAHVLECSEA
228The amino acid sequence of SEQ IDMAKDEEEFRGEMEERLVNEEYKIWEENTPFLYDLVITHA
497. The conserved G-protein betaLEWPSLTVQWLPDREEPPGEDYSVQEMILGTHTSDNEPN
WD-40 repeat domains areYLMLAQVQLPLEDAENDARQYDDERGEIGGFGCANGEVQ
underlined.VIQQINHDGEVNRARYMPQNPFIIATKTVSAEVYVFDYS
KHPSEPPQDGGCHPDLRLRGHNTEGYGLSWSPFEHGH LL
SGSDDAQICLWDI NVPAENEVLEAQQIFEVHEGVVEDVA
WHLRHEYLFGSVGDDRHLLIWDLRTSATNEPLHSVVAHQ
GEVNCLAFNPFNEWV LATGSADRTVELFDL REISSALHT
FSCHEEEVFQIGWSPENETI LASCSADRRLMVWDL SRID
EFQTPEDALDGPPELLFIHGGHTSEISDFSWNPCEDWVI
ASVAEDNILQIWQMAENIYHDEEDDMPPEEVV
229The amino acid sequence of SEQ IDMGKYNREGEGVGEVAVMEVSQGSLGVRTRARTLAAASSQ
498. The conserved cyclin-KDHRRLGASESVTTEHQSSAPPASPCVESSMHTCYLELR
dependent kinase inhibitor domainSRELEEFSRCYHSAHGATSHGESERSLSLSEPSRLAVSE
is underined.EARVASDESSHRVLQQQSSVAHSRNNSATFSHNAEPAEA
AQREERRDDDHTSARPSEAPHEDEDGMEVEASFGENVMD
LDSRERRTRETTPSSYTRDVETMETPGSTTRPPSNAGRR
RFQTEGGHGTR NQFNVPTTNEIEEFFAGAEQQEQRRFTD
RYNYDPVSDSPLPGRFEWVRLR P
230The amino acid sequence of SEQ IDMQNMEENVQSSWSLHGNEEICAR YEILERVSSGTYLDVY
499. The conserved
RGRREEDGLIVALEEVHDYQSSWREIEALQRLCGCPNVV
serine/threonine protein kinase
RLYEVILEFLTSDLYSVIESAENEGENGIPEAEVEAWMI
domain is underlined, and the
QILQGLANCHANW VIHRDLKPSNMLI SAYGILKLADFGS
serine/threonine protein kinase
MSFLERAIYEVEYELPQEDILADAPGERLMDEDDSVEGV
active-site signature is in bold.
WNEGEEDSSTAVETNFDDMAETANLDLSWENEGDMVMQG
FTSGVGTRWYRAPDFLYGATIYGEEIDLWSLGCILGELL
ILEPLFSGTSNIDQLSRLVEVLGLQQEENWPGCSNLPDY
RELCFPGDGSPVGLENHVPNCSDNMFSILERLVCYDPAA
RLNAEEIVENEYF VEDPYPVLTHELRVPSPLREENNFSE
DWAEWEDMEVDSDLENIDEFNVVHSSDGFCIKFS
231The amino acid sequence of SEQ IDMADVPESLQQEKDEQGTDKNCCDGKFQKEIDIDDMEEEY
502. The conserved histoneNESSIDDEEENLSDNVATNNMGTIPQGQACMAVTVEGIE
deacetylase family domain isHANSVGCGRNGREGSEEVTAAEDMGHVSIENIREQGRNR
underlined.KSSEQLLALYEQEGLLEDDEDDDDVDWEPFEGVTVQMKW
YCTNCTMANSDDSVHCDSCGEHRNSDILRQGFLASPYLP
AESPSSSDVPDERLEESKCVMTTLTPSISPMIGVCCSSL
QSE RRTVVGFDERMLLHSEIQMETYPHPERPDRLRAIAA
SLRAAGLFPGKCFSIPAREATCEELQTIHSLEHVNAVES
TSCGMLSHLSPDTYANEHSSLAARLAAGLCADLAKAIMT
GQAQNGFALVRPPGHHAGVKDSMGFCLHNNAAIAVSASR
VVGAKKVLIVDWDVHHGNGTQEIFEADQSVLYISLHRNG
EGFYPGSGAVTEVGSSKGEGYSVNIPWKCGGVGDNDYIF
AFQHAVLPIAEQFEPDLTIISAGFDAAKGDPLGRCEVTP
DGFAHMAQMLSCLSKGKMLVILEGGYNLRSISASATAVI
KVLL GDNPKALPIDIQPSKGGLQTLLEVFEIQSKYWSSL
KGHDQKLRSQWEAQYGSKKRKVIRKRHMHIVGGPVWWKW
GRKRVVYYHWFARVSSRKHL
232The amino acid sequence of SEQ IDMASGAGAAGVVEWHQKPPNPKNP VVFFDVTIGTIPAGRI
503. The conserved cyclophilin-
KMELFADIVPRTAENFRQFCTGEYRKAGIPIG YKGCHFH
type peptidyl-prolyl cis-trans
RVIIQFMIQA GDFVKGDGSGCISIYGSKFEDENFIAKHT
isomerase family domain is
GPGLLSMANSGPNTNGCQFFLTCAKCDWLDNKHVVFGRV
underlined and the cyclophilin-
LGEGLLVLRKIENVQTGQHNRPRLPCVIAECGEM
type peptidyl-prolyl cis-trans
isomerase signature is in bold.
233The amino acid sequence of SEQ IDMDHYYQDDFDYLVDDEMVDFADDVEDDVRTRRRSDIDSD
505. The conserved G-protein betaSENDFDSNNKSPDTTALQAKRGKDIQGIPWNRLNFTREK
WD-40 repeat domain is underlined.YRETRLQQYKNYENLPRPRRSRNLDKECTNFERGSSFYD
FRHNTRSVKATIVHFQLRNLVWATSKHNVYLMQNYSIMH
WSSLKQKGEEVLNVAGPIIPSVKHPGSSPQGLTRVQVSA
MSVKDNLVVAGGFQGELICKYLDKPGVSFCTKISHDENG
ITNAVEIYNDASGATRLMTANNDLAVRVFDTEKFTVLER
FSFPWSVNHTSVSPDGKLVAVLGDNADCLLADCKT GKTV
GTLRGHLDYSFAAAWHPDGYILATGNQDTTCRLWD VRKL
SSSLAVLKGRNGAIRSIRFSSDGRFMAMAEPADFVHLYD
TRQNYTKSQEIDLFGEIAGISFSPDTEAFFVGVADRTYG
SLLEFNRRRMNYYLDSIL
234The amino acid sequence of SEQ IDMDCSGDEEEEQFFESLEEMLSPSDSGSEAADNETGCRNA
506. The conserved G-protein betaDARSKYEIWKRAPSSIQERRQRFLVRMGLANPSELGNQV
WD-40 repeat domains areNSTSAESTCSTETANIPNGIERLRENSGAVLRTAGSSGR
underlined.KTNCKNVINIGLREGSVRSSSSSNGTPDVGEDNGEFGGT
IFSRSGGTWECMCKIKNLDSGKEFVVDELGQDGLWNKLR
EVGTDRQLTMDEFERSLGLSPLVQELMRRESGVAQADCN
GVHHHDAEISSSKRRSWLKALKSAAYSMRRPKEDQSNYD
SERSGRRSGSFDVPWGKPQWTKVRHYPKRYKEFTALYMG
QEIEAHEGSIWTMKFSLDGRYLASAGQDCVIHVREVIES
MRTFGADTPDLYASSAYFSMNGLQELVPLSIEDHANKNK
RGKIIGSKKSSNSDCIVLPNKVFQLS EEPVCSFHGHLLD
VFDLSWSPSQYLLSSSMDKTVRLWK LGH ESCLKVFSHND
IVTCIQFNPVDERYFISGSLDGKARIWS IPDRQVVDWSD
LREMVTAVCYTPDGQGGLVGSIKGSCRFYNTSGNKLQLE
NQLNVRSKKKKSSGKKITGFQFAPGGDSQKVLITSADSR
VRVYNGSELVCKYKGFRNTCSQISASFAPNGQHFVCASE
DSRVYIWNHESPRGSGARHEKSSWSHEHFLSQGVSVAIP
WSGMKLQPPVWNSPEFMLGQRENLLSLQGGKDVGCQNGL
LSREAGEGQESETPLHYISQVSHSCGSQNMVDRDGQDDL
SRYSACISDSRLSSFMAFPESPGNPDDLNSKVFFSDSSS
KGSATWPEEKLPPTRKQSRSNSTSSHYDTLKTHLGNTIQ
GQSGASAAVAWGLVIVTAGHGGEIRSFQNYGLPVRL
235The amino acid sequence of SEQ IDMPSIPAIGEFTVCEINRELLTTKDESDTQAKDAYAKILG
507. The conserved G-protein betaLVFPPISFQIEEGFGSASRQQFDQDLDREDTIVTPSTSE
WD-40 repeat domain is underlined.GTNALQEGGLLLKGVSVLKNILASSFGPIFSPNDTKVLK
KVELLQGISWHRHKHILAFISGSNQVTVHDFQDPEWR ES
SLLVSESQRGIEALEWRPNGGTTLSVACRGGICIWS ASY
PGSVAPVRSGVASFLGTSTRGSSVRWTLVDFLQIPGGKA
VTALSWSPTGRLLASASREDSSFTIWDVAQGVGTPLRRG
LGGISLLKWSPTGDYLFSAKPNGTFYLWETNTWTLEQWS
SSGGCVISATWGPDGRMLFMAFSESTTLGSLHFAGRPPS
LDAHLLPMELPEIGSITGGFGNIEKMAWDGCGERLAVSY
TGGDLMYVGLIAIYDTRRTPFISASLVGFIRGPGEQVKP
LAFAFHDKFKQGPLLSVCWSSGLCCTYPLIFRAH
236The amino acid sequence of SEQ IDMEEENAKHTEETRQVQVRFTTKLQPALRVPTTSIAIPAN
508. The conserved G-protein betaLTRYGLSDIVNTLLGNDKPQPFDFLVESELVRTSLEKLL
WD-40 repeat domains areLIKGISAEKILNIEYILAVVPPKQEEPSLHDDWVSVVDG
underlined.SYPNFIFSGSFDSIGRIWKGEGLCTHVLEGHRDAITSAA
FIMPSDSSDSFIN LATASKDRTLRLWQ FKPNEHMTNGKN
VRPYKLLRGHTSSVQTVSACPRRNLICSGSWDCSIKIWQ
TAGEMDIESNAGSVKKRKLEDSTEQIISQIEASRTLEGH
SQCVSSVVWLEKDT IYSASWDHSVRSWDV ETGVNSLTVG
CRKALHCLSIGGEGSALIAAGGADSVLRIWDPRMPGTFT
PILQLSSHKSWITACKWHPKSRHH LISASHDGTLKLWDV
RSKVPLTTLEAHKDKVLCADWWKEDCVISGGADSTLQIF
SNLNLT
237The amino acid sequence of SEQ IDMNRLRSKRNHILELRLGQSEPEKEATLASNRSRGTNAPI
509. The conserved RING-type zincVVEDDDDVVVSSPRSFALARSSVSQRSSRIPIVNEEDLE
finger is underlined.LRLGLAVTGRTSAEHNPRRRHGRVPPNKPIVLCDDAGEA
DQSSSKKRRTGQQLSSDVQSDESKEVKLTCAICISTMEE
ETSTI CGHIFCKKCI TNAIHRWKRCPTCRKKLAINNIHR
IYISSSTG
238The amino acid sequence of SEQ IDMEEPPPPAVLPSSEDTSIVSSHSFVNAPPTVPVGLDASI
510. The conserved G-protein betaPQISTPGINQPGLTIPVPPEAAPLTASLVAASAGMPPAV
WD-40 repeat domains areVPSFVRPAIVAHPSVMPPPSMPLAALPMPVASAVPVAAP
underlined and the splicing factorHFPPSTPNDNSITPSNPVPTPIVASSSVPPSVTIPGIAP
motif is in bold.LPFIAPIPVPSSRPVAPSPFMPPARPLGASVSVAMDVDN
TDEQDQDADNKGESPSSSPDHPEDPSAAEYEITEESRKV
RERQEQAIQELLLRRRAYALAVP TNDSSVRAPLRPLNEP
ITLFGEREMERRDRLEALMAKLDAEGQLEKLMKVQEEE E
AAANVDAEEVQEMEGPQVYPFYTEGSQELLKARTEITKF
SLPRAVSRLQRARRKREDPDEDEDEELKCVLQQSAQINM
DCSEIGDDRPLSGCAFSSDGTLLATSAWSGVTKLWSVPN
INKVATLKGHTERVTDVAFSPTNCHLATACADRTAMLWN
SE GVLMKTYEGHLDRLARLAFHPSGLYLGTASFDKTWRL
WD VNT GIELLLQEGHSRSVYGIAFQCDGSLAATCGLDGL
ARIWD LRT GRSILALEGHVKPVLGIDFSPNGYHLATGSE
DHTCRIWD LRK RQSVYIIPAHSHLVSQVKFEPQEGYFLV
TASYDSTAKVWS ARD FRSIKVLAGHEAKVTSVDITADGQ
YIATVSHDRTIKLWS SKNSTNDMNIG
239The amino acid sequence of SEQ IDMKR AYKLQEFVAHASNVNCLKIGKKSSRVLVTGGEDHKV
511. The conserved G-protein betaNMWA IGK PNAILSLSGHSSAVESVTFDSAEALVVAGAAS
WD-40 repeat domains areGTIKLWD LEE AKIVRTLTGHRSNCISVDFHPFGEFFASG
underlined and the Trp-Asp (WD)SLDTNLKIWD IRR KGCIHTYKGHTRGVNSIRFSPDGRWV
repeats signature is in bold.VSGGEDNIVKLWD LTA GKLMHDFKCHEGQIQCMDFHPQE
FL LATGSADRTVKFWD L ET FELIGSAGPETTGVRANIFN
PDGRTLLTGLHESLKVFS WEPLRCYDAVDVGWSKLADLN
IHEGKLLGCSYNQSCVGVWVVDISRVGPYAAGNVSRTNG
HNEAKLASSGHPSVQQLDNNLKTNMARLSLSHSTESGIK
EPKTTTSLTTTEGLSSTPQRAGIAFSSKNLPASSGPPSY
VSTPKKNSTSRVQPTTNFQTLSRPDIVPVIVPRSNSLRP
ETTSDAKKEMNNFGRVVPSTVSTKSTDVIKSGSNRDESD
KIDSINQKRMTGNDRTDLNIARAEQHVSSRLDNTNTSSV
VCDGNQPAARWIGAAKFRRNSPVDPVVSPHDRSPTFPWS
ATDDGVTCQPDRQVTAPELSKRVVEPGRARALVASWETR
EKALTADTPVLVSGRPPTSPGVDMNSFIPRGSHGTSESD
LTVSDDNSAIEELNQQHNAFTSILQARLTKLQVIRRFWQ
RNDLKGAIDATGKNGDNSVSADVISVLIERSEIFTLDIC
TVILPLLTRLLQSETDRHLTVAMETLLVLVKTFGDVIRA
TISATPTIGVDLQAEQRLERCNLCYVELENIKQILVPLI
RRGGAVAKSAQELSLALQEV
240The amino acid sequence of SEQ IDMAGSDENNPGVVGGAHVQEGLRVGAGKMGAGNVQQRRAL
512. The conserved cyclin N- andSNINSNIIGAPPYPCAVNKRVLSEKNVNSENDLLNAAHR
c-terminal family domains arePITRQFAAQMAYKQQLRPEENKRTTQSVSNPSKSEDCAI
underlined.LDVDDDEMADDFPVPMFVQHTEAMLEEIDRMEEVEMEDV
AEEPVTDIDSGDKENQLAVVEYID DLYMFYQKAEASSCV
PPNYNDRQQDINERMRGILIDWLIEVHYKFELNDETLYL
TVNLIDRFLAVQPVVKKKLQLVGVTAMLLACKYEEVSVP
VVEDLILISDRAYSRKEVLENERLNVNTLNFNMS V PTPY
VFMRRFLKAAQSDRKLELLSFFIIELSLVEYDMLKFPPS
LLAASAIYTALSTITRTKQWSTTCEWHTSYSEEQLLECA
RLMVTFHQRAGSGKLTGVHRKYSTSKFGHAARTEPANFL
LDFRL
241The amino acid sequence of SEQ IDMQAPREGKSAAAIVGMGKYMKKSKAIPRDVSLLEASPRS
513. Theconserved cyclin-PSATGVRTRAKTLASRRLRRASQRRPPPPAAAAAAAAPS
dependent kinaseinhibitor domainLDASPCPFSYLQLRSRRLRRFRLAPSPEARIDEGPAGSG
is underlined.SRGSRDASCSARTASSSGGVEGEGACVGRGDRGNGGECV
RDAAVDASYGENDLEIEDRDRSTRESTPCSLIRQSNANT
PPGSTTRQQSSCTAHRTQMS ILRSIPTSDEMEEFFAYAE
QRQQRSFIEKYNFDIVKDRPLPGRFEWVQVIP
242The amino acid sequence of SEQ IDMDGHSSHLAAQNRSRGSQTPSPSHSAASASATSSIHLRR
514. The conserved GCN5-related N-KLSAANASAASAAAAAAAAAAAADDHAPPFPPSSISADT
acetyltransferase family domain isRDGALTSNDDLESISARGGGAGDDSDDDSDDEEEDDGDN
underlined and the bromodomain isDGGSSLRTFTAARLENVGPAAARNRKIRAESNATVKVER
in bold.EDSAKDGGNGAGVGALGPAATSGAGSGSGTVPKEDAVRI
FTENLQASGAYSAREENLKREEEAGRLKFECLSNDGVDD
HMVWLIGLKNIFARQLPNMPKEYIVRLVNDRNHKS VMVI
RRNLVVGGITYRPYASQKFGEIAECAIKADEQVKGYGTR
LMNHLKQHARDVDGLTHFLTYADNNAVGYFIKQGFT KEI
YLDRDRWHGYIKDYDGGILMECKIDPKLPYTDLSTNVRR
QRQAIDEKIRELSNCHIVYQGIDFQKRDAGVPQNTIKME
DIPGLREAGWTPDQWGYSRFRGLSDQKRL TFFIRQLLKV
LNDHSDAWPFKEPVDAPEVPDYYDIIKDPMDLKTMTKRV
ESEQYYVTLEMFIADVKRMFAHARTYNSPDTIYFKIATR
LEAHFQSKVQSNLQSGAGKIQQ
243The amino acid sequence of SEQ IDMFNGNNDPELFKLAQEQMNRNSPAELAKIQQQMNSNPEL
515. The conserved TPR repeatNRMASESMKNNRPEDLRQAAEQLKHVRPEEMAEIGEKMA
domain is underlinedNASPEEIAAVRARADAQMTYEINAAKILRREGNELHSQG
RFRDASQKYLRAENNLRGIPSSEGKNLLLACSLNLNSCY
LKTRQYEECIKEGSEALACEEKN LKAFYRRGQAYRELGQ
LKDAVSDLRKAHEISPDD ETIAQVLRDTEESLTKEGGSA
PRGVVIEEITEEDETLASVNHESPSEYSEKRHQESEDAH
KGPINGDIMGQMTNSESLKALRGDPDAIRSFQNFISNAD
PTTLAAMGAGNAGEVSPDLIKTASSMIGKMSAEELQRNI
QLASSFPGENPYVTRNSDSNSNSFGNGSIPNVSPDNLRT
ASDMNSRNSPDDLQRNFEMASSSRGKDPSLDANHASSSS
GANLAANLNHILGESEPSSSYHIPSSSRNISSSPLSNFP
SSPGDMQEQIRNQMRDPANRQNFTSNMKNMSPENMANMG
KQFGLELSPEDAAKAQEANSSLSPEMLDRNNRWADRAQR
GVETAKKTRNWLLGRPGNILAICMLLLAVILHRLGFIGS
244The amino acid sequence of SEQ IDMIAAISWVPRGASRAVPEVAEPPSKEEIEEILKSGVVER
516. The conserved G-protein betaSGDSDGEEDDENNDAVASEKADEVSTALSAADALGRISR
WD-40 repeat domains areVTKAGSGFEDIADGLRELDNDNYDEEDEDVKLFSTGLGD
underlined.LYYPSNDMDPYLKDKDDDDDTEEIEDLSIKPNDSLIVGA
RTDDEVNLLEVYLLEPSLSDESNNYVHHEVVISEFPLCT
AWLDCPIKGGDKGNF IAVGSNEPAIEIWDL DIIDAVEPC
LVLGGQEELRRKRKKGKRASIKYREGSHTDSVLGLAWNK
EFRNI LASASADRQVKIWDV AAGKCNITMEHHTDKVQAV
AWNHHAPQVLLSGSFDHSVVNRDGRIPSHSGYRWSVTAD
VESLAWDPHSEHFFVVSLEDGTVRGFDVRAAISNSASQS
LPSFTLHAHEKAVSTISYNPAAPNL LATGSTDRMVKLWD
L SNNQPSCIASRNPKAGAVFSVSFSEDSPLLLAIGGSKG
RLEVWDTSSDAAVSRRFGRHGKPRTAEPGS
245The amino acid sequence of SEQ ID
MKFCKKYQEYMQGQEGKKLPGLGFKKLKKILKRCRRRDS
517. The conserved Zn-finger, RING
LHSQKALQAVQNPRTCPAHCSVCDGSFFPSLLEEMSAVL
domain is underlined, and the SPX,
GCFNKQAQKLLELHLASGFQKYLMWFKGKLRGNHVALIQ
N-terminal is in bold
EGKDLVTYALINAIAIRKILKKYDKIHLSTQGQAFKSQV
Q RMHMEILQSPWLCELIAFHINVRETKANSGKGHALFEG
CSLVVDDGKPSLSCELFDSIKLDIDLT CSICLDTVFDSV
SLTCGHIYCYMCACSAASVTIVDGLKAAEPKEKCPLC RE
ARVFEGAVHLDELNILLSRSCPEYWAERLQTERVERVRQ
AKEHWESQCRAFMGVE
246The amino acid sequence of SEQ IDMVSTQSTRENPSIFFPPPLKPWLLPVVLSLSLSRQLGMA
518. The conserved G-protein betaAAAAASLPFKKNYRSSQALQQFYAGGPFAVSSDGSFIAC
WD-40 repeat domains areNCGDSIKIVDSSNASLRPSIDCGSDTITALSLSPDGKLL
underlined.FSAGHSRQIRVWDLSTSTCLRSWKGHDGPVNSMACPVSG
GLLATGGADRKVMVWDVDGGFCTNFFKGHDGVVSTVLFE
PDSNRSL LFSGSDDGTIRVWDL LAKKCASTLRGHDSTVT
SLAFSEDGLTLLAAGRDRVVSLWDLHNYACKKTIPMYEV
LESVCVIHSGTVLASQLGLDDQLKVTKESAQNIHFITVG
ERGILRIWKSEGSVCLFKQEHSDVTVISDEDDSRSGFTA
AVMLPLDQGLLCVTADQQFLFYYPEKHPEGIFSLTLCRR
LVGYNEEIVDNKFLGEEENFLAVATNLEQVRVYELASMS
CSYVLAGHTETVLCLDTCISSSGRTL IVTGSKDNSVRLW
DS ESRHCIGVGVGHNGAVGAVAFSRKRQDF FVSGSSDRT
LKVWSL DGISEDGVDSTNLKAKAVVAAHDKDINSVAVAP
NDSLVCSGSQDRTACVWRLPDLVSVVVLKGHKRGIWSVE
FSPVDQCVLTASGDKTVKIWAISDGSCLKTFEGHVSSVL
RASFLTRGTQFVSCGADGLVKLWTVRTNECIATYDQHSD
KVWALAVGKKTEMLATGGSDAVVNLWYDSTASDKEDAFR
KEEEGVLKGQELENAVSDADYTKAIELALELRRPHKLFE
LFSELCRTREVGDRVERILSALSGEEVCLLLEYIREWNA
KPKLCHVAQSVLSQVFRILSPTEIVEIKGIGELLEGLIP
YSQRHFSRIDRLVRSTYLLDYTLTGMSVIEPEADRSAVN
DGSPDKSGLEKLEDGLLGENVGEEKIQNKEELESSAYKK
RKLPRSKDRSKKKSKNVVYADAAAISFRA
247The amino acid sequence of SEQ IDMDSAPRRKSGGINLPSGNSETSLRLDGFSGSSSSFRAIS
519. The conserved G-protein betaNLTSPSKSSSISDRFIPCRSSSRLHTFGLVERGSPVKEG
WD-40 repeat domains areGNEAYSRLLKAELFGSDFGSLSPAGQGSPMSPSKNMLRF
underlined.KTESSGPNSPFSPSILRQDSGFSSEASTPPKPPRKVPKT
PHKVLDAPSLQDDFYLNLVDWSSQNTLAVGLGTCVYLWS
ASNSKVTKLCDLGPNDGVCAVQWTREGSYISIGTSLGQV
QIWDGTQCKRVRTMGGHQTRTGVLAWNSRILASGSRDRV
ILQHDLRV PNEFIGKLVGHKSEVCGLKWSHDDRELASGG
NDNQLLVWN QH SQQPVLKLTEHTAAVKAIAWSPHQNGLL
ASGGGTADRCIRFWN TTNGHQTSSVDTGSQVCNLAWSKN
VNELVSTHGYSQNQINVWKYP SMAKVATLTGHSLRVLYL
AMSPDGQTIVTGAGDETLRFWN VFPSAKAPAPVKDTGLW
SLGRTHIR
248The amino acid sequence of SEQ IDMEDEAEIYDGVRAQFPLTFGKQSKPQTSLESVHSATRRG
520. The conserved G-protein betaGPAPAPAPASSSSLPSTTSPSAAGGAGKSSGLPSLSSSS
WD-40 repeat domains areTAWLEGLRAGNPPAGREAGIGSRGGDGEDGGRAMIGPPR
underlined.PPPGFSANDDGGGEDDDDDGDGVNVGPPPPPPGNLGDGD
DDEEEEEANIGPPRPPVVDSDEEEEEEEEENRYRLPLSN
EIVLKGHNKIVSALAVDPTGSRVLSGSYDYTVRNFDFQG
MNSRLSSFRDFEPVEGHQVRNLSWSPTADRFLCVTGSAQ
AKIYDRDGLTLGEFVKGDMYIRDLKNTKGHITGLTWGEW
HPKTKETILTSSEDGSLRIWDVNDFKSQKQVIKPKLARP
GRVPVTTCTWDREGKCIAGGIGDGSIQIWNLKPGWGSRP
DIHVEQAHADDITGLKFSSDGK ILLTRSFDDSLKVWDL R
LMKNPLKVFEDLPNHYAQTNIACSPDEQLFLTGTSVERE
STIGGLLCFFDRSKLELVSRIGISPTCSVVQCAWHPRLN
QIFATSGDKSQGGTHVLYDPTLSERGALVCVARAPRKKS
VDDFELKPVIHNPHALPLFRDQPSRKRQREKILKDPLKS
HKPELPMNGPGHGGRVGASKGSLLTQYLLKQGGNIRETW
MDEDPREAILKHADAAEKNPKFTRAYAETQPDPVFAKSD
SEDEDK
TABLE 12 — Eucalyptus in silico Data. In Table 12, the following numbers 1-12 represent the following tissues: 1 is bud reproductive; 2 is bud vegetative; 3 is cambium; 4 is fruit; 5 is leaf; 6 is phloem; 7 is reproductive; 8 is root; 9 is sap vegetative; 10 is stem; 11 is whole; and 12 is xylem.
SEQConsID
IDeucSppFamily123456789101112
13910Cyclin-0.250.110.200.73
dependant
protein
kinase
219213Cyclin-0.590.64
dependant
protein
kinase
336800Cyclin-0.110.36
dependant
protein
kinase
440260Cyclin-0.85
dependant
protein
kinase
541965Cyclin-0.350.86
dependant
protein
kinase
62906Cyclin-0.930.81
dependant
protein
kinase
71518Cyclin-0.080.280.080.060.11
dependant
protein
kinase
88078Cyclin-0.173.20
dependant
protein
kinase
99826Cyclin-0.360.230.150.040.240.43
dependant
protein
kinase
1010364Cyclin-0.111.520.13
dependant
protein
kinase
1111523Cyclin-0.150.060.152.40
dependant
protein
kinase
1224358Cyclin-0.760.070.040.24
dependant
protein
kinase
1339125Cyclin-0.23
dependant
protein
kinase
145362Cyclin-0.680.060.081.17
dependant
protein
kinase
1544857Cyclin-0.680.060.081.17
dependant
protein
kinase
161743Cyclin A0.192.100.060.15
1712405Cyclin A0.060.592.84
183739Cyclin B0.421.990.082.33
1922338Cyclin B0.86
2028605Cyclin B0.390.040.47
2141006Cyclin B0.71
226643Cyclin D0.850.830.061.060.080.26
2345338Cyclin D2.03
2446486Cyclin D0.30
2512070Cyclin-0.240.820.060.260.92
dependent
kinase
regulatory
subunit
266617Histone0.080.060.040.550.510.26
acetyltransferase
277827Histone2.270.110.04
acetyltransferase
288036Histone1.16
acetyltransferase
301596Histone0.170.160.082.980.880.260.980.71
deacetylase
315870Histone0.190.170.125.43
deacetylase
326901Histone1.210.082.011.160.08
deacetylase
336902Histone0.080.111.210.47
deacetylase
347440Histone0.481.230.150.220.480.202.02
deacetylase
358994Histone0.090.15
deacetylase
3624580Histone0.421.22
deacetylase
3737831Histone0.080.220.401.190.12
deacetylase
3834958MAT1 CDK-0.150.23
activating
kinase
assembly
factor
3922967Peptidylprolyl0.720.69
cis-
trans
isomerase
408599Peptidylprolyl0.460.080.500.170.510.283.01
cis-
trans
isomerase
419919Peptidylprolyl0.510.350.060.150.434.24
cis-
trans
isomerase
4215820Peptidylprolyl0.046.78
cis-
trans
isomerase
438327Peptidylprolyl0.060.046.86
cis-
trans
isomerase
444604Peptidylprolyl0.68
cis-
trans
isomerase
45966Peptidylprolyl0.591.020.540.690.500.930.590.9518.65
cis-
trans
isomerase
461037Peptidylprolyl0.59
cis-
trans
isomerase
474603Peptidylprolyl0.170.171.240.040.34
cis-
trans
isomerase
485465Peptidylprolyl1.210.080.660.110.290.166.99
cis-
trans
isomerase
496571Peptidylprolyl0.510.080.410.081.14
cis-
trans
isomerase
506786Peptidylprolyl0.420.330.060.410.04
cis-
trans
isomerase
517057Peptidylprolyl0.420.110.04
cis-
trans
isomerase
528670Peptidylprolyl1.560.390.200.12
cis-
trans
isomerase
539137Peptidylprolyl0.040.59
cis-
trans
isomerase
5410285Peptidylprolyl0.601.160.040.040.45
cis-
trans
isomerase
5510600Peptidylprolyl0.160.170.060.46
cis-
trans
isomerase
5611551Peptidylprolyl0.080.060.040.081.89
cis-
trans
isomerase
5720743Peptidylprolyl0.76
cis-
trans
isomerase
5823739Peptidylprolyl0.59
cis-
trans
isomerase
6031985Peptidylprolyl1.99
cis-
trans
isomerase
6132025Peptidylprolyl0.99
cis-
trans
isomerase
6232173Peptidylprolyl1.99
cis-
trans
isomerase
649143Retinoblastoma0.900.15
related
protein
65349WD40 repeat0.240.340.080.170.220.330.080.252.24
protein
66575WD40 repeat0.250.940.310.340.110.160.471.87
protein
67804WD40 repeat0.150.340.390.330.391.82
protein
68805WD40 repeat0.970.514.660.230.170.770.331.070.244.43
protein
69806WD40 repeat0.830.04
protein
702248WD40 repeat0.080.081.920.060.080.91
protein
713203WD40 repeat0.340.180.150.170.110.300.040.72
protein
723209WD40 repeat0.080.150.170.120.61
protein
734429WD40 repeat0.081.160.080.13
protein
744607WD40 repeat0.760.540.060.07
protein
754682WD40 repeat0.080.280.231.130.080.12
protein
765786WD40 repeat0.080.060.460.080.13
protein
775887WD40 repeat1.611.230.080.060.150.281.41
protein
785981WD40 repeat0.080.37
protein
796766WD40 repeat0.240.081.310.510.060.740.510.28
protein
806769WD40 repeat0.930.170.122.28
protein
816907WD40 repeat0.250.170.060.450.320.471.67
protein
827518WD40 repeat0.910.280.150.550.59
protein
837717WD40 repeat0.470.38
protein
847718WD40 repeat0.241.880.080.220.040.92
protein
857741WD40 repeat1.420.110.47
protein
867884WD40 repeat1.330.150.24
protein
878258WD40 repeat0.720.190.230.870.150.080.08
protein
888465WD40 repeat0.470.081.75
protein
898616WD40 repeat0.570.080.690.160.13
protein
908690WD40 repeat0.260.080.351.390.340.322.130.80
protein
918708WD40 repeat0.570.04
protein
928850WD40 repeat0.090.060.272.03
protein
939072WD40 repeat1.210.170.48
protein
949465WD40 repeat0.240.720.330.15
protein
959472WD40 repeat0.361.990.110.616.90
protein
969550WD40 repeat0.900.111.78
protein
9710284WD40 repeat0.240.081.821.220.160.470.28
protein
9810595WD40 repeat0.160.170.116.520.85
protein
9910657WD40 repeat0.060.12
protein
10012636WD40 repeat0.060.65
protein
10112748WD40 repeat1.500.080.061.670.040.38
protein
10212879WD40 repeat0.080.330.060.040.082.00
protein
10315515WD40 repeat0.350.30
protein
10415724WD40 repeat0.250.330.150.470.040.39
protein
10516167WD40 repeat0.240.52
protein
10616633WD40 repeat1.960.120.42
protein
10717485WD40 repeat0.65
protein
10818007WD40 repeat0.12
protein
10920775WD40 repeat0.170.08
protein
11023132WD40 repeat2.42
protein
11123569WD40 repeat0.910.91
protein
11223611WD40 repeat4.15
protein
11324934WD40 repeat0.340.04
protein
11425546WD40 repeat0.09
protein
11530134WD40 repeat0.07
protein
11631787WD40 repeat0.191.19
protein
11734435WD40 repeat0.350.08
protein
11834452WD40 repeat1.440.200.25
protein
11935789WD40 repeat0.20
protein
12035804WD40 repeat0.190.270.08
protein
12143057WD40 repeat0.300.57
protein
12246741WD40 repeat0.46
protein
12347161WD40 repeat1.78
protein
2356366WD40 repeat0.080.680.230.930.110.360.830.240.94
protein
23617378WD40 repeat0.650.120.08
protein
25245414Cyclin B3.13
25344328Cyclin-0.38
dependant
kinase
inhibitor
25415615Histone0.220.04
acetyltransferase
25517239Peptidylprolyl0.080.500.08
cis-
trans
isomerase
25618643WD40 repeat0.040.90
protein
25719127WD40 repeat0.040.89
protein
25822624WD40 repeat1.16
protein
25932424WD40 repeat0.50
protein
26037472WD40 repeat0.080.17
protein
TABLE 13 — Pine in silico data. ConsID
SEQpinus
IDRadiataFamily123456789101112
1241766Cyclin-1.020.051.580.150.220.220.182.164.91
dependant
protein
kinase
1252927Cyclin-0.160.190.110.140.040.360.380.17
dependant
protein
kinase
1267642Cyclin-0.220.210.050.07
dependant
protein
kinase
12713714Cyclin-0.110.11
dependant
protein
kinase
12816332Cyclin-0.540.260.140.040.91
dependant
protein
kinase
12921677Cyclin-0.050.140.17
dependant
protein
kinase
13027562Cyclin-0.41
dependant
protein
kinase
1311504Cyclin-0.160.360.350.210.540.090.65
dependant
protein
kinase
13215211Cyclin-0.130.150.190.19
dependant
protein
kinase
13320421Cyclin-0.040.050.95
dependant
protein
kinase
1343187Cyclin-0.340.150.040.180.38
dependant
protein
kinase
13515661Cyclin-0.040.13
dependant
protein
kinase
13613874Cyclin A0.310.270.150.05
13714615Cyclin A0.160.15
1384578Cyclin B0.470.140.130.220.740.38
13923387Cyclin B0.290.260.17
1406970Cyclin D0.140.270.04
14110322Cyclin D0.160.190.060.141.121.36
14222721Cyclin D0.270.36
14323407Cyclin D0.150.260.31
1441945Cyclin-0.280.550.410.161.625.020.220.720.393.06
dependent
kinase
regulatory
subunit
1458233Cyclin-0.21
dependent
kinase
regulatory
subunit
1468234Cyclin-0.160.11
dependent
kinase
regulatory
subunit
14722054Cyclin-0.050.220.18
dependent
kinase
regulatory
subunit
14812137Histone0.061.510.19
acetyltransferase
14912582Histone0.640.151.090.330.63
acetyltransferase
15015285Histone0.210.120.700.14
acetyltransferase
15117229Histone0.940.16
acetyltransferase
15220724Histone0.040.190.19
acetyltransferase
1534555Histone0.160.140.970.140.890.89
deacetylase
1544556Histone0.14
deacetylase
1555729Histone0.310.280.220.580.222.000.480.070.042.731.46
deacetylase
1567395Histone0.140.140.190.930.040.141.33
deacetylase
1579503Histone0.110.14
deacetylase
15811283Histone0.190.150.961.35
deacetylase
15912322Histone0.160.060.110.040.050.29
deacetylase
16123236Histone0.130.11
deacetylase
162171Peptidylprolyl0.070.46
cis-trans
isomerase
163172Peptidylprolyl0.190.110.180.110.46
cis-trans
isomerase
1641480Peptidylprolyl2.514.200.882.971.583.537.361.332.740.726.6210.14
cis-trans
isomerase
1681692Peptidylprolyl0.160.220.650.610.260.290.181.280.34
cis-trans
isomerase
1695313Peptidylprolyl0.140.070.370.17
cis-trans
isomerase
1706362Peptidylprolyl0.140.330.050.060.600.042.920.68
cis-trans
isomerase
1716493Peptidylprolyl0.420.110.210.110.040.250.32
cis-trans
isomerase
1726983Peptidylprolyl0.610.130.04
cis-trans
isomerase
1747665Peptidylprolyl0.110.390.050.620.25
cis-trans
isomerase
17512196Peptidylprolyl0.190.150.140.16
cis-trans
isomerase
17613382Peptidylprolyl0.250.060.070.040.870.15
cis-trans
isomerase
17716461Peptidylprolyl0.190.150.150.040.040.74
cis-trans
isomerase
17817611Peptidylprolyl0.240.110.270.410.99
cis-trans
isomerase
17919776Peptidylprolyl0.130.070.160.050.61
cis-trans
isomerase
18020659Peptidylprolyl0.150.19
cis-trans
isomerase
18122559Peptidylprolyl0.110.140.20
cis-trans
isomerase
18224188Peptidylprolyl0.23
cis-trans
isomerase
18327973Peptidylprolyl1.01
cis-trans
isomerase
1841353WD400.440.050.730.111.070.701.32
repeat
protein
1851978WD400.140.050.440.110.210.270.361.460.82
repeat
protein
1862810WD400.420.790.110.390.270.361.691.03
repeat
protein
1872811WD400.140.090.14
repeat
protein
1882812WD400.150.180.040.16
repeat
protein
1893514WD400.630.060.140.180.480.56
repeat
protein
1904104WD400.140.250.270.370.360.190.180.390.53
repeat
protein
1915595WD400.140.250.150.140.070.23
repeat
protein
1925754WD400.310.140.060.070.160.100.16
repeat
protein
1936463WD400.160.560.220.430.810.530.210.081.000.70
repeat
protein
1946665WD400.310.280.450.440.960.073.372.68
repeat
protein
1956750WD400.140.590.050.370.420.040.180.52
repeat
protein
1967030WD400.310.400.540.450.370.071.583.41
repeat
protein
1977854WD400.110.140.05
repeat
protein
1987917WD400.220.390.130.150.180.56
repeat
protein
1997989WD400.110.040.11
repeat
protein
2008506WD400.470.330.110.860.191.280.041.233.12
repeat
protein
2018692WD400.210.060.110.150.100.87
repeat
protein
2028693WD400.110.800.250.140.180.530.31
repeat
protein
2039170WD400.160.110.050.05
repeat
protein
2049408WD400.330.050.410.150.140.410.33
repeat
protein
2059522WD400.110.18
repeat
protein
2069734WD400.110.050.110.150.070.250.11
repeat
protein
2079815WD400.110.180.14
repeat
protein
20810670WD400.400.160.110.160.340.31
repeat
protein
20911297WD400.530.150.160.05
repeat
protein
21013098WD400.190.110.540.310.140.261.850.14
repeat
protein
21113172WD400.04
repeat
protein
21213589WD400.110.060.210.050.37
repeat
protein
21313608WD400.110.040.590.33
repeat
protein
21414299WD400.160.051.090.38
repeat
protein
21514498WD400.210.440.30
repeat
protein
21614548WD400.160.110.110.82
repeat
protein
21714610WD400.160.27
repeat
protein
21816090WD400.430.040.370.85
repeat
protein
21916722WD400.10
repeat
protein
22016785WD400.050.130.380.50
repeat
protein
22117094WD400.290.150.240.81
repeat
protein
22217527WD400.040.10
repeat
protein
22317591WD400.140.10
repeat
protein
22417769WD400.39
repeat
protein
22518047WD400.050.220.980.152.680.070.190.80
repeat
protein
22618414WD400.160.150.340.230.19
repeat
protein
22718986WD400.410.15
repeat
protein
22819479WD400.050.280.32
repeat
protein
22920144WD400.430.290.05
repeat
protein
23022480WD400.150.27
repeat
protein
23123079WD400.130.04
repeat
protein
23226739WD400.150.18
repeat
protein
23326951WD400.210.20
repeat
protein
23426529WEE1-like0.040.18
protein
237888WD400.110.18
repeat
protein
23814166Cyclin-0.160.050.05
dependant
kinase
inhibitor
2393189Cyclin-0.06
dependant
protein
kinase
2409356Histone0.110.220.46
acetyltransferase
24165Histone0.160.220.270.220.240.34
deacetylase
24214197Histone0.160.330.05
deacetylase
2439081Peptidylprolyl0.110.050.290.260.69
cis-trans
isomerase
24413417Peptidylprolyl0.060.59
cis-trans
isomerase
2455755WD400.16
repeat
protein
2466670WD400.140.05
repeat
protein
2477027WD400.140.151.300.15
repeat
protein
2487276WD400.140.110.05
repeat
protein
2497390WD400.310.140.110.441.290.38
repeat
protein
25012648WD400.050.060.050.94
repeat
protein
25113171WD400.190.630.190.34
repeat
protein
TABLE 14 — Oligo Table. Oligo SEQ
IDOligo IDMicroarray Oligo Seq
521Euc_003910_O_4GATTTTAAGTAACTCAATTAGCAGTTCCAACATTAAACCATTATTATTACCCCTTTTATC
522Euc_019213_O_1CTCAAAAAGTACTTGGATGCGTGCGGTGACAACGGACTCGAACCGTACACTGTCAAATCT
523Euc_036800_O_4TTGTCAAGTTGCAGGACGTAGTGCACAGTGAGAGGCGTCTATATCTAGTTTTTGAGTACT
524Euc_040260_O_1GAAGAAATTATATAACTAGATACAAGGTTAGCTAGGTATATAATAGCGGTACAAGTCTTT
525Euc_041965_O_1GGACAAATCAAGTAGAACTTCTCTCGGCAGCATCAGTTTTTCTAATCCATGCCTTGTTGC
526Euc_002906_O_1CTCAGTTCTGATAATGCCTCGGATATATGGCCGAGTGTTCGCTGGACGGCCTCTTATGTT
527Euc_001518_O_3GGAGATTCTGAACTGCAACAGCTCCTACACATTTTCAGACTGTTGGGTACTCCAAATGAA
528Euc_008078_O_2GACTGGTAAAATCGTTGCACTAAAAAAGGTCCGGTTTGACAACTTGGAACCTGAAAGCGT
529Euc_009826_O_4AAACACCAATCTATCAACACTGTCGAGTTTAGTCACTAGTAGAACCGGAGATAACAAACA
530Euc_010364_O_1CTATGATCCTGAGCGCAAGCAAGTTATGACCAATAGAGTCGTTACACTATGGTACCGAGC
531Euc_011523_O_1TGTTGTGAAGGTAGTTATAGCCATCGATTAGACAGTGATTAAAGTAGTACCCGTGCCAAT
532Euc_024358_O_2CCACATACAAGAGTTGTTACGCTACACATCCTATACCATCAAAGGAACGTTGGAATGCCA
533Euc_039125_O_3TATGATCGACACAAGCATTTTGTGTTGGAGCCTCAGCTAATTGTATGTCATCGAGTACTT
534Euc_005362_O_3AAAATTTTTGCTACGGATAATGTTGTGAGGCGAGGCAGTCGAAATTACGGAGGTTGACTT
535Euc_044857_O_1ATGCAGGGATCAAATTTGTGAGTACTACGTAAAATTTTGCTACGGAGGCGAGGCAGTCGA
536Euc_001743_O_1GAAGAATACAGGCTCGTACCTGATACACTGTACCTGACTGTTAACTACATAGATCGGTAT
537Euc_012405_O_1TCCACCCTAAATGCGATACGTGAAAAGTATAGACAACAGAAGGTAAACTATTCATTACTG
538Euc_003739_O_2AGGCTTCTAGTTGCGTTCCCCCAAACTACATGGATCGGCAGCAGGATATTAATGAGCGGA
539Euc_022338_O_2GAGAAAAATGACAGATTGATATCGATGATGATGACTGTCGTGTCATCAGTAGTGTGCTTT
540Euc_028605_O_5TTTCCAATTGTAGTTCGTCTTTTATTGTAACAATAAATTGATAGATACTGATTCGAAATA
541Euc_041006_O_1ACATTTATGCTAACTATAGGAGAACGGAGAATTGTAGCTGCGTCTCTGCTAACTACATGG
542Euc_006643_O_1TTCTGGCTTAAAGGCTATTCTTTGTGCACAATGACCTGAGGGAGGTCTCGACAGACCACT
543Euc_045338_O_1TTCATCCGGGTCCTGGTTATCATACTCTTATATATGTTGGGGAATAACGGTTCATATGTT
544Euc_046486_O_3GGGTGTGCTTAATAGTTCTTATTAGTCTTAGCTTATTATCTTTGATTGGACATGCTATAA
545Euc_012070_O_2CTTGCTAAGTAGACATGTTATATTTCTAATGCTTTGAGAACAATATTACAGTATAATTAG
546Euc_006617_O_2AATCATCGACTAGACCGATGGTCAAAGTGGTAATCATGTAATTAAACGCGTTTGTCATTG
547Euc_007827_O_2ATGGAAAAATCTATGGATATGAAGGATTGAAGATATCCGTCTGGGTAAGCTGTGTATCAT
548Euc_008036_O_3TTATGATTTGAGAAAACCCTTGCAGGCTGCGATTTGCGGATCATGACAGCATAGTTTTGC
549Euc_001596_O_2GTTTTGTTGTGAGGGCTTGGTAGGTTTTCATTATATTGTAATGTCGACGACAGAGATTTT
550Euc_005870_O_3CCAATTAATGTTACTGCTCAAGCTGACGTACCTGCGAAAAAAGCACCAGTGACTGCTAAT
551Euc_006901_O_3TGATGTCAAAACGTAGCTCTTTTTTGTGTGAGCTATCCTGCTAAATTAAACCTCAGCAAA
552Euc_006902_O_1ACATGAGTATTATGAATACTTCGGTCCTGACTATACACTTCATGTTGCTCCGAGTAACAT
553Euc_007440_O_2GAATTGGCGATCACAATCTACTGTAGTCAATACTCAAGTGGGAGGTGTAAATAGATTCCA
554Euc_008994_O_1GATCATGTGTAATCAGTATATCAGGTTAGAAACAGTACTCTTGAGCTTAGCGGGCACTGT
555Euc_024580_O_2TCCTGTGAAGGTGGTCGACTCAATCAAAAGGTACCTTGTAGATAAGGTACCTTTTCTCAA
556Euc_037831_O_5GCATTTTATACGACGGATAGAGTCATGACCGTATCTTTCCATAAGTTTGGGGACTTCTTC
557Euc_034958_O_3CCTCGTTTCTTTGCGGTTCGGACGCATCATGGATGTATCTCCAAAGAGTAATCTGTCGAT
558Euc_022967_O_2AATTCAGATCTATTAGTGAAAGTTGGCATGAGTCTCAATCTTAGGGGAATACAGTACGGA
559Euc_008599_O_3TGATATGAGTATCATAACTCGGATGGTGACAACTTTGTACTACGGTCGGCACCGGTAGAT
560Euc_009919_O_1CATATACAATCTTAGTGGATTAGCTGAGGTCGAAACTGACAAGAGTGATCGCCCGTTGGA
561Euc_015820_O_2CATGGCTAACGCTGGCCCTAGCACTAATGGGAGCCAATTTTTCATATGCACTGTAAAGAC
562Euc_008327_O_2AACAAAGTCTACCTTGACATTAGCATCGGTAACCCTGTCGGGAAACTAGTCGGAAGAATT
563Euc_004604_O_2TGTGCTTGGATATACTGTATAAGCATTCTATATTATGCTTGTTGGCTTCGTTTTGAGGGA
564Euc_000966_O_1TTAACGTCGACCGCTTCTCTGCCCCTTGAATTTTCCCGAGAAAACCAGGAACCTGCCAAA
565Euc_001031_O_1TGTTGAATACGATGTATTATAATGTTGGTGTCTTGGTGAAATACAGAATTATGCTTGCGT
566Euc_004603_O_2ATCGCTGTGGCTGATCTCGTCGCTCCGGCTTTTCATAAAAATCATGGCTGAGGCAATCGA
567Euc_005465_O_2CTCGCAACCCTATATCTCGCTCAGGCGAAGAAGTCTGAGGATTTGAAAGAGGTGACTCAC
568Euc_006571_O_1TGTTTTTGGGTACACGCAGTTAGGATAACTAGCATGAAAGCCCGATCCCGCATATACAGG
569Euc_006786_O_2GAGGACTAGCCGGAACTTCATCGAACTCTCTCGGAGGGGTTACTACGATAACGTCAAGTT
570Euc_007057_O_1GATGGCTAGCACTGTGTAGAAAGGTGAATTTAAAGTACTTGTCTACACTGCTTATTAAAT
571Euc_008670_O_2TGAGACTGTCTTGGCGTGTATTTTGGAATAAACTATTATCACGTTTTGTTAAATATAATA
572Euc_009137_O_3TTACAAAATGGCTCTCAGAAAGTATCGAAAGGCCCTGCGCTATCTGGATATCTGCTGGGA
573Euc_010285_O_2AATTTTATGTTTGCTACTGCTTAGTGCTTAATGGACTTGCGTAGGTATTCAAATTACAGA
574Euc_010600_O_1TGGAACCGTGGTATCGGCTGACGTTATCCGTGATTTTAAGACTGGAGATAGTTTATGCTA
575Euc_011551_O_2CTTTGATGTATCCTCAGTGTACTGCTTTTAGCTATGTATAGATCGAGTCAACTCATTGAA
576Euc_020743_O_3TTTTTATTATTTACCTTCGCCTTTACGCTGCATACGTTAATAGGTTATTATTTCCTTCAA
577Euc_023739_O_1ATTTGTCCATGACAATCGTAGTCGAAGACACGATACGCTCTTAGATGGTACGGAAATCTG
578Euc_031985_O_2TGAATAGAGATAACTTTTCTGAGTGTGAATTGGATATTACGTTGCAAATAGCCGAATGAA
579Euc_032025_O_2GCTTTAGGTTAGGGATCCCTGTAAGCTGATGATAGATATTGGAGATGGTACTTGTAAGAT
580Euc_032173_O_1TGTTGTGTTTGGAAAGGTGCTGTCTGGGATGGATGTTGTCCACAAGATTGAGGCTGAAGG
581Euc_009143_O_1GGAAAGCGGGGAATGAGCATGTGGATATTATCTCTTTCTACAATGAAATATTCATTCCTT
582Euc_000349_O_1CATCAGGACGTTGACTCTAATTAAGACATATGTGACAGAGCGCCCTGTTAATGCGGTTAC
583Euc_000575_O_2CTTTAGGTTTGATCTGTCTGTTTTGTCTATCCTGCGAGTTTCGAGCATGTGCGTGTGTGA
584Euc_000804_O_1CAGCCCCAATAGATACTGGCTCTGTGCCGCTACTGAGAACAGTATTAAAATCTGGGACCT
585Euc_000805_O_2AAGAATGAAGCTGATATGAGTGATGGAACTACGGGGGCCATGAGCTCAAATAAGAAGGTC
586Euc_000806_O_1TGACTACAATTAGCACCTCACCATTATCGAACTGTATAATTGTGCTTGCCTGCTATTATT
587Euc_002248_O_4TTGAAGCGGAAATATATATTTATGCTACTACATAAGTAATGTACTACTTGACAAGATGAG
588Euc_003203_O_1TACTCGATGTGGTATAGAATTTATCCAATGTACTCCTAAATGTAGATACATCGTGTATTG
589Euc_003209_O_2GCTTCGTCTGATACCACTATCAAGATAATAGGCGTGAGCAATAGCTCTGGATCACAGCAC
590Euc_004429_O_4GGTCGGCTTGCTAGTGTATCTGATGACAAGAGCATATCACTCTATGATTACTCATGAAGG
591Euc_004607_O_3GAAAGGAGAAAAGCATGGAGATCGATCTCGGAAACCTCGCATTCGACGTCGATTTTCATC
592Euc_004682_O_1GATTCAGTACCCGGATTCGCAAGTCAACCGGTTGGAGATAACTCCACATAAGCGGTACCT
593Euc_005786_O_1TTCCATGTATCAAGCCGCATCAATGTTTGTCGCTGCAATTAACATGTGTGCAGTCGATCC
594Euc_005887_O_2TTCAGCGCATTGTGTAAATGTAGATAGGTGATATATTTCTCGTTGCAATGTAGGGTAAGA
595Euc_005981_O_2TCCAATAATCACATTTACCATCAACAGGCATCAGCAACATACTGTTGTAGTGTAATTAAT
596Euc_006766_O_1GGGCATTCTGACTACCTGCACTGTATAGCTGCACGGAACTCTTCTAGTCAGATTATAACA
597Euc_006769_O_1AATCGTCTGGTAGATTGTCAAAAACTAATAAACCTGTGATTGATCCGGATTCTAGTAATG
598Euc_006907_O_2AGTTGAGGATTCTCCACTATGACAGCTCTCATGGCTTGAATCTAAAGTCATCTGGTTTTC
599Euc_007518_O_1GAACAATCATTCTGTAGAACACTAGAGTCTATATGCTTGACTGTATCGGTTAATTAATTC
600Euc_007717_O_1AGATAGCGATAGAGTTATACTGCATGTACTGAGGTAAATGTTTTGATTACTCCACCCAAT
601Euc_007718_O_1AAGAATTGTTAGGAGGTGTATACTTTCTGTAACTGTATTCAATGAGCATACACCTGACGG
602Euc_007741_O_2CAACTCATATAATGACTGGATTCTGGCAACCGCGTCTTCAGACACAACAGTTGGACTATT
603Euc_007884_O_1AGTGTAAAAGGATGCCCCTAATAGATTATATGCCAAGTGTAGTATATATAATAGTGCTTT
604Euc_008258_O_2AAGAATCTACAGTTGTCTTATGCTACTCTATTACTCAATTATGCTGTGCTATTGATTGAG
605Euc_008465_O_4TCTGAATACATACTTTGTGGTCTCTATAAAAGACCAATGATACAGGCATGGTCATTAATT
606Euc_008616_O_5TAAATCTTCTCATGTGCCTGGCGTAAATTTTGCAGTTATTACTAGACCAAGATAGTTTCA
607Euc_008690_O_4ACATGGATTCGATCAATCGCCACATGACAACTAAAACAAGCGGTTCACGTGATTGTAATT
608Euc_008708_O_4AGATGAGTATGCTCGGGTGTATGATATTCGCAATTACAAGTGGAATGGATCGCATAATTT
609Euc_008850_O_5TCTTTGATTCTGTTGTATGGTGTATCTTATTGTATCTTCTATCTGCCCCCCATGTAATTC
610Euc_009072_O_1TTCGTTGTGTAGTACTGGGAGTTACTACTTGTATGTATGTAAATCATGTGGCGTCTGTCC
611Euc_009465_O_1GGAGATGTGTAATATGTCTGAGCGGTCACACTCTAGCTGTTACATGCGTAAAGTGGGGAG
612Euc_009472_O_3CCACCGTTGCGTAACTCGAATAGCCGGATTTTCGTTTTCGTTTTTATTTCCCCGTTAATT
613Euc_009550_O_1TGAGATGCTCTGTGTGAGGACTTTTACGAAACTTGAATGGCCCGTAAGGACAATAAGCTT
614Euc_010284_O_3TGGGTTGTTGCGACGGGTTCTACAGATAAGACTGTTAAGTTATTTGATCTACGCAAGATC
615Euc_010595_O_1GCAGAGGTGCCTACATATGCTTTAGAATGCTAGTAGCTTGGAAGTGCAACACGCTCGTGA
616Euc_010657_O_1AGTAAAGTTTAACGACTATGCATCTGTCGTAGTATCAGCCGGCTATGATCGTTCAGTGCG
617Euc_012636_O_2CGTTAGGATAGTCTTTAAAGGAGTTGGTGATTATTGATTTCCACCCAATATATGTAGCGT
618Euc_012748_O_2GAGCAAGCTACTTACAAAAATCGACAGCGTCTTTACCTATCTGAACAGACAGATGGCAGT
619Euc_012879_O_2TCCTTCCGACAAGTACCGTATTGCAAGTTGTGGTATGGACAATACGGTTAAAATCTGGTC
620Euc_015515_O_1TTTCACTCGATGACGGTTGGCCGGATAAATAATCGCTTATATAGTCCTAATAAGTTCCAT
621Euc_015724_O_3ATATGTAGGTGGTAGAGGTGTGGATATTGCATAGACCGAACCTCCGCAGGTCCGCATTCT
622Euc_016167_O_1CCATTGAACTACTTATGGATTACTTTATACATGAAATATCATGCCGGAGTAATTTTGAGT
623Euc_016633_O_3AGCATTAGAGACCTGGATTTTAGTCTAGATTCAGAGTTTTTGGCTACGACATCTACTGAT
624Euc_017485_O_3AAAGGTTTATCCCTCATTGGATTTGATATATAAACTGAGAGTGTTTTGCCCCCCATTAAA
625Euc_018007_O_1GTACAGCGTGTATTTCTTGTTACGATACTTGAGGGGTTAGAGGCACCTACGAATTAGGAA
626Euc_020775_O_3ATATCCTTATGAATGAAGTTTGGATGATAAGTGGCGCCAGACTTTCTACTCACCCTTTTT
627Euc_023132_O_3TGATCACATCGTTGTTTGCAATAAGACGTCATCAATTTATATCATGACTCTACAGGGACA
628Euc_023569_O_2TTTTCCCAGTGTACTGCGAGAGTGATGCTACATAAGTTTACTCTTGTGTCTAACTTTTCC
629Euc_023611_O_1AGATTCTACAGATGGCGCTATACGAGCTGTTATACGGACATTTTATGACCATACACATCC
630Euc_024934_O_3TGCTACGGGAAACCAGGACAAAACTTGTAGGATTTGGGACATACGAAACTTATCTAAGTC
631Euc_025546_O_1CAAGTCATATAGTTACAGTGTCGCATGACAGAACAATTAAGCTCTGGACTAGTAACGACG
632Euc_030134_O_2TGCCACATCGTAACCATCATAGCACTTATCATCTAATTATGGTGAAAGGGAGTTATATAT
633Euc_031787_O_5GTTTATACTTATAAACAACAGAGAGACAACTGTACAGGTGTTGTAAACACTCCCAGTGTG
634Euc_034435_O_1CTGTGTTTTAGCCCGAGGGCCAATCACTTAGTTGCTACTTCGTGGGATAATCAGGTACGG
635Euc_034452_O_3GCAAAGTAGAGTTTAAGTTTCGTTGTGCTTGGACCGGAAAACTCACATGCTTAGAGTTTA
636Euc_035789_O_5AAGATTTGGGCATAACTTGTATGAACTTTTTCTGTTGTCGACACTGTAATTACACGAGCT
637Euc_035804_O_4AAACAGATGCATGTATGCTTCATAACTCTATAGATATGGAAATGTCACTGTACACTGATC
638Euc_043057_O_2TTATTGGTGCACAGGACGGAAAATTGCGCATATATTCTATTTCAGGTGATACATTAACAG
639Euc_046741_O_1AGGCACAGACACTTGCCTAAACCAATATACAAGGCAGGTATTCTAAGGCGCACCGTGAAT
640Euc_047161_O_4CATGCGAAGGTTTCTGGGAATTTTCAGTAGAAAATTCGGTCGTGGCGGCCATCCTCGATA
641Pra_001766_O_1TTAAGCTGATAGCTTTAGTTCCTACGTGGAATGTATAAATGCACCATTGTCCATAAGGCA
642Pra_002927_O_2GGATGCTCTGGTTACATGACTACTCCTTAGGGAATCAGTCAGACATTTTAAATAACTTCC
643Pra_007642_O_2TCATTAAGCGGTACTGGCAGAGGACATGTCTATTTATACAAGCAAATGGTCCTATTGGCT
644Pra_013714_O_1ATGTTGGTCAGACCTCAAATATTGTACTCCCCACACTAGGGAGCATTTACGGTGAATATA
645Pra_016332_O_1TCCTCTCGACCCTTAGAGTCCTCTGCGAATCTTGTTGTTAGTTACTGTGTACGCTGTAAC
646Pra_021677_O_3AAGCATGTTTTGAATTTATGGTGGTGGCATGTGGATATTTGAACTTGGTTGAGAAAAATT
647Pra_027562_O_2CATTCCTATTGAAGGGTCAACCTTTAATTTTGGCTAGCAGGACTGTATAGGATTATATGC
648Pra_001504_O_2TTATTGTATTTTAGATTCTTGATGGCCATCTAAACTTCTGGCTGCTTGGTGCAACATTGA
649Pra_015211_O_2ATAGCTAATGATTCCATGCTATCCATGGTATCTACTTCACGATAATAAAGGTCTTAGTCC
650Pra_020421_O_2CACCTAATAGGCCTGAGTATTGCTCACCACTATGCTGATATGGGGAGCAATAACGTTAGT
651Pra_003187_O_2TTTCTTTTCACTTTGTACTAATGATCATTGTGACCACAAAATCTTTATACACAATACAGA
652Pra_015661_O_1CTTGTCACTATCCTCATATTGATATCACCTCGTGTATGTTGTGGGGTGGCAAAATTACTT
653Pra_013874_O_1TATTTTAACTCAGCGACTTACCAGCCTAGTAAGCAATGGGGAGCTTGCATGTATTAGTTT
654Pra_014615_O_1ATTCGTCCTGGTCCTTTAGGACATGTACTTATGTCCATGCAAGTGCTTCTTGCCTAAGCT
655Pra_004578_O_2TTCTAGGCGATATATATCGCCGTAACTTTGGATGTGTTAAGAATATAGGGGATCATTAGC
656Pra_023387_O_3AGTTGCAGAGTGTGTAGCAACTGATGAGCATAGTTGTTATGTTTCTCAACTCAGTTGCAC
657Pra_006970_O_1AAGAAACTCATACACTGGACAGGCCAACCTTCCAAATATGTGTTTAGAAAACCTTTGTCT
658Pra_010322_O_1AAGGGGTGCTATCCATATCTAGAATCTACCATGCTCAATGAGGTATCTTCATTAGTATAC
659Pra_022721_O_1ATCTAATGCTAGTTTATTGATTTCTATGATCCAAGACCTCGTCATAGATCAAGTGCCTAG
660Pra_023407_O_1TTGTTATTAAATACCATTCAATATGCTTATGATTCATGAATGCTTAAGAGATTCTGCTGC
661Pra_001945_O_2GCTTCTAAACTGTAGAAGCCTGTTATCTTTAGACTCGTGGTTATGTGAACTACTTTTACA
662Pra_008233_O_1GGCTGTGGGGATTCGAGCCTGATGGTTATGCACTGTGGCCAGCAAGATGTTGAAGTTTTA
663Pra_008234_O_4GCCTGATGGTTATGCACTGTAAGTGATCTGATTTGATTAACTATTTTATCAATTAATTTT
664Pra_022054_O_2ATGGTCATTATCCGAGATAGTGCGCTTTGTCATGGGAAAATGACTATTGAATGTGAGTTT
665Pra_012137_O_2TTTTCTGGTGCATCCTTAACACAGCTTGGTTACATGGTGAATTACAGTATTTGAAGGAGT
666Pra_012582_O_2AGATTTAATGCCACTTAGGTGATCGGTGACCCACTTGTACATATAGATGTTGGCGATGTT
667Pra_015285_O_2AAGAAATTCATCAATTCTTTGAAATTATTGTTCCCTTTTGATGCGGCCCCTTTCTGGAGG
668Pra_017229_O_1TAAAGTATATTTTAGCCGCTGTTGTTGTAAATTTATGTTTTTCATTGCTATCAACATTTA
669Pra_020724_O_2GGTTTTCCTATAAGATGTATGAATTCGCACTGTGGTGCAATTTTATGAATTAAACTCAAA
670Pra_004555_O_1TTTACTATTCCGTCTGGGCTTAGAGATGTACGTTAATTGGTCATTTAAGACGACTCAGTT
671Pra_004556_O_5TCAAATCTAGTCAATATCCGTGTTGAGCTAAACAAGCGCTGAAAGTTTGCTCGAATCAGC
672Pra_005729_O_2AGAAAGTTGTGTACTAATTTGTATTGTAACGTCCATTTATCCAACGAGTCCTCCATTCAT
673Pra_007395_O_3CAGTACTGTATTCGAAGATCCTGAAAATTTACTAAAACAAATGGAATATCAACAACCTAG
674Pra_009503_O_1TTGCTCTATATAATTTGTGCTCGTGTGTGTACTTGAAGATCCATCCTCACATAGTCCAAT
675Pra_011283_O_1GTGTGTATAGTTTTATAACACTCTATGGTATCACTACCACTATGGGCCTGTTTAGTCCAA
676Pra_012322_O_3GAAGCAGAATCAGCTTTGACCAGTATTTAGTGTCTTGTATACAATTCTTGTTTCAGTGAA
677Pra_023236_O_3AAATCAAGATTAAAATCCGAAACCAAGGCTAACCAGCAAACTGTGAGGTGTACATTGTTG
678Pra_000171_O_2TTCCAAGCAGAAGGGCACATGTTGTGACATCAAGTAGTAGATTGTTCTGCAGATTCTGGT
679Pra_000172_O_1GTTAATGTAATACATTTAGTTTTTAGATAACTGTTAATGTGTAGTAAAGCACTAGGAAGA
680Pra_001480_O_3GAGGCTTCAAAGGTTTTTGTGTCTTTTCTAGTTATTATAAACGCTTCATAGGTTCCTAGG
681Pra_001692_O_2GAAGATTGTAAGTTGGGTGAACTTTTTTACCACGCTAGGTTGATCTATTTTAAGACTCTT
682Pra_005313_ORF_O1AAAATAGCTGCGCGTACCACAAAGGTGACAAACGCCGGATTTCTCTTATCAGACTTGTCA
683Pra_006362_O_1TTTAATTATCATAGTTTTATTCCGGCTATCTTGATCATTCACGGAAGTCCCGAGAGTCAA
684Pra_006493_O_3GTGGAGTGAACGTGGTTACTTCAATGGATTACCCTTCTATCGTGTCATTAAACACTTTGT
685Pra_006983_O_1GCTAACTCTTCTAGTTGAGATCTCCATCAATTAATGGATACAAACATTGAGTTTCACTTT
686Pra_007665_O_1GGATCACTACTGGATTCCGTTACATTAGTTATTGCAAGTTGGTTATTATGTACGTTTATA
687Pra_012196_O_1ATGAACAAATGCAATTACCCTGTTTTATTCTATCCCGCTTTAATTAATATTGGTCATGTT
688Pra_013382_O_1TTTGCTTGTGGATTGTACTGTGGTACATGGTATAAATCTATAGGCTATGTCGATTATTTT
689Pra_016461_O_1ATATAAGATATAAGATATTGCCAGCAAACTATTTGACAGGTTATTTAATAAAGTGTGCTA
690Pra_017611_O_1TTTTAAATGTGGACAGAGGCACTATAAGAATGCGAAATATCGTCGGAGCACGACTAATTG
691Pra_019776_O_1ATAGACTAGTTCTACAAAGCCCTAGGATGATGGACTTCATTTCTTTTGCATTAAGATGAA
692Pra_020659_O_1GATTTCTTATGGGGTTGGAACATTCCTCGCTGCCTTCTGGTAATATTAGGTTATGCGTTT
693Pra_022559_O_3AATTGAGGTTGACTGTGTACTTCTCCAGTGGACAGGAGAAAGCGATAAAATTCAAACGTT
694Pra_024188_O_5AAGGAAGGGCAAATAGAGCTCGCGCTCAAGAAATACCTTAAATCGATACGGTATTTGGAT
695Pra_027973_O_2TAATTTAAGAGCTATGAAACAACTACCTTTTGGAATGGTTTTGTTTTTAGCATCCCAATT
696Pra_001353_O_1TTGTAAATTATGCTGGTTCCATATGGGGGTTAATCAGTATCCTGGTTATTTGTGACACCA
697Pra_001978_O_3GTTGTGAACTATCAATAGACGGGGATGGTCCTTTTTAGCTGCTCCTTAAGCAGCTCAAAT
698Pra_002810_O_2TCAATTCCGGTCATATGTAGACGACTATAATGTTGTTTGTGTCCTATAACTATAGTGTTG
699Pra_002811_O_1CATTTTACACCCTATAACAAAATATAGTGTCATAAGTTTACACCAGGTAACAACTCTATA
700Pra_002812_O_3ATGGAGAGTTTTATTCATTACATGAAAGAGTATGTCACCTTTCGTGCTCCATCTATTGAT
701Pra_003514_O_1TTTCACGTCCTGTATACTCACTCAAGCAACTTTAGGATGAAGAGCTAAAGTATATCAAAG
702Pra_004104_O_2AATGCACTCTTTATAAAGTGGGATGAGGTATGTGTTTCCTTCCTATTGGCTAACCTGAAT
703Pra_005595_O_1ATTGGGCAATCGTTATTGATTTTACCTATCGCTATCTCACTGTCCGCCAATTTAGTGTAA
704Pra_005754_O_1TTTCAGCGGATATAAAGTCTTCCAACTTGTAAACCGGTGCTGTGAAGATTAAAAGTCCTT
705Pra_006463_O_1GCTTTAGAGGCAATGGTAGATTATGAAGTCAACACCAGGGAGTTTGACCGTTTGGGACAT
706Pra_006665_O_1CATTCAATTTGACATTGGAGTTTCAAGGCATTCCAAGGATAGCATGTACACAAGTTGAAT
707Pra_006750_O_1CATAAAATTACTATGGAAGTTGGATCATTATCTATGCCATAGTGGAGTAGAACTAGATTT
708Pra_007030_O_1CTCTTGATTCTAGAATCTAAACTACTACCTTGCGGACATGACTGAGCATCTCTCTAACAG
709Pra_007854_O_1CAGGGTTGTGCTAGTTTAACATTTTAACTTAATGTAATCATGTAAGCTTTAGAGAGGTGG
710Pra_007917_O_1GTAAATGTTTACATTGAGGTCATGCATGAGTGTTAATTACGCTTTCACTACTGTTCACTT
711Pra_007989_ORF_O2AATTAAAGCTTGGTTGTATGATCATTTGGGATCGAGAGTAGATTATGATGCTCCTGGGCA
712Pra_008506_O_1TTATCTAGCTAGAAGTTGTGAAATTAAGAGGGATGTGAGGATTGGGTTATAACTAGTGTA
713Pra_008692_ORF_O2AATGAATCAGGCATTAAAGCGGGAATCATTTATGACTTGGCAACCTGAAAATTCTATTAA
714Pra_008693_O_2TTCTTGACGTTTTAATATGGTATGGTATTAAATTTGGAAGGCCTATTCGATTGTTTGCAA
715Pra_009170_O_1TTCTTATAACCTGTACGATTGCCGATATATCACCAATTTTGCTGATTTTAATCTGAGTTT
716Pra_009408_O_1CAATTTCATATTCGGGTTCAATGTAGTGCCTCTCATTTTAGGGTGATAGCATGAGTTTTT
717Pra_009522_O_1TCCACAAGTTAACATAGGTAACTATCGACTGAAGTGAACTGGGGGGCAGAAGCTAACTAT
718Pra_009734_O_2TTTAGATAGCCATTTACATTTTACTTATTATTGGACTTGTAAAGATTTTTGTACCCTTGT
719Pra_009815_O_4TTGCTGAAATATTTCAAGCTGAAAGTTATGATTCTGGCCAAGAAGTCTACTGAAAATTTG
720Pra_010670_O_2AAACATAAGTTTGGCCCAGATTCGGTTTATCATAAAATCTGGCTGCATATAAGGTGTCAG
721Pra_011297_O_1ATGTTCTAGAATTTGTCTAAGCTAGCTACTGGTGTTTAACTGATATGGAAAACTTTTGCC
722Pra_013098_O_2TTTGGGGAGTACTTTAGTCAATAAAAGTGAAGTGAATCATGATATAAAGGGTTTAAGTAA
723Pra_013172_O_2AGAAGTTACTAATTTGTAGATAAATTCTAACGAAGGTGATGATAGCATACACGTAATGAA
724Pra_013589_O_2GAATTTTGATGGTAGCGTATGGTTGAAGGAAAACTTGGATATATCATGTAAACATTTTTC
725Pra_013608_O_1TTAATGAACCGCTTTTTCCTTGAGAGGCTATGAATGCCTGTAGAACTAATCCTTTAAGTA
726Pra_014299_O_2TTTCTCTAACACTATATTTTCTGGTATGACCGCTCTACATTGTATATTAACCCTTGCAAA
727Pra_014498_O_1TATATTCACTGTGCTGGGATTATCCTCTCCCCTTTTTGACCCACTGTTGTGTGTATTTGA
728Pra_014548_O_1GAGCATACAGCGTTATCTTTGAGACGAGTCATCAATGATAATATCCTCGTAAAAGGTTAC
729Pra_014610_O_2TTTATTCAATTACGACGGATTCAGTTGGCCTTTTGTAACATTCAAGTATCCATCTATCAC
730Pra_016090_O_2ATGTTCAGGGGTATTAAAAATTCAGAGGATAAATTTCCTCACTCTCAAGTGTTAGATGGT
731Pra_016722_O_2CAAAGTCTAGACGTTAATGTTTTGGAACTCTTTTTTCGAATTTGTGCCTATTGAATCACT
732Pra_016785_O_3TATAAATATATTGTACTGGGGATCCAAGACATGGCAATATATGTCGAGATTTTCATTTTC
733Pra_017094_O_3CTTTTGCATGAGTTCAAATGTCTTTGTGACATATTGTCTTGAACCACCGAGGATATATCA
734Pra_017527_O_2GTTTGTATGTCCAATAGATTATAACCTATTTACTGTGACACTATTCTTCACACCCATGTC
735Pra_017591_ORF_O2AGATCTAGTTGTTTCAGCATCGTTGGACCAAACTGTTCGTGTATGGGATATAAGTGGCCT
736Pra_017769_O_2TGCCGTATCAAAAGATTGGTACTTCCTTATGGACACACAAGATCGTAAGCATGGCTGAAT
737Pra_018047_O_2TTGATGGCCACATGAGTTGTTTATACAAGTCGTTGTTTTATGAGAGAACCTTCTTCAGAT
738Pra_018414_O_1ATTTCTATAGTGCCATATGCTTGTCGGTTGTCATTGACCTCTAATAGAATAGCCAGAGTA
739Pra_018986_O_1TTCACGGCAGTTGAACTAGTCATAGTGGAATATTATTTAAATGGTGTATTCTAGTCACAT
740Pra_019479_ORF_O1TGCAGGCGCTCTATAGTTCTGTTCTCTAGCATGAAGTGTGTATTTTATCTATTGTGGACC
741Pra_020144_O_1TGTCTTTAATCTTCAGGGTTCGTTACTAACAATTGAGCTCAAATCTCTATTCTGACCAGC
742Pra_022480_O_1CATTTATAGAGTTGTGCAAAATCACCCATAATGCTATGAATTGACAGGTGACTGTAATCT
743Pra_023079_O_2GGAGAAAATTTCCTATCCCTTTGTGGGTGTGTGAAAAACGAAATATAGAGGAACAATGTG
744Pra_026739_O_2ACCAATCATTTATTTGCAGTGTAGTTGATATGAAGGGAGAAATATGACAGTTGGTTTCAA
745Pra_026951_O_2AAGTTAATGTTCTCATAGGTTATTCATTGGAGTTGTCTCGTATGTACGCTGTGCCGTAGT
746Pra_026529_O_2CTCATAAATTGAGGCTTGCCTACGTTAATTGTTATATATGGAGAGCCATGCTAATTGTTA
747Euc_006366_O_2GCAGATCATGTAATTGTATCTCAAATTATAGTATCCGTATTCTGTACAAATGCTCCGGAA
748Euc_017378_O_1TCTTTACGCAGATGGTGACTGAAGCTGGTTCCGAGATCGGCATATGTAGCTGGTAGAGGT
749Pra_000888_O_1TTCACATTGAGGGTTGCCGTCGGTATTCGCCGATGATATCCTGTTTTACGCGCAACAGTT
750Pra_014166_O_1TCATTATTTAGGGTGCAGGCTGTATAAAATGTTGTAAATTGTAGTATCAATGTGTACAAT
751Pra_003189_O_1GCATTCACCACGACAGTAAAGTAATCATTATGATTACTAATGTATTGCTTTCATGGGGTG
752Pra_009356_O_4AAAGGGTATATTTTGTCTCATGTTGGGGTGATAATTCTCCCTGAAAGTCTCCAAAATATA
753Pra_000065_ORF_O_2AAATTTCCGGTTGCCATAGTCTAGTGGGGTGAGGGTTCATTCTAGGGGATTTATTGTGTT
754Pra_014197_ORF_O1GCAGTGATAAAGGTACTTCTTGGTGATAATCCTAAAGCCTTACCCATGGATATCCAGCCT
755Pra_009081_O_2TTCTTTAACAAGGTAAAAATCCCCCCCTTGGCATGTAGCTCAATTAGTTGTAATGGAACT
756Pra_013417_O_1AGTTGTAAACAGTGTAATAAGGAGCAGAAGTTGTGATAGCTTTTAGGAACGATAGACTTT
757Pra_005755_O_1TGAACCAATTCTTGTATATTAGATATGTAACATGTATGAATGTCCATAGAGCAGAGCTTT
758Pra_006670_O_2AGCCAGGCACGCTTAACTAAATTTCGTTTAGTTCACCATGACTATTCGTTGAACTTAATG
759Pra_007027_O_1CAAAACCCCTTGTAGGGTGGACTTCTGTTGTATCCAATTTTTATGGCATAATTAGCTAGT
760Pra_007276_O_1AATTTGGTGATTATTCCTTACCATATCGTACTGTACAGATACGGTAAGGTCGAAATATAT
761Pra_007390_ORF_O1CATGCCGTGATCGGTCGATTGCATTAAGTGCTGCAAGGATCAAATAGTGGCACTGTCATG
762Pra_012648_ORF_O1CAAACATAAATAAGGTTGCTACTTTAAAGGGACATACGGAACGAGTTACTGATGTGGCAT
763Pra_013171_O_2ATTTATGGATGAGGTACTCCTTATGAATATCTTCAAACTAAGAAATAACTATATATGCAA
764Euc_045414_O_2CTTGGTTTTTGTTGAGCTTTCTATTTCAAGCAATTTGTGATTGGGGGGTTCTGCATTCTT
765Euc_044328_O_2ATGTCTAAAGAGCCGTGATCTATGAGTAGATTAGAAACCGCCTTTTTAGTTGCAAACGCC
766Euc_015615_O_2TTGCAACAAGGTATACTTAGTCAGTCCTTGTTATGTATGTCTTTTGTCAACCCTTCAGGG
767Euc_017239_O_3GGCGGAATCCCTTTGTTCTTTCGAGCTTTACGTGACAAGTCGGCCAGAAAGCAGTAGCAT
768Euc_018643_O_3TTGATGTACGAGCCGCTATATCTAATTCTGCCTCCCAGTCACTGCCAAGTTTTACTCTTC
769Euc_019127_O_5GTCTTGCATGTCAGCTATTATACAGTCCTGTTTATAGTCCTGTGATGTAATAAAAAGCTG
770Euc_022624_O_3AAGTAGGAGATCGTGTAGAGAGAATACTTTCTGCTCTCAGCGGCGAAGAGGTTTGTCTGC
771Euc_032424_O_1AATTGTGAGTAGAATAGGAGAAACTTTTGTACAAGATTAATACGTGTGGCATAATAAGAT
772Euc_037472_O_1TGATGTGCAGTTTACATTATTATGGTTCGAGTATTATTTAGCTGCCCTATCTTAAGTCAT
TABLE 15 — Peptide Table.
PatentPatent
ProteinORFORF
SEQ IDTargetPatent PEPTIDE Sequencestartstop
261CDK type AMGDGSLGSGGRGNSGGGGGGGSRPEWLQQYDLIGKIGEGTYGLVFLARIKHPST3871820
NRGKYIAIRKFKQSKDGDGVSPTAIREIMLLREISHENVVKLVNVHINPVDMSL
YLAFDYADHDLYEIIRHHRDKVNQAINPYTVKSLLWQLLNGLNYLHSNWIIHRD
LKPSNILVMGEGEEQGVVKIADFGLARVYQAPLKPLSDNGVVVTIWYRAPELLL
GAKHYTSAVQMWAVGCIFAELLTLKPLFQGQEVKANPNPFQLDQLDKIFKVLGH
PTQEKWPMLVNLPHWQSDVQHIQRHKYDDNALGHVVRLSSKNATFDLLSKMLEY
DPQKRITAAQALEHEYFRMEPLPGRNALVPSSPGDKVNYPTRPVDTTTDIEGTT
SLQPSQSASSGNAVPGNMPGPHVVTNRPMPRPMHMVGMQRVPASGMAGYNLNPS
GMGGGMNPSGIPMQRGVANQAQQSRRKDPGMGMGGYPPQQKQRRF
262CDK type AMEKYQQLAKIGEGTYGIVYKAKDKKSGELLALKKIRLEAEDEGIPSTAIREISL991007
LKQLQHPHIVRLYDVVHTEKKLTLVFEFLDQOLKKYLDACGDNGLEPYTVKSFL
YQLLQGIAFCHEHRVLHRDLKPQNLLINMEGELKLADFGLARAFGIPVRNYTHE
VVTLWYRAPDVLMGSRKYSTQVDIWSVGCIFAEMVNGRPLFPGSSEQDQLLRIF
KTLGTPSLKTWPGMAELPDFKDNFPKYVVQSFKKICPKKLDKTGLDLLSRMLQY
DPAKRISAEQAMGHPYFKDLKLRKPKAAGPGP
263CDK type AMDQYEKIEKIGEGTYGVVYKAIDRSTNKTIALKKIRLEQEDEGVPSTAIREISL1201004
LKEMQHGNIVKLQDVVHSERRLYLVFEYLDLDLKKHMDSCPEFSKDTHTIKMFL
YQILRGISYCHSHRVLHRDLKPQNLLLDRRTNSLKLADFGLARAFGIPVRTFTH
EVVTLWYRAPEILLGSRHYSTPVDVWSVGCIFAEMVNRRPLFPGDSEIDELFKI
FRIMGTPNEDSWPGVTSLPDFKSTFPKWASQDLKTVTPTVDPAGIDLLSKMLCM
DPRRRITAKVALEHEYFKDVGVIP
264CDK type AMVMKSKLDKYEKLEKLGEGTYGVVYKAQDKTTKEIYALKKIRLESEDEGIPSTA23937
IREIALLKELQHPNVVRIHDVIHTNKKLILVFEFVDYDLKKFLHNFDKGIDPKI
VKSLLYQLVRGVAHCHQQKVLHRDLKPQNLLVSQEGILKLGDFGLARAFGIPVK
NYTNEVVTLWYRAPDILLGSKNYSTSVDIWSIGCIFVEMLNQKPLFPGSSEQDQ
LKKIFKIMGTPDATKWPGIAELPDWKPENFEKYPGEPLNKVCPKMDPDGLDLLD
KMLKCNPSERIAAKNAMSHPYFKDIPDNLKKLYN
265CDK type AMDQYEKVEKIGEGTYGVVYKAIDRLTNETIALKKIRLEQEDEGVPSTAIREISL1491003
LKEMQHGNIVRLQDVVHSENRLYLVFEYLDLDLKKHMDSSPDFAKDPRLVKIFL
YQILRGIAYCHSHRVLHRDLKPQNLLIDRRTNALKLADFGLARAFGIPVRTFTH
EVVTLWYRAPEILLGSRHYSTPVDVWSVGCIFAEMVNQRPLFPGDSEIDELFKI
FRILGTPNEDTWPGVTALPDFKSAFPKWPAKNLQOMVPGLNSAGIDLLSKMLCL
DPSKRITARSALEHEYFKDIGFVP
266CDK type B-1MEKYEKLEKVGEGTYGKVYKAKDKATGQLVALKKTRLEMDEEGVPPTALREVSL1991116
LQLLSQSLYVVRLLSVEHVDGGSKRKPMLYLVFEYLDTDLKKFIDSHRKGPNPR
PVPAATVQNFLYQLLKGVAHCHSHGVLHRDLKPQNLLVDKEKGILKIADLGLGR
AFTVPLKSYTHEVVTLWYRAPEVLLGSAHYSIGVDMWSVGCIFAEMVRRQALFP
GDSEFQQLLHIFRLLGTPTEKQWPGVTTLRDWHVYPQWEPQNLARAVPSLGPDG
VDLLSKMLKYDPAERISAKAALDHPFFDSLDKSQF
267CDK type B-2MERPATAAVSAMEAFEKLEKVGEGTYGKVYRAREKATGKIVALKKTRLHEDEEG41982
VPPTTLREISILRMLSRDPHIVRLMDVKQGQNKEGKTVLYLVFEYMETDLKKYI
RGFRSSGESIPVNIVKSLMYQLCKGVAFCHGHGVLHRDLKPHNLLMDKKTLTLK
IADLGLARAFTVPIKKYTHEILTLWYRAPEVLLGATHYSTAVDMWSVGCIFAEL
VTKQALFPGDSELQQLLHIFRLLGTPNEKMWPGVSSLMNWHEYPQWKPQSLSTA
VPNLDKDGLDLLSQMLHYEPSRRISAKAAMEHPYFDDVNKTCL
268CDK type CMGCVLGREVSSGIVTESKGRDSSEVETSKRDDSVAAKVEGEGKAEEVRTEETQK2912042
KEKVEDDQQSREQRRRSKPSTKLGNLPKHIRGEQVAAGWPSWLSDICGEALNGW
IPRRANTFEKIDKIGQGTYSNVYKAKDLLTGKIVALKKVRFDNLEPESVRFMAR
EILILRHLDHPNVVKLEGLVTSRMSCSLYLVFEYMEHDLAGLAASPAIKFTEPQ
VKCYMHQLLSGLEHCHNRRVLHRDIKGSNLLIDNGGVLKIGDFGLASFYDPDHK
HRMTSRVVTLWYRPPELLLGANDYGVGIDLWSAGCILAELLAGKPIMPGRTEVE
QLHKIYKLCGSPSEEYWKKYKLPNATLFKPREPYRRCIRETFKDFPPSSLPLIE
TLLAIDPAERGTATDALQSEFFRTEPYACEPSSLPQYPPSRKMDAKKRDDEARR
LRAASKGQADGSKKERTRDRRVRAVPAPEANAELQHNIDREKLISHANAKSKSE
KFPPPHQDGALGFPLGASHRFDPAVVPPDVPFTSTSFTSSKEHDQTWSGPLVDP
PGAPRRKKHSAGGQRESSKLSMGTNKGRRADSHLKAYESKSIA
269CDK type CMYSKSSAVDDSRESPKDRVSSSRRLSEVKTSRLDSSRRENGFRARDKVGDVSVM1072236
LIDKKVNGSARFCDDQIEKKSDRLQKQRRERAEAAAAADHPGAGRVPKAVEGEQ
VAAGWPVWLSAVAGEAIKGWLPRRADTFEKLDKIGQGTYSSVYKARDVTNNKIV
ALKRVRFDNLDTESVKFMAREIHILRMLDHPNVIKLEGLITSRMSCSLYLVFEY
MEHDLTGLASRPDVKFSEPQIKCYMKQLLSGLDHCHKHGVLHRDIKGSNLLIDN
NGILKIADFGLASVFDPHQTAPLTSRVVTLWYRPPELLLGASRYGVEVDLWSTG
CILGELYTGKPILPGKTEVEQLHKIFKLCGSPSDDYWRRLHLPHAAVFKPPQPY
RRCVAEIFKELPPVALGLLETLISVDPSQRGTAAFALRSEFFTASPLPCDPSSL
PKYPPSKEIDMKLREEEARRRGAAGGKNELEKRGTKDSRTNSAYYPNAGQLQVK
QCHSNANGRSEIFGPYQEKTVSGFLVAPPKQARVSKETRKDYAEQPDRASFSGP
LVPGPGFSKAGKELGHSITVSRNTNLSTLSSLVTSRTGDNKQKSGPLVSESANQ
ASRYSGPIREMEPARKQDRRSHVRTNIDYRSREDGNSSTKEPALYGRGSAGNKI
YVSGPLLVSSNNVDQMLKEHDRRIQEHARRARFDKARVGNNHPQAAVDSKLVSV
HDAG
270CDK type CMGCIPTIISDGRRRSAAPDKRRPRPRRSSSEGEAPPHATAAGSEGGESARGAPG821749
KERPEPAPRFVVRSPQGWPPWLVAAVGHAIGEFVPRCADSFRKLAKIGEGTYSN
VYKARDLVTGKTVALKKVRFDNLEAESIKFMAREILVLTRLNHPNVIKLEGPVT
SRMSSGLYLAFEYMEHDLSGIAARQNGKFTEPQVKCFMRQLLSGLEHCHNHDVL
HRDIKCSNLLIDNEGNLKIADFGLATFYDPERKQVMTNRVVTLWYRAPELLLGA
TSYGIGIDLWSAGCILAELLYGKPIMPGRTEVEQLHKIFRLCGSPSEAYWNKFK
LPNANIFKPPQPYARCIAETFKDFPPSALPLLETLLSIDPDERGTATTALNSEF
FAAEPHACEPSSLPKYPPSKEMDLKLIKEKTRRDSSKRPSAIHGSRRDGIHDRA
GRVIPAPEATAENQATLHRPRAMKKANPMSRSEKFPPAHNDGVVGSSANAWLSG
PASNAAPDSRRHRSLNQNPSSSVGKASTGSSTTQETLKVAPELLQVGSSSLHPC
HRMLVYGSNLTIRSK
271CDK type CMGCICAKQADRGPASPGSGILTGAGTGTGTRSSKIPSGLFEFEKSGVKEHGGRS1511560
GELRKLEEKGSLSKRLRLELGFSHRYVEAEQAAAGWPSWLTAVAGDAIQGLVPL
KADSFEKLEKIGQGTYSSVFRARELANGRMVALKKVRFDNFQPESIQFMAREIS
ILRRLDHPNIMKLEGIITSRMSNSIYLVFEYMEHDLYGLISSPQVKFSDAQVKC
YMKQLLSGIEHCHQHGVIHRDVKSSNILVNNEGILRIGDFGLANILNPKDRQQL
TSHVVTLWYRPPELLMGSTSYGVTVDLWSVGCVFAELMFRKPILRGRTEVEQLH
KIFKLCGSPPDGYWKMCKVPQATMFRPRHAYECTLRERCKGIATSAMKLMETFL
SIEPHKRGTASSALISEYFRTVPYACDPSSLPKYPPNKEIDAKHREEARRKKAR
SRVREAEVGKRPTRIHRASQEQGFSSNIAPKEKRSYA
272CDK type CMAVAAPGHLNVNESPSWGSRSVDCFEKLEQIGEGTYGQVYMAKEKKTGEIVALK821644
KIRMDNEREGFPITAIREIKILKKLHHENVIKLKEIVTSPGPEKDEQGRPEGNK
YKGGIYMVFEYMDHDLTGLADRPGMRFSVPQIKCYMRQLLTGLHYCHINQVLHR
DIKGSNLLIDNEGNLKLADFGLARSFSNDHNANLTNRVITLWYRPPELLLGATK
YGPAVDMWSVGCIFAELLHGKPIFPGKDEPEQLNKIFELCGAPDEINWPGVSKI
PWYNNFKPTRPMKRRLREVFRHFDRHALELLERMLTLDPSQRISAKDALDAEYF
WADPLPCDPKSLPKYESSHEFQTKKKRQQQRQHEETAKRQKLQHPPQHPRLPPV
QQSGQAHAQMRPGPNQLMHGSQPPVATGPPGHHYGKPRGPSGGAGRYPSSGNPG
GGYNHPSRGGQGGSGGYNSGPYPPQGRAPPYGSSGMPGAGPRGGGGNNYGVGPS
NYPQGGGGPYGGSGAGRGSNMMGGNRNQQYGWQQ
273CDK type CMGCICTKGILPAHYRIKDGGLKLSKSSKRSVGSLRRDELAVSANGGGNDAADRL6262782
ISSPHEVENEVEDRKNVDFNEKLSKSLQRRATMDVASGGHTQAQLKVGKVGGFP
LGERGAQVVAGWPSWLTAVAGEAINGWVPRRADSFEKLEKIGQGTYSSVYRARD
LETNTIVALKKVRFANMDPESVRFMAREIIIMRKLDHPNVMKLEGLITSRVSGS
LYLVFEYMDHDLAGLAATPSIKLTESQIKCYMQQLLRGLEYCHSHGVLHRDIKG
SNLLVDNNGNLKIGDFGLATFFRTNQKQPLTSRVVTLWYRPPELLLGSSDYGAS
VDLWSSGCILAELFAGKPIMPGRTEVEQLHKIFKLCGSPSEEYWKKSKLPHATI
FKPQQPYKRCLLETFKDFPSSALGLLDVLLAVEPECRGTASSALQNEFFTSNPL
PSDPSSLPEYPSSEEFDARLRDEEAREHEATAGEARGLESIREGSEESEVVPTS
NANADLEASIQERQEQSNPRSTGEEPGGTTQNNFILSGQSAEPSLNGSTQIGNA
NSVEALIVPDRELDSPRGGAELRRQRSFNQRRASQLSRFSNSVAVGGDSHLDCS
REEGANTQWRDEGFVARCSHPDGGELAGKHDWSHHLLHRPISLFEEGGEHSRRD
SIASYSPEKGRIHYSGPLLPSGDNLDEMLEEHERQIQNAVREARLDEVETEREY
ADHGQTESLLCWANGR
274CDK type DMDPDPSPDPDPPESWSIHTRREIIARYEILERVGSGAYSDVYRGRRLSDGLAVA131467
LEEVHDYQSAFREIEALQILRGSPHVVLLHEYFWREDEDAVLVLEFLRSDLAAV
IADASRRPRDGGGGGAAALRAGEVERWMLQVLEGVDACHRNSIVHRDLEPGNLL
ISEEGVLEIADFGQARILLDDGNVAPDYEPESFEERSSEQADILQQPETMEADT
TCPEGQEQGAITREAYLREVDEFEAENPRHEIDEETSIFDGDTSCLATCTTSDI
GEDPFKGSYVYGAEEAGEDAQGCLTSCVGTRWFRAPELLYGSTDYGLEVDLWSL
GCIFAELLTLEPLFPGISDIDQLSRIFNVLGNLSEEVWPGCTELPDYRTISFCE
IENPIGLESCLPNCSSDEVSLVRRLLCYDPAARATPMELLQDEYFTEEPLPVPI
SALQVPQSENSHDEDSAGGWYDYNDMDSDSDFEDFGPLEFTPTSTGFSIQFP
275CDK type DMDPDPSPSPDPPKSWSIHTRREIIARYEILERVGSGAYSDVYRGRRLSDGLAVA1131558
LKEVHDYQSAFREIEALQILRGSPHVVLLHEYFWREDEDAVLVLEFLRSDLAAV
IADASRRPRGGGVAPLRAGEGKRWMLQVLEGVDACHRNSIVHRDLKPGNLLISE
EGVLKIADFGQARILLDDGNVAPDYEPESEEERSSEQADILQQPETMEADTTCP
EGQEQGAITREAYLREVDEFKAKNPRHEIDKETSIYDGDTSCLATCTTSDIGED
PFKGSYVYGAEEAGEDAQGSLTSCVGTRWFRAPELLYGSTDYGLEVDLWSLGCI
FAELLTLEPLFPGISDIDQLSRIFNVLGNLSEEVWPGCTKLPDYRTISFCKIEN
PIGLESCLPNCSSDEVSLVRRLLCYDPAARATPMELLQDKYFTEEPLPVPISAL
QVPQSKNSNDEDSAGGWYDYNDMDSDSDFEDFGPLKFTPTSTGFSIQFP
276Cyclin AMSNQHRRSSFSSSTTSSLAKRHASSSSSSLENAGKAFAAAAVPSHLAKKRAPLG1871686
NLTNLKAGDGNSRSSSAPSTLVANATKLAKTRKGSSTSSSIMGLSGSALPRYAS
TKPSGVLPSVNPSIPRIEIAVDPMSCSMVVSPSRSDMQSVSLDESMSTCESFKS
PDVEYIDNEDVSAVDSIDRKTFSNLYISDAAAKTAVNICERDVLMEMETDEKIV
NVDDNYSDPQLCATIACDIYQHLRASEAKKRPSTDFMDRVQKDITASMRAILID
WLVEVAEEYRLVPDTLYLTVNYIDRYLSGNVMNRQRLQLLGVACMMIAAKYEEI
CAPQVEEFCYITDNTYFKEEVLQMESSVLNYLKFEMTAPTVKCFLRRFVRAAQG
VNEVPSLQLECMANYIAELSLLEYDMLCYAPSLVAASAIFLAKFVITPSKRPWD
PTLQHYTLYQPSDLGNCVKDLHRLCFNNHGSTLPAIREKYSQHKYKYVAKKYCP
PSIPPEFFHNLVY
277Cyclin AMNKENAVGTKSEAPTIRITRSRSKALGTSTGMLPSSRPSFKQEQKRTVRANAKR2381653
SASDENKGTMVGNASKQHKKRTVLNDVTNIFCENSYSNCLNAAKAQTSRQGRKW
SMKKDRDVHQSGAVQIMQEDVQAQFVEESSKIKVAESMEITIPDKWAKRENSEH
SISMKDTVAESSRKPQEFICGEKSAALVQPSIVDIDSKLEDPQACTPYALDIYN
YKRSTELERRPSTIYMETLQKDVTPNMRGILVDWLVEVSEEYKLVPDTLYLTVN
LIDRSLSQKFIEKQRLQLLGVTCMLIASKYEEICPPRVEEFCFITDNTYTSLEV
LKMESRVLNLLHFQLSVPTVKTFLRRFVQAAQVSSEVPSVELEYLANYLAELTL
VEYSFLKFLPSLMAASAVLLARWTLNQSDNPWNLTLEHYTKYKASELKAAVLAL
EDLQLNTSGSTLNAIREKYRQQKVNYSLLIHSKANHEIL
278Cyclin BMAGSDENNPGVVGGAHVQEGLRVGAGKMGAGNVQQRRALSNINSNIIGAPPYPC2351539
AVNKRVLSEKNVNSENDLLNAAHRPITRQFAAQMAYKQQLRPEENKRTTQSVSN
PSKSEDCAILDVDDDKMADDFPVPMFVQHTEAMLEEIDRMEEVEMEDVAEEPVT
DIDSGDKENQLAVVEYIDDLYMFYQKAEASSCVPPNYMDRQQDINERMRGILID
WLIEVHYKFELMDETLYLTVNLIDRFLAVQPVVKKKLQLVGVTAMLLACKYEEV
SVPVVEDLILISDRAYSRKEVLEMERLMVNTLHFNMSVPTPYVFMRRFLKAAQS
DKKLELLSFFIIELSLVEYDMLKFPPSLLAASAIYTALSTITRTKQWSTTCEWH
TSYSEEQLLECARLMVTFHQRAGSGKLTGVHRKYSTSKFGHAARTEPANFLLDF
RL
279Cyclin BMASRPIVPVQARGEAAIGGGAGKAAIGGGAGKQQKKNGAAEGRNRKALGDIGNL1581618
VTVRGIEGKVQPHRPITRSFCAQLLANAQAAAAAENNKKQAVVNVNGAPSILDV
PGAGKRAEPAAAAAAAVAKAAQKKVVKPKQKAEVIDLTSDSERAIEAKKKQQHH
EPTKKEGEKSSRRNMPTLTSVLTARSKAACGMTKKPKEKVVDIDAGDAHNELAA
FEYIEDIYTYYKEAENESLPRNYMSSQPEINEKMRAILVDWLIEIHNKFDLMPE
TLYLTINIIDRFLSVKAVPRRELQLLGMGALFTASKYEEIWAPEVNDLVCIADR
AYSHEQVLAMEKTILGKLEWTLTVPTHYVFLVRFIKASLGDRKLENMVYFLAEL
GVMNYATLTYCPSMVAASAVYAARCTLGLTPLWNDTLKLHTGFSESQLMDCARL
LVGYHAKAKENKLQVVYKKYSSSQREGVALIPPAKALLCEGGGLSSSSSLASSS
280Cyclin BMGLPDENNAALSKPTNLQVGGLEIGGRKFGQEIRQTRRALSVINQNLVGDRAYP2051530
CHVVNKRGHSKRDAVCGKDQVDPVHRPLTRKFAAQTASTQQHCIEEAKKPRTAV
QERNEFGDCIFVDVEDCQPSSENQPVPMFLEIPESRLDDDMEEVEMEDIVEEEE
EEPIMDIDGRDKKNPLAVVDYIEDIYANYRRTENCSCVSANYMAQQAOINEKMR
SILIDWLIEVHDKFDLMHETLFLTVNLIDRFLARQSVVRKKLQLVGLVAMLLAC
KYEEVSVPVVGDLILISDKAYTRKEVLEMESLMLNSLQFNMSVPTPYVFMRRFL
KAAESDKKLEVLSFFLIELSLVEYEMVKFPPSLLAAAAIFTAQCTLYGFKQWTK
TCEWHSNYTEDQLLECARMMVGFHQKAATGKLTGVHRKYGTSKFGYTSKCEPAN
FLLGEMKNP
281Cyclin BMGLPDENNAALSKPTNLQVGGLEIGGRKFGQEIRQTRRALSVINQNLVGDRAYP1741499
CHVVNKRGHSKRDAVCGKDQVDPVHRPLTRKFAAQTASTQQHCIEEAKKPRTAV
QERNEFGDCIFVDVEDCQPSSENQPVPMFLEIPESRLDDDMEEVEMEDIVEEEE
EEPIMDIDGRDKKNPLAVVDYIEDIYANYRRTENCSCVSANYMAQQADINEKMR
SILIDWLIEVHDKFDLMHETLFLTVNLIDRFLARQSVVRKKLQLVGLVAMLLAC
KYEEVSVPVVGDLILISDKAYTRKEVLEMEKLMLNSLQFNMSVPTPYVFMRRFL
KAAESDKKLEVLSFFLIELSLVEYEMVKFPPSLLAAAAIFTAQCTLYGFKQWTK
TCEWHSNYTEDQLLECARMMVGFHQKAATGKLTGVHRKYGTSKFGYTSKCEAAN
FLLGEMKNP
282Cyclin DMAMVQRQGHDPSSPQEQEDGPSSFLSDDALYCEEGRFEEDDGGGGGQVDGIPLF941332
PSQPADRQQDSPWADEDGEEKEEEEAELQSLFSKERGARPELAKDDGGAVAARR
EAVEWMLMVRGVYGFSALTAVLAVDYLDRFLAGFRLQRDNRPWMTQLVAVACLA
LAAKVEETDVPLLVELQEVGDARYVFEAKTVQRMELLVLSTLGWEMHPVTPLSF
VHHVARRLGASPHHGEFTHWAFLRRCERLLVAAVSDARSLKHLPSVLAAAAMLR
VIEEVEPFRSSEYKAQLLSALHMSQEMVEDCCRFILGIAETAGDAVTSSLDSFL
KRKRRCGHLSPRSPSGVIDASFSCDDESNDSWATDPPSDPDDNDDLNPLPKKSR
SSSPSSSPSSVPDKVLDLPFMNRIFEGIVNGSPI
283Cyclin DMEASYQPHHHGHLRQHDPSSSQQEEQVPFDALYCSEEHWGEEDEEEGLASDGLL1761342
SEERDHRLLSPRALLDQDLLWEDEELASLFSKEEPGGMRLNLENDPSLADARRE
AVEWIMRVHAHYAFSALTALLAVNYWDRFTCSFALQEDKPWMTQLSAVACLSLA
AKVEETQVPLLIDFQVEDSSPVFEAKNIQRMELLVLSSLEWKMNPVTPLSFLDY
MTRRLGLTGHLCWEFLRRCEMVLLSVISDCRFTCYLPSVIAASTMLHVINGLKP
RLDVEDQTQLLGILAMGMDKIDACYKLIDDDHALRSQRYSHNKRKFGSVPGSPR
GVMELCFSSDGSNDSWSVAASVSSSPEPHSKKSRAGEEAEDRLLRGLEGEEDDP
ASADIFSFPH
284Cyclin DMALQEEDTRRHYPTAPPFSPDGLYCEDETFGEDLADNACEYAGGGARDGLCEIK1501283
DPTLPPSLLGQDLFWEDGELASLVSRETGTHPCWDELISDGSVALARKDAVGWI
LRVHGHYGFRPLTAMLAVNYLDRFFLSRSYQRDRPWISQLVAVACLSVAAKVEE
TQVPILLDLQVANAKFVFESRTIQRMSLLLMSTLDWRMNSVTPISFFDHILRRF
GLTTNLHRQFFWMCERLLLSVVADVRLASFLPSVVATAAMLYVNKEIEPCICSE
FLDQLLSLLKINEDRVNECYELILELSIDHPEILNYKHKRKRGSVPSSPSGVID
TSFSCDSSNDSWGVASSVSSSLEPRFKRSRFQDQQMGLPSVNVSSMGVLNSSY
285Cyclin-MGQIQYSEKYFDDTYEYRHVVLPPDVAKLLPKNRLLSENEWRAIGVQQSRGWVH101367
dependentYAIHRPEPHIMLFRRPLNYQQQQENQAQQNMLAK
kinase
regulatory
subunit
286HistoneMGSIDPPKAEQNGTAAAAVADPGQKPGAGDAMPPPPPVKHSNGTAAEPDVATKR91352
acetyltransferaseRRMSVLPLEVGTRVMCRWRDGKYHPVKVIERRKLNPGDPNDYEYYVHYTEFNRR
LDEWVKLEQLDLNSVETVVDEKVEDKVTGLKMTRHQRRKIDETHVEGHEELDAA
SLREHEEFTKVKNIATIELGRYEIETWYFSPFPPEYNDCSKLYFCEFCLNFMKR
KEQLQRHMKKCDLKHPPGDEIYRSGTLSMFEVDGKKNKVYGQNLCYLAKLFLDH
KTLYYDVDLFLFYVLCECDDRGCHMVGYFSKEKHSEESYNLACILTLPPYQRKG
YGKFLIAFSYELSKKEGKVGTPERPLSDLGLLSYKGYWTRVLLDILKKHKANIS
IKELSDMTAIKADDILNTLQSLDLIQYRKGQHVICADPKVLDRHLKAAGRGGLE
VDVSKLIWTPYREQG
287HistoneMAQKHSTAPDPAAEFKKRRRVGFSGIDAGVDPNGCFKVYLVSREEEVGAPDSFQ891486
acetyltransferaseLDPVDLSHFFEEEDGKIYGYEGLKISVWVSCVSFHSYAEIAFESKSDGGKGITD
LWTALKNMFGETLVDNKDDFLQTFSKETQFIRSTVSAGEILKHKHSDDHVNDSV
SNLKVGSDVEAVRMIJMGDMTAGHLYSRLVPLVLLLVDGSSPIDVTDSSWELYLL
IQKTSDQQGNFHDRLLGFAAVYRFYHYPDSSRLRLGQILVLPLYQRKGYGRYLL
EVLNWVAIADDVYDFTIEEPVDNLQHLRTCIDVQRLLSFDKVQQAVNSTVSQLK
QGKLSKKTYIPRLLPPPSVVEDARKRFKINKKQFLQCWEILVYLGLDPADKSIQ
DYFSVISNRVRADILGKDSETAGKKVIEVPSDFDPEMSFVMHRAKAGGEANGIQ
VEDNQNKQEEQLQQLIDERLKDIKLIAEKVTQK
288HistoneMAQKHSTAPDPAAEPKKRRRVGFSGIDAGVDPNGCFKVYLVSREEEVGAPDSFC801477
acetyltransferaseLDPVDLSHFFEEEDGKIYGYEGLKISVWVSCVSFHSYAEIAFESKSDGGKGITD
LHTALKNMFGETLVDNKDDFLQTFSKETQFIRSTVSAGEILKHKHSDGHVNDSV
SHLKVGSDVEAVRMLMGDDTAGHLYSRLVPLVLLLVDGSNPIDVTDSSWELYLL
IQKTSDQQGNFHDRLLGFAAVYRFYHYFDSLRLRLGQILVLPLYQRKGYGHYLL
EVLHNVAIADDVYDFTIEEPVDNLQHLRTCIDVQRLLSFDKVQQAVNSTVSQLK
QGKLSKKTYIPRLLPPPSVVEDARKRFKINKKQFLQCWEILVYLGLDPADKSIQ
DYFSVISNRVRADILGKDSETAGKKVIEVPSDFDPEMSFVLHRAKAGGETNGIQ
VEDNQNKQEEQLQQLIDERLKDIKLIAQKVSRK
289HistoneMALPMEFWGVEVKAGQPLKVNPGNAKILHLSQASLGECKSSKGNESVPLHVKFG1601062
deacetylaseDQKLVLGTLSTENFPQLAFDLVFEKEFELSHNWKSGSVYFCGYKSVVEQDQDEF
SDLESDSEEEDLPMIGVENGKVAAQASAKTATASANASKVESSGKQKAKIPQPN
KVDEDDSDEDDDDEDEDESDEEGVDGEADSDEEEDESDEEETPKKAEIGKKKAA
DSATKTPVPAKKSKLPTPQKTDGKKGGHTATPHPAKQAGKNPANSANKSQSPKS
AGQVSCKSCSKTFNSDGALQSHSKAKHGGK;
290HistoneMEFWGVEVKAGQPLKVNPGNAKILHLSQASLGECKSSKGNESVPLHVKFGDQKL1721077
deacetylaseVLGTLSTENFPQLAFDLVFEKEFELSHNWKSGSVYFCGYKSVVHDDDDEFSDLE
SDSEEEDLPNIGVENGKVAAQASAKTATASANASKVESSGKQKASIPQPMKVDE
DDSDEDDDEDDDDEDESDEGVDGEADSDEEEDESDEEETPKKAEIGKKKAADSA
TKTPVPAKKSKLPTPQKTDGKKGGHTATPHPAKQAGKNPANSANKSQSPKSAGQ
VSCKSCSKTFNSDGALQSHSKAKHGGK
291HistoneMEFWGVEVKSGEPLNVEPGAETVVHLSQACLGETKEKTKESVLLYVHIGVQKLV66989
deacetylaseLGTLSADKFPQIPFDLVFEKSFKLSHNWKNGSVFFSGYKTLLPCGSDADSPYSD
SDTDEGLPINVTAQADVPAKKAPVTANANAAKPNLASAKQKVKIVESNEDGKNE
GDDDEDADVSSDDDAEDDSGDEDNVDGGDESSDEDDDDSEEGESSEEEEPKAQP
SKKKPADSVLKTPASDKKSKLETPQKTDGKKASEHVATPYPSKQAGKAIASKGQ
AKQQTPNSNEFSCKPCNKSFKSDQALQSHNKAKHGGS
292HistoneMDTGGNSLPSGPDGVKRRVCYFYDPEVGNYYLLQHMQVLRPVPARDRDLCRFHA1111541
deacetylaseDDYVAFLRSITPETQQDQLRQLRRFNVGEDCPVFDGLHSFCQTYAGGSVGGAVR
LNHGLCDIAINWAGGLHHARRCEASGFCYVNDIVLGILELLRQHERVLYVDIDI
HHGDGVEEAFYTTDRVNTVSFHKFGDYFPGTGDIRDIGYGKGRYYSLNVPLDDG
IDDESYHSLFRPIIGRVMEVFRPGAVVLQCGADSLSG0RLGCFNLSIRGHAECV
RYMRSFNVPVLLLGGGGYTIRNVARCWCYETGVALGLEVDDRMPQHEYYEYFGP
DYTLHVAPSNMENRNSRQLLEEIRSRLLENLSRLQHAPSVPFQERPPDTELPEA
DEDQEDPDERWDPDSDMDVDEDRRPLPSRVRRELIVEPEVRDQDSQRASIDHGR
GLDTTQEDNASIRVSDMNSNITDEQSVRNEQDNVNRPSEQIFPR
293HistoneMDTGGNSLPSGPDGVRRRVCYFYDPEVGNYYYGQGHPMKPHRIRMTHALLAHYG1161615
deacetylaseLLQHMQVLRPVPARDRDLCRFHADDYVAFLRSITPETQQDQLRQLRRFNVGEDC
PVFDGLHSFCQTYAGGSVGGAVRLNHGLCDIAINWAGGLHHARRCEASGFCYVN
DIVLGILELLRQHERVLYVDIDIHHGDGVEEAFYTTDRVHTVSFHRFGDYFPGT
GDIRDIGYGRGRYYSLNVPLDDGIDDESYHSLFRPIIGRVMEVFRPGAVVLQCG
ADSLSGDRLGCFNLSIRGHAECVRYNRSFNVPVLLLGGGGYTIRNVARCWCYET
GVALGLEVDDRNPQHEYYEYFGPDYTLHVAPSNMENRNSRQLLEDIRSRLLENL
SRLQHAPSVPFQERPPDTELPEADEDQEDPDERWDPDSDMDVDEDRRPLPSRVR
RELIVEPEVRDQDSQRASIDHGRGLDTTQEDNASIRVSDMNSMITDEQSVRMEQ
DNVNKPSEQIFPK
294HistoneMRPKDRISYFYDGDVGSVYFGPNHPMKPHRLCMTHHLVLSYELHTKMEIYRPHK1551453
deacetylaseAYPAELAQFHSPDYVEFLHRITPDTQHLFPNDLAKYNLGEDCPVFENLFEFCQI
YAGGTIDAARRLNNQLCDIAINWAGGLHHAKKCEASGFCYINDLVLGILELLKY
HARVLYIDIDVHHGDGVEEAFYFTDRVMTVSFHKFGDMFFPGTGDVKEIGGKEG
KFYAINVPLKDGIDDTSFTRLFKAIISKVVETYQPGAIVLQCGADSLAGDRLGC
FNLSIDGHSECVRFVKKFNLPLLVTGGGGYTKENVARCWVVETGVLLDTELPNE
IPENEYFKYFAPDYSLKIPRGNIVLENLNSKSYLSAIKVQVLENLRNIQHAPSV
QMQEVPPDFYIPDFDEDEQNPDERMDQHTQDKQIQRDDEYYDGDNDNDHNMDDS
295HistoneMTVAEDFHVNNRSKMVSQATPESRLTGGEDDNSLHNQVDELLCQELPERQVILE2282033
deacetylaseFEGTRPKPYFSDHNGGENSALGVRATEDDLNSDVEAEEKQKEMTLEDMYKNDGT
LYDDDEDDSDWEPVKRQVELMRWFCTNCTMVNVEDVFLCDICGEHRDSGILRHG
FYASPFMQDVGAPSVEAEVQESREDHARSSPPSSSTVVGFDEKMLLHSEVEMKS
HPHPERADRLQAIAASLATAGIFPGRCRSLPVREITKEELQMVHSSEHVDAVEM
TSHDMFSSYFTPDTYANEHSARAARIAAGLCADLASTIISGRSKNGFALVRPPGH
HAGIKHAMGFCLHNNAAVAALAAQGAGAKKVLIVDWDVHHGNGTQEIFDGNKSV
LYISLHRHEGGNFYPGTGAAHEVGTMGAEGYCVNIPWSRRGVGDNDYVFAFHHI
VLPIASAFAPDFTIISAGFDAARGDPLGCCDVTPAGYAQMTHMLSALSGGKLLV
ILEGGYNLRSISSSAVAVIKVLLGDSPISEIADAVPSKAGLRTVLEVLKIQRSY
WPSLESIFWELQSQWGMFLVDNRRKQIRKRRRVLVPIWWKWGRKSVLYHLLNGH
LHVKTKR
296HistoneMAAAPSSPPTNRVDVFWHDGMLSHDTGRGVFDTGSDPGFLQVLEKHPENPDRVR1101258
deacetylaseNMVSILKRGPISPFISWHTATPALISQLLSFHSPEYINELVEADKNGGKVLCAG
TFLNPGSWDAALLAAGNTLSAMKYVLDGKGKIAYALVRPPGHHAQPSQADGYCF
LNNAGLAVRLALDSGCKRVVVVDIDVHYGNGTAEGFYQSSDVLTISLHMNHGSW
GPSHPQSGSVDELGEOEGYGYNMNIPLPNGTGDRGYEYAVTELVVPAVESFKPE
MVVLVVGQDSSAFDPNGRQCLTMDGYRAIGRTIRGLADRHSGGRILIVQEGGYH
VTYSAYCLHATVEGILDLPDPLLADPIAYYPEDEAFPVKVVDSIKRYLVDKVPF
LKEH
297HistoneMVESSGGASLPSVGQDARKRRVSYFYEPTIGDYYYGQGHPMKPHRIRMAHHLIV501462
deacetylaseHYYLHRRMEISRPFPAATTDIRRFHSEDYVTFISSVTPETVSDPAFSRQLKRFN
VGEDCPVFDGIFGFCQASAGGSMGAAVKLNRGDSDIALHWAGGLHHAKKSEASG
FCYVNDIVLGILELLKVHKRVLYVDIDVHHGDGVEEAFYTTDRVMTVSFHKFGD
FFPGSGHIKDTGAGPGKNYALNVPLNDGIDDESFRGMFRPIIQKVMEVYQPDAV
VLQCGADSLSGDRLGCFNLSVKGHADCLRFLRSFNVPLMVLGGGGYTMRNVARC
WCYETAVAVGVEPENDLPYNEYYEYFGPDYTLHVEPCSMENLNAPKDLERIRNM
LLEQLSRIPHAPSVPFQMTPPITQEPEEAEEDMDERPKPRIWNGEDYESDAEED
KSQHRSSNADALHDENVEMRDSVGENSGDKTREDRSPS
298MAT1 CDK-MVVPSSNPHNREMAIRRRMASTFNKREDDFPSLREYNDYLEEVEEMTFNLIEGV176739
activatingDVPTIEAKIAKYQEENAEQIMINRAKKAEEFAAALAASKGLPPQTDPDGALNSQ
kinase assemblyAGLSVGTQGQYAPAIAGGQPRPTGMAPQPVPLGTGLDIHGYDDEEMIKLRAERG
factorGRAGGWSIELSKKRALEEAFGSLWL
299PeptidylpropylMAAIISCHHYHSCCSSLIASKWVGARIPTSCFGRSSTQSNNAASVRQFVTRCSS1501529
isomeraseSPSSRGQWQPHQNGEKGRSFSLRECAISIALAVGLVTGVPSLDMSTGNAYAASP
ALPDLSVLISGPPIKDPEALLRYALPINNKAIREVQKPLEDITDSLKVAGLRAL
DSVERNVRQASRVLKQGKNLIVSGLAESKKDHGVELLDKLEAGMDELQQIVEDG
NRDAVAGKQRELLNYVGGVEEDMVDGFPYEVPEEYKNMPLLKGRAAVDMKVKVK
DNPMLEECVFRIVLDGYNAPVTAGNFVDLVERHEYDGMEIQRADGFVVQTGDPE
GPAESFIDPSTEKPRTIPLEIMVDGEKAPVYGATLEELGLYKAQTKLPFNAFGT
MAMARDEFEDNSASSQIFWLLKESELTPSNANILDGRYAVFGYVTENQDFLADL
KVGDVIESVQVVSGLDNLANPSYKIAG;
300PeptidylpropylMAGEDFDIPPADEMNEDFDLPDDDDDAPVMKAGDEKEIGKQGLKKKLVKEGDAW2471971
isomeraseETPDNGDEVEVHYTGTLLDGTQFDSSRDRGTPFKFTLGQGQVIKGWDQGIKTMK
KGENAIFTIPPELAYGEAGSPPTIPPNATLQFDVELLSWTSVKDICKDGGIFKK
ILVEGEKWENPKDLDEVLVKYEFQLEDGTTIARSDGVEFTVKEGHFCPAVAKAV
KTMKKGEKVLLTVKPQYGFGEKGKPASGDEGAVPPNATLQITLELVSWKTVSEV
TDDKKVIKKILKEGEGYERPNEGAVVEVKLIGKLQDGTVFVKKGHDDCEELFKF
KIDEEQVVDGLDKAVMNMKKGEVALLTVAPEYAFGSSESKQDLAVVPPSSTVYY
EVELVSFVKDKESWDMNTEEKIEAAGKKKEEGNVIFKAGKYAKASKRYEKAVKY
IEYDTSFSEDEKKQAKALKVACNLNDAACKLKLKDYNQAEKLCTKVLELDSRNV
KALYRRAQAYIELSDLDLAEFDIKKALEIDPHNRDVKLEYKVLKEKVKEFNKKD
AKFYGNMFAKMSKLEPVEKTAAKEPEPMSIDSKA;
301PeptidylpropylMSTVYVLEPPTKGKVVLNTTHGPLDVELWPKEAPKAVRNFVQLCLEGYYDNTIF1361644
isomeraseHRIIKDFLVQGGDPTGSGTGGESIYGDAFSDEFHSRLRFKHRGLVACANAGSPH
SNGSQFFITLDRCDWLDRKNTIFGKITGDSIYNLSGLAEVETDKSDRPLDPPPK
IISVEVLWNPFEDIVPRAPVRSLVPTVPDVQNKEPKKKAVKKLNLLSFGEEAEE
EEKALVVVKQKIKSSHDVLDDPRLLKEHIPSKQVDSYDSKTARDVQSVREALSS
KKQELQKESGAEFSNSFREIAQDEDDDDDDASFDARMRRQILQKRKELGDLPPK
PKPKSRDGISARKERETSISRDKDDDDDDDQPRVEKLSLKKKGIGSEARGERMA
NADADLQLLNDAERGRQLQKQKKHRLRGREDEVLTKLETFKASVFGKPLASSAK
VGDGDGDLSDWRSVKLKFAPEPGKDRNTRNEDPNDYVVVDPLLEKGKEKFNRMQ
AKEKRRGREWAGKSLT;
302PeptidylpropylMASAISMHSSGLLLLQGTNGKDVTEMGKAPASSRVANMQQRKYGATCCVARGLT48836
isomeraseSRSHYASSLAFKQFSKTPSIKYDRMVEIKAMATDLGLQAKVTNKCFFDVEIGGE
PAGRIVIGLFGDDVPKTVENFRALCTGEKGFGYKGCSFHRIIKDFMIQGGDFTR
GNGTGGKSIYGSTFEDENFALKHVGPGVLSMANAGPSTNGSQFFICTVKTPWLD
NRHVVFGQVVDGNDVVQKLESQETSRSDVPRQPCRIVNCGELPLDG;
303PeptidylpropylMAASFTALSNVGSLSSPRNGSEIRRFRPSCNVAASVRPPPLKAGLSASSSSSFS49822
isomeraseGSLRLIPLSSSPQRKSRPCSVRASAEAAAAQSKVTNKVYLDISIGNPVGKLVGR
IVIGLYGDDVPQTAENFRALCTGEKGFGYKGSTVHRVIKDFMIQGGDFDKGNGT
GGKSIYGRTFKDENFKLSHVGPGVVSMANAGPNTNGSQFFICTVKTPWLDQRHV
VFGQVLEGMDIVRLIESQETDRGDRPRKRVVVSDCGELPVV;
304PeptidylpropylMAEAIDLTGDGGVMKTIVRRAKPDAVSPSETLPLVQVRYEGVLAETGEVFDSTH185751
isomeraseEDNTLFSFEIGKGSVISAWDTALRTMKVGEVAKITCKPEYAYGSTGSPPDIPPD
ATLIFEVELVACKPCKGFSVTSVTEDKARLEELKKQREIAAATKEEEKKRREEA
KAAAAARVQAKLDAKKGHGKGKGKAK;
305PeptidylpropylMGNPKVFFDMSIGGQPAGRIVMELYADVVPRTAENFRALCTGEKGAGRSGKPLH103621
isomeraseYKGSSFHRVIPGFNCQGGDFTAGNGTGGESIYGSKFADENFVKKHTGPGVLSMA
NAGPGTNGSQFFVCTAKTEWLDGKHVVFGQIVQGMDVVKAIEKVGSSSGRTSKP
VVVADCGQLS
306PeptidylpropylMPNPKVFFDMTIGGAAAGRVVMELYADTTPRTAENFRALCTGEKGVGRSKKPLH41559
isomeraseYKGSKFHRVIPSFMCQGGDFTAGNGTGGESIYGVKFADENFIKKHTGPGILSMA
NAGPGTNGSQFFICTTKTEWLDGKHVVFGKVVEGMEVVKAIEKVGSSSGRTSKP
VVVADCGQLP
307PeptidylpropylMAEAIDLTGQGGVMKTIVRRAKPDAVSPSETLPLVDVRYEGVLAETGEV˜DSTH127693
isomeraseEDNTLFSFEIGKGSVISAWDTALRTMKVGEVAKITCKPEYAYGSTGSPPDIPPD
ATLIFEVELVACKPCKGFSVTSVTEDKARLEELKKQREIAAATKEEEKKRREEA
KAAAAARVQAKLDAKKGHGKGKGKAK
308PeptidylpropylMATARSFFLCALLLLATLYLAQAKKSEDLKEVTHKVYFDVEIACKPAGRIVMGL28639
isomeraseYGKAVPKTAENFRALCTGEKGTGKSGKPLHYKGSSFHRIIPSFMLQGGDFTLGD
GRGGESIYGEKFADENFKLKHTGPGLLSMANAGPDTNGSQFFITTVTTSWLDGR
HVVFGKVLSGMDVVYKVEAEGRQSGTPKSKVVIADSGELPL
309PeptidylpropylMMRREISVLLQPRFVLAFLALAVLLLVFAFPFSRQRGDQVEEEPEITHRVYLDV135812
isomeraseDIDGQHLGRIVIGLYGEVVPRTVENFRALCTGEKGKSANGKKLHYKGTPFHRII
SGFMIQGGQVIYGDGKGYESIYGGTFADENFRIKHSHAGIISMVNSGPDSNGSQ
FFITTVKASWLDGEHVVFGRVIQGMDTVYAIEGGAGTYNGRPRKKVIIADSGEI
PKSKWDEER
310PeptidylpropylMWATAEGGPPEVTLETSMGSFTVELYFKHAPRTSRNFIELSRRGYYDNVRFHRI119613
isomeraseIKDFIVQGGDPTGTGRGGESIYGKKFEDEIKPELKHTGAGILSMANAGPNTNGS
QFFITLAPCPSLDGKHTIFGRVCRGMEIIKRLGSVQTDNNDRPIHDVKILRTSV
KD
311PeptidylpropylMSNPKVFFQILIGKMKAGRVVMELFAQVTPKTAENFRALCTGEKGIGRSGKPLH38562
isomeraseYKGSTFHRIIPNFMCQGGDFTRGNGTGGESIYGMKFADENFKIKHTGLGVLSMA
NAGPDTNGSQFFICTEKTPWLDGKHVVFGKVIDGYNVVKEMESVGSDSGSTRET
VAIEDCGQLSEN
312PeptidylpropylMDDDFEFPASSNVENDDDDGMDMDDMGGDVPEEEDPVASPAVLKVGEEREIGKA1091872
isomeraseGFKKKLVKEGEGWETPSSGDEVEVHYTGTLLDGTKFDSSRDRGTPFKFKLGRGQ
VIKGWDEGIKTMKKGENAIFTIPPELAYGESGSPPTIPPNATLQFDVELLSWSS
VKDICKDGGILKKVLVEGEKWDNPKDLDEVFVKYEASLEDGTLISKSDGVEFTV
GDGYFCAALAKAVKTMKKGEKVLLTVMPQYAFGETGRPASGDEAAVPPDASLQI
MLELVSWKTVSDVTRDKKVLKKTLKEGEGYERPNDGAAVQVRLCGKLQDGTVFV
KKDDEEPFEFKIDEEQVIDGLDRAVKNMKKGEVALVTIQPEYAFGPTESQQDLA
VVPANSTVYYEVELLSFVKEKESWEMNNQEKIEAAARKKEEGNAAFKAGKYVRA
SKRYEKAVRFIEYDSSFSDEEKQQAKTLKNTCNLNDAACKLKLKDFKEAEKLCT
KVLEGDGKNVKALYRRAQAYIQLVDLDLAEQDIKKALEIDPNNRDVKLEYKILK
EKVREYNKRDAQFYGNMFAKMNKLEHSRTAGMGAKHEAAPMTIDSKA
313PeptidylpropylMAKPRCFMDISIGGELEGRIVGELYTDVAPKTAENFRALCTGEKGIGPHTGAPL741159
isomeraseHYKGVRFHRVIKGFMVQGGDISAGDGTGGESIYGLKFEDENFDLKHERKGMLSM
ANSGPNTNGSQFFITTTRTSHLDGKHVVFGRVVKGMGVVRSVEHVTTAAGDCPT
VDVVIADCGEIPAGADDGIRNFFKDGDTYPDWPADLDESPAELSWWMDAVDSIK
AFGNGSYKKQDYKMALRKYRKALRYLDICWEKEGIDEVESSSLRKTKSQIFTNS
SACKLKLCDLKGALLDAEFAVRDGENNAKAYFRQGQAHMELNDIDAAAESFSKA
LELEPNDVGIKKELNAAKRKIFERREQEKRAYRKMFL
314PeptidylpropylMTKRKNPLVFLDVSIDGDPVERIVIELFADTVPRTAENFRSLCTGEKGVGKTTG542045
isomeraseKPLHYKGSYFHRIIKGFMAQGGDFSNGNGTGGESIYGGKFADENFKLAHDGPGL
LSMANGGPNTNGSQFFIIFKRQPHLDGKHVVFGKVNRGMEVVKKIEQVGSANGK
PLQPVKIVDCGETSETGTQDAVVEEKSKSATLKAKKKRSARDSSSESRGKRRQR
KSRKERTRKRRRYSSSDSYSSESSDSDSESYSSDTESESKSHSESSVSDSSSSD
GRRRKRKSTEREKLRRQRGKDSRGEQKSARYQRESREKSADSSSDSESESSSES
RSRDDKKKSSRRESARSVSKLKDAEANSPENLESPRDREIKKVEDNSSHEEGEF
SPENDVQHNGEGTDAKFGKYDQQEPESDGSKESSGSMEDSPERLANSVPQGSPS
SSPAHKASEPSSSIRARNPSRSPAPDGNSKRIRKGRGFTERFSYARRYRTPSPE
DVTYRPYHYGRRNFHDRRNDRYSNYRSYSERSPHRRYRSPPRGRSPPRYQRRRS
ESESVSESPGGNEGEYRGEDQSESESESESESPEEGSSPANKQLPLSERLESRL
GTEVDEHSPEEEESSSRSHDSSESESPDEVPDKHEGKAAPVSPARSESSSPSGE
GLVSYGDASPDSGIN
315PeptidylpropylMSVLLVTSLGDIVVDLHADECPLTCKNFLKLCEIKYYNGCVFHTVQKDFTAQTG531879
isomeraseDPTGTGTGGDSVYKFLYGDQAEFFNDEIHLDLKHSKTGTVAMASGGENLNASQF
YFTLEDDLDYLDGRHTVFGEVAEGLETLTEINEAYVDEKGEPYKNIRIEHTYIL
DDFFDDPPQLAELIPDASPEGKPKDEVVDDVELEDDWVPLDEQLGPAQLEEAIE
AKEAHSEAVVLESIGDIPDAEIKPPDNVLFVCKLNPVTEDEDLHTIFSEFGTVV
SADVIRDFKTGDSLCYAFIEFENKDSCEQAYFKNDNALIDDRRIKVDFSQSVAK
LWSQFKEKDSQAAKGKGCFKCGAPDHMARECPGSSTRQPLSKYILKEDNAQEGG
DDSEYEMVFDEDAPESPSHGKKEEGEDDEDDRHKMSEQSVEETKFNDEEGGHSV
DKHEQSEESKHEEDEMSEDSKASEAGEEEIDEDFPEEEEDGEKYTESHEDEDGK
RGDYEDYEKGRADVQTHGDERGDENYEEKSAAYDDGHEGAGAAREKDSNDDHHA
YREGYGDSEKGTEDEDDDGEGEEDDPSYEESSGHKDSSNGGEEEQKYRSGETDG
KSHPERSNEGDEEE
316PeptidylpropylMRPFNGGSSIACLVLVIAAGALAESQGPHLGSARVVFQTNYGDIEFGFFPGVAP7690
isomeraseRTVDHIFKLVRLGCYNTNHFFRVDKGFVAQVADVANGRTAPMNDEQRTEAEKTI
VGEFSNVKHVRGILSMGRYDDPDSAQSSFSILLGDAPHLDGKYAIFGRVTKGDE
TLKKLEQLPTRREGMFVMPTERITILSSYYYDTGAESCEEENSTLRRRLAASAV
EVERQRMKCFP
317PeptidylpropylMPNPKVFFDMQVGGAPAGRIVMELYADVVPKTAENFRALCTGEKGTGRSGKPLH83601
isomeraseFKGSSFHRVIPGFMCQGGDFTRGNGTGGESIYGEKFADENFVKKHTGPGILSMA
NAGPNTNGSQFFICTAQTSWLDGKHVVFGQVVEGLEVVRDIEKVGSGSGRTSKP
VVIADSGQLA
318PeptidylpropylMRFTSITSAIALFAAAASALDKPLDIKVDKAVECSRKTKAGDKIQVHYRGTLEA125535
isomeraseDGSEFDASYKRGQPLSFHVGKGQVIKGWDQGLLDNCPGEKRTLTIQPDWGYGSR
GMGPIPANSVLIFETELVEIAGVAREEL
319PeptidylpropylMGNPKVFFDMSIGGQPAGRIVMELYADVVPRTAENFRALCTGEKGAGRSGKPLH55573
isomeraseYKGSSFHRVIPGFMCQGGDFTAGNGTGGESIYGSKFADENFVKKHTGPGVLSMA
NAGPGTNGSQFFVCTAKTEWLDGKHVVFGQIVDGMDVVKAIERVGSSSGRTSKP
VVVADCGQLS
320PeptidylpropylMAVATRSRWVAMSVAWILVLFGTLALIQNRLSDTGASSDPKLVHRKVGEEKKKP147842
isomeraseDDLEEVTHKVFFDVEIGGKPAGRIVMGLFGKTVPKTVENFRALCTGERGIGKSG
KPLNYKGSQFHRIIPKFMIQGGDFTLGDGRGGESIYGNKFSDENFKLKHTDAGR
LSMTNAGPDTNGSQFFITTVTTSWLDGRHVVFGKVLSGMDVVHIUEAEGGQSGQ
PKSIVVISDSGELDL
321PeptidylpropylMAVTLHTNLGDIKCEIFCDEVPKAAEHNARGILSMANSGPNTNGSQFFIAYAKQ167487
isomerasePHLNGLYTIFGRVIHGFEVLDIMEKTQTGPGDRPLAEIRLNRVTIHANPLAG
322PeptidylpropylMAVATRSRWVANSVAWILVLFGTLALIQNRLSDTGASSDPKLVHRKVGEEKKKP195890
isomeraseDDLEEVTHKVFFDVEIGGKPAGRIVMGLFGKTVPKTVENFRALCTGEKGIGKSG
KPLNYKGSQFHRIIPKFMIQGGDFTLGDGRGGESIYGNRFSDENFKLKHTDAGR
LSMANAGPDTNGSQFFITTVTTSWLDGRHVVFGKVLSGMDVVHKIEAEGGQSGQ
PKSIVVISDSGELDL
323PeptidylpropylMGNPKVFFDMSIGGQPAGRIVMELYADVVPRTAENFRALCTGEKGAGRSGKPLH68586
isomeraseYKGSSFHRVIPGFMCQGGDFTAGMGTGGESIYGSKFA0ENFVKKHTGPGVLSMA
NAGPGTNGSQFFVCTAKTEWLDGKHVVFGQIVDGMDVVKAIEKVGSSSGRTSKP
VVVADCGQLS
324RetinoblastomaMSPVAANAMEEAAEFEVPAPVTPSKDDADTDAAVSRFLGFCKSKLGLAEGNCVQ1823265
related proteinSSTLLRKTAHVLRSSGTVIGTGTAEEAERYWFAFVLYTVRRVGERKAEDEQNGS
DETEVPLSRILKASVLNLIDFFKEIPQFVIKAGAIVSGIYGANWDSRLEAREMQ
TNYVHLCILCKFYKRICGEFFILNDAKDDMKSADSSTSQPVIMYQPFGWLLFLA
LRIHALSRFKDLVSSTNALVSVLAILIIHLPTRFRKFSISDSSQLVKRSEKGVD
LVGSLAYRYDTSEDEIKRTLEKANNVIAEILGITPPPASECKAENLENVDTDGL
IYFGNLMEETSLSSILSTLEKIYEDATRNDSEFDERVFINDDDSLLVSGSLSGA
AINLTGAKRKYDSFASPAKTITRPLSPSRSPASHINGIIGGTNLRITATPVATA
MTTAKWLRTFVSPLPSKPSTDLQGFLASCDRDVTSDVIRRANIILEAIFFNSPI
GERTVTGGLQNANLMDNMWAEQRRLEALKLYYRVLEAMCRAEAQILHSNNLTSL
LTNERFHRCMLACSAELVLATHKTVTMLFPAVLERTGITAFDLSKVIESFVRHE
ETLPRELRRHLNTLEERLLENMVWERGSSMYNSLVVARPALAPEINRLGLLPEP
MPSLDAIALLINFSSSGLPQSPVQKHEASPGQNGDIRSPKRISTEYRSVLVERN
FTSPVKDRLLALSNIKSKLPPPPLQSAFASPTRPHPGGGGETCAETAIHIFFSK
ITKLAAVRINANLERLQLSQQIKEGVYCLFQQILSQRTNLFFNRHIDQVILCCF
YGVAKINQINLTFREIIYNYRKQPQCKPQVFRNVFVDWSTRRNGKAGNEHVDII
SFYNEIFIPSVKPLLVELGPTGATTRTNRTSEVGNKNDAQCPGSPKISSFPTLP
DMSPKKVSASHNVYVSPLRSSKNDASISHSSKSYYACVGESTHAYQSPSKDLVA
INSRLNGNRKVRGTLNFDDVDAGLVSDSMVANSLYLQNGSSMSSSTAKSSEKPE
S
325WD40 repeatMRPILMKGHERPLTFLKYNREGDLLFSCAKDHTPTVWFADNGERLGTYRGHNGA1651145
proteinVWCCDVSRDSMRLITGSADTTAKLWSVQNGTQLFTFNFDSPARSVDFSIGDKLA
VITTDPFMELPSAIHVKRIARDPADQASESVLVLRGHQGRIARAVWGPLNKTII
SAGEDAVIRIWDSETGKLLRESDKETGHKKAVTSLMKSVDGSHFVTGSQDKSAK
LWDIRTLTLI KTYVTERPVNAVTMSPLLDHVVLGGGQDASAVTMTDHRAGKFEA
KFFDKILQEEIGGVKGHFGPINALAFNPDGKSFSSGGEDGYVRLHHFDPDYFNI
KI
326WD40 repeatMDKKRTVVPLVCHGHSRPVVDLFYSPITPDGFFLISASKDSSPMLRNGETGDWI5291569
proteinGTFEGHKGAVWSCCLDTNALRAASGSADFSAKLWDALSGDELHSFEHKHIVRSC
AFSEDTHLLLTGGVEKILRIFDLNRPDAPPREVDNSPGSIRTVAWLHSDQTILS
SCTDIGGVRLWDVRSGKIVQTLETKSPVTSSEVSQDGRYITTADGSTVKFWDAN
HFGLVKSYNNPCNIESASLEPKLGNKFIAGGEDMWVHIFDFHTGEEIGCNKGHH
GPVHCVRFSPGGESYASGSEDGTIRIWQTGPANNVEGDANPSNGPVTGKARVGA
DEVTRKVEDLQIGKEGKDWREG
327WD40 repeatMAEGLILKGTMRAHTDMVTAIAIPIDNSDMVVTSSRDKSIILWHLTKEEKVYGV1561136
proteinPRRRLTGHSHFVQDVVLSSDGQFALSGSWDGELRLWDLATGVSARRFVGHTKDV
LSVAFSIDNRQIVSASRDRTIKLWNTLGECKYTIQEGEAHTDWVSCVRFSPNTL
QPTIVSASWDRTIKVWNLTNCKLRNTLAGHNGYVNTVAVSPDGSLCASGGKDGV
ILLWDLAEGKRLYNLEAGAIIHSLCFSPNRYWLCAATENSIKIWDLESKSIVED
LRVDLKNEADKTDGTTTAASNKKVIYCTSLNWSADGSTLFSGYNDGVIRVWGTG
RY
328WD40 repeatMAEGLHLKGTMKAHTDMVTAIAVPIDNADMIVTSSRDKSIILWHLTKEDKVYGV901073
proteinPRRRLTGHSHFVQDVVLSSDGQFALSGSWDGELRLWDLATGVSARRFVGHTKDV
LSVAFSIDMRQIVSASRDRTIKLWNTLGECKYTIQEGEAHNDWVSCVRFSPNTL
QPTIVSASWDRTVKVWNLTNCKLRNTLQGHSGYVNTVAVSPDGSLCASGGKDGV
ILLWDLAEGKKLYSLEAGAIIHSLCFSPNRYWLCAATENSIKIWDLESKSIVED
LRVDLKNEADMSDGTTGAMSSNKKVIYCTSLNWSADGSTLFSGYNDGVIRVWGI
GRY
329WD40 repeatMAEGLHLKGTMKAHTDMVTAIAVPIDNADMIVTSSRDKSIILWHLTKEDKVYGV661049
proteinPRRRLTGHSHFVQDVVLSSDGQFALSGSWDGELRLWDLATGVSARRFVGHTKDV
LSVAFSIDNRQIVSASRDRTIKLWNTLGECKYTIQEGEAHNDWVSCVRFSPNTL
QPTIVSASWDRTVKVWNLTNCKLRNTLQGHSGYVNTVAVSPDGSLCASGGKDGV
ILLWDLAEGKKLYSLEAGAIIHSLCFSPNRYWLCAATENSIKIWDLESKSIVED
LRVDLKNEADMSDGTTGAMSSNKKVIYCTSLNWSADGSTLFSGYNDGVIRVWGI
GRY
330WD40 repeatMSGVPAPPFATTTPENGTMSSNSPAFHRDSDDDDDQGEVFLDDSDIIHEVAVDD2771512
proteinEDLPDADDEADEAEEADDSLHIFTGHNGEVYSLACSPTQATLVATGAGDDKGFL
WRIGHGDWAVELQGHKDSISSLAFSLDGQLLASGSLDGVIQIWDVPSGNLKGTL
DGPGGGIEWIRWHPKGHIILAGSEDSTVWMWNADKMAYLNMFSGHGNSVTCGDF
TPDGKTICTGSDDATLRIWNPKSGENIHVVKGHPYHAEGLTSMAISSDSGLAIT
GAKDGSVRIVNISSGRVVSSLDAHADSVEFVGLALSSPWAATGSLDQKLIIWDL
QHSSPRATCDHEDGVTCLSWVGASRFLASGCVDGKVRVWDSLSGDCVRTFHGHS
DAIQSLSVSANEEFLVSVSIDGTARVFEIAEFH
331WD40 repeatMGTSQHQLSSCLQLLPRRRGNKNLIFRRTMASGGAAAVAPPPGYKPYRHLKTLT331076
proteinGHVAAVSCVKFSNDGTLLASASLDKTLIIWSSAALSLLHRLVGHSEGVSDLAWS
SDSHYICSASDDRTLRIWSSRSPFDCLKTLRGHTDFVFCVNFNPQSSLIVSGSF
DETIRIWEVKTGRCLNVIRAHSMPVTSVHFNRDGSLIVSGSHDGSCKIWDTKNG
ACLKTLIDDTVPAVSFAKFSPNGKFILVATLNDTLKLWNYATGKFLKIYTGHKN
SVYCLTSTFSVTUGKYIVSGSEDRCICIWDLQGKNLIQKLEGHSDTVISVTCHP
SENKIASAGLDSDRTVRIWLQDA
332WD40 repeatMPSQKIETGHQDIVHDVANDYYGKRVATASSDTTIKIIGVSNSSGSQHLASLSG65973
proteinHKGPVWQVAWAHPKFGSILASCSYDGQVILWKEGNQNDWAQAHVFNDHKSSVNS
IAWAPHELGLCLACGSSDGNISVFTARPDGGWDTTRIEQAEPVGVTSVSWAPSM
APGALVGSGLLDPVQKLASGGCDNTVKVWKLYNGTWKMDCFPALQMHSDWVRIJV
AWAPNLGLPKSTIASASQDGTVVIWTVAKEGEQWQGKVLKDFKTPVWRVSWSLT
GNLLAVADGNNNVTLWNEAVDGEWQQVTTVEP
333WD40 repeatMKIAGLKSVENAHDESVWAAAWVPATESRPALLLTGSLDETVKLWRPDELALER821047
proteinTNAGHFLGVVSVAAHPSGVIAASASIDSFVRVFDVDTNATIATLEAPPSEVWQM
QFDPKGTTLAVAGGGSASIKLWDTATWELNATLSIPRPEQPKPSEKGNKKFVLS
VAWSPDGRRLACGSMDGTISIFDVARAKFLHHLEGHFMPVRSLVFSPVEPRLLF
SASDDAHVHMYDSEGKSLVGSMSGHASWVLSVDVSPDGAALATGSSDRTVRLWD
LSMRAAVQTMSNHSDQVWGVAFRPMAGAGVRAGGRLASVSDDKSISLYDYS
334WD40 repeatMEIDLGNLAFDVDFHPSEQLVASGLITGDLLLYRYGDGSSPEKLLEVRAHGESC431101
proteinRAVRFINDGKAILTGSPDCSILATDVETGSVVARVENAHEAAVNRLVNLTESTI
ATGDDNGCIKVWDTRQRSCCNTFSAHEDFISDMTFASDSMKLVVTSGDGTLSVC
NLRSNKVQTRSEFSEDELLSVVIMKNGRKVVCGTQSGTLLLYSWGFFKDCSDRF
VDLSPSSVDALLKLDEDRIIAGTENGLISLIGILPNRIIQPIAEHSDHPIERLA
FSHDKKFLGSISHDQTLKLWDLNDILGSEDSPSSQAAIDDSDSDEMDVDANPPD
SSKGNKKKHSGRGNDVGNANNFFADLGD
335WD40 repeatMSQQPSVILATASYDHTIRFWEAKSGRCYRTIQYPDSQVNRLEITPHKRYLAVA1421095
proteinGNPSIRLFDVNSNTPQPVMSFDSHTNNVMAVGFQYDGNWMYSGSEDGTVRIWDL
RARGCQREYESRGAVNTVVLHPNQTELISGDQNGNIRVWDLTANSCSCELVPEV
DTAVRSLTVMWDGSLVVAANNNGTCYVWRLLRGSQTMTNFEPLHKLQAHNGYIL
KCLLSPEFCEPHRYLATASSDHTVKIWNVEGFTLEKTLIGHQRWVWDCVFSVDG
AYLITASSDTTARLWSMSTGQDIRVYQGHHKATTCCALHDGAEGSPG
336WD40 repeatMEDAMDMEVEVEVEAEEHSPSSSNPSGSSFRRFGLKNSIQTNFGSDYVFEITPK611257
proteinFDWSLMGVSLSSNAVKLYSPTTGQYCGECRGHSDTVNGISFSGPSSPHVLHSCS
SDGTIRAWDTRSFKEVSCISAGPSQEIFSFSFGGSSQSLLSAGCKSQILFWDWR
NKKQVACLEDSHVDDVTQVCFVPHHQNKLISASVDGLICIFDTAGDIMDDEHME
SVINVGTSIGKVGIFGQTFEKLWCLTHIETLSVWDWKEGTNEANEFEDARKLASD
SWSLDHIDYFVDCHSAEEGEGLWVIGGTNAGTLGYFPVKYKGGAAIGSPEAVLG
GGHSDVVRSVLPMSGMAGTTSKTRGIFGWTGGEDGRLCCWLSDDSSATSRSWMS
SNLVLKSSRSHHKRNRHQPY
337WD40 repeatMSQEQEYPMEYAADDYDVGEVEDDMYFHERVMGDSDTDEDEEYDHLDNKITDTS1931527
proteinAADARRGKDIQGIPWERLSVTREKYRRTRIEQYKNYENVPQSGESSEKDCKPTR
KGGNYYEFWRNTRSVKSTILHFQLRNLVWSTTKHDVYLMSHFSIIHWSSLTCKK
TEVLDVYGHVAPREKHPGSLLEGFTQTQVSTLAVRDKLLIAGGFQGELICKNLD
RPGVSYCCRTTYDDNAITNAVEIYDYPSGAVHFMASNNDCGVRDFDNEKFELSR
HFTFPWPVNHTSLSPDGKLLVIVGDNPEGIVVDSQRGKTIRPLQGHLDFSFASA
WHPDGHIFATGNQDKTCRIWDIRNLSKSVAVLKGNLGAIRSIRFTSDGRFMAMA
EPADFVHVYDVKSGYEKEQEIDFFGEISGVSFSPDTESLFVGVWDRTYGSLLQY
NRCRNYSYLDSM
338WD40 repeatMGASSDPNPDVSDEEQKRSEIYTYEAPWHIYAMNWSVRRDKKYRLAIASLLDHP1091155
proteinAAAAAVPNRVEIVQLDDSTGEIRADPNLSFDHPYPATKAAFVPDKDCQRADLLA
TSSDFLRIWRIADDSSRVDLRSFLNGNKNSEFCRPLTSFDWNEAEPKRIGTSSI
DTTCTIWDIERETVDTQLIAHDKEVYDIAWGGVSVFASVSADGSVRVFDLRDKE
HSTIIYESSEPDTPLVRLGWNKQDPRYMATIIMDSAKVVVLDIRYPTMPVVELQ
RHQASVNAIAWAPHSSCHICTAGDDSQALIWDLSSMAQPVEGGLDPILAYTAGA
EIEQLQWSSSQPDWVAIAFSLKLQ
339WD40 repeatMRGGGGGGDATGWQEDAYRESVLKEREVQTRTVFRAAFAPSPSPSPSPDAVVVA711213
proteinSSDGSVASYSISACLSDHRLQSLRFADAKSQNVLEAEPACFLQGHDGPAYDVRF
YGEGEDSLLLSCGDDGRIRGWMWRDITSSEAHDHSQGNSAKPVLDLVNPQSRGP
WGALSPIPENNALAVDVKRGSIYAAAGDSCAYCWDVECGKIKTVFKGHSDYLHC
IAARNSSSQIITGSEDGTARIWDCRSGKCVQVIDPDKDHKRGFFASVSCLALDA
SESWLVCGRGRDLSVWSISASDCIAKISTNAPAQDVLFDDNQILLVGAEPLISR
LDMNGAVLSQIHCAPQSVFSVSLHQSGVTAVGGYGGLVDVISQFGSHLCTFRCK
CI
340WD40 repeatMEAPIIDPLQGDFPEVIEEYLEHGIMKCIAFNRRGTLLAAGCTDGSCIIWDFET1091785
proteinRGVAKELRDKECTAAITSVCWSKYGHRILVSASDKSLILWDVLSGEKIAHTTLQ
HTVLQACLHPGSSTPSICLACPFSSAPMIVDLNTGSTTALPVLTADVSNGATPL
SRNKTSDTSVTYSPCNACFNKHGDLVYAGTSKGEILIIDHKNVRVCAIVLVSGG
AVIKNVVFSRNGQYMLTNSNDRLIRIYKNLLPPKDGLKMLDELNESFWESDDVE
KLKAIGSKCLELLHEFQDSITRVQWKAPCFSGDGEWVIGGAASRGEHKIYIWDR
AGHLVKILEGPKEALMDLAWHPVHPIIISVSLTGLVYIWAKDYTENWSAFAPDF
KELEENEEYVEREDEFDLVPETEKVKGLDVHEDDEVDVLTVERDSVFSDSDMSQ
EELCFLPAVPCLDIPEQQDKCVGSCSKLPDGNHSGSPLSVEAGQNGNASNHMSS
PLEPMENSTADDTDGVRLKRKRKPSEKGLELQAEKVKKPVKPLKSSGRLSKTNK
PVIDPDSSNGVYGDDGSD
341WD40 repeatMRGVSWPEDGWNPSTSSSSQRNQQQAHAPRAVSGHAASHPSASNIFKLLVQREV3642685
proteinSPRSKHSSKKLWREASKCQPYPFQQSCEAVRDVRQGLISWVESASLRHLSAKYC
PLVPPPRSTIAAAFSPDGKILASTHGDHTVKLIDSQTGSCLKVLRGHRRTPWVV
RFHPLYPEILASGSLDHEVRLWDANTAECIGSRNFYRPIASIAFHARGELLAVA
SGHKLYIWHYNRRGETSSPTIVLRTQRSLRAVHFHPHAAPFLLTAEVNDLDSAD
SAMTLATSPGYLHYPPPTVYFADAHSHERSRLADELPLMPLPLLMWPSFTRDDG
RVPLQRIDGDVGLNGQQRVDSSSSVRLWTYSTPSGQYELLLSPVESGNSPSMPE
ETGWNAFSSAVEAEVSQSANDTVEDMEVQPEERNTQFFSFSDPRFWELPLLHGW
LVGQTQAGPRSVRQSSPGDIETQSAFGEVASVSPITSGVNPVSMDPSRFGGRSG
SRYRSPGSRGVHVTGPNNDGPRDENDPQSVVSKLRSELAASLAAAASTELPCTV
KLRIWPHDVKDPCAQLDLESCRLTIPHAVLCSEMGAHFSPCGRFLAACVACVLP
HLESDPGLHGQVNQDVTGVATSPTRHPISAHQIMYELRIYSLEEATFGIVLASR
PVRAAHCLTSIQFSPTSEHLLLAYGRRHSSLLKSIVIDGENTVPIYTILEVYRV
SDMELVRVLPSAEDEVNVACFHPSVGGGLIYGTKEGKLRILHYDSSHGLNLKSS
GFLDENVPEVQTYALEC
342WD40 repeatMDSAVAIAALSLVVGAAIALLFFGNYFRKRRSEVVAMAEADLQPHPKNPSRPPP961412
proteinQPAAKKVHAKSHAHGADKDKNKRHHPLDLNTLKGHGDSVTGLCFASDGRSLATA
CADGVVRVFKLDDASNKSFKFLRINLPAGGHPTAVAFGDGVSSVIVASQHLSGC
SLYMYGEEKPTNLDSNKQQTKLPMPEIKWEHHKVHEQKAILTLSGAAANYDSGD
GSTIIASCSEGTDIIIWHAKTGKILGNVDTNQLKNTMSAISPNGRFIAAAAFTA
DVKVWEIVYSKDGSVKGVTKVMQLKGHKSAVTWLCFTPNSEQIVTASKDGSIRI
WNINVRYHLDEDTKTLKVFPIPLQDSSGTTLHYERLSLSPDGKILAATHGSMLQ
WLCIETGKVLDTAEKAHDGDITCMSWAPQSIPTGDKKVNVLATASGDKKVKLWA
APPLPS
343WD40 repeatMEVEPKKASKTFPVKPKLKPKPRTPSGKTPESRYWSSFKTTHPLDNLSFSVPSL1161702
proteinAFSPSPPHLLAAAHSATVSLFSPHRTTISSFSDVVSSLSFRSDGQLLAASDLSG
LIQVFDVRSRTPLRRLRSHARPVRFVRYPVLDKLHLVSGGDDALVKYWDVAGES
VVSELRGHKDYVRCGDCSPADANCFVTGSYDHVVKLWDVRVRDGNRAATEVNHG
SPVQDVIFLPSGSLVATAGGNSVKIWDLIGGGRNVYSMESHNKTVTSICVGTMG
AQQSGEEGVQLRILSVGLDGYMKVFDYSRMKVTHSMRFPAPLLSIGFSPDSNVR
AIGTSNGILYVGKRKAKENAEGGANGILGLGSVEEPRRRVLKPSFYRYFHRGQS
EKPSEGDYLVMRPKKVKLAEHDKLLKKFQHKNALISVLGGNDPEKVVAVMEELV
ARRALLKCVLNLDADELGLILTFLHKNSTVPRYSSLLLGLAKKVIDLRLEDIRA
SDALKGHIRNLKRSVDEEIRIQEGLQEIQGMVSPLLRIAGRR
344WD40 repeatMQGGSSGVGYGLKYQARCISDVKADTDHTSFLTGTLSLKEENEVHLLRLSSGGT461101
proteinELICEGLFSHPSEIWDLSSCPFDQRIFSTVFSTGESYGAAVWQIPELYGQLNSF
QLEKIASLDAHSRKISCVLWWPSGRHDKLVSIDEENIFLWGLDCSKKSAQVQSQ
ESAGMLHNLSGGAWDPHDVNTVAATCESSIQFWDLRTMKKANSLESVHARDLDY
DMRKKHLLVTSEDESGVRVWDLRMPKAPIQEFPGHTHWTWAVRCNPDYEGLILS
AGTDSAVNLWWSSTASSDELISERLIDSPTRKLDPLLHSYNDYEDSVYGLAWSS
REPWIFASLSYDGRVVVESVKPFLSRK
345WD40 repeatMAEEEGSAELEQQLEEEFAVWKKNTPILYDLLISHALEWPSLTVHWAPLLPQPS231258
proteinSSAAAAAGDPSLAAHRLVLGTHTSDGAPNFLILADALLPSSESDHCGDDAVLPK
VEISQKIRVDGEVNRARFD4PQNHNIVGAKTNGCEVYVFDCSKQAAKQHDGGFDP
DLRLTGHDGEGYGLSWSPLKENYLLSASHQKKICLWDISAAAQDKVLGAMHVFE
AHEGAVGDASWHSKNDNLFGSAGDDCQLMIWDLRTNKAQQCVKAHEKEVNSVSF
NSYNDWILATASSDTTVGLFDNRKLTTPLHVFSSHEGEVLQVEWDPNHEAVLAS
SSEDRRVMVWDLNRIGDEQQEGDASDGPAELLFSHGGHKAKISDFSWNKNEPWV
ISSVAEDNSVQVWQMAESICGDDDDMQAMEGYI
346WD40 repeatMGNYGEEQSDQYFQALEETASVSDEGSNSSQCQSSGSGLDENVLQSLGFEFWTK4042644
proteinFPESVRARRNRFLMLTGLGISANSVDKEDAFPPSCNEIEVYTCKVTRDDGAVQR
SLDSYNCISLLQSSTSIRSNQEVESLRGDSLLSSFRGRSKESDDLTELCGMGCP
ESRRNAVSEFGSVSQGSIESLERIVASSPLVHPLLHRKLEYERELIETKQKMGA
GWLRKFGSATCISGRQGDTWSDPDDLEITAGMKMRRVRAHSSKKKYKELSSLYA
AQEFLAHEGSISTMKFSMDGQYLASAGEDTVVRVWKVTEEDRSERVNVTVDPSC
LYFALNESTQLASLNTNKEHIGRAKTFQRSSDSSCVILPLKVFQITEKPWHEFE
GHNGEVLDLSWSSKGYLLSSSTDKTVRLWRVGCDRCQRVYSHNDYVTCISFNPV
NENFFISGSIDGKVRIWNVFGGQVVAYIDCREIVSAVCYRSDGKGAIVGTMTGN
CLFYSIKDNHLQMDAQVYLHGKKKSPGKRITGFQFPPNDPGKLNITSADSVIRV
LSGLDVVCKLKGPRNSGGPNIATFTSDGKHVISASEDSNVYIWNYAGQDKTSSR
VKKIWSCESFWSSNASVALPWCGIRTVPEALAPPSRSEERRASCAENGENHHML
EEYFQKMPPYSPDCFSLSRGFFLELLPKGSATWPEEKLSDTSPPTVSSQAISKL
EYKFLKSACHSVLSSAHNWGLVIVTAGWDGRIRTYHNYGLPVRS
347WD40 repeatMDIDFKEYRLRCELRGHEDDVRGVCVCGDGSIGTSSRDRTVRLWAPSAGERRKY1072383
proteinEVARVLLGHKSFVGPLAWVPPSEELPEGGIVSGGMDTLVMAWDLRNGEAQTLKG
HQLQVTGIVLDGGDIVSASVDCTLIRWKNGQLTEHWEAHKAPIQAVIRLPSGEL
VTGSSDTTLKLWRGKTCTQTFVGHTDTVRGLAVMPDLGILSASHDGSIRLWAVS
GECLMEMVDHTSIVYSVDSHASGLIVSGSEDRFAKIWKDGVCFQSIEHPGCVWD
VKFLEDGDIVTACSDGTIRIWTNQEDRMANSTELELFDLELSSYKRSRKRVGGL
KLEELPGLEALQVPGTSDGQTKVIREGDNGVAYAWNSTELKWDKIGEVVDGPED
SMNRPALDGVQYDYVFDVDIGDGEPTRKLPYNRSDNPYDTADKWLLKENLPLSY
RQQIVEFILANSGQRDFNLDPSFRDPYTGSSAYVPGAPSQLAAKQARPTEKHIP
KKGMLVFDAAQFDGILKKINEFNNTLLSNQEKKNLSLTDIEISRLGAVVKILKD
TSHYHSSKFADADFDLMLKLLESWPYEMMFPVIDIFRNVILHPDGADGLLRHQE
DKKDVLMESIKRATGNPSVPANFLTSIRAVTNLFKNSAYYSWLQKHRSEMLDAF
SSCSSSSNKNLQLSYATLLLNYAVLLIEKKDEEGQSQVLSAALELAENESLEVD
ARYRALVAIGSLMLDGLVKRIALDFDVEHIAKAARTSKEAKIAEVGADIELLIK
QS
348WD40 repeatMEFTEAYKQSGPCCFSPNARFIAVAVDYRLVIRDTLSLKVVQLFSCLDRISYIE2431625
proteinWALDSEYILCGLYKRPMIQAWSLIQPEWTCKIDEGPAGIAYARWSPDSRHILTT
SDFQLRLTVWSLVNTACVHVQWPKHASKGVSFTRDGKFAAICTRHDCKDYINLL
SCHNWEIMGVFAVDTLDLADIQWSPDDSAIVIWDSPLEYKVLVYSPDGRCLFKY
QAYESGLGVKSVSWSPCGQFLAVGSYDQMLRVLSHLTWKT˜AEFTHLSNVRAPC
CAAIFKEVDEPLQIDMSELSLSDDYMQGNSGDAPEGHYRVRYDVTEVPITLPCQ
KPPADRPNPKQGIGLMSWSNDSQYICTRNDSMPTILWIWDMRHLELAAILVQKD
PIRAAVWDPTGTRLVLCTGSSHLYMWTPSGAYCVSVPLSQFNITDLKWNSDGSC
LLLKDKESFCCAAAPLPPDESSDYSSDD
349WD40 repeatMATIAALDDDMVRSMSIGAVFSDFVGKLNSLDFHRKDDILVTAGEDDSVRLYDI1261127
proteinANARLLKTTFHKKHGTDRVCFTHHPNSLICSSTKNLDTGESLRYISMYDNRSLR
YFKGHKQRVVSLCMSPINDSFMSGSLDHSVRNWDLRVNACQGILRLRGRPTVAY
DQQGLVFAVAMEGGAIKLFDSRSYDKGPFDAFLVGGDTSEVCDIKFSNDGKSVL
LSTTNNNIYVLDAYAGDKQCGFNLEPSPSTPIEASFSPDGQYVVSGSGDGTLHA
WNISRRNEVACWNSHIGVASCLKWAPRRAMFVAASTVLTFWIPNSEPELASAKG
EAGVPPEQV
350WD40 repeatMSVAELKERHRAATETVNSLRERLKQKRVQLLDTDVAGYARTQGKTPVTFGATD2571390
proteinLVCCRTLQGHTGKVYSLDWTPERNRIVSVSQDGRFIVWNALTSQKTHAIRLPCA
WVMTCAFAPNGQSVACGGLDSVCSIFNLNSPVDRDGNLPVSRNLSGHKGYVSSC
QYVPDGDAHLITGSGDQTCVLWDITTGLRTSVFGGEFQSGHTADVLSVSINGSS
PRIFVSGSCDSTARMWDTRVASRAVHTYHGHEGDVNAVKFFPDGNRFGTGSDDG
TCRLFDIRTGHELQVYYQQRGIDEIPHVTSIAFSISGRLLIAGYSNGDCFVWDT
LLAQVVLNLGSLQNSHEGRISCLGVSADGSALCTGSWDTNLKIWAFGGIRRVT
351WD40 repeatMKKRPRGASLDQAVVDIRRREVGGLSGLSFARRLAASEGLVLRLDIYNKLKGHR1781632
proteinGCVNTVGFNLDGDIVISGSDDRHVKLWDWQTGKVKLSFDSGHLSNVFQAKIMPY
TDDRSIVTCAADGQARHAQILEGGQVQTHLLAKHRGRAHKLAIDPGSPHIVYTC
GEDGLVQRLDLRSNTARELFTCREVYGTHVEVVHLNAIAIDPRNPNLFVIGGSD
EYARVYDIRNYKWNGSHNFGRSANYFCPSHLIGEAHVGITGLAFSGQSELLVSY
NDESIYLFTQEMGLGPDPLSASTKSVDSNSSEVTSPTAVNVDDNVTPQVYKGHR
NCETVKGVGFFGPKCEYVVSGSDCGRIFIWKKKGGQLIRVMAADKHVVNCIEPH
PHIPALASSGIENDIKIWTPKAIERATLPMNVEQLKPKARGWMNRISSPRQLLL
QLYSLERWPEHGGETSSGLAAGQEELTELFFALSANGNGSPDGGGDPSGPLL
352WD40 repeatMSKRGYKLQEFVAHSSNVNCLSIGKKACRLFLTGGDDCKVNLWAIGKPNSLMSL2902917
proteinCGHTNAVESVAFDSAEVLVLAGASSGVIKLWDVEEAKMVRGLTGHRSNCTAMEF
HPFGEFFASGSTDTNLKIWDIRRKGCIHTYKGHTRGISTIRFSPDGRWVVSGGN
DNVVKVWDLTAGKLLHDFKFHENHIRSIDFHPLEFLLATGSADRTVKFWDLETF
ELIGSSRPEAAGVRAIAFHPDGRTLFCGLEDSLKVYSWEPVICHDGVDMGWSTL
ADLCIHDGKLLGCSYYQSSVGVWVADASLIEPYGTNVKPQQKDSGDDEIEHQES
RPSAKVGTTIRSTSIMRCASPDYETKDIKNIYVDTASGNPVSSQRVGTTNFAKV
TQPLDFNDTPNLTLRRQGLVTETPDGLSGHVPSKSITQPKVVSRDSPDGKDSSR
RESITFSRTKPGMLLRPAHSRRPSSTKYDVDRLSACAEIGVLSSAKSGSESLVD
SFLNIKVAPEDGARNGCEDNHSSVKNVSVESERVLPLQTPKTEKCDQTVGFKEE
INSVKFVNGVAVVPGRTRTLVEKFEKREKLNSTEDQTINTPENPTLDKTPPPSL
AENEEKSDRLNIVERKATRMSSHNVTAEDRTPVTLVGSPEDQSTVMAPQRELPA
DESSKTPPLPVEDLEIHHGSNVSEDKATILSSQTVSEEDSKRSTLIRNFRRRDR
FKSTEGRSPVMATQRKLPTDESGKTSSLPMEDLEIKGGLNVSEDKATSFSSRAP
PREDRAHSALVRNVRKRDKFKSTNDTITVMVHQRGLSTDEASTVSVERVERRQL
SNNVENPLNNLPPHSVPPTTTRGEPQYVGSESDSVNHEDVTELLLGNHEVFLST
LRSRLTKLQVV
353WD40 repeatMSTFLTGTALSNPNPNKSYEVVQPPMDSVSSLSFNPKANFLVATSWDNQVRCWE1481197
proteinIVRSGTSLGTTPKASISHQQPVLCSTWKDDGTTVFSGGCDKQVKNWPLSGGQPM
TVAMHDAPIKEISWIPEMNLLVTGSWDKTLRYWDTRQANPVHIQQLPERCYALT
VRHPLMVVGTADRNLIIYNLQSPQTEFKRISSPLKYQTRCLAAFPDQQGFLVGS
IEGRVGVHHLDDSQQSKNFTFKCHREGSEIYSVNSLNFHPVHHTFATAGSDGAF
NFWDKDSKQRLRAMSRCSQPIPCSTFNNDGSIFAYSACYDWSKGAENHNPATAK
TYIFLHLPQESEVKGRPRLGTTGRK
354WD40 repeatMEVEAQQRDVNNVMCQLVDPEGTTLGPPMYLPQDVGPQQLQQMVNKLLSNEDKL1401567
proteinPYTFYISDQELVVPLESYLQKNKVSVEKVLSIVYQPQAIFRIRPVNRCSATIAG
HSEAVLSVAFSPDGKQLASGSGDTTVRLWDLSTQTPMFTCKGHKNWVLSIAWSP
DGKHLVSGSKAGEIQCWDPLTGQPSGNPLVGHKKWITGISWEPVHLSSPCRRFV
SSSKDGDARIWDVTLRRCVICLSGHTLAVTCVKWGGDGVIYTGSQDCTIKVWET
SQGKLIRELKGHGHWVNSLALSTEYVLRTGAFDHTGKQYSSAEEMKQVALERYK
KMKGNAPERLVSGSDDFTMFLWEPSVSKHPKTRNTGHQQLVNHVYFSPDGQWVA
SASFDKSVKLWNGITGKFVAAFRGHVGPVYQISWSADSRLLLSGSKDSTLKIWD
IRTKKLRRDLPGHADEVFAVDWSPDGEKVVSGGKDKVLKLWMG
355WD40 repeatMDAGSAHSSSNHKTQSRSPLQEQFLQRRNSRENLDRFIPNRSAMDFDYAHYMLT3761737
proteinEGRKGKENPAVSSPSREAYRKQLAETLNMNRTRILAFKNKPPTPVELIPHELTS
AQPAKPTKTRRYIPQTSERTLDAPDLLDDYYLNLLDWGSSNVLSIALGNTVYLW
NASDGSTSELVTIDDETGPVTSVSWAPDGRHIAVGLNNSDVQLWDSADNRLLRT
LRGGHRSRVGSLAWNNHILTTGGMDGLIVNNDVRVRSHIVDTYRGHTQEVCGLK
WSASGQQLASGGNDNILHIWDRSTASSNSPTQWLHRLEEHTAAVKALAWCPFQG
NLLASGGGGGDRTIKFWNTHTGACLNSVDTGSQVCALLWNKNERELLSSHGFTQ
NQLTLWKYPSMVKIAELTGHTSRVLFMAQSPDGCTVASAAGDETLRFWNVFGVP
EVAKPAPKANPEPFAHLNRIR
356WD40 repeatMEEAIPFKNLPSREYQGHKKKVHSVAWNCTGTRLASGSVDQTARVWHIEPHGEG691010
proteinKVKDIELKGHTDSVDQLCWDPRHADLIATASGDKTVRLWDARSGKCSQQAELSG
ENINITYKPDGTHVAVGNRDDELTILDVRKFKPIHKRKFNYEVNEIAWNMSGEM
FFLTTGNGTVEVLAYPSLRPVDTLMAHTAGCYCIAIDPVGRYFAVGSADSLVSL
WDISEMLCVRTFTKLEWPVRTISFNHTGDYVASASEDLFIDISNVQTGRTVHQI
PCRAAMNSVEWNPKYNLLAYAGDDKNKYQADEGVFRIFGFESA
357WD40 repeatMGKDEEEMRGEIEERLINEEYKVWKKNTPFLYDLVITHALEWPSLTVEWLPDRE1491423
proteinEPPGKDYSVQKLVLGTHTSENEPNYLMLAQVQLPLEDAENDARHYDDDRADVGG
FGCANGKVQIIQQINHDGEVNRARYMPQNSFIIATKTVSAEVYVFDYSKHPSKP
PLDGACSPDLRLRGHSTEGYGLSWSKFKQGHLLSGSDDAQICLWDINATPKNKS
LDAMQIFKVHEGVVEDVAWHLRHEYLFGSVGDDQYLLIWDLRTPSVTKPVQSVV
AHQSEVNCLAFNPFNEWVVATGSTDKTVKLFDLRKISTALHTFDAHKEEVFQVG
WNPKNETILASCCLGRRLMVWDLSRIDEEQTPEDAEDGPPELLFIHGGHTSKIS
DFSWNTCEDWVVASVAEDNILQIWQMAENIYHDEDDVPGEESNKGS
358WD40 repeatMMRGFSCTEDGDAPSTSSTSPPPPPPPPHRQQMQAPRASSSSSGQPTSRRSTGN3652677
proteinVFKLLARREVSPRSKHSLKKFWGEASECQLCPFQQSYEAVRDVRRSLISWVEAF
SLQHLSAKYCPLMPPPRSTIAAAFSPDCKILASTHGDHTVRLIDSQTGSCLKVL
RGHRRTPWVVRFHPLYPEILASGSLDHEVHLWDANTAECIGSRNFYRPIASIAF
HAQGDLLAVASGHKLYIWHYNRSGETSSPTIVLRTPRSLRAVHFHPHAAPFLLT
AEVNDLDLTDSAMTLATSPGYLHYPPPTIYLADAHSNERSRLEDELPLMPSPLL
MWPSFTRDDGRATLPHIGGDVGLSGQQRVDSLSSGQYEFHPSPIEPSSSTSMHE
EMGTDPFSSVRESEVTQSAMNIVDNTEVQPEERSTYSFSFSDPRFWELPSVYGW
LVGQTQAAPRTAPSPGALETASALGEVASVSPVRSEFMPGGMDQPRLGGRSGSG
CRSSGSRMMRTAGLNDHPHQENYPQSVVSKLRSELEASLAAAASTELPCTVKLR
VWPYDMKDPCALFRSESCRLTIPHAVLCSEMGAHFSPCGRFFAACVACVLPQLE
ADPVLHGQVDPDVTGVATSPTRHPVSAYQIMYELRIYSLEEATFGMVLASRSIR
AAHCLTSIQFSPTSEHLLLAYGRRHNSLLKSIVIDGENTVPIYSILEVYRVSDM
ELVRVLPSAEDEVNVACFHPSVGGGLVYGTKEGKLRILQIDSSGGLNPKSTGFL
DENMAEVPTYALEC
359WD40 repeatMGEGDLPRTEAGVLRGHEGAVLAARFNGDGNYCLSCGKDRTIRLWNPHRGIHIR24923
proteinTYKSHGREVRDVHCTSDNSKLISCGGDRQIFYWDVSTGRVIRRFRGHDSEVNAV
KFNDYASVVVSAGYDRSVRAWDCRSHSTEPIQIINTFQDSVMSVCLTKTEIIGG
SVDGTVRTFDIRIGREISDDLGQPVNCISMSNDGNCILASCLDSTLRLVDRSAG
ELLQEYKGHTCKSYKLDCCLTNTDAHVAGGSEDGYVFFWDLVDASVISKFRAHS
SVVTSVSYHPKEDCMITASVDGTIKVWKT
360WD40 repeatMACIKGVGRSASVAMAPDGGYLATGTMAGTVDLSFSSSASLEIFGLDFQSDDRD2213598
proteinLPLIAESPSSERFNRLSWGKNGSGSDEFSLGLIAGGLVDGTIGLWNPLSLIRSE
AGDKAIVGHLSRHKGPVRGLEFNVIAPNLLASGADDGEICIWDLAAPREPSHFP
PLRGSGSAAQGEISFLSWNSKVQHILASTSYNGTTVVWDLKKQKPVISFSDSVR
RRCSVLQWNPDLATQLVVASDEDSSPTLRLWDMRNIMSPVKEFAGHTRGVIAMS
WCPNDSSYLVTCAKDNRTICWDTVTGEIVCELPAGSNWNFDVHWYPKIPGVISA
SSFDGKIGIYNVEGCSRYGVRENEFGAATLRAPKWFKRPVGASFGFGGKVVSFH
TRSTGGPSVNSSEVFVHDIITEQTLVSRSSEFEAAIQSGDRPSLRALCEKKSQH
CESTDDQETWGFLKVLLEDDGTARSKLLAHLGFDIPTETNDGSQEDLSQQVNAL
GLEDVTADKVVQEDNNESMVFPTDNGEDFFNNLPSPRADTPVSTSADGFPTVNA
AVEPSQDEVDGLEESSDPSFDDSVQRALVVGDYKAAVALCMSANRLADALVIAH
VGGASLWESTRDKYLKMSRLPYLKVVFAMVNNDLQSLVDTRPLKFWKETLAILC
SFAQGEEWAMLCNSLASKLMAAGNNLAATLCFICAGNIDKTVEIWSRSLATEHD
GMSYMDLLQDLMEKTIVLALASGQKQFSASVCKLVEKYAEILASQGLLTTAMDY
LKLLGTDDLSPELAVLRDRIAFSVEAEKGANISAFNGSQDPRGAVYGVDQSNYG
MVDTSQHYYPEAAQPQVPHTVPGSPYGENYQQPFGSSFGRGYNTPMQYQAPSQA
SMFVPSEPPQNAQPSFVPTPVTSQPTTRSQFIPAPPLALRNPEQYQQPTLGSHL
YPGSVNPTFQPLPHAPGPVAPVPPQVSSVPGQNMPQAVAPTQMRGFMPVTNPGV
VQNPGPISMQPATPIESAAAQPVVSPAAPPPTVQTADTSNVPAPQKPVIATLTR
LYNETSEALGGSRANPAKKREIEDNSRKIGALFAKLNSGDISKNAADKLVQLCQ
ALDNGDYSTALQIQVLLTTSEWDECNFWLATLKRNIKTRQNVRLS
361WD40 repeatMKERGKGAGRSVDERYTQWKSLVPVLYDWLANHNLVWPSLSCRWGPQLEQATYK441447
proteinNRQRLYLSEQTDGSVPNTLVIANVEVVKPRVAAAEHISQFNEEARSPFVKKFKT
IIHPGEVNRIRELPQNSKIVATHTDSPDVLIWDVETQPNRHAVLGASTSRPDLI
LTGHKDNAEFALAMSPTEPFVLSGGKDRYVVLWSIQDHISTLAADPGSAKSPGS
AGTNNKQSSKAAGGNDKTGDSPSIEPRGVYLGHGDTVEDVTFCPSSAQEFCSVG
DDSCLILWDARTGSSPAIKVEKAHHADLHCVDWNPHDVNLILTGSADNTVRMFD
RRNLTSGGVGSPVHTFEGHNAAVLCVQWSPDKSSVFGSSAEDGILNIWDHEKIG
RKI ETVGSKVPNSPPGLFFRHAGHRDKVVDFHWNSSDPWTIVSVSDDGESTGGG
GTLQIWRMIDLIYRPEEEVLAELDKFKSHILSCTS
362WD40 repeatMAKIAPGCEPVAGTLTPSKRREYRVTNRLQEGKRPLYAVVFNFIDSRYFNVFAT1961314
proteinVGGNRVTVYQCLEGGVIAVLQSYIDEDKDESFYTVSWACNIDRTPFVVAGGING
IIRVIDAGNEKIHRSFVGHGDSINEIRTQPLNPSLIVSASRDESVRLWNVHTGI
CILIFAGAGGHRNEVLSVDFHPSDKYRIASCGMDNTVRIWSMKEFWTYVEKSFT
WTDLPSKFPTKYVQFPVFIAPVHSNYVDCNRWLGDFVLSKSVDNEIVLWEPKMK
EQSPGEGSVDILQKYPVPECDIWFIKFSCDFHYHSIAIGNREGKIYVWELQSSP
PVLIARLSHPQSRSPIRQTAMSFDGSTILSCCEDGTIWRWDAITASTS
363WD40 repeatMNTAMHFGAGWRSIAEMGYTMSRLEIEPESCEDEKSLDGVGNSQGPNELPRCLD1931668
proteinHELAHLTNLKSRPHEHLIRDFPGRRALPVSTVKMLAGRECNYSRRGRFSSADCC
HMLSRYVPVNGPSPLDQMNSRAYVSQFSADGSLFVAGFQGSHIRIYNVDKGWKC
QKNILTKSLRWTITDTSLSPDQRYLVYASMSFIVHIVDIGSAAMDSLAMITEIH
EGLDFSADSGPYSFGIFSVKFSTDGREVVAGSSDDSIYVYDLVANKLSLRIPAH
ESDVNTVCFADESGHIIYSGSDDTYCKVWDRRCLSARNKPAGVLMGHLEGITFI
DSRGDGRYFISNGKDQTIKLWDIRKMGSDICRRGFRNFEWDYRWMDYPPRARDS
KHPFDLSVATYKGHSVLRTLIRCYFSPVHSTGQKYIYTGSHDSCVYIYDVVTGA
QVAALKHHKSPVRDCSWHPEYPMIVSSSWDGDIVKWEFFGNGETEIPANKKRIR
RRHLY
364WD40 repeatMEFQPQAPKKRGRKPKPKEDKKEEQLHQPPPPPPPQQQAAPAPAPAATRSSTSG781634
proteinSAGGRDRRPQQQHAVDEKYARWKSLVPVLYDWLANHNLLWPSLSCRWGPQLEQA
TYKNRQRLYISEQTDGSVPNTLVIANCEVVKPRVAAAEHVSQFNEEARSPFIRK
YKTIIEPGEVNRVRELPQNPNIVATHTDSPDVLIWDVESQFNRHAVYGATASRP
NLILTGHQENAEFALAMCPAEPFVLSGGKDKTVVLWSIQDHITASATDQTTNKS
PGSGGSIIKKTGEGNEETGNGPSVGPRGIYCGHEDTVEDVAFCPSTAQEFCSVG
DDSCLILWDARVGTNPVAKVEKAHNGDLHCVDWNPHDNNLILTGSADNSVNNFD
RRNLTSNGVGSPVYKFEGHKAAVLCVQWSPDKPSVFGSSAEDGLLNIWDYERVD
KKVDRAPNAPAGLFFQHAGHRDKIVDFHWNAADPWTMVSVSDDCDTAGGGGTLQ
IWRMSDLIYRPEEEVLAELENFKAHVLECSKA
365WD40 repeatMGIFEPYRAVGYITTGVPFSVQRLGTETFVTVSVGKAFQVYNCAKLSLVLVGPQ852826
proteinLPKKIRALASYREYTFAAYGSDIGIFKRAHQLATWSGHTAKVCLLLLFGEHILS
VDVDGNAYIWAFKGMNYNLSPVGHILLDSNFTPSCIMHPDTYLNKVILGSQEGP
LQLWNISTKTKLYEFKGWNSSVSSCVSSPALDVVAVGCADGKIHVHNIRYDEEL
VTFSHSMRGSVTALSFSTDGQFLLASGSSSGVVSIWNLDKRRLQSVIRDAHDGS
IISLHFFANEPVLMSSSADNSIRMWIFDTSDGDPRLLRFRSGHSAPPLCIRFYA
NGRHILSAGQDRAFRLFSVVQDQQSRELSQRHVSRRAKKLELKEEEIKLKPVIA
FDVAEIRERDWCNVVTSHMDTPQAYVWRLQNFVIGEHILRPCPNKPTFVKACMI
SACGNFAILGTAGGWIERFNLQSGISRGSYIDQLEGTNSAHDGEVVGVACDATN
TLMISAGYAGDIKVWDFEGRELKSRWEIGSSLVKISYHRLNGLLATVADDFIIR
LFDAVALRMVRRFEGHTDRITDLCFSEDGKWLLSSSMDGSLRIWDIILARQVDA
VFVDVSITALSLSPNMDILATTHVDQNGVFLWVNQSMFSGDSDINLYASGKEVV
TVKLPSVSSVEGSQVEESNEPTIRHSESKDVPSFRPSLEQIPDLVTLSLLFKSQ
WQSLINLDIIKVRNRPVEPPKKFEKAPFFLPSIPSLSGEILFKPSEMSDKGDMK
ADEDKSKITPEVPSSRFLQLLHSCSEARNFSPFTTYIKGLSPSTLDLELRMLQI
IDDDAVDADADDPQDVDKRQELLSIELLMDYFIHEISCRSNFEFVQALVRLFLK
IHGETIRRQSVLQNKAKVLLETQCSVWQRVDKLFQGARCMVAFLSNSQF
366WD40 repeatMEETKVTCGSWIRRPENVNLAVLGRSPRRRGSAALEIFAFDPKSTSLSSSPLVA741246
proteinHVIEEIEGDPLAIAVHPNGEDIVCFASSGSCLSFELSGQESNLKLLTKELPPLR
GIGPQKCMAFSVDGSRFATGGVDGRLRILEWPSLRIILDEPRAHKSIRDLDFSL
DSEFLATTSTDGSARIWKAEDGLPCTTLTRRSDEKIELCRFSKDGTRPFLFCTV
QRGDKAVTGVWDISTWNKIGHKRLLRRPAVVMSISLDGKYLAQGSKDGDMCVVE
VKKNEVSHWSKRLHLGTSLTSLEFCPIERVVITTSDEWGVLVTKLNVPADWKAW
QVYLLLLGLFLASLVAFYIFYENSDSFWGFPLGKDQPARPKIGSVLGDPKSADD
QNMWGEFGPLDM
367WD40 repeatMADPVEHQHQQHQQHQLQQQRRRGWRIQGGQYLGEISALCFLHLPPPPLSLSSS1004377
proteinPVLSLSSGLDSESRDRFACSFRFPSAGSGSQVSLFDLASGAMVRTFYVFRGIRV
HGIVLGCADFPGGSSSSSSTLDYVIAVYGERRVKLFRLSVRLGRGAGEGSGTVL
SADLELVSAAPRLSHWVMDVRFLKENGTSEDELQRCLTVAIGCSDNSIRLWDVD
KCSFVLAVSSPERCLLYSMRLWGDNLEDLQVASGTIYNEILIWKVVPNHDAPSS
NELTEEGLTNSCAGNSVHECLRYEAYHICRLVGHEGSIFRIAWSSDGSKLVSVS
DDRSARIWEVHCRVQYSEDAGEVGLLFGHSARVWDCYISDNLIVTAGEDCSCRV
WGLDGQQHDVIKEHIGRGIWRCLYDPWSSLLVTGGFDSAIKVHKLDASLAEASA
KQSNIKDLSDGTELFTTHLPNSSGHSGHMDSKSEYVRCLSFSCEDVMYIATNHG
YLYHAKLCNDGDLRWTELAQVSNEVQIICMELLPSNPYDPRIDADDWVAVGDGR
GWTTVVRVVKNSDSPKVSTSFSWAAEMDRQLLGIHWCKSLGHRFIFTADPRGAL
KLWRFFEVSQSSSLYPENSFRISLIAEFKSDLGARIMCLDVAFESELLICGDLR
GNLVLFPLLKDLLLDTFVVSAAKISPVNHFKGAHGISAVSSISVAHNSFNHIEL
RSTGADGCICYMEYDKGLQSLNFVGMKQVKELSMIESVSTENESTGYRTSGSYA
SGFASTDFIIWNLVTEAKVLQVSCGGWRRPHSYYLGDVPEMKNCFAYVKDDIIY
IRRHWIKDSKDKILPQNLRLQFHGREVHSLCFVTGDFQLRKNKQSSWIVTGCED
GTVRLTRYTQCTDNWSSSKLLGEHVGGSAVRSICCVSNIHTTSSGTSVSDVKGI
ENLPKDIRGTLMEDECNPSLLISVGAKRVLTSWLLRRRKQDGKEDDVTDLQEAE
NSSLPSSAGSSTFSFQWLSTDMPVKYSVPSRKSGSIKKLIGVSDTNVRCKSLLP
DSEALQSKVSAVDKNEDDWRYLAVTAFLVRHSGSRLIVCFIIVACSDATLAIRA
LVLPYRLWFDVALMVPLSSPVLSLQHVIIGRCQLPDENVQIGNVYVVISGATDG
SIAFWDLTESVEAFMRRLSNIHLEKFMDCQKRFRTGRGSQGGRWWRSLSKIACK
EQPINDPVTAKAIKELNRKLTGGVACGSSSSMLDASPELDSNAANSSFEIIEVN
PFHVLNGVHQSGVNCLHVCETKHGQSSDGRFLYQLVSGGDDQALHLLKFEVLVQ
PPVQVFDVPNSDIRNSILVEEFLLDEQNQKTKCTIEFISQEKIASAHNSAVKGV
WTDGTWVFSTGLDQRVRCWISKDRGTPTELAHFIISVPEPEALDARSICWDQYQ
IAVAGRGMQMIEFHVPSSEIR
368WD40 repeatMPYKLSATLSNHSSDVRAVASPSDDLILSASRDSTAISWFRQSPSSFTPASVIR582439
proteinAGSRFVNAIAYLPPTPRAPQGYAVVGGQDTVVNVFALGPGDKEEPEYTLVGHTD
NVCALSVNSDDTIISGSWDKTAKVWKDFALVYDLKGHQQSVWAVLAMNEKEFLT
ASADRTIKYWVQHKTMQTYEGHRDAVRGLALIPDIGFASCSNDSEIRVWTMGGD
VVYTLSGHTSFVYSLSVLPNGDLVSAGEDRSVRVWRDGECSQVIVHPAISVWAV
STMPNGDIISGSSDGVVRVFSESEKRWATASELKALEDQIASQSLPSQQVGDVK
KTDLPGPEALSVPGKKAGEVKMIRSGDVVEAHQWDSLASSWQKIGEVVDAIGSG
RKQLHDGKEYDYVFDVDIQEGAPPLKLPYNVSENPYTAAQRFLEQNDLPTGYLD
QVVKFIEQNTAGVKLGNDGYVDPFTGASRYQPATQSTSNTASSSYMDPFTGGSR
HIAESAPSNVPQGSHATGIIPFSKPIFFKLANVSANQAKMFQFDEVLRNEISTA
TLANRPDEVIMVNETFTYLSKVVTSTSSARTSLGWIHIETIMQILDRWPVPQRF
PVIDLGRLVTAYCMNAFSGPGDLEKFFSCLFRTSEWTSITSGSKALTKAQETNV
LLLERTIANSLDGAPLNDMEWIKQIFRELAQTPQLVLNKSHRLALASVLFNFSC
IGLKGPVPADVRTLHLTIILQVLRSPNDDPEVAYRTCVALGNMLYSDKTRGTPR
DAQSPSPTELKSAVAAIKGGFSDPRINDVHREIMSLI
369WD40 repeatMPPQKIESGHKDTVHDLAMDYYGKRLATASSDHTINVVGVSSSGSQHLATLIGH1591064
proteinQGPVWQISWAHPKFGSLLASCSYDGRVIIWREGNPNEWTQAQVFEEHKSSVNSV
AWAPHELGLCLACGSSDGNISVFTARQDGGWDTSRIDQAHPVGVTSVSWAPSTA
PGALVGSGMMEPVQKLCSGGCDNTVKVWKLYNRVWKLDCFPVLQMHTDWVRDVA
WAPNLGLPKSTIASASQDGRVIIWTLAKEGDQWQGKVLYDFRTPVWRVSWSLTG
NILAVADGNNNVSLWNEAVDGEWIQVSTVEP
370WD40 repeatMSAPMLEIEARDVVKIVLQFCKENSLHQTFQTLQSECQVSLNTVDSIETFVADI1181665
proteinNSGRWDAILPQVAQLKLPRNTLEDLYEQIVLEMIELRELDTARAILRQTQAMGV
MKQEQPERYLRLEHLLVRTYFDPNEAYQDSThEKRRAQIAQALAAEVTVVPPSR
LMALVGQALKWQQHQGLLPPGTQFDLFRGTAAMKQDVDDMYPTTLSHTIKFGTK
SHAECARFSPDGQFLVSCSVDGFIEVWDYMSGKLKKDLQYQADETFMMHDDPVL
CVDFSRDSEMLASGSQDGKIKVWRIRTGQCLRRLERAHSQGVTSVLFSRDGSQL
LSTSFDGSARIHGLKSGKQLKEFRGHSSYVNDAIFSNDCSRVITASSDCTVKVW
DVKTSDCLQTFKPPPPLRGGDASVNSVHLFPKNADHIVVCNKTSSIYIMTLQGQ
VVKSLSSGKREGGDFVAACVSPKGEWIYCVGEDRNLYCFSCQSGKLEHLMKVHE
KDVIGVTHHPHRNLVATYSEDSTMKLWKP
371WD40 repeatMDLLQSYAEDNDGDLGRHSSPEPSPPRLLPSKSAAPKVDDTTLALTVAQTNQTL571628
proteinARPIDPSQHAVAFNPTYDQLWAPICGPAHPYAKDGIAQGMRNHKLGFVEDAAIG
SFLFDEQYNTFQRYGYAADPCASTGNEYVGDLDALKQNDGISVYNIRQQEQKKY
AEEYAKKKGEERGEGGREKAEVVSDKSTFHGKEERDYQGRSWIAPPKDAKATND
HCYIPKRLVHTWSGHTKGVSAIRFFPKHGHLILSAGMDTKVKIWDVFNSGKCMR
TYMGHSKAVRDISFCNDGTKFLTAGYDKNIKYWDTETGKVISTFSTGKIPYVVK
LHPDDEKQNILLAGMSDKKIVQWDMNTGQITQEYDQHLGAVNTITFVDDNRRFV
TSSDDKSLRVWEFGIPVVIKYISEPHMHSMPSISLHPNTNWLAAQSLDNQILIY
STRERFQLNKKKRFAGHIVAGYACQVNFSPDGRFVMSGDGEGRCWFWDWKSCKV
FRTLKCHEGVCIGCEWHPLEQSKVATCGWDGLIKYWD
372WD40 repeatMESNGNLEQTLQDGRIYRQLNSLIVAHLRDHNFPQAASAVALATMTPLNVEAPR2501566
proteinNRLLELVARGLAVEKGELLRGVSHAGTNDLGGSIPASYGLVPAPWTAIDFSSLR
DTKGMSKSFTKHETRHLSDHKNVARCARFSTDGRFFATGSADTSIKLFEVSKIK
QMNLPDSTDGAIRAVIRTFYDHTHPVNDLDFHPQNTVLISAAKDHTVKFFDYSK
ATAKRAFRVIQDTHNVRSVAFHPSGDFLLAGTDHPIPELYDVNTFQCYLSANVP
EFAVNAAINQVRYSSSGGMYVTASKDGTIRFWDGASANCVRSIAGAHGAAEVTS
ANFTKDQRYVLSCGKDSTVELWEVGTGRLVKQYLGATHNQLRCQAVFNNTEEFV
LSIDEPSNEIVVWDAMTAEKVARWPSNHNGPPRWIEHSPTEAAFVSCGTDRSIR
EWEETH
373WD40 repeatMSNFQGEDGEYVADDFEAEDGDEELHGRESADPESDVDEIDTPSNRFTDTTADQ1061434
proteinARRGRDIQGIPWERLSITREKYRRTRLEQYKNYENVPQSGEKSGKDCTVTEKGN
SFYEFRRNSRSVKSTILHFQLRNLVWATSKHDVYLMSNYSVVHWSSLTGKKSEV
LNLAGHVAPNEKHPGSLLEGFTQTQVSTLAVKDRFLVAGGFQGELICKFLDRPG
ISFCSRTTYDDNAITNAVEIYVSPSGGIHFIASNNDCGVRDFDMENFELSRHFR
FPWPVNHTSLSPDGKLLVIVGDDPEGILVDAKTGKTINPLRGHLDFSFASEWHP
DGVTFATGNQDKTCRIWDIRNLSKSIAVLKGNLGAIRSIRYTSDGRYMAIAEPA
DFVHVYDTKTGYKKEQEIDFFGEISGMSFSPDTESLFIGVWDRTYGSLLEYGRR
RNFSYLDCLV
374WD40 repeatMGVEEDLEDLNALAESTDAAVDGQAALASAVDSVTLQPAPPILPPVIPPPAVPV1901917
proteinVAPVPTIPPVLRPLAPLPIRPPVLRPPAPKRDEAGSSDSDSQHDGTAAGSTAEY
EITEESRLVRERHEKAMQDLNMKRRGAALAVPTNDKAVRARLRRLGEPMTLFGE
REMERRDRLRMLMAKLDAEGQLEKLMKAHEDEEAAASAAPEDVEEEMLQYPFYT
EGSKALFNARIDIARFSITRAALRLERARRRRDDPDEDVDAEIDWALKKAESLS
LHCSEIGDDRPLSGCSFSHDGRLLATCSMSGVAKLWDTCRNPQVNRVLTLKGHT
ERATDVAFSPVQNHIATASADRTARLWNTEGTILKTFEGHLDRLGRIAFHPSGK
YLGTTSFDKTWRLWDIESGEELLLQEGHSRSIYGIDFHRDGSLVASCGLDALAR
VWDLRTGRSILALEGHVKPVLGVSFSPNGYHLATGGEDNTCRIWDLRKKKSLYT
IPAHANLISEVRFEPQEGYFLVTASYDTTAKVWSARDFKPVRTLSVHEAKITSV
DITADASHIVTVSHDRTIRLWTSNDDVKEQAMDVD
375WD40 repeatMVKAYLRYEPAAAFGVIASVESNIAYDASGRHLLAPALERVGVWHVRQGVCTRA1022942
proteinLAPSASSAAGPSLAVTAIASSPSSLIASGYADGSIRIWDFEKGSCETTLNGHKG
AVSVLRYGKLGSLLASGSRDNDIILWDVVGETGLYRLRGHRDQVTDLVFLDSDR
KLVSSSKDKYLRVWDLETQHCMQIVGGHHSEIWSLDTDPEERYLVTGSADPELR
FYTVKNDSSDERSEADASGGVGNGDLASHNKWDVLKQFGEIQRQSKDRVATVRF
NKNGNLLACQAAGKLVEVFRVLDEAEAKRRARRRLHRKREKRGADVNENGDSSR
GIGEGHDTMVTVADVFRLLQTIRASKRICSISFCPVAPKSSLATLALSLNNNLL
EFHSIEADKTSKMLTIELQGHRSDVRSVTLSSDNTLLMSTSHNSVKIWNPSTGS
CLRTIDSGYGLCGLIVPQNKHALIGTKDGAIEIFDVGSGTCIEVVEAHGGSIRS
IVAIPNQNGFVTGSADHDIKFWEYGMRQKPGDNSKHLTVSNVRTLKMNDDVLVV
AVSPDAQKIAVALLDCTVRVFFMDSLKLMHSLYGHRLPVLCLDISSDGDLIVTG
SADKNLMIWGLDFGDRHKSIFAHGDSIMAVQFVGNTHYMFSVGKDRLVKYWDAD
KFELLLTLEGHHADIWCLAISNRGDFLVTGSHDRSIRRWDRTEEPFFIEREKEK
RLEEMFESDLDNAFGNKYVPKEEIPEEGAVALAGKKTQETLSATDSIIEALDIA
EVELKRIAEHEEEKNNGKTAEFHPNYVMLGLSPSDFILRALSNVQTNDLEQTLL
ALPFSDALKLLSYLKDWTTYPDKVELVSRIATVLLQTHYNQLVSTPAARPLLTT
LEDILHKKVKECKDTIGFNLAAMDHLKQLMALRSDALFQDAKVKLLEIRSQLSK
RLEERTDPREAKRRKKKQKKSTNMHAWP
376WD40 repeatMGGVQAEREDKDKVSLELTEEILQSMEVGMTFRDYSGRISSMDFHRASSYLVTA751079
proteinSQDESIRLYDVASATCLKTINSKKYGVDLVSFTSHPMTVIYSSKNGWDESLRLL
SLHDNKYLRYFKGHHDRVVSLSLCPRNECFISGSLDRTVLLWDQRAEKCQGLLR
VQGRFATAYDDPGLVFAIAFGGCVR4FDARKYEKGFFEIFSVGGDVSDANVVKF
SNDGRLMLLTTTDGHIHVLDSFRGTLLYTFNVKPTSSKSTLEASFSPEGMEVIS
GSGDGSVYAWSVRGGKEVASWLSTDTEPPVIKWAPGNLMFATGSSELSEWIPQL
SKLGAYVGRK
377WD40 repeatMAAFGAAPAGNHNPWKSSEVIQPPSDSVSSLCFSPRANHLVATSWDNQVRCWEL991148
proteinTKNGASVTSVPKASMSHDQPVLCSAWKDDGTTVFSGGCDKQAKMWSLMSGGQPV
TVAMHDAPIKEIAWIPEMNVLVTGSWDKTLKYWDTRQSNPVHTQQLPERCYANT
VRYPLMVVGTADRNLIVENLQNPQAEFKRFSSPLKYQTRCVAAFPDQQGFLVGS
IEGRVGVHHLDDSQISKNFTFKCHRDNNDIYSVNSLNFHPVHHTFATAGSDGTF
NFWDKDSKQRLKAMSRCSQPIPCSTFWNDGTIYAYSVCYDWSKGAENHNPATAK
TYIFLHLPQESEVKAKPRVGTTNRK
378WD40 repeatMNCSISGEVPEEPVVSTKSGHVFERRLIERYVSDYGKCPVSGEPLTMDDVLPVK2321806
proteinMGKIVKPRPLQAASIPGLLSIFQNEWDSLMLSWFALEQQLHTARQELSHALYQH
DAACRVIARLKKERDEARSLLALAERQIPMTASSDIAVWAPAMSNGRKASLDEE
PGYAGKKMRPGISASIIAEITDCNLALSQQRKKRQIPSTLAPVEDLERYTQLSS
YPLHKTGKPGITSLDICHSKDIIATGGIDTSAVLFDRSSGQIMSTLSGHSKKVT
SVWFDAQGDMVLTGSADKTVRIWQGSEDGSYNCRHILKDHTAEVQAITVHATNN
YFATASLDWTWCFYEFSTGLCLTQVEGASGSEGYTSAAFHPDGLILGTGTSNAD
VKIWDVKTQANVTTFSGHTGAITAISFSENGYFLATAAQDGVKLWDLRKLKNFR
TFSAYDKDTGTNSVEFDHSGCYLGLAGSDIRVYQVASVKSEWNCVKTFPDLSGT
GKVTCVKFGPDSKYIAVGSMDHWLRIFGLPSEDGANES
379WD40 repeatMAAPGVETLKKEIKELKEKIAQHRLDTDGEQPLPAAAKSKSVPEVSAALRQRRI721124
proteinLKGHFGKIYALHWSADSRHLVSASQDGKLIIWNGFTTNKVHAIPLRSSWVMTCA
YSPSGNLVACGGLDNLCSVYKVPHGGNKESSSAQKTYGELAQHEGYLSCCRFIK
DNEIVTSSGDSTCILWDVETKTPKAIFNDHTGDVMSLAVFDDKGVFVSGSCDAT
AKLWDHRVHRQCVMTFQGHESDINSVQFFPDGDAFGTGSDDSSCRLFDIRAYQQ
INKYSSQKILCGITSVAFSKTGKSLFAGYDDYMTYVWDTLSGNQVEVLTGHENR
VSCLGVSEDGKALATGSWDTLLKIWA
MGGVEDESEPASKRNKLSSRVLRGLANGSSRTEPAAGSSLDLMARPLPIEGDES3152069
VIGSKGVIKRVEFVRLIAKALYSLGYEKSGARLEEESGIPLQSSVVNLFMQQIS
DGLWDESVVTLHKIGLSDENLVKSASFLILEQKFLELLDQEKANDALKTLRTEI
TPLCIKNSRVRELSSCIISPSSCGLLNQNKRNSTRARSRSELLEELQKLLPPAV
IIPERRLEHLVEQALVLQTDACMLHNSIDMEMSLYTDHQCGKEHIPCRTLQILQ
SENDEVWLVQFSHNGKYLASASNDRSAIIWEVDENGSVSLKHKLTGHQKPISSV
CWSPDDRQLLTCGVGETVRRWDVSSGECLRVYEKAGHGLISCAWFPDGKWICYG
VSDRSICMCDLEGKEIECWKGQRTLSISDLEITSDGKQIISICRETAILLLDRE
AKYERMIEENQTITSFSLSKDNRYLLVMLLNQEIHLWDIKGDFRLVAKYKGLKR
SRFVIRSCFGGLKQAFVASGSEDSQVYIWHKGSGELIEPLPGHSGAVNCVSWNP
ANHHMLASASDDRTIRIWGLMELNTRHKGARPNGVHYCNGNGTS
381WD40 repeatMTQLAETYACMPSTERGRGILIAGNPKPGSNSVLYTNGRSVVILNLDNPLDISV
proteinYAEHAYPATVARFSPNGEWVASADSSGAVRIWGAYNDHVLKKEFKVLSGRIDDL
QWSPDGLRIVASGDGKGKSLVRAFMWDSGTNVGEFDGHSRRVLSCAFKPTRPFR
IVTCGEDFLVNFYEGPPFKFKLSRRDHSNFVNCLRFSPDGNRFISVSSDKKGII
YDGKTGEKIGELSSDGGHTGSIYAVSWSPDSKQVITVSADKSAKIIWISEDGSG
NLRKTLTSSGSGGVDDMLVGCLWQNNHLVTVSLGGTISIYTAGDLDKAPVSFSG
HMKNVSSLSVLKGDPKVILSSSYDGLIIKWIQGIGFSGRVQRKESTQIKCLAAV
DEEIVTSGYDNKVCRVSGSGDAEFIDIGCQPKDLSLALQCPEFALVSTDTGVVL
LRGAKIVSTINLGFAVTASTVAPDGTEAIIGAQDGKLRIYSISGDTLTEEAVLE
KHRGAISVIHYSPDLSMFASGDLNREAVVWDRASREVRLKNILYHTARINCLAW
SPDSSTVATGSLDTCVIIYEVDKPASNRLTIKGAHLGGVYGLAFTDDFSVVSSG
EDACIRVWKINRQ
382WD40 repeatMKVKVISRSTDEFTRERSQDLQRVFRNFDPNLRTQEKAVEYVRALNAAKLDKVF1301488
proteinARPFVGAMDGHVDSVSCMAKNPNYLKGIFSGSMDGDIRLWDIASRRTVCQFPGH
QGPVRGLAASTQGQILVSCGIDSTVRLWNVPVATLGESDGTHENLAKPLAVYVW
KNAFWAVDHQWDGELFATAGAQVDIWNQNRSQPISSFEWGTQTVISVRFNPGEP
NVLATSGSDRSITLYDLRMSSPTRKVIMRTKTNAISWNPMEPMNFTAANEDCNC
YSYDARKLEEAKCVHKDHVSAVMDIDYSPTGREFVTGSYDRTVRIFQYNGGHSR
EVYHTKRMQRVFCVKFSCDASYVISGSDDTNLRLWKAKASEQLGVVLPRERRKH
EYHEAVKSRYKHLPEVKRIVRHRHLPKPIYKAGILRRTVNEADRRKEERRKAHS
APGSSSAEPLRKRRIIKEIE
383WD40 repeatMVRSIKNPKKAKRKNKGSKNGDGSSSSSSIPSNPTKVWQPGVDKLEEGEELQCD2691693
proteinPSAYNSLHAFHIGWPCLSFDIVRQTLGLVRTEFPHQVYFVAGTQAEKPTWNSIG
IFKVSNITGKRRELVPSEPTDDADEESDSSDSDEDSDDEVGGSGTPILQLRKVG
HEGCVNRIRAMNQNPHICASWGDSGHVQIWDFSSHLNALAESEADVSQGASSVF
NQAPLVKFGGHKDEGYALDWSPLVPGRLVSGDCKNSIHLWEPTSGSTWNVDSTF
FIGHAASVEDLQWSPTEENVFASCSVDGTIAIWDTRLGKTPAASFKAHDADVNV
ISWNRLATCMLASGCDDGTFSIHDLRLLKEGDSVVAHFEYHKHPVTSIENSPEE
ASTLAVSSADCQLTIWDLSLEKDEEEEAEFKAKTKEQVNAPEDLPPQLLFVHQG
QKDLKELHWHAQIPGMIVSTAADGFNILNPSNIQSTLPSDGA
384CDK type AMERYKVIKELGDGTYGSVWKALNQQTHEIVAIKKMKRKYYIWEECINLREVKSL11632545
RKLNHPNIIKLKEVIRENNELFFIFEYMECNLYQIMKERSTPFSETAIIKFCYQ
ILQGLSYMHRNGYFHRDLKPENLLVTSDLIEIADFGLAREVLTSPPYTDYVSTR
WYRAPEVLLQSPTYTTAIDMWAVGAILAELFTLHPLFPGESELDEIYKICGVLG
TPDYETWPDGMQLAAFRNFIFPQFLPVNLSVLIPHASPEAIDLITRLCSWDPQK
RPTAEQALHHPFFRIGMSIPLSLGGHFQDNTCAAEVDTNFHSKKACKGRGNGEK
ESSLECFLGLSLGLKPSLGHLGAMGSQGVGAVKQEVGSSPGCQSNPKQSLFQVL
NSBAILPLFSSSPNLNVVPVKSSLPSAYTVNSQVNWPTIAGPPAAAVTVSTLQP
SILGDFKIFGKSMGLASQYAGKEASPFS
385CDK type AMGEMGRGINNSSNNNNSNRPAWLQHYDLVGKIGEGTYGLVFLARSKLPNNRGLR1521582
IAIKKFKQSKDGDGVSPTAIREIMLLREFSHENVVKLVNVHINHVDMSLYLAFD
YAEHDLYEIIRHHREKLNHHNINQYTVKSLLWQLLNGLNYLHSNWIVHRDLKPS
NILVMGEGEEHGVVKIADFGLARIYQAPLKPLSDNGVVVTIWYBAPELLLGAKH
YTSAVDMWAVGCIFAELITLKPLFQGVEVEASPNPFQLDQLDKIFKVLGHPTIE
KWPTLMNLPHWSKNLQQIQQHKYDNAGLHIGPIPAKSPAYDLLSKMLEYDPRKR
ITAAQALEHEYFRIDPQPGRNALVPSQPGEKAINYPPRLVDANTDFDGTIAPQP
SQVSSGNAPSGSIASAAVPAVRPLPQQMQLMGMQRMQNPGMAAFNLGAQASNSG
LNHNNIALQRGSSQQQAHQQVRRKEPNSGFPNTGYPPPPRSRRL
386CDK type B-1MDKYEKLEKVGEGTYGKVYKARDKMTGQLVALKKTRLEMDEEGVPPSSLREISL3891297
LQMLSQSIYVVRLLCVEHVTKKGKPLLYLVFEYLDTDLKKFIDYRRSVNAGPLP
QNVIQSEMYQLLKGVAHCHSHGVLHRDLKPQNLLVDKSKGLLKVGDLGLGRAFT
VPLKCYTHEVVTLWYRAPEVLLGSTHYSTPVDIWSVGCIFAEMVRRQPLFPGDC
EIQQLLHIFTLLGTPTEEMWPGVKRLRDWHEYPQWKPENLAPAVPNLSPTGLDL
ISKMLQCDPAKRISAEAAMNHPYFDDLDKSQF;
387CDK type B-1MDGYEEMDKVGEGTYGKVYMARDKKTGQLVALKKTRLENDGEGIPPTALREISL38946
LQMLSQDIYIVRLLDVKHTENKLGKPLLYLVFEYMESDLKKYIDSYRRSHTRNP
PSMIKSFMYQLCRGVAYCHSRGVMHRDLKPHNLLVDKEKGVLKIADLGLSBAFT
VPVKKYTHEIVTLWYRAPEVLLGATHYSLPVDIWSVGCIFAEMSRMQALFTGDS
EVQQLNNIFRFLGTPNEEVWPGVTKLKDWHIYPEWKPQDISHAVPDLEPSGLDL
LSQMLVYEPSKRISAKKALEHPYFDDLDKSQF
388CDK type B-1MDAYEKLEKVGEGTYGKVYKAKDKNTGQLVALKKTRLESDDEGIPPTALREISL1801088
LQMLSQDIHIVRLLDVEHTENKNGKPLLYLVFEYMDSDLKKYIDGYRRSHTKVP
PKIIKSFMYQLCQGVAYCHSRGVMHRDLKPHNLLVDKQRGVVKIADLGLGRAFT
IPIKKYTHEIVTLWYRAPEVLLGATHYSTPVDIWSVGCIFAEMVRLQALFIGDS
EVQQLFRIFSFLGTPNEEIWPGVTKFRDWHIYPQWKPQDISSAVPDLEPSGVDL
LSKMLVYEPSKRISAKKALEHPYFDDLDKSQF
389CDK type B-1MDSYEKLEKVGEGTYGKVYKAKDKKTGKLVALKRTRLENDGEGIPPTALREISL40948
LQMLSQDMNIVRLLDVEHTENKNGKPLLYLVFEYMDSDLKKYVDGYRRSHTKMP
PKIIKSFMYQLCQGVAYCHSRGVMHRDLKPHNLLVDKQRGVLKIADLGLGRAFT
VPIKKYTHEIVTLWYRAPEVLLGATHYSTPVDIWSVGCIFAEMSRMHALFCGDS
EVQQLMSIFKFLGTPNEGVWPGVTKLKDWHIYPEWRPQDLSRAVPDLEPSGVDL
LTKMLVYEPSKRISAKKALQHPYFDDLDKSQF
390CDK type B-1MEKYEKLEKVGEGTYGKVYKGRDKRTGRLVALKKTPFHQEEGIPPTAIREISLL2291134
KSLSQCIYIVKLLDVKASFNGKGKHVLFNVFEYADSDLEKHIDAHRQCNTRLSP
RSIQSYMFQLCKGIAYCHSHGVLHRDLKPQNILVDQKIGLLEIADLGLGRACTV
PIKSYTFEVVTLWYRAPEVLLGAKRYSMALDIWSLGCIFAELCNLQALFAGDSQ
IQQLINIFRLLGTPNEQLWPGVTQLSDWHEFPQWRPQQLSKVVFNLDPNGVDLL
SKMLQYDPAKRISAKEALDHPYFQSLDKSQF
391CDK type CMGCVCGKPSARAADYVESPAEKGASSNSRSSSMASRRLVAPAVMDQGIDAENGH1052642
EGDYRTKLRGKQSNGADPVSLLSDDAEKQRHSRHHQHQQHHPIRPHHLRPQGEF
VPNANSNPRFGNPPRHIEGEQVAAGWPAWLTAVAGEAIEGWIPRRADSFEELDIC
IGQGTYSNVYKARDLDTGKIVALKKVRFDNLEPESVRFMAREIQVLRRLDHPNV
VKLEGLVTSRMSCSLYLVFEYMDHDLAGLAACPGIRFTEPQVKCYMQQLLRGLD
HCHSRGVLHRDIKGSNLLIDNGGILKIADFGLATFFHPDQRQPLTSRVVTLWYR
PPELLLGATEYGVAVDLWSTGCILAELLAGRPIMPGRTEVEQLHKIFKLCGSPS
EDYWKKSRLPHATIFKPQQPYKRCVAETFKDFPPSALALMEVLLAIEPADRGTA
TSALKSDFFTTKPLACDPSSLPRYPPSKEFDAKIRDEEARRQRAAGGRGRDAAR
RPSRESRAIPAPEANAELAISIQKRRLSSQGPSKSKSEKFNPQQEDGAVGFPIE
PPRPMHIGIDAGATSRMYSQQFGPSHSGPLSNQISSSIWGENQKEDEIQMAPGR
PSRSSKATISDFRRPGACAPQPGADLSHLSSLVATARSNAGIDTHKDRSGMWQH
NRIDAIDGVHNNGKHEFLEVPEHPNRQDWTRFQQPESFKGLDNYHLQDLPATHH
RKDERVASKEATMNWQGYGGQGGDKIHYSGPLLPPSGNIDEILKEHERHIQHAV
RRARQDKGRPQRSNLSQNEREAFEHRSFVSGVNGNAGYSDLVNELPISVGSNRL
RVSRTRGTEEIVELRELEREPLSSVMEKYEREHEM
392CDK type CMGCVCAKQSDILGEPESPKVKGSNLASSRWSVSSETKQLPQHSDSGILHHQHYY1872580
HPRDESDEAKLKESNYGGSKRRTRQGRDPADLDMGIFVRTPSSQSEAELVAAGW
PAWMAAFAGEAIHGWIPRRAESFERLYRIGQGTYSNVYKARDLDNGRIVALKKV
RFDSLDAESVRFMAREILVLRKLDHPNIVKLEGLVTSEVSSSLYLVFEYMEHDL
AGLAACPGIKFTEPQVKCYMQQLLQGLDHCHRHGVLHRDIKGSNLLIDNGGILR
IADFGLATFFYPDQKQLLTSRVVTLWYRPPELLLGATDYGVAVDIWSAGCILAE
LLAGKPILPGRTEVEQLHKIFKLCGSPSEDYWKESKLPHATIFKPQHPYKSCIA
EAFKDFSPSALALLETLLAIEPGHRGEASGALKSEFFTTEPLSCDPSSLPKYPP
SREFDAKLRAQETRRQRDVGVRGHGSEAARRTSRLSRAGPTPNEGAELTALTQK
QHSTSHATSNIGSEKPSTRKEDYTAGLHIDPPRPVNHSYETTGVSRAYDAIRGV
AYSGPLSQTHVSGSTSGRRPRRDHVKGLSGQSSLQPSRPFIVSDSRSERIYEKS
HVTDLSNHSRLAVGRNRDTTDPHRSLSTLMQQIQDGTLDGIDIGTHEYARAPVS
STKQKSAQLQRPSALKYVDNVQLQNTRVGSRQSDERPANKESDMVSHRQGQRIH
CSGPLLHPSANIEDLLQRHEQQIQQAVRRAHHGKREALSNRSSLPGKKPVDHRA
WVSSGRGNKESPYFRGKGNKELSDLRGGPTAKVTNFRQKVM
393CDK type CMAVANPGQLNLQEAPSWGSRSVNCFEKLEQIGEGTYGQVYMAKEIETGEIVALK2201749
RIRMDNEREGFPITAIREIKLLKKLQHENVIKLKEIVTSPGPEKDEQGKSDGNK
YNGSIYMVFEYMDHDLTGLAERPGMRFSVPQIRCYMKQLLIGLHYCHINQVLHR
DIRGSNLLIDNNGILKLADFGLARSFCSDQNGNLTNRVITLWYRPPELLLGSTK
YGPAVDMWSVGCIFAELLYGRPILPGKNEPEQLTKIFELCGSPDESMWPGVSKL
PWYSNFKFQRQMKRRVRESFKNFDRHALDLVEKMLTLDPSQRISAKDALDAEYF
WTDPVPCAPSSLPRYEPSHDFQTKRKRQQQRQHDEMTKRQKISQHPPQQHVRLP
PIQNAGQGHLPLRPGPNPTMHNPPPQFPVGFSHYTGGPRGAGGQNRHPQWIRPL
HAAQGGGYNANRGYGGPPQQQGGGYPPHGMGNQGPRGGQFGGRGAGYSQGGPYG
GPVGGRGPNVGGGNRGPQFWSEQ
394CDK type DMQNMEDNVQSSWSLHGNKEICARYEILERVGSGTYSDVYRGRRKADGLIVALKE4381748
VHDYQSSWREIEALQRLCGCPNVVRLYEWFWRENEDAVLVLEFLPSDLYSVIKS
GKNKGENGIPEAEVKAWMIQILQGLADCHANWVIHRDLKPSNLLISADGILKLA
DFGQARILEEPEAIYEVEYELPQEDIVADAPGERLMEEDDSVKGVRNEGEEDSS
TAVETNFGDMAETANLDLSWKNEGDMVMQGFTSGVGTRWYHAPELLYGATIYGK
SIDLWSLGCILGELLILEPLFSGTSDIDQLSRLVKVLGTPTEENWPGCSNLPDY
RKLCFPGDGSPVGLKNHVPSCSDSVFSILSRLVCYDPAARLNAKEVLENKYFVE
DPYFVLTHELRVPSPLREENNFSEDWAKWKDMEADSDLENIDEFNVVHSSDGFC
IKFS
395CDK type DMDLNQYPEDLNPELPEGTDNVDNPDNNKGSPVPSPHPPLKPLDPSERYRKGITL2401631
GQGTYGIVYKAFDTVTNKTVAVKKIHLGKAKEGVNVTALREIKLLKELSHPNII
QLIDAYPHKQNLHIVFEFMETDLEAVIKDRNLVFSPADIKSYLQMTLKGLAVCH
KKWVLHRDMKPNNLLIAADGQLKLGDFGLARLFGSPDRKFTHQVFAVWYRAPEL
LFGAKQYGPAVDIWATGCIFAELLLRKPFLQGVSDLDQIGKIFAAFGTPRQSQW
PDVASLPDFVEFQFVPAPSLRSLFPMASEDALDLLSKNFTLDPKNRITAQQALE
HRYFSSVPAPTRPDLLPKPSKVDSSRPPKHASPDGPVVLSPSKARRVMLFPNNL
AGILPKQVSQSTTGGTPIEFDMPTQKLREVCPRSRITESGKKHLKRKTMDMSAA
LDECAREQEGQEGKTILDPDHQRSAKKEKHM
396Cyclin AMAGGQENCVRITRARAACVSKASAPVIQSQVDSKKSRKRAPKRAAVDDLAANAS2521604
GSQPKRRAVLGDVTNLHAAATDCLSTAEDQVDAPNPSIKGRARNKKKEARTSTK
VVKDEIHPESNPLADHSSNLSECQKPPAAKLAEQRSLRGVPSKAKQGGSSNSQS
CSKHTDIDRDHTDPQMCTTYVEDIYEYLRNAELKNRPSANFMSTAQNDITPNMR
AILVDWLVEVSEEYKLVPDTLYLTVSYIDRYLSANPTSRHKLQLLGVSCMLIAS
KYEEVCPPHVEEFCYITDNTYTRDEMLSMERKILIFLNFEMTKPTTKSFLRRFV
RASQAGNKAPSLHMEFLANYLAELTLMECSFLQYLPSLIAASTVFLSRLTLDFL
TNPWNPTLAHYTGYKASQLRDCVMAIYNVQMNRKGSTLVAIREKYQQHKFKCVA
SLPPPPFIAERFFEDTPN
397Cyclin AMTGTQASNVRITRARAAKSTLNNALPPLPPAQGKPRGKRAATESNISGFSVAAE2611817
PLKRRAVLSDVSNICKEAAAVDCLKKPKAVKVVSQNANAKGRGRGIPRNNKKIT
QEAEIKKETSPAICNVDDASAGNAIGDDKQNNNVNPLKEVQDNPKELNPIAEQI
SVHPHCKQSVEKPNEKEIVVSDNKAAIASLKQQSTLQSLRIPKQPKYSLKQGNP
VPLANLHEDVGRSSCSDFIDIDSEYKDPQMCTAYVTDIYANMRVVELKRRPLPN
FMETTQRDINANMRSVLIDWLVEVSEEYKLVPDTLYLTVSYIDRFLSANVVNRQ
RLQLLGVSCMLVASKYEEICAPPVEEFCYITDNTYKKEEVLEMEISVLNRLQYD
LTTPTTKTFLRRFIRAAQASCKVSSLHLEFMGNYLAELTLVEYDFLKYLPSLIA
AAAVFVARMTLDPMVHPWNSTLQHYTGYKVSDMRDCICAIHDLQLNRKGCTLAA
IREKYNQPRFKCVANLFPPPIISPQFLIDNEV
398Cyclin BMAAPNQNALLINNNNRRPLVDIGNLVGALNAQCNISKNGARKRAFGDIGNLVED1671576
LDAKCTISKYWVRKRPRTNFGVNANKGASSSTQGQGIVVRGEQKAWDRIVWGNK
QSCAIKMNAQHVTATQRGTAISISDIIDSSVQDGGIKAPSQLRARKQTVRTVTA
TLTARSEDSLRDVLEVPPGIDDGDRDNPLAVVEYVEDIYHFYRKIEVRSCVPPD
YMTRQLEIKDSMRGVIIDWLIEVHRTFLLMPETLYLTVNIIDRYLSIQSVTRNE
LQLNGITAMFIASKYEEISPPKINDLVYITKDAYTSKQIVNMEHTILNRLKFKL
TVPTPYVFLVRFLKAAGPDKVMKNLAFFLVDLCLLHYKMIKYSPSMLAAAAVYT
AQCTLKRHPYWNKTLILHIGYSEAHLRECAHLMADLHLKAEGSNLKSVYKKYSY
PIFGSVAFLSPARIPAGTVAAPAIDKCAHQIYLRNLR
399Cyclin BMFPNKQTQGLVQNKKMASKAAQPKANVPPQRVPPAANNRRALGDIGNIVADVGG1831598
KCNVTKDGVNGKPLAQVSRPITRSBGAQLLAQAAANKGISAANNQTQVPVVIPK
ADVRGNKQRRTSRSKDIPPTTVVTNESDDCVIIEQAQRIKPTCNHNVGAVGNKE
KPQLLTAKPKSLTASLTSRSAVALRGFRFDDEMTEAEEDPLPNIDVGDRDNQLA
VVEYVEDIYKFYRRTEQMSCVPDYMPRQQEINPKMRAVLINWLIEVHYRFGLMP
ETLYLTTNLIDRYLATQLVSRSNYQLVGATAMLLASKYEEIWAPEMNDFLDILE
NKFERKHVLVNEKANLNKLRFHLTVPTPYVFLVRFLKAAASDEEMENLVFFLME
LSLMQYVMIKFPPSMLAAAAVYTAQITLKKTTVWNDVLKRHTGYSEIDLKECTR
LMVAFHQSSEESKLNVVFKKYSMPEYDSVALIKPAKLPA
400Cyclin DMAPSFDCVANAYIESCEDQEKLRQNAQILAQSGENDVDEPVSNLVQRETHYMLP981126
EDYLQRLRNRTLDVNVRREAVGWILKVHSFYNFGAPTAYLAVNYLDRFLSRHRM
PQGVKAWMIQLMAVACLSLAAKMEETQVPLPSDLQREDARFIFQARTIQRHELL
ILSTLQWGMRSITPFSFIDYFAYRAVQGHGHGNDATPKAVMSRAIELILSTTEE
IDFMEYRPSAIAAAALLCAAEEVVPLQAVHYKRALSSSITDVDKDKMFGCYNLI
QETIIEGGCYWTPMSLQSTEKTPVGVLDAAACLSNTPTSSYSVKPYASVTAAKR
RKLNEICSALLVSQAHPC
401Cyclin DMAANFWTSSHCKELLDAEKVGIVHPLDKDQGLTQEDVKIIKINMSNCIRTLAQY148894
VKLRQRVVATAITYCRRVYTRKSFTEYDPQLVAPTCLYLASKAEESTVQAKLVI
FYMKKYSKHRYEIKDMLEMEMKLLEALDYYLVIYHPYRPLIQFLQDAGLNDLKV
TAWALVNDTYRTDLILTYPPYMIALACIYFACIMEEKDAQAWFEELRVDMNEIK
NISMEIVDYYDNYRVIPDEKNNSALNKLPHRF
402Cyclin DMAPALSSSYECLSHLLCAEDASNVVGCWDEDESKIFCEEEEGFGIQHFPDFPVP2871363
DDDEIRVLVRKESQYMPGKSYVQSYQNLGLDFTARQNAIGWILKVHGSYNEGPL
TAYLSINYLDRELSRNPLPKAKVWMLQLLSVACLSLAAKMEETQVPLLLDLQAE
EPDFLFEPRTIQRNELLVLSTLEWRMLSVTPFSFVDYFLQGGGGRKPPPRAMVA
RANELIFNTHTVLDFLEHRPSAIAAAAVICAAEEVLPLEAAQYKETILSCSLVD
KEWVFGSYNLIQEVLIEKFSTPKKAKSASSSIPQSPVGVLDAFCLSNNSNNTSL
EASLSVNLYASVAAKRRKLNDYCNTWRMFQHSTC
403Cyclin DMAPNCIDCAPSDLFCAEDAFGVVEWGDAETGSLYGDEDQLHYNLDICDQHDEHL2511348
WDDGELVAFAEKETLYVPNPVEKNSAEAKARQDAVDWILKVHAHYGFGPVTAVL
SIWYLDRFLSANQLQQDKPWMTQLAAVACLSLAAKMDETEVPLLLDFQVEEAKY
IFESRTIQRMELLVLSTLEWRMSPVTPLSYIDHASRNIGLENHHCWIFTMRCKE
I LLNTLRDAKFLGLLPSVVAAAIMLHVIKETELVNPCEYENRLLSAMKVNKDMC
ERCIGLLIAPESSSLGSFSLGLKRKSSTINIPVPGSPDGVLDATFSCSSSSCGS
GQSTPGSYDSNNSSILCISPAVIKKRKLNYEFCSDLHCLED
404CyclinMPQIQYSEKYTDDTYEYRHVVLPPETAKLLPKNRLLNENEWRAIGVQQSRGWVH229510
dependentYAIHRPEPHIMLFRRPLNYQQNQQQQAGAQSQPMGLKAQ
kinase
regulatory
subunit
405CyclinMQQIEYSEKYYDDTYEYRHVELPPDVARLLPKNRLLTENEWRGIGVQQSRGWVH92409
dependentYAIHCSEPHIMLFRRPLNYEQNHQHPEPHIMLFRRPLNCQPNHQPQAHHPT
kinase
regulatory
subunit
406CyclinMQQIEYSEKYYDDTYEYRHVELPPDVARLLPKNRLLTENEWRGIGVQQSRGWVH64381
dependentYAIHCSEPHIMLFRRPLNYEQNHQHPEPHIMLFRRPLNCQPNHQPQAHHPT
kinase
regulatory
subunit
407CyclinMPQIQYSEKYYDDTYEYRHVVLPPDVARLLPKNRLLNEMEWRGIGVQQSRGWVH68349
dependentYAIHRPEPHIMLERRHLNYQQNQQQQAQQQPAQAMGLQA
kinase
regulatory
subunit
408HistoneMALVETEPVTLIHPEEPKKFKKRPTPGRGGVISHGLTEEEARVKAIASIVGAMV1251849
acetyltransferaseEGCRKGEDVDLNALKAAACRRYGLSRAPKLVEMIAALPDGERAAVLPKLKAKPV
RTASGIAVVAVMSKPHRCPHIATTGNICVYCPGGPDSDFEYSTQSYTGYEPTSM
RAIRARYNPYVQTRSRIDQLKRLGHTVDKVEFILMGGTFMSLPADYRDYFIRNL
HDALSGHTSSNVEEAVCYSEHSATKCIGLTIETRPDYCLGPHLRQMLSYGCTRL
EIGVQSTYEDVARDTMRGHTVAAVADCFCLARDAGFKVVAHMMPDLPNVGVERD
MESFREFFSNPAFRADGLKIYPTLVIRGTGLYELWKTGRYRHYPPEQLVDIIAR
VLALVPPWTRVYRVQRDIPMPLVTSGVEKGNLRELALARNDDLGLKCRDVRTRE
AGIQDIHHKIRPEVVELVRRDYCANEGWSTFLSYEDTRQDILVGLLRLRKCGHN
TTCPELKGRCSIVRELHVYGTAVPVHGRDADKLQHQGYGTLLMEQAERIAWKEH
RSIKIAVISGVGTRHYYRKLGYELEGPYMMKYLN
409HistoneMLGFRDLYTSICSHLQRASGRLPIIAAATSLISTPEIAAVEKENKAPNSVDKMG701602
acetyltransferaseMGSADESGRFSTSNGQFMNMNNGVVKEEWKGGVPVVPSAPTTVPVITNVKLETP
SSFDHDMARKRKLGFLPLEVGTRVLCKWRDGKFHPVKIIERRKLPNGATNDYEY
YVHYTEFNRRLDEWVKLEQLELDSVETDADEKVDDKAGSLKMTRHQKRKIDETH
VEGHEELDAASLREHEEFTKVKNITKIELGRYEIETWYFSPFPSEYNNCEKLYF
CEFCLNFMKRKEQLQRHMRKCDLKHPPGDEIYRSGTLSMFEVDGKKNKVYAQNL
CYLAKLFLDHKTLYYDVDLFLFYILCECDERGCHMVGYFSKEKHSEESYNLACI
LTLPPYQRKGYGKFLISFSYELSKKEGKVGTPERPLSDLGLLSYRGYWTRVLLD
ILKKHKSNISIKELSDMTAIKADDVLSTLQGLDLIQYRKGQHAICADPKVLDRH
LKAVGRGGLEVDVCKLIWTPYKEQ
410HistoneMGSLDESTCSEEIRDEGKDSIRTKFKVESTVNNAQNGGNDNSKKKRAAGLPLEV1401465
acetyltransferaseGIRLLCKWRDSKLHPVKIIERRKLPNGFPQDYEYYVHYTEFNRRLDEWVKLEQF
ELDSVETDADEKIEDKGGSLKMTRHQKRKIDEIHVEEGQGHEDFDPASLREHEE
FTKVKNIAKVELGRYEIETWYFSPFPPEYSHCEKLFFCEFCLNFMKRKEQLQRH
MRKCDLKHPPGDEIYRHGTLSMFEVDGKKNKIYGQNLCYLAKLFLDHKTLYYDV
DLFLFYVLCECDDRGCHVVGYFSKEKHSDEAYNLACILTLPPYQRKGYGKFLIA
FSYELSKKEGKVGTPERPLSDLGLLSYRGYWTRILLDILKKQRGNISIKELSQM
TAIKVEDVISTLQVLDLIQYRKGQHVICADPKVLDRHLKAAGIAGLEVDVSKLI
WTPYKEQCG
411HistoneMASAPMVGCDQSRDKHRWVESKVYMRKGHGKGSKGNAGFNAQNSTAQVRRENDN6282565
acetyltransferaseMGNSIADNGKSEAASEGLSSLSRKQITVNQDHPPNETSSMPAVGGLQNIDTHVT
FKLEGCSKQEIWELRKKLTNELEQVRGTFKKLEARELQLRGYSVSAGVNTSYSA
SQFSGNDMRNNGGKEVTSEVASGGAITPKQAQRESNPPRQLSISLMEMNQAASD
MGEKGKRTPKANQYYRHSEFVLGKDKFPPAESKKSKSTGNKKISQSKVFSKETM
QVGKEFMPQKSVNEVFKQCSLLLTKLMKHKYGWVFNLPVDAQALGLHDYHTIIK
RPMDLGTVKSKLEKNLYNSPASFAEDVKLTFSNAMTYNPKGHEVHTMAEQLLQL
FEERWKTIYEEHLDGKHRFGSGQGLGASSSTKKLPFQDSKKNIKKSEPAGGPSP
PKPKSTNHHASRTPSAKKPKAKDPHKRDMTYEEKQKLSTNLQNLPQERLELIVQ
IIKKRNPSLCQHDEEIEVDIDSFDTETLWELDRFVTMYKKSLSKMKKKALLADQ
AKRASEHGSARNKHPMIGRELPMNNKKGEQGEKVVEIDHMPPVNPPVVEVEKDG
VYAKRSSSSSSSSSDSGSSSSDSDSGSSSGSESDAYAATSPPAGSNTSARG
416HistoneMMETGGNSLPSGPDGVKRKVAYFYDPEVGNYYYGQGHPMKPHRIRNTHALLVQY3652251
deacetylaseGLHKEMQILKPYPARDRDLCRFHADDYVAFLRGITPETIQDQVKALKRFNVGDD
CPVFDGLYQYCQTYAGGSVGGAVKLNHKLCDIAINWAGGLHHAKKCEASGFCYV
NDIVLAILELLKYHKRVLYVDIDIHHGDGVEEAFYTTDRVMTVSFHKFGDYFPG
TGDIRDIGCGKGKYYAVNVPLDDGIDDESFQSLFKPIIQQVMLVYNPEAIVLQC
GADSLSGDRLGCFNLSVKGHAECVRYMRSFNVPLLMVGGGGYTVRNVARCWCYE
TGVAVGVEIDDRMPQHEYYEYFGPDYTVHVAPSNMENKNTKQYLDKIRSKILEN
INSLPCAPSAQFQVQPPDTDFPELEEEDYDERTRSHKWDGASCDSDSENGDLKH
RNHDVEESAFPRHNLANISYNTKIKLEGVGTGGLDMAAGTDTKKNDESFEAMDY
ESGEELRQDHFASTINASQPCDPALLTGVQNQLQSTDTVKPIEQSGNAPGIPPP
SVATVSTGTRPSSISRTSSLNSMSSVKQGSILGPNPPQGLNASGLQFPVPTSNS
PIRQGGSYSITVQAPDKQGLQNHMKGPQNMPGNS
417HistoneMPPKDRVAYFYDGDVGSVYFGPNHPMKPHRLCMTHHLVLSYELHKKMEIYRPHK1561454
deacetylaseAYPVELAQFHSADYVEFLHRITPDTQHLFTKELVKYNMGEDCPVFENLFEFCQI
YAGGTIDAAHRLNNQICDIAINWSGGLHHAKKCEASGFCYINDLVLGILELLKH
HARVLYVDIDVHHGDGVEEAFYFTDRVMTVSFHKYGDMFFPGTGDVREVGEREG
KYYAINVPLKDGIDDASFTRLFKTIITKVVDIYQPGAIVLQCGADSLAGDRLGC
FNLSIDGHAQCVRIVKKFNLPLLVTGGGGYTKENVARCWSVETGVLLDTELPNE
IPDNDYIKYFAPDYSLKINTAGNMENLNSKTYLSAIKVQVMENLRAIQHAPSVQ
MHEVPPDFYIPDIDEDELNPDERMDQHTQDRQIQRDDEYYDGDNDIDHDMEEAS
418HistoneMDSSKSEEANILHVFWHEGMLNHDLGTGVFDTLEDPGFLEVLEKHPENADRVRN2031348
deacetylaseMLSILRKGPIAPYTEWHTGRAAYLSELYSFHRPDYVDMLAKTSTAGGKTLCHGT
RLNPGSWEAALLAAGTTLEAMRYILDGHGKLSYALVRPPGHHAQPTQADGYCFL
NNAGLAVELAVASGCKRVAVVDIDVHYGNGTAEGFYERDDVLTISLHMNHGSWG
PSHPQTGFHDEVGRGKGLGFNLMVPLPNGTGDKGYEHAMHELVVPAISKFMPEM
IVLVIGQDSSAFDPNGRECLTMEGYRKIGQIMRQQADQFSGGRLVVVQEGGYHI
TYAAYCLHATLEGVLCLPHPLLSDPIAYYPFHDIYSERVTFIKNYWQGIISTTD
KRN
419HistoneMEESGNALVSGPDGSKRRVTYFYDADIGNYYYGQGHPMRPHRMRMAHNLIVHYG2291644
deacetylaseLHQRMEVCRPHLAQSKDIRAFHTDDYIHFLSSVAPDTQQEQLRQLKRFNVGEDC
PVFDGLFNFCQSSAGGSIGAALKLNRKDADIAINWAGGLHHAKKCEASGFCYVN
DIVLGILELLKVHQRVLYIDIDIHHGDGVEEAFYTTDRVMTVSFHKFGDYFPGT
GHIKDVGYGKGKYYALNVPLNDGIDDESYKHLFRPIIQKVMEVYQPEAVVLQCG
ADSLSGDRLGCFNLSVKGHADCVRFVRSFNIPLMLVGGGGYTIRNVARCWCYET
AVAVGVEPQDKLPYNEYYEYFGPDYTLYVAPSNMENLNTEKDLEKMRNVLLEQL
SKIQHTPSVPFQERPPDTEFNDEEEEDMEKRSKCRIWDGEYVGSEPEEDGKLPR
FDADTYERSVLKHENKRLVPVSNVEPLKRIKQEEDGAAV
412HistoneMEGHSGALGFGQGESRSSQSPNLSPSPSHSASASVTSSGQKRKRNEVEHAGVAS551818
acetyltransferaseNSTGMFAVPPSHIYSHLHPMSMSMPMPMHNSHPSSLSESRDGALTSNDDDDNLT
GGNQSQLDSMSAGNTDGREDFDDEDDDDDDEEDDDEVEGDEEDQDHDPDADDDS
DDGHDSMRTFTAARLDNGAPNSRNLKPKADAAGVAIAPTVKTEPILDTVKEEKV
SGNNNNNSVSANNAQVAPSGSAVLLSAVKEEANKPTSTDHIQTSGAYCAREESL
KREEDADRLKFVCFGNDGIDQHMIWLIGLKNIFARQLPNMPKEYIVRLVMDRSH
KSVMIIKQNQVVGGITYRPYLSQKFGEIAFCAITADEQVKGYGTRLMNHLKQHA
RDVDGLTHFLTYADNNAVGYFIKQDFTKEIKLEKERWHGYIKDYDGGILMECKI
DPKLPYTDLPANIRWQRQTIDERIRELSNCHIVYSGIDIQRKEAGIPREPIRVE
DIPGLKEAGWTTDQWGHSRFRLLNSPSEGLPNRQVLHAFMRSLHKAMVEHADAW
PFKEPVDPRDVPDYYDIIKDPMDVKRMFTNARTYNTHETIYYKCANR
413HistoneMEESGNSLTSGPDGSKRRVSYEYDSDIGNYYYSQGHPMKPHRIRMAHSLIVHYA2591710
deacetylaseLDEKMEVCRPNLLQSRELRVFHADDYISFLQSVTPETQHEQLRQLKRFNVGEDC
PVFDGLYNFCQTYAGGSVGAAIKLNNKEADIAINWSGGLHHAKKCEASGFCYVN
DIVLAILELLKVHQRVLYIDIDIHHGDGVEEAFYSTDRVMSVSFHKFGDYFPGT
GHLKDVGYGKGKYYSLNVPLNDGIDDESYKNLFRPIIQKVMEIYQPEAVVLQCG
ADSLSGDRLGCFNLSVKGHADCVRFLRSFNVPLVLVGGGGYTIRNVARCWCYET
AVAVGVEPQDKLPYNEYYEYFGPDYTLHVAPSNMENQNSARELAKIRNTLLEQL
KRIQHVPSVPFQERPPDTKFPEEDEEDYEKRPKGHKWGGEYFGSESDEEQEPQN
RDIDISDKPGIRRQSPPNVEAAKKIKVEEEDGDIGIVNENDGAKWPLGEAG
414HistoneMEESGNSLTSGPDGSKRRVSYFYDSDIGNYYYSQGHPMKPHRIRMAHSLIVHYA3561807
deacetylaseLDEKNEVCRPNLLQSRELRVFHADDYISFLQSVTPETQHEQLRQLKRFNVGEDC
PVFDGLYNFCQTYAGGSVGAAIRLNHKEADIAINWSGGLHHAKKCEASGFCYVN
DIVLAILELLKVHQRVLYIDIDIHHGDGVEEAFYSTDRVNSVSFHKFGDYFPGT
GHLKDVGYGKGKYYSLNVPLNDGIDDESYKNLFRPIIQKVMEIYQPEAVVLQCG
ADSLSGDRLGCFNLSVRGHADCVRFLRSFNVPLVLVGGGGYTIRNVARCWCYET
AVAVGVEPQDKLPYNEYYEYFGPDYTLHVAPSNMENQNSAKELAKIRNTLLEQL
KRIQHVPSVPFQERPPDTKFPEEDEEDYEKRPKGHKWGGEYFGSESDEEQKPQN
RQIDISDKPGIRRQSPPUVEAAKKIKVEEEDGDIGIVNENDGAKWPLGEAG
415HistoneMEFWGVEVKPGEALTCDPGDERYLHMSQAAIGDKEGAKENERVSLYVHVDGKKF2611298
deacetylaseVLGTLSRGKCDQIGLDLVFEKEFKLSHTSQTGSVFVSGYTTVDHEALDGFPDDE
DLESSEDEEEELAQITTLTAKENGGKTGAKPVKPESKSSVTDKAAAKGKPEVKP
PVKKQEDDSDSDEDEDEDEDEDEDDDDEDDEDMKDASASDDGDEEDDSDEESDD
DEEEDEETPKPAAGKKRPMPASDNKSPATDKKAKITTPAGGQKPGADKGKKTEH
IATPYPKHGAKGPASGVKGKETPLGSKQTPGSKVKNSSTPESGKKSGQFKCQSC
SRDFATEGALSSHNAAKHGGK
420HistoneMPPKDRVAYFYDGDVGSVYFGPNHPMKPHRLCMTHHLVLSYELHKKMEIYRPHK1561454
deacetylaseAYPVELAQFHSADYVEFLERITPDTQHLFTKELVKYNMGEDCPVFENLFEFCQI
YAGGTIDAAHRLNNQICDIAINWSGGLHHAKKCEASGFCYINQLVLGILELLKH
HARVLYVDIDVHHGDGVEEAFYFTDRVMTVSFHKYGDMFFPGTGDVKEVGEREG
KYYAIHVPLKDGIDDASFTRLFKTIITKVVDIYQPGAIVLQCGADSLAGDRLGC
FNLSIDGHAQCVRIVRKFNLPLLVTGGGGYTKENVARCWSVETGVLLDTELPNE
IPDNDYIKYFAPDYSLKINTAGNMENLNSKTYLSAIKVQVMENLRAIQHAPSVQ
MHEVPPDFYIPDIDEDELNPDERMDQHTQDRQIQRDDEYYDGDNDIDHDMEEAS
421HistoneMDLNLVSHGEEEEGVRRRKVGIVYDERMCKHATPEDQPHPEQPDRIRVIWDKLN272222
deacetylaseSAGVLHKCVMVEAKEASEEQLAGVHSRKHIEVMKSIGTARYNKKKRDKLAASYE
SIYFSQGSSEAALLAAGSVVEISEKVASGELDAGVAIVRPPGHHAEADKAMGFC
LFNNIAIAAKHLVHERPELGVQEVLIVDWDVHHGNGTQHMFWTDPHVLYFSVHR
FDAGTFYPGGDDGFYDKIGEGKGAGYNINVFWEQGKCGDADYLAVWDHVLVPVA
KSYDPDMVLISGGFDAALGDPLGGCRLTPYGYSLMTKKLMEFAGGKIVLALEGG
YNLRSLADSFLACVEALLKDGPSRSSVLTHPFGSTWRVIQAVRKELSSFWPALN
EELQLPRLLKDASESFDKLSSSSSDESSASEDEKKIAEVTSIMEVSPDPSSILA
LTAEDIAQPLAGLKIEEAGTDSQRSSDHTLLDLTNDDTQKLKQFEGEIFVMIGD
EESVPSASSSKDQNESTVVLSKSNIKAHSWRLTFSSIYVWYASYGSNMWHPRFL
CYIEGGQVEGMARRCCGSEDKTPPQRIQWKVVPHRMFFGRSYTNTWGSGGVSFL
DFNCSDTSEAHVCLYKITLAQFNDLLLQENNLNCGTEHPLVDLSSIDAIRNGNS
ILELIKDSWYGTLIYLGMEGGLPIVTFTCSVCDVEKFKHGQLPLCPPSSRYENI
LIRGLVQGKKLSEDDATAYIRAASTSFLL
422HistoneMADEDLDLSDVGEVEDEPGEEIESTPPLAVGQEKEINSLALKKKLLKVGTRWET711759
deacetylasePENGDEVTVHYTGTLPDGTKFDSSRDRGEPFTFKLGQGQVIKGWDQGIVTMKKG
ERALFTIPPELAYGSSGVRPTIPPNATLQFDVELLSWTNIVDVCNDGGILKRII
SEGEKYERPKDPDEVTVKYEAKLEDGTLVAKSPEEGVEFYVNDGHFCPAIAKAV
ETMERGEEVILTIKPTYAFGERGKDAEEGFAAIPPNATLTTSLELVSFKAVIAV
TEDKKVIKKILKEADGYDKPSDGTVVQIRYTAELQDGTIFEKKGYEGEEFFQFV
VDEEQVIAGLDKAVETMKTGEIALITIGAEYGFGNFETQRDLAVIPPNSTLIYE
VEMISFTKEKESWDMDTTEKIEASKQKKEQGNSLFKVGKYQRAAKKYEKAAEYI
EHDSSFSAEEKKQSKVLKVSCNLNHAACRLKLKDFKEAVKLCSKVLELESQNVK
ALYRRAQAYIETADLDLAEFDIKKALEIEPQNREVQLEYKILKQKQIEYNKKDA
KLYGNMFARLNKLEAFEGKVLS
423PeptidylprolylMADEGLELSDVAEVEDEPGEEFESAPPLVVGQEKELNSSGLKKKLLKAGTRCET3582040
isomerasePENGDEVTVHYTGTLLDGTKFDSSRDRGEPFTFNIGQGQVIKGWDQGIVTMKKR
EHALFTIPPELAYGASGMPPTIPPNATLQFDVELLSWTNIVDVCKDGGILKRII
SDGEKYERPKDPDEVTVKYEAKLEDGMLVAKSPEEGVEFYVNDGNFCPAIVKAV
KTMKKGENVTLTIKPAYAFGEQGKDAEEGFAAIPPNATITINLQLVSFKAVKEV
TEDKKVIKKILKEADGYDKPSDGTVVQIRYTAKLQDGTIFEKKGYAGEEPFQFV
VDEEQVIAGLDKAVETMKTGEVALITIGPEYGFGNIETQRDLAVIPPYSTLIYE
VEMVSFTKEKESWDMNTTENIEASKQRKEQGNSLFKVGKYLRAAKKYDKAAKYI
EHDNSFSAEEKKQSKVLKVSCNLNHAACCLRLKDFEKAVKLCSKVLELESQNYR
ALYRRAQAYIETADLDLAEFDIKKALEIEPQNREVRLEYLILKQKQIEYNKKDA
KLYGNMFARQNKLEAIEGKD
424PeptidylprolylMPNPKVFFDMQVGGAPAGRIVMELYADVVPKTAENFRALCTGEKGTGRSGKPLH238756
isomeraseFKGSSFHRVIPGFMCQGGDFTRGNGTGGESIYGEKFADENFVKKHTGPGILSMA
NAGPNTNGSQFFICTAQTSWLDGKHVVFGQVVEGLEVVRDIEKVGSGSGRTSKP
VVIADSGQLA
425PeptidylprolylMPNPKVFFDMQVGGAPAGRIVMELYADVVPKTAENFRALCTGEKGNGRSGKPLH285803
isomeraseFKGSSFHRVIPGFMCQGGDFTRGNGTGGESIYGEKFADENFVKKHTGPGILSMA
NAGPNTNGSQFFICTAQTSWLDGKHVVFGQVVEGLEVVRDIEKVGSGSGRTSKP
VVIADSGQLA
426PeptidylprolylMPNPKVFFDMQVGGAPAGRIVMELYADVVPKTAENFRALCTGEKGTGRSGKPLH190708
isomeraseFKGSSFHRVIPGFMCQGGDFTRGNGTGGESIYGEKFADENFVKKHTGPGILSMA
NAGPNTNGSQFFICTAQTSWLDGKHVVFGQVVEGLEVVRDIEKVGSGSGRTSKP
VVIADSGQLA
427PeptidylprolylMPNPKVFFDMQVGGAPAGRIVMELYADVVPKTAENFRALCTGEKGTGRSGKPLH156674
isomeraseFKGSSFHRVIPGFMCQGGDFTRGNGTGGESIYGEKFADENFVKKHTGPGILSMA
NAGPNTNGSQFFICTAQTSWLDGKHVVFGQVVEGLEVVRDIEKVGSGSGRTSKP
VVIADSGQLA
428PeptidylprolylMADDFELPESAGMNENEDFGDTVFKVGEEKEIGKQGLKKLLVKEGGSWETPETG1761912
isomeraseDEVEVHYTGTLLDGTKFDSSRDRGTPFKFKLGQGQVIKGWDQGIATMKKGENAV
FTIPPDLAYGESGSQPTIPPNATLKFDVELLSWASVKDICKDGGIFEEIIKEGE
KWEHPKEADEVLVKYEARLEDGTVVSKSEEGVEFYVEDGYFCPAFAIAVKTMKK
GEKVLLTVEPQYGFGHQGREAIGNDVARSTNATLLVDLELVSWKVVDEVTDDKK
VLKKILKQGEGYERPNDGAVVKVEYTGKLEDGTIFEEKGSDEEPFEFMAGEEQV
VDGLDRAVMTMEKGEVALVSVAAEYGYQTEIKTDLAVVPPKSTLIYEVELVSFV
EEKESWDMNTAEEIEAAGKKKEEGNALFKVGKYFRASKKYEEATKYIEYDTSFS
EEEKKQSKPLKVTCNLNNAACKLKLKDYTQAEKLCTKVLEVESQNVKALYRRAQ
AYIQTADLELAELDIRKALEIDPNNRDVKLEYRALKEKQKEYNKREAKFYGNMF
ARMSKLEELESRKSGSQRVETANKEEGSDAMAVDGESA
429PeptidylprolylMAASLTPLGAGLAYATIYDQAKVRKLEPTKRSLIALCQHSDSQHRRFITRKYHV64765
isomeraseNVQILNRRDAIRLIGLAAGLCIDLSLMYDARGAGLPPQENAKLCDTTCEKELEN
APMITTESGLQYKDIEIGNGPSPPIGFQVAANYVAMVPSGQVFDSSLDKGQPYI
FRVGSGQVIKGLDEGLLSMKVGGKRRLYIPGPLAFPKGLNSAPGRPRVAPSSPV
IFDVSLEFIPGLESEEE
430PeptidylprolylMSAASLSADMAIRGTILGKTALHVLGPQVVSQCRQPVMFKCPPHTLRKMRFSAQ93881
isomeraseDLQSKNFYSGFTPFKSVFISTSKRSWQAGSARANSQDAAFQSKVTTKCFLDIEI
GGDPAGRIVLGLFGEDVPKTAENFRALCTGEKGFGYKGSSFHRIIKDFMLQGGD
FDRGDGTGGKSIYGRTFEDENFKLAHVGPGVLSMANAGPNTNGSQFFICTVRTP
WLDKRHVVFGQVIEGMEIVKKLESEETNRTDRPKRPCRIVDCGELP
431PeptidylprolylMGRIKPQTLLQQSKKKKVPGRISVSTIIVCNLIIIFLMFSLVGIYRQRAKRNRA3721070
isomeraseTSRSDGDEEMENFGRSKINSVPHQAIVNTTKGLITLELFGKSSAHTVEKFVEWS
ERGYFNGLPFYRVIKHFVIQVGDPKFAGNREDWTVGGQLNVQLEFSPKHEAFML
GTSKLEDQGDGFELFITTAPIPDLNDKLNVFGRVIKGQDVVQEIEEVDTDEHFQ
PKSPIIINDVRLKDEL
432PeptidylprolylMARQSTLLLFWSLVFLGAIVFTQAKHEELEEVTHKVYFDVDIAGKPAGRVVIGL28594
isomeraseFGKAVPKTVENFRALCTGEKGVGKSGKPLHYKGSFFHRIIPSFMIQGGDFTLGD
GRGGESIYGTKFADENFKLKHTGPVFITTVTTDWLDGRHVVFGKIISGMDVVYK
VEAEGRQSGQPKRKVRIADSGELSMD
433PeptidylprolylMARQSTLLLFWSLVFLGAIVFTQAKHEELEEVTHKVYFDVDIAGKPAGRVVIGL34648
isomeraseFGKAVPKTVENFRALCTGEKGVGKSGKPLHYKGSFFHRIIPSFMIQGGDFTLGD
GRGGESIYGTKFADENFKLKHTGPGFLSMANAGPDTNGSQFFITTVTTDWLDGR
HVVFGKIISGMDVVYKVEAEGRQSGQPKRKVKIADSGELSMD
434PeptidylprolylMEMDEIQEQSQPQSSEKQDISQESDTGNDKTINAEKITSENAEVEEDDMLPPKV4811611
isomeraseNTEVEVLHDKVTKQIIKEGSGNKPSRNSTCFLHYFAWAESTMHKFQDTWQEQQP
LELVLGRERKELSGFAIGVAGMKAGERALLHVDWQLGYGEEGNFSFPNVPPRAN
EMALAYMGDDFMFQLFGKYKDMANAVKNPCHLNMAQCLLKLNRYEEAIGQCNMV
LAEDEKNIKALFRRGKARATLGQTDDAREDFQKVRKFSPEDKAVIRELRLLAEH
DKQVYQKQKEMFKGLFGQKPEQKPKKLHWFVVFWQWLLSMIRTIFRNRSKTD
435PeptidylprolylMAGAGEGTPEVTLETSMGPITVELYHKHAPKTCRNFLELSRRGYYNNVKFHRVI93584
isomeraseKDFMVQGGDPTGTGRGGESIYGPRFEDEITRDLKHTGAGILSMANAGPNTNGSQ
FFISLAPTPWLDEKHTIFGRVCKGMDVVKRLGNVQTDKNDRPIHDVKILRTTVK
D
436PeptidylprolylMMDPELMRLAQEQMSKISPDELMIQ4QRQIMANPDLMRMASENMKNLKPEDIRFA2501869
isomeraseAEQMKNVRKEEMAEISERISRASPEEIEAMKARANLQSAYQLQVAQNLKDQGNQ
LHARMRYSEAAEKYLQARNNLTGIPFSEAKSLLLASSSNLMSCYLKTGQYEECV
QTGSEVLAYDAMNVKALYRRGQAYKQIGKLELAVADLRKAVEVSPEDETIAQAL
REASTELMEKGGTQDQNGPRIEEIIEEEAVQPTAEKYPQSAPWJTSVTEDVSDD
EQGSEDQNGFSRDSFQATNAPDGQMYAESLRNLTENPDMLRTMQSLMKNVDPDS
LVALSGGKLSPDMVKTVSGMFGRNSPEEIQNMMKMSSTLSRQNPSTSSRFDDIT
RGHSNMDSSPQSVSVDNDLFEENQNRVGESSTNLSSSAAFSGMPNFSAEMQEQV
RNQMNDPATRQMFTSMIQNMSPEMMASMSEQFGVKLSPEDAVKAQNAMASLSPN
DLDRLMNWATRLQTAIDYARKIRNWILGRPGLIFAISMLLLAIILHRFGYIGD
437PeptidylprolylMGVEREILRPGNGPRPRPGQSVTVHCTGYGRNEDLSQKFWSTKDPGQKPFTFTI84422
isomeraseCQGRVIRGWDEGVLDNQLGEIFKLRCSPDYGYGSNGFPAWGIRPNSVLVFEIEV
LSVN
438PeptidylprolylMPNPRCYLDITIGEELEGRILVELYSDVVPRTAENFRALCTGEKGIGPHTGVPL1281213
isomeraseHYKGLPFHRVIKGFMIQGGDISAQNGTGGESIYGLKFDDENFQLKHERRGMLSM
ANSGPNTNGSQFFITTTRTSHLDGRHVVFGKVIKGMGVVRGIEHTPTESNDRPS
LDVVISDCGEIPEGSDDGIANFFKDGDLYPDWPADLDEKSAEISWWMNAVDSAK
CFGNENYKKGDYKMALRKYRRALRYLDICWEKEEIDEERSNHLRKTKSQIFTNS
SACKLKLGDLKGALLDTEFAMRDGEDNVKALFRQGQAYMALKDVDSAVASFRKA
LQLEPNDAGIRKELAVATKMINDRRDQERRAYARMFQ
439PeptidylprolylMGDVIDLNGDGGVLRTIIRSAKPGANQPTEDLPNVDVHYEGTLADTGEVFDTTR265837
isomeraseEDNTLFSFELGKGTVIKAWDIAVKTMKVGEVARITCKPEYAYGSAGSPPDIPEN
ATLIFEVELVACKPRKGSTFGSVSDEKARLEELRKQREIAAASKEEEKKRREEA
KATAAARVQAKLEARRGQGRGKGKSKGK
440PeptidylprolylMGLGLRIASASFLPIFNIMATRSLCILLVCFIPVLAHVLSLQDPELGTVRVYFQ38781
isomeraseTTYGDIEFGFFPHVAPRTVEHIYKLVRLGCYNSNHFFRVDRGFVAQVADVVGGR
EVPLNSEQRKEGEKTIVGEFSEVKHVRGILSMGRYSDPDSASSSFSILLGNAPH
LDGQYAVFGKVTKGDDTLKRLEEVPTRQEGIFVMPLERIRILSTYYYDTNERES
NLTCDHEVSILKRRLVESAYEIEYQRRKCLP
441PeptidylprolylMASRRSLRTMNVWPTLPPLVLLLLLCFSSMSSSVVAKKSDVSELQIGVKHKPKS38526
isomeraseCDIQAHRGDRIRVHYRGSLTDGTVFDSSFERGDPIEFELGSGQVIKGWDQGLLG
MCVGERRKLRIPSRLGYGAQGSPPKIPGGATLIFDTELVAVNGKGISNDGDSDL
442PeptidylprolylMSGAPAERPISYFDITIGGKPIGRIVFSLYADLVPRTAENFRALCTGERGIGRS371158
isomeraseGRPLCYAGSGFHRVIRGFMCQGGDFTAGNGTGGESIYGEKFEDEAFPVRHTKPF
LLSMANAGKDTNGSQFFITVSQTPHLDDRHVVFGEVIRGRSIVRAIENYPTASG
DVPTSPIIISACGVLSPDDPSLAASEETIGDSYEDYPEDDDSDVQNPEVALDIA
RKIRELGNRLFKEGQIELALKEYLESIRYLDVHPVLPDDSPPELKDSYDALLAP
LLLNSALAALRTQPADAQTAVKNATRALERLELSDADKAKALYRRASAHVILKQ
EDEAEEDLVAASQLSPEDMAISSKLKEVKDEKKKKREEEKRAFKKMFSS
443PeptidylprolylMASSLRSSLFSSWALDSRSVCSLFNLNPGKMGLPSISTPLNWRTCCCSHSSELL61768
isomeraseELNEGLQSSRRRTVMGLSTVIALSLVYCDEVGAVSTSKRALRSQRVPEDEYTTL
PNGLRYYDLKVGSGTEAVKGSRVAVHYVARWRGITFMTSRQGMGITGGTPYGFD
VGASERGAVLKGLDLGVQGMRVGGQRILIVPPELAYGNTGIQEIPPNATLEFDV
ELISIRQSPFGSSVKIVEG
444WD40 repeatMGAIEDEEPPLKRLKVSSPGLRRGLEEEAPSLSVGSVSILMAKSLSLEEGETVG4212172
proteinSEGLIRRVEFVRIITQALYSLGYQKAGALLEEESGILLQSSNVALFRKQILDGK
WDESVVTLRGIDQVEVEGNTLKAASFLILQQKFFELLDKGNIPEAMKTLRLEIS
PMQLNTKRVHELASCIVFPSRCEELGYSKQGNPKSSQRMKVLQEIQQLLPPSIM
IPEKRLERLVEQALNVQREACIFHNSLDPALSLYTDHQCGRDQIPTTTLQVLES
HKNEVWFLQFSNNGKYLASASKDCSAIIWEITEGDSFSMKHRLSAHQKPVSFVA
WSPDDKLLLTCGIEEVVKLWNVETGECKLTYDKANSGFTSCGWFPDGERFISGG
VDKCIYIWDLEGKELDSWKGQGMPKISDLAVTSDGKEIISICGDNAIVMYNLDT
ETERLIEEESGITSLCVSKDSRFLLLNLANQEIHLWDIGARSKLLLKYKGHRQG
RYVIRSCFGGSDLAFVVSGSEDSQVYIWHRGNGELLAVLPGHSGTVNCVSWNPV
NPHVFASASDDYTIRIWGVNRNTFRSKNASSSNGVVHLANGGP
445WD40 repeatMPGTTAGAGIEPIEFQSLKKLSLKSLKRSFDLFASLHGEPQPPDQRSQRIRIAC1631647
proteinKVRAEYEVVKNLPTLPQREVGSSVSNSNVGETHSSLTTNQAQGFPTDTSGDLSK
DEGREITSIAVHLQPQTGLIDGKAGAIAGTSTAISSVGSSDRYQPSAAIMKRLP
SKWPRPIWHPPWKNYRVISGHLGWVRSVAFDPGNEWFCTGSADRTIKIWEVATG
KLKLTLTGHIEQIRGLAVSSRHPYLFSAGDDKQVKCWDLEYNKAIRSYHGHLSG
VYCLALHPTLDILCTGGRDSVCRVWDIRTKAQIFALSGHENTVCSVFTQAIDPQ
VVTGSHDTTIKLWDLAAGKTMSTLTYHKKSVRAIAKHPFEHTFASASADNIKKF
KLPKGEFLHNMLSQQKTIVNAMAINEDNVLVSAGDNGSLWFWDWKSGHNFQQAQ
TIVQPGSLDSEAGIYALQYDITGSRLVSCEADKTIKMWKEDETATPESHPINFK
APKDIRRF
446WD40 repeatMRPILMKGNERPLTFLKYNRDGDLLFSCAKDHTPTVWYGHNGERLGTYRGHNGA1921172
proteinVWCCDVSRDSTRLITSSADQTAKLWNVETGAQLFSFNFESPARAVDLAIGDKLV
VITTDPFMELPSAIHIKRIEKDLSKQTADSVLTITGIKGRINRAVWGPLNSTII
SGGEDSVVRIWDSETGKLLRESDKETGHQKPITSLCKSADGSHFLTGSLDKSAR
LWDIRTLTLIKTYVTERPVNAVAISPLLDHVVIGGGQEASHVTTTDRRAGKFEA
KFFHKILEEEIGGVKGHFGPINSLAFNPDGRSFASGGEDGYVRLHHFDPDYFHI
KM
447WD40 repeatMRPILMKGHERPLTFLKYNRDGDLLFSCAKDHTPTVWYGHNGERLGTYRGHNGA1311111
proteinVWCCDVSRDSTRLITSSADQTAKLWNVETGNQLFSFNFESPARAVDLAIGDKLV
VITTDPFMELFSAIHIKRIEKDLSKQTADSVLTITGIKGRINRAVWGPLNSTII
SGGEDSVVRIWDSETGKLLRESDKETGHQKAITSLCKSADGSHFLTGSLDKSAR
LWDIRTLTLIKTYVTERPVNAVAISPLLDHVVIGGGQEASHVTTTDRRAGKFEA
KFFHKILEEEIGGVKGMFGPINSLAFNPDGRSFASGGEDGYVRLHHFDPDYFHI
KM
448WD40 repeatMAENNVGDFIPLDRQEYPSKPAPGAVDSSFWKSFKKKEVSRQIAGVTCINFCPE1491726
proteinPPHDFAVTSSTRVHIYDGKSCELKKTITKFKDVAYSGVFRSDGQIIAAGGETGV
IQVFNAKSQMVLRQLKGHGRPVRVVRYSPQDKLHLLSGGDDSMVKWWDITTQEE
LLNLEGHKDYVRCGAASPSSVNLWATGSYDHTVRLWDLRNSKTVLQLKHGKPLE
DVLFFPSGGLLATAGGNVVKVWDILGGGRPIHTMETHQKTVMAMCISKVPRSGQ
ALGDAPSRLVTASLDGYNKVFDLDHFKVTHSARYPAPILSMGISSLCRTMAVGT
SSGLLFIRQRKGQIEDKIHSDSSGLQVNPVNDEKDSAVLKPNQYRYYLRGRSEK
PSEGDYVVKRMAKVYFQEYDKDLRHFNHSKALVSALKAADSKGTVAVIEELVAR
KRLIQTLSILNLDELELLINFLSRFILVPKYSRFLISLTDRVLDARAVDLGKSE
NLKKQIADLKGIVVQELRVQQSMQELQGIIEPLIRASAR
449WD40 repeatMDVETSPTGNKRTYTRLPRQVCVFWQEGRCTRESCNFLHVDEPGSVKRGGAT9482228
proteinNGFAPKRSYNGSDERDTLAAGPPGGSRRNISARWGRGRGGIFISDERQKIRNKV
CNYWLAGNCQRGEECKYLHSFVMGSDVKFLTQLSGHVKAIRGIAFPSDSGKLYS
GGQDKKVIVWDCQTGQGTDIPLNDEVGCLMSEGPWIFVGLPNAVKAWNILTSTE
LSLVGPRGQVHALAVGNGMLFAGTHDGSILAWKFSPASNTFEPAASLVGHTQAV
VSLVSGADRLYSGSMDKTIRVWDLGTFQCLQTLRDHTSVVMSLLCWDQFLLSCS
LDNTVKVWVATSSGALEVTYTHNEEHGVLALCGMNDEQAKPVLLCSCNDNTVRL
YDLPSFSERGRIFSRNEVRTFQIAPGGLFFTGDATGELKVWNWATQKS
450WD40 repeatMSVQELRERHAAATAKVNALRERIKAKRLQLLDTDVATYASSNGRTPISFSFTD3321465
proteinLVCCRTLQGHTGKVYSLDWTSEKNRIVSASQDGRLIVWNALTSQKTHAIKLPCA
WVMTCAFSPSGQAVACGGLDSVCSIFQLNNQLDRDGHLPVSRILSGHRSYVSSC
QYVPDGDTHVITGSGDRTCIQWDVTTGQRIAIFGGEFPLGHTADVMSVSISAAN
PKEFVSGSCDTTTRLWDTRIASRAIRTFHGHEADVNTVKFFPDGLRFGSGSDDG
TCRLFDIRTGHQLQVYRQPPRENQSPTVTAIAFSFSGRLLFAGYSNGDCFVWDT
ILEKVVLNLGELQNTHMGRISCLGLSADGSALCTGSWDKNLKIWAFGGHRKIV
451WD40 repeatMKVKIISRSTDEFTRERSNDLQRVFRNFDPNLHTQARAQEYVRALNAAKLDKIF2321590
proteinAKPFLAAMSGHIDGISAMAKSPRHLKSIFSGSVDGDIRLWDIAARRTVQQFPGH
RGAVRGLTVSTEGGRLISCGDDCTVRLWDIPVAGIGESSYGSENVQKPLATYVG
KNSFRAVDYQWDSNVFATGGAQVDIWDHDRSEPTNSFAWGSDTVISVRFNPAEK
DIFATTASDRSIVLYDL8MASPLNKLIMQTRNNAIAWNPREPMNFTAANEDCNC
YSYDMRRMNISTCVHQDHVSAVMDIDYSPSGREFVTGSYDRTVRIFPYNAGHSR
EIYHTKRMQRVFCVKFSGDATYVVSGSDDANIRLWKAKASEQLGVLLPRERKRH
EYLDAVKERFKHLPEIKRIERHRHLPKPIYKAALLRHTVNAAAKRKEERKRAHS
APGSVVTNPLRKKRIVAQLE
452WD40 repeatMDHYYQDDFDYLVDDEMVDFADDVEDDVRTRRRSDIDSDSEMDFDLNNKSPDTT2071550
proteinALQAKRGKDIQGIPWNRLNFTREKYRETRLQQYKNYENLPRPRRSRNLDKECTN
FERGSSFYDFRHMTRSVKATIVHFQLRNLVWATSKHNVYLMQNYSIMHWSSLRQ
KGEEVLMVAGPIVPSVKHPGSSPQGLTRVQVSAMSVKDNLVVAGGFQGELICKY
LDKPGVSFCTKISHDENGITNAVEIYNDASGATRLMTANNDLAVRVFDTEKFTV
LERFSFPWSVNHTSVSPDGKLVAVLGDNADCLLADCKTGKTVGTLRGHLDYSFA
AAWHPDGYILATGNQDTTCRLWDVRKLSSSLAVLKGRMGAIRSIRFSSDGRFMA
MAEPADFVHLYDTRQNYTKSQEIDLFGEIAGISFSPDTEAFFVGVADRTYGSLL
EFNRRRMNYYLDSIL
453WD40 repeatMAEALVLRGTMEGHTDAVTAIATPIDNSDMIVSSSRDKSILLWNLTKEPEKYGV211171
proteinPRRRLTGHSHFVQDVVISSDGQFALSGSWDSELRLWDLNTGLTTRRFVGHTKDV
LSVAFSIDNRQIVSASRDRTIRLWNTLGECKYTIQPDAEGHSNWISCVRFSPSA
TNPTIVSCSWDRTVKVWNLTNCKLRNTLVGHGGYVNTAAVSPDGSLCASGGKDG
VTMLWDLAEGKRLYSLDAGDIIYALCFSPNRYWLCAATQQCVRIWDLESKSIVA
DLRPDFIPNKRAQIPYCTSLSWSADGSTLFSGYTDGKIRVWGIGHV
454WD40 repeatMAAIKSTSRSASVAFAPDAPLLAAGTMAGAIDLSFSSLANLEIFKLDFQSDDPE2213679
proteinLPVVGECPSNERLNRLSWGSAGGSFGIIAGGLVDGTINIWNPATLINSEDNGDA
LIARLEQHTGPVRGLEFNTISTNLLASGAEDGELCIWDLANPTAPTHFPPLKGV
GSGAQGEISFLAWNRKVQHILASTSYSGTTVVWDLRRQKPIISFPDATRRRCSV
LQWNPDASTQLIVASDDDNSPTLRAWDLRNTISPYKEFVGRSRGVIANSWCPSD
SLFLLTCAKDNRTLCWDTGSGEIVCELPAGANWNFDVQWSPKIPGILSTSSFDG
KIGIHNIEACSRNVSGEVEFGGAIVRGGPSALLKAPKWLERFAGVSFGFGGRLA
SFRFSTVAQAADHRHSEVFIHNLVTEDNLVIRSTEFEAAIADGEKVSLRALCDR
KAEESQSDEEKETWNFLRVMFEDEGTARTKLLEHLGFKVQSEENGDLQETHSSK
IDDIGSEIGKTLTLDDKTEEDVLPQLKGGQDAAIPQDNGEDFFDNLHSPKESVS
LSHVGNDFVGEKDKDMVVNGAEIEHETEDLTEYSDWNEAIQHSLVVGDYKGAVL
QCLSANRMADALIIAHLGGNSLWEKTRDEYLKKAKSSYLKVVSAMVNNDLTGLV
NSRPLKSWKETLAMLCTYSQREEWTVLCDNLASRLIAAGNVMAATLCYICAGNI
EKTVEIWSRSLKYDYDGRSFVDRLQDVMEKTVVLALATGQKRVSPSLSKLVENY
AELLASQGLLTTAMEYLKLLGTEESSHELSILRDRLYLSGTDNKVEASSFPFET
RQDLTESQYNMHQTGFGAPETQKNYQENVHQVLPSGSYTDNYQPTANTHYIAGY
QPAPQQQPSFQNYFTPASYQPAPSPNVFYPSQVSQAEQSNFAPPVNQPPMKTFV
PSTPPILRNVDQYQTPSLNPQLYQGVSSATVETHPYQTGAPASVSVGTTPGQPS
VVPNFMVPGPVTAPTVTPRGFMPVTTPTQHPLGSANPPVQPQSPQSSQVQSVTA
ATTPPPTIQNVDTSNVAAEIRPVIGTLRRLYDETSEALGGARANPAKRREIEQN
SRRIGSLFAKLNSGDISSNAASKLVHLCQALESRDYATAFQIQVGLTTSDWDEC
SFWLAALKRMIKVKQNNR
455WD40 repeatMAGAADSQLQTLSERDSTPNFKNLHTREYAAHKKKVHSVAWNCTGTKLASGSVD2691252
proteinQTARVWNIEPHGHSKTKDLELKGHADSVDQLCWDPKHSELLATASGDRTVRLWD
ARSGKCSQQVELSGENINITFKFDGTHIAVGNRDDELTIIDVRKFKPLHKRKFS
YEVNEIAWNTTGELFFLTTGNGTVEVLSYFSLQVLHTLVAHTAGCYCIAIDPIG
RYFAVGSADALVSLWDLSEMLCVRTFTELEWPVRTISFNHDGQYIASASEDLFI
DIADVQTGRTVHQISCRAAMNSVEWNPKYNLLAFAGDDKNKYMQDEGVFRVFGF
ETP
456WD40 repeatMAATSPVGAGSGRELANPPTDGISNLRFSNHSDHLLVSSWDRKVRLYDASANSL2141242
proteinKGQFVEGGPVLDCCFHDDASGFSGSADNTVRRYDFSTRKEDILGRHEAPVRCVE
YSYAAGQVITGSWDKTLKCWDPRGASGQEKTLVGTYSQLERVYSMSLVGHRLVV
ATAGRHINVYDLRNNSQPEQRRESSLKYQTRCVRCYPNGTGFALSSVEGRVAME
FFDLSEAGQAKKYAFKCHRKSEAGRDTVYPVNAIAFHPIYGTFATGGCDGYVNV
WDGNNKKRLYQYSKYPTSIAALSFSRDGRLLAVASSYTFEEGEKPHEPDAVFVR
SVNEAEVKPKPKVYAAPP
457WD40 repeatMASDDEEGFKNEEAPGVVDEAEVQEGLRACFPLSFGKQEKKQAPLESIHSATKR1192065
proteinPEDPRPRRQLGPPRPPPSILAEQEDSDRFVGPPRPPQFVRDDNDDGEAEIMIGP
PRPPAQYSDDHDNEETIGPPKPSYLEKGEETDQMVGPSKRGSDDETSGDSDDGD
DAVDFRVPLSNEIVLRGHTKVVSALAIDQTGSRVLTGSYDYSVRMYDFQGMTSQ
LKSFRQLEPAEGHQVRSLSWSPTSDRFLCVTGSAQAKIFDRDGLTLGEFVKGDM
YLRDLKNTRGHISGLTCGEWHPKEKQTILTCSEDGSLRIWDVNDFNTQKQVIKP
KLAKPGRVPVTACAWGRDGKCIAGGVGDGSIQVWNLKPGWGSRPDLYVAKGHDD
DITGLQFSADGNILLTRSTDETLKVWDLRKAITPLQVFRDLPNNYAQTNVAFSP
DERLIFTGTSVERDGMSGGLLCFYDRQTLELVLRIGVSPVHSVVRCTWHPRHNQ
VFATVGDKREGGAHILYDPALSERGALVCVARAPRKKSLDDFEAKPVIHNPHAL
PLFRDEPSRKRQREKARMDPMKSQRPDLPVTGPGFGGRVGSTKGSLLTQYLLKE
GGLIKETWMEEDPREAILKYADVAARDPKFIAPAYAQTQPETVFAETDSEEEQK
458WD40 repeatMKERGQSHAGQPSVDERYTQWKSLVPVLYDWLANHNLVWPSLSCRWGPQMHQAT1861550
proteinYKNSQRLYLSEQTDGTVPNTLVIATCEVVKPRVAAAEHISQFNEEARSPFVKKF
KTIIHPGEVNRIRELPQNSKIVATHTDGPDVLIWDVDTQPNRQATLGAADSRPD
LVLTGHKDNAEFALAMSPSAPFVLSGGKDKCVLLWSIQDHISAATEPSSAKASK
TPSSAHGEKVPKIPSIGPRGVYKGHKDTVEDVQFCPSNAQEFCSVGDDSALILW
DARNGNEPVIKVEKAHNADLHCVDWNPHDENLILTGSADNSVRNFDRRNLTSSG
VGSPVHKFEGHSAPVLCVQWCPDKASVFGSAAEDSYLNVWDYEKVGKNVGKKTP
PGLFFQHAGHRDKVVDFHWNSFDPWTIVSVSDDGESTGGGGTLQIWRMSDLIYR
PEDEVLAELERFRAHILSCQNK
459WD40 repeatMSSLSRELVFLILQFLDEEKFKESVHKLEQESGFFFHMKYFDEKAQAGEWDEVE2443671
proteinRYLSGFTKVDDNRYSMKIFFEIRKQKYLEALDRQDRAKAVDILVKDLKVFSTFN
EELYKEITQLLTLDNFRENEQLSKYGDTKSARTIMMSELKKLIEANPLFREKLI
YPNLKASRLRTLINQSLNWQHQLCKNPRPNPDIKTLFTDHACGPPMGARTPTQP
TASLGVLPKATTFTPIGPHGPFPSSSTATSGLASWMSMPNMVTSPQAPVAVGPS
VPVPPNQATLLKRPRTPPGSSSVVDYQTADSEQLIKRLRPVSQSIDEATYPGPT
LRVPWSTDDLPKTLARALNEPYPVTSIDFHPSQQTFLLVGTKNGEITLWEVGSR
EKLATRSFKIWDNANCSNHLEAAFVKDSSVSINRVLWSPDGTLIGIAFTKHLVH
TYTFQGLDLRQHLEIDAHVGGVNDLAFSHPNKQLCVVTCGDDKMIKVWDAVTGR
RLYNFEGHDAPVYSVCPHHKENIQFIFSTAVDGKIKAWLYDHLGSRVDYDAPGH
SCTTMMYSADGTRLFSCGTSKEGESFLVEWNESEGAIKRTYSGLRKKGSGVVQF
DTTQNHFLAVGDEHLIKFWDMDSTNMLTSCDAEGGLLNLPRLRFNKEGSLLAVT
TVNGIKILANADGQKLLRTMENRTFDLPSRAHIDAASATSSPATGRMERIERTS
SANTVSGINGVDPAQSSEKLRLSDDLSEKTKIWKLTEITDSIQCRCITLPENAA
EPASKVSRLLYTNSGVGLLALGSNAVHKLWKWNRSEQNPSGKATASVHPQRWQP
TSGLLMTNDITDINPEEAVPCIALSKNDSYVMSASGGKVSLFNMMTFKVMTTFM
PPPPASTFLAFHPQDNNIIAIGMEDSTIHIYNVRVDEVKTKLKGHQKRITGLAF
SSTQMILVSSGADAQLCVWNTETWEKRRSKTIQMPVGKTVSGDTRVQFHSDQLH
ILVVHETQLAIYDAYKLERQYQWVPQDALSAPILYATYSCNRQLIYATFSDGHI
GVYDAEILRPRCRIAPTTYLSSGTSSSTSLPLVVAAHPHEPNQFAIGLSDGAVQ
VLEPSESEGKWGVSPPPENGWPAVVAGPSTSNQGSEQAPR
460WD40 repeatMAKDEEEFRGEMEERLVNEEYKIWKKNTPFLYDLVITHALEWPSLTVQWLPDRE1631431
proteinEPPGKDYSVQKMILGTHTSDNEPNYLMLAQVQLPLEDAENDARQYDQERGEIGG
FGCANGKVQVIQQINHDGEVNRARYMPQNPFIIATKTVSAEVYVFDYSKHPSKP
PQDGGCHPDLRLRGHNTEGYGLSWSPFKHGHLLSGSDDAQICLWDINVPAKNKV
LEAQQIFKVHEGVVEDVAWHLRHEYLFGSVGDDRHLLIWDLRTSATNKPLHSVV
AHQGEVNCLAFNPFNEWVLATGSADRTVKLFDLRKISSALHTFSCHKEEVFQIG
WSPKNETILASCSADRRLMVWDLSRIDEFQTPEDALDGPPELLFIHGGHTSKIS
DFSWNPCEDWVIASVAEDNILQIWQMAENIYHDEEDDMPPEEVV
461WD40 repeatMSPGVKQTGSQKFESGHQDVVHDVTMDYYGKRIATCSA0RTIRLFGLNASDTPS1551081
proteinLLASLTGHEGPVWQVAWAHPKFGSMLASCSYDGRVIIWREGQQENEWSQVQVFK
EHEASVNSISWAPNELGLCLACGSSDGSITVFTCREDGSWDKTKIDQAHQVGVT
AVSWAPASAPGSLVGQPSDPIQKLVSGGCDNTAKVWKFYNGSWKLDCFPPLQMH
TDWVRDVAWAPNLGLPKSTIASCSQDGKVVIWTQGKEGDKWEGRILNDFKIPVW
RVNWSLTGNILAVADGNNSVTLWREAVDGDWNQVTTVQ
462WD40 repeatMSSGVKQTGSQKFESGHQDVVHDVTMDYYGKRIATCSADRTIKLFGMNTSDTPT5371463
proteinLLASLTGHEGPVWQVAWARPKFGSMLASCSYDRRVIIWREGQQENEWSQVQVFK
EHEASVNSISWAPHELGLCLACGSSDGSITVFTGREDGSWDKTKIDQAHQVGVT
AVSWAPASAPGSLVGQPSDPVQKLVSGGCDNTAKVWKFYNGSWKLDCFPPLQMH
TDWVRDVAWAPNLGLPKSTIASCSQDGRVVIWTQGKEGDKWEGKILNDFKTPVW
RISWSLTGNILAVADGNNNVTLWIFEAVDGEWNQVTTVQ
463WD40 repeatMKKRSRPSNGHLSTAAKNKSRKTAPITKDPFFDSAHNRNKSKGKGKSRGKGEEI2841909
proteinESSDEDDDAIGRDAPAEEEEEIAEEERETADEKRLRVAKAYLDKIRAITKANEE
DNEEEAGEDEETEAERRGKRDSLVAEILQQEQLEESGRVQRQLASRVVTPSKLV
ECRVVKRHKQSVTAVALTEDDLRGFSASKDGTIIHWDVETGASEKYEWPSQAVS
VSSSFEVSKTQKGKGSKKQGSKHVLSMAVSSDGRYLATGGLDRYIHLWDTRTQK
HIQAFRGHRGAVSCLAFRQGTQQLISGSFDRTIKLWSAEDRAYMDTLYGHQSEI
LAVDCLRKERVLSVGRDHTLRLWKVPEETQLVFRGHAASLECCCFINNEDFLSG
SDDGSIELWSMLRKKPVFMARNAHGHAIVENLSEDTSTREEPDEEVTTRQLPNG
NSIGNGMTNQMGITPSVESWVGAVTVCRGTDLAASGAGNGVVRLWAIENSSKSL
RALHDIPLTGFVNSLTFARSGRFLIAGVGQEPRLGRWGRIQAARNGVTLCPIEL
S
464WD40 repeatMAATFGTINTATSPHNPNKSFEIVQPPNDSISSLSFSPKANYLVATSWDNQVRC6101659
proteinWEVLQTGASMPKAAMSHDQPVLCSTWKDDGTAVFSAGCDKQAKMWPLLTGGQPV
TVAMHDAPIKDIAWIPEMNLLATGSWDKTLKYWDTRQSNPVHTQQLPERCFALS
VRHPLMVVGTAQRNLIIFNLQNPQTEFRRISSPLKYQTRCVAAFPDKQGFLVGS
IEGRVGVHHVEEAQQSKNFTFKCHRDSNDIYAVNSLNFHPVHQTFATAGSDGAF
NFWDKDSKQRLKAMARSNQPIPCSTFNSQGSLYAYAVSYDWSKGAENHNPATAK
HHILLHVPQESEIKGKPRVTTSGRK
465WD40 repeatMVVMDKGTHQTNEDESESEFIDEDDVIDEISIDEEDLPDADVEGEDVQEDNKRS2411452
proteinEPDENSSSLDDAINTFEGHEDTLFAVACSPVDATWVASGGGDDKAFMWRIGHAT
PFFELKGHTDSVVALSFSNDGLLLASGGLDGVVRIWDASTGNLINVLDGPGGGI
EWVRWHPKGHLVLAGSEDYSTWMWNADLGKCLSVYTGHCESVTCGDFTPDGKAI
CTGSADGSLRVWNPQTQESKLTVKGYPYHTEGLTCLSISSDSTLVVSGSTDGSV
HVVNIKNGKVVASLVGHSGSIECVRFSPSLTWVATGGMDKKLMIWELQSSSLRC
TCQHEEGVMRLSWSLSSQHIITSSLDGIVRLWDSRSGVCERVFEGHNDSIQDMV
VTVDQRFILTGSDDTTAKVFEIGAF
466WD40 repeatMPVFRTAFNGYAVKFSPFVETRLAVATAQNFGIIGNGRQNVLELTPNGIVEVCA2231173
proteinFDSSDGLYDCTWSEANENLVVSASGDGSVKIWDIALPPVANPIRSLEEHAREVY
SVDWNLVRKDCFLSASWDDTIRLWTIDRPQSMRLFKEHTYCIYAAVWNPRHADV
FASASGDCTVRIWDVREPNATIIIPAHEHEILSCQWNRYNDCMLVTGSVDKLIK
VWDIRTYRTPMTVLEGHTYAIRRVKFSPHQESLIASCSYDMTTCMWDYRAPEDA
LLARYDHHTEFAVGIDISVLVEGLLASTGWDETVYVWQHGMDPRAC
467WD40 repeatMDSRNRRSRLNLPPGMSPSSLHLETTAGSPGLSRVNSSPSTPSPSRTTTYSDRF2511777
proteinIPSRTGSRLNGFALIDKQPQPLPSPTRSAAEGRDDASSSSASAYSTLLRNELFG
EDVVGPATPATPEKSTGLYGGSRDSIKSPMSPSRNLFRFKNDHGGNSPGSPYSA
STVGSEGLFSSNVGTPPKPARKITRSPYKVLDAPALQDDFYLNLVDWSSNNVLA
VGLGTCVYLWSACTSKVTKLCDLGVNDSVCSVGWTPQGTHLAVGTNIGEVQIWD
TSRCKKVRTMGGHCTRAGALAWSSYILSSGSRDRNILHRDIRVQDDFIRKLVGH
KSEVCGLKWSYDDRELASGGNDNQLLVWNQQSAQPLLRFNEHTAAVKAIAWSPH
QHGILASGGGTADRCLRFWNTATDTRLNCVDTGSQVCNLVWCKNVNELVSTHGY
SQNQIMVWRYPSMSKLATLTGHTLRVLYLAISPDGQTIVTGAGDETLRFWSIFP
SPKSQSAVHDSGLWSLGRTHIR
468WD40 repeatMERKKVVVPIVCHGNSRPIVDLFYSPVTPDGLFLISASKDSSTMLRNGETGDWI3671419
proteinGTFEGHKGAVWSCCLDNRALRAASGSADFSAKIWDALTGDELHCFVHKHIVRAC
AFSESTSLLLTGGHEKILRIFDLNRPDAPPKEVDNSPGSIRTVAWLHSDQTILS
SNSDAGGVRLWDLRTEKIVRVLETKSPVTSAEVSQDGRYITTADGNSVKFWDAN
HFGMVKSYTMPCMVESASLEPTMGNMFVAGGEDMWVRLFDFHTGEEIACNKGHH
GPVHCVRFAPGGESYSSGSEDGTIRIWQTLNMNSEENESYGVNGLSGKVRVGVD
DVVQRVEGFQITADGHLNDKPEKPNP
469WD40 repeatMERYSQGTQKKSEIYTYEAPWQIYGMNWSVRKDKKFRLGIGSFLEEYNNRVEII2841303
proteinELDEESGEFKSDPRLAFDHPYPTTKIMFVPDKECQRPDLLATTGDYLRIWQVCE
DRVEPKSLLNNNKNSEFCAPLTSFDWNDADPKRIGTSSIDTTCTIWDIEKEVVD
TQLIAHDKEVYDIAWGEVGVFASVSADGSVRVFDLRDKEHSTIIYESSQPETPL
LRLGWNKQDPRFIATILMDSCKVVILDIRFPTLPVAELQRHQASVNTIAWAPHS
PCHICTAGDDSQALIWELSSVSQPLVEGGGLDPILAYTAAAEINQLQWSSMQPD
WVAIAFSNEVQILRV
470WD40 repeatMQSENNLDESLHLREVQELQGHTDTVWAVAWNPVTGIDGAPSMLASCSGDKTVR6841784
proteinIWENTHTLNSTSPSWACRAVLEETHTRTVRSCAWSPNGKLLATASFDATTAIWE
NVGGEFECIASLEGHENEVKSVSWSASGMLLATCGRDKSVWIWDVQPGNEFECV
SVLQGHTQDVKMVQWHPNRDILVSASYDNSIKVWAEDGDGDDWACMQTLGNSVS
GHTSTVWAVSFNSSGDRHVSCSDDLTLMVWDTSINPAERSGNAGPWKHLCTISG
YHDRTIFSVHWSRSGLIASGASDDCIRLFSESTDDSVTPVDGTSYKLILKKEKA
HSMDVNSVQWHPSEPQLLASASDDGRIKIWEVTRINGLANSH
471WD40 repeatMKRAYKLQEFVARASNVNCLKIGKKSSRVLVTGGEDHKVNNWAIGKPMAILSLS3362738
proteinGHSSAVESVTFDSAEALVVAGAASGTIKLWDLEEAKIVRTLTGHRSNCISVDFH
PFGEFFASGSLDTNLKIWDIRRKGCIHTYKGHTRGVNSIRFSPDGRWVVSGGED
NIVKLWDLTAGKLMHDFKCHEGQIQCMDFHPQEFLLATGSADRTVKFWDLETFE
LIGSAGPETTGVRANIFNPDGRTLLTGLHESLKVFSWEPLRCYDAVDVGWSKLA
DLNIHEGKLLGCSYNQSCVGVWVVDISRVGPYAAGNVSRTNGHNEAKLASSGHP
SVQQLDNNLKTNMARLSLSHSTESGIKEPKTTTSLTTTEGLSSTPQRAGIAFSS
KNLPASSGPPSYVSTPKKNSTSRVQPTTNFQTLSRPDIVPVIVPRSNSLRPETT
SDVKKEMNNFGRVVPSTVSTKSTDVIKSGSNRDESDKIDSINQKRMTGNDKTDL
NIARAEQHVSSRLDNTNTSSVVCDGNQPAARWIGAAKFRRNSPVDPVVSPHDRS
PTFPWSATDDGVTCQPDRQVTAPELSKRVVEPGRARALVASWETREKALTADTP
VLVSGRPPTSPGVDMNSFIPRGSHGTSESDLTVSDDNSAIEELMQQHNAFTSIL
QARLTKLQVIRRFWQRNDLKGAIDATGKMGDHSVSADVISVLIERSEIFTLDIC
TVILPLLTRLLQSETDRHLTVAMETLLVLVKTFGDVIRATISATPTIGVDLQAE
QRLERCNLCYVELENIKQILVPLIRRGGAVAKSAQELSLALQEV
472WD40 repeatMSTLEIEARDVIKIVL0FCKEMSLHQTFQTLQNECQVSLNTVDSLETFVADINS811622
proteinGRWDVILPQVAQLKLPRKKLEDLYEQIVLEMIELRELDTARAILRQTQAMGFMK
QEQPERYLRLEHLLVRTYFDPREAYHESSKEKRRSQIAQALASEVTVVPPSRLM
ALIGQSLKWQQHQGLLPPGTQFDLFRGTAAVKADEEEMYPTTLAHTIKFGKQSH
PECARFSPDGQYLVSCSVDGFIEVWDYISGKLKKDLQYQADDSFMMHDDAVLCV
DFSRDSEMLASGSQDGKIKVWRIRTGQCLRRLERAHSQGVTSLSFSRDGSQLLS
TSFDSTARIHGLKSGKALKEFRGHTSYVNDAIFTSDGGRVITASSDCTVKVWDV
KTTDCIQTFKPPPPLKGGDVSVNSVHLFPKNSEHIVVCNKASSIYIMTLQGQVV
KSFSSGKREGGDFVAACISPKGEWIYCVGEDRNIYCFSQQSGKLEHLMKAHDKD
IIGVTPHPHRNLLVTYSEDSTMKIWKP
473WD40 repeatMDIELEDQPFDLDFHPSAPIVAVALITGRLQLFRYVDISSEPERLWTVTAHTES3991460
proteinCRAARFINAGSSVLTASPDCSILATNVETGQPVARLDNAHGAAINCLTNLTEST
IASGQENGIIKVWDTRQNSCCNKFKAHEDYISDMEFVPDTMQLLGTSGDGTLSV
CNLRKNKVHARSEFSEDELLSVALMKNGKKVVCGSQEGVLLLYSWGYFKDCSDR
FVGHPHSVDALLKLDEDTVLTGSSDGIIRVVSILPNKMIGVIGEHSSYPIERLA
FSHDRNVLGSASHDQILKLWDIHYLHEDDEPETNKQEAVNDENVDMDLDVDTEK
RPRGSKRKKRAEKGQTSSQKQSSDFFADI
474WD40 repeatMDRIQQIPHTCVARKINLPLGMSKESLALNLPANLAPTMSPPSITYSDRFIPSR2071673
proteinKASNFEEFALPDETSPSPNSAGGQSSSTNGEGRDDACAAYSALLRTELFPATPD
KTEGCRRPVIGSPSGNVFRFKSQQCKSQSPFSLCPVGEDGDLSETGAVARKTTR
EIPRSPFKVLDAPALQDDFYLNLVDWSSHNILAVGLSACVYLWSASSSKVTKLC
DLGLDDNVCSVAWTQRGTYLAVGTNNGGVQIWDAAHCKQVRTMEGHCTRVGTLA
WNSHILSSGGRDRNILQRDIRAQDDFVSKFSGHKSEVCGLKWSYDNRELASGGN
DNQLFVWNQQSQQPVLKYNEHTAAVKAIAWSPHQHGLLASGGGTADRCIRFWNT
ATNTSLNCVDTGSQVCNLVWSKNVNELVSTHGYSQNQIIVWRYPTMSKLATLTG
HTLRVLYLAISPDGQTIVTGAGDETLRFWNVFPSSKTQQNTIRDMGVWSSGRTH
IR
475WD40 repeatMAGGQGEGEEKVDKLSMELTEDVMKSMEIGAVFKDYNGKINSLDFHRTNNYLVT2631309
proteinASDDEAIRLFDTASATWQKTSYSKKYGVDLICFTNHQTSVLYSSKNGWDESLRH
LSLMDNKYLRYFKGHHDRVVSLCMSPKGECFMSGSLDRTVLLWDLRIDECQGLI
RVRGRPAVAYDEQGLVFAISNEGGLIKMFDARLYDKGPFDTFVVEGDKSEASGI
KFSNDGKLILLSTMDSNIHVLDAYQGTTVHSFSVEAVPNGGEAVPNGGTLEASF
SPDGKFVISGSGNGNIHAWSVNSGREVACWTTEGVIPAVVKWAPRRLMFASGSS
VLSLWVPDLSELASLTGSNSNSAY
476WD40 repeatMHRVGSTGNTSNSSRPRREKRLTYVLNDANDSRHCSGINCLVISKLSLLGGNDY2322529
proteinLFSGSRDGTLKRWELADDSAVCSATFESHVDWVNDAVLTGETLVSCSSDTTLKT
WRPFSDGVCTRTLRQHSDYVTCLAAASKNSNIVASGGLGREVFIWDIEAAMAPV
SRTSEAMDDDTSNGVLSSGNSVLSTTVRSTNATNSASLHTSQLQGYTPIAAKGH
KESVYALANNDVGTLLVSGGTEKVVRVWDPRSGAKQMKLRGHTDNVRALILDST
GRFCLSGSSDSIIRLWDLGQQRCVHSYAVHTDSVWALASTPNFSHVYSGGRDLS
LYLTDLTTRESLLLCMEKHPLLRLTLQDDSIWVATTDSSLHRWPAEGQNPPKMF
QRGGSFLAGNLSFTRARACLEGSAPVPVNTQPSFVIPGSPGIVQHEILNNRRHV
LTKDAEGTVKLWEITRGAVLDDYGKVSFEEKKEELFEMVSIPAWFTMDTRLGSM
SVHLDTPQCFTAEMYAVDLNVPDAPEEQKINLAQETLRGLLAHWLSRRRQRLAT
QASANGDFPAGQENALRNHISSRIDVHDDAETHIAGILPAFDFSTTSPPSIITE
GSQGGPWRKKITDLDGTEDEKDFPWWCLECVLHGRLSPRESLKCSFYLHPYEGT
TVQVLTQGKLSAPRILRIQKVINYVLEKNVLDRPLDSSNSETTFTPGLSGNQSH
AAVVGDGSLRSGARVWQQKAKPLVEILCNNQVLSPDMSLATVRTYIWKKPDDLY
LYYRLVQNR
477WD40 repeatMMKGKTIQMQAAHQNHDGETSVACVLWDWHAKHLITAGADNTILIHSYPSSSSS562950
proteinKPITLRHHKNAVTALAINSNVRSLASGSVDHSVKLYSYPGGEFQSNVTRFTLPI
RSLAFNKSGELLAAAGDDEGIKLISTIDNSIARVLKGHNGPVTSISFDPKNEFL
ASSDSDGTVIYWELSTGKPVHTLKKIAPNTTSNPTSLNQISWRPDGEMLAVPGR
KSSVSMYDRDTAEKLFSLKGGHSDTICSLAWSPNGKYIATAGTDRQVMVWDADR
RQDIDKQRFDNPICSVAWRPSDNALAVIDVLGRFGVWESPIASHMKSPADGAER
YDNMEDEEPLMARYEEELEDSVSGSLNEIINDDDDDDEMGKIPRKILQKKPSVK
VEKGKEESWAKAFRSGQDSFKLKSANQEAFQPGATQRQSGKRNFLAYNNLGSVI
TFDNDGFSHIEVDFHDIGRGCRVPSMTDYFGFTMASLSESGSVFGSPQKGEKNP
STLMYRPFSSWANNSEWSMRFPMGEEVKAVALGSGWVAAVTSLNFLRVFSEGGL
QKFVLSMDGPVVTAAGYENLLVVVSHASNPLLSGDQVLSFTVYDISQKTCPLSG
RLPLSPGSHLTWLGFSEEGLLSSYDSEGNLRVFTNDYNGCWVPIFSAARERRSE
TESIWNVGLNSTQVFCVVCKLPDTYPQVAPKPVLSVLNLSLPLACSDLGADDLE
NEYLRGSLLLSQMQKKAEDAVACGRESNMEEDSIFKMEAALDRCLLRLIANCCK
GDRLVRATELARLLSLERSLQGAIELVSAMRLPMLAERFNTILEERILQENMET
ISCRRLTSEAQDMDTPISISVKQVSYGANLGDSPFLPNRQVEPKHSTPVFSRPD
TICEVDTSEAIAKGCDAQNGNIKSGDAEVQPASHNDSIQKPSNPFARASNTSAN
QAVQRNASLLSSIKQMKTATENEGKRKERARSGSLPQKPAKQSKIS
478WD40 repeatMRQKRKGHQVDDPKYSVQTPQEDDTPNESGPASEEVESSDEEGGNSSNIEDDII1932577
proteinYSSSEEDPVVSSDYEEDEDAESDAEGVTAEQELEGDIDNALQNYMGTLTVLSNF
HGENLKNAEGEDTSGDDDDEEEMPKRAEESDSPEDENDERPKRAEESDFSEDED
EERPKRAEESDSSEDEVPSRNTVGDVPLRWYKDEQHIGYDIKGKRIKKQPKKDQ
LDSFLASTDDSSDWRKVYDEYNDEEVELTKDEIKFISRLRRGTIPHADVNPYEP
YVDWFDWKDKGHPLSMAPEPKRRFIPSKWEAKRVVKLVRAIRKGWITFQKAEEK
PRFYLMWGDDLKPSEKMANGLSYIPAPKPRLPGHEESYNFPPEYIPTQEEINSY
QLMYEEDRPKFIPKRFDSLRNVPAYDRFLSEIFERCLDLYLCPRTRKKRINIDP
ESLIPKLPKFKDLQPFPSICFLEYKGHTGAVSCISPESSGQWLASGSKDGTVRI
WEVETARCLKVWDIGRPIQHIAWNPVSQLSILAVAVDEEVLVLNTGLGSEDSQE
KVAELLHVKSKPVSADDLGDNTSLTRWIKHEKFDGIKLTHLKPVHLISWHHKGD
YFATVAPDGNTRAVLVHQLSKQQTQNFFKKMQGRVVHVLFHPSRAIFFVATKTH
VRVYDLVKQQLVRRLVTGLHEVSSMAVHHKGDNLLVGSKEGKVCWFDHDLSTQP
YKTLKNHSKDIHSVAFHDSYPLFASCSDDCKAYVFYGLVYSDLLQNFLIVPLKV
LQGHQSVNGMGVLDCQFHPKQPWLFTAGADSVVKLYCN
479WD40 repeatMMSLRRGFEESLVPAKRQKTELSTVTYGDGPRRTSSLESPIMLLTGHHAAIYTM1871233
proteinRFNPTGTVIASGSHEREIFLWNVHGDCRNFMVLKGHRNAVLDLHWTTDGCQIIS
ASPDKTLRAWDVETGRQIRKMAEHSSFVNSCCPSRRGPPLVVSGSDDGTAKLWD
LRHRGAIQTFPDKYQITAVGFSDAADKIYSGGIDNEIKVWDLRRGEVTMRLQGH
TDTITGMQLSSDGSYLLTNSMDCSLRIWDMRPYAPQNRCVKILTGHQHNFEKNL
LKCSWSSDGSKVTAGSADRMVYIWDTTTRRILYKLPGHTGSVNETGFHPTQPII
GSCSSDRQIYLGEIEPNVGYQAVI
480WD40 repeatMEFSDTYKHTGPCCFSPDARYLAIAVDYRLVIRDVVTLKVVQLYSCMDKISNIE511436
proteinWALDSEYILCGLYKRAMVQAWSLSQPEWTCKIDEGPAGIAHARWSPDSRHIITT
SDFQLRLTVWSLVNTACIHIQWPKHASKGVSFTQDGKFAAIATRRDCKDYVNLL
SCHTWEVMGTFTVDTIDLADLEWSPNDSAIVVWDSPLEYKVLIYSPDGRCLFKY
QAYDSWLGVKTVAWSPCSQFLAVGSYDQTLRTLNHLTWKPFAEFVHVSTVRGPA
SAVVFKEVEEPWNLDVSGLHLNDDNAHDIQDGKPAEGHSRVRYKVVEFPVNVSS
QRHPVDKPNPKQGIGLLAWSRDSQYLFTRNDNMPTALWIWDICRLELAALLIQK
EPIRAAAWDPVYPRVALCTGSSHLYMWTPSGACCVNIPLPQFVVSDLKWNPDGT
SMLLKDRESFCCTFVPMLPEFNDDETNEE
481WD40 repeatMAKLIETHSCVPSTERGRGILIAGDAKTNSIIYCNGRSVIMRNLDNPLEASVYG5252351
proteinEHSYPATVARFSPNGEWVASGDTSGTVRIWGRGSDHTLKYEYKALAGRIDQLEW
SADGQRIVVCGDSKGKSMVRAFMWDSGTNVGEFDGHSRRVLSCSFKPTRPFRVA
TCGEDFLVNFYEGPPFRFKTSHRDHSNYVNCVRFAPDGSKFITVGSDRKGVIFD
GKMGEKIGELSKEGGHTGSIYAASWSPDSKQVLTVSADKSAKIWEISETGNGTV
KKTLTFGSQGGADDMLVGCLWLNDYLITVSLGGIVSLLSAVDPDKPPKTISGHM
KSINAIALSLQSGQSEVCSSSYDGVIVRWILGVGYAGRVERKDSTQIKCLATIE
GELVTCGFDNKVRRVPLLSEQHKESEPIDIGAQPKDLDVAVGCPELTFVSTDAG
IIIIRASKIVSTTNVGYAVTAAAISPDGTEAVVGGQDGRLRVYSIKGDTLLEES
VLERHRGPINAIRFSPDGSMFASGDLNREAVVWDRITREVKLKNMVYHTARINC
IAWSPDSSKVATGSLDTCILIYEVGKPASSRITIKGAHLGGVYGLAFSDQSTVI
SAGEDACVRVWSLP
482WD40 repeatMPQPSVILATAGYDHTVRFWEATSGRCYRTLQYPDSQVNHLEITPDKQYLAAAG1521099
proteinNPHIRLFEVNSNNPQPVISYDSHTNNVTAVGFQCDGKWMYSGSEDGTVKIWDLR
APGFQREYESRAAVNTVVLHPNQTELISGDQNGNIRVWDLNANSCSCELVPEDT
AVRSLTVMWDGSLVVAANNHGTCYVWRLMRGTQTMTNFEPLHKLQAHMSYILKC
LLSPEFCEHHRYLATTSSDQTVKIWNVDGFTLERTLTGHQRWVWDCVFSVDGAF
LVTASSDSTARLWDLSTGEAIRTYQGHHKATVCCALHDGTDGASC
483WD40 repeatMLTKFETKSNRVRGLSFHPKRPWILASLHSGVIQLWDYRNGTLIDKFDEHDGPV4704114
proteinRGVHFHKTQPLFVSGGDDYKIKVWNYKMRQCLFTFVGHLDYIRTVHFHNEYPWI
VSASDDQTIRLWNWQSRVCISVLTGHNHYVNSASFHPKEDLVVSASLDQTVRVW
DISGLRKKTVSPADDLSRLAQMNTDLFGGGDVVVKYVLEGHDRGVNWAAFHTSL
PLIVSGADDRQVKLWRMNDTKAWEVDTLRGHTNNVSCVIFHARQDIIVSNSEDK
SIRVWDMSKRTSVQTFRREHDRFWILAAHPEMNLLAAGHDSGMIVFKLERERPA
YVVYGGSLLYVKDRYLRTYEFATQKDNPLIPIRKPGSIGPNQGFRSLSYSPTEN
AILICSDADGGAYELYAVPKDSHGRSDTVQEAKKGLGGSAVFVARNRFAVLDKN
HNQVTIKNLKNEVTKKFDLPVTADALFYAGTGNLLCRSEDSVFLFDMQQRTVLG
EIQTPNVRYVVWSNDMENVALLSKHTIIIASKKLSSTCSLHETIRVKSGAWDDN
GIFMYSTLNHIKYCLPNGDSGIIKTLDVPVYITKVSGKSLYCLDRDGKNRVIQI
DITECLFKLALSKKKYDYVINMIRNSQLCGQAIIAYLQQRGFPEVALHFVRDER
TRFNLAVESGNIEIAVASAKEIDEKDHWYRLGVEALRQGNAGIVEYAYQRTKNF
ERLSFLYLITGNLDKLSKNLRIAEMKNDVMGQFHNALYLGDIQERIRILEESGE
LHLAYATASLHGLADIADRLAADLGGNIPVLPPGKKSSLLMPPAPILHGGDWPL
LRVTRGIFEGGLENSTSAAYEEEDEEAAADWGEDIDIENIEGENGEATVLDDQE
VKGGEDDEGGWDMEDLELPPDVAAANVGTNQKTLFVAPTLGMPVSQIWMQKSSL
AGEHAAAGNFETALRLLTRQLGIKNFSPLKPLFLELYMGSHTFLPSFASVPAFS
LALQRGWSESASPNIRGPPALVYRLSVLEEKLTVAYRATTEGRFSEALRLFLNI
LETIPVIVVDSRKEIDEVKELIGIAKEYVLGLRMEVKRKEIRDDAVRQQELAAY
FTHCNLQKAHLKLALLNAMGISYRCKNYNTAANFARRLLETDPSSNHATKARQV
LQVCERNLQDATQLNYDFRNFFVVCGATFTPIYRGQKEVSCPYCMARFVPDIAG
KLCSICDLAIVGSDASGLFCFATQTR
484WD40 repeatMDLLQNYQDDSEDSNPELRNHPPLEDATATSAPAGVENETSSSPDSSPLRLALP1962007
proteinAKSCAPDVDETLMALGVPGSEKKNNHNKPIDPTQHSVTFNPSYDQLWAPLYGPA
HFYAKDGIAQGMRNHKLGFVEDSAIEPFMFDEQYNTFHRYGYAADPSASLGSHI
VGDLESLKKNDGASVYNLPKREHKRQKLEKKMIQKDENEEEEKEVGEEVDNPST
EEWLKKNRKSPWAGKKEGLQTELTEEQKKYAQEHAEKKGDREKGEKVEIVDRTT
FHGKEERDYQGRSWIDPPKDAKATNDHCYIPKRWVHTWSGHTRGVSAIRFFPKY
GHLLLSAGMDTKVKIWDVFNSGKCMRTYMGHSKAVRDISFSNDGSRFLSAGYDR
NIKLWDTETGKVISTFSTGKIPYVVKLHPDEDKQNVLLAGMSDKKIVQWDMNSG
EITQEYDQHLGAVWTITFVDNNRRFVTSSDDKSLRVWEFGIPVVIKYISEPHMH
SMPSISLHPNTNWLAAQSLDNQILIYSTRERFQLNKKKRFAGHIAAGYACQVNF
SPDGRFVMSGDGEGRCWFWDWKTCKVFRTLKCHD14VCIGCEWHPLEQSKVATCG
WDGMIKYWD
485WD40 repeatMARKGLGTDPAIGSLMSSKRRKEYKVTNRFQEGKRPLYAIAFNFIDARYHNIFA2141323
proteinTAGGTRVTIYQCLEGGAISVLQAYVDDDRDESFYTLSWACDVNGSFLLVAGGHN
GIIRVLDVANEKVHKSFVGHGDSVMEIRTQALKPSLILSASKDESVRLWNVQTG
ICILIFAGAGGHRNEVLSVDFHPSDVYRIASCGMDNTVKIWSMKEFWTYVEKSF
TWTDLPSKFPTKYVQFPVFIAAVHSNYVDCTRWLGNFILSKSVDNEVVLWEPYS
KEQSTSDGVVDILQKYPVPECDIWFIKFSCDFHYNSMAVGNREGKVYVWELQSS
PPNLIARLSHAHCKNPIRQTAISHDGSTILCCCDDGSMWRWDVVQ
486WD40 repeatMESGAGGSVGARVPSAKPEMLQQPPYSNGDDDNDMERGTAPVPSSNPNTVSKWE682146
proteinLDKDFLCPICMQTMKDAFLTACGHSFCYMCIMTHLNNKSNCPCCSLYLTNNQLF
PNFLLNKLLKKTSACQMASTASPVENLCLSLQQGAEVSVKELDFLLTLLAEKKR
KMEQEEAETNMEILLDFLQRLRQQKQAELNEVQADLHYIKQDILALEKRRLELS
RARERYSRKLHMLLDDPMDTTLGHAAIDDGNNVRTAFVRGGQGDAISGKFQQKK
AEIKAQASSQGMQKRANFCHSDSQVLPTLSGLTIARKRRVLAQFDDLQECYLQK
RRRWATQLRKQCDGGLRKERDGNSISREGYHAGLEEFQSILTTFTRYSRLRVIS
ELRHGDLFHSANIVSSIEFDRDDELFATAGVSRRIKVFDFATVVNEPADVHCPV
VEMSTRSKLSCLSWNKCIKSQIASSDYEGIVTVWDVNTRQSVMMYEEHEKRAWS
VDFSRTEPTRLISGSDDGKVKVWCTRQETSVLNIDMKANICCVKYNPGSSYYVA
VGSADHHIHYYDLRNPSVPLYEFNGHRKTVSYVKFISTNELASASTDSTLRLWD
VRDNCLVRTFKGHTNEKNFVGLTVNSEYIACGSETNGVFVYHKAISKPAAWHQF
GSPDLDDSDDDTSHFISAVCWKSESPTMLAANSQGTIKVLVLAP
487WD40 repeatMANYVDSKKNFKCVPALQQFYTGGPFRLSSDGSFLVCACNDEVKVVDLATGSVK8743705
proteinNTLEGDSELIVALALTPDNKYLFSASRSTQIKFWDLSSATCKRTWKAHNGPVAD
MACDASGGLLATAGADRSILVWDVDGGYCTHSFRGHQGVVTTVIFHPDPHCLLL
FSGSDDATVRIWDLVAKKCISVLEKHFSTVTSLAISENGWNLLSAGRDKVVNIW
DLRDYHCRATIPTYEPLEAVCVLPTGSRLVSVMNQSRALPENRKKSGAAPVYFL
TVGERGIVRIWYSEGALCLYEQKSSDAIISSDKDELKGGFVSAVLLPLTQGVMC
VTADQRFLFYNLDESDEGKCDLKVSKRLIGYNEEIVDLKFLGDEEKFLAVATNL
EQVRNYDLSSMTCVYELSGHTDIVLCLDTVVFSGHSLLASGSKDHTVRIWDTES
KSCICVAAGHMGAVGAVAFSKKAKNFFVSGSSDRTIKVWSFASVLDFGGISKSI
KLSSQAAVAAHDKDINSVAVAPNDSLICTGSQDRTARIWRLPDLVPVLVLRGHK
RGVWCVEFSPVDQCVMTASGDKTIRIWALSDGSCLKTFEGHTASVLRASFLTRG
TQFVSSGADGLLRLWTIKSNECIATFDQHEDKIWAMAVGKKTEMLATGGSDSLV
NLWHDCTTTDEEEALLKEEEAALKDQELLNALADTDYVKAIQLAFELRRPYKLL
NVFTELYSKGHAQDQIQKVIRELGNEELRLLLEYVREWNTKPKFAHVAQFVLFQ
LFWVLPPKEIIEVQGISELLEGLIPYAQRHYSRIDRLMRSTFLLDYTLSSMSVL
SPTETDLSSSNLLARTADPLHAQIDQFHPThFPEPNLTPIQSLLDSGNTDSVEV
TARRAKKKRVSGNDSEKTTVAEVKIGDMENAFDEPDVADQGSSRKHKPASSKKR
KSIAVGNASIKRIASGNAVTIALQV
488WD40 repeatMESSCSSMNSNRHSTEKRCLRPLQKQGASMNKHSSDRFIPARGSIDLDVARFMV3601754
proteinTQKQKDNNDIHALSPSPSPSKKAYQKEMADTLLKNAGAADNNCRILSFNGKSST
VSQGSQENVLANLSISRRARRYIPQSADRTLDAPDLLDDYYLNLLDWSSTNVLS
TALGNTVYLWDASNSSISELLIADEEEGPVTSVSWAPDGSQIAVGLNNSVVQLW
DSQSNKKLBALKGHHDRVGALSWNGPILTTGGLDGIIINHDVRTRDHIVQTYKG
HTQEVCGLKWSPSGQQLASGGNDNLLYIWDKSMASHNPSSQYFHQLDEHCAAVK
ALAWCPFQTNLLASGGGTSDGSIKFWNTQTGACLNTVDTHSQVCSLLWNRHERE
LLSSHGLNQNQLTLWKYPSMVKITELTGHTARVLHMAQSPDGYTVASAAADETL
KFWQVFGAPDASKKTKTKDTKGAFNMFHMHIR
489WD40 repeatMLDEIVADEEEEFNIWRKNTPLLYDVVITHALEWPSLTVQWLPDRHQSPTKDYS1851384
proteinLQKMIVGTHTSGDEPNYLMIAEVQMPLQYSEDGNVGGFESTEAKVHIIQQIMHE
GEVNRAQYMPQNSFIIATKTVSSDVYVFDYTKHSSNAPQERVCNPELILKGHTN
EGYSLSWSPLKEGQLLSGSNDAQICFWDINAASGRKVVEAKQIFKVHEGAVEDV
SWHLKHEYLFGSVGDDCHLLIWDTRTAAPNKPQHSVVAHESEVNSLAFNPFNEW
LLATGSADKTVKLFDLRKLSCSLHTFSNHTEEVFQIEWSPMNETILASSGGDRR
LMVWDLRRIGDEQTSEDAEDGPPELIFIHGGHTSKISDFSWNLHDDWLIASVAE
DNILQIWQMAENIYHDDADIL
490WD40 repeatMTKEDHGESRDEMGERMVNEEYKLWKKNTPFLYDLVITHALEWPSLTVQWLPPS2411533
proteinCEQQQQIIKQDDIDHPNTQMVILGTHTSDNEPNYLILAEVQLHDGTEDEDGDGD
VKRPQDKMKPGTSGGAMGKVRILQQINHQKEVNRARYNPQKPTIIATKTVNADV
YVFDYSKHPSKPPQEGRCNPELRLQGHESEGYGLSWSPLKEGHLLSASDDAQIC
LWDITAATKAPKVVEANQIFRYHDGPVEDVAWHAIHDHLFGSVGDDHHLLLWDI
RNDSEKPLHIVEAHQAEVNCLAFNPFNEWIVATGSADRTVALHDIRKLDKVLHT
CAHHMEEVFQIGWSPQNGAILASCGSDRRLMVWDLSRIGDEQNPEDAEEAPPEL
LFIHGGHTSKISDFSWNPAEEWVIASVAEDNILQVWQMSEHIYNDDWDSPTA
491WD40 repeatMAMAMGDENAADPVEEFNIWKKNTPFLYDLVITHALEWPSLTVQWLFDRHQSST2301435
proteinADYSLQKNIVGTHTSEDEFNYLMIAEVQIPLQNSEDNIIGGFESTEAKVQIIQK
INHEGEVNKARYMPQNSFVIATKTVSSDVYVFDYSKHPSKAPQERVCNPELILK
GHSNEGYGLSWSPLKEGYLLSGSNDAQICLWDINAAFGKKVLEANQIFKVHEGA
VGDVSWHLKHEYLFGSVGDDCHLLIWQMRTAAPNKPQQSVIAHQSEVNSLAFNP
FNEWLLATGSMDKTVKLFDLRKLSCSLHTFSNHTDQVFQIEWSFMNETILASSG
ADRRLMVWDLARIGETPEDEEDGPPELLFVHGGHTSKISDFSWNLNDDRVIASV
AEDNILQIWQMAENIYHDDEDML
492WD40 repeatMGLFEPFRALGYITDGVPFAVQRRGIETFVTLSVGKAWQIYNCAKLIPVLVGPQ1012857
proteinMQRKIRALACWRDFTFAATGHDIAVFRRAHQVATWSGHKAKVTLLLSFGQHVLS
VDLEGCLFIWAVAEVNQNKPFIGQIQLGEKFSPSCIMHPDTYLNKVLIGSEEGT
LQLWNVNTRKKLYEFKGWGSSIRCCVSSPALDVVGIGCSDGKIHVHNLRYDEEI
VTFMHSTRGAVTALSFRTDGQFLLAAGGSSGVISIWNLEKKKLQSVIKDAHDSS
VCSLHFFANEPVLMSSATDNSIKNWIFDTTDGEARLLKYRSGHSAPPMCIRYYG
KGRHILSAGQDRAFRIFSVIQDQQSRELSQGHVGKRAKKLKVKDEEIKLPPVIA
FDAAEIRERDWCNVVTCHLDDPCAYTWRLQNFVIGEHILKPCLEDPTPVKSCSI
SACGNFAVLGTEGGWLERFNLQSGISRGTYIDIGEKRQCAHNGAVVGLACDATN
TLLISGGYNGDIKVWDFKGRELKFRWEIEVPLIKIVYHPGNGILATAADDMILR
LFDVTAMRLVRIFVGHMDRVTDLCFSGDGKWLLSSSMDGTIRVWDIISSRQLNA
MHMDSAVTALSLSPGMQMLATTHVGHNGIYLWANRMIYSKATDIEPFISGKQVV
RVSMPTVSSKRESEEGDEKRTIVAESNVNKSDVSGSLIGDSYSAQLTPELVTLA
LLPKAQWQSLVNLDIIKMRNKPIEPPKKPEKAPFFLPSLPTLSGERIFIPSSMN
GDGDQDETRNDKTVFEARGKKLGGESLSFMQLLQSCAKIKDFTTFTNYLKGLSP
SAVDMELRLLQIVDNENISETEHSVELQGIGMLLDYFVNEVSCNNNFEFVQALI
RLFLKIHGETIRCQVSLQEKARKLLEIQSSTWERL0TSFQNARCMITFLSSSQF
493WD40 repeatMIAAVCWVPKGVAKVLPDSAEPPTQEEIQELLKCNVVAESDDNEDSDEESEEMD431548
proteinTETDKNTDAVAKALAAANALGSQSSDFQRQHKVDDIANGLKELDMDHYDDEDEG
IDIFGSGSLGNCYYPANDMDPYLVEQDDDDEDEIEDMTIKPSDLIILSARNEDD
VSHLEVWIYEEETEEGGSNMYVHHDIILPAFPLSLAWLDCNLKCGEKGNFVAVG
TMQPEIELWDLDVLDEVEPAVVLGGAVKDEASGKTTKLKKKKKNKQAVNFKEGS
HTDAVLGLAWNMEYRNVLASASADKSVKIWDIVAEKCEHTMQPHTDKVQAVAWN
PNQATVLLSGSFDRSVIMMDMRAPTHSGIRWPVPADVESLAWDPHTDHSFMVSA
EDGTVRGFDIRAAASTADFDGKPMFILHAHDKAVCAISYNPAAPSLLTTGSTDK
MVKLWDITNNQPSCIASTNPNVGAVFSAAFSKNSPFLLATGGSKGILHVWDTLD
NSEVARRFGKFRPQN
494WEE1-likeMIMDENEFCDIFSLRKRLCLLSSQEGEEFEELEAMSQLDAGEFTVTGWEEVVAI2061657
proteinAEDDVNTGILSQDLFSSQDYCTPSQPQDSTDLDSRDKAPCPLSPVKSTIQRKRC
RPELLSNPPDSIQFSFQRLERVRSEESIQSSSQQLARVRSEVSSSDDFKTPKIT
ASGQKNYVSQSALALRARVMSPPCIKNPYLDENEELNERIQRSTRRSPACVTPI
QSGACLSRYPADFHELEEIGRGNFSRVYKALNRLDGCCYAVKCSQSELRLDTER
KVALMEVQSLAALGPHKNIVGYETAWFENDHLYIQMELCDHNLTTANDRGILRT
DTDFLEAVYQIAQALEFIHGRGVAHLDVKPENIYVRDGTYKLGDFGRATLINGT
LHVEEGDARYMSREILNDNYEHLDKVDMFSLGATFFELLMRKQYPGSGKRIDRD
TEIKIPILPGFSIYFQKLLQDLVSNDPGKRPSAKDVLKNPIFNKVRGAKEV
495WD40 repeatMLAPALEMEPVEPQSLKKLSFKSLKRALDLFSPVEGQIAPPDPESKKMRISYKL1171580
proteinNFEYGGGSGSEDQVPKRKESGAAQNQGQQAAGASNALALPGPEGSKIPPMEKSQ
NALTVGPSLRPQGLNDVGLHGKGTAIISASGSSDRNLSTSAIMERLPSRWPRPV
WHPPWKNYRVISGHLGWVRSIAFDPSNQWFCTGSADRTIKIWDLASGRLKLTLT
GHIEQIRGLAVSSKHTYMFSAGDDKQVKCWDLEQNKVIRSYHGHLSGVYCLALH
PTIDILLTGGRDSVCRVWDIRSKMQIFALSGHDNTVCSVFARPTDPQVVTGSHD
TTIKFWDLRHGKTMTTLTNHKKSVRAMAQHPKENCFASASADNIKKFQLPRGEF
LHNMLSQQKTIINTMAVMEEGVMATGGDNGSLWFWDWKSGHNFQQAHTIVQPGS
LESEAGIYALSYDLTGSRLVSCEADKTIKMWKEDELATPETHPLNFKPPKDIRR
F
496WD40 repeatMEEAAKEQSAGSGKPKLLRYGLRSAAKPEEDKKEEQLHQPPPPPPPQQQAAPAP1111700
proteinAPAATRSSTSGSAGGRDRRPQQQHAVDEKYARWKSLVPVLYDWLANHNLLWPSL
SCRWGPQLEQATYKNRQRLYISEQTDGSVPNTLVIANCEVVKPRVAAAEHVSQF
NEEARSPFIRKYKTIIHPGEVMRIRELPQNPNIVATHTDSPDVLIWDVESQPNR
HAVYGATASRPNLILTGHQENAEFALAMCPAEPFVLSGGKDKTVVLWSIQDHIT
ASATDQTTNKSPGSGGSIIKKTGEGNEETGNGPSVGPRGIYCGHEDTVEDVAFC
PSTAQEFCSVGDDSCLILWDARIGTNPVAKVEKAHNGDLHCVDWNPHDNNLILT
GSADNSVNMFDRRNLTSNGVGSPVYKFEGHKAAVLCVQWSPDKPSVFGSSAEDG
LLNIWDYERVDKKVDRAPNAPAGLFFQHAGHRDKIVDFHWNTADPWTMVSVSDD
CDTAGGGGTLQIWRMSDLIYRPEEEVLAELENFKAHVLECSKA
497WD40 repeatMAKDEEEFRGEMEERLVNEEYKIWKKNTPFLYDLVITHALEWPSLTVQWLPDRE1441412
proteinEPPGKDYSVQKMILGTHTSDNEPNYLMLAQVQLPLEDAENDARQYDDERGEIGG
FGCANGKVQVIQQINHDGEVNRARYMPQNPFIIATKTVSAEVYVFDYSKHPSKP
PQDGGCHPDLRLRGHNTEGYGLSWSPFKHGHLLSGSDDAQICLWDINVPAKNRV
LEAQQIFKVHEGVVEDVAWHLRHEYLFGSVGDDRHLLIWDLRTSATNKPLHSVV
AHQGEVNCLAFNPFNEWVLATGSADRTVKLFDLRRISSALHTFSCHKEEVFQIG
WSPKNETILASCSADRRLMVWDLSRIDEFQTPEDALDGPPELLFIHGGHTSKIS
DFSWNPCEDWVIASVAEDNILQIWQMAENIYHDEEDDMPPEEVV
498Cyclin-MGKYMRKGKGVGEVAVMEVSQGSLGVRTRARTLAAASSQK0HRRLGASKSVTTK7931683
dependantHQSSAPPASPCVESSMHTCYLELRSRKLEKFSRCYHSAHGATSHGESKRSLSLS
kinaseEPSRLAVSEEARVASDKSSHRVLQQQSSVAHSRNNSATFSHNAKPAKAAQRKER
inhibitorRDDDNTSARPSEAPHEDEDGNEVEASFGENVMDLDSRFRRTRETTPSSYTRDVE
TMFTPGSTTRPPSNAGRRRFQTEGGHGTRNQFHVPTTNEIEEFFAGAEQQEQRR
FTDRYNYDPVSDSPLPGRFEWVRLRP
499CDK type DMQNMEENVQSSWSLHGNKEICARYEILKRVSSGTYLDVYRGRRKEDGLIVALKE4152196
VHDYQSSWREIEALQRLCGCPNVVRLYEVILEFLTSDLYSVIKSAKNKGENGIP
EAEVKAWMIQILQGLANCHANWVIHRDLKPSMMLISAYGILKLADFGSMSFLKR
AIYEVEYELPQEDILADAPGERLMDEDDSVKGVWNEGEEDSSTAVETNFDDMAE
TANLDLSWKNEGDMVMQGFTSGVGTRWYRAPDFLYGATIYGKEIDLWSLGCILG
ELLILEPLFSGTSNIDQLSRLVKVLGLQQKKNWPGCSNLPDYRKLCFPGDGSPV
GLKNHVPNCSDNMFSILERLVCYDPAARLNAKEIVENKYFVEDPYPVLTHELRV
PSPLREENNFSFDWAKWKDMEVDSDLENIDEFNVVHSSDGFCIKFS
500HistoneMAPVKRIEPEKTKANEGKPKRRKVAFAIDTGIEANDCISLHLVSTPEEMRDAEG1091653
actyltransferaseVEDQSLSFNPEYMQHFVGEHGKIYGYKGLKIDVWLNALSFHAYVDIQYESKVEE
GKSEKEATDLTDIMKRIFGRGLVEDRNAFIQSFSSNSQSIESMIHNEGERIATR
EILTDKGLSAQGDSERLGVSNEIFRLELSDPQIREWHARLEPLVLLFVEGSQPI
EQDDPKWEMYIRVQRESLSGGSAVCRLLGFCTVYRFYHYPDTTRLRISQILVFP
PYQGKGHGLLLLEAVNKTAVSRDSYDVTVEEPSESLQELRDCMDTIRLLSFEPV
MPAVKSAVQKLKEANPSDKGAADHCLEGNVNNETVTTSSTKPKNKSGWFPPPGL
VEEVRKHLKISKKQFKRCWEILLYLNLDRSDSQCEDKYHISLMEQIMSELFDKS
SEKSAKGKRVIDIDNEYDNSKTFIMVRTRNPGNGEGFLPEALEGGMEVSQEDQL
KSLFEERLEEIAQIAEKVPSLCKALQMP
501HistoneMPEDRKKILEALAAKRKAEAESGEKKKRQKSSLNPAKPVSKPVSKPVGGIGSKG3431023
deacetylaseKSTSAPISSTKAKSKHKEEVKAKRVTKNDRYETDEDDESEEEEDLDSESDDDEL
SDEDSEDDIKSKSVKKLPPQSKGKAPVKGISSSNGKGRQEKGKGIMKDKGKAKA
KVEESSSDAEGDSDDDGGDLSDDPLQEVDPSMILPSRTRRRASQPTNYQFANMS
GDDDDDDDSD
502HistoneMADVPESLQQEKDSQGTDKNCCDGKFQKEIDIDDMEEEYNESSIDDEEENLSDN4172351
deacetylaseVATNNMGTIPQGQACMAVTVEGIEHANSVGCGRNGREGSEEVTAAEDMGHVSIE
NIREQGRNRKSSEQLLALYEQEGLLEDDEDDDDVDWEPFEGVTVQMKWYCTNCT
MANSDDSVHCDSCGEHRNSDILRQGFLASPYLPAESPSSSDVPDERLEESKCVM
TTLTPSISPMIGVCCSSLQSERRTVVGFDERMLLHSEIQMETYPHPERPDRLRA
IAASLRAAGLFPGKCFSIPAREATCEELQTIHSLEHVNAVESTSCGMLSHLSPD
TYANEHSSLAARLAAGLCADLAKAINTGQAQNGFALVRPPGHHAGVKDSMGFCL
HNNAAIAVSASRVVGAKKVLIVDWDVHHGNGTQEIFEADQSVLYISLHRHGEGF
YPGSGAVTEVGSSKGEGYSVNIPWKCGGVGDNDYIFAFQHAVLPIAEQFEPDLT
IISAGFDAAKGDPLGRCEVTPDGFAHMAQMLSCLSKGKNLVILEGGYNLRSISA
SATAVIKVLLGDNPKALPIDIQPSKGGLQTLLEVFEIQSKYWSSLKGHDQKLRS
QWEAQYGSKKRKVIRKRHMHIVGGPVWWKWGRKRVVYYHWFARVSSRKHL
503PeptidylprolylMASGAGAAGVVEWHQKPPNPIQJPVVFFDVTIGTIPAGRIKMELFADIVPRTAEN69641
isomeraseFRQFCTGEYRKAGIPIGYKGCHFHRVIKDFNIQAGDFVKGDGSGCISIYGSKFE
DENFIAKHTGPGLLSMANSGPNTNGCQFFLTCAKCDWLDNKHVVFGRVLGEGLL
VLRKIENVQTGQHNRPKLPCVIAECGEM
504PeptidylprolylMAKLVSSVCAFSCQQRHPHSRPRFLSNRDHYNHYHNHSHYHNVCYFPPMMNNQQ1721623
isomeraseQLQKQKRMTTKTITSLFKCNSSNHTLLKGLKEFMGFKFRLQAAMLSCEHSILGR
VFAIFFIVHQAAAPFPFNHFDNWLVPPASAVLYSPNTKVPRTGEVALRKSIPAN
PAMKSIQDFLEDIYYLLRFPQRKPYGTMEGDVKSALQIAINEKDSILGSVPLDM
KERGLQLYNFLIDGQGGLQVLIEYIKEKDPDKVSVNLSSSLDTIAQLELLQAPG
LPYLLPEEYQQYPRLNGRATIEFTMEKGDNSMFSVSSGGGLQRTATIQVVLDGY
SAPLTAGNFTKLVIDGAYNGLKLKTTEQAVISDNERAEAGFNLPIEILPAGGFE
PLYRTTLSVQDGELPVLPLSVYGAIAMAHNTISEDYSSPSQFFFYLYDKRNAGL
GGLSFDEGQFSVFGYTTVGICEILPQLKTGDIIKSAKLVDGFDHLVLPSSST
505WD40 repeatMDHYYQDDFDYLVDDEMVDFADDVEDDVRTRRRSDIDSDSENDFDSNNKSPDTT2311768
proteinALQAKRGKDIQGIPWNRLNFTREKYRETRLQQYKNYENLPRPRRSRNLDKECTN
FERGSSFYDFRHNTRSVKATIVHFQLRNLVWATSKHNVYLMQNYSIMHWSSLKQ
KGEEVLNVAGPIIPSVKHPGSSPQGLTRVQVSAMSVKDNLVVAGGFQGELICKY
LDKPGVSFCTKISHDENGITNAVEIYNDASGATRLMTANNDLAVRVFDTEKFTV
LERFSFPWSVNHTSVSPDGKLVAVLGDNADCLLADCKTGKTVGTLRGHLDYSFA
AAWHPDGYILATGNQDTTCRLWDVRKLSSSLAVLICGRNGAIRSIRFSSDGRFMA
MAEPADFVHLYDTRQNYTKSQEIDLFGEIAGISFSPDTEAFFVGVADRTYGSLL
EFNRRRMNYYLDSIL
506WD40 repeatMDCSGDEEFEQFFESLEEMLSPSDSGSEAADNETGCRNADARSKYEIWKRAPSS3762943
proteinIQERRQRFLVRMGLANPSELGNQVNSTSAESTCSTETANIPNGIERLRENSGAV
LRTAGSSGRKTHCKNVINIGLREGSVRSSSSSNGTPDVGEDNGEFGGTIFSRSG
GTWECMCKIKNLDSGKEFVVDELGQDGLWNKLREVGTDRQLTMDEFERSLGLSP
LVQELMRRESGVAQADCNGVHHHDAEISSSKRRSWLKALKSAAYSMRRPKEDQS
NYDSERSGRRSGSFDVPWGKPQWTKVRHYRKRYKEFTALYMGQEIEAHEGSIWT
MKFSLDGRYLASAGQDCVIHVREVIESMRTFGADTPDLYASSAYFSMNGLQELV
PLSIEDHANKMKRGKIIGSKKSSNSDCIVLPNKVFQLSEEPVCSFHGHLLDVFD
LSWSPSQYLLSSSMDKTVRLWKLGHESCLKVFSHNDIVTCIQFNPVDERYFISG
SLDGKARIWSIPDRQWDWSDLREMVTAVCYTPDGQGGLVGSIKGSCRFYNTSG
NKLQLENQLNVRSKKKKSSGKKITGFQFAPGGDSQKVLITSADSRVRVYNGSEL
VCRYKGFRNTCSQISASFAPNGQHFVCASEDSRVYIWNHESPRGSGARHEKSSW
SHEHFLSQGVSVAIPWSGMKLQPPVWNSPEFMLGQRHNLLSLQGGKDVGCQNGL
LSREAGEGQESETPLHYISQVSHSCGSQNMVDRDGQDDLSRYSACISDSRLSSF
MAFPESPGNPDDLNSKVFFSQSSSKGSATWPEEKLPPTRKQSRSNSTSSHYDTL
KTHLGNTIQGQSGASAAVAWGLVIVTAGHGGEIRSFQNYGLPVRL
507WD40 repeatMPSIPAIGEFTVCEINRELLTTKDESDTQAKDAYAKILGLVFPPISFQIEEGFG1071498
proteinSASRQQFDQDLDREDTIVTPSTSEGTNALQEGGLLLKGVSVLKNILASSFGPIF
SPNDTKVLKKVELLQGISWHRHKHILAFISGSNQVTVHDFQDPEWRESSLLVSE
SQRGIEALEWRPNGGTTLSVACRGGICIWSASYPGSVAPVRSGVASFLGTSTRG
SSVRWTLVDFLQIPGGKAVTALSWSPTGRLLASASREDSSFTIWDVAQGVGTPL
RRGLGGISLLKWSPTGDYLFSAKPNGTFYLWETNTWTLEQWSSSGGCVISATWG
PDGRNLFMAFSESTTLGSLHFAGRPPSLDAHLLPMELPEIGSITGGFGNIEKMA
WDGCGERLAVSYTGGDLMYVGLIAIYDTRRTPFISASLVGFIRGPGEQVKPLAF
AFHDKFKQGPLLSVCWSSGLCCTYPLIFRAH
508WD40 repeatMEEENAKHTEETRQVQVRFTTKLQPALRVPTTSIAIPAHLTRYGLSDIVNTLLG1181425
proteinNDKPQPFDFLVESELVRTSLEKLLLIKGISAEKILNIEYILAVVPPKQEEPSLH
DDWVSVVDGSYPNFIFSGSFDSIGRIWKGEGLCTHVLEGHRDAITSAAFIMPSD
SSDSFINLATASKDRTLRLWQFKPNEHMTNGKMVRPYKLLKGHTSSVQTVSACP
RRMLICSGSWDCSIKIWQTAGEMDIESNAGSVKRRKLEDSTEQIISQIEASRTL
EGHSQCVSSVVWLEKDTIYSASWDHSVRSWDVETGVNSLTVGCRKALHCLSIGG
EGSALIAAGGADSVLRIWDPRMPGTFTPILQLSSHKSWITACKWHPKSRHHLIS
ASHDGTLKLWDVRSKVPLTTLEAHKDKVLCADWWKEDCVISGGADSTLQIFSNL
NLT
509WD40 repeatMNRLRSKRNHILELRLGQSEPERFATLASNRSRGTNAPIVVEDDDDVVVSSPRS186797
proteinFALARSSVSQRSSRIPIVNEEDLELRLGLAVTGRTSAEHNPRRRHGRVPPNKPI
VLCDDAGEADQSSSKKRRTGQQLSSDVQSDESKEVKLTCAICISTMEEETSTIC
GHIFCKKCITNAIHRWKRCPTCRKKLAINNIHRIYISSSTG
510WD40 repeatMEEPPPPAVLPSSEDTSIVSSHSFVNAPPTVPVGLDASIPQISTPGINQPGLTI3872456
proteinPVPPEAAPLTASLVAASAGMPPAVVPSFVRPAIVAHPSVMPPPSMPLAALPMPV
ASAVPVAAPHFPPSTPNDNSITPSMPVPTPIVASSSVPPSVTIPGIAPLPFIAP
IPVPSSRPVAPSPFMPPARPLGASVSVAMDVDNTDEQDQDADNKGESPSSSPDH
PEDPSAAEYEITEESRKVRERQEQAIQELLLRR8AYALAVPTNDSSVRARLRRL
NEPITLFGEREMERRDRLRALMAKLDAEGQLEKLMKVQEEEEAAANVDAEEVQE
MEGPQVYPFYTEGSQELLKARTEITKFSLPRAVSRLQRARRKREDPDEDEDEEL
KCVLQQSAQINMDCSEIGDDRPLSGCAFSSDGTLLATSAWSGVTKLWSVPNINK
VATLKGHTERVTDVAFSPTNCHLATACADRTANLWNSEGVLMKTYEGHLDRLAR
LAFHPSGLYLGTASFDETWRLWDVNTGIELLLQEGHSRSVYGIAFQCDGSLAAT
CGLDGLARIWDLRTGRSILALEGNVKPVLGIDFSPNGYHLATGSEDHTCRIWDL
RKRQSVYIIPAHSHLVSQVKFEPQEGYFLVTASYDSTAKVWSARDFRSIKVLAG
HEAKVTSVDITADGQYIATVSHDRTIKLWSSKNSTNDMNIG
511WD40 repeatMKRAYKLQEFVAHASNVNCLKIGKKSSRVLVTGGEDHKVNMWAIGKPNAILSLS3592761
proteinGHSSAVESVTFDSAEALVVAGAASGTIKLWDLEEAKIVRTLTGHRSNCISVDFH
PFGEFFASGSLDTNLKIWDIRRKGCIHTYKGHTRGVNSIRFSPDGRWVVSGGED
NIVKLWDLTAGKLMHDFKCHEGQIQCMDEHPQEFLLATGSADRTVKFWDLETFE
LIGSAGPETTGVRANIFNPDGRTLLTGLHESLKVFSWEPLRCYDAVDVGWSKLA
DLNIHEGKLLGCSYNQSCVGVWVVDISRVGPYAAGNVSRTNGHNEAKLASSGHP
SVQQLDNNLKTNMARLSLSHSTESGIREPKTTTSLTTTEGLSSTPQRAGIAFSS
KNLPASSGPPSYVSTPKKNSTSRVQPTTNFQTLSRPDIVPVIVPRSNSLRPETT
SDAKKEMNNFGRVVPSTVSTKSTDVIKSGSNRDESDKIDSINQKRMTGNDKTDL
NIARAEQHVSSRLDNTNTSSVVCDGNQPAARWIGAAKFRRNSPVDPVVSPHDRS
PTFPWSATDQGVTCQPDRQVTAPELSKRVVEPGRARALVASWETREKALTADTP
VLVSGRPPTSPGVDMNSFIPRGSHGTSESDLTVSDDNSAIEELNQQHNAFTSIL
QARLTKLQVIRRFWQRNDLKGAIDATGKMGDHSVSADVISVLIERSEIFTLDIC
TVILPLLTRLLQSETDRHLTVAMETLLVLVKTFGDVIRATISATPTIGVDLQAE
QRLERCNLCYVELENIKQILVPLIRRGGAVAKSAQELSLALQEV
512Cyclin BMAGSDENNPGVVGGAHVQEGLRVGAGKMGAGNVQQRRALSNINSNIIGAPPYPC2381648
AVNKRVLSEKNVNSENDLLNAAHRPITRQFAAQMAYKQQLRPEENKRTTQSVSN
PSKSEDCAILDVDDDKMADDFPVPMFVQNTEAMLEEIDRMEEVEMEDVAEEPVT
DIDSGDKENQLAVVEYIDDLYMFYQKAEASSCVPPNYMDRQQDINERMRGILID
WLIEVHYKFELMDETLYLTVNLIDRFLAVQPVVKKKLQLVGVTAMLLACKYEEV
SVPVVEDLILISDRAYSRKEVLENERLMVNTLHFNMSVPTPYVFMRRFLKAAQS
DKKLELLSFFIIELSLVEYDMLKFPPSLLAASAIYTALSTITRTKQWSTTCEWH
TSYSEEQLLECARLMVTFHQRAGSGKLTGVHRKYSTSKFGHAARTEPANFLLDF
RL
513Cyclin-MQAPREGKSAAAIVGMGKYMKKSKAIPRDVSLLEASPRSPSATGVRTRAKTLAS59859
dependantRRLRRASQRRPPPPAAAAAAAAPSLDASPCPFSYLQLRSRRLRRPRLAPSPEAR
kinaseIDEGPAGSGSRGSRDASCSARTASSSGGVEGEGACVGRGDRGNGGECVRDAAVD
inhibitorASYGENDLEIEDRDRSTRESTPCSLIRDSNANTPPGSTTRQQSSCTAHRTQMSI
LRSIPTSDEMEEFFAYAEQRQQRSFIEKYNFDIVKDRPLPGRFEWVQVIP
514HistoneMDGHSSHLAAQNRSRGSQTPSPSHSAASASATSSIHLKRKLSAANASAASAAAA441829
acetyltransferaseAAAAAAAADDHAPPFPPSSISADTRDGALTSNDDLESISARGGGAGDDSDDDSD
DEEEDDGDNDGGSSLRTFTAARLENVGPAAARNRKIKAESNATVKVEKEDSAKD
GGNGAGVGALGPAATSGAGSGSGTVPESDAVKIFTENLQASGAYSAREENLKRE
EEAGRLRFECLSNDGVDDHMVWLIGLKNIFARQLPNMPKEYIVRLVMDRNHKSV
MVIRRNLVVGGITYRPYASQKFGEIAFCAIKADEQVKGYGTRLMNHLKQHARDV
DGLTHFLTYADHNAVGYFIKQGFTKEIYLDKDRWHGYIKDYDGGILMECKIDPK
LPYTDLSTMVRRQRQAIDEKIRELSNCHIVYQGIDFQKRDAGVPQNTIKMEDIP
GLREAGWTPDQWGYSRFRGLSDQKRLTFFIRQLLKVLNDHSDAWPFKEPVDARE
VPDYYDIIKDPMDLKTMTKRVESEQYYVTLEMFIADVERNFANARTYNSPDTIY
FKIATRLSAHFQSKVQSNLQSGAGKIQQ
515PeptidyiprolylMFHGMMDPELFKLAQEQMNRNSPAELAKIQQQMMSHPELMRMASESMKNMRPED1091866
isomeraseLRQAAEQLRHVRPEEMAEIGEKMANASPEEIAAVRARADAQMTYEINAAKILEE
EGNELHSQGRFKDASQKYLHAKNNLKGIPSSEGKNLLLACSLNLMSCYLETRQY
EECIEEGSEALACEEKNLKAFYRRGQAYRELGQLEDAVSDLRKAHEISFDDETI
AQVLRDTEESLTEEGGSAPRGVVIEEITEEDETLASVNHESFSEYSEERHQESE
DAHKGPINGDIMGQMTHSESLEALEGDPDAIRSFQNFISNADPTTLAAMGAGNA
GEVSPDLIKTASSMIGEMSAEELQKMIQLASSFPGENPYVTRNSDSNSNSFGNG
SIPNVSPDMLKTASDMNSEMSPDDLQRMFEMASSSRGKDPSLDAHHASSSSGAN
LAANLNHILGESEPSSSYHIPSSSRNISSSPLSHFPSSPGDMQEQIRNQMEDPA
MRQMFTSMMENMSPEMMANNGKQFGLELSFEDAAEAQEAMSSLSPEMLDKMMRW
ADRAQRGVETAKRTKNWLLGRPGMILAICMLLLAVILHRLGFIGS
516WD40 repeatMIAAISWVPRGASKAVFEVAEPPSKEEIEEILKSGVVERSGDSDGEEDDEHHDA2121815
proteinVASEKADEVSTALSAADALGRISKVTKAGSGFEDIADGLRELDMDNYDEEDEDV
KLFSTGLGDLYYPSNDMDPYLKDKDDDDDTEEIEDLSIEPMDSLIVCARTDDEV
NLLEVYLLEPSLSDESNMYVHHEVVISEFPLCTAWLDCPIKGGDKGNFIAVGSM
EPAIEIWQLDIIDAVEPCLVLGGQEELEKEKEKGKKASIKYKEGSHTDSVLGLA
WNKEFRNILASASADRQVKIWDVAAGKCWITMEHHTDEVQAVAWNHHAPQVLLS
GSFDHSVVMEDGRIPSHSGYRWSVTADVESLAWDPHSEHFFVVSLEDGTVRGFD
VHAAISNSASQSLPSFTLHAHEKAVSTISYNPAAPNLLATGSTDEMVKLWDLSW
WQPSCIASRNPKAGAVFSVSFSEDSPLLLAIGGSKGRLEVWDTSSDAAVSRRFG
KHGEPETAEPGS
517WD40 repeatMEFCEEYQEYMQGQEGEKLPGLGFRKLKEILERCRRRDSLHSQKALQAVQNPRT2071193
proteinCFAHCSVCDGSFFPSLLEEMSAVLGCFNEQAQKLLELHLASGFQKYLMWFEGEL
RGNHVALIQEGKDLVTYALINAIAIRKILEKYDEIHLSTQGQAFKSQVQRMEME
ILQSPWLCELIAFHIWVRETEANSGEGHALFEGCSLVVDDGKPSLSCELFDSIE
LDIDLTCSICLDTVFDSVSLTCGHIYCYMCACSAASVTIVDGLEAAEPKEKCPL
CREARVFEGAVHLDELNILLSRSCPEYWAERLQTERVERVRQAREHWESQCRAF
MGVE
518WD40 repeatMVSTQSTRENPSIFFPPPLKPWLLPVVLSLSLSRQLGMAAAAAASLPFKKNYRS62786
proteinSQALQQFYAGGPFAVSSDGSPIACNCGDSIRIVDSSNASLRPSIDCGSDTITAL
SLSPDGKLLFSAGHSRQIRVWDLSTSTCLRSWKGHDGPVMSMACPVSGGLLATG
GADRKVMVWDVDGGFCTHFFKGHDGVVSTVLFHPDSNRSLLFSGSDDGTIRVWD
LLAKKCASTLRGHDSTVTSLAFSEDGLTLLAAGRDKVVSLWDLHNYACKKTIPM
YEVLESVCVIHSGTVLASQLGLDDQLKVTKESAQNIHFITVGERGILRIWKSEG
SVCLFHQEHSDVTVISDEDDSRSGFTAAVMLPLDQGLLCVTADQQFLFYYPEKH
PEGIFSLTLCRRLVGYNEEIVDMKFLGEEENFLAVATNLEQVRVYELASMSCSY
VLAGHTETVLCLDTCISSSGRTLIVTGSKDNSVRLWDSESRHCIGVGVGHMGAV
GAVAFSRKRQDFFVSGSSDRTLKVWSLDGISEDGVDSTNLKAKAVVAAHDKDIN
SVAVAPNDSLVCSGSQDRTACVWRLPDLVSVVVLKGHKRGIWSVEFSPVDQCVL
TASGDKTVKIWAISDGSCLKTFEGHVSSVLRASFLTRGTQFVSCGADGLVRLWT
VRTNECIATYDQHSDRVWALAVGKKTEMLATGGSDAVVNLWYDSTASDKEDAFR
KEEEGVLKGQELENAVSDADYTKAIELALELRRPHKLFELFSELCRTREVGDRV
ERILSALSGEEVCLLLEYIREWNAKPRLCHVAQSVLSQVFRILSPTEIVEIKGI
GELLEGLIPYSQRHFSRIDRLVRSTYLLDYTLTGMSVIEPEADRSAVNDGSPDK
SGLEKLEDGLLGENVGEERIQNREELESSAYRRRRLPRSKDRSRKKSKNVVYAD
AAAISFRA
519WD40 repeatMDSAPRRRSGGINLPSGMSETSLRLDGFSGSSSSFRAISNLTSPSKSSSISDRF2131726
proteinIPCRSSSRLHTFGLVERGSPVKEGGNEAYSRLLKAELFGSDFGSLSPAGQGSPM
SPSKNMLRFKTESSGPNSPFSPSILRQDSGFSSEASTPPKPPRKVPKTPHKVLD
APSLQDDFYLNLVDWSSQNTLAVGLGTCVYLWSASNSKVTKLCDLGPNDGVCAV
QWTREGSYISIGTSLGQVQIWDGTQCRRVRTMGGEQTRTGVLAWNSRILASGSR
DRVILQHDLRVPNEFIGELVGHRSEVCGLKWSHDDRELASGGNDNQLLVWNQHS
QQPVLKLTEHTAAVKAIAWSPHQNGLLASGGGTADRCIRFWNTTMGRQTSSVDT
GSQVCNLAWSKNVNELVSTHGYSQNQIMVWKYPSMAKVATLTGHSLRVLYLAMS
PDGQTIVTGAGDETLRFWNVFPSAKAPAPVKDTGLWSLGRTHIR
520WD40 repeatMEDEAEIYDGVRAQFPLTFGKQSKPQTSLESVHSATRRGGPAPAPAPASSSSLP1012110
proteinSTTSPSAAGGAGKSSGLPSLSSSSTAWLEGLRAGMPRAGREAGIGSRGGDGEDG
GRANIGPPRPPPGFSANDDGGGEDDDDDGDGVMVGPPPPPPGNLGDGDDDEEEE
EANIGPPRPPVVDSDEEEEEEEEENRYRLPLSNEIVLKGHNKIVSALAVDPTGS
RVLSGSYDYTVRMFDFQGMNSRLSSFRDFEPVEGHQVRNLSWSPTADRFLCVTG
SAQAKIYDRDGLTLGEFVKGDMYIRDLKNTKGHITGLTWGEWHPKTKETILTSS
EDGSLRIWDVNDFKSQKQVIKPRLARPGRVPVTTCTWDREGRCIAGGIGDGSIQ
IWNLKPGWGSRPDIHVEQARAQDITGLRFSSDGKILLTRSFDDSLKVWDLRLMR
NPLKVFEDLPNHYAQTNIACSPDEQLFLTGTSVERESTIGGLLCFFDRSKLELV
SRIGISPTCSVVQCAWHPRLNQIFATSGDKSQGGTHVLYDPTLSERGALVCVAR
APRKKSVDDFELRPVIHNPHALPLFRDQPSRKRQRERILKDPLKSHKPELPMNG
PGHGGRVGASKGSLLTQYLLKQGGMIKETWMDEDPREAILKHADAAEKNPKFTR
AYAETQPDPVFAKSDSEDEDK
TABLE 16 — BLAST Sequence Alignment Table.
SEQBlastX topBlastX eBlastXBlastX
IDTargetPatent IdentifierhitGene namevalueidentitiesoverlap
1CDK type AeucalyptusSpp_003910Q9FRN5PUTATIVE0367492
SERINE/THREO
NINE KINASE
2CDK type AeucalyptusSpp_019213O44000CDC2-LIKEe−160217290
PROTEIN
KINASE TPK2
3CDK type AeucalyptusSpp_036800Q40789PROTEIN0259294
KINASE
P34CDC2
4CDK type AeucalyptusSpp_040260Q27168CDC2e−156208304
5CDK type AeucalyptusSpp_041965Q43361CDC2PA mRNA.e−159274294
SPTREMBL
6CDK type B-1eucalyptusSpp_002906Q9FYT9Cyclin-e−159269305
dependent
kinase B1-1
7CDK type B-2eucalyptusSpp_001518Q9FSH4B2-TYPE0270315
CYCLIN
DEPENDENT
KINASE
8CDK type CeucalyptusSpp_008078Q9LDC1CRK1 protein0415558
9CDK type CeucalyptusSpp_009826Q9LNN0F8L10.90392716
protein.
SPTREMBL
10CDK type CeucalyptusSpp_010364Q8GZA7Putativee−172309499
cyclin-
dependent
protein
kinase.
11CDK type CeucalyptusSpp_011523Q8W2N0Cyclin-e−165273405
dependent
kinase CDC2C
12CDK type CeucalyptusSpp_024358P93320CDC2MSC0448523
PROTEIN
13CDK type CeucalyptusSpp_039125O80540F14J9.260418743
protein
14CDK type DeucalyptusSpp_005362O80345CDK-e−180305483
activating
kinase 1AT
(Cdk-
activating
kinase
CAK1At)
15CDK type DeucalyptusSpp_044857O80345CDK-e−177302477
activating
kinase 1AT
(Cdk-
activating
kinase
CAK1At)
16Cyclin AeucalyptusSpp_001743Q39879MITOTIC0360508
CYCLIN A2-
TYPE
17Cyclin AeucalyptusSpp_012405Q39878MITOTICe−179278470
CYCLIN A2-
TYPE
18Cyclin BeucalyptusSpp_003739Q9LDM4F2D10.10e−148288466
(F5M15.6)
19Cyclin BeucalyptusSpp_022338P93557Mitotice−168310476
cyclin
20Cyclin BeucalyptusSpp_028605Q40337B-likee−158300439
cyclin.
SPTREMBL
21Cyclin BeucalyptusSpp_041006Q40337B-likee−158300439
cyclin
22Cyclin DeucalyptusSpp_006643Q9SXN7NtcycD3-11E−73177404
protein
23Cyclin DeucalyptusSpp_045338Q8LK74Cyclin D3.1e−101190332
protein.
SPTREMBL
24Cyclin DeucalyptusSpp_046486Q9ZRX7CYCLIN D3.2e−126196373
PROTEIN
25Cyclin-eucalyptusSpp_012070CAB69358SEQUENCE 18E−648388
dependentFROM PATENT
kinaseWO9841642
regulatory
subunit
26HistoneeucalyptusSpp_006617O803781810371395
acetyltransferase(Fragment)
27HistoneeucalyptusSpp_007827Q9FJT8Histonee−148260465
acetyltransferaseacetyltransferase
HAT B
28HistoneeucalyptusSpp_008036Q9FJT8Histonee−149262465
acetyltransferaseacetyltransferase
HAT B.
SPTREMBL
30HistoneeucalyptusSpp_001596Q9M4T5Putative7E−76156305
deacetylasehistone
deacetylase
HD2
31HistoneeucalyptusSpp_005870Q9M4T4Putative7E−66144318
deacetylasehistone
deacetylase
HD2c
(AT5g03740/F17C15 —
160)
32HistoneeucalyptusSpp_006901HDAC_ARATHHistone0405499
deacetylasedeacetylase
(HD)
33HistoneeucalyptusSpp_006902AAM13152HISTONE0427499
deacetylaseDEACETYLASE
34HistoneeucalyptusSpp_007440Q8W508HISTONE0369428
deacetylaseDEACETYLASE
35HistoneeucalyptusSpp_008994Q8LD93Histone0354536
deacetylasedeacetylase,
putative
36HistoneeucalyptusSpp_024580Q94EJ2At1g08460/T27G7_7e−165274373
deacetylase(HDA8).
SPTREMBL
37HistoneeucalyptusSpp_037831Q9FML2Histone0356464
deacetylasedeacetylase.
SPTREMBL
38MAT1 CDK-eucalyptusSpp_034958Q8LES8Hypothetical4E−47101190
activatingprotein
kinase
assembly
factor
39Peptidylprolyl001209EGXC004488HTTL40_SPIOLPeptidylprolyl0329392
isomerasecis-
trans
isomerase,
chloroplast
precursor
40Peptidylprolyl010310EGXD012820HTQ9FJL3PEPTIDYLPROLYL0453579
isomeraseISOMERASE
41Peptidylprolyl010310EGXD013036HTO82646HYPOTHETICAL0302521
isomerase57.1 KDA
PROTEIN (EC
5.2.1.8)
42Peptidylprolyl010316EGXF999037HTBAB39983PUTATIVEe−115146172
isomerasePEPTIDYLPROLYL
CIS-
TRANS
ISOMERASE,
CHLOROPLAST
43Peptidylprolyl010324EGXF002118HTAAK32894AT5G13120/T19L5 —e−122179264
isomerase80
44Peptidylprolyl011019EGKA001923HTAAM14253HYPOTHETICALe−108146188
isomerase20.3 KDA
PROTEIN
45PeptidylprolyleucalyptusSpp_000966Q8L5T1Peptidylprolyl1E−91155170
isomeraseisomerase
(Cyclophilin)
(EC
5.2.1.8)
46PeptidylprolyleucalyptusSpp_001037Q8VX73CYCLOPHILINe−120155169
isomerase(EC 5.2.1.8)
47PeptidylprolyleucalyptusSpp_004603AAM14253HYPOTHETICALe−108146188
isomerase20.3 KDA
PROTEIN
48PeptidylprolyleucalyptusSpp_005465Q9SP02Cyclophilin2E−93172204
isomeraseROC7 (EC
5.2.1.8)
(AT5g58710/mzn1 —
160)
(Pepti . . .
49PeptidylprolyleucalyptusSpp_006571O49605EC 5.2.1.89E−98169224
isomerase(Cyclophilin-
like
protein)
(Peptidylprolyl
50PeptidylprolyleucalyptusSpp_006786Q93VG0Cyclophilin5E−82142164
isomerase(EC 5.2.1.8)
(Peptidylprolyl
cis-
trans
51PeptidylprolyleucalyptusSpp_007057Q38901Cytosolic3E−84144172
isomerasecyclophilin
(EC 5.2.1.8)
(Peptidylprolyl
52PeptidylprolyleucalyptusSpp_008670Q9FJL3PEPTIDYLPROLYL0423596
isomeraseISOMERASE
53PeptidylprolyleucalyptusSpp_009137Q9C566Cyclophilin-e−168285361
isomerase40 (EC
5.2.1.8)
(Expressed
protein)
54PeptidylprolyleucalyptusSpp_010285Q9LY75Cyclophylin-e−160345658
isomeraselike protein
(EC 5.2.1.8)
(Peptidylprolyl
55PeptidylprolyleucalyptusSpp_010600Q93YQ8HYPOTHETICAL0346475
isomerase50.1 KDA
PROTEIN
(FRAGMENT)
56PeptidylprolyleucalyptusSpp_011551Q9ZVG4T2P11.13e−115154192
isomerasePROTEIN
57PeptidylprolyleucalyptusSpp_020743Q8VXA5PUTATIVEe−125161172
isomeraseCYCLOSPORIN
A-BINDING
PROTEIN
58PeptidylprolyleucalyptusSpp_023739FK21_NEUCRFK506-3E−4974112
isomerasebinding
protein
precursor
(FKBP-21)
60PeptidylprolyleucalyptusSpp_031985Q8L8W5Cyclophilin-1E−82155229
isomeraselike protein
(EC 5.2.1.8)
(Peptidylprolyl
61PeptidylprolyleucalyptusSpp_032025Q9LPC7F22M8.71E−4599160
isomeraseprotein (EC
5.2.1.8)
(Peptidylprolyl
cis-
trans
62PeptidylprolyleucalyptusSpp_032173Q8L8W5Cyclophilin-4E−83156229
isomeraselike protein
(EC 5.2.1.8)
(Peptidylprolyl
64RetinoblastomaeucalyptusSpp_009143Q9SLZ4Retinoblastoma-07041008
relatedrelated
proteinprotein
65WD40 repeateucalyptusSpp_000349AAK49947TGF-BETA0291326
proteinRECEPTOR-
INTERACTING
PROTEIN 1
66WD40 repeateucalyptusSpp_000575Q9LW17WD-40 repeate−168282341
proteinprotein-like
(Expressed
protein)
67WD40 repeateucalyptusSpp_000804GBLP_SOYBNGuanine0291326
proteinnucleotide-
binding
protein beta
subunit-like
68WD40 repeateucalyptusSpp_000805GBLP_MEDSAGuaninee−171291327
proteinnucleotide-
binding
protein beta
69WD40 repeateucalyptusSpp_000806GBLP_MEDSAGuaninee−171291327
proteinnucleotide-
binding
protein beta
subunit-like
70WD40 repeateucalyptusSPP_002248AAL86002HYPOTHETICAL0261388
protein43.8 KDA
PROTEIN
71WD40 repeateucalyptusSPP_003203Q9SY00Putative WD-e−144236317
proteinrepeat
protein
(AT4G02730/T5J8 —
2)
72WD40 repeateucalyptusSPP_003209AAM14986HYPOTHETICALe−160259302
protein32.6 KDA
PROTEIN
73WD40 repeateucalyptusSPP_004429Q9SZQ5HYPOTHETICAL0260322
protein34.3 KDA
PROTEIN
74WD40 repeateucalyptusSPP_004607AAC27402EXPRESSED0253356
proteinPROTEIN
75WD40 repeateucalyptusSPP_004682AAK00964HYPOTHETICAL0264313
protein35.3 KDA
PROTEIN
76WD40 repeateucalyptusSPP_005786Q944S2At2g47790/F17A22.18e−155264396
protein(Expressed
protein).
SPTREMBL
77WD40 repeateucalyptusSPP_005887Q94AB4AT3g13340/MDC11 —0332446
protein13
78WD40 repeateucalyptusSPP_005981Q8L4X6WD-repeat0315348
proteinprotein
GhTTG2.
SPTREMBL
79WD40 repeateucalyptusSPP_006766Q8L4M1Putative WD-e−137234369
protein40 repeat
protein
80WD40 repeateucalyptusSPP_006769Q9LJC6RETINOBLASTOMA-0372566
proteinBINDING
PROTEIN-LIKE
81WD40 repeateucalyptusSPP_006907Q94C94Hypothetical0446812
proteinprotein.
82WD40 repeateucalyptusSPP_007518Q93ZN5AT4G00090/F6N15_80311436
protein
83WD40 repeateucalyptusSpp_007717O82266At2g47990e−180327528
proteinprotein
(Hypothetical
58.9 kDa
protein)
84WD40 repeateucalyptusSpp_007718Q8RWD8Hypotheticale−173278350
proteinprotein.
SPTREMBL
85WD40 repeateucalyptusSpp_007741Q8LA40Putative WD-e−158269409
protein40 repeat
protein,
MSI2
86WD40 repeateucalyptusSpp_007884Q9FHY2Similaritye−149316765
proteinto unknown
protein
87WD40 repeateucalyptusSpp_008258Q9LHN3EMB|CAB63739.10524758
protein(AT3G18860/MCB22 —
3)
88WD40 repeateucalyptusSpp_008465Q9FLS2WD-repeat0366460
proteinprotein-like
89WD40 repeateucalyptusSpp_008616Q9LYK6Hypotheticale−148252321
proteinprotein
90WD40 repeateucalyptusSpp_008690Q9SW94G PROTEIN0326376
proteinBETA SUBUNIT
91WD40 repeateucalyptusSpp_008708Q8L862Hypotheticale−167297487
proteinprotein
92WD40 repeateucalyptusSpp_008850O22725F11P17.70402853
proteinprotein.
SPTREMBL
93WD40 repeateucalyptusSpp_009072Q9SAJ0F23A5.2 (forme−176288350
protein2) (mRNA
export
protein,
putative)
94WD40 repeateucalyptusSpp_009465Q9FLX9NOTCHLESS0384475
proteinPROTEIN
HOMOLOG
95WD40 repeateucalyptusSpp_009472Q9SZA4WD-REPEAT0374457
proteinPROTEIN-LIKE
PROTEIN
96WD40 repeateucalyptusSpp_009550Q9FKT5Gb|AAF54217.1e−167275313
protein(Hypothetical
protein)
97WD40 repeateucalyptusSpp_010284O22466WD-40 repeat0397423
proteinprotein MSI1
98WD40 repeateucalyptusSpp_010595Q94C94Hypothetical0419789
proteinprotein
99WD40 repeateucalyptusSpp_010657Q94AH2HYPOTHETICAL0243298
protein33.1 KDA
PROTEIN
100WD40 repeateucalyptusSpp_012636Q8L611Hypothetical07561133
proteinprotein
101WD40 repeateucalyptusSpp_012748AAD10151PUTATIVE WD-0375469
protein40 REPEAT
PROTEIN,
MSI4
102WD40 repeateucalyptusSpp_012879Q8VZY6FERTILIZATION-0291377
proteinINDEPENDENT
ENDOSPERM
PROTEIN
103WD40 repeateucalyptusSpp_015515Q8LPI5Putative WD-0360493
proteinrepeat
protein.
SPTREMBL
104WD40 repeateucalyptusSpp_015724O22607WD-40 repeat0395522
proteinprotein MSI4
105WD40 repeateucalyptusSpp_016167Q93YS7Putative WD-0663917
proteinrepeat
membrane
protein
106WD40 repeateucalyptusSpp_016633Q9SUY6HYPOTHETICALe−174240384
protein43.8 KDA
PROTEIN
107WD40 repeateucalyptusSpp_017485Q8RXC4Hypothetical06501348
protein144.7 kDa
protein
108WD40 repeateucalyptusSpp_018007O94289WD repeat-e−129302794
proteincontaining
protein
109WD40 repeateucalyptusSpp_020775Q8W403Sec13pe−150242304
protein
110WD40 repeateucalyptusSpp_023132AAK52092WD-40 REPEAT0458515
proteinPROTEIN
111WD40 repeateucalyptusSpp_023569Q9XIJ3T10O24.21.0404576
proteinSPTREMBL
112WD40 repeateucalyptusSpp_023611Q8L4J2Cleavagee−174301438
proteinstimulation
factor 50K
chain
(Cleavage
stimulation
113WD40 repeateucalyptusSpp_024934Q94AB4AT3g13340/MDC11 —0343444
protein13. WD-
repeat
protein-like
SPTREMBL
114WD40 repeateucalyptusSpp_025546O22212Hypothetical0352566
protein61.8 kDa
Trp-Asp
repeats
containing
protein
115WD40 repeateucalyptusSpp_030134Q9LVF2Genomic DNA,0677946
proteinchromosome
3, P1 clone:
MIL23
116WD40 repeateucalyptusSpp_031787AAL91206WD REPEAT0264329
proteinPROTEIN-LIKE
117WD40 repeateucalyptusSpp_034435Q9SAJ0F23A5.2(forme−178290349
protein2) (mRNA
export
protein,
putative).
SPTREMBL
118WD40 repeateucalyptusSpp_034452Q94BR4Hypothetical0381525
proteinprotein
(Putative
pre-mRNA
splicing
factor
119WD40 repeateucalyptusSpp_035789P93563Guanine3E−88171356
proteinnucleotide-
binding
protein beta
subunit
120WD40 repeateucalyptusSpp_035804Q9FNN2WD-repeat0356589
proteinprotein-
like.
SPTREMBL
121WD40 repeateucalyptusSpp_043057Q9LV35WD40-repeat0472610
proteinprotein.
SPTREMBL
122WD40 repeateucalyptusSpp_046741Q93VK1AT4g28450/F20o9 —0363452
protein130
123WD40 repeateucalyptusSpp_047161Q9ZUN8Putative WD-0350473
protein40 repeat
protein
124CDK type ApinusRadiata_001766Q9M3W7PUTATIVEe−128237436
CDC2-RELATED
PROTEIN
KINASE CRK2.
459 e−128
125CDK type ApinusRadiata_002927Q9FRN5PUTATIVE0349470
SERINE/THREO
NINE KINASE
126CDK type B-1990309PRCA009171HTQ9FYT8Cyclin-e−145244303
dependent
kinase B1-2
127CDK type B-1pinusRadiata_013714Q9FYT8CYCLIN-e−174222304
DEPENDENT
KINASE B1-2
128CDK type B-1pinusRadiata_016332Q9FYT8CYCLIN-e−178228304
DEPENDENT
KINASE B1-2
129CDK type B-1pinusRadiata_021677Q9FYT8CYCLIN-e−176229304
DEPENDENT
KINASE B1-2
130CDK type B-1pinusRadiata_027562Q9FYT8Cyclin-e−118211304
dependent
kinase B1-2
131CDK type CpinusRadiata_001504Q9LNN0F8L10.90434790
protein
132CDK type CpinusRadiata_015211Q9LNN0F8L10.90371746
protein
133CDK type CpinusRadiata_020421P93320Cdc2MsC0318432
protein
134CDK type DpinusRadiata_003187O80345CDK-e−137226485
ACTIVATING
KINASE 1AT
(CDK-
ACTIVATING
KINASE
CAK1AT)
135CDK type DpinusRadiata_015661Q947K6CDK-0266407
ACTIVATING
KINASE.
136Cyclin ApinusRadiata_013874Q96226Cycline−108223474
137Cyclin ApinusRadiata_014615CAC27333PUTATIVE A-0332390
LIKE CYCLIN
(FRAGMENT)
138Cyclin BpinusRadiata_004578O65064Probable9E−87162217
G2/mitotic-
specific
cyclin
(Fragment)
139Cyclin BpinusRadiata_023387O04389B-like2E−98220466
cyclin
140Cyclin DpinusRadiata_006970P93103CYCLIN-D1E−75135293
LIKE PROTEIN
141Cyclin DpinusRadiata_010322CAC17049SEQUENCE 33e−131171254
FROM PATENT
WO0065040
142Cyclin DpinusRadiata_022721P93103CYCLIN-D1E−76137289
LIKE PROTEIN
143Cyclin DpinusRadiata_023407Q9SMD5CYCD3,28E−90139278
PROTEIN
144Cyclin-pinusRadiata_001945Q947Y1PUTATIVE5E−557486
dependentCYCLIN-
kinaseDEPENDENT
regulatoryKINASE
subunitREGULATORY
SUBUNIT
145Cyclin-pinusRadiata_008233CAB69358SEQUENCE 14E−496586
dependentFROM PATENT
kinaseWO9841642
regulatory
subunit
146Cyclin-pinusRadiata_008234CAB69358SEQUENCE 14E−496586
dependentFROM PATENT
kinaseWO9841642
regulatory
subunit
147Cyclin-pinusRadiata_022054CAB69358SEQUENCE 18E−557082
dependentFROM PATENT
kinaseWO9841642
regulatory
subunit
148HistonepinusRadiata_012137Q9FK40Histone0496555
acetyltransferaseacetyltransferase
(AT5g50320/MXI22 —
3)
149HistonepinusRadiata_012582O803781810354402
acetyltransferase(Fragment)
SPTREMBL
150HistonepinusRadiata_015285O803781810342401
acetyltransferase(Fragment)
151HistonepinusRadiata_017229Q9LNC4F9P14.9e−118268585
acetyltransferaseprotein
152HistonepinusRadiata_020724Q9AR19Histonee−177355639
acetyltransferaseacetyltransferase
GCN5
(Expressed
protein)
153HistonepinusRadiata_004555AAM13152HISTONE0331488
deacetylaseDEACETYLASE
154HistonepinusRadiata_004556AAM13152HISTONE0331488
deacetylaseDEACETYLASE
155HistonepinusRadiata_005729Q9M4U5Histone9E−62154348
deacetylasedeacetylase
2 isoform b
156HistonepinusRadiata_007395AAM13152HISTONE0335426
deacetylaseDEACETYLASE
157HistonepinusRadiata_009503Q8W508Histone0365427
deacetylasedeacetylase
158HistonepinusRadiata_011283AAM19887AT1G08460/T27G7_70255366
deacetylase
159HistonepinusRadiata_012322Q9FML2HISTONE0327435
deacetylaseDEACETYLASE
(PUTATIVE
HISTONE
DEACETYLASE)
161HistonepinusRadiata_023236Q8RX28Putativee−144238390
deacetylasehistone
deacetylase
162PeptidylprolylpinusRadiata_000171Q9FJL3PEPTIDYLPROLYL0364549
isomeraseISOMERASE
163PeptidylprolylpinusRadiata_000172Q38949FK5060365552
isomeraseBINDING
PROTEIN
FKBP62
(ROF1)
164PeptidylprolylpinusRadiata_001480Q8VXA5PUTATIVEe−125161172
isomeraseCYCLOSPORIN
A-BINDING
PROTEIN
168PeptidylprolylpinusRadiata_001692FKB7_WHEAT70 kDa0418553
isomerasepeptidylprolyl
isomerase
(EC 5.2.1.8)
169PeptidylprolylpinusRadiata_005313AAB64339FKBP-TYPE1E−97135175
isomerasePEPTIDYLPROLYL
CIS-
TRANS
ISOMERASE
170PeptidylprolylpinusRadiata_006362BAB39983PUTATIVE3E−77129168
isomerasePEPTIDYLPROLYL
CIS-
TRANS
ISOMERASE,
CHLOROPLA . . .
290 3e−77
171PeptidylprolylpinusRadiata_006493Q9C835Hypothetical2E−62128235
isomerase26.4 kDa
protein (EC
5.2.1.8)
(Peptidylprol . . .
172PeptidylprolylpinusRadiata_006983AAK96784CYCLOPHILINe−103151204
isomerase
174PeptidylprolylpinusRadiata_007665Q9LDC0FKBP-likee−138239378
isomeraseprotein
(Genomic
DNA,
chromosome
3, P1 clone:
175PeptidylprolylpinusRadiata_012196Q93VG0Cyclophilin4E−74132160
isomerase(EC 5.2.1.8)
(Peptidylprolyl
cis-
trans
176PeptidylprolylpinusRadiata_013382Q9C588HYPOTHETICAL0288581
isomerase60.2 KDA
PROTEIN
177PeptidylprolylpinusRadiata_016461O04287IMMUNOPHILIN9E−6688109
isomerase
178PeptidylprolylpinusRadiata_017611Q9C566Cyclophilin-e−163276360
isomerase40 (EC
5.2.1.8)
(Expressed
protein)
179PeptidylprolylpinusRadiata_019776AAM14253HYPOTHETICALe−110146190
isomerase20.3 KDA
PROTEIN
180PeptidylprolylpinusRadiata_020659AAO63961Hypothetical7E−85159227
isomeraseprotein
SPTREMBL
181PeptidylprolylpinusRadiata_022559AAK43974PUTATIVE2E−73113153
isomerasePEPTIDYLPROLYL
CIS-
TRANS
ISOMERASE
182PeptidylprolylpinusRadiata_024188Q9P3X9PEPTIDYLPROLYLe−122210379
isomeraseCIS-
TRANS
ISOMERASE
(EC 5.2.1.8)
183PeptidylprolylpinusRadiata_027973Q9SR70T22K18.113E−69125171
isomeraseprotein
(AT3g10060/T22K18 —
11)
184WD40 repeatpinusRadiata_001353Q9FNN2WD-repeat0317590
proteinprotein-
likeSPTREMBL
185WD40 repeatpinusRadiata_001978PRL1_ARATHPP1/PP2A0341502
proteinphosphatases
pleiotropic
regulator
PRL1
186WD40 repeatpinusRadiata_002810AAK49947TGF-BETA0273326
proteinRECEPTOR-
INTERACTING
PROTEIN 1
187WD40 repeatpinusRadiata_002811AAK49947TGF-BETA0273326
proteinRECEPTOR-
INTERACTING
PROTEIN 1
188WD40 repeatpinusRadiata_002812AAM15129HYPOTHETICALe−127225521
protein58.9 KDA
PROTEIN
189WD40 repeatpinusRadiata_003514Q9FJ94Similaritye−137242445
proteinto myosin
heavy chain
kinaseSPTREMBL
190WD40 repeatpinusRadiata_004104GBB_ORYSAGuanine0294378
proteinnucleotide-
binding
protein beta
subunit
191WD40 repeatpinusRadiata_005595Q9FTT9PUTATIVE0320459
proteinDKFZP564O0463
PROTEIN
192WD40 repeatpinusRadiata_005754Q94JT6At1g78070/F28K19 —e−168294451
protein28SPTREMBL
193WD40 repeatpinusRadiata_006463GBLP_MEDSAGuaninee−152261324
proteinnucleotide-
binding
protein beta
subunit-like
. . . 538 e−152
194WD40 repeatpinusRadiata_006665AAM20553HYPOTHETICAL06551169
protein119.9 KDA
PROTEIN.
1229 0.0
195WD40 repeatpinusRadiata_006750AAM13119HYPOTHETICALe−158264312
protein35.4 KDA
PROTEIN. 560
e−158
196WD40 repeatpinusRadiata_007030Q9LJN8MITOTICe−169284335
proteinCHECKPOINT
PROTEIN. 595
e−169
197WD40 repeatpinusRadiata_007854Q8H919Putative WD0429644
proteindomain
containing
protein
198WD40 repeatpinusRadiata_007917AAD10151PUTATIVE WD-0353462
protein40 REPEAT
PROTEIN,
MSI4
199WD40 repeatpinusRadiata_007989Q9LRZ0Genomic DNA,0480687
proteinchromosome
3, TAC
clone: K20I9
200WD40 repeatpinusRadiata_008506MSI1_LYCESWD-40 repeat0364420
proteinprotein MSI1
201WD40 repeatpinusRadiata_008692Q8W403Sec13pe−134218301
protein
202WD40 repeatpinusRadiata_008693Q8W403Sec13pe−137222301
protein
203WD40 repeatpinusRadiata_009170Q9M0V4U3 snoRNP-e−127244524
proteinassociated-
like
protein.
SPTREMBL
204WD40 repeatpinusRadiata_009408Q9SAJ0F23A5.2(FORMe−171282350
protein2). 602 e−171
205WD40 repeatpinusRadiata_009522Q8RXQ4Hypotheticale−129231395
protein43.8 kDa
protein
206WD40 repeatpinusRadiata_009734AAO27452Peroxisomale−142227317
proteintargeting
signal type
2 receptor.
SPTREMBL
207WD40 repeatpinusRadiata_009815AAM20433CELL CYCLE0326500
proteinSWITCH
PROTEIN
208WD40 repeatpinusRadiata_010670AAN72058Expressede−157264345
proteinprotein
209WD40 repeatpinusRadiata_011297AAM13100WD REPEATe−157262337
proteinPROTEIN
ATAN11
210WD40 repeatpinusRadiata_013098AAM13153HYPOTHETICALe−136229352
protein39.1 KDA
PROTEIN. 487
e−136
211WD40 repeatpinusRadiata_013172Q8H0T9Hypothetical0437860
proteinprotein
212WD40 repeatpinusRadiata_013589AAK52092WD-40 REPEAT0448512
proteinPROTEIN
213WD40 repeatpinusRadiata_013608AAC27402EXPRESSEDe−141202358
proteinPROTEIN
214WD40 repeatpinusRadiata_014299Q9XED5Cell cycle0335488
proteinswitch
proteinSPTREMBL
215WD40 repeatpinusRadiata_014498Q9FH64WD REPEATe−152206329
proteinPROTEIN-LIKE
216WD40 repeatpinusRadiata_014548Q93ZS6HYPOTHETICAL0505763
protein82.2 KDA
PROTEIN
217WD40 repeatpinusRadiata_014610Q9M298Hypothetical0450922
protein104.7 kDa
protein
218WD40 repeatpinusRadiata_016090Q9SIY9Putative WD-0442802
protein40 repeat
proteinSPTREMBL
219WD40 repeatpinusRadiata_016722O22826Putativee−159257310
proteinsplicing
factorSPTREMBL
220WD40 repeatpinusRadiata_016785AAG60193PUTATIVE0344464
proteinWD40 PROTEIN
221WD40 repeatpinusRadiata_017094Q9LV35WD40-REPEAT0406604
proteinPROTEIN
222WD40 repeatpinusRadiata_017527Q9AYE4Hypotheticale−154254314
protein35.3 kDa
protein
223WD40 repeatpinusRadiata_017591080706F8K4.2109051218
proteinprotein
224WD40 repeatpinusRadiata_017769Q9XIJ3T10O24.210446607
protein
225WD40 repeatpinusRadiata_018047Q8VZY6FERTILIZATION-0285373
proteinINDEPENDENT
ENDOSPERM
PROTEIN
226WD40 repeatpinusRadiata_018414Q947M8COPI0455638
protein
227WD40 repeatpinusRadiata_018986Q9LFE2WD40-repeat0518886
proteinprotein
228WD40 repeatpinusRadiata_019479Q9SZA4WD-repeate−156276454
proteinprotein-like
protein
229WD40 repeatpinusRadiata_020144Q8W514MSI TYPE0288413
proteinNUCLEOSOME/CHROMATIN
ASSEMBLY
FACTOR C
230WD40 repeatpinusRadiata_022480Q8W514MSI typee−167287426
proteinnucleosome/chromatin
assembly
factor C
231WD40 repeatpinusRadiata_023079Q8W514MSI typee−169283397
proteinnucleosome/chromatin
assembly
factor C.
SPTREMBL
232WD40 repeatpinusRadiata_026739Q93YS7Putative WD-0591918
proteinrepeat
membrane
protein.
SPTREMBL
233WD40 repeatpinusRadiata_026951Q93VS5AT4g18900/F13C5 —e−163290503
protein70
(Hypothetica
1 protein)
234WEE1-likepinusRadiata_026529Q9SRY9F22D16.3e−122209451
proteinPROTEIN
235WD40 repeateucalyptusSpp_006366Q8LF96PRL1 protein0374492
protein
236WD40 repeateucalyptusSpp_017378O22607WD-40 repeat0371453
proteinprotein MSI4
237WD40 repeatpinusRadiata_000888O22466WD-40 repeat0364420
proteinprotein MSI1
238Cyclin-pinusRadiata_014166Q9FKB5GENOMIC DNA,5E−42114304
dependantCHROMOSOME
kinase5, TAC
inhibitorCLONE: K24G6
(CYCLIN-
DEPENDENT
239CDK type DpinusRadiata_003189Q9M5G4CDK-8E−2156100
activating
kinase
240HistonepinusRadiata_009356Q9FJT8Histone7E−85187510
acetyltransferaseacetyltransferase
HAT B
241HistonepinusRadiata_000065Q9LPW6F13K23.85E−1871209
deacetylaseprotein.
242HistonepinusRadiata_014197Q8GXJ1Putativee−170308519
deacetylasehistone
deacetylase
243PeptidylprolylpinusRadiata_009081Q9ZRQ9Cyclophiline−106185190
isomerase(EC 5.2.1.8)
(Peptidylprolyl
cis-
trans
244PeptidylprolylpinusRadiata_013417Q8H4T0Putativee−140235345
isomerasePeptidylprolylcis-
trans
isomerase
protein
245WD40 repeatpinusRadiata_005755Q9SKW4F5J5.6.e−143144319
protein
246WD40 repeatpinusRadiata_006670Q9LDG7WD-40 repeate−163393960
proteinprotein-like
(MJK13.13
protein)
247WD40 repeatpinusRadiata_007027Q8GWR1Hypotheticale−157276470
proteinprotein.
248WD40 repeatpinusRadiata_007276Q9LF27Hypotheticale−138235428
protein47.3 kDa
protein
249WD40 repeatpinusRadiata_007390Q94AH4PUTATIVE3E−1753158
proteinRING ZINC
FINGER
PROTEIN. 91
3e−17
250WD40 repeatpinusRadiata_012648O22212Hypothetical0324561
protein61.8 kDa
Trp-Asp
repeats
containing
protein
251WD40 repeatpinusRadiata_013171Q8H0T9Hypothetical.0437860
proteinprotein.
252Cyclin BeucalyptusSpp_045414Q9LDM4F2D10.10e−142255423
(F5M15.6)
253Cyclin-eucalyptusSpp_044328Q9FKB5GENOMIC DNA,1E−54121260
dependantCHROMOSOME
kinase5, TAC
inhibitorCLONE: K24G6
(CYCLIN-
DEPENDENT
254HistoneeucalyptusSpp_015615Q9AR19Histone0390563
acetyltransferaseacetyltransferase
GCN5
(Expressed
protein)
255PeptidylprolyleucalyptusSpp_017239Q8GWM6Hypothetical0364591
isomeraseprotein
256WD40 repeateucalyptusSpp_018643Q93VS5AT4g18900/F13C5 —0229327
protein70
(Hypothetical
protein)
257WD40 repeateucalyptusSpp_019127Q9SRX9F22D16.14e−131232337
proteinprotein.
SPTREMBL
258WD40 repeateucalyptusSpp_022624Q9LFE2WD40-repeat0594868
proteinprotein
259WD40 repeateucalyptusSpp_032424Q8LPL5Cell cycle0255327
proteinswitch
protein
260WD40 repeateucalyptusSpp_037472Q9SK69Putative WD-0461677
protein40 repeat
protein
(AT2G20330/F11A3.12)

Claims as granted

4 claims

Log in to read the claims of this application.

Log in to unlock

Classifications

8 codes
IPC · International Patent Classification
Section A — Human necessities
  • A01H5/00
Section C — Chemistry; metallurgy
  • C07K14/415
  • C12N15/82
  • C12N15/29
USPC · US Patent Classification
435/419800/319800/298435/320.1

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoomJan 2005Jul 2005Jan 2006Jul 2006Jan 2007Jul 2007Jan 2008Jul 2008Jan 2009Jul 2009Jan 2010USPTOApplicantRestriction requirementNon-final rejectionFinal rejectionAdvisory actionNotice of allowance
USPTOApplicanthover for detail · click to open
Pendency
4.8 y
1,741 days filing → grant
Office actions
2
after a restriction
Responses
3
no RCE
Interviews
2
examiner interview summaries
Examiner
Cynthia Collins
art unit 1638 · TC 1600
Citations: 120 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Log in to unlock

Chain of title

⤢ drag to zoom2006200820102012201420162018202020222024Owner 3Owner 4liens, releases & corrections
TitleLienhover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock